It is my privilege to introduce this year’s edition of Baylor Neonatology Guidelines, now in the 26th year of its publication. The editors of these guidelines – Drs. Fernandes, Pammi and Katakam – are continuing the legacy of Dr. James Adams and his tradition of generating practical, up-to-date and evidence-based guidelines that provide bedside clinicians with a ready reference for patient care. The editors, section editors, and various authors have worked hard to preserve relevant material from the guidelines and add new relevant information. They have continued to incorporate more and more the GRADE system of categorizing the evidence supporting these guidelines, and expanded the pool of authors in this edition. Community neonatology colleagues, nurse practitioners, dietitians, and fellows are all members of author teams now.

The Baylor Neonatology Guideline book is used extensively in our Newborn Center (including the Mother Baby Unit), the Ben Taub NICU, and our Community Neonatology neonatal units. It ensures consistency of care among the large number of clinicians in our Newborn Center and at multiple locations in the Houston area. It has been, and will remain one of the most valuable resources and a distinguishing asset of the Neonatology Section. In addition, it is a resource for practicing neonatologists all over the world. Most importantly, these guidelines ensure that we provide excellent high-quality care to NICU infants and their families and improve their outcomes. As the Service Chief and Section Head of Neonatology, it has been my honor to support the team of editors and authors who have worked hard to bring us this distillation of evidence, experience, and clinical wisdom.

Gautham Suresh, MD, DM, MS, FAAP
Professor of Pediatrics, Baylor College of Medicine
Section Head and Service Chief of Neonatology
Texas Children's Hospital
Preface

We are pleased to release the 26th revision of “Guidelines for the Acute Care of the Neonate”, a compendium of multidisciplinary collaboration between members of the Newborn Center at Texas Children’s Hospital and Baylor College of Medicine. This edition is dedicated to the two legends of the BCM Neo Section who left lasting legacies - Dr. Arnold J. Rudolph, who taught us the art of neonatology and Dr. James Adams, who, in addition to being an educator extraordinaire, was singularly influential in developing the ‘BCM Neo Guidelines’ over the first 24 years.

The ‘Baylor Neo Guidelines’, as this handbook is fondly referred to, is meant to serve as a resource for neonatology fellows, pediatric housestaff, nurse practitioners, nurses and other clinicians who care for sick neonates in Baylor-affiliated hospitals. This body of work is reflective of general principles, concepts, and treatment recommendations that are agreed upon by the authors, editors, and section members. When appropriate, national guidelines are cited to help with the decision-making process. Also, regional traits unique to the southeast Texas or Houston are considered when appropriate. The guidelines are reviewed and revised annually (or more frequently as needed) as new evidence and recommendations for clinical care become available. Users should refer to the most recent edition of these guidelines, which may be downloaded for free from ‘Physician publications’ tab of the Baylor Neonatology website (www.neonate.net).

Starting with the 25th edition, we began qualifying our clinical recommendations using the ‘GRADE’ framework for rating quality of evidence and strength of recommendations. Our guidelines cite the quality of evidence and the strength of our recommendations whenever possible. Our chapter authors and section editors have worked hard to create the content you see within and will monitor their areas of clinical interest for emerging evidence that may be of value to the bedside clinician caring for a sick neonate. We look forward to serving you in the coming years.

Sincerely,

Caraciolo J. Fernandes, MD
Mohan Pammi, MD, PhD
Lakshmi Katakam, MD, MPH

Disclaimer

These are guidelines only and may not be applicable to populations outside the BCM Affiliated Hospitals. These guidelines do not represent official policy of Texas Children’s Hospital, Ben Taub General Hospital, BCM, or the BCM Department of Pediatrics, nor are they intended as universal practice guidelines or standards of care. Specific circumstances often dictate deviations from these guidelines. Each new admission and all significant new developments must be discussed with the fellow on call and with the attending neonatologist on rounds. All users of this material should be aware of the possibility of changes to this handbook and should use the most recently published guidelines.
Contributing Authors

All authors are members of the faculty at Baylor College of Medicine in the Department of Pediatrics, Section of Neonatology and attending physicians at Texas Children’s Hospital, unless otherwise noted. Allied health contributors are all members of the Texas Children’s Hospital staff.

Senait Adebo, MD
Assistant Professor

Diane Anderson, PhD, RD, LD
Associate Professor

Athis Arunachalam, MD
Assistant Professor

Mufeed Ashraf, MD
Assistant Professor

Sangeetha Athis Rajh, MD
Instructor

Melinda Colleen Brand, PhD, RN, NNP-BC
Neonatal Nurse Practitioner

Elizabeth Bacon, MS, RD, LD, CNCS,CSP
Neonatal Dietitian

Ashley S. Bruns, DO
Perinatal-Neonatal Fellow

Rebecca J. Burke, MD
Perinatal-Neonatal Fellow

Melissa M. Carbalaj, MD
Assistant Professor

Amy Carter MS, RD, LD
Neonatal Dietitian

Laura Caudill, RD, CLEC, LD
Neonatal Dietitian

Mary F. Colby-Hale, MSN, APRN, NNP-BC
Neonatal Nurse Practitioner

William J. Craigien, MD
Professor
Department of Molecular & Human Genetics

Bridget Cross MSN, APRN, NNP-BC
Neonatal Nurse Practitioner

Milena Cuevas Guaman, MD
Assistant Professor

Viral Dave, MD
Assistant Professor

Jonathan Davies, MD
Assistant Professor

Stephanie Blair Deal, MD
Assistant Professor

Chris K. Dischler, MSN, APRN, NNP-BC
Neonatal Nurse Practitioner

Leah Elizondo, MD
Neonatal-Perinatal Fellow

Nidia B. Espinosa, MS, RD, LD
Neonatal Dietitian

Regine Fortunov, MD
Assistant Professor

Mayra Freeman-Ladd, MD
Assistant Professor

Bheru Gandhi, MD
Assistant Professor

Catherine Gannon, MD
Assistant Professor

Joseph Garcia-Prats, MD
Professor

Ann Gerges, MD
Assistant Professor

Jamie Gilley, APRN, MSN, NNP-BC
Neonatal Nurse Practitioner

Ganga Gokulakrishnan, MD, MS
Assistant Professor

Laura Collins, MBA, RD, LD
Neonatal Dietitian

Sharada H. Gowda, MD
Assistant Professor

Charleta Guilloiry, MD, MPH
Associate Professor

Amy B. Hair, MD
Assistant Professor

Patrice Hochhevar, RD, CNCS, LD
Neonatal Dietitian

Karen E. Johnson, MD
Associate Professor

Lakshmi Katakam, MD, MPH
Associate Professor

Simone Yousef Kass, MD
Assistant Professor of Neurology

Mona Khattab, MD, MS
Assistant Professor

Seema Lalani, MD
Associate Professor

Department of Molecular & Human Genetics

Timothy C. Lee, MD
Associate Professor
Division of Pediatric Surgery

Kriti Kaingappan, MBBS
Associate Professor

Jenelle Little, MD
Assistant Professor

Pablo Lohmann, MD
Assistant Professor

Laura Lucas, MS, RD, CSP, LD
Neonatal Dietitian

Ashley Lucke, MD
Neonatal-Perinatal Fellow

Agnes Mandy, RD, LD
Associate Professor

George T. Mandy, MD
Associate Professor

L. Adriana Massieu, RD, CNSC, LD
Neonatal Dietitian

Tiffany McKee-Garrett, MD
Associate Professor

Jamie J. McKissick, MSN, APRN, NNP-BC
Neonatal Nurse Practitioner

Tiffany L. Molina, MD
Neonatal-Perinatal Fellow

Alice Obuobi, MD
Assistant Professor

Scott W. Osborne, MD
Assistant Professor

Lisa Owens, DO
Senior Faculty

Mohan Pannmi, MD
Associate Professor

Shweta Parmekar, MD
Assistant Professor

Frank X. Placencia, MD
Assistant Professor

Jennifer L. Placencia, PharmD
Clinical Pharmacy Specialist-NICU

Muralidhar Penumkumar, MBBS
Assistant Professor

Maria Kristine Reyes, MD
Assistant Professor

Christopher J. Rhee, MD
Assistant Professor

Danielle R. Rios, MD, MS
Assistant Professor

Emily Rodman, PharmD, BCPPS
Clinical Pharmacy Specialist-NICU

Charles Roitsch, DO
Neonatal-Perinatal Fellow

Elizabeth Sager, MD
Neonatal-Perinatal Fellow

Rita Shah, MD
Assistant Professor

Michael E. Speer, MD
Professor

Nathan C. Sundgren, MD, PhD
Assistant Professor

Alana Thomas, MD
Assistant Professor

Cecilia Torres-Day, MD
Assistant Professor

Lois M. Tracy, MSN, APRN, NNP-BC
Neonatal Nurse Practitioner

Santiago O. Valdes, MD
Assistant Professor
Section of Pediatric Cardiology

Gregory Valentine, MD, DTM
Neonatal-Perinatal Fellow

Nidhi Paulose Varghese, MD
Assistant Professor
Division of Pulmonary Medicine

Bernadette White, MD
Neonatal-Perinatal Fellow

Lindsay Whittington, RN, VA-BC
Staff Nurse

Contributors
Endocrinology section was written with the advice of the Pediatric Endocrine and Metabolism Section, in particular, Lefki P. Karaviti, MD and George Jea, MD. Environment section, in particular NICU Environment, written with the advice of Carol Turnage-Carriger, MSN RN CNS and Lisa Davenport MSN, RN, CNS. Infectious Disease section was written with the advice of the Pediatric Infectious Disease Section, in particular, Drs. Carol J. Baker, Judith R. Campbell, Morven S. Edwards, and Flor Munoz-Rivas. Human Immunodeficiency Virus (HIV) section written with the advice of the Allergy & Immunology Section. Nutrition section was written with the advice of Nancy Hurst, PhD, RN, IBCLC, and Kristina Tucker, RN, IBCLC.
## Section 1. Care of Very Low Birth Weight Babies

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 1.1</td>
<td>General Care (Babies &lt; 1500 grams)</td>
<td>2</td>
</tr>
<tr>
<td>Ch. 1.2</td>
<td>Specialized Care for ELGAN Babies</td>
<td>3</td>
</tr>
<tr>
<td>Ch. 1.3</td>
<td>Umbilical Catheters</td>
<td>4</td>
</tr>
</tbody>
</table>

## Section 2. Respiratory Care

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 2.1</td>
<td>Delivery Room Stabilization</td>
<td>10</td>
</tr>
<tr>
<td>Ch. 2.2</td>
<td>Control of Breathing and Apnea of Prematurity</td>
<td>11</td>
</tr>
<tr>
<td>Ch. 2.3</td>
<td>Management of Neonatal Respiratory Distress</td>
<td>13</td>
</tr>
<tr>
<td>Ch. 2.4</td>
<td>Non-Invasive Respiratory Support</td>
<td>14</td>
</tr>
<tr>
<td>Ch. 2.5</td>
<td>Weaning from CPAP and Nasal Cannula</td>
<td>17</td>
</tr>
<tr>
<td>Ch. 2.6</td>
<td>Conventional Ventilation of Preterm and Term Neonates</td>
<td>18</td>
</tr>
<tr>
<td>Ch. 2.7</td>
<td>High-frequency Oscillatory Ventilation</td>
<td>22</td>
</tr>
<tr>
<td>Ch. 2.8</td>
<td>Bronchopulmonary Dysplasia</td>
<td>24</td>
</tr>
<tr>
<td>Ch. 2.9</td>
<td>Prevention of Bronchopulmonary Dysplasia</td>
<td>30</td>
</tr>
<tr>
<td>Ch. 2.10</td>
<td>Interdisciplinary Care and Discharge Planning of the Ventilator Dependent Patient</td>
<td>31</td>
</tr>
<tr>
<td>Ch. 2.11</td>
<td>Pulmonary Hypertension in Lung Diseases</td>
<td>32</td>
</tr>
<tr>
<td>Ch. 2.12</td>
<td>Congenital Diaphragmatic Hernia</td>
<td>33</td>
</tr>
<tr>
<td>Ch. 2.13</td>
<td>Neonatal ECMO</td>
<td>35</td>
</tr>
</tbody>
</table>

## Section 3. Cardiac Care

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 3.1</td>
<td>Cardiovascular Physiology</td>
<td>40</td>
</tr>
<tr>
<td>Ch. 3.2</td>
<td>Circulatory Insufficiency</td>
<td>43</td>
</tr>
<tr>
<td>Ch. 3.3</td>
<td>Congenital Heart Disease</td>
<td>50</td>
</tr>
<tr>
<td>Ch. 3.4</td>
<td>Arrhythmias</td>
<td>56</td>
</tr>
</tbody>
</table>

## Section 4. Environment

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 4.1</td>
<td>NICU Environment</td>
<td>60</td>
</tr>
<tr>
<td>Ch. 4.2</td>
<td>Thermal Regulation</td>
<td>63</td>
</tr>
</tbody>
</table>

## Section 5. Endocrinology

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 5.1</td>
<td>Approach to Disorders of Sexual Development</td>
<td>68</td>
</tr>
<tr>
<td>Ch. 5.2</td>
<td>Hypothyroxinemia of Prematurity</td>
<td>70</td>
</tr>
<tr>
<td>Ch. 5.3</td>
<td>Steroid Therapy for Adrenal Insufficiency</td>
<td>71</td>
</tr>
<tr>
<td>Ch. 5.4</td>
<td>Hypoglycemia</td>
<td>72</td>
</tr>
<tr>
<td>Ch. 5.5</td>
<td>Transitional Neonatal Hypoglycemia</td>
<td>72</td>
</tr>
<tr>
<td>Ch. 5.6</td>
<td>Persistent Hypoglycemia</td>
<td>74</td>
</tr>
</tbody>
</table>

## Section 6. Genetics

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 6.1</td>
<td>Inborn Errors of Metabolism</td>
<td>78</td>
</tr>
<tr>
<td>Ch. 6.2</td>
<td>Genetic Testing</td>
<td>85</td>
</tr>
</tbody>
</table>

## Section 7. Hematology

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ch. 7.1</td>
<td>Approach to the Bleeding Neonate</td>
<td>88</td>
</tr>
<tr>
<td>Ch. 7.2</td>
<td>Platelet Disorders</td>
<td>89</td>
</tr>
<tr>
<td>Ch. 7.3</td>
<td>Transfusion of Blood Products</td>
<td>90</td>
</tr>
<tr>
<td>Ch. 7.4</td>
<td>Pathophysiology and Differential Diagnosis of Jaundice</td>
<td>92</td>
</tr>
<tr>
<td>Ch. 7.5</td>
<td>Management of Neonatal Jaundice</td>
<td>94</td>
</tr>
<tr>
<td>Ch. 7.6</td>
<td>Polycythemia</td>
<td>97</td>
</tr>
<tr>
<td>Ch. 7.7</td>
<td>Neonatal Thrombosis</td>
<td>99</td>
</tr>
</tbody>
</table>
### Section 8. Infectious Diseases

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1</td>
<td>Bacterial Sepsis</td>
<td>104</td>
</tr>
<tr>
<td>8.2</td>
<td>Group B Streptococcus (GBS)</td>
<td>105</td>
</tr>
<tr>
<td>8.3</td>
<td>Cytomegalovirus (CMV)</td>
<td>107</td>
</tr>
<tr>
<td>8.4</td>
<td>Fungal Infection (Candida)</td>
<td>107</td>
</tr>
<tr>
<td>8.5</td>
<td>Gonococcal Disease</td>
<td>110</td>
</tr>
<tr>
<td>8.6</td>
<td>Hepatitis B</td>
<td>110</td>
</tr>
<tr>
<td>8.7</td>
<td>Hepatitis C</td>
<td>111</td>
</tr>
<tr>
<td>8.8</td>
<td>Herpes Simplex Virus (HSV)</td>
<td>112</td>
</tr>
<tr>
<td>8.9</td>
<td>Human Immunodeficiency Virus (HIV)</td>
<td>113</td>
</tr>
<tr>
<td>8.10</td>
<td>Respiratory Syncytial Virus (RSV)</td>
<td>114</td>
</tr>
<tr>
<td>8.11</td>
<td>Rotavirus</td>
<td>115</td>
</tr>
<tr>
<td>8.12</td>
<td>Syphilis, Congenital</td>
<td>115</td>
</tr>
<tr>
<td>8.13</td>
<td>Tuberculosis</td>
<td>116</td>
</tr>
<tr>
<td>8.14</td>
<td>Varicella-Zoster Virus (VZV)</td>
<td>117</td>
</tr>
<tr>
<td>8.15</td>
<td>Zika Virus</td>
<td>118</td>
</tr>
</tbody>
</table>

### Section 9. Neurology

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.1</td>
<td>Encephalopathy</td>
<td>122</td>
</tr>
<tr>
<td>9.2</td>
<td>Seizures</td>
<td>124</td>
</tr>
<tr>
<td>9.3</td>
<td>Cerebral Hemorrhage and Infarction</td>
<td>126</td>
</tr>
<tr>
<td>9.4</td>
<td>Neural Tube Defects</td>
<td>128</td>
</tr>
<tr>
<td>9.5</td>
<td>Drug-exposed Infants</td>
<td>129</td>
</tr>
<tr>
<td>9.6</td>
<td>Pain Assessment and Management</td>
<td>132</td>
</tr>
<tr>
<td>9.7</td>
<td>Vein of Galen</td>
<td>134</td>
</tr>
</tbody>
</table>

### Section 10. Newborn Care

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.1</td>
<td>Routine Care</td>
<td>138</td>
</tr>
<tr>
<td>10.2</td>
<td>Cardiac Murmurs</td>
<td>140</td>
</tr>
<tr>
<td>10.3</td>
<td>Dental</td>
<td>140</td>
</tr>
<tr>
<td>10.4</td>
<td>Dermatology</td>
<td>141</td>
</tr>
<tr>
<td>10.5</td>
<td>Extracranial Swelling</td>
<td>142</td>
</tr>
<tr>
<td>10.6</td>
<td>Feeding</td>
<td>143</td>
</tr>
<tr>
<td>10.7</td>
<td>Hospital Discharge</td>
<td>146</td>
</tr>
<tr>
<td>10.8</td>
<td>Neuromusculoskeletal</td>
<td>147</td>
</tr>
<tr>
<td>10.9</td>
<td>Newborn Screening</td>
<td>150</td>
</tr>
<tr>
<td>10.10</td>
<td>Urology</td>
<td>151</td>
</tr>
</tbody>
</table>

### Section 11. Gastroenterology

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.1</td>
<td>Spontaneous Intestinal Perforation</td>
<td>156</td>
</tr>
<tr>
<td>11.2</td>
<td>Intestinal Failure and Intestinal Rehabilitation</td>
<td>157</td>
</tr>
<tr>
<td>11.3</td>
<td>Cholestasis</td>
<td>158</td>
</tr>
<tr>
<td>11.4</td>
<td>Intravenous Lipid Emulsions</td>
<td>160</td>
</tr>
<tr>
<td>11.5</td>
<td>Gastroesophageal Reflux (GER)</td>
<td>161</td>
</tr>
</tbody>
</table>

### Section 12. Nutrition

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.1</td>
<td>Initiation and Intravenous Fluids</td>
<td>164</td>
</tr>
<tr>
<td>12.2</td>
<td>Parenteral Nutrition</td>
<td>165</td>
</tr>
<tr>
<td>12.3</td>
<td>Enteral Nutrition</td>
<td>167</td>
</tr>
<tr>
<td>12.4</td>
<td>Nutrition Assessment</td>
<td>178</td>
</tr>
<tr>
<td>12.5</td>
<td>Guidelines for Oral Feeding</td>
<td>179</td>
</tr>
<tr>
<td>12.6</td>
<td>Discharge Nutrition Preparation</td>
<td>181</td>
</tr>
</tbody>
</table>
Section 1: Care of Very Low Birth Weight Babies

Editors: Mohan Pammi and George Mandy

1.1 General Care (Babies <1500 Grams) .............2
  George Mandy
  Bernadette White

1.2 Specialized Care for ELGAN Babies ............3
  George Mandy
  Mohan Pammi

1.3 Umbilical Catheters ....................................... 4
  Mona Khattab
  Mohan Pammi
1.1 General Care (Babies < 1500 grams)

Example of Admission Orders

Each infant’s problems will be unique. Appropriate routines will vary by gestation and birth weight. Each order, including all medication doses and IV rates, must be individualized. In current practice each infant has a basic admission order set in the EMR. Additional orders are added per individual indication. The following categories of orders are common in VLBW infants.

Indicate

- Unit of admission (e.g., NICU) and diagnosis.

Order

- A humidified convertible incubator is preferred for infants with BW < 1250 grams or < 32 weeks. If servo-control mode of incubator is used, indicate servo skin temperature set point (usually set at 36.5°C).
- If only radiant warmer is available use plastic wrap blanket to reduce evaporative water loss for babies who weigh 1250 grams or less. Always use radiant warmer in servo-control mode.

Monitoring Orders

- Cardio-respiratory monitor.
- Oximeter - oxygen saturation target 90-95% for premature infants and term babies with acute respiratory distress (alarm limits 88-96%).
- Vital signs and blood pressure by unit routines unless increased frequency is indicated.
- Umbilical artery catheter (UAC) or peripheral arterial line to BP monitor if invasive monitoring is done.

Metabolic Management Orders

- I&O measurements.
- Type and volume of feeds or NPO.
- IV fluids or parenteral nutrition.
- If arterial line is in place, order heparinized NS at keep open rate per unit guidelines.

If a double lumen UVC or PICC, order heparinized NS at 0.3 cc/hr for UVC, 0.5 cc/hr for PICC

Respiratory Orders

- If infant is intubated, order ET tube and size.
- Standard starting ventilator settings for infants with acute lung disease:
  - Ventilator orders should include mode and settings:
    - CPAP – Bubble CPAP, level of continuous airway pressure
    - SIMV – rate, PIP, Ti, PEEP
    - A/C – PIP, Ti, PEEP, Back Up Rate
    - VG – Vt, Pmax, PEEP, Rate, Ti
    - FiO2 – as needed to maintain target saturations

Diagnostic Imaging

- Order appropriate radiographic studies.

- Order cranial US between 7 and 14 days of life.

- Labs
  - Admission labs: CBC with differential and platelets, blood type, Rh, Coombs, glucose
  - Obtain results of maternal RPR, HIV, GBS and hepatitis screens.
  - Order other routine labs.
  - Order labs to manage specific conditions as needed (e.g., electrolytes at 12 to 24 hours of life).
  - Order newborn screen at 24 to 48 hours of age and DOL 14.

Medication Orders

Medication orders commonly include:

- vitamin K – 0.5 mg IM.
- eye prophylaxis – erythromycin ophthalmic ointment.
- surfactant replacement (as indicated) – (indicate BW, product and dose needed) (Sec 2- Respiratory Care).
- antibiotics – if infant is considered to be at risk for sepsis (Ch 8.1-Bacterial Sepsis).
- caffeine citrate (for infants BW 1250 grams or less) – 20 mg/kg loading dose followed by 5-10 mg/kg/day given once daily. Initiate therapy within first 10 days of life.
- Vitamin A (for infants BW 1000 grams or less) – if available, give 5000 IU intramuscularly every Monday Wednesday and Friday for a total of 12 doses.
- Prophylactic indomethacin – see below (for babies ≤ 26 weeks gestation or ≤ 800 g. birth weight)

Screens and Follow-up

- Order hearing screen before hospital discharge. Hearing screens should be performed when the baby is medically stable, > 34 weeks postmenstrual age and in an open crib.
- Order ophthalmology screening for ROP if:
  - less than or equal to 1500 grams birth weight or 30 weeks’ gestation or less
  - 1500 to 2000 grams birth weight or greater than 30 weeks’ gestation with unstable clinical course where physician believes infant is at risk for ROP.
- Before discharge,
  - observe infant in car safety seat for evidence of apnea, bradycardia, or oxygen desaturation,
  - offer CPR training to parents,
  - schedule high-risk follow-up clinic as recommended below,
  - write orders for palivizumab as appropriate.
- Schedule other laboratory screening tests as recommended below.

Suggested Lab Studies

These labs are appropriate for many VLBW admissions to NICU and are provided as a general guideline. Many babies
Table 1-1. Admission labs

<table>
<thead>
<tr>
<th>Test</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC, platelets</td>
<td>at admission</td>
</tr>
<tr>
<td>Blood culture, ABG</td>
<td>at admission, if appropriate</td>
</tr>
<tr>
<td>Glucose screening</td>
<td>at 30 minutes of age</td>
</tr>
<tr>
<td>Electrolytes, glucose</td>
<td></td>
</tr>
<tr>
<td>BUN</td>
<td>12 or 24 hours of age (depends on infant’s size and metabolic stability)</td>
</tr>
<tr>
<td>Calcium (ionized)</td>
<td>at 24 and 48 hours of age</td>
</tr>
<tr>
<td>Total Serum Bilirubin</td>
<td>at 24 hours of age or if visibly jaundiced (depends on size, presence of bruising, ABO-Rh status)</td>
</tr>
<tr>
<td>Newborn screens</td>
<td></td>
</tr>
<tr>
<td>First screen</td>
<td>at 24 to 48 hours of age</td>
</tr>
<tr>
<td>Second screen</td>
<td>Repeat newborn screen at 14 days</td>
</tr>
</tbody>
</table>

Table 1-2. Labs during early hospitalization, days 1 to 3

<table>
<thead>
<tr>
<th>Test</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrolytes, glucose</td>
<td>Every 12 to 24 hours (depends on infant’s size and metabolic stability)</td>
</tr>
<tr>
<td>BUN</td>
<td>24 and 48 hours of age</td>
</tr>
<tr>
<td>Calcium (ionized)</td>
<td>at 24 hours of age</td>
</tr>
<tr>
<td>TSB</td>
<td>every 24 hours of age (depends on size, presence of bruising, ABO-Rh status, pattern of jaundice)</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>every 24 to 48 hours of age (depends on size, previous hematocrit, and ABO-Rh status)</td>
</tr>
</tbody>
</table>

will not require this volume of tests, others will require more. Review this list with the Attending Neonatologist. Review scheduled labs during daily rounds and eliminate those no longer necessary (Table 1–1 and Table 1–2).

**Follow-up**

In addition to high risk developmental follow up, many VLBW infants will require specific follow-up for CNS, cardiac, renal, ophthalmologic, or otologic function as well.

**Cranial ultrasounds (US)** - Order US for infants ≤ 1500 grams birth weight between 7 and 14 days of age. When the baby reaches term or at discharge, another US is recommended to detect cystic periventricular leukomalacia (PVL). Infants with US that demonstrates significant IVH require follow-up ultrasounds (weekly, every other week, or monthly) to identify progression to hydrocephalus.

**Screening for retinopathy of prematurity (ROP)** – Initial and follow-up eye exams by a pediatric ophthalmologist should be performed at intervals recommended by the American Academy of Pediatrics. If hospital discharge or transfer to another neonatal unit or hospital is contemplated before retinal maturation into zone III has taken place or if the infant has been treated by ablation for ROP and is not yet fully healed, the availability of appropriate follow-up ophthalmologic examination must be ensured and specific arrangements for that examination must be made before such discharge or transfer occurs.

**Development Clinic** – TCH Infants who weigh less than 1500 grams at birth should be scheduled for the Desmond Developmental Clinic at four months adjusted age. Infants with HIE, Twin-Twin Transfusion syndrome or those requiring ECMO should also be referred. Patients in these categories should have an initial developmental consultation and evaluation before discharge. Other infants whose clinical course placing them at high risk will be scheduled on an individual basis.

**Hearing screen** – Perform a pre-discharge hearing screen on all infants admitted to a Level 2 or 3 nursery. Infants with congenital cytomegalovirus (CMV), bronchopulmonary dysplasia (BPD), or meningitis and infants treated with ECMO might have a normal screen at discharge but later develop sensorineural hearing loss.

**Monitoring for anemia** – Laboratory testing (a hemoglobin/hematocrit with a reticulocyte count, if indicated) to investigate the degree of physiologic anemia of prematurity should be considered as needed based upon clinical status, need for positive pressure or oxygen support, size, recent phlebotomies, and most recent hematocrit. Frequency of such testing may vary from every 1 to 2 weeks in the sick, tiny premature infant on positive pressure support to once a month or less in a healthy, normally growing premature infant. Efforts should be made to cluster such routine sampling with other laboratory tests.

### 1.2 Specialized Care for ELGAN Babies

The following care procedures are recommended initial management for Extremely Low Gestational Age Neonates born at ≤ 28 weeks.

**Prompt Resuscitation and Stabilization**

Initiate prompt resuscitation and stabilization in the delivery room with initiation of CPAP, or intubation and surfactant replacement if needed.

**Volume Expansion**

Avoid use of volume expanders. But if given, infuse volume expanders over 30 to 60 minutes. Give blood transfusions over 1 to 2 hours. A pressor agent such as dopamine is preferable to treat nonspecific hypotension in babies without anemia, evidence of hypovolemia, or acute blood loss.

**Respiratory Care**

Determination of the need for respiratory support in these infants after delivery should include assessment of respiratory effort and degree of distress. ELBW infants who are vigorous and have good respiratory effort at birth should be placed on NCPAP immediately. If respiratory distress develops or pulmonary function subsequently deteriorates, the infant should be intubated and given early rescue surfactant (within first 2 hours). *(See Ch 2.3 Management of Respiratory Distress)*. The goal of care is maintenance of adequate inflation of the immature lung and early, selective surfactant replacement in those exhibiting respiratory distress to prevent progressive atelectasis. Achieving adequate lung inflation and assuring correct ET tube position before dosing are essential for uniform distribution of surfactant within the lung (correct ET position may be assessed clinically or by radiograph).

After initial surfactant treatment, some babies will exhibit a typical course of respiratory distress and require continued ventilation and/or repeat surfactant doses. However, many will have rapid improvement in lung compliance. Rapid improvement in lung compliance necessitates close monitoring and prompt reduction in ventilator PIP (or VT) and FiO₂. Initial reduction in ventilator settings after surfactant should be determined by clinical assessment (e.g., adequacy of chest rise).
A major benefit of the Volume Guarantee ventilator mode is the “self-weaning” function it provides. As lung compliance improves, ventilator PIP is progressively reduced to maintain the chosen target tidal volume. Monitor clinically and obtain blood gases within 30 minutes of dosing and frequently thereafter. When ventilator support has been weaned to minimal levels, attempt extubation and place infant on nasal CPAP. Minimal support includes:

- FiO₂ 30% or less
- PIP 20 cm or less
- VT 4-4.5 ml/kg (VG)
- Rate less than 25/min if on SIMV
- PEEP 5-6 cm

In extremely immature infants, the decision to extubate must be individualized. Rapid extubation after surfactant administration may not be possible or desirable in some of these infants.

### Caffeine Citrate

Evidence indicates that caffeine citrate started during the first 10 days of life in infants with BW 1250 grams or less decreases the rate of bronchopulmonary dysplasia without short term adverse effects and improves neurodevelopmental outcome at 18 months. All infants with a BW 1250 grams or less (whether or not on positive pressure ventilation) should be started on caffeine citrate (20 mg/kg loading dose followed by 5 to 10 mg/kg maintenance dose) within the first 10 days of life. It should be continued until drug therapy for apnea of prematurity is no longer needed.

### Prophylactic Indomethacin

Prophylactic indomethacin significantly reduces occurrence of symptomatic PDA, PDA ligation and, to a lesser extent, grade IV IVH in ELGAN babies. Administer indomethacin (if available) during the first 12 hours of life to babies less than or equal to 26 weeks gestation or less than or equal to 800 grams birth weight as follows:

- First dose: (within first 12 hours) – 0.1 mg/kg of birth weight
- Second dose: (24 hours after first) – 0.1 mg/kg of birth weight
- Third dose: (48 hrs. after initial dose) – 0.1 mg/kg of birth weight

Monitor platelet count daily. Subsequent doses should be held if infant is oliguric (< 0.5 ml/kg/hr), platelets fall below 50,000, overt bleeding occurs or infant requires corticosteroids for circulatory support.

### Measures to Minimize Blood Pressure Fluctuations or Venous Congestion

- Do admission weight and measurements. Infants in incubator/warmers should have daily weights performed using the in-bed scale.
- Take vital signs from monitors.
- Routine suctioning during the first 24 to 48 hours of life usually is not necessary. If routine suctioning becomes necessary, sedation may be needed to blunt effects.
- Minimize peripheral IVs, heel punctures, etc. Use the umbilical venous catheter (UVC) for glucose infusions.

Infuse normal or half normal saline via the umbilical arterial catheter (UAC), and use the UAC to draw needed blood gases, lab work, and glucose screening.

- Repeatedly observe infants for signs of loss of airway or of airway dysfunction related to ET-tube displacement or obstruction.
- A humidified convertible incubator is preferred. If a radiant warmer is used for a VLBW infant, cover infant with plastic wrap to reduced evaporative water and heat loss.

### 1.3 Umbilical Catheters

#### Background

Although umbilical artery and vein catheters are widely used, the potential for serious complications is significant. Reported complications requiring catheter removal range from 5.5-32% for UACs and 10-50% for UVCs. CLABSI is a complication of umbilical catheterization and indwelling vascular catheters account for a major proportion of hospital acquired infections.

Severe complications of UVC placement (excluding CLABSI) include: vena cava or right atrial thrombosis, portal vein thrombosis, hepatic vein thrombosis, hepatic hematoma or infarct. Percardial effusion and tamponade also occur. Duration of catheterization and catheter position are the most commonly associated risk factors. The appropriate central position is achieved in 30-73% of attempts. One prospective observation study of 100 neonates using serial ultrasound demonstrated: 64% - satisfactory position, 12% in liver, 15% below liver and 8% in a portal vein or branch. “Silent” portal vein thrombosis was detected in 43%, with significant increase in risk after 6 days duration. Portal vein thrombosis in considered a major complication of UVC use because of its association with long term portal hypertension. Severe complications do occur in infants with appropriate catheter position. However, any position other than the ideal central location is accompanied by significantly increased risk of serious events or adverse long-term outcome.

Risks of UAC placement include vasospasm, thrombosis, systemic embolization, organ ischemia or injury to a lower extremity. “High” position (T6-T9) UACs and 10-50% for UVCs. CLABSI is a complication of umbilical catheterization and indwelling vascular catheters account for a major proportion of hospital acquired infections.

#### Common Indications for UVC

- <1250 g BW
- >4 PIV attempts
- Hypoglycemia
- Need for high osmolar infusion (Ca, Mg or >12.5% glucose) or certain vasoactive drugs
- Need for PGE infusion
- Resuscitation
- Exchange transfusion or partial exchange
- Potential ECMO (especially CDH)
- Patients with severe cardiopulmonary compromise- as individually selected
Potential Indications for Double Lumen UVC
- < 1000 g BW
- PGE
- ECMO likely

Common Indications for UAC
- < 1000 g or < 26 weeks
- Cardiopulmonary compromise requiring frequent blood gas or BP monitoring
- CHD requiring specific care or interventions
- Potential ECMO
- Respiratory distress following resuscitation

Contraindications for Umbilical Catheterization
- Patient has active infection (positive blood cultures, specific signs of systemic infection)
- Abnormal or distorted anatomy that produces catheter malposition (relative)
- Abdominal wall defects: omphalocele, gastroschisis
- NEC
- Vascular compromise of lower extremities or target organs.
- Thrombosis of target vessel

Catheter Size
- 3.5 Fr. for < 1500 g
- 3.5 - 5 Fr for > 1500 g
- 8 Fr – a specially designed catheter for exchange transfusion in term sized infants

UVC Catheter Placement Position
Optimal catheter position is junction of IVC and right atrium. This corresponds to a position just above the diaphragm or between the T9-10 vertebrae. There are several published formulae and graphs to estimate the required depth of placement of UVCs, none of which is perfectly predictive. Based on consensus, the Baylor Neonatology Division recommends the modified Shukla formula:

\[
\text{Insertion depth} = \frac{3 \times \text{BW in kg} + 9 \text{ cm}}{2}
\]

This formula reduces the incidence of over insertion without increasing that of under insertion. In a recent RCT the authors reported a low rate of correctly positioned UVC catheters but no difference between use of this formula and that of classic graphs derived from body surface measurements (31% vs 28%).

If a suboptimal catheter position must be used for initial stabilization, obtain alternate access as soon as possible. If UVC catheter is in liver, pull back to low position if catheter must be used temporarily to achieve stabilization. Avoid infusion of medications or hyperosmolar solutions if not in central position.

A low-lying UVC should only be used for temporary vascular access when suitable alternative access is not available or patient condition is critical and unstable. In these circumstances the catheter should be replaced as soon as possible by either an optimally placed UVC (second attempt at UVC placement), a PICC or peripheral IV.

UAC Catheter Position
Optimal catheter tip position is above the diaphragm between T6-T9. This is the “high” position recommended in most publications. A Cochrane database systematic review concluded the “high” position resulted in fewer vasospastic, ischemic and thrombotic complications as compared to low lying catheters.

There are several published formulae and graphs to estimate the required depth of placement of UACs, none of which is perfectly predictive. By consensus, the Baylor Neonatology Division recommends use of the weight based formula of Shukla and Ferrara:

\[
\text{Depth of insertion} = (3 \times \text{BW in kg}) + 9 \text{ cm}
\]

A recent RCT comparing use of the Shukla weight based formula to use of graphs derived from body surface measurements reported a significantly higher rate of correct UAC positioning using the weight based formula (91% vs 50%, \(p=0.001\))

Duration of Catheterization
Umbilical catheters should be removed as soon as possible.

Recommended maximum duration of use:
- UAC < 5 days
- UVC < 7 days Any special circumstance necessitating prolonged duration should be documented in the medical record

At TCH, the Vascular Access Team (VAT) is available 24/7 to assist with alternative central access. However, availability of PICC placement is limited in many other Baylor affiliated nurseries.

“Second Attempt” at Catheter Placement
A second attempt at successful catheter placement is not precluded but should be restricted to the time frame of the original procedure. An exception is that of catheter placement for exchange transfusion or partial exchange, as these
procedures may occur later in the clinical course. We do not recommend the “2 catheter” technique for repeat attempts.

**Indications for Umbilical Catheter Removal**

**CLABSI**
If essential for medications, remove as soon as medications completed or alternative route established

Do not keep for blood sampling only unless frequent sampling is essential and alternate access not feasible.

**NEC**
UAC – Vascular thrombosis or persistent vasospasm or ischemia of lower extremity (not promptly improved by warming contralateral extremity)

**Confirmation by Imaging and Documentation in the Medical Record**
Because estimation of catheter position by formulae or graphs often leads to excessively high or low placement of the catheter tip, radiographic confirmation is essential. Insertion to correct estimated depth does not guarantee proper position of catheter tip. Radiographic (or occasionally US) confirmation of position should be obtained after catheter placement or re-positioning. The procedure of umbilical catheter placement is not complete until there is clear radiographic documentation of optimal catheter position.

The EMR procedure note should document: (a) if the initial radiograph reveals the catheter to be too high, the extent by which the catheter was pulled back prior to obtaining the follow up radiograph; (b) the final depth of placement of the catheter; (c) reasons for leaving a sub-optimally placed catheter in place if this is necessary.

**Maintenance of Umbilical Catheters in an Optimal Position**
Umbilical catheters, even if optimally placed, may become displaced if patient is moved, the abdomen becomes distended or if they are not secured well. They are also at risk of accidental dislodgement with serious consequences, bleeding. The depth of insertion of the catheter should be documented by the bedside nurse each shift and should be reviewed by the clinical team as part of daily patient rounds and the continued need should be documented in the medical record. If the depth of insertion is found to be different from the original depth, or if there is suspicion of displacement or misplacement, a radiograph or ultrasound study should be obtained.

**Possible Variances**
A small proportion of patients have complex clinical circumstances that may necessitate longer than recommended duration of an umbilical catheter or short term use of a low lying UVC. Such instances must be individualized and the attending physician must determine and document the risk versus benefit evaluation. The medical record note should document reasons for the alternate care strategy employed and more desirable options sought as soon as possible.
Potential variances include:

1. Critical CDH patients
2. 23-24 week ELGAN
3. Persistent hypoglycemia
4. Long term PGE
5. Need for frequent lab work
6. Limited availability of alternative vascular access

Miscellaneous

1. Do not infuse medications or TPN through UAC
2. Presence of an umbilical catheter does not preclude trophic feeds.
3. Avoid air in catheter set up – many neonates still have anatomic R-L shunts.

Suggested Reading


Section 2: Respiratory Care
Editors: Caraciolo Femandes, Lakshmi Katakam, and Binoy Shivanna

2.1 Delivery Room Stabilization .................................. 10
Regine Fortunov
Nathan C. Sundgren

2.2 Control of Breathing and Apnea of Prematurity .................. 11
Rita Shah
Lisa Owens

2.3 Management of Neonatal Respiratory Distress ...................... 13
George Mandy
Pablo Lohmann
Jennifer Placencia

2.4 Non-Invasive Respiratory Support ............................... 14
Shweta Parmekar
Bheru Gandhi
Joseph Garcia-Prats

2.5 Weaning from CPAP and Nasal Cannula ........................... 17
Lakshmi Katakam
Binoy Shivanna

2.6 Conventional Ventilation of Preterm and Term Neonates ............ 18
Pablo Lohmann
Lakshmi Katakam

2.7 High-frequency Oscillatory Ventilation (HFOV) ..................... 22
Jonathan Davies
Bheru Gandhi

2.8 Bronchopulmonary Dysplasia .................................... 24
Milenka Cuevas Guaman
Rita Shah

2.9 Prevention of Bronchopulmonary Dysplasia ........................ 30
Milenka Cuevas Guaman
Lakshmi Katakam

2.10 Interdisciplinary Care and Discharge Planning of the Ventilator Dependent Patient.. 31
Joseph Garcia-Prats
Lois Tracy

2.11 Pulmonary Hypertension in Lung Diseases ........................ 32
Danielle R. Rios
Nidhy Paulose Varghese

2.12 Congenital Diaphragmatic Hernia .................................. 33
Milenka Cuevas Guaman
Jamie Gilley

2.13 Neonatal ECMO ................................................... 35
Chris Dischler
Joseph Garcia-Prats
Jamie Gilley
2.1 Delivery Room Stabilization

Overview
In the delivery room, 4-10% of all term and late preterm newborns receive positive-pressure ventilation (PPV), but only 1 to 3 per 1000 receive chest compressions. NRP prepares team members to respond to resuscitations in a standardized format and encourages using teamwork behaviors to communicate effectively with each other. We describe here evidence based approaches to stabilizing a newborn’s respiratory and cardiovascular status in the delivery room.

 Continuous Positive Airway Pressure (CPAP) First
“CPAP first” approach with rescue surfactant therapy has been shown to be superior to intubation and prophylactic surfactant administration for prevention of bronchopulmonary dysplasia (BPD). Preterm infants treated with early CPAP in the delivery room are not at greater risk for any major adverse outcomes. Randomized clinical trials have demonstrated that premature infants of gestational age (GA) 24 weeks and above can be effectively stabilized on CPAP without intubation or surfactant administration. Thus, a spontaneously breathing preterm newborn should be stabilized on CPAP first whenever possible.

In practical terms, a CPAP first strategy requires team effort and coordination. It takes time for a preterm infant to transition and demonstrate consistent respiratory effort, establish lung volume and maintain stable oxygen saturations.

1. We recommend that all neonates ≤30 weeks GA be placed on CPAP immediately on arrival to the warmer in the delivery room. Neonates who are between 30 and 34 weeks GA should be stabilized with CPAP only if signs of respiratory distress are noted.
2. The initial steps of the NRP algorithm, including assessment of respiratory effort and heart rate, can be performed while the baby is receiving CPAP.
3. PPV is indicated in the first 60 seconds of life if the infant is gasping, not breathing or if the heart rate is <100 beats per minute. Neonates may require alternating between PPV and CPAP until a consistent spontaneous breathing pattern is established.
4. Adjust FiO₂ during resuscitation using the minute specific saturation targets specified in the NRP guidelines. It is common for newly born preterm infants to temporarily require higher FiO₂ to achieve target saturations until the lungs are optimally recruited. Providers may opt to wait and administer surfactant after NICU admission if high oxygen requirement is the only indication for intubation.
5. Infants who are ≥30 weeks GA may be able to wean from CPAP in the delivery room. Monitor closely for symptoms of loss of functional residual capacity, hypoxia and increased work of breathing during the weaning process.

CPAP failure can occur in up to 50% of babies stabilized with a ‘CPAP first’ approach. Therefore, it is critical that strategies aimed at optimizing CPAP delivery are not limited to the delivery room and are continued during and after NICU admission. Early caffeine administration can be considered to decrease the likelihood of CPAP failure.

Positive Pressure Ventilation (PPV)
“Ventilation of the newborn’s lungs is the single most important and effective step in neonatal resuscitation” – NRP guidelines.

Providing effective ventilation is the foundation for resuscitation in the delivery room. PPV or delivery of a set pressure can be accomplished using devices such as a flow inflating (anesthesia) bag, T-piece resuscitator or self-inflating bag to move air in and out of the lungs. These devices can be used with a number of patient interfaces such as mask, endotracheal tube (ETT), laryngeal mask airway (LMA) or tracheostomy tube. In the delivery room, the starting pressures used for resuscitation are a PEEP of 5 cm H₂O and PIP of 20-25 cm H₂O. Great caution should be taken to limit lung injury during resuscitation and ensure that excessive or high pressures are not delivered intentionally or unintentionally. There is little evidence comparing flow-inflating bags to t-piece resuscitators and therefore it is unclear if one is superior to the others. Using the T-piece resuscitator allows users to set PIP and PEEP and not inadvertently deliver higher than intended pressures. When using the different type of resuscitation bags, providers must use a pressure gauge to closely monitor and deliver consistent and safe pressures with each breath, being mindful of the frequency and pressure being delivered at any given time, and not simply rely on subjective measures or the “feel” of lung compliance.

Assessment of effective ventilation relies on heart rate and chest rise. The most important indicator of effective ventilation is a rising heart rate. Thus, after 15 seconds of PPV, the heart rate response should be assessed. ECG is recommended for continuous and accurate assessment of heart rate. If the heart rate is NOT rising after providing PPV for 15 seconds, then chest rise must be assessed. If the heart rate is NOT rising but there IS good chest rise, then ventilation may be effective and the patient needs more time to show a response. Continue with PPV that moves the chest for a total of 30 seconds before deciding on further interventions. If the heart rate is NOT rising and the chest is NOT moving then ventilation is NOT effective. Take corrective steps using the mnemonic MR. SOPA (see Fig 2-1) until you are able to provide PPV that moves the chest for 30 seconds.

Alternative Airway
If PPV by face mask does not result in adequate chest rise or has not increased the heart rate, then an alternative airway such as ETT or LMA should be placed.

The LMA is used infrequently in the neonatal population. However, it should be considered in cases where the provider is unable to ventilate effectively and unable to place an ETT. A recent Cochrane review comparing LMA and bag mask ventilation noted comparable efficacy and decreased resuscitation and ventilation times as well as the decreased need for endotracheal intubation with LMA use (weak recommendation, low to moderate quality evidence).
NRP no longer recommends routine intubations for the presence of meconium stained amniotic fluid. However, if an infant is not responding to PPV and airway obstruction due to meconium is suspected, a meconium aspirator can be used after intubation to suction and clear the airway. Suctioning of meconium should occur before providing PPV via ETT. An LMA cannot be used for suctioning meconium.

Circulatory Resuscitation
When optimizing ventilation does not adequately stabilize an infant, circulation must be supported by chest compressions and medications (primarily epinephrine) after effective ventilation has been established. The NRP algorithm emphasizes the need for an alternative airway BEFORE beginning chest compressions, highlighting the importance of providing effective ventilation and the difficulty of coordinating optimal positioning for chest compressions and bag mask ventilation.

If the heart rate of an infant is <60 beats per minute despite effective ventilation, then chest compression should be initiated and continued for at least 1 minute and until the heart rate is >60 bpm. The ratio of coordinated chest compressions to breaths is 3:1. If the need for resuscitation is thought to be primarily of cardiac origin, then NRP recommends a higher ratio of 15:2, as dictated by PALS algorithm, may be used. If chest compressions do not result in heart rate >60 bpm, epinephrine should be given IV or IO (0.1 to 0.3 mL/kg of 1mg/10mL concentration) as the first line medication.

Notable NRP Updates
1. www.aap.org/nrp
2. The pulse oximeter sensor may be attached to the baby first or to the monitor first as the difference in signal acquisition is small.
3. Leave the cap of the T-piece uncovered when giving free-flow oxygen. This provides a consistent approach for delivering free flow oxygen and CPAP and decreases the potential to inadvertently deliver high pressures.

2.2 Control of Breathing and Apnea of Prematurity
Respiratory drive originates in the CNS (the initiator) and signals are transmitted via afferent pathways to the remote respiratory pump mechanism (the responder). Information regarding the response of the respiratory pump is relayed back to the CNS, which automatically adjusts the nature of subsequent breaths. This modulation function is facilitated by certain modifiers which promote more precise adjustment of the control-of-breathing mechanism.

Periodic breathing consists of short, recurring pauses in respiration of 5-10 second duration. Pathologic apnea is usually defined as the complete cessation of airflow for 15-20 seconds or greater, typically associated with bradycardia and/or oxygen desaturation. However, hypoxia or bradycardia may occur with pauses of shorter duration. The incidence of apnea increases progressively with decreasing gestational age, particularly below 34 weeks. Apnea may be central or obstructive but in premature infants usually is mixed.

Factors contributing to abnormal control-of-breathing or apnea
- Central respiratory drive
- Maintenance of airway patency
- Respiratory pump

Central Respiratory Drive
Fetal respiratory control is characterized by periodic breathing alternating with periods of apnea. Fetal respirations are accompanied by normal heart rate variability, an important sign of fetal well-being. The prematurely delivered fetus continues to exhibit alternating periodic breathing and apnea in the postnatal state. Maturation is the most important factor determining rhythmic respiratory drive in the neonate. In premature infants, central respiratory drive is diminished and improves progressively with increasing PCA (particularly beyond 34 weeks).

Sleep State
Control of breathing is most disorganized and periodic during REM sleep. Immature infants spend most of their time asleep and approximately 65% of sleep time is REM sleep. Therefore, they are quite vulnerable to apneic episodes.

Temperature
A stable thermal environment promotes rhythmic breathing and thermal fluctuations promote apnea. In one study up to 90% of apneic episodes in premature infants occurred during fluctuations in the thermal environment. About two thirds occurred during an increase in air temperature and the rest when the temperature was falling. Therefore, use of techniques to maintain stability of the thermal environment, such as servo-control, are essential to the proper management of an infant with apnea.

Chemoreceptors
Chemoreceptor function is impaired in immature infants as indicated by:
1. Depressed ventilatory response to CO₂ which is more pronounced in infants with apnea
2. Hyperoxia reduces carotid body response, which may induce apnea
3. Preterm infants exhibit a biphasic ventilatory response to hypoxia. Initially peripheral chemoreceptor (carotid body) activity is stimulated and induces a transient increase in minute ventilation. However, by 3-5 minutes this response becomes blunted due to superimposed central respiratory depression. This depressed ventilatory response may exacerbate frequency or severity of apneic episodes.

Lung Volume
Maintaining an ideal resting lung volume or functional residual capacity (FRC), enhances rhythmic respiratory drive while a low lung volume exacerbates periodic breathing and apnea. Maintaining lung volume is a role of the respiratory pump.

Airway Patency and Airway Receptors
A system of conducting airways and terminal lung units exist to promote respiratory gas exchange between the environment and the alveolar-capillary interface as well as provide humidification.
A complex set of neuromuscular functions and reflexes protects the patency of the upper airway and may be impaired by immaturity, illness or drugs. Like the other components of control of breathing, maintaining airway patency is primarily a function of maturity, but this function may be further modified by additional factors. Disorders of upper airway function that affect control of breathing do so primarily in the form of fixed obstruction or hypopharyngeal collapse.

**Nose**

Newborn infants usually are considered obligate nose breathers and, thus, depend upon nasal patency for adequate ventilation. However, about 30% of term infants demonstrate mixed oro-nasal breathing during both quiet sleep and REM sleep. During such episodes, the distribution of tidal volume is 70% nasal and 30% oral. About 40% of term infants respond to airway occlusion with sustained oral breathing, although with reduced tidal volume. In a premature infant, however, compensatory mechanisms are poor and nasal obstruction commonly exacerbates apnea. It is essential to assure adequate nasal patency in such infants.

**Hypopharynx**

Intact hypopharyngeal function is the most important factor in maintaining upper-airway patency during infancy and inadequate integration of this complex function is the primary cause of obstructive apnea. The upper airway is a collapsible tube subjected to negative pressure during inspiration. When airway resistance increases (as in neck flexion or nasal obstruction), the upper airway is subjected to greater inspiratory negative pressure.

Pharyngeal muscle function is immature and poorly coordinated in very preterm infants and is further impaired during sleep. This reduced hypopharyngeal tone leads to pharyngeal collapse and obstructive apnea. Flexion of the neck exacerbates the degree of airway obstruction. These factors are the main contributors to obstructive apnea in premature infants.

The primary effect of CPAP in managing apnea is that of splinting the hypopharynx and opposing pharyngeal collapse and obstructive apnea. Xanthisenes enhance the function of the hypopharyngeal musculature. Avoid flexion of the neck at all times. Most sudden flurries of apnea in premature infants are related to the loss of upper-airway patency.

**Larynx and Trachea**

The larynx and trachea are more rigid than the hypopharyngeal structures and are more resistant to airway collapse. However, laryngeal function may be impaired by immaturity, edema, or vocal cord dysfunction. Any of these entities producing airway obstruction would exacerbate control-of-breathing problems.

**Respiratory Pump**

The respiratory pump consists of lungs, the bony chest cage, the diaphragm, the intercostal muscles, and the accessory muscles of respiration. The developmental and functional aspects of each are closely related to gestational age. The respiratory pump serves 2 important functions in relation to control of breathing:

1. Maintains an adequate resting lung volume (Functional Residual Capacity), which facilitates rhythmic, rather than oscillatory, central respiratory drive. An ideal FRC allows each breath to be taken from an efficient point on the pressure-volume curve and is a reservoir for continued oxygen uptake between tidal breaths.

2. Produces adequate tidal gas exchange and normal oxygen and carbon dioxide tensions in arterial blood, which provides normal chemoreceptor feedback to maintain rhythmic central respiratory drive.

The structurally and functionally immature respiratory pump of a premature infant is a main contributor to apnea of prematurity.

**Bony Thorax**

Ribs are rigid, bony structures that lift the chest cage and expand its volume when the intercostal muscles contract during inspiration. In an immature infant, the ribs are thin and poorly mineralized. These pliable, cartilaginous structures may be unable to resist the retractive forces of the lung and chest wall and may fail to maintain an adequate FRC. On occasion, the chest cage may be so pliable that the chest wall collapses during inspiration, resulting in inadequate tidal volume and uneven distribution of ventilation. Lack of rigidity in the bony thorax of a premature infant is an important component in apnea of prematurity.

**Intercostal Muscles**

The intercostal muscles contract to expand the bony thorax during inspiration. They also maintain resting tone at end-expiration to promote the continuous negative pleural pressure necessary to maintain an adequate FRC. This mechanism is disorganized during REM sleep in premature infants, resulting in loss of chest wall stability, leading to loss of lung volume and exacerbation of apnea. These effects of immaturity can be opposed with the use of CPAP and xanthisenes.

**Diaphragm**

The diaphragm works in conjunction with the bony chest and intercostal muscles to promote uniform expansion of the internal thoracic volume. This promotes efficient tidal breathing and maintains FRC. Functional efficiency of the diaphragm may be impaired by reduction in muscle fiber mass or contractile strength, supine posture, or changes in configuration. Postural tone loss in the diaphragm often occurs during REM sleep in premature infants. Strength of contraction and efficiency of resting tone are enhanced by xanthisenes.

**Apnea of Prematurity**

Central respiratory drive and upper-airway patency are poorly integrated in infants less than 32-34 weeks’ gestation. Thus, the incidence of apnea is high in such infants. These infants are extremely vulnerable to the effects of REM sleep, nasal or pharyngeal airway obstruction, or intercurrent illness. Infants born at 25 weeks gestation or less may continue to exhibit immature control of breathing at term and, occasionally, out to 44 weeks PMA. Basal control of breathing improves significantly in many infants after 32-34 weeks but introducing new tasks, such as feeding, may be accompanied by episodes of cyanosis, hypoxemia, or bradycardia. These are not episodes of apnea and they occur during the waking state. They are manifestations of immature pharyngeal mechanisms resulting in impaired coordination of suck/swallow and breathing.

Improved understanding of control of breathing in infants has led to the introduction of effective management tools to deal with apnea of prematurity. Usually it is possible to significantly reduce the frequency and severity of such episodes. Decisions to
treat are based on frequency of episodes and whether the episodes produce bradycardia or hypoxemia that requires significant intervention.

**Treatment of Apnea**
All infants with apnea should be nursed in a stable thermal environment using servo-controlled incubators. It is critical to avoid flexion of the neck and airway closure. Assure adequate oxygenation in an infant with apnea or periodic breathing both while awake and asleep. Some apneic infants may not maintain desired target oxygen saturation and thus best practices would indicate the need to treat the underlying cause e.g. V/Q mismatch, central apnea etc. Monitor adequacy of nasal patency.

**Xanthines**
These agents enhance rhythmic respiratory drive, enhance CO₂ response, reduce REM sleep, enhance resting pharyngeal muscle tone, and strengthen force of contraction of the diaphragm. They affect both central and obstructive apnea. Over 75% of apnea of prematurity episodes can be significantly modified with xanthine therapy alone. Caffeine citrate is the drug of choice for apnea of prematurity because of its wide therapeutic index and reduced cardiovascular effects. It increases respiratory rate and minute ventilation with little effect on tidal volume or heart rate. It may be given intravenously or enterally.

**Nasal CPAP**
Nasal CPAP enhances rhythmic control of breathing primarily by opposing pharyngeal collapse and minimizing obstructive apnea. By itself, the technique is effective in controlling about one third of apneic episodes in premature infants. Nasal CPAP is most effectively delivered using short, silastic, double nasal prongs, which minimize nasal trauma and have the lowest possible flow resistance. Initiate CPAP with 5-6 cm H₂O pressure. Increase pressures if necessary but levels above 8 cm H₂O should be needed only rarely. Immature infants requiring CPAP to control their apnea often need it until they reach a gestational age at which pharyngeal muscle control begins to mature (32-34 weeks). However, in babies born at 27 weeks gestation or less the need for CPAP may persist for a much longer duration.

**Role of Anemia**
Anemia, particularly progressive physiologic anemia of prematurity, may exacerbate the frequency or severity of apnea. Transfusion of PRBCs may produce a short-term reduction in the frequency of apnea in such infants. There is no evidence to support long-term resolution of apnea following transfusion. Neither the incidence of apnea nor the response to transfusion is related to the actual hematocrit value.

**Role of Gastroesophageal Reflex**
There is no evidence of a causal relationship between GER and apnea of prematurity. There is no relation between reflux frequency or duration and apnea frequency or severity. Current evidence does not support the use of anti-reflux medications to treat apnea of prematurity and these medications may be associated with increased morbidity.

**Medications**
**Caffeine Citrate**
Loading dose is 20 mg/kg followed by an initial maintenance dose of 5 mg/kg given once daily. If apnea persists, maintenance dose may be increased to maximum of 10 mg/kg/day. The therapeutic range for serum levels is 10 to 20 mg/L. but current evidence does not support a role for routine monitoring of serum caffeine levels because of poor correlation between serum levels and adequacy of control of apnea. We typically discontinue caffeine at 34 to 36 weeks PMA if no apnea spells occur for 5 to 7 days. Cardiopulmonary monitoring should continue for another 7 days until caffeine has been eliminated. Please note that infants born at 25 weeks gestation or less may continue to exhibit immature control of breathing at term and, occasionally, out to 44 weeks PMA.

**Preparation for Discharge**
Most preterm infants achieve physiologic stability between 36-37 weeks PMA. However, premature infants have greater risk of “extreme” apnea events than term infants up to 44 weeks PMA. Approximately 80% of premature infants are free of apnea/bradycardia by the time they are otherwise ready for discharge. However, maturation of respiratory control may be delayed out to 43-44 weeks PMA in babies born at very early gestational ages or those with a complex medical course. Otherwise healthy preterm infants off of xanthines have a low risk of significant episodes of recurrent apnea if they are apnea free for an observation period of up to 7 days. Please note that bouts of apnea may be increased in very preterm infants associated with elective surgical procedures, ophthalmologic exams and 2 month vaccinations (rarely after 4 month vaccinations).

Home apnea monitors are rarely indicated in management of persistent apnea of prematurity and should not be used to facilitate home discharge in infants who have not achieved stability of respiratory control. Home monitors are not indicated for prevention of SIDS in preterm infants. Pneumograms are of no value in predicting SIDS and are not helpful in identifying patients who should be discharged on home monitors.

Use of laboratory analysis of breathing patterns (Multichannel Study) and consideration for home monitoring may be indicated in the rare infant with severe, prolonged apnea/bradycardia or those suspected of apnea events secondary to some other process (GER, feeding disorder, prior BRUE, upper airway dysfunction or discrepancy between clinical and bedside monitor data regarding event frequency). In such cases, consideration of a Pediatric Pulmonary consultation should be entertained.

### 2.3 Management of Neonatal Respiratory Distress
The primary lung diseases producing respiratory symptoms and respiratory failure in newborns are Respiratory Distress Syndrome (RDS), retained fetal lung fluid (or transient tachypnea of the newborn, TTN), pneumonia, and meconium aspiration syndrome. Many of these conditions have overlapping presentation and can be managed using the following strategies.

**“CPAP First” Strategy**
Current evidence indicates that early CPAP is an effective strategy for providing respiratory support for preterm infants, even for those who are extremely low birth weight (ELBW infants). CPAP initiated immediately after birth, with subsequent selective use of surfactant has been noted to be at least as safe and effective as intubation and prophylactic surfactant administration. Preterm infants treated with early CPAP alone
are not at increased risk of adverse outcomes. Further, early CPAP reduces the need for subsequent surfactant treatment or mechanical ventilation. A recent meta-analysis demonstrated that early CPAP combined with selective surfactant use results in lower rates of death or BPD as compared to intubation and prophylactic surfactant administration. This strategy of using CPAP first has also been endorsed recently by AAP.

**Surfactant**

(Also see Sec 1 - Care of Very Low Birth Weight Babies.) Surfactant administration to preterm infants with RDS reduces mortality, incidence of pulmonary air leaks and risk of death or CLD at 28 days of life. Recent evidence indicates early NCPAP combined with selective use of surfactant if RDS develops (rescue strategy) is the optimal strategy to reduced risk of death or BPD.

**Rescue Treatment**

We recommend surfactant treatment for babies who require 40-60% O₂ despite optimizing CPAP delivery. Rescue surfactant given within the first two hours of life to infants with established RDS is associated with reduced risk of death, air leaks and death or BPD compared to delayed treatment. Some treated infants may benefit from 2 or more doses. Repeat dosing is recommended for patients with a continued oxygen requirement greater than 40-60%, 12 hour after the last surfactant dose.

- Spontaneously breathing infants with RDS requiring 40-60% oxygen despite nasal CPAP are candidates for endotracheal (ET) intubation, MV and rescue surfactant or INSURE (intubation, surfactant treatment, extubation to CPAP). Dosing should be repeated as needed for up to 3 total doses (Curosurf®), although most infants require only one dose. Lung mechanics may improve rapidly, requiring rapid weaning of FIO₂, PIP (or VT), or ventilator rate. Continue positive pressure ventilation until weaned to minimal settings, then attempt extubation and place infant on nasal CPAP
- Outborn infants with RDS already on MV are candidates for rescue surfactant if they exhibit a persistent O₂ requirement of 40-60%.

**Surfactant Product Selection and Administration**

Always assure proper ET position (clinically- by auscultation) prior to dosing to avoid instillation into a main stem bronchus. Commonly used surfactant products include those of bovine (Survanta®, Infasurf®) and porcine (Curosurf®) origin. A recent meta-analysis of 5 RCT’s reported a reduction in mortality, need for repeat dosing and duration of mechanical ventilation associated with use of porcine surfactant versus the bovine product beractant.

**Curosurf®**

Curosurf® has the additional benefit of lower dosing volume, longer half-life and more rapid onset of effect. Initial dose is 2.5 ml/kg of birth weight. Up to 2 subsequent doses of 1.25 ml/kg may be given at 12 hour intervals. There may be a situation in which a patient born at an outside hospital may receive a dose of beractant (Survanta®) prior to transfer to TCH and need a second dose of surfactant. In this situation, we would give poractant (Curosurf®) 1.25 ml/kg/dose when second dose of the original product is due.

During or immediately following the dosing procedure lung compliance may improve rapidly. Continued monitoring of chest excursion is essential to allow rapid reduction in ventilator PIP or VT as improvement occurs. An ABG should be obtained soon after dosing to avoid hyperventilation or over-distension of the lungs associated with surfactant administration.

**Surfactant Replacement for Term Infants with Hypoxic Respiratory Failure**

Current evidence indicates surfactant treatment improves oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term babies with hypoxic respiratory failure associated with RDS, meconium aspiration, pneumonia or sepsis, and some cases of idiopathic PPHN. Benefits are greatest for infants requiring positive pressure ventilation with oxygenation index of 15 on 2 separate, serial measurements. In this setting, up to 3 doses of surfactant may be necessary. No benefits of surfactant therapy have been reported in infants with CDH and use in this population is based on unit consensus.

**2.4 Non-Invasive Respiratory Support**

**Nasal CPAP**

Nasal constant positive airway pressure (NCPAP) is used for managing apnea of prematurity, maintaining lung recruitment in premature infants, and as early intervention in acute respiratory distress syndrome (RDS)

There are various types of devices and patient interfaces available to delivery CPAP. Continuous flow CPAP is the mode delivered by most neonatal ventilators. Bubble CPAP is a specific type of continuous flow CPAP that is thought to be superior to ventilator delivered CPAP based on observational studies reporting enhanced gas exchange with bubble CPAP as compared to conventional delivery systems. A recent RCT reported reduced post-extubation failure with bubble CPAP as compared to a variable flow CPAP system. Bubble CPAP delivery system is currently the method of choice in the Baylor nurseries. The continuous flow should be adequate to produce bubbling most of the time, but this varies with infant position and opening of the mouth. Begin with 5 to 6 cm H₂O pressure and increase by 1- to 2-cm increments. CPAP pressures of 5 to 8 cm H₂O usually are optimal to manage apnea or acute lung disease with continuous flow devices, however pressures greater than 8 cm H₂O are needed rarely.

**Patient Interface**

The interface used for CPAP delivery has traditionally been nasal prongs. However, recent literature suggests that CPAP delivered by nasal mask interface may be more beneficial. There have been 4 randomized control trials that studied CPAP failure rate, defined as the need for mechanical ventilation within 72 hours, between CPAP masks versus prongs. When the results of these studies are combined, patients receiving CPAP via mask had a lower CPAP failure rate than those receiving CPAP via nasal prongs (low quality evidence). There are 6 randomized trials that studied nasal injury from CPAP mask versus prongs. There was no difference noted in nasal injury rate between the two interfaces (low quality evidence). Based on this evidence, there has been a change in unit policy to now start with and primarily use nasal mask as the default CPAP interface. Prongs can still be used if the mask fails to provide adequate CPAP or in the case of pressure injury. Please refer to the CPAP interface
algorithm found throughout the NICU (currently being implemented as a unit wide QI project).

**Indications for CPAP**

**Apnea of Prematurity**

Nasal CPAP reduces the frequency of the obstructive component of mixed apnea of prematurity. The primary effect is to maintain upper airway patency until hypopharyngeal function matures. A secondary effect is to maintain adequate lung volume. Pharyngeal function usually improves after 31 to 32 weeks.

**Maintenance of Lung Recruitment**

Nasal CPAP is used in this setting to oppose high chest wall compliance and low lung volume in VLBW infants. Inborn infants ≤ 30 weeks’ gestation are placed on nasal CPAP at birth to maintain lung recruitment. Larger infants also may be candidates if they appear immature, have RDS or are at risk for postnatal chest wall dysfunction or apnea. Nasal CPAP also is used for maintaining lung recruitment post-extubation in select infants.

**Acute Lung Disease**

We recommend nasal CPAP for all premature infants with respiratory distress and oxygen requirement of 40% or greater to maintain appropriate lung recruitment and oxygen saturation.

With continuous flow devices, begin with 5 cm H₂O. Pressures of 5 to 8 cm usually are adequate; pressures over 8 cm H₂O are rarely indicated. In some patients, lung over distension may occur at these levels. Inadequate response to nasal CPAP includes persistent O₂ requirement above 40 % or severe apnea.

**High Flow Nasal Cannula**

High flow respiratory therapy involves delivery of inspiratory gas flows exceeding those of normal spontaneous breathing. It is important that gas delivery with any HFNC device be heated and humidified to prevent mucosal injury. Two primary mechanisms of action for HFNC therapy have been described.

**CPAP Effect**

Pharyngeal end expiratory pressure during HFNC is dependent upon gas flow and level of leak around the nasal cannula (NC). In presence of 30-50% leak (open system), only minimal distending pressure (0-3 cm H₂O) is delivered. However, if a tight fitting NC is used (closed system) pharyngeal/esophageal pressures delivered may be quite high as gas flows exceed 1-2 LPM. These variances make attempts to produce CPAP effects with HFNC’s problematic, since pharyngeal distending pressures are not monitored. Evidence regarding effects of HFNC on work of breathing in neonates is inconclusive and data are limited regarding effect on lung volume and recruitment. A randomized crossover study showed no difference between patients treated with CPAP and HFNC in WOB and thoraco-abdominal asynchrony or oxygen saturations.

**Enhanced Dead Space Ventilation (Pharyngeal Washout) Effect**

A different effect of HFNC is that of NC flow rates that exceed the patient’s spontaneous inspiratory flow (> 2 LPM for neonates) and minimize entry of room air. Clinical and fluidic studies suggest that gas flows of 3-8 LPM with 30-50% NC leak produces “purging” of nasopharyngeal dead space during expiration with enhancement of CO₂ elimination. Available evidence suggests this effect may be the primary mechanism for reported benefits of HFNC therapy in adults and older pediatric patients. In this application, HFNC must be used as an “open” system that maximizes nasopharyngeal purging with flow of 3-8 LPM and 40-50% NC leak, using each vendor’s specifically recommended NC sizes. Evidence in neonates regarding this mechanism is limited. Washout times at different settings between HFNC and CPAP and mouth open and closed conditions, studied in an in vitro model, showed times were significantly longer for CPAP versus HFNC in the closed mouth setting.

**Use in Neonates**

Use of HFNC in the NICU environment has increased, but the primary mechanism of action in neonates has not been identified. Studies have compared HHNC therapy to various forms of conventional CPAP in premature infants. However, the evidence is inconclusive as to the superiority of HFNC over CPAP.

**Infants ≤ 28 weeks**

A meta-analysis of 15 studies examined current evidence on HFNC use for post extubation respiratory support. Subgroup analysis of one of the included trials revealed superiority of NCPAP for babies < 28 weeks gestation. Otherwise, CPAP has been noted to be superior for post extubation support of babies ≤ 26 weeks and ELBW infants. In a retrospective analysis, ELBW infants who received HFNC had higher rates of death or BPD when compared to infants who received CPAP alone. Infants in the HHHFNC group also had more days of mechanical ventilation, use of postnatal steroids, and days on supplemental oxygen. Time to initiate and achieve full PO feeds was also longer in the HHHFNC group. At present, we do not recommend HHHFNC for management of support of ELBW infants following birth.

**Infants > 28 weeks**

Per Cochrane Review done in 2016, when HFNC is used for post extubation support (6 studies), there was no difference in rate of treatment failure, need for re-intubation, death or BPD. However, nasal trauma was significantly lower among patients treated with HFNC, compared to CPAP. Several of these studies allowed “rescue” with CPAP or NIPPV for patients failing HFNC, resulting in reduced need for re-intubation. A meta-analysis of HFNC compared to CPAP for primary support of early neonatal respiratory disorders found no difference in primary outcome of death or BPD or pneumothorax. HFNC resulted in longer duration of respiratory support. For the treatment of early respiratory distress, results from one larger multicenter RCT demonstrated a significantly higher number of infants meeting study failure criteria among those randomized to HFNC. However, in another RCT including 28 to 42 weeks infants reported similar efficacy and safety of HFNC and CPAP in treating early respiratory failure. At present we do not have enough evidence to make a strong recommendation for or against HFNC.

Any device used for HHHFNC in a neonate should be specifically designed to deliver flows in the 3-8 LPM range. The vendor’s specifically sized nasal cannulae should be used to allow the recommended 40-50% leak. Most devices do not provide measurement of pharyngeal distending pressure but some include a pressure pop-off valve to prevent delivery of extremely high distending pressures. If HFNC is used, it should
always be in conjunction with an oxygen blender to maintain saturations in target range and avoid hyperoxia.

**Oxygen**

Goals of acute and chronic administration of oxygen are to avoid potential hazards of hypoxemia and hyperoxemia, especially in premature infants. No clear relationship has been established between specific arterial PO\(_2\) values and adequacy of tissue oxygenation. PaO\(_2\) in a newborn is not constant; it varies widely throughout the day, especially in mechanically ventilated infants or those with BPD.

In emergency situations, administer oxygen in amounts sufficient to treat cyanosis. As soon as this immediate goal is achieved, initiate SpO\(_2\) monitoring to evaluate adequacy of oxygenation and determine further needs. An oxygen blender and pulse oximeter should be available at the delivery of all infants. Initiate emergency resuscitation with 30% O\(_2\) for premature infants and room air for term infants. Adjust subsequent FiO\(_2\) based upon pulse oximetry values.

Administration of oxygen via oxyhood should be considered as the mode of choice since a more accurate measurement of the FiO\(_2\) being delivered is possible. Administration of oxygen via NC is a particularly difficult issue because of imprecise measurements and poor control of delivered FiO\(_2\). A multicenter study found 27% of babies on NC were receiving less than 23% effective FiO\(_2\) and 9% were receiving room air. The inspired oxygen concentration achieved by use of NC oxygen administration can be estimated using Table 2-1a and Table 2-1b.

**Monitoring**

**Pulse Oximetry**

Oxygen administration to neonates is most commonly monitored today with pulse oximetry. Movement artifacts and low pulse pressure may impair the efficacy of this technique. Artifacts of saturation measurement also may occur in the presence of high-intensity light, greater than 50% Hgb F, and some radiant

---

### Table 2-1a. Calculation of effective FiO\(_2\), Step 1

<table>
<thead>
<tr>
<th>Flow, L/min</th>
<th>Factor With Weight (kg) of</th>
<th>0.7</th>
<th>1.0</th>
<th>1.25</th>
<th>1.5</th>
<th>2.25</th>
<th>3.0</th>
<th>3.5</th>
<th>4.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01</td>
<td></td>
<td>1.0</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.03 (1/32)</td>
<td></td>
<td>4.3</td>
<td>2.2</td>
<td>2.2</td>
<td>1.1</td>
<td>1.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.06 (1/16)</td>
<td></td>
<td>9.6</td>
<td>6.4</td>
<td>4.3</td>
<td>2.2</td>
<td>2.2</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.125 (1/8)</td>
<td></td>
<td>18.1</td>
<td>12.1</td>
<td>8.6</td>
<td>4.4</td>
<td>4.4</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.15</td>
<td></td>
<td>21.1</td>
<td>15.1</td>
<td>10.8</td>
<td>6.6</td>
<td>5.4</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.25 (1/4)</td>
<td></td>
<td>36.2</td>
<td>25.2</td>
<td>17.13</td>
<td>10.8</td>
<td>7.6</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.5 (1/2)</td>
<td></td>
<td>71.5</td>
<td>50.4</td>
<td>33.25</td>
<td>20.17</td>
<td>14.13</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>0.75 (3/4)</td>
<td></td>
<td>100.</td>
<td>75.0</td>
<td>60.38</td>
<td>30.25</td>
<td>21.19</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>1.0 (1.0)</td>
<td></td>
<td>100.</td>
<td>100.</td>
<td>80.67</td>
<td>50.40</td>
<td>33.25</td>
<td>25.29</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>1.25</td>
<td></td>
<td>100.</td>
<td>100.</td>
<td>100.83</td>
<td>63.50</td>
<td>42.36</td>
<td>31.26</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>1.5</td>
<td></td>
<td>100.</td>
<td>100.</td>
<td>100.75</td>
<td>60.50</td>
<td>43.38</td>
<td>28.50</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2.0</td>
<td></td>
<td>100.</td>
<td>100.</td>
<td>100.100</td>
<td>80.67</td>
<td>57.50</td>
<td>25.70</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2.5</td>
<td></td>
<td>100.</td>
<td>100.</td>
<td>100.80</td>
<td>67.50</td>
<td>54.25</td>
<td>22.50</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>3.0</td>
<td></td>
<td>100.</td>
<td>100.</td>
<td>100.100</td>
<td>100.80</td>
<td>67.50</td>
<td>25.70</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Adapted from equations 3 and 4 in ref 1 of the source publication. The rule of thumb (implicit in the table) is that, for most infants in the STOP-ROP study, if flow (in liters per minute) exceeds body weight (in kilograms), then the effective FiO\(_2\) equals the nasal cannula oxygen concentration.

### Table 2-1b. Calculation of effective FiO\(_2\), Step 2

<table>
<thead>
<tr>
<th>Effective FiO(_2) With Oxygen Concentration of</th>
<th>0.21</th>
<th>0.22</th>
<th>0.25</th>
<th>0.30</th>
<th>0.40</th>
<th>0.50</th>
<th>0.60</th>
<th>0.70</th>
<th>0.80</th>
<th>0.90</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.03</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.06</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.125</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.15</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.25</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.5</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>0.75</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>1.0</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>1.5</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>2.0</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>2.5</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>3.0</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
<td>0.21</td>
</tr>
</tbody>
</table>

Table 2-1b. Calculation of effective FiO\(_2\), Step 2

Adapted from equations 3 and 4 in ref 1 of the source publication. The rule of thumb (implicit in the table) is that, for most infants in the STOP-ROP study, if flow (in liters per minute) exceeds body weight (in kilograms), then the effective FiO\(_2\) equals the nasal cannula oxygen concentration.

warmed. Oxygen therapy targeted to maintain a defined range of oxygen saturation values decreases the need for supplemental oxygen, reduces duration of oxygen use, and reduces risk of severe ROP.

Pulse oximetry measures $O_2$ saturation of hemoglobin, not the PaO$_2$; thus, at saturation ranges above 95% it is insensitive in detecting hyperoxemia. This shortcoming is of particular importance when oxygen is administered to premature infants less than 1500 grams. A strategy of targeted oxygen saturation is used for oxygen administration with or without positive pressure support. In premature infants or term infants with acute respiratory distress, adjust oxygen administration to maintain SpO$_2$ in the 90-95% range. For infants with congenital heart disease, pulmonary hypertension or BPD (especially if term or beyond), oxygen delivery and targeted oxygen saturation must be individualized.

**Arterial Blood Gas**

Arterial oxygen tension (PaO$_2$) measured under steady state conditions is the classic technique for determining the efficiency of gas exchange between the lungs and pulmonary capillary blood. Most sources consider 50 to 80 mmHg to be the usual range for newborn PaO$_2$. However, in a controlled NICU environment, PaO$_2$ in the range of 40 to 50 mmHg may be acceptable.

**Capillary Blood Gas**

This technique tends to underestimate PaO$_2$ and is unreliable for oxygen monitoring. Capillary sampling may be useful for determining pH and PCO$_2$, but should not be used as a tool for oxygen monitoring.

**Nasal intermittent positive pressure ventilation (NIPPV)**

NIPPV is a form of non-invasive ventilation where PIP is delivered at a set frequency, superimposed on continuous PEEP. A meta-analysis in 2016 showed that early NIPPV is better than NCPAP in treating preterm infants with RDS by preventing the need for primary intubation and ventilation (moderate quality evidence). There was no decrease in the risk of developing CLD noted in this meta-analysis. A recent trial in 2013 also compared NIPPV versus NCPAP in 1009 ELBW infants less than 30 weeks and found no difference in the rate of survival without BPD at 36 weeks PMA. However, a meta-analysis in 2017 found that NIPPV reduced the incidence of extubation failure within 48 hours to 7 days after extubation. The number needed to be treated with NIPPV to prevent one extubation failure is 8. Studies that used synchronized NIPPV delivered from a ventilator showed benefit more consistently. Again, there was no difference noted in the rate of CLD (moderate quality evidence). Ventilators currently available in Baylor NICUs can only provide non-synchronized NIPPV and therefore NIPPV is currently not recommended for routine use in our units.

**Bi-level Positive Airway Pressure (BiPAP)**

BiPAP ventilation delivers alternating levels of continuous positive airway pressures at a set non-synchronized rate, using a mask or prongs. Compared to NIPPV this system provides breaths at lower pressures and longer inflation times. Current evidence indicates that BiPAP is not superior to NCPAP for management of infants with RDS or for apnea of prematurity. This mode is not routinely used in the Baylor NICUs but if there is a specific need for this ventilation mode in a given patient, it can be discussed with the unit Medical Director on an individual basis.

# 2.5 Weaning from CPAP and Nasal Cannula

Based on the best available evidence, the following recommendations were developed to wean infants from CPAP and nasal cannula oxygen therapies. The goal of this protocol is to promote a safe and effective weaning of CPAP and oxygen therapy in premature infants in order to decrease oxygen toxicity (and its effects on ROP and chronic lung disease), reduce unnecessary use of positive pressure and oxygen, prevent exacerbations of underlying lung disease, and avoid CPAP-related nasal and facial injuries.

**Eligibility Criteria**

Infants can be considered to be safe to trial off CPAP if they meet all of the following criteria:

- PMA > 30 weeks
- FiO$_2$ < 40%
- No respiratory distress (RR<60/min; no significant chest retractions)
- No concurrent treatment for PDA or sepsis
- Absence of significant apneas and bradycardias
- Absence of major congenital abnormality

**Choosing between Heated Humidified High-Flow Nasal Cannula (HFNC) vs Low-Flow Nasal Cannula (LFNC)**

Typically, oxygen requirement an infant has is reflective of the severity of the underlying lung disease: therefore, the greater the oxygen requirement, the more severe the lung disease and greater the need for respiratory support. Based on available evidence, we recommend that infants on CPAP requiring FiO$_2$ of 21%, < 30%, and 30 – 40% can be weaned to room air, LFNC, or HFNC, respectively. If the infant meets the criteria for LFNC therapy, we suggest that you refer to Tables 2-1a and 2-1b to determine the flow that is required to deliver < 30% FiO$_2$ and titrate to maintain maintaining saturations.

**Weaning HFNC and LFNC**

The recommended SpO$_2$ targets are between 90 – 95% in infants receiving supplemental oxygen. Refer to the algorithm (Fig 2-2) for guidance on titrating and weaning off HFNC and LFNC. Once you are down to 1L/min NC flow, we suggest that you can either wean the flow (Fig 2-2) or use a blender to titrate oxygen delivery. Using a blender at very low flow rates, under 0.5L/min, seems to be equivalent of giving no respiratory pressure support. Irrespective of mode of weaning you choose (blender vs. flow), we suggest that you pay attention to the infant’s saturations and ensure that they are in the target range. If the infant’s oxygen saturations are persistently greater than 95%, wean delivered oxygen to avoid oxygen toxicity (e.g. ROP). We also recommend performing an oxygen reduction test at 35 weeks PMA based on the NICHD criteria as explained below to assess whether the infant actually needs supplemental oxygen to maintain the SpO$_2$ targets.
Oxygen Reduction Test
Infants consistently maintaining SpO₂ targets between 90 – 95% on a FiO₂ ≤ 30% without any respiratory distress, apnea, or bradycardias are eligible for this test. Infants requiring FiO₂ > 30%, CPAP or any form of positive pressure, or are having respiratory distress, apnea, or bradycardias are not eligible for this test. For eligible infants receiving low-flow nasal cannula oxygen therapy, keep the flow constant and reduce the oxygen concentration by 2% every 10 minutes until the FiO₂ is 21% making sure that the infant is stable and the oxygen saturations remain ≥ 88%. Once the FiO₂ is 21%, decrease flow by 0.1 L/min every 10 minutes to zero flow. It is recommended that the nasal cannula be removed from the nares but left affixed to the face, to not disturb the infant during the test. We recommend that the infant’s heart rate, respiratory rate, oxygen saturation, and frequency of apnea and bradycardias be recorded every minute starting 15 minutes prior to the test and continue throughout the testing period. The infant is considered to have passed the test if the oxygen saturation remains ≥ 88% in room air. A rapid pass is defined as oxygen saturation ≥ 96% for 15 minutes in room air. If the oxygen saturation is between 88 to 95% in room air, the infant should be monitored with documentation of heart rate, respiratory rate, and frequency of apnea and bradycardia every minute for 60 minutes in room air. The infant is considered to have passed the test only if the oxygen saturations are ≥ 88% during this 60-minute monitoring in room air. Test failure is defined as oxygen saturation 80 to 87% for 5 minutes or less than 80% for 1 minute. If the infant meets any of these criteria, the nasal cannula needs to be immediately resumed.

2.6 Conventional Ventilation of Preterm and Term Neonates (Mechanical Ventilation)

Intubation
Premedication for Non-Emergent Intubations
Premedication for elective intubation improves physiologic stability, reduces time to intubation and decreases number of attempts necessary for successful intubation.

The AAP recommends the following strategy:
1. A narcotic analgesic is recommended (e.g. fentanyl)
2. A vagolytic agent should be considered (e.g. atropine)
3. Use of a muscle relaxant should be considered (e.g. vecuronium or rocuronium) depending upon clinical circumstances

Potential adverse events include:
1. Fentanyl-induced chest wall rigidity. Avoid high doses and infuse drug slowly over 2-5 minutes. Have naloxone, a muscle relaxant and appropriate sized LMA immediately available.

2. Failure to intubate after administration of a muscle relaxant. Maintain effective ventilation with bag mask ventilation via face mask or LMA. Short-acting agents may be reversed with atropine and neostigmine.

Prior to administration of premedication, please ensure that all procedural equipment and emergency medications are readily available.
Endotracheal Tube Positioning

ETT should be positioned so that the tip of the tube lies in the mid-trachea. On a chest radiograph, this corresponds to the tip being below the level of the clavicles and above the bifurcation of the trachea (approximately level of T3 - T4). Since an infant’s positioning can influence ETT positioning, it is important that all chest x-rays are obtained with the infants head placed in midline position (not flexed or extended) and both arms positioned at the sides. This will allow us to make an accurate assessment of the tube position and prevent unnecessary adjustments.

Importance of Adequate Lung Recruitment

In order for effective ventilation and pulmonary gas exchange to occur, lung inflation (recruitment) must be adequate. In neonatal mechanical ventilation, this “open lung” strategy is achieved by applying adequate levels of PEEP (or MAP during HFOV), tailored to the lung compliance of each individual patient. In infants without lung disease, appropriate PEEP is 4-5 cmH₂O. For those with poorly compliant or atelectatic lungs, PEEP levels up to 8 cm H₂O or more may be necessary.

Overview of Mechanical Ventilation

Conventional ventilation modes are recommended for initial management of neonates requiring ventilator support. The preferred strategy for majority of neonatal patients is using volume-targeted ventilation with support for each patient breath using the Assist Control (A/C) mode to minimize work of breathing (A/C + VG) or support of set number of breaths using SIMV (SIMV + VG). Volume targeted ventilation is accomplished by monitoring of expired tidal volumes and adjusting of ventilator parameters (either manually or automated) in an attempt to minimize lung injury by providing adequate minute ventilation with the lowest effective PIP and tidal volume delivered in the most consistent manner.

HFOV on the other hand is reserved as a rescue strategy for neonates who are unable to ventilate or oxygenate adequately on conventional ventilation. It should also be considered for infants requiring high pressures on conventional ventilator (placing them at high risk for barotrauma), for patients with congenital anomalies (such as CDH) that put them at high risk for lung injury, and for infants with signs of severe air leak (see Ch 2.7 High Frequency Ventilation).

Volume Guarantee (VG)

During conventional time-cycled, pressure-limited, neonatal ventilation (TCPL), delivered tidal volume (Vt) is determined by PIP, inspiratory time, compliance of the respiratory system and magnitude of ET tube leak. Lung mechanics and leak change can change quickly over the course of a day. As a result, delivered Vt varies widely on any fixed combination of ventilator settings with Pressure Control modes (PC). “Volume-targeted” ventilation (VTV) allows inspiratory pressure to fluctuate up to which the inflation pressure can be increased by the ventilator to achieve the targeted volume. Measurements of exhaled volume are made at the ventilator Y-connector, and the microprocessor adjusts working pressure to maintain the target volume. VG significantly reduces the proportion of delivered ventilator breaths that are outside the target range, promotes more stable oxygen saturation and reduces working pressures. The VG lowers the working PIP as lung compliance improves (“self-weaning”) and may be a useful as a safety feature during rapid changes in compliance (such as following surfactant administration).

We recommend A/C + VG as primary mode of ventilation for babies < 32 weeks PCA, and to continue until extubation. As with all modes of mechanical ventilation, blood gases, chest excursion and other indicators of ventilation must be monitored closely to avoid over ventilation and hypocarbia.

Initial Settings

Mode: A/C + VG + PEEP with Draeger VN500

Vt Target: 4.0-6.0 ml/kg (for infants <1000g, 4.5-5.0 ml/kg and for infants >1000g, 4.0-4.5 ml/kg)

Adjustments: Vt can be changed in increments of 0.5 ml/kg.

Pmax (PIP limit): Initially set at 25-28 cm H₂O. This allows the ventilator to choose adequate “working” PIP to deliver target Vt and overcome variable ET tube leaks. “Working” PIP will usually be below this set value. Subsequently, adjust Pmax to 3-5 cm above the “working” PIP.

Note: If the manual inflation button on the ventilator is pressed, the manual breath will be delivered at the set Pmax. Ventilator delivered manual breaths are not volume-controlled. For patient safety, adjust Pmax downward as lung compliance improves and working PIP decreases. Maintain ~ 3-5 cm H₂O difference between Pmax and “working” PIP.

PEEP: ≥5 cm

Low Tidal Volume Alarm: activated – this will alarm if expired Vt < 90% of set Vt

Trigger Sensitivity: set at highest sensitivity initially

Ti (Inspiratory Time): 0.3 sec (if slope 0.08 sec.)

If Ti ≤ 0.25 sec is used, it may be necessary to decrease slope to 0.02-0.04 sec

Ventilator Back Up Rate (BUR): Use of 30/min has been associated with optimal spontaneous breathing and patient triggering of breaths. Infants with apnea or very low spontaneous breathing rate may require higher back up rates to maintain adequate minute ventilation. Back up breaths are unsynchronized and are reported to require higher working PIP to deliver target Vt.

Circuit Gas Flow: 6-8 LPM

Maintenance of VG Ventilation

During VG ventilation, the Vt of each patient-triggered breath is the sum of that provided by the ventilator and that of patient effort. As compliance improves, the ventilator will “auto-wean” (thus avoiding over-distension of the lungs) and a greater proportion of the Vt will be supplied by patient effort. Depending on the PCO₂, the target Vt may be adjusted in 0.5 ml/kg increments in association with adjustment of the Pmax to remain 3-5 cm above working PIP. If target Vt is too high, hypocarbia or diminished spontaneous breathing may occur. If
target \( V_t \) is set too low, there may be tachypnea and increased work of breathing, as infant is forced to contribute an excessive proportion of his own effort to the total \( V_t \). This can lead to progressive atelectasis and extubation failure.

“Low Tidal Volume” Alarm – can indicate \( P_{max} \) is too low, presence of large ET tube leak, ET tube malposition, forced exhalation, abdominal “splinting”, deterioration of lung mechanics or inadequate \( T_i \) to achieve pressure plateau.

ETT Leak - large leaks around ETT impair delivery of adequate \( V_t \) in any ventilator mode. VG usually can be used with up to 45-50% leak. Draeger VN500 provides automatic leak compensation by increasing inspiratory gas flow and wave form pattern. If persistent large leaks generate frequent Low Tidal Volume alarms or impair adequate ventilation, ensure proper ET tube position and adjust patient position. On occasion, persistent large leaks may require re-intubation with larger size tube.

Adjusting Circuit Gas Flow - If there is no pressure plateau during inflation (flow does not fall to 0 by end of inspiration), flow rate or \( T_i \) should be increased to overcome reversible ET tube leak. If pressure plateau is longer than needed to complete inflation, consider reducing circuit gas flow or \( T_i \).

Adjusting \( T_i \) - Effect of \( T_i \) can be evaluated with the ventilator graphic display. If \( T_i \) is too long, pressure plateau is held after cessation of inspiratory flow and there is no further increase in \( V_t \).

Weaning VG Ventilation
When a patient is on VG mode, PIP is automatically weaned as lung compliance improves. In A/C mode, the infant controls the respiratory rate and therefore ventilator rate. Reducing the BUR has no effect on delivered rate and ventilation unless the infant’s spontaneous respiratory rate is low or absent. Therefore, the main parameters reduced during weaning are \( FiO_2 \) and the target \( V_t \). Do not wean target \( V_t < 4 \text{ ml/kg} \) because working inflation pressure will be very low and the infant will be breathing essentially on ET-CPAP with increased work of breathing and risk of fatigue or atelectasis. Under such circumstances, consider extubation. See Table 2-3

### Indications for Extubation
- \( FiO_2 < 30\% \)
- Target \( V_t \) is weaned to 4-4.5 ml/kg range
- MAP is < 8-10 cm H\(_2\)O
- Blood gases are satisfactory

Adequate spontaneous breathing
- Breathing pattern appears comfortable

Prolonged Mechanical Ventilation
For VLBW infants who require prolonged mechanical ventilation (> 4-6 weeks), the clinician should review the infant’s status and make specific decisions regarding the appropriate mode of on-going ventilator support. This decision may be aided by consultation with the unit Medical Director. VG may play a role in prolonged ventilation of some infants but selection of primary mode of ventilation (SIMV, PSV, A/C, etc.) will vary depending on a number of clinical factors.

Synchronized Ventilation
Synchronized modes are preferred in acute and chronic ventilation of infants to improve consistency of oxygenation, reduce work of breathing and reduce discomfort on the ventilator. VN500 ventilators detect patient respiratory efforts by measuring ET tube airflow with a hot wire anemometer.

Current evidence is limited to observational studies, which report reduced mean airway pressure, reduced work of breathing, reduced need for sedation, less fluctuation in cerebral blood flow velocity, and reduced ventilator days associated with use of synchronized ventilation as compared to non-synchronized IMV. Most current neonatal ventilators provide synchronized ventilation as SIMV, Assist–Control (A/C) or Pressure Support Ventilation (PSV). In each of these modes, the patient breathes spontaneously while triggering some or all of the ventilator support breaths. Each of these modes of synchronized ventilation provide for a mandatory back up ventilation rate in case of apnea.

### SIMV
In SIMV, the patient’s spontaneous respiratory efforts trigger a preset number of mandatory breaths per minute (usually set at 20 - 40). Between mandatory ventilator breaths additional spontaneous breaths occur entirely with patient’s effort, without support. The operator sets the ventilator breath rate, PIP (or \( V_t \)) and Tinsp.

#### Table 2-3: Assessing Readiness for Extubation

<table>
<thead>
<tr>
<th></th>
<th>AC-VG</th>
<th>SIMV-VG</th>
<th>SIMV-PC</th>
<th>AC-PC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tidal Volume or PIP</strong></td>
<td>4-5 ml/kg (generating PIP &lt;25)</td>
<td>4-5 ml/kg (generating PIP &lt;25)</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td><strong>Mean Airway Pressure</strong></td>
<td>8-10</td>
<td>8-10</td>
<td>8-10</td>
<td>8-10</td>
</tr>
<tr>
<td><strong>PEEP</strong></td>
<td>5-6</td>
<td>5-6</td>
<td>5-6</td>
<td>5-6</td>
</tr>
<tr>
<td><strong>Rate</strong></td>
<td>Spontaneous breathing above back up rate of 30</td>
<td>20-25</td>
<td>20-25</td>
<td>Spontaneous breathing above back up rate of 30</td>
</tr>
<tr>
<td><strong>FiO(_2)</strong></td>
<td>≤ 30%</td>
<td>≤ 30%</td>
<td>≤ 30%</td>
<td>≤ 30%</td>
</tr>
</tbody>
</table>
Initial Ventilator Settings

- **Mode**: SIMV + PEEP (VG preferred)
- **Rate**: 20 to 40 per minute
- **PIP**: 20 to 25 cm H₂O
  (if VG not used, adjust PIP as needed to achieve a tidal volume of 4-6 ml/kg)
- **PEEP**: 5 cm H₂O
- **Ti**: 0.3 - 0.4 seconds
- **System flow**: 8 to 10 L/min
- **FiO₂**: Adjust for desired saturation

Ventilator Adjustments

Oxygenation is a function of FiO₂ and mean airway pressure, which is determined by the PIP, PEEP, and the inspiratory time. These parameters influence PaO₂.

Ventilation (minute ventilation) is a function of respiratory rate and tidal volume. These settings influence PaCO₂. In general, moderate hypercapnia (PCO₂ ~ 60 mmHg) is acceptable, but hypocapnia (PCO₂ less than 35 mmHg) should be promptly corrected since it can be reflective of over distention of the lung by high-volume ventilator breaths and hypocapnia can cause decrease in cerebral blood flow. Continued vigilance is necessary to detect improving lung compliance to avoid lung over distention and alveolar rupture. This may occur rapidly after a dose of exogenous surfactant.

If oxygenation remains poor or severe hypercapnia occurs on SIMV, alternative management may be required. If PIP of 30 cm H₂O or greater or MAP >12 to 14 cm H₂O is necessary with conventional ventilation, or if severe hypercapnia persists, the patient is a candidate for rescue HFOV.

Indications for Extubation

- **FiO₂ ≤ 40%**
- **PEEP ≤ 6 cm H₂O**
- **PIP 18-20 cm H₂O**
- **Rate ≤ 25 and breathing pattern appears comfortable**

Either nasal CPAP or supplemental O₂ may be necessary post extubation depending upon patient’s PMA and clinical status.

Table 2-3 displays ventilator settings for which to consider extubation in most term and preterm infants. Depending on the clinical situation, some infants may either tolerate extubation at higher settings or be suboptimal candidates for extubation at these settings for non-respiratory reasons.

Assist–Control (A/C)

In A/C mode, the patient breathes at his own spontaneous rate and each patient breath triggers a ventilator breath. A backup mandatory IMV rate is set by the user in case of apnea. In theory, A/C mode optimizes synchronization of patient and ventilator breaths and unloads work associated with asynchronous breathing. One observational study reported lower PIP, reduced variability of oxygenation and reduced work of breathing with AC + VG as compared to SIMV + VG. However, no specific long-term benefits have been established for this technique.

A/C mode with VG is recommended for initial ventilation VLBW infants, those with CDH or those with other forms of pulmonary hypoplasia. In hypoplastic lungs, increases in delivered tidal volume—even at high ventilator pressures—is limited by poor compliance and the underlying low maximal lung volume. In such patients, minute ventilation can only be maintained by high breath rates—whether spontaneous or ventilator delivered. A/C is also suitable for improving comfort of many larger infants with acute lung diseases requiring ventilator support.

All modes of synchronized ventilation must provide a backup mandatory ventilation rate in case of apnea. In either of the fast rate synchronized modes, the inspiratory time should be limited to 0.3 seconds or less to avoid breath stacking, since the infant’s spontaneous respiratory rate may be high.

Pressure Support Ventilation (PSV)

PSV is a patient triggered mode of ventilation similar to A/C. However, unlike A/C, the patient’s own breathing pattern determines the inspiratory flow pattern, Tinsp, Texp and I:E ratio. With each breath, inspiratory gas flow is delivered at a set pressure until that inspiratory flow decreases to a predetermined level (usually 15-25% of peak flow). PSV may be used alone or in combination with SIMV. In adult studies, PSV reduces work of breathing, improves patient comfort and allows better patient control of respiratory rate and flow characteristics during spontaneous breaths. In limited studies in neonates, SIMV + PSV has been associated with improved consistency of SpO₂ values and reduced need for mechanical ventilation on day 28 of life compared to SIMV alone. However, total duration of mechanical ventilation and oxygen dependency at 36 weeks GA was unchanged. PSV levels ≥10cm H₂O above PEEP may be necessary to overcome work of breathing of most ventilator circuits and small ET tubes. Levels of 10-15 cm H₂O are associated with optimal patient comfort and reduction in work of breathing.

Chronic Mechanical Ventilation

It can be unclear for physicians what the best mode of support is for infants who are ventilator dependent beyond 4-6 weeks of life. The decision being whether to continue support with a conventional volume targeted ventilator mode or change to a more individualized strategy employing techniques such as PSV, prolonged inspiratory time or manipulation of inspiratory flow patterns. Depending upon individual patient physiology, such a strategy might utilize either volume targeted or pressure limited approach.

Infants with severe BPD may require a more prolonged period of mechanical ventilation. Poor chest wall function with atelectasis and pulmonary edema causing low lung compliance are dominant features of this disease process known as “new BPD”. As a group, such infants have significantly reduced ventilation and effective tidal volumes. During this period, continuing acute care ventilator strategies such as A/C + VG or SIMV + VG are appropriate for many. Attempts to minimize FiO₂ and Vt should continue, but current evidence suggests that Vd/Vt worsens and target Vt necessary to maintain adequate ventilation rises with advancing postnatal age in ventilator dependent ELBW infants. Target Vt required averages 6 ml/kg (range 5.8 ml/kg) beyond 3 weeks of age. Most of these infants progressively improve over a variable period of time. As lung function improves they can be weaned by reductions in PIP or target Vt (VG mode) and vent rate.
A small proportion of infants remain ventilator dependent beyond 6-8 weeks of age and evolve into “classic BPD”. During this evolution, uneven airway resistance and anatomic / physiologic dead space increase. Continued use of the AC + VG mode in patients with significant uneven airway obstruction and long airway time constants may result in progressive gas trapping and hyperinflation. These patients should be evaluated closely to identify a long-term ventilator strategy. Uneven airway obstruction and high Vd/Vt are major components of the pulmonary physiology of “classic” BPD, and some develop symptomatic bronchomalacia. Chronic ventilation represents a significant challenge. Some patients require a more selective ventilator strategy with slower ventilator rates, longer inspiratory time and splitting of airways with moderately high levels of PEEP. This often necessitates use of higher tidal volumes (10-12 mL/kg) than those employed for acute care ventilation and longer inspiratory times (≥0.6 s). These patients may benefit from a demand flow ventilator which allows for the combination of SIMV + PSV + PEEP which matches inspiratory gas flow more closely to patient demands. Use of volume-targeted ventilation or VG is desirable in attempt to maintain consistency of minute ventilation and adequate oxygenation. Stability of minute ventilation and adequate oxygenation can benefit from HFOV. This often necessitates use of higher tidal volumes (10-12 mL/kg) than those employed for acute care ventilation and long airway time constants may result in progressive gas trapping and hyperinflation. These patients should be evaluated closely to identify a long-term ventilator strategy. Uneven airway obstruction and high Vd/Vt are major components of the pulmonary physiology of “classic” BPD, and some develop symptomatic bronchomalacia. Chronic ventilation represents a significant challenge. Some patients require a more selective ventilator strategy with slower ventilator rates, longer inspiratory time and splitting of airways with moderately high levels of PEEP. This often necessitates use of higher tidal volumes (10-12 mL/kg) than those employed for acute care ventilation and longer inspiratory times (≥0.6 s). These patients may benefit from a demand flow ventilator which allows for the combination of SIMV + PSV + PEEP which matches inspiratory gas flow more closely to patient demands. Use of volume-targeted ventilation or VG is desirable in attempt to maintain consistency of minute ventilation and adequate oxygenation.

Pressure controlled TCPL ventilation may be superior for optimizing distribution of ventilation in patients with severe uneven airway obstruction. Gas trapping can occur if ventilator rates greater than 20-30/min are employed in face of severe, uneven airway obstruction. Likewise, if rapid spontaneous breathing continues after initiating PSV, inadequate expiratory time and lung hyperinflation may occur.

Close monitoring is necessary in attempt to optimize oxygenation and reduce hypoxia, minimize PVR and risks of high RV afterload leading to cor pulmonary. Reductions in FiO2 or ventilator support should be done in small increments with several days of observation for signs of deterioration between weaning of each parameter.

Over time, lung growth and remodeling result in increasing stability of oxygenation and improving lung mechanics. When oxygen requirements fall to 50% or less, the patient can be “tested” for improvement by a small reduction in ventilator rate or PIP (Vt). Infants on SIMV + PSV + PEEP can be slowly weaned by increasing spontaneous breathing time on PSV alone every few days. Weaning must be done carefully because several days may be required for these patients to exhibit signs of clinical deterioration after a small reduction in level of support. When FiO2 required decreases to 40% or less and the infant is comfortable breathing on low (10 cm H2O) PSV - extubation may be attempted. At this point, many can be successfully extubated despite a ventilator PIP or Vt significantly higher than the target values used during ventilator weaning of acute lung disease.

After weaning from mechanical ventilation, most infants with moderate-severe BPD require supplemental oxygen for additional weeks or months. Close monitoring of SpO2 to detect subtle hypoxia is critical (Ch 2.8-Bronchopulmonary Dysplasia). The role of CPAP or HFNC post extubation in BPD infants is poorly studied. NCPAP devices may produce agitation in older infants. Although the theoretical benefits of enhanced diffusive effects and CO2 removal reported for HFNC systems seem desirable, little objective data exists at present to guide use of this technique in infants with BPD.

### Table 2-4. Useful respiratory equations

<table>
<thead>
<tr>
<th>Equation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \Delta pH = AP_{CO2} \times 0.008 )</td>
<td>Respiratory acidosis and pH</td>
</tr>
<tr>
<td>Mean airway pressure ( MAP = PEEP + ((PIP - PEEP) \times \left[ \frac{1}{T_I + T_E} \right]) )</td>
<td>Mean airway pressure</td>
</tr>
<tr>
<td>Oxygen content ( CO_2 = (1.39 \text{ mL/g} \times SaO_2 \times Hb) + (0.003 \text{ mL/mm Hg} \times PaO_2) )</td>
<td>Oxygen content</td>
</tr>
<tr>
<td>Alveolar air equation ( PAO_2 = FI_0(71.3) - PaCO_2 / 0.8 )</td>
<td>Alveolar air equation</td>
</tr>
<tr>
<td>A-a oxygen gradient ( AaDO_2 = PAO_2 - PaO_2 )</td>
<td>A-a oxygen gradient</td>
</tr>
<tr>
<td>Oxygen index ( OI = MAP \times FI_0 / 100 / PaO_2 )</td>
<td>Oxygen index</td>
</tr>
<tr>
<td>Airway resistance–laminar flow ( R = (8 \times \text{ length} \times \text{ viscosity}) / (\pi \times \text{ radius}^4) )</td>
<td>Airway resistance–laminar flow</td>
</tr>
<tr>
<td>Compliance ( C = \Delta V / \Delta P )</td>
<td>Compliance</td>
</tr>
<tr>
<td>Pressure drop as gas (of given density and viscosity) flows through a tube (of given length [L] and radius [r]) ( \frac{\Delta P}{\Delta V} = \frac{\pi \times R^4}{8 \times \text{ density} \times \text{ viscosity}} )</td>
<td>Pressure drop as gas (of given density and viscosity) flows through a tube (of given length [L] and radius [r])</td>
</tr>
</tbody>
</table>

### 2.7 High-frequency Oscillatory Ventilation (HFOV)

HFOV is a technique for maintaining effective gas exchange and oxygenation with lower tidal volumes than those usually employed for conventional mechanical ventilation. This may reduce airway distension during tidal ventilation and potentially reduce airway injury.

Some centers use HFOV electively as a primary ventilation strategy for RDS. Current evidence does not demonstrate any long-term benefits for this strategy when compared to rescue use. Although individual studies have reported a reduction in risk of BPD or long-term airway dysfunction, this effect was inconsistent across studies. Pulmonary air leaks occurred more frequently in the HFOV group.

Complications include tracheal injury, pulmonary hyperinflation, and air leak. Over distension of the lung with impairment of long-term survival, neurologic status, or lung function. Recruitmen strategy has not demonstrated any superiority in analysis of studies using the current recommended lung.

### Indications for Use

- **Respiratory failure**: for infants who are ≥ 34 weeks GA and at high risk for requiring ECMO, with or without iNO, can benefit from HFOV. This includes infants with PPHN, sepsis, pneumonia, RDS, meconium aspiration, CDH or pulmonary hypoplasia. One study reported a reduced need for ECMO in patients in these categories treated with HFOV plus iNO as compared to either modality alone. Of note, iNO can be delivered via HFOV.

- **Severe, acute lung disease**: HFOV is recommended when conventional ventilator PIP reaches or exceeds 28- to 30-cm H2O or mean airway pressure exceeds the 12- to 14-cm H2O range (10 cm H2O in babies < 1000 g). This strategy attempts to minimize peak airway pressures applied to the lung. Although short-term improvement in oxygenation or patient status at 28 days of age has been reported, meta-analysis of studies using the current recommended lung recruitment strategy has not demonstrated any superiority in long-term survival, neurologic status, or lung function.

- **Severe air-leak syndrome**: producing persistent hypoxemia despite conventional fast-rate ventilation with short
inspiratory times may benefit from HFOV, but no superiority of this technique for management of air leaks has been demonstrated.

**Physiology**

Gas exchange on the oscillator appears to result from bias flow in the airway tree induced by the high-frequency pulsations as well as by enhancement of molecular diffusion. These effects are superimposed upon the usual mechanisms of pendelluft, cardiogenic mixing, and convective flow to short pathway lung units. The basic concepts of the three-compartment lung model remain operative in oscillator decision making. Open, poorly ventilated lung units determine PO\(_2\) and well-ventilated units determine PCO\(_2\). In some PPHN patients, distribution of ventilation is uniform (e.g., “pure” PPHN), while in others it is quite non uniform (e.g., meconium aspiration syndrome). It is important to differentiate this before initiating HFOV, just as with conventional ventilation, because the ventilator strategy will be influenced by characteristics of regional time constants in the lung. Just as with conventional mechanical ventilation, the approach to ventilation (PCO\(_2\)) and oxygenation (PO\(_2\)) should be evaluated independently as each is influenced by specific parameters.

**Management**

Current clinical guidelines are based primarily upon strategies for the Sensor Medics oscillator. The device has six controls. For most clinical situations, only mean airway pressure (Paw) and oscillatory pressure amplitude (ΔP) are varied. Frequency is less often changed based on PCO\(_2\). Bias flow, piston centering, and percent inspiratory time are set initially and rarely vary throughout the course.

**Ventilation (PCO\(_2\))**

Manage ventilation by adjusting ΔP. In the Provo Multicenter Trial (surfactant + high volume strategy), average ΔP for initial treatment was 23 cm H\(_2\)O. At a given mean airway pressure, CO\(_2\) removal occurs via the high-frequency tidal volume (bias flow) created by the ΔP. With a 3.5 mm ET tube, 80% of the proximal oscillatory pressure will be attenuated across the tube. With a 2.5 mm ET tube, 90% will be lost. Thus, it is desirable to use the largest, shortest ET tube possible and to be certain the tube is as straight as possible.

Increasing ΔP improves ventilation and lowers PCO\(_2\). If PCO\(_2\) remains excessive despite maximum ΔP, the frequency may be reduced to 10 Hz to take advantage of the frequency dependence of ET tube attenuation. At lower frequency, there is less ET tube attenuation and a larger distal ΔP (and oscillatory tidal volume) in relation to proximal ΔP. This secondary strategy may lower PCO\(_2\) and increase PO\(_2\) levels, particularly if uneven airway obstruction is present. If ventilation is excessive (PCO\(_2\) too low), lower ΔP.

**Control of Oxygenation (PO\(_2\))**

Oxygenation is managed by changes in mean airway pressure (Paw). Increasing Paw improves PO\(_2\). The general strategy is to recruit and maintain normal lung volume using relatively high Paw during the acute phase of lung disease. Paw is then weaned as the disease process improves.

Begin HFOV with Paw set to 2 cm H\(_2\)O higher in VLBW infants and 2 to 3 cm H\(_2\)O higher in term babies than the previous level on the conventional ventilator just before initiating HFOV. Increase the Paw until adequate oxygenation is achieved. In multicenter studies, the average Paw for initial treatment was 11 to 19 cm H\(_2\)O, however some patients may require higher levels. When adequate oxygenation occurs, concentrate on weaning FiO\(_2\). When FiO\(_2\) falls below 60% to 70%, begin to wean Paw in 1- to 2-cm H\(_2\)O decrements.

**Monitoring**

- blood gases – to monitor PCO\(_2\) and PO\(_2\)
- chest X ray – to estimate lung volume
- pulse oximetry –to monitor saturations

**Special Considerations**

- In non-homogeneous lung diseases such as meconium aspiration, pneumothorax, and pulmonary interstitial emphysema (PIE), emphasize weaning Paw and ΔP, while accepting higher PaCO\(_2\), lower PaO\(_2\), and FiO\(_2\) > 0.7. These disorders have uneven expiratory time constants and therefore at increased risk of gas trapping.
- Remain vigilant to avoid over-inflating the lung on HFOV. Inadvertent increases in lung volume and intrapleural pressure associated with improving compliance could decrease venous return and circulatory function, increase cerebral vascular congestion, or result in air leak.
- Serial chest X-rays are necessary to monitor for hyperinflation. A suggested schedule is:
  - first chest x-ray within 1 to 4 hours of initiating HFOV
  - every 12 hours during the first 24 hours on HFOV
  - then once daily and as needed based on clinical picture
- On chest radiograph, the diaphragms should be at the T8.5 to T9 level, if lung anatomy is normal. In pulmonary hypoplasia or CDH, this estimate cannot be used, so do not try to inflate the lungs to these volumes.
- Maintain an unrestricted airway during HFOV. Limit suctioning to minimal frequency necessary to maintain airway patency.
- Sudden, unexplained bradycardic events that occur with no other demonstrable cause might signal rapid improvement in lung compliance and the need to wean pressures more aggressively. Sudden increase in PCO\(_2\) and decrease in PO\(_2\) usually indicates airway obstruction, which may be due to secretions in the airway or inadequate positioning of the ETT.
- Patient and head position should be rotated every 12 hours to avoid pressure injuries to the skin and dependent atelectasis. Use of a swivel on the end of the HFOV tubing facilitates rotation of the head in infants who are unstable.
2.8 Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) is the clinical evolution of an injury sequence initiated by perinatal factors that disrupt pulmonary angiogenesis and development, stimulate inflammation or produce physical injury to the highly vulnerable immature lung (e.g., mechanical ventilation). It is defined according to the NICHD consensus workshop (see Table 2.5).

Etiology and Pathogenesis

BPD results from immature lung’s susceptibility to risk factors—both prenatal and postnatal—thought to set in motion a cascade of inflammation and oxidative stress. Prenatal factors include placental dysfunction, fetal growth restriction, chorioamnionitis, and genetic predisposition. Postnatal factors that potentiate lung injury include surfactant deficiency, mechanical ventilation, excessive oxygen administration, infection, microbial dysbiosis, and patent ductus arteriosus. Mechanisms of injury include volutrauma, barotrauma, inflammation, impaired vasulogenesis, and delayed alveolar development.

Although the exact nature of the triggering event for lung injury remains unknown, 4 pathways contribute to the clinical evolution of BPD:

- Anatomic injury to airways and alveoli
- Accelerated production of elastic tissue
- Impaired angiogenesis, alveolarization and lung growth.
- Activation of an inflammatory response

These events promote airway and mucosal dysfunction, impair gas exchange and cause interstitial edema.

Pathophysiology

Severe BPD exhibits increased lung water, increased uneven airway resistance, and decreased dynamic lung compliance, which becomes frequency dependent. Physiologic dead space is high and respiratory rate is increased. Uneven airway obstruction leads to gas trapping and hyperinflation with severe pulmonary clearance delay. Bronchomalacia is common and may produce acute episodes of expiratory airway collapse associated with absent air entry and severe hypoxemia. Such events are often mistaken for asthma and treated with bronchodilators, which may exacerbate airway collapse. Pulmonary function testing during the first 6 months of life reveals little improvement in lung mechanics. However, significant improvement occurs after the first year. By 3 years of age, compliance is near normal and airway resistance has improved. However, in most patients abnormal airway resistance persists indefinitely, and worsens in some. Although classic asthma develops in some, more than half of these children have little response to bronchodilators.

The BPD injury sequence also is associated with impairment of structure, growth, and function of the pulmonary circulation. There is obliteration of small pulmonary arterioles, smooth muscle proliferation, diminished angiogenesis and abnormal vasoreactivity.

A 3-compartment model can be used to describe the complex disease heterogeneity and fragile heart-lung interaction in these patients. In the first compartment, there is destruction of the small airways, airspace-capillary interface, and blood vessels, effectively reducing the cross-sectional area of the pulmonary vascular bed and gas exchange surface. In the second compartment, uneven airway obstruction and increased airway resistance produces a population of over distended but under ventilated (“slow”) lung units in which alveolar hypoxia induces pulmonary vasoconstriction with subsequent increase in an already-elevated baseline PVR. This leaves the third compartment, with relatively well-ventilated lung units and intact vasculature, having to accept a disproportionate amount of pulmonary blood flow. The blood vessels of this compartment, already maximally dilated, can accept this additional flow only at the expense of high right ventricular afterload, high microvascular pressures (in both pulmonary and systemic circuits), and resultant fluid filtration into the perivascular interstitium.

Many of these infants exhibit echocardiographic evidence of moderate pulmonary hypertension (abnormal tricuspid flow velocity, RVH, or dysfunction of the interventricular septum) and the elevated RV pressures can quickly rise to systemic levels with even small changes in pulmonary function. The chronically elevated pressures also inhibit and overwhelm pulmonary and systemic lymphatic drainage mechanisms. Any further reduction in ventilation or fall in PaO2 in the underventilated compartment (e.g., mucous plugging, bronchospasm, or reduction in FiO2) induces additional hypoxic vasoconstriction and forces yet more blood through the well-ventilated compartment, with further increase in pulmonary edema.

Understanding this fragile heart-lung interaction is critical in patient management. Only time and lung growth actually improve underlying lung function in the BPD patient. The primary goal of day-to-day management is maintenance of an environment that minimizes pulmonary vascular resistance by optimizing ventilation and alveolar PO2. This prevents the vicious cycle of pulmonary edema causing deterioration in pulmonary function, increasing hypoxemia time and progressive worsening of pulmonary hypertension. If unchecked, such a course can result in cor pulmonale, right ventricular failure, and death.

Other associated cardiovascular abnormalities include left ventricular hypertrophy, systemic hypertension and development

<table>
<thead>
<tr>
<th>Table 2.5. Definition of BPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Severity</strong></td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Severe (type 1)</td>
</tr>
<tr>
<td>Severe (type 2)</td>
</tr>
</tbody>
</table>

*A day of oxygen treatment is considered treatment with >21% inspired oxygen for more than 12 hours. The consensus workshop definition states that “infants treated with oxygen >21% and/or positive pressure for nonrespiratory disease (e.g., central apnea or diaphragmatic paralysis) do not have BPD unless they also develop parenchymal lung disease and exhibit clinical features of respiratory distress.”
of systemic to pulmonary collaterals. The contribution of these collaterals to the course of BPD is poorly understood.

**Tracheobronchomalacia**

Airway obstruction in BPD may be produced by (1) intraluminal accumulation of mucous and epithelial debris, (2) extraluminal compression of small airways by interstitial edema fluid, and/or (3) increased airway smooth muscle tone. In addition, 15-34% of infants with ventilator dependent BPD have tracheomalacia or bronchomalacia, producing episodes of large airway collapse. These episodes are characterized by abrupt onset of increased work of breathing, cyanosis, and poor air exchange on auscultation. It is important to differentiate these events from reactive airway episodes because use of inhaled bronchodilators may worsen the course of bronchomalacia. At present, bronchomalacia is much more common than reactive airway disease in BPD patients less than 6 months old. Infants with this type of episodic events should undergo bronchoscopy while breathing spontaneously. Many will have 50%-100% airway collapse on evaluation and effect of PEEP can be evaluated during the procedure. PEEP is the mainstay treatment for opposing airway collapse while awaiting growth and improved stability of the airway tree. PEEP values of 8-18 cm H₂O have been reported in the management of these patients, but use of levels above 10-12 cm H₂O may produce significant patient discomfort or impairment of ventilation and circulatory function. Infants receiving unusually high levels of PEEP must be monitored closely.

**Role of Mechanical Ventilation**

Although live-saving, mechanical ventilation can lead to lung injury via the interplay of barotrauma, volutrauma, and atelectrauma. Recent research implicates volutrauma rather than barotrauma in the genesis of ventilator-induced lung injury (VILI). Relative risk of BPD increases with decreasing PCO₂ during mechanical ventilation, an effect particularly striking with PCO₂ values below 29 mm Hg. In animals, if the chest is bound to prevent lung expansion, transpulmonary pressures above 50 cm H₂O may be applied without air leak or lung injury. Chest binding also prevents pulmonary edema induced by high tidal volume lung expansion. This suggests that acute lung injury is determined by the relationship between delivered tidal volume and maximum lung volume (Vmax) rather than any absolute value of applied volume or pressure. As tidal volume approaches the Vmax of these small lungs, airways become damaged by overdistension and an inflammatory process is initiated. Volume-induced injury may occur in immature lungs that have a low Vmax even at low ventilator pressures because the delivered tidal volume plus any PEEP applied may be at or above the Vmax for those lungs. In such circumstances, shearing and disruption is associated with necrosis of bronchial mucosa in small airways and potential for tracheobronchomalacia in large airways.

**Clinical Course**

Most patients with BPD today have been exposed to antenatal steroids, received surfactant, are usually premature infants with continued need for mechanical ventilation after the first 48 hours of life. These infants have what’s described as “new BPD,” which is milder and shorter in duration compared to classic or “old BPD” seen in the pre-surfactant era. Primary pathology of today’s BPD is that of impaired alveolarization and vascular growth. Such infants may remain ventilator-dependent for several weeks and then improve progressively. During this period of ventilator dependency, lung compliance is poor, dead space is increased and interstitial edema is present but there is less airway injury and obstruction than that of classic BPD. Lungs are opaque on chest x-ray rather than exhibiting uneven hyperinflation. Optimizing PEEP, use of synchronized ventilation, fluid restriction (130-150 ml/kg) and diuretics are primary tools of management available. Inhaled bronchodilators or steroids have little effect and are not indicated for routine use. A subset of extremely immature infants may develop the more severe and prolonged “classic” course of BPD and require prolonged mechanical ventilation with high levels of support. Classic BPD is dominated by uneven airway obstruction, bronchomalacia, and hyperinflation.

**Phenotypes of BPD**

Because the etiology of BPD is complex and multifactorial, infants with the disease can have varied clinical manifestations. These manifestations are the result of *overlapping* phenotypes and the clinical course is dictated by the relative contribution of each component. Three different categories of disease have been described: lung parenchymal disease, pulmonary vascular disease, and airway disease. Therefore, it is important to avoid a “one-size-fits-all” approach to the management of these patients.

**Acute Course and Diagnosis**

An initially improving clinical course during the first 1 to 2 weeks of life is followed by deteriorating pulmonary function, rising oxygen requirements, and opacification of lung fields that were previously clear on chest radiograph. Wide swings in PaO₂ and O₂ saturation values are characteristic. Despite treatment of PDA, aggressive management of apnea, and no evidence of infection, the infant remains ventilator-dependent. Microvascular permeability increases, leading to symptomatic pulmonary edema. Necrosis of bronchial mucosa is widespread, producing increasing uneven airway obstruction. Airway obstruction by necrotic debris promotes atelectasis alternating with areas of gas trapping within the lung. A process of exclusion establishes BPD as the cause of persistent ventilator dependency.

**Course of Chronic Ventilator Dependency**

Features of this phase include bronchiolar metaplasia, hypertrophy of smooth muscle, and interstitial edema producing uneven airway obstruction with worsening hyperinflation of the lung. Obliteration of a portion of the pulmonary vascular bed is accompanied by abnormal growth of vascular smooth muscle in other sites. Active inflammation slowly subsides to be replaced by a disordered process of structural repair. During the early weeks of this phase, infants remain quite unstable with frequent changes in oxygen requirement and characteristic episodes of acute deterioration that require increases in ventilator support. After 6 to 8 weeks, the clinical course becomes more static as fibrosis, hyperinflation, and pulmonary edema come to dominate the clinical picture. Increased airway smooth muscle is present and tracheobronchomalacia may become apparent as episodes of acute airway collapse with severe hypoxemia. This phase evolves over 3 to 9 months, during which time growth and remodeling of lung parenchyma and the pulmonary vascular bed is associated with gradual improvement in pulmonary function and heart-lung interaction.
In most infants, extubation can be attempted from stable ventilator settings once oxygen requirement gradually falls to consistently 40% or less, infant is anabolic (as demonstrated by weight and linear growth trends), and the infant is beyond the phase characterized by wide swings in oxygen saturations described earlier. However, the infant remains vulnerable to pulmonary edema and reactivation of the inflammatory process within the lungs with deterioration in function. Most patients continue to exhibit significant pulmonary hypertension and attempts to wean oxygen or positive pressure support too rapidly may precipitate acute cor pulmonale.

Long-term monitoring
Over the first year of life, active inflammation diminishes and the process of repair and remodeling of the lung becomes more orderly. Lung growth and remodeling slowly progresses, allowing improving pulmonary function and decreasing need for positive pressure support. However, lung mechanics remain quite abnormal; hyperinflation, fibrosis, and cysts may remain visible on radiographs. Most such infants can be discharged to continue care at home. Many of these infants exhibit persistent evidence of fixed airway obstruction and some have episodes of typical asthma. Close monitoring of adequacy of oxygenation remains essential to avoid a subtle rise in PVR and insidious development of cor pulmonale.

Management of BPD
Primary goals of comprehensive BPD management include:

- **Prevention of infection** with an emphasis on working toward removal of indwelling central lines
- **Optimal nutrition for growth and repair**
- **Intensive neurodevelopmental assistance**, including prevention of narcotic or sedative habituation
- **Minimal impact respiratory support**: adequate lung growth for recovery of an infant with severe BPD requires months.
- **Prevention of cor pulmonale**

Nutritional Support
Complete nutrient intake must be provided despite significant fluid restriction. Although adequate calories may be provided using fat or carbohydrate additives, the intake of protein, minerals, and micronutrients will be insufficient unless they, too, are supplemented. Long-term dietary intake should meet all guidelines of the AAP for term and preterm infants. Periodic evaluation by a pediatric nutritionist is beneficial.

Fluid Restriction
Infants with BPD have increased lung water and may benefit symptomatically from fluid restriction to control pulmonary edema. The balance between fluid restriction, adequate growth, and stability of lung function requires frequent reassessment. In preterm infants, modest fluid restriction (150 mL/kg/day) and proper long-term nutrition often can be achieved using fortified human milk or one of the commercial mineral-enhanced premature formulas. These provide good quality protein intake, trace nutrients, and increased calcium and phosphorus supplements to optimize bone mineral uptake. When the infant reaches term, a standard or mineral- and protein-enriched transitional formula may be substituted. Severe impairment of lung mechanics may necessitate restricting fluids to 110-130 mL/kg/ day. (Sec 12 - Nutrition) Patients should be weighed every 3-7 days; measure height and head circumference weekly. Serum urea nitrogen, calcium, phosphorus, and alkaline phosphatase values should be determined periodically. Nutritional and growth parameters should be reviewed frequently with a pediatric nutritionist.

Chronic Mechanical Ventilation: Minimal Impact Respiratory Support
Table 2.6 depicts a comparison of ventilator strategies and goals during progression of early disease to established severe BPD. Accordingly, the ventilator goals have shifted from a weaning strategy aimed at early extubation in an effort to prevent the development of BPD to a strategy that minimizes day-to-day variation in respiratory care so the emphasis can be placed on nutritional and neurodevelopmental support. A more detailed description of chronic mechanical ventilation has been described in a previous section.

Oxygen Use and Monitoring
Oxygen use and monitoring is a critical component of BPD care. Chronic or recurrent alveolar hypoxia exacerbates pulmonary hypertension and increases mortality risk for patients with BPD. In moderate to severe BPD, supplemental oxygen is the primary tool to minimize pulmonary vascular resistance and prevent cor pulmonale. However, oxygen also may exacerbate lung injury and risk of retinopathy in preterm infants. In preterm infants with evolving BPD who have not reached full retinal maturation, adjust FiO2 to maintain SpO2 in the 90-95% range. Older infants with severe BPD or echocardiographic evidence of pulmonary hypertension require close attention to oxygen use and monitoring with daily review of stability of oxygenation.

The need for supplemental O2 often extends well beyond the period of positive pressure ventilator support. The impact of oxygen on outcome of BPD cannot be overemphasized. Attempted reductions in FiO2 must be monitored closely and adverse effects on PVR or pulmonary edema may not be apparent for several days after a reduction. (See Ch. 2.5 Weaning from CPAP and Nasal Cannula)

Neurodevelopment
The care environment is critical for chronically ventilator-dependent infants. The adverse impact of the intensive care environment upon development must be blunted during a long period of hospitalization.

The time course of evolving BPD coincides with critical period of neurodevelopment. A respiratory strategy that de-emphasizes day-to-day-variation and addresses the long-time constant physiology of obstructive lung disease will minimize air hunger, ventilator dysynchrony, and gas trapping, making the need for sedatives and paralytics less likely. Consequently, a primary goal of mechanical ventilation must be to support the infant’s ability to derive optimal benefit from developmental therapies and maintain engagement with their environment, caregivers, and family. If support or oxygen is weaned too quickly as demonstrated by fatigue with developmental therapies, the infant’s neurodevelopmental progress can be compromised. Use of multidisciplinary team care has been associated with improvement in neurodevelopmental outcome and reduction in need for hospital re-admission post NICU discharge.

A multidisciplinary team, directed by an experienced neonatologist and pediatric pulmonologist, can define each
infant’s needs and maintain focus on a consistent long-term plan of care. In hospital, parents and care providers must work together to plan a friendly, play-oriented environment that includes the infant’s own toys and possessions when applicable. Control light and noise. Some patients have associated neurologic dysfunction, hearing deficits, or feeding disorders, and the resources to manage these problems must be integrated into weekly schedules.

Screening
Perform hearing screening before 6 months (or by 34-36 weeks PMA if no longer on mechanical ventilation) of age to allow early intervention by an audiologist, if needed. Developmental assessment should begin during the hospital stay and continue as part of long-term follow-up after discharge. Specific attention to oral-motor dysfunction and feeding disorders may be necessary.

Surveillance and Management of Pulmonary Hypertension in the Patient with BPD
The presence of moderate to severe pulmonary hypertension in BPD patients has been associated with significant mortality risk. Treatment begins with optimizing oxygenation. Evidence of efficacy of pulmonary vasodilators such as iNO or sildenafil in BPD is limited but use is increasing. A role of Brain Natriuretic Peptide (BNP) levels in patients with BPD has not been established and monitoring trends of these values is of unclear clinical significance at this time.

The following are the recommendations by the BPD Collaborative for the monitoring and treatment of infants at risk for pulmonary hypertension, which complicates the course of 25% of patients with severe BPD. The pulmonary hypertension service may be consulted to help optimize care in patients with severe BPD and pulmonary hypertension. Universal screening of all patients with BPD is not recommended for our units but screening may be considered for select patients with signs and symptoms concerning for pulmonary hypertension.

Diagnosis and Treatment:
1. Echocardiography to assess for tricuspid regurgitant jet velocity, septal flattening, RV dilation, and other parameters of RV function. Cardiac catheterization should be considered prior to initiating long-term therapy to assess severity of disease and potential contributing factors, such as left ventricular diastolic dysfunction, anatomic shunts, pulmonary vein stenosis, and systemic collaterals
2. If pulmonary hypertension present:
   a. Evaluate and treat respiratory disease, including assessing for hypoxemia, aspiration, and structural disease
   b. Avoid hypoxemia (maintain oxygen saturation between 92% and 95%)
   c. Consider therapeutic agents
3. Therapies:
   a. iNO can be started at 20 ppm for symptomatic or severe pulmonary hypertension
   b. Transition from iNO to sildenafil as feasible starting at 0.5 mg/kg q8h and advancing to 2 mg/kg q6h. Monitor for desaturations secondary to V/Q mismatch and systemic hypotension.
   c. If unable to wean from iNO, consider the addition of an ETRA or a prostacyclin analog. Liver function should be monitored if on an ETRA.
4. Monitoring: Cardiac catheterization or serial echocardiography is recommended to monitor response to therapy.

Table 2-6. Comparison of ventilator strategies and goals during progression of early disease to established BPD.

<table>
<thead>
<tr>
<th>Early (BPD prevention)</th>
<th>Strategies to prevent acute lung injury</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Low tidal volumes (5-8 ml/kg)</td>
</tr>
<tr>
<td></td>
<td>2. Short inspiratory times</td>
</tr>
<tr>
<td></td>
<td>3. Increased PEEP as need for lung recruitment without overdistention (as reflected by high peak airway pressures)</td>
</tr>
<tr>
<td></td>
<td>4. Achieve lower FiO2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strategies for gas exchange:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Adjust FiO2 to target SpO2 (range: 91%-95%)</td>
</tr>
<tr>
<td>2. Permissive hypercapnia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Late (established BPD)</th>
<th>Strategies for effective gas exchange:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Marked regional heterogeneity</td>
</tr>
<tr>
<td></td>
<td>• Larger tidal volumes (10-12 mL/kg)</td>
</tr>
<tr>
<td></td>
<td>• Longer inspiratory times (≥0.6 s)</td>
</tr>
<tr>
<td></td>
<td>2. Airways obstruction</td>
</tr>
<tr>
<td></td>
<td>• Slower rates allow for better emptying, especially with larger tidal volumes (10-20 bpm)</td>
</tr>
<tr>
<td></td>
<td>• Complex roles for PEEP with dynamic airway collapse</td>
</tr>
<tr>
<td></td>
<td>3. Interactive effects of ventilator strategies</td>
</tr>
<tr>
<td></td>
<td>• Changes in rate, tidal volume, inspiratory and expiratory times, and pressure support are highly interdependent</td>
</tr>
<tr>
<td></td>
<td>• Overdistension can increase agitation and paradoxically worsen ventilation</td>
</tr>
<tr>
<td></td>
<td>4. Permissive hypercapnia to facilitate weaning</td>
</tr>
<tr>
<td></td>
<td>5. Adjust FiO2 to target high oxygen saturations</td>
</tr>
</tbody>
</table>

Medications

Diuretics
Infants with BPD have increased lung water and are susceptible to gravity-induced atelectasis and alveolar flooding. Systematic reviews have demonstrated improvement in short-term lung mechanics and reduced need for supplemental oxygen among premature infants with BPD treated with diuretics. However, no long-term benefits have been established on mortality, duration of oxygen supplementation, length of stay, or need for subsequent re-hospitalization. Potential side effects include severe electrolyte imbalance, increased calcium loss and osteopenia, ototoxicity and nephrocalcinosis. The most commonly used diuretics are thiazides and furosemide.

Thiazides
Thiazide diuretics act upon the early distal renal tubule. Hydrochlorothiazide (2 mg/kg per dose twice daily) or chlorothiazide (20 mg/kg per dose twice daily) are usually administered enterally. In some studies, this regimen has improved lung mechanics and reduced urinary calcium excretion; in other studies the regimen has been less effective. Thiazide diuretics may be associated with increased loss of potassium and phosphorus. These agents are less potent than furosemide. However, they may be adequate in many infants, especially in those already fluid restricted to 130 mL/kg/day or less. In the single RCT available, addition of spironolactone to a thiazide regimen did not alter lung mechanics, oxygen requirement or electrolyte balance. Although thiazides sometimes are used in attempts to prevent or ameliorate nephrocalcinosis, evidence of efficacy of this strategy is lacking.

Furosemide
Furosemide, a potent loop diuretic, improves short-term lung function by both its diuretic effect and a direct effect on transvascular fluid filtration. Furosemide, in periodic doses, should only be used in patients inadequately controlled by thiazides alone.

Chloride Supplements
Chronic diuretic therapy induces hypochloremic metabolic alkalosis with total body potassium depletion. Infants receiving chronic diuretics need chloride supplementation of 2 to 4 mEq/kg/day in addition to usual nutritional needs. This should be provided as potassium chloride with no sodium chloride provided unless serum sodium < 130 mEq/L. Serum chloride should be > 90 mg/dL and never maintained < 85 mg/dL. In general, total potassium and sodium chloride supplementation should not exceed 5 mEq/kg/day without consideration of reducing diuretic use. The combination of furosemide and thiazide is untested and may have a severe effect on electrolytes.

Inhaled Medications
Use of inhaled bronchodilator and anti-inflammatory agents is a complex issue in management of BPD. Numerous studies have demonstrated increased resting airway resistance in older infants with classic BPD and have reported variable responses following administration of beta-2 agonists or inhaled steroids to ventilator-dependent infants. However, these studies report only short-term results. Evidence for long-term benefit is lacking and no evidence based guidelines currently exist for use of these agents in management of BPD. The only model for use of these agents currently available is that provided by the recommendations of the NIH Asthma Consensus Panel. It is recognized that BPD is not asthma but episodic wheezing and signs of reactive airway disease increase in frequency in BPD patients after 1-3 months post-term. Metered dose inhaler (MDI) systems with valved spacers are the currently recommended method for delivery if inhaled medications are used.

Although wheezing events are common, episodes of true reactive airway disease are uncommon during the first 2-3 months of life in most infants with BPD. Bronchomalacia and airway collapse are being recognized with increasing frequency in infants with signs of airway obstruction or sudden onset of reduced air flow. Initial management of acute deterioration in chronically ventilator-dependent infants should include careful attention to airway patency, synchronized ventilation, consistency of oxygenation and fluid balance. Evaluation for possible infection should be done. In patients remaining unstable with progressive hypercapnia or high oxygen requirement, a short trial (48 hours) of a short acting beta agent (SABA) such as albuterol or an inhaled steroid (5-7 days) may be tried. However, a SABA should not be used for chronic maintenance therapy.

Short Acting Beta-Adrenergic Agents
Denjean described a dose-response relationship for ventilator-dependent premature infants using an MDI to administer 1 or 2 puffs (0.09 or 0.1 mg) of albuterol via a commercial spacer device. Resting airway resistance was significantly reduced and lung compliance improved. However, this was a short term observational trial only performed upon babies 2 to 3 weeks of age with evolving BPD. A subsequent Cochrane meta-analysis found no effect of bronchodilator therapy on mortality, duration of mechanical ventilation or oxygen requirement when treatment was instituted within 2 weeks of birth. No beneficial effect of long-term B2 bronchodilator use has been established and data regarding safety are lacking. In children with asthma, prolonged use of albuterol may be associated with a diminution in control and deterioration in pulmonary function in association with increased V/Q mismatch within the lungs. We do not recommend routine use of SABA’s in management of BPD. In chronic lung disease, SABA’s such as albuterol or L-albuterol should be restricted to rescue therapy in select patients with objective evidence of reactive airway disease and a response to inhaled therapy and should not be used for chronic maintenance therapy. Infants felt to need SABA’s more than 1-2 times per week should receive further evaluation (including work up for bronchomalacia) and a defined plan for long-term care.

Inhaled Corticosteroids
Current evidence regarding the role of inhaled steroids for the prevention or treatment of BPD in premature infants is uncertain. An RCT that evaluated the long-term effects of inhaled budesonide in ELBW infants found no difference in neurodevelopmental impairment between infants receiving early budesonide or placebo but more importantly, increased mortality was seen in the budesonide group. A Cochrane systematic review, (which did not include long-term follow-up results from the Bassler study) found that early administration of inhaled steroids to VLBW neonates was effective in reducing death or CLD at 36 weeks’ PMA (moderate quality evidence). The use of prophylactic inhaled steroids in ELBW or VLBW infants is not recommended for patients in our unit because of conflicting evidence and concern for increased mortality. Inhaled steroids may be considered for acute episodes of respiratory failure in older infants.
Use of Systemic Steroids in Management of Severe Chronic Lung Disease

Postnatal corticosteroids have been used in neonatal cardiopulmonary care for:

- Symptomatic management of refractory hypotension
- Early treatment to prevent BPD
- Treatment after 7 days of age to ameliorate the evolving lung injury sequence and facilitate extubation.
- Treatment of severe respiratory failure requiring very high ventilator and oxygen support.

Despite numerous RCT’s and systematic reviews, serious concern and controversy remain regarding use of corticosteroids to prevent or treat BPD. Postnatal dexamethasone use is associated with short-term improvement in pulmonary function and reduced risk of BPD or death at 36 weeks PMA - but increased risk of neurodevelopmental impairment. Hydrocortisone appears to have lower risk of adverse neurologic outcome but pulmonary benefits of treatment after the first week of life have not been demonstrated in studies to date. Hydrocortisone appears to have lower risk of adverse neurologic outcome but pulmonary benefits of treatment after the first week of life have not been demonstrated in studies to date.

Prophylactic hydrocortisone, initiated at birth, was associated with improved survival without BPD in one recent RCT. However, meta-analysis of eight previous trials failed to demonstrate an overall benefit on pulmonary outcome.

The most recent AAP Policy Statement regarding postnatal use of systemic steroids (Pediatrics 2010; 126:800-808 (Reaffirmed 2014) concluded:

- Significant risk is associated with the use of high dose dexamethasone (0.5 mg/kg/day) and use of this therapy is not recommended for prevention or treatment of BPD.
- Low dose dexamethasone (<0.2 mg/kg/day) may facilitate extubation and may decrease short- and long-term adverse effects associated with high dose dexamethasone. Current data are insufficient to allow specific recommendations.
- Prophylactic low dose hydrocortisone (1 mg/kg/day), given from birth, in extremely preterm infants may increase survival without BPD without adversely affecting neurodevelopmental outcomes. Because this approach is new, based solely on one study, and requires extensive discussions on the risks and benefits of exposing all extremely low birth weight infants to this interventions, we cannot recommend this therapy for the prevention of BPD at this time.
- Higher dose hydrocortisone (3-6 mg/kg/day) given after the first week of life has not been shown to improve rates of survival without BPD in any RCT. Existing data are insufficient to make a recommendation regarding treatment with high dose hydrocortisone.

The AAP acknowledges that in select groups of infants the benefits of short course of corticosteroid therapy may outweigh the risks by mitigating risk of BPD. A meta-regression analysis of 20 RCT’s reported that postnatal corticosteroid (mostly dexamethasone) treatment of infants with BPD risk > 65% resulted in reduction in occurrence of death or CP compared to controls. In 2011 the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) developed a Web-based BPD estimator based on data from the Neonatal Research Network (https://neonatal.rti.org/index.cfm). The estimator uses simple demographic information and respiratory support data to estimate risk of BPD, categorized by severity. This tool can be used in clinical practice to help identify infants at high risk for BPD who may benefit from steroid treatment.

Infants 23-24 weeks gestation that remain on mechanical ventilation >14 days with an oxygen requirement > 30% are at very high risk for BPD. The Cochrane review of 21 RCTs examined the risks and benefits of late systemic postnatal steroids (age > 7 days) in preterm infants with evolving lung disease. The evidence suggests that therapy may reduce mortality and BPD at 36 weeks’ PMA, however, there is limited evidence to determine the adverse long term effects. Based on current evidence, the clinician might choose, with parental agreement, and discussion of long and short term risks and benefits, to administer a short course of corticosteroid therapy to those patients at high risk of BPD who cannot be weaned from mechanical ventilation (weak recommendation, moderate quality evidence).

If a decision is made to initiate corticosteroid therapy, we recommend low dose dexamethasone given twice daily according to the following tapering schedule derived from the DART Study, 2006, and Canadian Pediatric Society, 2015:

- 0.075 mg/kg/dose every 12 hours (6 doses)
- 0.05 mg/kg/dose every 12 hours (6 doses)
- 0.025 mg/kg/dose every 12 hours (4 doses)
- 0.01 mg/kg/dose every 12 hours (4 doses)
- Cumulative dose = 0.89 mg/kg/day

Corticosteroid Treatment Beyond the Newborn Period.

If systemic steroids are necessary for an infant with severe BPD who is beyond 44-48 weeks PMA, use of prednisone or methylprednisolone according to guidelines of Asthma Expert Panel III (2007) is recommended.

Exacerbation of Acute Lung Inflammation

Abrupt deterioration in pulmonary function may occur in older infants who have had a stable course and modest oxygen requirement for several weeks. Differential diagnosis includes acquired infection, worsening pulmonary hypertension, or the insidious onset of symptomatic cor pulmonale. However, many such episodes represent either accumulation of edema fluid in the lung or reactivation of the inflammatory process itself. These episodes may require significant increases in inspired oxygen concentration and ventilator support as well as additional fluid restriction and diuretics. Inhaled steroids or short-term albuterol may be required in select patients. Severe exacerbations in older infants occasionally require a pulse course of systemic corticosteroid therapy. Little published information is available to guide selection of rescue agents in the BPD patient during the first year of life. In this circumstance, recommendations of the NIH Expert Panel III for treatment of acute exacerbations of asthma in young infants should be followed.
Management of Acute Reactive Airway Disease

Sections of Neonatology, Department of Pediatrics, Baylor College of Medicine

Episodes of severe bronchospasm leading to respiratory decompensation are uncommon during the first 3 months of life. Acute episodes of poor air flow and hypoxemia are more likely to be result of airway collapse associated with tracheobronchomalacia. However, if an infant with BPD develops acute, persistent wheezing with gas trapping and deterioration in lung function, oxygen saturation should be closely monitored and a chest X-ray and measurement of PCO2 should be obtained.

Emergency management of severe airway reactivity in infants with BPD is based upon consensus panel guidelines for asthma management published by the NIH. However, BPD is not asthma and these guidelines do not provide specific dosage recommendations for the first year of life. At present, albuterol (90 mcg per puff) or levalbuterol (45 mcg per puff) are the rescue agents of choice. Either may be given by MDI and spacer, 2 puffs every 4 to 6 hours for 24 to 48 hours, and then progressively weaned.

For severe episodes, either may be given by MDI and spacer, 2 to 4 puffs as frequently as every 20 minutes for 3 doses. Dosage should then be weaned to 2 puffs every 4 to 6 hours for 24 to 48 hours. Albuterol is not recommended for chronic maintenance therapy. If an occasional episode is particularly severe or persistent, addition of inhaled steroids may be necessary. Several studies suggest BPD infants with episodic wheezing are less responsive to bronchodilator therapy than asthmatic infants of similar age.

Discharge Planning

This encompasses the transition from mechanical ventilation to the home environment. In some cases, it involves preparation for home care requiring mechanical ventilation (Ch. 2.10 Interdisciplinary Care and Discharge of the Ventilator Dependent Patient). Although the lungs have improved, both structure and function remain quite abnormal. Even in infants no longer requiring ventilator support, additional months or years of lung growth will be required to overcome the remaining derangements of mechanics. Multidisciplinary care, including nutritional and neurodevelopmental assessments, should continue into the outpatient setting. The pediatric pulmonologist plays a central role in coordinating post-discharge care, and accordingly, must be closely involved in discharge planning. Close monitoring of adequacy of oxygenation is essential to prevent subtle increases in PVR leading to insidious development of cor pulmonale. Influenza vaccine is particularly important for these patients. After discharge, palivizumab prophylaxis against RSV infection also is recommended for infants with BPD who are younger than 2 years of age and have required medical therapy for BPD within 6 months of the anticipated season for RSV.

2.9 Prevention of BPD

Several strategies have been studied and identified to be effective in reducing a premature infant’s risk of BPD. It is crucial that clinicians follow the approaches listed below to minimize the risk of lung injury during the NICU course. By optimizing the use of medications such as caffeine and vitamin A (dosed according to unit guidelines), ensuring that our center maintains a high antenatal steroid rate, utilizing CPAP first strategy (with rescue surfactant therapy), and taking steps to minimize ventilator days, ventilator related injury (by using gentle ventilation strategies such as volume targeted ventilation), unplanned extubations, and blood stream infections, we can have a profound impact on the long-term outcomes of premature infants. Practitioners in the NICU encounter many opportunities, on a daily basis, to make decisions that can influence a patient’s risk of BPD and the associated neurodevelopmental outcome. By weaning ventilator support as early and quickly as possible, by optimizing CPAP, and preventing unplanned extubations, we can minimize the duration of mechanical ventilation, which has been identified as the most effective strategy for prevention of BPD. While an infant is being supported with mechanical ventilation, use gentle ventilation strategies such as volume targeted ventilation (VG mode) whenever possible, making adjustments based on blood gases and clinical parameters as frequently as possible, to limit volutrauma related lung injury. Be mindful of oxygen saturations, even after an infant is extubated and is in the convalescent phase of lung disease, and make adjustments to ensure saturations are maintained in the target range of 90-95%. Preventing lung injury and BPD is a team effort. Our bedside nurses, respiratory therapists, dietitians, pharmacists and trainees can play a big role in ensuring that the few measures identified to mitigate the risk of BPD are followed closely and thoroughly.

In our NICUs at Baylor a large Quality improvement initiate is in progress by the ‘Avoiding Lung Injury or ALI’ team. This multidisciplinary team reviews our local data related to respiratory outcomes, identifies areas in need of improvement and makes changes to care practices following the model for improvement (PDSA cycles). Therefore, please follow the protocols and algorithms that are being implemented as part of the QI projects closely to ensure that your practices are consistent with most recent unit recommendations.

- **Oxygen saturation targeting.** Oxygen is one of the most commonly used medication in the NICU and its main use is to alleviate hypoxic respiratory failure. Similar to other medications, oxygen use in humans is associated with significant adverse effects across all age groups. Neonates, particularly preterm infants, are highly vulnerable to oxygen toxicity because of an anatomic and functional immature anti-oxidant defense system. Retinopathy of prematurity, bronchopulmonary dysplasia, and ischemic brain injury are some of the serious adverse effects associated with oxygen use in premature infants. Currently oxygen therapy is titrated based on the oxygen saturations measured using pulse oximetry (SpO2). However, it is important to realize that SpO2 at upper limits cannot accurately reflect tissue oxygen levels because of the flat upper portion of the oxygen-hemoglobin dissociation curve. For example, at a SpO2 of 100%, the PaO2 can range from 80 – 600 mm Hg 4, oxygen levels which are highly toxic to the retina, lungs, and brain. Similarly, SpO2 consistently below 90% is associated with increased mortality in extremely low birth weight infants. Although the optimal physiological limits of SpO2 in preterm infants are unknown, our current recommendation is to maintain the SpO2 between 90-95% based on the outcome of recent trials 5. This holds true even for premature infants who have bronchopulmonary dysplasia and pulmonary hypertension. To minimize
oxygen toxicity, we strongly recommend to use blended oxygen with any form of oxygen administration and titrate the FiO₂ to maintain SpO₂ between 90 – 95%. Regardless of the mode of respiratory support used, FiO₂ should be adjusted to maintain saturations in the target range and minimize oxygen toxicity.

- **Early nasal CPAP.** Two meta-analyses have demonstrated a reduction in death or BPD associated with early application of NCPAP in combination with selective use of surfactant. A failed trial of early CPAP should not preclude ongoing attempts to wean an infant from the ventilator.

- **Gentle Ventilation or Volume Targeted Ventilation.** A recent Cochrane meta-analysis of 12 RCT’s reported significant reductions in death or BPD associated with volume targeted ventilation (VTV). We recommended VTV in the form of Volume Guarantee (VG) as the default mode of ventilation for acute neonatal lung disease.

- **Minimizing Ventilator Days.** Strongest evidence for preventing BPD includes limiting duration of mechanical ventilation. Therefore daily efforts should be made to assess ventilator requirements and adjust based on clinical parameters and blood gases. Once an infant is identified to meet criteria for extubation readiness, attempt extubation immediately (rather than waiting for a convenient time or day) unless limited by special circumstances.

- **Permissive hypercapnia.** Identified as a strategy that can reduce incidence of lung injury when compared to traditional ventilator strategies aimed for normocapnia. Ideal target Co₂ levels have not been clearly identified.

- **Unplanned extubations.** Follow unit guidelines for securing ETT and adjusting tube position. Consider periodic chest x-rays to confirm tube position in long-term intubated patients. Taking these measures and ensuring that patient’s airway is handled carefully during routine care and patients. Taking these measures and ensuring that patient’s airway is handled carefully during routine care and procedures can prevent inadvertent extubations which in turn can result in bagging, clinical deterioration and potential need for emergent re-intubation.

- **Extubation failure.** Optimizing caffeine dosing, post-extubation respiratory support via CPAP or NIPPV can reduce chances of extubation failure.

- **Caffeine.** A multicenter randomized trial (CAP Trial) involving more than 2000 infants less than 1250 grams at birth reported a reduction in need for oxygen at 36 weeks PMA and improved neurologic outcome at follow-up in babies receiving routine caffeine administration initiated during the first 10 days of life. Based on two meta-analyses, caffeine administration is recommended for all infants born < 1250 grams (strong recommendation, moderate quality evidence.).

- **Vitamin A.** Meta-analysis of 10 RCT’s demonstrated a modest reduction in CLD at 36 weeks’ PMA with administration of vitamin A to very low birth weight infants. We recommend administration of prophylactic vitamin A (if available) to babies < 1000 grams, beginning during the first week of life. Give 5000 IU intramuscularly Monday, Wednesday and Friday for a total of 12 doses (strong recommendation, moderate quality evidence).

- **Fluid Management.** It is recommended that excess fluid administration be avoided and attempts be made to maintain infants who are receiving mechanical ventilation with even or slightly negative water balance during their early course.

## 2.10 Interdisciplinary Care and Discharge Planning of the Ventilator Dependent Patient

A decision to undertake home ventilation requires careful patient selection, frank discussions with family members and a firm commitment by them to this complex home care. Only a small proportion of infants requiring chronic ventilation are suitable candidates. If home ventilation appears appropriate and is the desire of the family, consult the Discharge Planning Coordinator to begin investigation of available home care services. As planning develops the care team will be asked to order specific equipment and supplies for home care needs.

- Consult a Pediatric Pulmonologist to determine (a) can they accept the role of home ventilator care in the patient (b) what specific ventilator support modes and monitoring do they anticipate will be used at home and (c) what additional testing do they require in preparing for home care.

- The Nurse Manager responsible for the patient’s NICU care team. The Nurse Manager, in conjunction with a tracheostomy care educator, will be responsible for assuring completion of parent teaching and documentation in the medical record.

### Criteria for Discharge to Home Ventilation

- **Parent commitment and completion of all aspects of training for the prescribed care at home by family caregivers.** The AAP recommends training at least two family caregivers and assessment of their ability prior to discharge. Acquisition of parent skills should be documented in the nursing discharge teaching records.

- **Stable recent respiratory course with FiO₂ < 40%.** Discharge of a patient with persistent PCO₂ values of 70 mm Hg or greater would be feasible only in face of normal pH, otherwise stable course and close collaboration with Pulmonary Service.

- **Tracheostomy in place and mature.** At present non-invasive modes of support (BIPAP, NCPAP, and Mask CPAP) are not used in our program for BPD home care. When tracheostomy is considered for long term ventilator care, the potential role of a feeding gastrostomy should be discussed.

- **Minimal weight for home ventilation is usually > 2500 g.** Specifications for the LTV 1150 home ventilator recommend weight 5 kg or above to allow delivery of minimal TV of 50 ml. However, these devices can deliver lower TV to smaller infants if operated in Pressure Control or Pressure Support mode.

- **Stable respiratory course maintained for several days following switch to pediatric circuit and home ventilator.**

- **Evaluation of family circumstances by Social Services Department.**

- **Evaluation of physical adequacy of home setting by the home care company (lighting, power supply, access to
emergency hospital facilities, etc.) The physician should work with Social Services and the Discharge Coordinator to make formal request to the electric power provider company to place patient on a priority list for assistance in case of prolonged outage.

- One family member should be completely trained in all aspects of home ventilator care. A second family member should be trained in infant CPR, recognition of airway emergencies and replacement of tracheostomy tube.

### Migration to Home Ventilator
Most patients initially will receive SIMV/PSV at home but this will vary depending upon status. Some patients may be moved to volume control ventilation on their conventional ventilator and average expired tidal volume recorded for several days. In older infants, an expired CO₂ monitor may be useful also during switch to home ventilator. If patient is stable a pediatric circuit then may be placed on the conventional ventilator. Adjustments in machine Vt again may be required. If patient remains stable he may then be switched to the home ventilator. This often requires additional adjustments in machine Vt. After a stable period on the home ventilator, infant seat/car seat testing of SpO₂ and PCO₂ in the semi-upright position should be performed. Modified positioning, as well as special infant seats, car seats or strollers may be required. At this point an HME may be introduced for short test periods to determine tolerance and proper size.

Current home ventilators are approved for weight 5 kg or above and minimal TV of 50 ml. Some infants otherwise ready for home ventilator care may be too small for the minimal TV limit of 50 ml and must remain on pressure controlled SIMV/PSV or SIMV only.

### Monitoring and Equipment for Home Ventilation
- Pulse oximeter
- Suction machine and supplies (including replacement tracheostomy tubes)
- Portable O₂ tank
- Tracheostomy care supplies
- O₂ concentrator
- Mask/bag

### Special Issues
- Humidification – standard ventilator humidifier will be used for the ventilator at home.
- HME’s (heat moisture exchanger) are used for short-term periods when patient and ventilator travel outside the home. If patient is stable, however, a period of 1-2 hours without humidification is acceptable.
- Use of speaking valves in home ventilation/tracheostomy patients may be introduced for short periods prior to discharge. However, some patients may not yet tolerate these (especially those with significant bronchomalacia on PEEP > 8cm H₂O).

### 2.11 Pulmonary Hypertension in Lung Diseases
Pulmonary hypertension (PH) associated with preterm lung disease belongs to Group 3 in the World Health Organization classification of PH. Its pathogenesis and pathophysiology differs from pulmonary arterial hypertension (PAH) and persistent pulmonary hypertension of the newborn (PPHN). The etiology of pulmonary vascular disease associated with BPD is multifactorial in nature; injury can result from both prenatal and postnatal factors. Prenatal risk factors include hypertensive diseases of pregnancy, intrauterine growth retardation, infection and/or genetic/epigenetic factors, while postnatal risk factors include hyperoxia, mechanical ventilation, infection, acute or chronic tissue hypoxia, heart dysfunction and presence of shunts. These factors cause altered angiogenesis and alveolarization, abnormalities in vascular tone and vasoreactivity, impaired metabolic function, decreased alveolar-capillary surface area for gas exchange, and abnormal pulmonary vasculature structure. The end result is pulmonary hypertension: a pulmonary vascular system with marked increase in pulmonary vascular resistance. The elevated resistance prevents forward flow of blood through the lungs, which manifests as worsening hypoxemia and right heart failure.

Increased duration and severity of respiratory support is associated with development of significant late PH. While PH is highly prevalent in infants with severe BPD, the relationship between severity of BPD and PH is not always linear; infants with mild or no BPD can also have evidence of increased pulmonary vascular resistance. Although many infants will develop BPD, PH only affects a minority at discharge. However, premature infants with severe BPD and severe PH have higher mortality rates. Therefore, timely diagnosis combined with appropriate intervention is crucial for improved prognosis.

### Diagnosis
Certain subsets of NICU patients should be monitored closely for development of PH, especially those with history of oligohydramnios, IUGR, slower than expected rate of clinical improvement, severe BPD at 36 weeks postmenstrual age, congenital heart defects that put them at increased risk of PH and recurrent cyanotic episodes, poor growth, or persistent pulmonary edema. Echocardiography may demonstrate signs of PH, including increased tricuspid regurgitation and changes in the right ventricle shape/size/function, septal position, right ventricular ejection time to pulmonary artery acceleration time (RVET:PAAT) ratio, and direction of shunt flow. Echo can also be used to evaluate for “benign” shunts that may be contributing to the clinical picture or to assess for reversal of flow pattern in known shunts indicating changes in pulmonary pressures. Caution must be taken as under- and over- estimation of pulmonary arterial pressure is possible with echo.

Other imaging that can be helpful in the diagnosis include chest films to evaluate pulmonary vascular markings and heart size and, on occasion, CT chest with angiography Baseline BNP may be obtained and trended with repeat echo studies.

Cardiac catheterization is the gold standard for diagnosis of PH and is often used in children and adults. It can be used to confirm the presence of PH and assess severity, evaluate cardiac anatomy and assess for other abnormalities (shunt lesion, systemic-pulmonary collaterals, and pulmonary venous irregularities),
assess hemodynamics including RV and LV function, and evaluating therapeutic responses. It is, however, an invasive procedure which requires clinical stability and, typically, a minimum size of 1.5 kg. These criteria often affect the candidacy of former preemies with severe BPD.

Cardiac catheterization is recommended if: (strong recommendation, low quality evidence)
- Significant PH despite optimal management of lung disease and associated morbidities
- Anticipate long-term chronic PH therapy
- Unexplained, recurrent pulmonary edema

**Management of PH in the NICU**

1. **Management of chronic respiratory failure:** This is a crucial component of the management of PH. Acute and/or chronic respiratory failure must be addressed quickly and appropriately to minimize impact to an abnormal pulmonary vascular system. Ensure adequate respiratory support using ventilator techniques which minimize under- or over-inflation because of the negative effects on PVR associated with low or high lung volumes (strong recommendation, high quality evidence). In patients with suspected structural airway abnormalities, consider flexible and/or rigid bronchoscopy to evaluate their airways.

2. **Nutrition:** Nutrition should be optimized; this is often difficult in the infant with PH because of caloric expenditure and fluid restriction.

3. **Oxygen:** The goal is to reduce or eliminate hypoxic episodes. Target saturation ranges in infants with PH should be set at 91-95%. Desaturations below 85% and hyperoxia >97% should be avoided. (strong recommendation, high quality evidence)

4. **Diuretics:** Titrated to effect, especially important in the setting of shunt lesions. Use can be considered as long as cardiac preload is adequate (strong recommendation, low quality evidence).

5. **Inhaled nitric oxide:** Used in range of 1-20 ppm; methemoglobin levels should be monitored. iNO is indicated if PaO₂ is <100 mmHg (while receiving 100% oxygen) or if oxygenation index is >25 (strong recommendation, high quality evidence).

6. **If the patient does not respond to the above interventions, obtain PH team consult for further management.**

**Prognosis**

PH medications have been used with success in various neonatal populations; however, optimization of respiratory status remains the principal therapy for most infants who have PH associated with BPD. Therefore, while PH is a risk factor for increased mortality in this vulnerable group, with adequate growth, proper respiratory support, and management of comorbid conditions, the prognosis for the majority of this population is generally excellent. Few infants will have chronic PH requiring medical therapies past early childhood. Risk for acute PH (i.e., associated with acute respiratory failure in the setting of a respiratory infection) in later life remains but also typically decreases over time.

**2.12 Congenital Diaphragmatic Hernia (CDH)**

When CDH is diagnosed before birth, fetal MRI is typically obtained at our center. The percentage of herniated liver (% HL) and observed-to-expected fetal lung volumes (O/E) obtained from MRI should be used in prenatal counseling to educate families on disease severity and mortality risks in CDH patients (strong recommendation, moderate quality of evidence). The Brindle Prediction Score, a risk assessment tool derived from the CDH Study Group database, is based on clinical parameters and can be used to calculate the mortality risk of CDH patients as low, intermediate or high. The Brindle Prediction Score should not be used for individual patient decisions regarding the use of ECMO or other medical management (strong recommendation, low quality of evidence).

Practitioners should measure and document the following factors for each patient with CDH: side of the defect, total lung volume (TLV), lung-to-head ratio (LHR), observed-to-expected lung-to-head ratio (O/E-LHR), stomach position and lung-to-thorax ratio (weak recommendation, moderate quality of evidence). Pre-established objective criteria should be used to score the severity of cardiac lesions. The presence of a major cardiac anomaly is associated with an increased risk of mortality (strong recommendation, moderate quality of evidence).

The oxygenation index should be used for management decisions in CDH patients (strong recommendation, low quality of evidence). The SNAP II Score, Wilford Hall/Santa Rosa Clinical Prediction Formula, Congenital Diaphragmatic Hernia Study Group (CDHSG) formula, the best PaCO₂ at 1 hour of life and 24 hours of life, and the highest pre-ductal O₂ saturation value during the first 24 hours of life should not be used to predict survival or make decisions about treatment options for CDH patients (strong recommendation, low quality of evidence).

**Strategy of respiratory management**

1. Monitor pre-ductal oxygen saturations for primary decision making

2. Facilitate spontaneous breathing (minimize sedation or neuromuscular blockade)

3. Use gentle, low volume ventilation in attempt to minimize trauma to the underdeveloped lungs

For a known CDH delivery, the on-call neonatal ECMO clinician at TCH should be alerted to the impending delivery, and the presence of a crystalloid-primed ECMO circuit in the ECMO storage area should be confirmed. At the TCH Perinatal Center, a neonatology faculty member attends the delivery.

At the time of delivery, immediate intubation should occur to avoid bag-mask ventilation. A pre-ductal saturation monitor should be immediately placed. A 10 French Replogle tube should be placed and attached to intermittent suction.

CDH patients should be initially ventilated with the conventional ventilator using AC/VG mode with the initial settings listed below. Initial ventilation should be with 100% FiO₂ (recommendation, low quality of evidence). Pre-ductal saturations should be targeted to ≥70% for the first ten minutes after birth; increasing to ≥80% for the first two hours of life. Thereafter, pre-ductal oxygen saturations should be ≥85%
Section 2—Respiratory Care

Management of Hypotension

Hypotension in CDH patients is multifactorial and evaluation for specific etiologies often requires evaluation of effective blood volume status and determination of cardiac positioning, filling and myocardial function by echocardiogram. Low dose dopamine (up to 10 micrograms/kg/min) is recommended for initial pharmacologic management of non-specific hypotension. If hypotension requires dopamine of 10 micrograms/kg/min or more, hydrocortisone (1 mg/kg/dose Q8h) should be initiated per consensus guidelines. Dopamine infusion may continue to be titrated up to a maximum of 20 micrograms/kg/min, following which low-dose epinephrine infusion is added. Persistent hypotension requiring increasing pressor support should prompt an evaluation of cardiac function by echocardiography. Addition of special agents such as milrinone should be based upon specific evaluation of cardiac function, blood lactate levels, and other parameters of systemic blood flow and oxygen delivery.

Additional Indications for ECMO

- OI > 40 on 2 separate measurements
- PO2 persistently < 40 mmHg or
- Lactate rising above 3.0
- MAP on HFOV > 17 cm H2O
- Pre-ductal SpO2 < 85% with pH < 7.15

Initial Ventilator Settings

- PEEP: 5-6 mmHg
- TV: 4-5 ml/kg
- Back-up rate: 40 breaths/minute
- iT: 0.3 seconds
- Pmax: 3-5 above measured PIP
- FiO2: adjust as needed for target pre-ductal saturations of ≥ 80%

HFOV Settings

- MAP: 13 (or 2 above that on conventional ventilator)
- iT: 0.3
- Hz: 10
- DeltaP: sufficient to produce perceptible chest ‘jiggle’

The decision to offer ECMO is made by the neonatal ECMO clinician and the Pediatric Surgery faculty jointly. Some infants may require CDH repair on ECMO.

Most symptomatic CDH patients need continued fluid restriction and diuretic support for a prolonged period of time. CDH repair can be considered when physiologically stable: FiO2 < 0.5, pre-ductal SpO2 85-95%, normal blood pressure for gestation, lactate < 3 mmol/L, urine output ≥ 2 ml/kg/hr.

All CDH patients should be monitored for pulmonary hypertension. All post-ECMO CDH patients should have a pre-discharge head MRI, a neurodevelopmental evaluation and follow-up, and a hearing assessment.

Goal parameters

- pH 7.20 or greater with lactate 3mmol/L or less
- PCO2 50-70 mmHg, PO2 40-90 mmHg
- Pre-ductal saturations > 80% (first 2 hours of life)
- Pre-ductal saturation > 85% (beyond 2 hours of life)

Clinicians should consider switching the mode of ventilation to HFOV for CDH patients that cannot achieve target PCO2 on conventional ventilation with PIP < or equal to 28 (weak recommendation, low quality of evidence). Once on HFOV, increase MAP (max of 17) and Delta P as required to achieve goal parameters.

A trial of iNO may be initiated, but evidence of benefit in CDH is lacking. Current evidence does not support routine surfactant replacement therapy. However, clinicians may consider surfactant replacement in CDH patients treated with Fetal Tracheal Occlusion or those delivered at ≤ 37 weeks gestation (strong recommendation, weak quality of evidence). Surfactant should not be used routinely in the non-FETO term CDH patient at birth (strong recommendation, low quality of evidence). Near infrared spectroscopy (NIRS) readings should not be used for patient care management (strong recommendation, low quality of evidence).

ECMO should be considered for CDH patients that cannot achieve saturations and/or blood gas targets with maximal HFOV support (weak recommendation, low quality of evidence).
2.13 Neonatal ECMO

Neonatal ECMO improves survival of term or late preterm infants with hypoxic respiratory failure who are failing high levels of conventional ventilator support. The most common underlying conditions for patients needing ECMO at our center include PPHN (30% of TCH Neo ECMO patients), meconium aspiration, RDS, sepsis or congenital diaphragmatic hernia (63% of Neo ECMO). Survival to discharge following ECMO for neonatal respiratory failure currently reported in the large international Extracorporeal Life Support Organization (ELSO) data base is ~75%. Mortality risk is greatest among infants with CDH and acquired pneumonia.

**Hypoxic Respiratory Failure**

Respiratory failure indices associated with mortality risk of 80% or greater include:

- $\text{PaO}_2 < 50$ mmHg for 2-12 hrs
- $\text{AaDO}_2 > 600$ mmHg for 4-12 hrs
- $\text{PaO}_2 < 35$ mmHg for 2-12 hrs

**These have not been validated for CDH patients**

**General Inclusion/Exclusion Criteria for ECMO in the NICU**

- Gestational age ≥ 34 weeks, weight ≥ 2.0 kg, age less than one month (**
- No significant coagulopathy or uncontrolled bleeding
- No major intracranial hemorrhage
- Reversible lung disease with mechanical ventilation < 10-14 days duration
- No uncorrectable congenital heart defect
- No lethal congenital anomalies
- No evidence of irreversible brain damage

**Selection criteria must be individualized for certain preterm infants, fetal tracheal occlusion patients, severe air leak syndromes and viral pneumonia. On rare occasion, patients may exhibit HIE and hypoxic respiratory failure requiring both active body cooling and ECMO.**

**Baylor/TCH Primary Indications**

ECMO should be considered for eligible infants with severe hypoxic respiratory failure after medical management has been optimized (100% $\text{O}_2$, iNO, vent settings of PIP 30 cm H$_2$O or greater and MAP 17 cm H$_2$O or greater on HFOV).

Additional indications include:

- $\text{OI} > 40$ on 2 separate serial measurements
- $\text{PO}_2$ persistently < 40 mmHg or lactate > 3.0

Infants may benefit from surfactant replacement prior to consideration for ECMO – however, efficacy of surfactant replacement has not been demonstrated in infants with CDH.

**ECMO Mode**

Neonatal ECMO may be conducted as VenoArterial (VA) or VenoVenous (VV) bypass support. Use of VV ECMO is preferred whenever possible. VA ECMO is reserved for select patients requiring circulatory support or those too small for VV cannulation. Circulatory dysfunction does not preclude a trial of VV ECMO because function frequently improves after initiation of VV support.

**Preparation for Bypass**

A detailed Neonatal ECMO Order Set exists in the EMR for ordering lab work and appropriate blood products and medications, as well as the process of initial circuit priming and preparation. K+ and ionized Ca++ of prime blood is checked prior to initiation of bypass. If ionized Ca++ is very low, 1-3 doses of Ca gluconate or Ca chloride may be given just before initiation of ECMO.

**Initiation of Bypass**

Following cannulation, circuit flow is gradually increased over 15-30 minutes to a test flow rate of 100-125 ml/kg/min. This flow usually provides adequate $\text{O}_2$ delivery on VA ECMO. Pump flow above 125-140 ml/kg on VV ECMO may result in deterioration of systemic oxygenation due to recirculation. If pump flow cannot be increased or pump cutout occurs - infuse volume expanders in 10-15 ml/kg increments. Blood volume expansion is often necessary following the initiation of ECMO. If pump cutout continues – evaluate cannula position. Subsequent flow adjustments are made per individual patient needs.

Adequate ECMO flow is indicated by:

- $\text{SaO}_2$ ≥ 90% (pre-ductal)
- $\text{SvO}_2$ >65-75% (not accurate during VV ECMO)
- Arterial lactate ≤ 3.0
- Prompt capillary refill

**Anticoagulation**

The ECMO circuit induces ongoing procoagulant activation necessitating continuous anticoagulation with heparin. At the time of cannulation 50 units/kg of heparin are given, followed by continuous infusion of 25 units/kg/hour. Subsequent infusion rate is determined by results of Coagulation Panel (every 6 hours X 48, then every 6-12 hours daily) and ACT (every 1-2 hours) values.

**Target values during ECMO include:**

- Anti-Factor Xa assay (“heparin level”) = 0.2-0.5 (accuracy reduced if TSB > 10 or plasma free Hgb > 200)
- Platelets ≥ 100,000
- Fibrinogen > 200mg/dl
- PT ≤ 17 sec
- PTT = 70-100 sec
- PTT Hepzyme ≤ 37 sec
- D-dimer = none
- Antithrombin > 80 - 100%
- ACT = 160-200

(**has poor correlation with Anti-Factor Xa activity**) ACT, PTT and Anti-Xa values are often discordant during monitoring of heparin therapy, since each measures different aspects of the complex coagulation cascade. When discrepancies exist or a complex coagulation issue is present, immediate consultation with the Coagulation Pathology Team is recommended (available 24/7).
Patient Care During ECMO
A complete order set for all phases of ECMO is available in the EMR system.

Respiratory Care
“Lung rest” is a primary goal during ECMO using IMV rate 10-20, PIP 20-22 cm H₂O and PEEP 10 cm H₂O. Most patients can be progressively weaned off INO – though this must be individualized in CDH infants. Patient oxygen delivery and SpO₂ are maintained by adjustments in pump flow and Hgb concentration (not ventilator parameters). On VA ECMO, target SvO₂ (pre-oxygenation saturation) is 65-75%. Sweep gas flow and oxygen concentration usually should be adjusted to maintain monitored post oxygenator PO₂ (not baby) in 200-250 mmHg range and PCO₂ approximately 35-40 mmHg. Monitor pre-ductal SpO₂ continuously (target 90-95%) with periodic ABG and lactate determinations.

Fluid Management
Fluid administration and slow continuous ultrafiltration (SCUF) are used to minimize adverse effects of positive fluid balance and pulmonary edema. SCUF is a form of continuous renal replacement therapy (CRRT) that utilizes the hydrostatic pressure difference across a semi-permeable membrane to remove plasma water. Some small solutes also are removed by convection. Fluid restriction for patients on ECMO is accomplished by concentrating medications, minimizing flushes and restricting blood products to defined indications only. Restrict primary IV fluids to 50 ml/kg/day on day of life #1. Within 6-12 hours after the baby is placed on ECMO attempt to begin ultrafiltration (background rate-BUFR*) to remove the daily volume of (1) medications, (2) drips and flushes, (3) maintenance infusions for lines. This volume should be calculated prospectively for the next 24 hours and the rate adjusted accordingly. By day of life #2, begin TPN at 50 ml/kg/day and IV lipids at 5 ml/kg/day. If the attending would like to increase the volume of TPN and IL over the 55 ml/kg/day, determine the total volume of TPN and IL over the 55 ml/kg/day and remove this extra volume by UF (alimentation rate—AUFR**). This rate should be adjusted prospectively as one increases the total amount of TPN and IL administered. The use of UF allows you to increase the TPN and IL as needed to attain good nutrition (90 -100 Kcal/kg/day—3 -4 grams/kg/day of protein, 15 ml/kg/day of lipid, 10-16 grams/kg/day of carbohydrate). Daily volume of blood components given for replacement of hemoglobin and coagulation factors also should be removed by UF (a ‘Blood Products Neutral’ strategy). However, blood products given for blood volume expansion should not be removed by UF. Thus, each day’s target ultrafiltration rate is determined by calculating the projected next day’s BUFR + AUFR. However, body fluid removal by UF may be associated with blood volume depletion. As a result, periodic blood volume replacement will be necessary during UF to maintain adequate pre-load and circulatory function. This requires frequent re-evaluation of the status of the vascular pre-load and circulatory sufficiency. The ideal ultrafiltration rate may not be achievable in some patients.

**BUFR—add daily volume of medications, drips and flushes and maintenance fluids for lines and divide by 24 = X ml/hour

**AUFR—[Total desired volume of TPN (X ml/kg) + IL (X ml/kg) for next 24 hours] MINUS [baseline 50 kg TPN + IL 5ml/kg] ml = XX volume divide by 24 hours = X ml per hour

EXAMPLE:
Desired TPN (100 ml/kg) +IL (15/kg) = volume (115 ml) X birth weight (3 kg) = 345 ml per day
Baseline TPN (50 ml/kg) + IL (5 ml/kg) = volume (55ml) X birth weight (3 kg) = 165 ml per day
Desired 345 ml MINUS baseline 165 ml = 180 ml Divided by 24 hours EQUALS 7.5 ml per hour (AUFR)

Analgesia
Analgesia during ECMO is provided as continuous infusion morphine 0.01 mg/kg/hr or fentanyl 1-2 micrograms/kg/hr. Morphine is preferred because tolerance and signs of dependency develop very rapidly with fentanyl (within 3-5 days with fentanyl compared to 5-7 days with morphine) and due to a greater adhesion loss of fentanyl to the circuit. Initiate morphine infusion at 0.01 mg/kg/hr. If pain/sedation is not adequately controlled, administer a one hour equivalent bolus of the current dose then increase the infusion by 0.01 mg/kg/hr. This can be continued in a stepwise fashion every 30-60 minutes until desired pain score is achieved. Assess pain and sedation effect 30 minutes to one hour after increases in dose. Do not increase continuous infusion by more than 0.01 mg/kg/hr as neonates have decreased elimination and increased CNS sensitivity which can lead to adverse events. If fentanyl is used, initiate infusion at 1 microgram/kg/hr and titrate by 0.5-1 microgram/kg/hr using a strategy similar to that outlined above. High doses of fentanyl (up to 20 micrograms/kg/hr) may be needed by day 6 of ECMO.

Circulation
During VA ECMO, adequate BP and perfusion are usually maintained with typical circuit flow of 100-130 ml/kg/min, allowing pressors to be weaned off or to low level. NV ECMO, however, depends upon the native cardiac output and circulatory regulation, thus making need for ongoing pressor support more likely. Frequent lab sampling and increased capillary permeability produce depletion of vascular volume throughout the course of ECMO. Periodic transfusions are necessary to maintain HCT ≥ 40% and provide adequate blood volume and pre-load. Occasional patients develop hypertension (MBP>65 mmHg) requiring treatment.

Weaning From ECMO
Recovery of native cardiopulmonary function is indicated by signs of improving oxygenation during reductions in ECMO support. Lung function may be assessed further by a 10-15 min challenge breathing 100% O₂. Increase in PaO₂ to 150-200 mmHg or greater indicate improved V/Q matching and decreasing PVR below systemic levels. When evidence of improvement is present, pump flow may be incrementally decreased while monitoring PaO₂ and pre-ductal SpO₂. Do not wean flow below 50-60 ml/kg/min or absolute value of 100 ml/min. If the patient tolerates trial reduction in flow with adequate SpO₂ and circulation, a 15 minute “trial off” (VA ECMO) may be attempted with ventilator parameters adjusted to provide increased support. With NV ECMO (which is in series with the native circuit) a “trial off” may be simulated by simply disconnecting the sweep gas from the oxygenator and plugging the connection ports.
Special Considerations

Decisions regarding ECMO must be individualized for certain patients – especially those with CDH infants, premature infants (<34 weeks) or those having complex or multiple anomalies. Such circumstances may require a STAT meeting of medical and surgical members and the Neonatal ECMO Team.

Surgery on ECMO

1. 8-12 hours pre-op, obtain confirmation from surgical team for maintaining the following:
   - Fibrinogen > 200
   - Platelets > 150,000

2. Order blood products (in addition to emergency blood kept at bedside):
   - 1 unit PRBC’s
   - 2 units platelets
   - 1 unit FFP

3. Order the following:
   - X-ray plate positioned in container beneath patient
   - Pleurovac set up if chest tube to be used.
   - Medications to be available at bedside include extra analgesics/sedation (morphine, fentanyl, midazolam), normal saline, 5% albumin.

4. Discuss with Surgery and Anesthesia teams any specific needs for other blood products, medications or special equipment.

5. Intra-operative fluids will be administered via the ECMO circuit; however, the anesthesiologist should be provided an IV site for emergency use.

6. A peripheral IV will be needed for Amicar infusion. Amicar is given directly to the patient and not into the ECMO circuit or a UVC in CDH patients. The surgical team will order specific dosing. Typically a bolus of 100 mg/kg will be given 30 minutes before incision and continued as an infusion of 30 mg/kg/hr. Amicar administration is usually continued for approximately 48 hours, but this is individualized depending upon patient parameters and the surgeon’s determination of post-operative status. If renal failure (creatinine > 1.2, urine output < 2 ml/kg/hour), dose should be reduced to 25% of standard dose.

7. Target ACT values:

   **Usual ACT values:**

   | During Surgery | 120-140 sec |
   | 0-24 Hours Post-Op | 130-150 sec |
   | 24-48 hours Post-Op | 160-180 sec |

8. The surgical team will provide specific orders for target ACT values after surgery. Amicar sometimes is stopped before 48 hours. Do not do a “trial off” during Amicar infusion or for 12 hours after discontinuation.

Suggested Reading List and Resources


Section 3: Cardiac Care
Editors: Krithika Lingappan and Danielle R. Rios

3.1 Cardiovascular Physiology ............................40
   Scott W. Osborne
   Christopher Rhee

3.2 Circulatory Insufficiency ...............................43
   Krithika Lingappan
   Danielle R. Rios

3.3 Congenital Heart Disease ...............................50
   Sharada H. Gowda
   Scott W. Osborne
   Jennifer L. Placencia

3.4 Arrhythmias ................................ ...............56
   Emily Rodman
   Santiago O. Valdes
3.1 Cardiovascular Physiology

At birth, infants must make rapid cardiopulmonary adaptations to the extraterine environment. One of the most complex adaptations is the transition from the fetal to the postnatal circulatory pattern.

Fetal Circulation

The fetal circulation is a ‘circulation in parallel’, wherein blood is pumped from the heart to the placenta as well as the rest of the body. Gas exchange in the fetus occurs in the placenta, an organ of high flow and low resistance, which receives 50-55% of the fetal cardiac output.

- **Maternal placental circulation** - Maternal blood enters the intervillous space via uterine spiral arteries, bathing the fetal villi with blood, and leaving via uterine veins, located at the basilar layer of the intervillous space.

- **Fetal placental circulation** - The fetal vessels are closed within these villi, which project into the intervillous space, and have no direct connection with the maternal blood.

- **Crossing the placenta** - Maternal nutrients and other components cross the placental barrier, via simple or facilitated diffusion, active transport, bulk flow, pinocytosis, or breaks in the three tissue layers within the villi in order to reach fetal blood.

Oxygenated blood (PAo2 30 mmHg, SaO2 70%) leaves the placenta through the single umbilical vein. It then bypasses the hepatic vasculature and right heart via fetal shunts (ductus venous, foramen ovale), ensuring the blood stays oxygen-rich as it enters the left heart. This arrangement allows the left heart, which provides one-third of the fetal cardiac output, to preferentially pump this oxygenated blood to the brain, myocardium, and peripheral circulation. Figure 3-1 depicts the distribution of fetal blood flow as percentages of the combined fetal cardiac output.

The right heart, provides two-thirds of the fetal cardiac output, as it receives deoxygenated blood from the venae cavae, diverts it away from the lungs and across the ductus arteriosus to the descending aorta and to umbilical arteries (PAo2 15 mmHg, SaO2 30%) for reoxygenation in the placenta. The low oxygen tension of the fluid-filled fetal alveoli induces hypoxic pulmonary vasoconstriction, which elevates the pulmonary vascular resistance (PVR) and facilitates the right-to-left shunting of blood through the ductus arteriosus. Additionally, fetal hypoxia is also a contributing stimulus to the production of prostaglandin E, which maintains ductal patency.

Transitional Circulation

After birth, as a crying baby takes its first breaths of air, the mechanical stretch of the newly inflated lungs and relief of alveolar hypoxia, decrease the PVR and dramatically increase pulmonary blood flow. Concurrently, clamping the umbilical cord removes the low-resistance placental flow, resulting in a rise in the systemic vascular resistance (SVR). Both cold stress and catecholamine surges further increase SVR. As left-sided heart pressures increase and right-sided pressures fall, the foramen ovale closes. Decrease in intraluminal ductal blood flow and relief of fetal hypoxia begin the process of functional PDA closure. The right ventricular output falls, while the left ventricular output increases (newborn LVO is 200-250 ml/kg/min), such that the two outputs are equal. The end result is an oxygenator (pulmonary circulation) that is in series with the systemic circulation.

Under normal conditions, this process of transition is largely completed within 24 hours. However, in some pathologic states, it may persist for 3 to 10 days. During this time, the function of a circulation in series is disturbed by persistent patency of the ductus arteriosus and foramen ovale, and the potential for abnormal mixing of blood between the systemic and pulmonary circulations. Blood may flow either along the pulmonary-to-systemic circuit (right-to-left shunt) and cause hypoxemia or it may flow along the systemic-to-pulmonary circuit (left-to-right shunt) and cause pulmonary congestion. The direction of shunting is primarily driven by the relationship between systemic and pulmonary vascular resistance. The main determinants of resistance to blood flow in the pulmonary circuit are degree of alveolar hypoxia, and size of the vascular bed, (reduced size can result in an increase in resistance as seen in patients with hypoplastic lungs).

Disturbances of the transitional circulation can be associated with parenchymal pulmonary disease, persistent pulmonary hypertension of the newborn (PPHN), congenital heart disease, and patent ductus arteriosus (PDA). Each is discussed in its respective section.
## Oxygen Physiology

### Oxygen Delivery

Oxygen delivery (DO\(_2\)) is the amount of oxygen available to the body in one minute. It is the product of cardiac output (CO) and arterial oxygen content (CaO\(_2\)).

\[
DO_2 = CO \times CaO_2
\]

CaO\(_2\) includes the oxygen bound to hemoglobin within the red blood cells plus the oxygen dissolved in the blood:

\[
CaO_2 = 1.37 (ml O_2/g Hb) \times Hb (g/dl) \times SaO_2 + [0.003 \times PaO_2]
\]

Increasing the arterial oxygen content, via blood transfusion and raise in hemoglobin levels or augmenting the cardiac output will improve oxygen delivery (Table 3-2).

### Oxygen Consumption

The Fick principle can be used to determine cardiac output (CO) if the following are known:

- Amount of oxygen consumed per time (VO\(_2\))
- Oxygen content of arterial blood (CaO\(_2\))
- Oxygen content of venous blood (CvO\(_2\))

CO can be calculated using these variables as it is a product of oxygen consumption and the difference in arterial-venous oxygen content:

\[
CO = VO_2 \times (CaO_2 - CvO_2)
\]

VO\(_2\) is affected by both oxygen delivery and oxygen extraction:

\[
VO_2 = CO/ (CaO_2 - CvO_2)
\]

### Balancing Oxygen Delivery and Consumption

By driving the process of aerobic respiration at the cellular level, oxygen molecules are the final electron acceptor in a series of reactions that result in the synthesis of ATP. Under normal resting conditions, oxygen delivery equals oxygen consumption with significant reserve to carry out this process and easily meet the body’s energy needs.

When either oxygen delivery falls or oxygen consumption rises, an organism attempts to maintain an adequate ATP supply to meet the increased demand, first by redistribution of blood flow, capillary recruitment, and increased oxygen extraction.

At a critical DO\(_2\), these compensatory mechanisms fail, and the organism turns to anaerobic metabolism with resultant lactic acidosis in an attempt to meet the increased energy requirements (Fig 3-2). If the underlying imbalance is unable to be restored, the integrity of cell membranes is lost as ATP-pumps fail, and the hypoxia results in cell death.

### Assessment of Oxygen Delivery and Consumption

**Lactate** - The presence of an elevated lactate (>2.0 mmol/L) tends to be a late finding that represents ongoing anaerobic cellular respiration and an impaired balance between oxygen delivery and consumption. Optimal measurement of lactate is through a specimen obtained via arterial puncture or indwelling catheter. Capillary specimens may be used as a method of trending lactate levels but should not be considered diagnostic.

**Mixed venous saturation and oxygen extraction ratio (OER)** - Oxygen extraction is normally 25% to match the delivery and consumption. If arterial saturation is at 100%, then the mixed venous saturation is 75%. When oxygen extraction increases in the setting of rising energy needs, the oxygen extraction ratio (OER) becomes a useful measurement.

\[
OER = VO_2/DO_2 = (SaO_2 – SvO_2)/SaO_2
\]

Beyond the critical DO\(_2\) inflection point (Fig 3-2), when the OER exceeds 50-70% (or SvO\(_2\) is 30-50%), the gradient of the VO\(_2)/DO_2\) curve demonstrates a near 1:1 relationship, indicating that all delivered oxygen is extracted. Table 3-2 describes a general interpretation of OER numbers.

### Table 3-1. Considerations for improving oxygen transport balance

<table>
<thead>
<tr>
<th>Minimizing oxygen consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure normothermia</td>
</tr>
<tr>
<td>Treat agitation and pain</td>
</tr>
<tr>
<td>Decrease work of breathing via respiratory support</td>
</tr>
<tr>
<td>Treat arrhythmia</td>
</tr>
<tr>
<td>Treating underlying comorbidities (e.g., sepsis)</td>
</tr>
<tr>
<td>Controlling seizures</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maximizing oxygen delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increasing blood oxygen content through RBC transfusion</td>
</tr>
<tr>
<td>Optimize alveolar oxygen tension and lung volumes, avoiding atelectasis or overinflation</td>
</tr>
<tr>
<td>Improving cardiac output</td>
</tr>
<tr>
<td>- Correction of acidosis</td>
</tr>
<tr>
<td>- Assisted ventilation</td>
</tr>
<tr>
<td>- Administration of volume</td>
</tr>
<tr>
<td>- Inotropic support</td>
</tr>
<tr>
<td>- Improve SVR:PVR balance to favor systemic blood flow if there is high Qp:Qs</td>
</tr>
<tr>
<td>- Administer PGE if there is outflow obstruction</td>
</tr>
</tbody>
</table>

### Table 3-2. Interpretation of oxygen extraction ratio (OER)

<table>
<thead>
<tr>
<th>OER</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-30%</td>
<td>Normal</td>
</tr>
<tr>
<td>30-40%</td>
<td>Elevated</td>
</tr>
<tr>
<td>40-50%</td>
<td>Impending shock</td>
</tr>
<tr>
<td>&gt;50%</td>
<td>Onset of shock, tissue hypoxia, lactate begins to accumulate</td>
</tr>
</tbody>
</table>

---

Near-infrared spectroscopy (NIRS) - Local tissue oxygen saturation can be measured using (NIRS) in order to assess the microcirculation for aberrations in oxygen delivery and consumption. NIRS-derived tissue SO\textsubscript{2} readings may serve as surrogates for SvO\textsubscript{2} in calculating OER at the bedside. Trend in NIRS measurements should be interpreted within the context of the patient’s clinical status and other markers of DO\textsubscript{2}-VO\textsubscript{2} balance. A deviation decreasing from a patient’s baseline may yield more information than a particular saturation value at any given point in time. Some fluctuation from the baseline may be expected during periods of agitation, handling, or procedures.

Cardiac Output
Systemic cardiac output (CO) is the volume of blood ejected from the left ventricle in a minute. It is the product of the heart rate (HR) and stroke volume (SV); Stroke volume is the volume of blood ejected from the left ventricle per beat. The systemic blood pressure (BP) is a product of the cardiac output and systemic vascular resistance (SVR). The neonate depends mainly on heart rate and preload to increase cardiac output.

\[
\text{CO} = \text{SV} \times \text{HR} \\
\text{BP} = \text{CO} \times \text{SVR}
\]

Stroke volume is dependent on three factors:

1. **Preload** - is the end-diastolic volume (EDV), or volume in the ventricle after filling. Preload increases with increased circulating blood volume, venous tone, ventricular compliance, atrial contractility, or with decreased intrathoracic pressure. As per the Frank-Starling mechanism, increasing preload leads to increased stretching of cardiac muscle fibers, leading to increased force of contraction and stroke volume (Fig 3-3).

2. **Contractility** - the force and velocity of a contraction. Increased contractility leads to an increase in stroke volume (Fig 3-3).

3. **Afterload** - the force that resists myocardial fiber contraction during systole. It is directly related to ventricular wall stress, and the end-systolic volume (ESV) or volume in the ventricle after ejection. An increase in afterload will decrease stroke volume for a given preload (Fig 3-4).

Balance of Pulmonary and Systemic Blood Flow
Normally at birth, blood flow through the lungs (Qp) is equal to the blood flow through the left heart and the systemic circulation (Qs), resulting in a Qp:Qs ratio that is close to 1. This balance is disturbed in many forms of congenital heart disease. Large right-to-left shunts (e.g. pulmonary atresia) can result in Qp < Qs and ratio <1, indicating that there is insufficient pulmonary blood flow, which can present as cyanosis. In contrast, large left-to-right shunts (e.g. large VSD) can result in Qp>Qs and ratio >1, which is reflective of excessive pulmonary blood flow state and can present as congestive heart failure (CHF).

Calculation of Qp:Qs and Resistance

\[
\frac{Q_{\text{pulmonary}}}{Q_{\text{systemic}}} = \frac{\text{Aorta O}2 \text{ sat} − \text{SVC O}2 \text{ sat}}{\text{Pulm venous O}2 \text{ sat} − \text{Pulm artery O}2 \text{ sat}}
\]

\[
PVR = \frac{\text{Mean PA pressure} − \text{Mean LAP}}{\text{Pulmonary blood flow}}
\]

\[
SVR = \frac{\text{Mean aortic P} − \text{Mean RAP}}{\text{Systemic blood flow}}
\]

Where  
LAP – Left atrial pressure
RAP – Right atrial pressure

The Qp:Qs ratio can be altered by changes in systemic and peripheral vascular resistance (SVR, PVR), as shown in Table 3-3.

### Table 3-3. Interventions to alter SVR and PVR

<table>
<thead>
<tr>
<th>Factors that Increase SVR</th>
<th>Factors that Decrease SVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothermia</td>
<td>Hyperthermia</td>
</tr>
<tr>
<td>Oxygen</td>
<td>Metabolic acidosis</td>
</tr>
<tr>
<td>Agitation/crying</td>
<td>Meds: PGE (↓↓)</td>
</tr>
<tr>
<td>Knee-chest position</td>
<td>Nitroprusside</td>
</tr>
<tr>
<td>Meds: Dopamine, Epinephrine, Norepinephrine</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Factors that Increase PVR</th>
<th>Factors that Decrease PVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercarbia, respiratory acidosis</td>
<td>Hypocarbia, respiratory alkalosis</td>
</tr>
<tr>
<td>Metabolic acidosis</td>
<td>Supplemental oxygen</td>
</tr>
<tr>
<td>Low FiO2 – subambient FiO2, alveolar hypoxemia</td>
<td>Meds: iNO, PGE (↓↓)</td>
</tr>
<tr>
<td>Pulmonary vascular under- or maldevelopment</td>
<td></td>
</tr>
<tr>
<td>Meds: Catecholamines</td>
<td></td>
</tr>
</tbody>
</table>

Evaluation of Suspected Cardiac Disease

**Vital Signs**

**Pulse Oximetry** - Pulse oximeter probes should be attached to the right hand and either foot to give pre-ductal and post-ductal saturations to provide information regarding blood flow patterns through the PDA. In severe aortic coarctation or interruption, oxygen saturation in the feet is lower than in the right hand. This differential cyanosis is due to shunting of deoxygenated blood in the pulmonary artery through the PDA into the aorta. In D-TGA with severe coarctation or D-TGA with pulmonary hypertension, oxygen saturation in the feet is higher than in the right hand, a phenomenon known as reverse differential cyanosis. This occurs due to shunting of oxygenated blood from the pulmonary artery through the PDA into the aorta.
**Blood Pressure** - Blood pressure measurements have little utility in the diagnosis of cardiac diseases. However, an upper extremity to lower extremity systolic BP gradient may indicate aortic coarctation. Cuff BP can be influenced by an infant’s state of distress and agitation, and may give erroneous readings. A normal newborn may have up to a 15 mmHg gradient between upper and lower extremities. Non-invasive BP measurements are better for monitoring hemodynamic changes than for making a diagnosis.

**Physical Examination Findings**

**Pulses** - Systemic hypoperfusion is characterized by weak central and peripheral pulses, delayed capillary refill time, and hypotension is common in cardiac lesions with ductal-dependent systemic blood flow. In coarctation of aorta, there may be a delay between radial/brachial and femoral pulses. Other cardiac conditions associated with systemic hypoperfusion include cardiomyopathies and arrhythmias.

**Color** - Central cyanosis is a manifestation of arterial oxygen desaturation. The degree of cyanosis depends on the concentration of desaturated hemoglobin (> 5 g/dl). Polycythemic infants have more profound cyanosis despite relatively modest arterial desaturation. Conversely, anemic infants may appear pink despite significant arterial desaturation. Infants that are cold may have significant peripheral cyanosis that is not due to arterial oxygen desaturation.

**Respiratory Status** - Cardiac lesions with systemic hypoperfusion leading to acidosis and those causing pulmonary over circulation can lead to respiratory distress, including tachypnea with or without increased work of breathing.

**Cardiac Impulse** - Palpation of cardiac impulse can provide clues to cardiac disease. Cardiac impulse will be felt on the right chest wall in dextrocardia. An increased right or left ventricular impulse indicates increase in ventricular blood volume.

**Heart Sounds** - Auscultation of heart sounds and murmurs is rarely diagnostic in newborns. Auscultation of the second heart sound (S2) is important in diagnosing cardiac disease. A single S2 is associated with significant pulmonary hypertension, TGA, and pulmonary atresia. The characteristic “to-and-fro” systolic-diastolic murmur is heard in conditions such as absent pulmonary valve syndrome, truncus arteriosus with truncal stenosis and regurgitation. Heart murmurs may be absent in severe heart disease; and therefore cannot be used to exclude congenital heart disease.

**Abdomen** - Hepatomegaly may be present in conditions with elevated systemic venous pressure, such as congestive heart failure and total anomalous pulmonary venous connection.

**Workup**

**Hyperoxia Test** - The hyperoxia test may be a useful tool for differentiating between pulmonary and cardiac causes of hypoxemia. The infant is placed on 100% oxygen for ≥ 10 minutes and a pre-ductal (right radial) arterial blood gas sample is obtained and compared to a pre-test specimen. If this results in a rise in PaO₂ greater than 20-30 mmHg (with typical PaO₂ <100 mmHg) or increase of 10% in SpO₂ is observed, a pulmonary etiology is likely. In infants with fixed right to left cardiac shunts or in conditions where mixing of systemic and pulmonary circulations occur, there will be a minimal rise in PaO₂ (with typical PaO₂ <100 mmHg). The hyperoxia test does not rule out cardiac disease. Cardiac lesions in which the hyperoxia test may not be diagnostic include large left to right shunts, systemic hypoxemia, and mixing of pulmonary and systemic venous return with unobstructed pulmonary blood flow (TAPVR without obstruction).

**Laboratory Tests** - Basic lab tests such as CBC, ABG with lactate, and Chem10 should be considered. In ill-appearing infants, such as those with increasing tachypnea or poor perfusion, an ABG with lactate should be obtained urgently.

**Radiography** - Heart size can be inferred by comparing the width of the cardiothymic silhouette to the width of the chest wall. Cardiomegaly is present if this ratio is > 0.65. The degree of pulmonary vascularity (normal, increased, or decreased) may indicate the type of cardiac lesion.

**EKG/ECHO** - Except for arrhythmias, an EKG is rarely diagnostic for cardiac diseases in the newborn period. Endocardial cushion defects are characterized by superior QRS axis. Echocardiography is the gold standard for delineating cardiac anatomy.

**CT/MRI** - These modalities may be useful in select cases.

### 3.2 Circulatory Insufficiency

The intact circulation delivers oxygen to tissues at a rate that meets metabolic needs. Failure to do so results in circulatory insufficiency. Although hypotension may be part of the clinical syndrome, circulatory insufficiency may exist without hypotension. Shock is best defined as circulatory dysfunction that produces inadequate tissue perfusion to multiple organs. Parameters that suggest inadequate tissue perfusion include:

- Low arterial systolic or diastolic blood pressure
- Reduced urine output
- Poor capillary refill, peripheral pallor, or cyanosis
- Lactic acidosis
- Increased arterial-venous O₂ content difference or decreased mixed venous oxygen saturation, both of which reflect an increase in oxygen extraction

**Blood Pressure**

In the preterm infant and in the NICU, it is common to define “hypotension” as a mean arterial pressure that is less than the gestational age in weeks. However, this approach does not identify the presence of inadequate systemic blood flow, and benefit in treating values below these thresholds is unclear. Although BP is an easily measured circulatory parameter, it is an insensitive indicator of organ blood flow and tissue oxygen delivery. The other indicators of circulatory status described previously must be evaluated and the entire clinical picture considered. Tables 3-4 and 3-5 represent BP thresholds in the preterm and term neonatal population.
Table 3-4. Blood pressure thresholds (3rd percentile) according to postconceptual age in preterm infants

<table>
<thead>
<tr>
<th>Postconceptual Age (weeks)</th>
<th>Systolic (3rd percentile)</th>
<th>Mean (3rd percentile)</th>
<th>Diastolic (3rd percentile)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>32</td>
<td>26</td>
<td>15</td>
</tr>
<tr>
<td>25</td>
<td>34</td>
<td>26</td>
<td>16</td>
</tr>
<tr>
<td>26</td>
<td>36</td>
<td>27</td>
<td>17</td>
</tr>
<tr>
<td>27</td>
<td>38</td>
<td>27</td>
<td>17</td>
</tr>
<tr>
<td>28</td>
<td>40</td>
<td>28</td>
<td>18</td>
</tr>
<tr>
<td>29</td>
<td>42</td>
<td>28</td>
<td>19</td>
</tr>
<tr>
<td>30</td>
<td>43</td>
<td>29</td>
<td>20</td>
</tr>
<tr>
<td>31</td>
<td>45</td>
<td>30</td>
<td>20</td>
</tr>
<tr>
<td>32</td>
<td>46</td>
<td>30</td>
<td>21</td>
</tr>
<tr>
<td>33</td>
<td>47</td>
<td>30</td>
<td>22</td>
</tr>
<tr>
<td>34</td>
<td>48</td>
<td>31</td>
<td>23</td>
</tr>
<tr>
<td>35</td>
<td>49</td>
<td>32</td>
<td>24</td>
</tr>
<tr>
<td>36</td>
<td>50</td>
<td>32</td>
<td>25</td>
</tr>
</tbody>
</table>


Table 3-5. Blood pressure thresholds according to postnatal age in healthy term neonates

<table>
<thead>
<tr>
<th>Threshold</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>95th percentile</td>
<td>Systolic</td>
<td>78</td>
<td>83</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>57</td>
<td>62</td>
<td>64</td>
</tr>
<tr>
<td>50th percentile</td>
<td>Systolic</td>
<td>65</td>
<td>69</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>48</td>
<td>51</td>
<td>53</td>
</tr>
<tr>
<td>5th percentile</td>
<td>Systolic</td>
<td>54</td>
<td>57</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>39</td>
<td>41</td>
<td>41</td>
</tr>
</tbody>
</table>

Table 3-6. Common factors contributing to systolic hypotension

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Clinical Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low preload</td>
<td>Decreased pulmonary blood flow</td>
</tr>
<tr>
<td>Failure of adaptation after change in loading conditions</td>
<td>Loss of &quot;low-resistance&quot; placenta after birth</td>
</tr>
<tr>
<td>Impaired diastolic filling causing obstructive shock</td>
<td>Ligation of a hemodynamically significant PDA</td>
</tr>
<tr>
<td>Impaired contractility due to myocardial injury</td>
<td>Myocardial involvement after perinatal hypoxic-ischemic injury</td>
</tr>
<tr>
<td>Developmental conditions</td>
<td>Viral or metabolic cardiomyopathy</td>
</tr>
<tr>
<td>Low preload</td>
<td>Ischemic injury due to anomalous coronary arteries</td>
</tr>
</tbody>
</table>

Table 3-7. Common factors contributing to diastolic hypotension

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Clinical Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enlarged vascular bed</td>
<td>Patellar ductus arteriosus</td>
</tr>
<tr>
<td>Vasodilation</td>
<td>Systemic inflammatory response syndrome (NEC or septic shock)</td>
</tr>
<tr>
<td>Hypovolemia</td>
<td>Capillary leak (NEC or septic shock)</td>
</tr>
<tr>
<td></td>
<td>Hemorrhage (intracranial, feto-maternal, etc.)</td>
</tr>
<tr>
<td></td>
<td>Transepidermal water loss</td>
</tr>
<tr>
<td></td>
<td>Excessive urine losses (physiologic diuresis, post-obstructive diuresis, diabetes insipidus)</td>
</tr>
</tbody>
</table>

Pathophysiology of Hypotension

Assessment of the individual systolic or diastolic blood pressure values along with exam findings may provide clues as to the etiology of the hypotension. Treatment of hypotension should be guided by the underlying etiology and interventions should be directed accordingly. Systolic hypotension is indicative of decreased stroke volume with subsequent low left ventricular output, which can result from insufficient preload, poor contractility, or increased afterload (Table 3-6). Diastolic hypotension suggests diminished systemic vascular resistance or depleted/inadequate intravascular volume (Table 3-7).
Management of Circulatory Insufficiency

Figure 3-5 describes an overview of the management of circulatory insufficiency by etiology.

Role of echocardiography

In patients with poor oxygenation of unclear etiology or refractory hypoxemia, an echocardiogram should be done early to rule out structural heart disease (strong recommendation, moderate quality evidence). In patients with structurally normal hearts, echocardiography can serve as a direct measure of cardiac function and should be considered in refractory hypotension, severe pulmonary hypertension, and hemodynamically unstable states. Echocardiography can assist in delineating the physiology and can be used to evaluate preload, afterload, and contractility so that medical therapy can be tailored accordingly. If LV dysfunction is present, agents that cause an increase in afterload may lead to further LV systolic function deterioration and, therefore, should be avoided. Assessments of LV filling can help guide fluid management, On the other hand, knowing whether the patient is in a high versus low cardiac output state can guide therapy in patients with RV dysfunction. It is important to have this information in order to choose appropriate therapeutic agents, avoid agents that may cause harm, and evaluate the effect of the targeted interventions.

Persistent Pulmonary Hypertension of the Newborn (PPHN) is characterized by a delayed drop in pulmonary vascular resistance and persistence of right-to-left shunting through fetal pathways, that results in severe hypoxemia. The elevated PVR also diminishes pulmonary blood flow and pulmonary venous return, which leads to decreased preload and systolic hypotension.

The causes of PPHN can be classified into 3 overlapping categories based on underlying pathophysiology:

- **Underdevelopment**, hypoplastic pulmonary vasculature with decreased cross-sectional area and blood flow results in a decreased surface area for gas exchange and a fixed increase in PVR (e.g., CDH, pulmonary hypoplasia).

- **Maldevelopment** lung parenchyma is normal but the pulmonary vasculature has been remodeled with increased smooth muscle cell thickness and distal extension of muscle to vessels that are usually non-muscular (e.g., idiopathic/genetic, meconium-aspiration syndrome, CDH, intrauterine closure of the ductus with NSAID exposure, intrauterine hypoxia/stress)

- **Maladaptation** -pulmonary vasculature bed that is structurally normal but is abnormally reactive (constricted) due to parenchymal lung disease and inflammatory processes (e.g., asphyxia, sepsis, hypoxia, meconium-aspiration syndrome, RDS, pneumonia)

PPHN presents in the first 24 hours of life, usually in the term or late preterm infant, and is associated with cyanosis and respiratory distress. It should be suspected in conjunction with lung or cardiac disorders as well as in clinical scenarios when intrauterine stress is apparent (e.g., asphyxia, meconium-staining of amniotic fluid). Exam findings might include a prominent precordial impulse and a narrowly-split, accentuated P2 component of the second heart sound.

Hypoxemia that is poorly responsive to supplemental oxygen is the hallmark of PPHN. Oxygenation is typically labile, but there is often little effect on ventilation. The extrapulmonary right-to-left shunting can produce differential cyanosis, which can be detected by the gradient between pre- and post-ductal PaO2 and oxygen saturations.

Echocardiography can be useful in patients with PPHN for several reasons. It can be used to discern the degree and direction of shunting through fetal pathways. Evaluate RV and LV function and rule out structural heart disease. More specifically, the presence of tricuspid regurgitation, septal flattening and RV dilation are suggestive of elevated right ventricular pressure.

Central to the management of PPHN is vasodilation of the pulmonary bed and reduction of PVR to promote pulmonary blood flow and oxygenation. In the term or preterm newborn, treatment includes supplemental oxygen, ventilatory support, and consideration of surfactant therapy with the goal of maintaining preductal saturations between 91% and 95%. Vasodilation is achieved primarily through oxygen and inhaled nitric oxide (iNO), but additional pulmonary vasodilators (e.g., milrinone, sildenafil) may be needed. iNO is indicated for treatment of PPHN in mechanically ventilated term and late preterm newborns to improve oxygenation and reduce the need for ECMO if PaO2<100 mmHg or OI>25 (strong recommendation, moderate quality evidence,). Oral sildenafil may be considered for treatment of PPHN, especially if iNO is not available (weak recommendation, low quality evidence). Intravenous sildenafil may be considered for PPHN in critically ill patients, especially those with an unsatisfactory response to iNO. If necessary, oxygen delivery can be further optimized by improving arterial oxygen content through transfusion of red blood cells.

Other means of reducing PVR include maintenance of adequate lung recruitment via mechanical ventilation, prevention of acidosis, and minimization of agitation through sedation. During the first few hours of life, the target values for infants with acute PPHN include pCO2 of 45-60, pH >7.25, and lactate <5 mmol/L.

If echocardiogram demonstrates good LV function, an agent like vasopressin can raise SVR while simultaneously lowering PVR. If function is poor, cardiac output can be augmented with inotropes (e.g., dobutamine, epinephrine). Right or left ventricular dysfunction in the setting of elevated PVR may be an indication for a lusitrope like milrinone (weak recommendation, low quality evidence). PGE1 infusion may be considered as a means to unload a high-pressure right ventricle by reopening a closed PDA or maintaining duc tal patency in preterm and term neonates with no VSD (weak recommendation, very low quality evidence).

Normothermia and euglycemia should be maintained. Comorbidities should be treated (e.g., surfactant for lung disease, antibiotics for sepsis).

Extracorporeal membrane oxygen (ECMO) may be necessary when hypoxic respiratory failure is refractory to the therapies described above. ECMO is not recommended in infants <34 weeks and/or <2kg. The indications for ECMO are discussed in the specific ECMO section.
Figure 3-5. Algorithm for assessment and treatment of hypotension according to systolic, diastolic, and combined systolic and diastolic categories. Republished with permission of LWW, from Avery's Neonatology Pathophysiology and Management of the Newborn, MacDonald MG, Seshia MMK, 7th ed, 2016; permission conveyed through Copyright Clearance Center, Inc.
Cardiogenic Shock

Cardiogenic shock is not a common condition in neonates during the first few days after birth. It is characterized by inadequate tissue perfusion that results from poor myocardial contractility related to one of the following:

- hypoxia, acidosis, or both, most commonly a result of perinatal asphyxia, heart disease, or lung disease
- hypoglycemia
- high cardiac output resulting in myocardial ischemia or cardiac failure secondary to a large PDA or an A-V fistula
- myocardial ischemia or infarction related to an anomalous coronary artery
- myocardial insufficiency related to myocarditis or primary cardiomyopathies
- myocardial ischemia or cardiac failure related to severe left ventricular obstructive disorders
- circulatory collapse related to supraventricular tachycardia, cardiac surgery or ECMO.

Chronic manifestations of cardiogenic shock are pulmonary and hepatic congestion with respiratory distress and peripheral circulatory failure. Poor pulses and capillary refill, cardiomegaly, hepatomegaly, and gallop rhythm may be present.

Treatment approaches to cardiogenic shock fall into four major areas:

- **Fluid restriction and diuretics**: Reduction of circulating blood volume with reduction of venous return leads to a drop in cardiac filling pressures and relieves pulmonary edema and circulatory congestion. When considering diuretics, exercise caution to avoid reducing preload to a degree that further impairs cardiac output.

- **Augmentation of myocardial contractility**: Multiple agents can be used to improve myocardial performance, depending on the clinical situation and based on which ventricle is more impaired. Dobutamine, epinephrine, and dopamine all have inotropic properties. Milrinone may be preferred when RV dysfunction predominates.

- **Afterload reduction and vasodilators**: This therapy is used to reduce cardiac workload by reducing peripheral vascular resistance and myocardial afterload. Although evidence in neonates is limited, milrinone is most commonly chosen in this setting.

- **Management of arrhythmia** (Ch 3.4-Arrhythmias)

---

**Septic Shock**

Clinically, septic shock represents the collective effects of circulating bacterial toxins on systemic and pulmonary capillary beds, leading to multi-organ hypoperfusion and cellular anoxia. Little is known about septic shock in neonates, but the pathophysiology seen in adults is assumed to apply to neonates.

Hemodynamic consequences of septic shock relate to effects of endotoxin on pre- and post-capillary sphincters, especially alpha-adrenergic receptors, and the release of various vasoactive substances (histamine, serotonin, epinephrine/norepinephrine, kinins). Initially, constriction of pre- and post-capillary sphincters produces ischemic anoxia at the cellular level. As anaerobic metabolism and lactic acidosis dominate, the pre-capillary sphincter relaxes and the stage of stagnant anoxia is established. During this stage, profound capillary pooling occurs, capillary permeability increases, and intravascular fluid is lost to the interstitial compartment. This loss of effective blood volume decreases venous return to the heart, leading to a reduction in cardiac output, further exacerbating tissue hypoperfusion. SVR may be low, high, or normal during this process.

Effects of vasoactive substances on the lung include a rise in pulmonary artery pressure, increase in pulmonary capillary pressure, and increase in fluid filtration from microvasculature in the lung leading to pulmonary interstitial edema. This leads to progressive compromise of pulmonary function with resultant hypoxemia.

Such effects on the systemic and pulmonary circulation soon lead to profound tissue anoxia and progress to irreversible shock. Early stages of septic shock manifest by an intense peripheral vasocostriction with maintenance of normal or elevated arterial pressure. Progressive fall in urine output may occur. As vascular pooling progresses, hypotension and metabolic (lactic) acidosis occur.

The treatment of septic shock is dictated by the presentation or stage of the systemic inflammatory response syndrome (i.e., whether it is warm or cold shock):

- **Volume expansion** increases effective blood volume, enhances venous return to the heart, and improves cardiac output. Although volume expansion is the mainstay therapy of septic shock, it may be accompanied by pulmonary congestion and exacerbation of respiratory dysfunction. The accompanying pulmonary edema often requires use of CPAP or mechanical ventilation. Once effective preload has been restored with crystalloid and/or colloid, SVR can be augmented via a peripheral vasoconstrictor (e.g., vasopressin, dopamine).

- **Inotropic and pressor agents**. Use of these agents in septic shock is complex, and selection depends on the clinical circumstances.

  If the presentation is characterized by a vasodilatory response (e.g., warm shock), the goal of therapy is to increase SVR with agents like vasopressin, dopamine, or epinephrine. If there is LV dysfunction, then an agent that improves contractility should be considered as well.

  If the presentation is characterized by a low output state with vasoconstriction (e.g., cold shock), the goal of therapy...
is to improve myocardial performance with inotropic agents like dobutamine or epinephrine.

- **Corticosteroids** block the effects of endotoxin and inflammatory mediators on vascular tone and the integrity of the capillary membrane. They also increase response of receptors to endogenous and exogenous catecholamines. Evidence of efficacy in newborns is lacking, but some infants who are refractory to the above measures may exhibit an increase in blood pressure in association with short-term administration of systemic steroids.

### Hypovolemic Shock
Hypovolemia is an uncommon cause of hypotension in preterm infants, especially in the absence of evident blood loss. Common etiologies of hypovolemia in the first 24 hours of life:

- Umbilical cord or placental laceration, such as placenta previa or velamentous cord insertion
- Redistribution of fetal blood volume to placenta associated with maternal hypotension, cesarean section, uterine rupture, etc.
- Placental abruption
- Acute twin-to-twin transfusion syndrome
- Intrapartum (terminal) asphyxia or umbilical cord compression (e.g., tight nuchal cord) may prevent placental transfusion to fetus or occasionally results in mild blood loss into the placenta (in general, however, intrapartum asphyxia is not associated with serious hypovolemia)

### Autonomic Dysregulation of the Premature Infant
Hypotension in the VLBW infant can be common and is likely to be multifactorial in etiology. Immaturity of the autonomic nervous system often results in decreased systemic vascular tone. This is further complicated by the premature myocardium’s inability to adapt to the increased afterload that accompanies removal of the low resistance placental circuit. In this population, insensible water loss, relative adrenal insufficiency, and patent ductus arteriosus further contribute to the diastolic hypotension, which tends to respond best to agents which augment SVR. Additionally, the myocytes and the calcium-dependent contraction mechanisms of the premature heart are underdeveloped, limiting their ability to augment contractility in response to inotropes.

### Patent Ductus Arteriosus
Persistent patent ductus arteriosus in small premature infants may cause increasing left-to-right shunting, progressive pulmonary edema, and deterioration of respiratory function. It is a primary cause of diastolic hypotension in VLBW infants. Its clinical presentation and management are discussed in Ch 3.3 Congenital Heart Disease.

### Adrenal Insufficiency
Adrenal insufficiency most likely contributes to or plays a complicating role in the development of hypotension in certain at-risk neonates like premature infants or those with an underlying endocrine abnormality. In these at-risk patient groups, consider hydrocortisone to support the blood pressure, particularly when the hypotension is refractory to pressors.

### Medical Therapy

#### Volume expansion
- **Bolus infusions of volume expanders are not recommended unless specific evidence of hypovolemia is present.** There is no relationship between hematocrit, blood volume, and blood pressure in non-specific hypotension in premature infants. Effects of bolus infusion of volume expanders, if used, are transient and may be detrimental. Repeated boluses may lead to fluid overload or increased risk of IVH. In premature infants, excess fluid intake is associated with higher mortality.

Crystalloid and colloid fluids have been shown to have equivalent efficacy except in instances of active hemorrhage or profound anemia. Initial hematocrit may be useful in estimating the magnitude of volume replacement but subsequent hematocrit values cannot be used as a sole guide to determine adequacy of volume replacement. We recommend normal saline boluses in 10 mL/kg increments until colloids such as PRBCs are available. Use of 5% albumin infusions is not recommended as it is associated with fluid retention and increased risk of impaired gas exchange. Transfusion of whole blood or packed red blood cells may be necessary up to a maximum central hematocrit of 55%. Monitoring arterial pressure, body weight, serum sodium, and urine output is essential. Central venous pressure measurements and cardiac size on x-ray may also be helpful in assessment of the fluid status of the neonate.

- **Corticosteroids**—block the effects of endotoxin and inflammatory mediators on vascular tone and the integrity of the capillary membrane. Corticosteroids also induce the enzyme involved in transformation of norepinephrine to epinephrine and increase the responsiveness of the receptors for endogenous and exogenous catecholamines.

They have been shown to increase BP within 2-6 hours in refractory hypotension. Some observational studies have reported a statistical association between hypotension and serum cortisol levels < 15 mcg/dl (“relative adrenal insufficiency”) in preterm infants. However these levels are poor predictors for actual occurrence of hypotension or response to treatment with hydrocortisone. We do not recommend routine measurement of cortisol levels.

1. **Give a single dose of 1 mg/kg IV Hydrocortisone**
2. **If hypotension and circulatory dysfunction persists or recurs over next 4-6 hours, continue treatment with hydrocortisone 1 mg/kg/dose every 8 hours for 24-48 hours, and taper off steroids by day 5 if tolerated (strong recommendation, low quality evidence.)**
3. **As BP improves, attempt to wean off pressor agents**

The safety and long-term benefits of short-course hydrocortisone therapy for hypotension are not clear. Use of corticosteroids in premature infants has been associated with adverse neurologic outcome and increased risk of intestinal perforation, especially if used in conjunction with indomethacin. Therefore, we do not recommend concurrent administration of hydrocortisone and indomethacin. Hyperglycemia and impaired bone mineralization have also been associated with corticosteroid use.
Dobutamine—stimulates myocardial α-1 and β-1 receptors resulting in increased contractility and heart rate. Although it also stimulates both β-2 and α-1 receptors in the vasculature, the cumulative result is some vasodilation in addition to the inotropic and chronotropic effects. Dobutamine increases cardiac output by augmenting stroke volume. Though it has been consistently shown to be inferior to dopamine in raising BP, both SVC flow and pulmonary blood flow have been shown to be higher in patients treated with dobutamine. The use of dobutamine may be considered for inotropic support when left ventricular function is impaired based on clinical or echocardiographic evidence (weak recommendation, low quality evidence). Therapy should be initiated at 5 mcg/kg/min and titrated to effect. Usual dosing range for neonates is 2-15 mcg/kg/min.

Dopamine—is the most frequently prescribed medication for nonspecific hypotension, though its overall use has declined in the last decade. It is no longer the preferred agent in pediatric and adult patients due to its effect on heart rate and its arrhythmogenic potential. Dopamine stimulates both adrenergic and dopaminergic receptors. In adults, it has been shown to have variable dose-related activation of receptors, but it is unclear if similar receptor activation occurs in neonates. Moreover, it appears that neonates have activation of receptors at lower doses with variable results. For example, at 6-8 mcg/kg/min some neonates demonstrate an increase in left ventricular output with a moderate increase in MBP while others demonstrate a decrease in left ventricular output with a larger increase in MBP. Dopamine has also been shown to increase oxygen consumption, cause hyponatremia, decrease thyrotropin secretion, and increase PVR > SVR. When used, it should be started at 5 mcg/kg/min and titrated to effect (strong recommendation, low quality evidence). If no effect is seen with doses of 10-15 mcg/kg/min, addition of another agent should be considered.

Epinephrine—potent stimulator of α and β receptors. It increases heart rate, stroke volume, SVR, and PVR (the increase in SVR is roughly equal to the increase in PVR). Epinephrine has been shown to be equal to dopamine in increasing BP, but was also associated with higher heart rate, hyperglycemia, and increased lactates in studies using moderate to high dosing ranges. Epinephrine may be considered in patients when improvement of systolic performance is desired and may be a better option than dopamine when concern for hypoxic respiratory failure is present (strong recommendation, low quality evidence). Dosing should be initiated at 0.01-0.03 mcg/kg/min and titrated to effect. Usual dosing range should be 0.01-0.3 mcg/kg/min.

Milrinone—is an inotropic drug that increases cAMP levels by direct inhibition of phosphodiesterase and prevention of cAMP degradation. It has an inotropic effect on the heart and a dilating effect on veins and arterioles, and does not depend on neurotransmitter stores or receptors. Milrinone can simultaneously increase cardiac output and decrease PVR, without a significant increase in myocardial oxygen demand. It has been shown to improve oxygenation in severe PPHN. Milrinone is, also, of benefit in patients weaning from cardiopulmonary bypass and those with right ventricular failure. In the neonatal population, it is used in patients with low cardiac output associated with congenital heart disease or myocardial dysfunction. (weak recommendation, low quality evidence).

Milrinone can cause hypotension and should be considered only when blood pressure is adequate. Toxicities include arrhythmias, tremor, thrombocytopenia, and vomiting. It should be avoided in patients with oliguria or anuria due to increased risk of toxicity. Recommended starting dose is 0.375 mcg/kg/min (no loading dose necessary) and range is 0.375-0.75 mcg/kg/min.

Vasopressin—induces vasoconstriction via multiple mechanisms and has minimal to no inotropic or chronotropic effect. Its effects on the cardiovascular system are not fully understood, but vasoconstrictive effects are preserved during hypoxia and severe acidosis. A retrospective review of use at TCH showed that it increased BP and urine output without causing hyponatremia. Vasopressin should be considered when goal of treatment is systemic vasoconstriction, especially when oxygenation is a concern in the setting of normal LV function (weak recommendation, low quality evidence). It should also be considered a viable option in hypotension when tachycardia or increased inotropy would be contraindicated. Vasopressin is usually started at 0.01 units/kg/hr and titrated to effect. Usual dosage range is 0.005-0.04 units/kg/hr.

Inhaled Nitric Oxide is a selective pulmonary vasodilator which causes smooth muscle relaxation by activating guanylyl cyclase leading to increased cGMP levels. Treatment with iNO has been shown to reduce need for ECMO in patients with hypoxic respiratory failure among term and near-term population. Use in prevention of BPD has not been well studied and is not recommended at this time. It can be used for the purpose of “rescue” in select premature infants with severe pulmonary hypertension. iNO should be considered in infants with hypoxic respiratory failure where increased preload is a concern due to inadequate pulmonary blood flow (strong recommendation, low quality evidence). In addition, select premature and term neonates may benefit from iNO in the setting of persistent or severe pulmonary hypertension. Initiation of therapy is recommended in patients with a gestational age greater than 34 weeks, if a patient requires mechanical ventilation has an Oxygenation Index (OI) of at least 25 on two separate measurements.

OI = (Mean Airway Pressure × FiO\textsubscript{2} / PaO\textsubscript{2}) × 100

Before initiating iNO it is important to exclude congenital heart disease.

Inhaled nitric oxide is administered via the ventilator circuit at an initial dose of 20 ppm. Optimal lung recruitment is necessary prior to iNO administration. Response to therapy is defined as an improvement in PaO\textsubscript{2} of at least 10 mmHg or increase in oxygen saturations of at least 5%. Higher doses confer no additional benefit and should not be used.

If there is no response to optimized ventilation plus 20 ppm of iNO, the patient is classified as a non-responder and we recommend to wean iNO every 15 minutes in increments of 5 ppm. At 5 ppm, we recommend to wean by increments of 1 ppm every 1-2 hours until discontinued.
If a patient is a responder to iNO and stable for 4 hours, begin to wean FiO2 by decrements of 2-5%. When FiO2 has decreased to 60% and patient is stable, wean iNO every hour in decrements of 5 ppm. At 5 ppm attempt to wean by decrements of 1 ppm every 1-2 hours.

Wean iNO with caution at concentrations below 5 ppm because precipitous deterioration in oxygenation has been reported at these low levels. When iNO is discontinued it may be necessary to increase FiO2 as much as 15%.

When using iNO, NO and nitrogen dioxide (NO2) levels are continuously monitored. If the NO2 level reaches >3 check the delivery system, ventilator circuit, and detection device, and decrease the NO concentration by 50% every 15 minutes until the NO2 concentration is below 3 PPM. If the NO2 level ever exceeds 5 PPM, attempt to discontinue iNO.

Measure methemoglobin (metHb) concentration 24 hours after initiation of therapy. If metHb concentrations are greater than 7%, wean iNO if possible. If high met Hb levels persist despite weaning or discontinuing therapy, consider treatment with PRBC transfusion, IV methylene blue, or IV vitamin C, based upon clinical situation. At iNO doses of 20 ppm, levels of metHb greater than 5% to 10% are uncommon and rarely produce acute symptoms.

### Treatment of Heart Failure (Selected Therapies)

**Diuretics**—Diuretics act to decrease cardiac preload by reducing extracellular fluid volume. Despite the lack of long term efficacy and mortality data from pediatric clinical trials, diuretics are routinely used for symptom relief in the acute management of symptomatic heart failure. Loop diuretics (e.g., furosemide) are the first line agents for treatment of heart failure (weak recommendation, low quality evidence). If diuresis with loop diuretic is inadequate, addition of a thiazide diuretic may be considered. Oral bioavailability of furosemide is poor and consider using a 1:2 conversion factor when transitioning from IV to PO furosemide dosing.

**ACE Inhibitors**—By inhibiting the production of angiotensin II and aldosterone, ACE inhibitors cause vasodilation, reduction in systemic vascular resistance, decrease in afterload, and an increase in cardiac output. In addition, ACE inhibitors attenuate cardiac remodeling that contributes to heart failure progression. Because of its short half-life, captopril requires frequent dosing, from 2-4 times daily. Enalapril has a longer duration of action due to the long half-life of its active metabolite enalaprilat and can be administered once to twice daily. Due to lack of data comparing ACE inhibitors, the selection is generally based on ease of dosing, patient response, and tolerability (weak recommendation, low quality evidence). Adverse effects of ACE inhibitors include hypotension, hyperkalemia, increased blood urea nitrogen (BUN), increased serum creatinine, anuria, acute kidney injury, and rare angioedema. The use of ACE inhibitors in preterm infants has been associated with a high incidence of acute kidney injury.

**β-blockers**—In adults, β-blockers have been shown to decrease mortality and morbidity through reversal of adrenergic myocardial dysfunction, attenuation of neuro hormonal systems, antiarrhythmic effect, and negative chronotropic effect. It is unclear if β blockers exert the same effects and benefits for pediatric patients with heart failure. Propranolol is the most commonly used agent for treating hypertension and arrhythmias among infants. Carvedilol, a non-selective β-antagonist with α-1 adrenergic blocking activity, is commonly used in pediatric heart failure patients. It has vasodilatory, anti-oxidant, anti-proliferative, and anti-apoptotic properties. Although carvedilol has not been directly compared with other β-blockers, the broad suppression of adrenoceptors is believed to contribute to improved outcomes in patients with chronic heart failure. Propranolol and carvedilol are available as a liquid formulation, allowing for ease of administration in infants and young children.

Adverse effects of β-blockers include hypotension and mild worsening of heart failure symptoms, especially at onset of treatment. Therefore, it should be avoided in acute decompensated heart failure. Contraindications include symptomatic bradycardia/heart block and significant hypotension. Caution is recommended in patients with reactive airway disease.

### 3.3 Congenital Heart Disease

Congenital heart disease typically presents in the newborn period but can present up to the first year of life. Most serious and life threatening lesions that require urgent intervention usually present within the first several days of life. Timing and mode of presentation depend upon the type of lesion or ductus arteriosus closure, and fall in pulmonary vascular resistance. A differential for congenital heart diseases based on symptoms is presented in Table 3-8. Other differential diagnoses to consider when working up a patient for congenital heart disease include sepsis, primary pulmonary disease, anemia, and metabolic disorders.

**Asymptomatic Neonates**—Early detection of neonatal CHD remains challenging because clinical findings may be subtle or absent immediately after birth. Studies have shown that pulse oximetry is an effective, though not infallible, screening measure. Thus, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the American College of Cardiology Foundation (ACCF) have recommended universal screening of all newborns with pulse oximetry to improve identification of infants with CHD (Ch 10.9 Newborn Screening). In addition to pulse oximetry screening, careful review of the history and physical examination of the infant remain imperative.

### Basic Physiology & Management of Neonatal Cardiac Disease

**Presentation in newborn period:**

**Cyanosis**—bluish discoloration of the tissues results when the absolute level of reduced hemoglobin in the capillary bed exceeds 5 g/dL. The appearance of cyanosis depends upon the total amount of reduced hemoglobin rather than the ratio of reduced to oxyhemoglobin.

**Shock**—hypoxemia and hypoperfusion resulting in increased oxygen extraction ratio, and DO2/VO2 mismatch.

**Acidosis**—increased lactate production due to anaerobic metabolism.

**Differential Cyanosis**—difference of >5% in the oxygen saturation measured in the right hand (predisctal) and either foot (post ductal) identifies infants with differential cyanosis.
Differential cyanosis also occurs in infants with structurally normal hearts who have persistent pulmonary hypertension of the newborn.

**Reversed Differential Cyanosis** may occur in patients with transposition of the great arteries (TGA) associated with either coarctation or pulmonary hypertension. In these infants, oxygen saturation is higher in the lower extremity as the right ventricle is engaged in the systemic circulation and is responsible for the majority of systemic blood flow.

**Ductal Dependent Pulmonary Circulation**

**Right-sided obstructive lesions**

**Critical Pulmonary Stenosis**—characterized by complete or near complete obstruction of right ventricular outflow with resultant decrease in pulmonary blood flow. Ductal patency needs to be maintained pharmaceutically (PgE) postnatally. Depending upon the degree of obstruction, balloon valvuloplasty of the pulmonary valve or surgical valvuloplasty may be considered.

**Pulmonary Atresia with intact ventricular septum**—the atretic pulmonary valve may result in varying degrees of hypoplasia of the right ventricle. Pulmonary blood flow is provided by a PDA and requires PgE. The right ventricle may be significantly hypertensive and in certain cases may provide coronary blood flow in a retrograde fashion to the myocardium (RV dependent coronary circulation). Cardiac catheterization is needed to delineate coronary anatomy and feasibility of pulmonary valve perforation or PDA stenting. Surgical interventions may include the single ventricle pathway, eventual biventricular repair, or orthotopic cardiac transplantation.

**Tricuspid Ate rsia**—no communication exists between the right atrium and right ventricle, resulting in right ventricular hypoplasia and obligatory right-to-left atrial shunting. PgE may be needed to provide pulmonary blood flow. Physiology depends upon associated lesions (VSD, pulmonary stenosis, coarctation, TGA). Surgical interventions depend on the physiology and may include aortopulmonary shunts, pulmonary banding, and eventual Fontan palliation.

**Ebstein’s Anomaly**—inferior displacement of the posterior and septal tricuspid leaflets result in an “atrialized” right ventricle. The right ventricular cavity size is reduced, the tricuspid valve is regurgitant (often severely), and right ventricular outflow is obstructed. This increases right atrial size producing the characteristic chest radiograph where the cardiac silhouette fills the thoracic cavity. There may be functional pulmonary atresia if right ventricular function is insufficient to generate enough force to open the pulmonary valve. Cyanosis results from right-to-left shunting at the atrial level, but typically improves as pulmonary vascular resistance (PVR) decreases in the neonatal transition period. Surgical interventions depend upon right ventricular size and function and the ability to repair the tricuspid valve.

**Tetralogy of Fallot (TOF)**—classically, is a constellation of four anatomic defects: an overriding aorta, right ventricular hypertrophy, pulmonary stenosis, and an anterior malaligned ventricular septal defect. The clinical presentation depends upon the degree of pulmonary stenosis. “Pink tets” have limited PS and saturations may be stable in the 90’s. Infants with significant PS have decreased pulmonary blood flow (Qp:Qs <1), resulting in cyanosis and hypoxia (expected saturations 75-85%). In these lesions, pulmonary blood flow may be ductal-dependent and PgE may be required to maintain ductal patency. Interventions that increase pulmonary blood flow by altering PVR may be helpful. Palliation with a BT shunt may be needed in the neonatal period prior to surgical repair. “Tet spells” (hypercyanotic spells) are thought to relate to infundibular spasm causing an acute decrease in pulmonary blood flow. Measures that may temporize these events include knee to chest positioning, sedation, volume expansion, and vasoactive medications to raise SVR. Beta blockade may reduce spasm and increase diastolic filling time.

Also within the spectrum of tetralogy are:

**TOF with pulmonary atresia**—the pulmonary valve is atretic requiring alternative pathways to provide pulmonary blood flow. The range includes pulmonary arteries that may be reasonably well-developed and supplied by a PDA to absent pulmonary arteries with blood flow supplied by major aortopulmonary collateral arteries (MAPCAs). Imaging and cardiac catheterization is necessary to delineate anatomy to determine interventional strategy. This may include ductal...
stenting and later definitive repair or pulmonary artery rehabilitation and eventual unifocalization for MAPCAs.

**TOF with Absent Pulmonary Valve** – the pulmonary valve is hypoplastic or absent and there is resultant stenosis and pulmonary insufficiency. In utero, this may cause dilation of the normally-connected pulmonary arteries, often severe, which postnatally results in bronchial compression and respiratory failure. Neonatal repair is typical with respiratory failure continuing post-operatively due to severe malacia.

**Acyanotic Lesions with Left to Right Shunt**

Patients with defects involving a large left to right shunt typically become symptomatic over time due to increased pulmonary blood flow (Qp:Qs >1) and present with respiratory distress, pulmonary congestion, and eventually congestive heart failure. Oxygen saturations are usually normal. Examples of diseases in this category include VSD, ASD, atroventricular septal defects, PDA, and AP window. ASDs are typically not symptomatic in the first year of life; an infant with a symptomatic ASD should be evaluated for left-sided obstructive lesion as a cause of augmented left to right shunting.

Medical therapy for infants who show signs of pulmonary over circulation includes diuretics (furosemide, diuril, aldactone) and ACE inhibitors (captopril/enalapril). Palliation with pulmonary artery banding may be appropriate in symptomatic infants who have not reached an adequate size or age for definitive repair.

**Complete Mixing with Normal or Increased Pulmonary Blood Flow**

**Total Anomalous Pulmonary Venous Connection (TAPVC)**

- In TAPVC, mixing occurs as pulmonary venous return joins systemic venous return at the level of the SVC, right atrium, coronary sinus, or IVC. Cardiac output is dependent upon right to left shunting through an atrial septal defect. If pulmonary venous return is unobstructed, there is increased pulmonary blood flow leading to tachypnea and respiratory distress with mild cyanosis. Repair is usually performed in the first month of life. In obstructed TAPVC, however, pulmonary venous hypertension and edema develop along with profound systemic hypoxia. Obstructed TAPVC is most likely to occur with infracardiac type TAPVC but can occur with all types. Surgical repair is emergent and may be complicated by postoperative pulmonary artery hypertension.

**Truncus Arteriosus** - a failure of septation of the great vessels resulting in complete mixing of the circulations in a single truncal vessel. In the absence of obstruction to pulmonary blood flow, as pulmonary vascular resistance decreases after birth, partitioning of the cardiac output favors the pulmonary circulation. The infant may present with mild tachypnea and saturations of approximately 85% (or lower if there is branch pulmonary stenosis or pulmonary edema). As PVR decreases and Qp:Qs becomes elevated, oxygen saturations may be normal. The infant may also have a wide pulse pressure due to diastolic runoff from the aorta to the low-resistance pulmonary circuit or incompetence of the truncal valve, resulting in poor coronary and systemic perfusion. Close attention should be given to ST segments as an indicator of myocardial ischemia. Workup should include serum ionized calcium due to the association with DiGeorge Syndrome. Truncus arteriosus is typically repaired in the first month of life.

In these lesions, supplemental oxygen and other interventions that decrease PVR may be deleterious due to increase in pulmonary blood flow at the expense of systemic blood flow. In a similar fashion, PgE is usually not helpful and may lead to worsened systemic perfusion (unless coarctation or interrupted aortic arch is present).

**Parallel Circulations with Poor Mixing**

**Dextro-Transposition of the Great Arteries (D-TGA)** - characterized by ventriculoarterial discordance where the aorta leaves the right ventricle supplying deoxygenated blood to the systemic circulation, while the pulmonary artery leaves the left ventricle, sending oxygenated blood back to the pulmonary circulation. With the two circulations in parallel, communication is required at the atrial, ventricular, and/or ductal levels. Atrial-level shunting is most critical for mixing and is needed regardless of presence of a VSD. Ductal-level shunting (L→R) increases LA pressure and further improves atrial-level mixing. Management in the neonatal period includes PgE and balloon atrial septostomy, if needed. Surgical repair, the arterial switch procedure, is usually performed in the first 2 weeks of life.

**Double-Outlet Right Ventricle (DORV)** - Neonates with DORV have more than 50% of both great arteries arising from the right ventricle. Depending upon the amount of conal muscle, these arteries may be normally-related, malposed (side-by-side), or transposed (aorta rightward of the pulmonary artery). The most common forms in descending order are:

DORV with subaortic VSD and PS- results in TOF-like physiology as blood from the left ventricle passes through the VSD to the aorta. Cyanosis is generally progressive and these infants may have hypercyanotic spells.

DORV with sub-pulmonary VSD and side-by-side great arteries (the Taussig-Bing anomaly)- blood flows from the left ventricle and preferentially enters the pulmonary artery resulting in transposition physiology (saturations in pulmonary artery > saturations in aorta). Balloon atrial septostomy may be required and surgical repair is generally during the neonatal period.

DORV with subaortic VSD and no PS- with little obstruction to pulmonary blood flow, congestive heart failure develops as PVR drops, similar to VSD physiology. Diuretics are the mainstay of medical therapy with surgical intervention usually in early infancy.

**Single ventricle**

Single ventricle physiology involves complete mixing of systemic and venous blood, which may occur at various levels (e.g. atrial-level shunting in tricuspid or mitral atresia). The oxygen saturation in the ventricle and great arteries depend on the relative systemic and pulmonary blood flow which is dictated by pulmonary and systemic vascular resistance. If pulmonary blood flow is unrestricted, a decrease in PVR may lead to increased pulmonary blood flow and decreased systemic oxygen delivery. One of the great arteries typically originates from the hypoplastic outlet chamber. Goals in the neonatal period include preservation of pulmonary arterial
anatomy with maintenance of low PVR, relief of subaortic obstruction, if present, and repair of any pulmonary venous obstruction. Surgical repair is staged (Hypoplastic Left Heart Syndrome (HLHS) Section).

**Ductal-Dependent Lesions for Systemic Blood Flow**

In these lesions, the PDA is essential to maintain systemic blood flow (R→L). At the time of ductal closure, these infants present with signs of poor systemic perfusion characterized by weak or absent peripheral pulses, metabolic acidosis, and shock.

**Coarctation (usually juxtaductal) and Interrupted Aortic Arch (IAA) -** results in increased afterload and diminished perfusion to distal tissues due to narrowing or obstruction of the aorta. Management in the neonatal period includes PgE and therapies for CHF and/or poor systemic perfusion if present. Repair is done in early infancy when the patient is stable. In females with coarctation, Turner syndrome should be considered. Patients with IAA should be screened for DiGeorge Syndrome (22q11) deletion due to its high likelihood (~50%).

**Hypoplastic Left Heart Syndrome (HLHS)**- involves varying degrees of left-sided valvular stenosis with LV and/or aortic hypoplasia. Management in the preoperative period includes PgE administration and careful prevention of excessive pulmonary blood flow. Surgical repair typically involves three stages: (1) Norwood procedure in the neonatal period, characterized by an atrial septectomy, creation of a “neoorta” to provide systemic blood flow and a mechanism to provide pulmonary blood flow via either an aortopulmonary shunt Blalock-Taussig shunt (BTS) or RV to PA shunt (Sano shunt); (2) the bidirectional Glenn procedure at 3-6 months of age, which involves takedown of the BTS or Sano shunt and connection of SVC to the right pulmonary artery; and (3) the Fontan procedure is done at 2-4 years of age, involves connecting the IVC to the right pulmonary artery, fully separating the pulmonary and systemic circulations.

**Critical AS-** presents in a similar fashion to HLHS and requires PgE infusion. Balloon dilation is the procedure of choice if left-sided structures are amenable to biventricular repair. A Norwood approach may be needed if there is marked annular hypoplasia, unicuspid aortic valve, ventricular hypoplasia/dysfunction, or associated subaortic obstruction.

**Shone’s complex (or variant)-** a constellation of left-sided anomalies of varying degrees. Classically, this includes parachute mitral valve, supravalvar ring, coarctation of the aorta, and subaortic obstruction with multiple levels of resistance leading to decreased cardiac output and left-atrial hypertension. PgE infusion is often required.

**General Care of Neonates with Congenital Heart Disease Care Environment**

Maintaining an environment with appropriate neurodevelopmental stimuli remains essential for the care of these neonates. Attention to pain, discomfort, and agitation are vital in the cardiac patient as these behaviors increase oxygen demand in a patient already at risk for suboptimal oxygen delivery. Use of non-pharmacologic comfort measures such as developmental positioning aids, bundling, and oral sucrose should be considered. Sedatives and/or narcotics should be judiciously provided in cases of pain or agitation not alleviated by non-pharmacologic measures. Elevated temperature or cold stress may increase oxygen consumption. Therefore, normothermia should be ensured by maintaining servo-controlled temperature regulation or frequent measurement of body temperature if the infant is dressed and bundled. While low-ambient lighting is common practice in the NICU, it does impair ability to assess physical appearance of the neonate. Overall appearance, skin color, and perfusion should be assessed regularly under appropriate lighting.

**Monitoring**

Monitoring should include vital signs, continuous pulse oximetry, and physical assessment. Continuous blood pressure monitoring should be considered during periods of clinical instability and during periods of changing physiology. Upper extremity cuff blood pressure monitoring may be employed during periods of stability and should be performed every 3 hrs. Four-extremity blood pressure monitoring should be performed upon admission for all patients and regularly in those with suspicion for aortic arch hypoplasia. Multi-site (cerebral, renal) NIRS should be considered at admission. Laboratory investigations may include regular monitoring of blood gas and lactate levels, particularly when there is concern for inadequacy of systemic blood flow or cardiac output.

Optimal measurement of lactate is obtained by arterial puncture or indwelling line. Capillary lactate specimens may be used as a method for trending lactate levels, but should not be considered diagnostic or be interpreted without consideration of the overall clinical picture. Additionally, electrolytes, BUN, and creatinine should be followed, particularly for those receiving diuretic therapy. Renal indices may also serve as a surrogate maker for systemic blood flow.

**Vascular Access**

For those with unclear physiology or expected to have surgery in the first week of life, it is recommended to establish umbilical artery and umbilical venous access at the time of delivery or admission. Peripherally inserted central venous catheters should be considered if umbilical venous access cannot be established. These catheters should be removed when no longer necessary. Despite clinical stability, the potential for decompensation requiring urgent therapy (PgE, adenosine, vasoactive medications, and volume resuscitation) exists for many neonates with cardiac disease. Therefore, maintaining peripheral access can be important in these infants once central lines are removed. In general, preoperative infants with a diagnosis of HLHS prior to stage I repair, IAA awaiting arch advancement, and coarctation of the aorta to be repaired with a thoracotomy should not have peripheral arterial line placed in right arm since the site is likely needed for surgery.

**Nutrition**

Nutritional support remains of critical importance for this group of neonates. Many may have an increased basal metabolic rate and without appropriate nutritional support may experience negative nitrogen balance in the perioperative period. The majority will not be fed enterally in the first day of life. A reasonable approach is to provide adequate dextrose-containing clear fluid until the cardiac diagnosis is elucidated and anticipated course discussed. All neonates with PgE-dependent lesions should receive TPN to avoid negative
nitrogen balance. If enteral feeding is provided, consideration of adequacy of mesenteric blood flow must be considered. Safe enteral feeding has been documented during PgE infusion. For infants with PgE-dependent systemic blood flow who are expected to have cardiac surgery within the first month of life, there is a risk for mesenteric hypoperfusion. Therefore, those infants should receive an exclusive human milk diet (EBM or DEBM) without fortification in the pre-operative period with slow progression of feeding volume up to 40-60 mL/kg/day (weak recommendation, low quality evidence). In addition, infants with PgE-dependent pulmonary blood flow may also have risk for mesenteric hypoperfusion. For these infants, they should also receive an unfortified human milk diet until need for PgE is determined with slow advancement of feeds by 20 mL/kg/day as tolerated (weak recommendation, low quality evidence). If PgE is being trialed off, infants should have feeds held for the first 24-48 hours off PgE. If the infant remains hemodynamically stable, feeds can be restarted at the previous volume and advanced per protocol. For those neonates, controversy remains regarding safety of providing orogastric/nasogastric tube feeds. Although many practitioners believe that the neonate’s behavior of refusal of oral feeding may be an early indication of bowel hypoperfusion/ischemia, there is no evidence to support this belief.

Growth failure is a common problem in this population, especially in the setting of pulmonary over circulation physiology characterized by tachypnea and increased work of breathing. The dietary regimen should be individualized according to clinical needs, and may include fortification of EBM or provision of higher calorie formula (24-30 kcal/oz.). Neonates with cardiac disease are at higher risk of necrotizing enterocolitis (NEC) primarily in association with mesenteric hypoperfusion. Premature infants are at even greater risk due to intestinal immaturity. As caloric density is increased, careful attention should be given to osmolality of the feeding, as hyperosmolar solutions may predispose to NEC.

**Respiratory Management**

Consideration of cardiopulmonary interaction and effect of respiratory support on cardiac function is critical in this population. Increased work of breathing increases oxygen consumption, which in the face of impaired cardiac output or without a compensatory increase in oxygen delivery, may lead to tissue hypoxia. Provision of positive pressure ventilation may ease the work of breathing and improve oxygen transport balance. However, some patients may have a mild-moderate degree of increased work of breathing, but demonstrate adequate balance of oxygen delivery and consumption and appear comfortable on exam. Such patients may be treated medically and followed closely for signs of decompensation. Care should be taken to optimize pH, alveolar oxygen tension, and lung volumes, avoiding atelectasis or hyperinflation. Positive pressure ventilation leads to a decrease in LV afterload but may impair systemic venous return and decrease right ventricular output.

**Prematurity**

Preterm infants with cardiac disease have higher morbidity and mortality than term infants with similar conditions, even at late preterm gestation. These infants have impaired temperature regulation, limited hemodynamic reserve, and immature cardiac muscle, brain, kidney, lungs, and intestines. Morbidities associated with immaturity include IVH, seizures, impaired neurodevelopment, metabolic acidosis, renal failure, infection, respiratory insufficiency, BPD, NEC, and feeding difficulties. Preterm infants have a less muscularized pulmonary vasculature, which places them at risk for earlier onset of pulmonary over circulation with increased risk for heart failure owing to the immature myocardium. Low birth weight is associated with increased surgical mortality and therefore surgery is often delayed until an appropriate weight has been attained. However, delayed surgery may lead to worsening of clinical status and is also associated with increased mortality and morbidities such as poor growth, and prolonged exposures to central venous access, elevated pulmonary blood flow, ventricular volume overload, PgE, and hypoxemia. This requires great attention to trend in the clinical status and regular communication with cardiovascular teams.

**Interdisciplinary Considerations**

Optimal care of these neonates requires collaboration between the neonatology and cardiology services, and at times cardiovascular intensive care and cardiovascular surgery. Daily rounds should be interdisciplinary and include shared decision-making with continuing discussions as changes arise. These infants may also have associated conditions necessitating input from other clinical services. Genetic evaluation and consultation should be considered for neonates with congenital heart defects. For those undergoing surgical intervention, nephrology should be consulted in anticipation of post-operative peritoneal dialysis. Routine renal and head ultrasonography in the absence of additional anomalies is not indicated.

**Cardiac Developmental Outcomes Program**

Infants with critical heart disease have been found to be at greater risk for and have higher rates of developmental, learning, and/or behavior problems later in life. These issues are often subtle and not easy to recognize at an early age. The Cardiac Developmental Outcomes Program at Texas Children’s Heart Center provides regular neurodevelopmental assessments and referrals for children from infancy through adolescence who have undergone cardiac procedures during the early stages of life. All hospitalized infants that have undergone cardiac surgery or cath procedures at less than 3 months of age should be referred. Exceptions to this include infants who have undergone PDA ligation alone or those with Down Syndrome (should be referred to Meyer Center Developmental Down Syndrome Clinic instead). Consult should be placed prior to discharge from the NICU.

**Stabilization during Clinical Decompensation**

Deterioration of clinical status may occur within minutes or over several days. The aim of monitoring is to prevent decompensation by allowing the team to intervene accordingly. Indicators of impending shock or arrest include increased oxygen extraction with low NIRS values, rising lactate levels (late sign), poor pulses and perfusion, agitation, diaphoresis, hypoxemia, tachycardia or bradycardia. In the event of clinical instability, rapid response is critical.
access should be ensured as soon as possible. Laboratory investigations (ABG with lactate, chemistry, hemoglobin/hematocrit) and ancillary studies should be ordered as indicated.

Treatment of Ductal-Dependent Lesions
Prostaglandin E1 (PgE)
Prostaglandin E1 is indicated for the treatment of ductal-dependent lesions to ensure ductal patency until surgery can be performed (strong recommendation, low quality evidence). In general, the more severe the cyanosis or the systemic hypoperfusion, the more urgent the administration of PgE. If there is doubt regarding diagnosis and the infant is symptomatic, it is reasonable to begin treatment with PgE while further evaluation is undertaken. PgE decreases both SVR and PVR, but PVR to a greater degree and may lead to pulmonary over circulation in at-risk infants.

The response of the ductus arteriosus to PgE is related to the time since spontaneous closure. Cyanosis in newborn infants is usually recognized shortly after ductal closure. Therefore, these infants respond well to PgE. Those with cyanosis at several weeks of age should not be assumed to be unresponsive to PgE. If the ductus arteriosus had recently closed, it may still respond to treatment.

Infants with coarctation of the aorta may be able to survive for several days with marginal blood flow through the obstruction prior to decompensation. Although they might respond to PgE, they have the highest likelihood of not responding and of needing urgent surgery.

Long-term infusion of PgE does permit a period for maturation of the lungs and nutrition. The risk that pulmonary vascular disease will develop within several months is small. Therapeutic response is indicated by increased pH in those with acidosis or by an increase in oxygenation (P_{O_2}) usually evident within 30 minutes.

Adverse events include hypotension, fever, flushing, and apnea which is most frequent in premature infants and at higher doses but can also occur in full-term infants. Apnea can occur several hours after starting PgE. Using the lowest effective dose can decrease the risk of apnea.

Patent Ductus Arteriosus (PDA)
A persistent PDA in the preterm infant presents a unique management challenge. The degree of shunting through the PDA is directly related to size and volume of shunt through the ductus arteriosus and indirectly related to PVR. In the setting of low PVR, a large left-to-right shunt will lead to volume overload of left atrium and ventricle. A substantial increase in LV output is required to maintain systemic blood flow. Diastolic blood pressure may be diminished by shunting through the ductus, leading to impaired myocardial and coronary perfusion and a “steal” of blood from peripheral organs. Signs of a significant PDA include hyperactive precordium, wide pulse pressure, bounding pulses, respiratory failure, pulmonary edema, and both systolic and diastolic hypotension. Retrograde flow in the abdominal aorta is associated with risk for NEC and feeding difficulties.

Appropriate management of PDA in the preterm infant remains controversial because of lack of effect of treatment on long-term outcome. No benefits have been established for treatment of an asymptomatic PDA, a PDA during the first 3 days of life, or a small PDA not requiring positive pressure support. It is not necessary to withhold feedings in such patients. Treatment of a large PDA may reduce short-term need for mechanical ventilation but no benefits on long-term outcome have been established. Currently available strategies include: (1) prevention (2) conservative management, or (3) treatment of symptomatic PDA (medical or surgical).

Prophylactic Indomethacin
In randomized trials, the use of prophylactic indomethacin in VLBW and ELBW infants was found to reduce the incidence of symptomatic PDA, PDA surgical ligation, and severe IVH. However, there is no evidence of effect on mortality or reduction in severe neurodevelopmental delay. In observational studies the use of prophylactic indomethacin was reported to be associated with an increase in the rates of spontaneous intestinal perforation. In patients with an increased risk of intestinal ischemia, such as those with IUGR, the risks of prophylactic indomethacin may outweigh the benefits. We do not recommend routine use of prophylactic indomethacin in infants with the following risk factors: a history of absent or reversed end diastolic flow in the umbilical artery, IUGR, or perinatal asphyxia.

In infants without risk factors, administer indomethacin (if available) during the first 12 hours of life to babies ≤ 26 weeks gestation or ≤ 800 grams birth weight as follows:

- **First dose:** (within first 12 hours) – 0.1 mg/kg of birth weight
- **Second dose:** (24 hours after first dose) – 0.1 mg/kg of birth weight
- **Third dose:** (48 hours after initial dose) – 0.1 mg/kg of birth weight

Monitor platelet count daily. Subsequent doses should be held if infant is oliguric (< 0.6 ml/kg/hr), thrombocytopenic (platelets < 50,000), has overt signs of bleeding, or infant requires treatment with corticosteroids.

Treatment of PDA
Medical or surgical treatment usually is reserved for symptomatic infants with moderate to large PDA with large left to right shunts or signs of myocardial dysfunction on echocardiogram. Treatment reduces short term need for mechanical ventilation in some of these patients but no benefits on long-term outcome have been established.

Conservative management includes modest restriction of fluid intake ± diuretics, avoidance of further decrease in PVR, permissive hypercapnia, or increased PEEP as shunt limiting strategies, and use of vasoactive medications. Extreme volume restriction or diuresis is of no benefit in clinically significant PDA and may further impair systemic perfusion. Total fluid intake in ELBW infants of more than 150-170 ml/kg/day in the first days of life is a risk factor for symptomatic PDA.

**Ibuprofen Treatment**
Pharmacologic closure of symptomatic PDA with cyclooxygenase inhibitors is the treatment of choice if conservative management is inadequate (strong recommendation, moderate quality evidence).
Contraindications to ibuprofen treatment include active bleeding or infection, platelet count < 60,000 or coagulopathy, NEC, significant renal dysfunction (serum creatinine > 1.6 mg/dL or urine output < 0.6 ml/kg/hr) or clinical condition requiring ducal dependent blood flow.

**Administration and Monitoring**
- **First dose:** 10 mg/kg of birth weight
- **Second dose:** (24 hours after initial dose) 5 mg/kg of birth weight
- **Third dose:** (48 hours after initial dose) 5 mg/kg of birth weight. Include birth weight on all orders for ibuprofen lysine.

The drug should be infused over 15 minutes through the IV port closest to insertion site. Safety of administration via umbilical catheter has not been evaluated and is not recommended. Ibuprofen is incompatible with TPN. If necessary interrupt TPN for 15 minutes and flush with normal saline or dextrose prior to and after ibuprofen administration.

If PDA closes or is significantly improved after an interval of 48 hours or more from completion of the first course of treatment, no further doses are necessary. It is recommended that second and third dose be withheld if urine output < 0.6 ml/kg/hr. Ibuprofen may displace bilirubin from binding sites, decrease platelet adherence, or alter signs of infection. The drug may decrease efficacy of thiazide and loop diuretics, ACE inhibitors, and beta-blockers.

Shortages of ibuprofen may require alternative use of indomethacin. Dosing should follow product insert guidelines.

**Treatment Failure**
If the PDA fails to close or re-opens after the first 3 dose course, and remains symptomatic, options include:
- Administer one or more additional course(s) of ibuprofen
- Surgical ligation of PDA may be considered

**Indomethacin Treatment**
If ibuprofen is not available, indomethacin may be used. Recommended dosage depends upon age of infant at time of therapy. A course of therapy is defined as three IV doses given at 12-24 hour intervals, with careful attention to urine output. If anuria or marked oliguria (urine output < 0.6 ml/kg/hr) is evident at time of second or third dose, no additional doses should be given until renal function has returned to normal.

<table>
<thead>
<tr>
<th>Age at first dose</th>
<th>Dose 1 (mg/kg)</th>
<th>Dose 2 (mg/kg)</th>
<th>Dose 3 (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;48 Hours</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>2-7 Days</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>7 Days</td>
<td>0.2</td>
<td>0.25</td>
<td>0.25</td>
</tr>
</tbody>
</table>

If PDA closes or is significantly reduced after an interval of 48 hours or more from completion of first course, no further doses are necessary.

**Treatment Failure**
If PDA fails to close or reopens after first 3 dose course and patient remains symptomatic options include:
- Administer a second course of 1-3 doses separated by 12-24 hour intervals. An echocardiogram is desirable before initiating a second course but may not be possible in some instances.
- Surgical ligation of PDA

### Surgical Treatment
PDA ligation may be required due to failure of medical management or clinical instability. Surgical ligation has been associated with adverse neurodevelopmental outcomes, although causality has not been established due to numerous confounding factors in this population. Changes in cardiopulmonary physiology may lead to a severe post ligation cardiac syndrome (PLCS) in up to 50% of preterm infants, characterized by oxygenation failure and systemic hypotension requiring cardiopulmonary support between 8-12 hours of surgery. Cardiac output is compromised as a result of changes in myocardial loading conditions with acute increase in afterload and decreased preload. Symptoms typically resolve by 24 hours post-intervention. Therapies aimed at lowering afterload, such as milrinone, may be beneficial. Other surgical morbidities may include vocal cord paralysis and thoracic duct trauma resulting in chylothorax.

**Catheter Closure**
In recent years, catheter device closure of PDA has begun to become more common in extremely premature neonates. Advances in available device technology have allowed this procedure to be performed in this population. Catheter closure of PDA is available at TCH in patients who providers believe not to be ideal candidates for medical or surgical treatment. Candidacy for catheter closure depends on clinical status of the patient including but not limited to need for high respiratory support and LA/ LV enlargement on echocardiogram. The procedure is performed via a venous approach and can be safely performed in infants <1000 grams if necessary. In a recent case series, the rate of PLCS appeared to be less than that seen in surgical ligation, however, further study is required. If primary team is considering catheter closure for a NICU patient, consultation with cardiology and the cath lab team should be initiated to determine candidacy. Discussion of post-catheterization monitoring and complications can be found in the Hematology Section (Chapter 7.7 Neonatal Thrombosis).

### 3.4 Arrhythmias
The observation of an abnormally fast or slow heart rate may be the first sign of arrhythmia. The ideal method to calculate heart rate and diagnose arrhythmias is by an EKG. Count all QRS complexes in a period of 6 seconds and multiply by 10 to obtain beats/minute or measure the R-R interval in milliseconds and 60,000/R (ms) = heart rate in bpm.

**Supraventricular Tachycardia (SVT)**
This is a group of mostly narrow-complex tachycardias caused by re-entry of electrical impulses through an accessory pathway between the atria and ventricles or the AV node.

**Atrioventricular Reentrant Tachycardia (AVRT)**
In neonates with pre-excitation/WPW, a delta wave, short PR, and wide QRS is seen on the baseline EKG in sinus rhythm as conduction occurs through the accessory pathway between the atria and ventricles. Those with concealed accessory pathways
do not exhibit pre-excitation. In AVRT, the electrical impulse is conducted from the atria down the AV node, His-Purkinje system and then up the accessory pathway back to the atria to complete the reentrant circuit. Heart rate is typically 250-300 beats/min. On the EKG, P waves can fall between the QRS complexes or be superimposed on the T wave. There is little to no variation in the R-R intervals. In neonates, AVRT is the more common etiology for SVT.

**Atrioventricular Nodal Reentrant Tachycardia (AVNRT)**

AVNRT occurs due to the presence of dual pathways in the AV node: one pathway with fast conduction, generally with long effective refractory period and one pathway with slow conduction and a shorter effective refractory period. The reentrant circuit is initiated when a premature atrial contraction (PAC) is blocked during the refractory period of the fast-conducting pathway, leading to conduction down the slow pathway and up the fast pathway, thereby establishing the reentrant circuit. On an EKG, the P waves may be difficult to discern as they are superimposed on the QRS complex. There is little to no variability in the R-R intervals. In neonates, AVNRT is less frequent.

**Treatment**

Any neonate with SVT should be assessed promptly for hemodynamic instability (e.g. change in activity, tachypnea, poor feeding, pallor, poor peripheral pulses, and perfusion). It is not uncommon to have neonates that are asymptomatic with short episodes of SVT. For hemodynamically compromised infants, synchronized electrical cardioversion with 0.5-1.0 J/kg is indicated. In both AVRT and AVNRT, the goal of initial therapy is blocking the AV node conduction, thereby interrupting the reentry circuit. This may be achieved by vagal maneuvers (e.g. elicit gag with NG tube or apply ice to the face) or rectal stimulation. When applying ice to the face, place the bag over the face and ears for 15 seconds. In ill neonates, vagal maneuvers should not be continued for more than 5 minutes before trying other modalities. If unsuccessful, IV adenosine should be administered by rapid infusion using the 2-syringe technique. Intravenous esmolol, sotalol, procaainamide, or amiodarone may be used as alternatives if adenosine is unsuccessful. Long-term management of SVT depends on frequency, severity, and ease with which the episodes terminate. Treatment, when indicated, is usually with beta-blockers. Transcatheter ablation of accessory pathways is performed in older children.

**Adenosine** – This medication has a short half-life (6-10 seconds) and should be administered at 0.1 mg/kg via rapid IV push, followed by a rapid flush, through IV access that is closest to the heart to ensure adequate delivery of the drug to the myocardium before metabolism. Dose is increased to 0.2 mg/kg if patient is unresponsive to the first dose. Despite extensive experience with adenosine, adverse effects have been noted, including the generation of atrial and ventricular tachyarrhythmias, asystole, and bronchospasam. Therefore, the code cart should be readily available when administering adenosine.

**Propranolol** – This enteral β-blocker is first line therapy for uncomplicated SVT or atrial tachycardia in neonates and infants. Usual starting dose is 4 mg/kg/day divided q6 hours. Propranolol has been rarely associated with hypoglycemia, hyperkalemia, and increased airway resistance. For patients needing an intravenous β-blocker option, esmolol is the preferred agent due to its rapid onset and half-life.

**Esmolol** – This is a very useful pharmacologic agent in patients who experience recurrent or sustained SVT. This β-blocker has class II antiarrhythmic properties and can be used as a continuous infusion for treatment of supraventricular or ventricular arrhythmias. Esmolol is often used when a quick onset and short half-life of β-receptor blockade are beneficial. Adverse events are similar to those of other β-blockers and consist of bradycardia and hypotension.

**Sotalol** – This is a class III anti-arrhythmic with some weak beta-blocker properties. It is used as a second line agent in SVT patients that fail therapy with propranolol. Starting dose is usually ~120-150 mg/m2/day divided every 8 hours enterally. Sotalol can also be used for termination of an active arrhythmia that is unresponsive to adenosine. Sotalol prolongs repolarization and can lead to QTc prolongation and arrhythmias. Patients should have daily ECGs to monitor QTc when initiating sotalol therapy.

**Flecainide** – This is a class lc anti-arrhythmic that is used as a second line agent in the management of SVT and atrial tachycardias. Starting dose is usually 120-150 mg/m2/day divided every 8 hours enterally. Milk impairs the absorption of flecainide so it cannot be given within 1 hour of dairy products including breastfeeding formulas. If patient has a decreased intake of feeds, monitor for toxicities and obtain flecainide levels. Flecainide blocks sodium channels slowing the upstroke of the action potential. Daily ECGs should be performed during initiation and up-titration of flecainide to monitor QRS duration.

**Amiodarone** – For patients who are unresponsive to β-blockade, a class III antiarrhythmic may be successful in terminating SVT. IV bolus dose is 5 mg/kg for active arrhythmias infused over 20-60 minutes in a patient with a pulse. Given the long half-life, a loading dose of 20 mg/kg/day is given which is eventually decreased to a maintenance dose of 5-10 mg/kg/day. Many adverse effects are associated with amiodarone therapy, including pulmonary fibrosis, thyroid toxicity, corneal deposits, hepatotoxicity, decreased growth, developmental delay, dermatologic hypersensitivity, and arrhythmias (e.g., Torsades). A baseline evaluation for potentially affected organ system function is warranted. Hypotension is a common adverse event after the intravenous administration of amiodarone. Intravenous amiodarone is incompatible with numerous solutions including heparin. Therefore, it is recommended that amiodarone be infused via a dedicated line and flushes with heparin in normal saline be avoided.

**Atrial Flutter**

Atrial flutter is a rapid heart rhythm caused by an extra electrical pathway in the atria (macroreentrant circuit). This leads to rapid regular atrial contractions (>250 per minute) with variable conduction. It is usually a narrow complex tachycardia. It often produces “sawtooth” waves in the electrocardiogram. In children, it is most commonly seen in association with CHD, but can also be seen in healthy neonates. The majority are asymptomatic and present in the
first 48 hours of life. Treatment of choice is synchronized cardioversion (0.5-1 J/Kg). One can also consider trans-esophageal pacing. In patients with structurally normal hearts, neonatal atrial flutter usually does not recur and no long term medications are needed.

**Congenital Complete AV Block**

In congenital complete AV block, there is no electrical communication between the atria and the ventricles. The p-waves are completely dissociated from the QRS complexes. The atrial rate is usually in the 120-150 bpm range and the ventricular rate is in the 50-80 bpm range. The most common cause is maternal autoimmune disorders (lupus, Sjogren’s syndrome) but one needs to also evaluate for CHD that can be associated with AV block (Heterotaxy syndrome, congenitally corrected transposition). Another cause that can mimic complete AV block is long QT syndrome, so it’s important to always measure QTc interval in patients with suspected AV block. Treatment depends on hemodynamic status. Some patients have an adequate escape rate and are asymptomatic. For patients that require treatment, isoproterenol drip or epinephrine can provide temporary heart rate support. In emergencies, transcutaneous pacing can be used. Pacemaker placement is the permanent therapy for these patients.

**Suggested Reading List:**

**Circulatory Insufficiency**


**Arrhythmias**

Section 4: Environment
Editors: George Mandy and Mohan Pammi

4.1 NICU Environment ........................................60
   Colleen Brand
   Mohan Pammi

4.2 Thermoregulation ........................................63
   Bridget Cross
   George Mandy
4.1 NICU Environment

The environment of NICU infants includes inanimate and animate sources of stimulation. The inanimate environment includes sound, lighting, bedding, temperature, odors, and airflow. The animate environment includes caregivers and parents. The short-term impact of environment on preterm and term infants has been well studied, but its role in brain development and developmental outcomes remains under investigation.

Effects of Environment

Manipulating the perinatal sensory experience of embryos and neonates through enhancement or deprivation alters patterns of early perceptual and behavioral development. These alterations depend on the type and amount of stimulation, as well as its timing relative to an infant’s level of developmental maturity. Although research suggests that the NICU environment and experiences influence outcomes, many interventions do not have an accumulated evidence base to support use in the NICU. Prevention of harm takes precedence over the developmental and environmental stimulation of a baby when the baby is fragile or immature. Avoiding under stimulation of a stable and more maturely functioning infant is encouraged. Child life and developmental pediatric specialists are available when needed.

The onset of function of sensory systems proceeds sequentially:

1. tactile
2. vestibular
3. chemical (gustatory-olfactory)
4. auditory
5. visual

The first four systems become functional in the protected intrauterine environment, while the visual system is relatively unstimulated prenatally. The intrauterine environment buffers the fetus by reducing concurrent or multimodal stimulation; likewise, the NICU environment offers low stimulation to tactile, vestibular, gustatory, and olfactory systems. The type, timing, and amount of stimulation is substantially increased including unfiltered auditory and visual stimulation. These are dramatically different from what nature intended for a developing fetus. Observation of each infant’s physiologic and behavioral responses to the environment assists caregivers and parents in determining appropriate modifications and adaptations that support an infant’s continued stability and smooth functioning.

Therapeutic Handling and Positioning

The tactile sense is the first sensory system to develop in utero and is functional for pain, temperature, and pressure by the age of viability. Tactile sensation forms the basis for early communication and is a powerful emotional exchange between infants and parents. Handling and positioning techniques promote comfort, minimize stress, and prevent deformities while creating a balance between nurturing care and necessary interventions. Touch, individualized to an infant’s tolerance and thresholds initiates the bond between infant and family. Balancing routine or aversive tactile stimulation such as procedures and tests with pleasurable or benign touch is essential. The type, timing, and amount of stimulation must be considered individually according to an infant’s stability and medical condition.

Handling

The extent of handling can effect changes in infants. Premature infants demonstrate cry expression, grimacing, and respiratory rhythm and rate occur with touch and handling. Physiologic alterations in blood pressure, heart rate, and respiratory rhythm and rate occur with touch and handling. Hypoxemia can occur with non-painful or routine caregiving activities such as suctioning, repositioning, taking vital signs, diaper changes, and electrode removal. Those changes can be minimized with some handling techniques, including

- Avoid sudden postural changes by slowly turning an infant while containing extremities in a gently tucked, midline position.
- Use blanket swaddling and hand containment to decrease physiologic and behavioral distress during routine care procedures such as bathing, weighing, and heel lance.
- Immediately return infants to supportive positioning or swaddling after exams, tests, or procedures to avoid prolonged arousal, fluctuating vital signs, or both.

Skin-to-skin holding, also known as kangaroo care (KC), stimulates all of the early developing senses. It provides warmth and the sensation of skin against skin (tactile), rhythmic rise and fall of chest (vestibular), scent of mother and breast milk if lactating (olfactory), and quiet parent speech and heartbeat (auditory). KC is appropriate as soon as an infant is stable enough to transfer to the parent’s chest. Benefits of KC improve include:

- improved state organization including increased frequency and duration of sleep and less crying
- increased weight gain
- decreased nosocomial infection
- increased maternal milk volume and increased breast feeding at discharge
- maintenance of skin temperature
- less variability in heart rate and transcutaneous oxygen
- decreased apnea and/or bradycardia

Mothers who provide skin to skin holding or Kangaroo Care (KC) report less depression and perceive their infants more positively than non-KC mothers. KC mothers are more responsive to infant cues, and their infants demonstrate more alerting and longer eye gaze with their mothers. KC is associated with increase in successful breast feeding. At 6 months, KC infants are more socially engaging and score significantly higher on the Bayley Motor and Psychomotor developmental indices.

Acuity, maturation, and behavioral responses of each infant change over time requiring continual reassessment of the amount, type, and timing of tactile interventions during the hospital course. Since touch can be disruptive to maturing sleep-wake states, avoid touching a sleeping infant for care or nurturing unless absolutely necessary.
Positioning
Prolonged immobility and decreased spontaneous movement increase the risk of position-related deformities. Factors associated with short- and long-term postural and motor abnormalities include illness, weakness, low muscle tone, immature motor control, and treatments such as ECMO and sedation. Common malpositions include:

- abduction and external rotation of the hips
- shoulder retraction
- scapular adduction
- neck extension
- postural arching
- abnormal molding of the head

Primary goals for positioning are comfort, stability of physiologic systems, and functional posture and movement. Before birth, the uterus provides a flexible, circumferential boundary that facilitates physiologic flexion as the uterine space becomes limited during advancing pregnancy. In comparison, in the NICU infants may lie flat in an extended posture with extremities abducted and externally rotated while their heads are frequently positioned toward the right. In time, muscle contractures and repetitive postures can lead to abnormal posture and movement. Therapeutic positioning promotes neurobehavioral organization, musculoskeletal formation, and neuromotor functioning.

Containment
Infants who are unable to maintain a gently flexed position may benefit from containment using a blanket (or blankets) or commercial products to provide boundaries strategically placed to achieve a tucked, flexed position. Gentle, flexible boundaries contain while allowing controlled movements that promote flexor–extensor balance without the disorganization or stress of uncontrolled movement. Use of boundaries does not ensure appropriate positioning, and an infant’s appearance and comfort are more important than commercial products or many blankets in a bed. Physical and occupational therapists are available to assist with appropriate positioning.

Just as in the womb, a newborn’s postnatal resting posture is predisposed to physiologic flexion with some limited range of motion in knees, hips, elbows, and shoulders to support muscle strength and normal flexor–extensor balance over time. Daily physical activity of low birth weight preterm infants improves bone growth and development. Infants who are restless or who fight containment and who are able to maintain flexed postures unassisted are ready to gradually transition out of positioning aids and boundaries. Older infants with chronic cardiorespiratory or other prolonged health problems may need to keep their boundaries.

Correct Positioning
Correct positioning includes:

- neutral or slight flexion of the neck
- rounded shoulders
- flexed elbows and knees
- hands to face or in midline
- tucked body or trunk
- partial flexion of hips adducted to near midline
- lower boundary for foot-bracing or complete circumferential boundary that supports position and calms infants.

Each position has advantages and disadvantages.

**Prone position** - improves oxygenation and ventilation. Reflux is decreased when the head of the bed is raised about 30 degrees. Prone positioning places an infant at risk for flattened posture unless a prone roll is used.

**Side lying** - is the least studied position. It encourages midline orientation, hand-to-mouth activity, calming, and, with appropriate boundaries, a flexed, tucked position. Although some suggest that side lying may contribute to atelectasis of the dependent lung, no evidence supports this hypothesis.

**Supine positioning** - appears to be the least comfortable and most disorganizing position for preterm infants, with decreased arterial oxygen tension, lung compliance, and tidal volume compared to prone. However, since the supine position reduces the risk of SIDS, it is recommended for infants close to discharge and at home.

**Proper Positioning Techniques**
Proper positioning techniques can prevent the formation of positional deformities including:

- Plagiocephaly - abnormal molding of an infant’s head shape due to external forces applied either pre- or postnatally.
- Dolichocephaly - lateral flattening or narrow, elongated head shape of preterm infants that occurs over time due to their soft, thin skulls.
- Brachycephaly - flattened occiput, alopecia (bald spot), and deformation of the ipsilateral ear and forehead.
- Torticollis (“twisted neck”) - with limited movement and head tilted to one side due to shortening of the sternocleidomastoid muscle.

These conditions may be prevented by

- using bedding with decreased interface pressure to reduce external forces against the vulnerable preterm head
- varying positions
- providing care and stimulation to infants from both sides of the bed

**Products** - Foam mattress overlays and gel products, including mattresses and pillows, exhibit the lowest interface pressures. Memory foam bedding accentuates preterm head molding. One goal of these products is to prevent brachycephaly (recommended by the American Academy of Pediatrics through the “tummy to play” program). Once brachycephaly occurs, physical therapy, helmets, or both are required for progressive head reshaping. Surgery usually is not required unless the scalp deformation includes craniosynostosis.
Multidisciplinary Team - The team concept that underlies neonatal care also extends to developmental care.

- Child life specialists and clinical nurse specialists facilitate therapeutic positioning and handling, create individual positioning and handling plans, teach staff and parents general principles of positioning and handling, and teach parents infant massage. Music therapy is available through the child life department.

- Occupational and physical therapists, especially in difficult cases, facilitate therapeutic positioning and therapeutic touch, increase handling tolerance of sensitive infants, improve oral-motor function, enhance movement and equilibrium, support improved motor patterns, foster relaxation and sensory integration, create or order appropriate assistive devices (e.g., kid cart, tumble form chair), and teach parents infant massage.

- Speech and language therapists may advise regarding speaker valve use in infants who have tracheostomies and early language/communication needs.

- Developmental assessment provides individualized risk, neurodevelopmental and behavioral evaluations, evidence-based recommendations, parent/family counseling support and multidisciplinary collaboration.

- Department of Physical Medicine and Rehabilitation consults may be helpful in cases with persistent tone/mobility issues.

- Social workers provide psychosocial family and community resource support.

Environmental Factors

Tastes and Odors

Infants frequently are exposed to unpleasing scents such as alcohol and povidone iodine. Taste rarely is stimulated prior to oral feeding. Some evidence suggests that

- olfactory and gustatory learning begins in utero
- preterm infants around 26 weeks’ gestational age prefer sweet to bitter taste
- maternal odor reduces crying and increases mouthing behaviors
- the sweetness of sucrose modulates pain response in term and preterm infants

Exposure to biologically meaningful odors and tastes such as maternal scent, colostrum, and breastmilk eventually might prove beneficial as a means of fostering parent recognition, calming, and pleasurable experience. Even infants who are not yet orally fed might enjoy the scent of milk or a small taste of breast milk applied to the lips.

Sound

The acoustic environment of the NICU has not been implicated in hearing loss but might influence auditory processing and language development of NICU graduates. Acoustic stimulation results in physiologic responses in a fetus as early as 23 to 25 weeks’ gestation. In the womb, exposure to sound is primarily to maternal sounds, the most important being the mother’s voice. In the NICU, sound is unpredictable and does not reflect the intrauterine or normal home environment that is important for auditory and language development.

Effects of Sound

Sudden loud sounds in the NICU cause physiologic and behavioral responses in term and preterm infants including sleep disruption, agitation, crying, avoidance behaviors, tachycardia/bradycardia, tachypnea, irregular respiration/apnea, decreased oxygen saturations, mottled skin, peripheral vasoconstriction or increased systemic blood pressure. Such disruptions can interfere with an infant’s clinical progress and stable behavioral functioning. It has not been established whether sounds in the NICU are related, directly or indirectly, to delays in speech and language development and problems in articulation and auditory processing, which are observed in higher rates in preterm infants than in full term infants.

Concerns include the potential disruption of developing auditory and communication pathways by sound distortion, irrelevant noise, and interference with maternal and paternal sounds during critical periods of development. Infants’ sensitivity to environmental noise is demonstrated by how easily sleep is disrupted. Noise levels from 70 to 75 dB disrupt sleep states in one half of healthy term infants after only 3 minutes and in all infants after 12 minutes. Many infants wake from light sleep after exposure to just 55 to 65 dB. Preterm infants are in light sleep for almost 70% of the day, causing them to be particularly vulnerable to fluctuating sound levels.

Interventions

The best available evidence suggests that a background noise level of 50 dB is desirable, with noise exceeding 55 dB only 10% of the time and noise never exceeding 70 dB. An ongoing sound measurement program is an essential component of this approach including consideration of the following:

- An infant’s exposure to sound should include time with parents in a quiet, ambient environment that does not interfere with normal speech.

- Although earphones or earplugs are not recommended, brief use of neonatal ear protection devices might be necessary during tests such as magnetic resonance imaging or other procedures known to produce loud noises.

- Personnel are a main source of sound in the NICU. Practical sound limitation measures include
  » speak in low to moderate volumes
  » conduct rounds and report away from the bedside of sleeping or sound sensitive infants
  » keep pagers and phones on vibrate mode
  » close incubator portholes quietly
  » avoid placing equipment on top of incubators

- Rouse infants gently with soft speech or gentle touch to prevent rapid state changes before examination or other tactile procedures.

- Encourage parent-infant time together.
• Limit time when musical mobiles or tapes are used until older pre-term or term infants demonstrate ongoing physiologic and behavioral stability during auditory supplementation.

All NICU staff must work together toward minimizing the potential detrimental influence of the sound environment while promoting natural parent involvement to support opportunities for auditory development.

**Light, Vision, and Biologic Rhythms**

The visual system receives little stimulation in the uterus. As a result, preterm infants, in particular, are ill-prepared for the intense visual stimulation of the NICU because maturation and differentiation of retinal connections to the visual cortex develop in the NICU rather than during the last trimester in utero. Early stimulation of the immature visual system in animal models alters development of the visual system as well as other sensory systems.

**Effects of Light**

Light has not been implicated in the development of retinopathy of prematurity. Studies that recommend reduced lighting or cycled lighting have not included long-term follow-up on the impact of either strategy on the developing visual system or other sensory systems, other ophthalmic sequelae, or disturbances in visual processing. Although studies using reduced lighting for preterm infants demonstrate no short-term negative effect on vision or medical outcomes, abrupt increases in lighting can result in decreased oxygen saturation in preterm infants. Evidence is insufficient to show that day-to-night cycling of light supports earlier development of circadian rhythm in preterm infants.

For acutely ill and preterm infants, reduced lighting appears to be a safe alternative to continuous, bright lighting in the NICU. Providing cycled lighting from 34 weeks may be beneficial. Development of circadian rhythm is more likely to be supported by infant maturation, cycled lighting, and decreased nighttime disruptions for care.

Preterm infants demonstrate brief alerting and attention around 30 to 32 weeks but can easily become stressed and disorganized by the effort. Careful attention to physiologic and behavioral manifestations of each infant, term or preterm, provides information concerning individual tolerance for light and visual stimulation.

**Parents: The Natural Environment**

The most natural environment possible for any infant includes the touch of the mother’s breast or father’s chest, the gentle motion of rocking or of parents’ breathing, the odor and taste of breast milk, and the scents, tendon vocalizations, and heartbeats of the parents. The case for providing these experiences as early and as often as possible is compelling.

When a visit to the hospital is impossible, difficult, or inconvenient, parents of infants born at certain outlying hospitals may use Family Vision. This is a program offered by Neonatal Telemedicine, using videoconferencing technologies to enable families to see their infants and speak to their nurses. This option, especially appealing to mothers who have just delivered, remains available after mothers are discharged. Family members, including siblings, may participate. Residents, fellows, nurse practitioners, and attending physicians are notified by text page of a visit scheduled to one of their patients; as with an actual bedside visit, participation is welcome and encouraged but is not necessary. Members of the medical team may initiate a visit if doing so would aid in communication with the family. We are systematically evaluating how family participation in this program affects bonding, stress, and trust.

**Conclusion**

Application of an environmental intervention or modification requires an understanding of developmental principles and careful consideration of medical status, corrected age, current thresholds and sensitivities, emerging capabilities, risk of harm, and potential benefits. What works for one infant may not be appropriate for another. Assessment of infant response during and after any environmental modification is essential.

### 4.2 Thermal Regulation

Large surface area and increased thermal conductance (poor insulation) accelerate heat loss in infants. Evaporative heat loss is increased by bathing or failure to dry off amniotic fluid. Heat loss by radiation to cold incubator walls or objects in a cold delivery room is a major cause of thermal stress in babies. Estimated heat loss by infants in the delivery room may be as high as 200 kcal/kg per minute, which far exceeds their maximal heat production. Core temperature may fall 2°C (3.6°F) within 15 minutes after delivery (Table 4-1).

Placement of the baby away from a window and the use of warmth maintaining hats provide additional protection against excess heat loss.

<table>
<thead>
<tr>
<th>Type of heat loss</th>
<th>Environmental temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation: cool room and walls</td>
<td>30°C (86°F) 33°C (91°F) 36°C (97°F)</td>
</tr>
<tr>
<td>Convection: breezy air currents</td>
<td>43% 40% 34%</td>
</tr>
<tr>
<td>Evaporation: not dried quickly</td>
<td>37% 33% 19%</td>
</tr>
<tr>
<td>Conduction: cold blankets on</td>
<td>16% 24% 56%</td>
</tr>
<tr>
<td></td>
<td>5% 3% 1%</td>
</tr>
</tbody>
</table>

**Responses to Cold Environment**

**Shivering** - involuntary muscular activity.

**Voluntary muscular activity** - not very important in babies.

**Non-shivering thermogenesis** - a major mechanism of heat production in infancy, which is under CNS control (mediated by the hypothalamus). This mechanism is induced by epinephrine via oxidation of fat (especially active in brown fat deposits). Temperature receptors in the trigeminal nerve distribution of the face are particularly sensitive to cold mist or oxygen. Measured oxygen consumption is the best indicator of heat loss and heat production. Oxygen consumption may increase up to 2.5 times basal levels at air temperature 28°C to 29°C (82°F to 84°F). In a cold environment, first a rise in oxygen consumption and endogenous heat production occurs then a fall in skin and core temperature if heat loss continues to exceed heat production (Fig 4-1). Hypoxia inhibits the metabolic response to cold.
Consequences of Thermal Stress

- Increased oxygen consumption and carbon dioxide production. Oxygen uptake and carbon dioxide excretion already may be impaired if respiratory disease is present.
- Acidemia.
- Increased norepinephrine secretion causing pulmonary vasoconstriction.
- Increased affinity of hemoglobin for oxygen, which causes impaired release at tissue level.
- Increased free fatty acids, which compete with bilirubin for albumin binding.

Preterm infants are especially vulnerable. Hypothermia is also associated with serious morbidities, such as increased respiratory issues, hypoglycemia, and late-onset sepsis. Because of this, admission temperature should be recorded as a predictor of outcomes as well as a quality indicator (Class I, LOE B-NR).

Normal Temperature Ranges

**Axillary temperatures:** 36.5-37.4 °C (97.7-99.3 °F) for term and preterm infants in open crib (AAP/ACOG 2012). It is recommended that the temperature of newly born non-asphyxiated infants be maintained between 36.5°C and 37.5°C after birth through admission and stabilization.

**Core temperatures:** 36.5-37.5°C (97.7-99.5°F) for term and preterm infants. (Ranges reported in numerous oxygen consumption studies when O2 consumption minimal)

Recommended room temperature for neonatal care units - 22-26°C (72-78°F) (AAP/ACOG 2007)

Management

**Delivery Room**

Recommended DR air temperature:
- WHO – 25°C (77°F)
- NRP – 26°C (78°F)
- AAP/ACOG – 26° C (78° F)

Dry off amniotic fluid thoroughly and remove any wet linen. Perform resuscitation and stabilization under a preheated radiant warmer. Minimize evaporative and radiant losses by covering infant or swaddling in a plastic bag or with plastic wrap blanket.

Various combinations of these strategies may be reasonable to prevent hypothermia in infants born at less than 32 weeks of gestation.

The addition of a thermal mattress, warmed humidified gases and increased room temperature were all effective in reducing hypothermia. For all the studies, hyperthermia was a concern, but harm was not shown. Hyperthermia (greater than 38.0°C) should be avoided due to the potential associated risks.

Early skin-to-skin contact should be the normal initial practice for healthy newborns including those born by cesarean delivery at 35 weeks or more.

**Transport**

Use a transport incubator with air temperature initially adjusted according to Table 4-2. Plastic bags and stocking caps can be additional measures to minimize heat loss. Gel warming pads may also be used to prevent hypothermia when the infant is removed from its heated environment. Thermal environment should be adequate to keep axillary temperature in the range of 97.7° to 99.3 °F.

Selection of Appropriate Thermal Environment

- Place infant < 32 weeks and/or < 1250 grams in a pre-warmed convertible incubator (e.g. Giraffe Omnibed®). These devices can be operated in either the closed incubator mode or open radiant warmer mode. For ELBW babies the incubator mode is often combined with a high humidity (>85%) environment during the first 7 days of life.
- Place infants between 32 and 35 weeks and > 1250 grams in a pre-warmed standard incubator.
- Place infant’s > 35 weeks and/or 1700 grams on a pre-warmed Radiant Warmer or Open Crib.
- For infants who are medically stable, consider kangaroo care with parents as a tool for thermoregulation.

**Incubators**

Recent model incubators provide two options for control of heater output:

1. Servo control of skin temperature ("Baby Control") or
2. Automated control of incubator air temperature ("Air Control").

**Automatic control of incubator air temperature** - In this mode the incubator can be programmed to automatically maintain air temperature at a value pre-selected by the user. Initial air temperature setting is selected from a temperature data set such as Table 4-2 or that contained in the incubator computer. Infant axillary temperature is monitored periodically and the desired air temperature setting is progressively reduced as the infant matures. This mode is appropriate for larger, more mature and stable infants. This should not be confused with servo control of skin temperature as discussed below.
with minimal oxygen consumption. Axillary temperature which clinically approximates the neutral thermal environment metabolic rate. Set the servo control to maintain anterior apnea. Provides the most rigid control of environmental Servo control of skin surface temperature

Guidelines for Acute Care of the Neonate, Edition 26, 2018

Table 4-2. Neutral thermal environmental temperatures: Suggested starting incubator air temperature for clinical approximation of a neutral thermal environment

<table>
<thead>
<tr>
<th>Age and Weight</th>
<th>Temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Starting</td>
</tr>
<tr>
<td>0-6 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>6-12 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>12-24 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>24-36 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>36-48 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>48-72 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>72-96 h</td>
<td>&lt;1200 g</td>
</tr>
<tr>
<td></td>
<td>1200-1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>4-12 d</td>
<td>&lt;1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>4-5 d</td>
<td>31.0</td>
</tr>
<tr>
<td>5-6 d</td>
<td>30.9</td>
</tr>
<tr>
<td>6-8 d</td>
<td>30.6</td>
</tr>
<tr>
<td>8-10 d</td>
<td>30.3</td>
</tr>
<tr>
<td>10-12 d</td>
<td>30.1</td>
</tr>
<tr>
<td>12-14 d</td>
<td>&lt;1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td></td>
<td>&gt;2500 g1</td>
</tr>
<tr>
<td>2-3 wk</td>
<td>&lt;1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td>3-4 wk</td>
<td>&lt;1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td>4-5 wk</td>
<td>&lt;1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
<tr>
<td>5-6 wk</td>
<td>&lt;1500 g</td>
</tr>
<tr>
<td></td>
<td>1500-2500 g</td>
</tr>
</tbody>
</table>

*as well as >36 weeks’ corrected gestation
Adapted from: Care of the high-risk neonate by Fanaroff, AA; Klaus, MH. 2nd ed. 1979;102-103. Reprinted with permission of Elsevier – Health Sciences permission conveyed through Copyright Clearance Center.

Servo control of skin surface temperature - used for smaller, younger, less stable infants or those with significant apnea. Provides the most rigid control of environmental temperature and produces the lowest, most consistent metabolic rate. Set the servo control to maintain anterior abdominal wall skin temperature between 36.2°C and 36.5°C, which clinically approximates the neutral thermal environment with minimal oxygen consumption. Axillary temperature usually is maintained in the 97.7° to 99.5°F range. If the servo set point must be below 36.2°C to keep axillary temperature below 99.5°F and equipment is functioning properly with no evidence of infection, the infant may be too mature for the servo control environment. Consider switching to a manual control incubator or open crib.

Hybrid incubators (Giraffe Omnibed® or similar model) - hybrid incubators of this type are preferred for infants less than 32 weeks’ gestational age or 1250 grams at birth. This incubator may be used either as a radiant warmer or an incubator. When used as an incubator, the Omnibed® allows humidification of the environment, which can significantly decrease insensible water/heat losses, and radiant heat loss by the baby. An in-bed scale makes it easier to obtain frequent weights on the baby for assistance in fluid and nutritional management.

Radiant Warmers

Manual temperature control - avoid using this mode because of dangers of severe overheating. If used to pre-warm the bed, heater power should not be set above 75% maximum.

Servo control of skin temperature - use for all infants requiring open access care under a radiant warmer. Radiant warmers do little to decrease heat loss but provide powerful heat replacement at the expense of increased evaporative water loss. Set servo control to maintain anterior abdominal skin temperature at 36.2° to 36.5°C to minimize metabolic rate and apnea. Under such circumstances, axillary temperature usually is in the range of 97.7° to 99.5°F. If temperature falls out of this range, care provider should evaluate carefully for evidence of equipment malfunction, excessive sources of heat loss or gain or possible infection.

Weaning from Incubator Servo Control Mode to Automatic Air Control Mode

Begin weaning from skin temperature servo control to air control mode when infant is clinically stable, heat requirements are decreasing and infant weighs at least 1250 grams. Place infant on air control mode while dressed in clothes, hat, diaper and/or blanket. Some babies who are stable and maturing rapidly may not require this step, since their incubator air operating temperature may have already been decreased to the range of 28.5°C by the skin temperature servo control mechanism.

Weaning from incubator Air Control to Open Crib

Weaning should begin when the following criteria have been met:

• Infant is ≥ 1500 grams or ≥ 34 weeks gestation
• Tolerance of enteral feeds
• Five (5) days of consistent weight gain
  » (< 38 weeks: 10-20 g/kg/day)
  » (> 38 weeks: 20-30 g/kg/day)
• Only occasional brief apnea/bradycardia episodes
• Physiologically stable
• Minimal incubator air temperature of less than 28°C for at least 8 hours
• Pay consideration to the LGA, SGA, the mature preterm infant and the IUGR patients when weaning external heat source.

**Ancillary Measures**

**Swaddling** - decreases heat loss in open cribs or standard incubators by increasing insulation at skin surface. Stocking caps should be used also.

**Plastic Wrap Blanket** - decreases evaporative water loss under radiant warmers and, therefore, reduces evaporative heat loss. Can also be used to reduce radiant heat loss in an incubator. Infants less than 1250 grams should be admitted directly into a hybrid incubator when available. Humidification of the environment obviates the need for a plastic wrap blanket.

**Humidity** - decreased transepidermal water loss and minimizes evaporative heat loss. Increased Humidity (> 85%) is recommended for all infant’s < 29 weeks and/ or < 1250 grams for the first 7 days of life.

**Weaning to Open Crib**

Delay in weaning preterm infants to an open crib is associated with prolongation of hospitalization and delay in achieving full oral feeding. Current evidence suggests incubator weaning can begin when most infants reach 1500g or 34 weeks. When infant can maintain axillary temperature in the normal range with incubator air temperature of approximately 28-28.5°C, infant may be placed in an open crib with frequent temperature monitoring initially.

**The Hypothermic Infant**

Hypothermia implies heat loss exceeding heat production. The response varies among infants of different size and gestational age, but cooling may trigger a hypermetabolic response leading to agitation, tachypnea, tachycardia and acidosis. Slow rewarming (less than 0.5°C/h) of unintentionally hypothermic newborns (temperature less than 36°C) may be prudent at hospital admission. The simplest approach is to place infant under a radiant warmer with servo control of anterior abdominal wall skin temperature and set point at 36.5°C. Monitor infant temperature closely. Apnea or hypoglycemia may occur during rewarming, even in more mature infants. Remember: hypothermia may be a subtle sign of sepsis, especially in VLBW infants.

**Suggested Reading**


Section 5: Endocrinology
Editors: Catherine Gannon and Krithika Lingappan

5.1 Approach to Disorders of Sexual Development .................................................68
   Frank Placencia

5.2 Hypothyroxinemia of Prematurity .........................................................70
   Mary F. Colby-Hale
   Joseph Garcia-Prats

5.3 Steroid Therapy for Adrenal Insufficiency ..............................................71
   Krithika Lingappan

5.4 Hypoglycemia .......................................................................................72
   Catherine Gannon

5.5 Transitional Neonatal Hypoglycemia .....................................................72
   Catherine Gannon

5.6 Persistent Hypoglycemia ..........................................................................74
   Catherine Gannon
5.1 Approach to the Management of Disorders of Sexual Development

**Definition**
Disorders of sex development (DSD) is a broad term used to describe congenital conditions in which the development of the chromosomal, gonadal and anatomic sex is atypical. DSDs are classified based on karyotype:

- **46, XX DSDs**, which include disorders of gonadal (ovarian) development, and disorders of androgen excess, including congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency.
- **46, XY DSDs**, which include disorders of gonadal (testicular) development, disorders of androgen synthesis or action and hypogonadotropic hypogonadism.
- **Sex Chromosome DSDs**, which include mixed gonadal dysgenesis (45, X/46, XY karyotypes) and mosaic and chimeric sex chromosome karyotypes.

DSDs occur in approximately 1 in 4,500 live births. Minor abnormalities may be more common. A comprehensive and prompt evaluation is required when the external genitalia are sufficiently ambiguous to hamper sex assignment, are inconsistent with prenatal results, or could potentially involve a life-threatening condition or comorbidity such as Congenital Adrenal Hyperplasia (CAH) or hypogonadotropic hypogonadism associated to hypopituitarism.

Clinical findings that should prompt an evaluation include:

- **Micropenis**, defined as penile length < 2.5 cm in a term infant,
- **Clitoromegaly**, defined as clitoral length > 0.9 cm in a term infant,
- **Penoscrotal or perineal hypospadias**,
- **Hypospadias with unilateral or bilateral non-palpable testis**
- **Apparent female genitalia with an inguinal or labial mass**,
- **Non palpable testes in an apparent male with an abnormal CAH screen**,
- **Discrepancy between antenatal karyotype and postnatal phenotype**.

**General Concepts: The Multidisciplinary Team Approach**
Management of an infant with a DSD is complex and requires a coordinated effort between multiple specialties. Providers should support the family and encourage holding, feeding and interacting with the infant as normally as possible. Terms with negative connotations should be avoided. And most importantly, it is critical **NOT** to assign sex until a diagnosis is reached. Gender neutral terms such as “your baby”, “Baby Smith”, "gonads" (instead of testicles or ovaries), “genital folds” (instead of scrotum or labia), “genital tubercle” (instead of clitoris or penis) should be used when communicating with parents and between providers.

All infants should be evaluated by the Gender Medicine Team, which is composed of pediatric endocrinologists, geneticists, urologists, gynecologists, neonatologists, psychologists, pathologists, social workers and ethicists. The team guides the diagnostic workup and, once results are available, meets with the family for sex assignment. The process of sex assignment is family-centered and involves a discussion of the different components of sex: chromosomes, genes, hormones, internal structures, external structures, reproductive function and societal values. In all cases, sex assignment should occur prior to discharge.

Parents should be continuously educated concerning the issues being assessed in their infant. Because of the complexity of the diagnoses of DSD, such education can be overwhelming to a parent who is already stressed due to lack of a sex assignment in their newborn. One member of the team, typically the primary neonatologist or the pediatrician should be the main source of information for the family in the early stages of the baby’s evaluation. The final decision concerning gender assignment will rest with the parents. Thus, it is imperative that they understand the pros and cons of the recommendation of the multidisciplinary team. This typically requires several meetings of the specialists and family to help the parents reach an informed decision.

**Medical Emergencies**

**Congenital Adrenal Hyperplasia (CAH)**
CAH is a group of autosomal recessive disorders characterized by the inability to produce cortisol due to an enzyme deficiency in the steroid synthesis pathway *(Fig 5-2)*. CAH is a medical emergency as it may be associated with cortisol and aldosterone deficiency. If untreated, the infants may develop a salt wasting crisis (e.g., hyponatremia, hyperkalemia, hypovolemia, and shock). CAH should be suspected in infants with frank genital ambiguity, apparent male genitalia with non-palpable gonads, clitoromegaly, or elevated 17-hydroxyprogesterone on the newborn screen.
The most common form of CAH is caused by 21-hydroxylase deficiency. In this condition, cortisol precursors are diverted to adrenal androgen production and the external genitalia of a 46, XX fetus becomes virilized. Internal genitalia are unaffected.

The diagnosis is made by measuring the adrenal steroid precursors, including 17-hydroxyprogesterone before and after administering Cosyntropin (high dose ACTH stimulation test). Treatment involves the replacement of hydrocortisone, fludrocortisone, and sodium chloride. In clinically unstable patients or patients with a high clinical suspicion for CAH, hydrocortisone at 100 mg/m² IV can be started after drawing the sample, while awaiting results.

**Hypogonadotropic Hypogonadism**

Hypogonadotropic hypogonadism is a group of conditions caused by deficient production of gonadotropins: LH and FSH. Fetal gonadotropins are required for androgen production, testicular descent and penile growth. Therefore, male neonates with congenital hypogonadotropic hypogonadism may present with micropenis and cryptorchidism. Hypogonadotropic hypogonadism should be suspected in infants with micropenis (usually without hypospadias) or cryptorchidism, particularly if associated with other midline defects or a history of hypoglycemia.

Hypogonadotropic hypogonadism may present isolated or in combination with other pituitary deficiencies such as ACTH, TSH and GH. In this case, it is considered a medical emergency as patients may develop adrenal crisis or hypoglycemia due to lack of cortisol and GH, respectively. Therefore, in infants in whom hypogonadotropic hypogonadism is suspected, all pituitary axes need to be evaluated and treated accordingly.

**Evaluation of a Baby with Ambiguous Genitalia**

As different conditions may result in the development of atypical genitalia, there is no single test that will lead to the diagnosis in all affected patients. To better utilize resources, diagnostic evaluation should start with a detailed history and physical exam, followed by genetic, hormonal and imaging studies.

**History**

- Maternal drug history (virilizing drugs, e.g., progestins, finasteride, or phenytoin), or Maternal virilization (androgen-secreting tumors in the adrenals or the ovary).
- Consanguinity of the parents

**Initial investigations**

**Genetics**

- Karyotype. A karyotype should be obtained urgently, as it helps develop a differential diagnosis and to plan further investigations.
- FISH studies using probes specific for X (DX 1) and the Y (SRY) chromosome should be obtained and mosaicism should be excluded.
• Comprehensive microarrays (CMA), whole Exome sequencing (WES) and other single gene analysis may be needed depending on the clinical situation.

Internal Genitalia Anatomy
• Pelvic ultrasound exam should be ordered to assess presence of Mullerian structures (uterus or uterine remnants), gonads, and to exclude renal anomalies
• Magnetic resonance imaging (MRI) of the abdomen and the pelvis, exploratory laparoscopy, evaluation under anesthesia, cystoscopy, and urogenital contrast studies may be necessary for complete evaluation.

Hormonal Tests
• 17-Hydroxyprogesterone is useful to diagnose 21-OH hydroxylase deficiency (responsible for 90% of CAH). If the levels are non-diagnostic or if the infant needs to be started on steroids, perform an ACTH (250 mcg of Cosyntropin for infants > 3kg or 125 mcg for infants < 3kg) stimulation test. This will accentuate the block in the metabolic pathway.
• Testosterone, dihydrotestosterone, and Anti-Mullerian Hormone (AMH). Testosterone is produced by testicular Leydig cells and is converted to a more active form, dihydrotestosterone. AMH is produced by the Sertoli cells. Male levels of these hormones represent hormonally active testicular tissue. Adequate levels of dihydrotestosterone rule out 5-alpha-reductase deficiency.
• Gonadotropins (LH, FSH). Raised basal levels are consistent with primary gonadal failure; low levels can be a sign of hypogonadotropic hypogonadism.
• Other tests such as inhibin B levels, estradiol, and Human chorionic gonadotropin (HCG) stimulation tests may be necessary depending on the clinical situation.

5.2 Hypothyroxinemia of Prematurity
Introduction
Hypothyroxinemia is defined by the state screening program as a total thyroxine (T4) level <90% of samples screened on that day. In infants <32 weeks' gestation, hypothyroxinemia of prematurity with normal or low thyrotropin (TSH) levels is common. The serum levels of thyroid hormones in premature infants are considerably lower than those in term infants as both the thyroid gland hormone biosynthesis and the hypothalamic-pituitary axis (HPA) are immature and thyroid-binding globulin levels are low. The degree of hypothyroxinemia is also related to gestational age and the severity of neonatal disease. Further, pharmacologic agents may inhibit TSH secretion (e.g., glucocorticoids, dopamine). In these preterm infants, a period of approximately 6–8 weeks of hypothyroxinemia occurs, and is more severe at shorter gestational ages. Very low birth weight (VLBW) infants also have an 8-fold increased risk for development of transient primary hypothyroidism with low T4 levels and marked elevations in TSH. It is uncertain whether this condition contributes to adverse neurodevelopmental outcome or whether treatment with T4 during this period results in improved developmental outcome.
The prevalence of permanent hypothyroidism in preterm infants is comparable to that of term infants. It is important to distinguish transient hypothyroxinemia from primary or secondary hypothyroidism.

**Epidemiology**

The prevalence of hypothyroidism is 1 in 4,000, however, the prevalence of hypothyroxinemia is not known.

**Diagnosis**

Because levels of total and free T4 in premature infants are low, distinguishing physiologic hypothyroxinemia from true central (secondary hypothalamic or hypopituitary) hypothyroidism is often difficult. In extremely low birth weight infants, the first newborn screen (NB S) result often has low T4 and normal TSH. In infants with low T4 and normal TSH who are asymptomatic, repeat the NB S (if the second screen has not yet been sent) and simultaneously measure free T4 and TSH in the hospital laboratory. If the thyroid function tests, or the repeat NB S, or both are abnormal, order a free T4 by equilibrium dialysis (remember that heparin, Lasix, high free fatty acid concentrations interfere with this determination by displacing T4 from binding proteins and falsely elevating free T4 concentrations) and then obtain an endocrinology consultation when the results of the T4 by ED are back.

Clinical findings that suggest central hypothyroidism include:
- micropenis
- cleft lip or cleft palate
- midline facial hypoplasia
- nystagmus
- hypoglycemia
- prolonged indirect hyperbilirubinemia
- evidence of abnormal adrenal function, deficiencies of growth hormone, prolactin, or gonadotropins
- central diabetes insipidus
- radiologic evidence of structural head abnormalities (hypothalamus, pituitary gland, IVH)

**Treatment**

True congenital hypothyroidism should be treated with replacement thyroxine (levothyroxine sodium, 8–10 mcg/kg per day, given orally; the IM or IV dose is 50% to 75% of the oral dose). Follow the infant’s thyroid function (TSH, free T4, and total T4) 2 and 4 weeks after instituting replacement therapy. A pediatric endocrinologist should guide further therapy and follow-up. A Cochrane analysis does not support the treatment of transient hypothyroxinemia of prematurity to reduce neonatal mortality, improve neurodevelopmental outcome, nor to reduce the severity of respiratory distress syndrome. The power of the meta-analysis used in the Cochrane review to detect clinically important differences in neonatal outcomes is limited by the small number of infants included in trials. Subsequent treatment trials have been too small or not designed to assess outcome and thus there are no compelling data to make generalized treatment recommendations. Future trials are warranted and should be of sufficient size to detect clinically important differences in neurodevelopmental outcomes.

**Prognosis**

In most patients, hypothyroxinemia is transient and resolves completely in 4–8 weeks. However, the frequency of follow-up thyroid function studies should be based on the clinical picture and the degree of hypothyroxinemia.

**5.3 Steroid Therapy for Adrenal Insufficiency**

**Etiology**

Maternal cortisol is converted to cortisone by the placenta during gestation which prevents the suppressive effect on the fetal hypothalamic pituitary adrenal axis (HPA). At birth, a surge of fetal cortisol levels is seen, which is much higher in spontaneous labor compared to induced labor or cesarean delivery. Evidence suggests that the fetal adrenal cortex does not produce cortisol de novo until late in gestation (approximately 30 weeks gestation) when increased levels of cortisol have the needed effect of inducing the maturation required for extrauterine life.

Factors predisposing neonates to adrenal insufficiency include developmental immaturity (i.e., in preterm infants) and relative adrenal insufficiency. Relative adrenal insufficiency is defined as the production of inadequate levels of cortisol in the setting of a severe illness or stressful condition. Proposed mechanisms for relative adrenal insufficiency have included cytokine-related suppression of ACTH or cortisol synthesis, cytokine-induced tissue resistance to cortisol actions, hypoperfusion or hemorrhage of the adrenal gland (i.e., which can occur with sepsis), or limited adrenocortical reserve.

**Signs and Symptoms**

Signs and symptoms of acute adrenal insufficiency include:
- Hypoglycemia
- Hyponatremia and hyperkalemia (seen in mineralocorticoid deficiency, e.g., aldosterone deficiency or congenital adrenal hyperplasia)
- Cardiovascular dysfunction resulting in hypotension and shock, often non-responsive to volume and ionotropic therapy

**Evaluation of Hypothalamic-Pituitary-Adrenal Axis and Function**

Evaluation should be performed 2–7 days after finishing a course of steroids which lasted >2 weeks. If the evaluation demonstrates a non-responsive result, the evaluation should be repeated in 6–8 weeks.

**Laboratory Testing**

The following laboratory testing should be sent:
- Perform adrenal gland stimulation test by administering 1 microgram of Cosyntropin IV and check cortisol level 30 and 60 minutes after administration of ACTH
- A baseline cortisol level >10 mcg/dL and total stimulated level >18 mcg/dL or a change from baseline of >10 mcg/dL indicates a normal response. If there is a question regarding adequacy of response, pediatric endocrinology consultation should be obtained.
Section 5—Endocrinology

5.4 Hypoglycemia

Neonatal hypoglycemia is common and appropriate management remains a subject of controversy. However, recent evidence has clarified important physiologic and prognostic differences between transient neonatal hypoglycemia (TNH) occurring during the first 24-48 hours of life and hypoglycemia persisting beyond that time period or presenting later.

Blood glucose (BG) values are lowest during the initial 48 hours of life and transient values ≤40 mg/dL are common. Current evidence does not identify a BG concentration or threshold that is “safe” or a level inevitably associated with irreversible brain injury. Individual BG values must be evaluated in conjunction with assessment of patient risk, neurologic behavior and presence of other contributing factors.

Point of care testing (POCT) and iStat-type devices are convenient for glucose screening and are used by most hospitals for bedside testing. However, they evaluate the whole BG value, with limited accuracy in the hypoglycemia range. It is essential to confirm low BG values with a clinical laboratory plasma glucose (PG) specimen. However, if a POCT value is low, appropriate intervention should not be delayed while awaiting confirmatory laboratory testing.

Whole BG values (POCT devices) are ~15% lower than PG (laboratory) values. The BG value also depends on the patient’s hematocrit, and PG sent to the laboratory may be lower if not immediately tested due to metabolism of glucose by erythrocytes. “BG” will be used in this section and, unless specifically stated, can refer to either plasma glucose (laboratory method) or whole blood glucose (POCT method).

5.5 Transitional Neonatal Hypoglycemia (≤48 hours of life)

Fetal blood glucose (BG) values at term are about 10 mg/dL less than those of the mother. Fetal insulin is responsive to fetal glucose concentrations, but fetal glucose values are primarily determined by maternal concentrations. Fetal insulin functions to regulate fetal growth. Obligate cerebral glucose utilization is high in neonates, and the ability to utilize alternate fuels such as ketones and lactate for cerebral metabolism is limited in the first two days. Following birth, mean BG values in healthy term neonates diminish and reach a nadir of 50-60 mg/dL at 1-2 hours of age. Values subsequently increase over the next 2-3 days to a mean >70 mg/dL.

The most common cause of hypoglycemia in neonates is transient neonatal hypoglycemia (TNH), impairment of the metabolic transition from intrauterine to extrauterine life, which typically resolves by 48 hours.

Infants at high risk for TNH include:
- Infants of diabetic mothers
- LGA infants
- Infants with fetal growth restriction (SGA infants)
- Preterm infants <37 weeks GA, especially those requiring NICU care.
- Other neonates with unstable cardiopulmonary function, infection, polycythemia, or neurologic injury.

Approximately 50% of infants in these risk groups exhibit at least 1 BG value ≤47 mg/dL during the first 48 hours of life, and 19% have values ≤37 mg/dL. In one prospective study, recurring episodes occurred in 19%, and 6% had their initial episode after 24 hours of age. Eighty percent were asymptomatic, 15% were too lethargic to feed and 7% were jittery. Most symptomatic neonates have BG values <25 mg/dL, as do those with hyperinsulinism or genetic hypoglycemic disorders. Importantly, symptoms of hypoglycemia are non-specific and can occur with other neonatal conditions.

Recent evidence suggests that TNH is a disorder of insulin dysregulation. Transient immaturity exists in the suppression of insulin secretion as plasma glucose levels fall during the early hours following birth. This results in a state of “functional” hyperinsulinism in which insulin levels may be in the “normal” range but are not appropriate for the observed plasma glucose concentrations. This dysfunctional regulation of insulin suppresses production of free fatty acids and ketones, making them unavailable as alternate energy sources for cerebral metabolism. Although the majority of infants with transient neonatal hypoglycemia remain asymptomatic, BG values fall to quite low levels in some.

Management of TNH

Evidence linking hypoglycemia and adverse neurologic outcome has been conflicting. Although some studies have associated asymptomatic hypoglycemia with developmental delay and poor academic achievement, current evidence does not identify a specific BG value or threshold below which cerebral injury will occur. Treatment studies have also reported conflicting outcomes.

Glucose screening. Babies in the high risk categories noted above should receive glucose screening at 3 hours of age. Babies may require continued monitoring during the first 24 to 48 hours until BG values stabilize >60 mg/dL. Several clinical scenarios occur among these high risk patients. Management strategy must be individualized and depends upon BG value, risk and clinical findings.

Need for intervention will usually involve one of the following clinical scenarios:
- Symptomatic neonates. Symptomatic infants (seizures, temperature instability, respiratory distress, lethargy, apnea, inability to orally feed, or marked jitteriness) with a BG value <40 mg/dL should be given a bolus of 2 mL/kg of
D10W followed by a continuous glucose infusion of 5-8 mg/kg/min, titrated to maintain BG >60 mg/dL. Failure to provide the continuous infusion may result in recurrence of hypoglycemia. One should not wait for the results of laboratory PG levels to initiate management of symptomatic infants. The use of higher concentration dextrose (12.5% dextrose in water) allows the baby to continue to feed orally without giving excessive free water. Dextrose concentrations higher than 12.5% require central venous access.

- Late preterm (34-36 6/7 weeks) infants and term IDM, SGA or LGA infants who are stable and asymptomatic. These infants should be offered feeds within one hour after birth (breastfeeding, oral or gavage feeding with human milk or formula) and have BG tested 30 minutes after the feed. Frequent feeding should continue every 2-3 hours with BG monitoring prior to each feed. The initial treatment target is a progressive rise in BG value to >45 mg/dL in the first 4 hours of life. Monitoring of BG values should continue for 12-24 hours. If BG values >45 mg/dL cannot be achieved with frequent feedings, supplementation with IV dextrose will be necessary. When BG values are stable >60 mg/dL and oral feeding is established, weaning of dextrose-containing IV fluids can be attempted with BG checks after each wean.

- At risk neonates who are NPO and asymptomatic. Perinatal conditions requiring NICU care place infants at risk for hypoglycemia and delayed initiation of feedings. These include preterm infants <34 weeks, infants with cardiopulmonary disease, and other high risk conditions that preclude successful enteral feeds. These infants should be started on an IV dextrose infusion providing 5-7 mg/kg/min and have BG checked by 30-60 minutes of life. Babies <25 weeks gestation should be started at a GIR of 4-6 mg/kg/min. This GIR is effective in preventing hypoglycemia in most high-risk patients. However if BG >45 mg/dL cannot be maintained, administer an IV bolus of 2 mL/kg of D10W followed by an increase in GIR by 10-20%.

**Subsequent Management**

TNH should resolve by 48 to 72 hours of life. Prior to discharge of an infant who required glucose supplementation as treatment for TNH, the clinician must be certain that infant can maintain normal BG values during several feeding cycles on a routine diet. This is particularly important if the infant required intervention with IV dextrose or was symptomatic. Those with symptoms,
very low values, or need for high levels of IV dextrose supplementation (GIR >10-12mg/kg/min) are suspect for a persistent disorder of glucose metabolism and are candidates for further evaluation prior to discharge. A high index of suspicion is necessary to promote early diagnosis of hyperinsulinism and other persistent hypoglycemia disorders before severe, recurrent episodes occur, as these have been associated with developmental disabilities.

**Glucose Calculations**

Glucose Infusion Rate (GIR) = mg glucose/kg/min =

\[
\text{\% dextrose \times fluid goal} \\
\text{144}
\]

(e.g., D_{12.5}W at 80 ml/kg/day: 12.5 \times 80/144 = 6.9 mg/kg/min).

% Dextrose to order using Total Fluid Goal:

\[
\left( \frac{\text{GIR Goal (mg/kg/min) \times 1.44}}{\text{Total fluid goal (ml/kg/day)}} \right) \times 100
\]

GIR Goal (mg/kg/min) \times 1.44 = gm glucose /kg/day
Then divide by fluid goal (ml/kg/day) =
Dextrose per mL \times 100 = g/100 mL

(e.g., GIR goal of 10 mg/kg/min in 80 mL/kg/day:
10 mg/kg/min \times 1.44 = 14.4 g/kg/day ÷ 80 \times 100 = 18 g/100 mL
(18 % dextrose in IV fluid).

### 5.6 Persistent Hypoglycemia

Persistent hypoglycemia is defined as the need for glucose supplementation beyond 48-72 hours of life to maintain BG values > 60 mg/dL. A thorough diagnostic work up is essential because many entities producing persistent hypoglycemia impair mobilization of glucose or availability of alternate energy pathways, especially those providing fuel sources for cerebral metabolism. As a result, the entities discussed here are associated with high risk of severe symptomatic hypoglycemia with resulting brain injury. Disorders producing hyperinsulinism or impairment of fatty acid oxidation are particularly important.

Hyperinsulinism should be considered in neonates requiring a GIR > 10 mg/kg/min as well as any neonate with persistent and frequent hypoglycemic episodes. The diagnosis of hyperinsulinemic hypoglycemia cannot be made by solely measuring insulin concentrations at the time of a hypoglycemic episode. Identification of a specific etiology requires a battery of laboratory studies obtained during an episode of hypoglycemia.

It is critical to use history and physical examination, as well as the clinical picture, to narrow the differential diagnosis. Sending laboratory tests without guidance from the clinical picture may lead to a non-diagnostic evaluation. For example a newborn with micropenis and undescended testicles will require a pituitary evaluation rather than an insulin or acyl carnitine concentrations. Lab tests should be obtained once persistent hypoglycemia is determined when the infant becomes hypoglycemic (BG < 60 mg/dL) either spontaneously or in concert with a planned weaning of the glucose infusion rate or monitored fasting. Pediatric Endocrinology Service consultation should be obtained after results of the initial testing as found in Figure 5-5 are known, but before treatment begins.

Causes of persistent hypoglycemia are listed below to help determine the etiology. *(Fig 5-6)*

### Causes of Persistent Hypoglycemia

#### Disorders of Insulin Secretion and Production

Persistent hyperinsulinemic hypoglycemia of infancy (congenital hyperinsulinism)
- Infants of diabetic mothers
- Perinatal stress
- Erythroblastosis fetalis
- Beckwith-Wiedemann Syndrome

#### Endocrine Abnormalities

- Hypothalamic/Pituitary dysfunction
- Central adrenal insufficiency
- GH deficiency
- A combination GH and adrenal insufficiency as part of panhypopituitarism
- Primary adrenal insufficiency
- Congenital adrenal hyperplasia
- Congenital adrenal hypoplasia
- Adrenal hemorrhage

#### Disorders of Ketogenesis and Fatty Acid Oxygenation

- Fatty acid oxidation disorders, MCAD being the most common
- Disorders of carnitine transport/carnitine deficiency

#### Defects in Amino Acid Metabolism:

- Maple syrup urine disease
- Propionic acidemia
- Methylmalonic acidemia

#### Inborn Errors of Glucose Production:

- Glycogen storage disease
- Disorders of gluconeogenesis - pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase
- Hereditary Fructose Intolerance

### Evaluation of Persistent Hypoglycemia

Ongoing hypoglycemia beyond the first 48 hours of life, and particularly beyond the first week, increases the concern for an underlying hypoglycemia disorder. In these neonates, it is suggested to begin laboratory evaluation between 72 hours and 7 days for most, so that persistent hypoglycemia may be excluded before discharge home. Testing is performed when the BG is <50 mg/dL, either spontaneously or as part of a diagnostic fast because tests performed when the BG is normal are not generally helpful. *(strong recommendation, high quality evidence)*
Figure 5-5. Persistent hypoglycemia evaluation flow diagram

- POC glucose < 50 mg/dL
  - Draw critical sample: Serum glucose, insulin, B-OH-butryate, free fatty acids (see box on the right for lab tubes and blood volumes required)
  - Administer Glucagon (IM injection): Dose: 0.5 mg if < 3 kg, 1 mg if > 3 kg

1. Check POC glucose at 15, 30, 45 and 60 minutes as a safety measure
2. Check serum (lab) glucose at 30 minutes to determine glucose
3. Check growth hormone and cortisol at 60 minutes

IV Dextrose at appropriate rate to maintain BG > 60 mg/dL

Critical Sample Baseline Labs:
- Before Glucagon administration:
  - Glucose: 1 x 1 mL gray potassium oxalate/sodium fluoride tube
  - Insulin: 1 x 0.6 mL amber microtainer with gel
  - BOHB: 1 x 0.6 mL green lithium heparin with gel microtainer
  - FFA: 1 x 3 mL red no additive tube (minimum 0.2 mL serum)
- After Glucagon administration:
  - Glucose (at 30 min): 1 x 1 mL gray potassium oxalate/sodium fluoride tube
  - GH (at 60 min): 1 x 3 mL red additive tube, serum, draw volume 3 mL, min volume 0.5 mL
  - Cortisol (at 60 min): 1 x 0.6 mL green lithium heparin with gel microtainer


Figure 5-6. Persistent hypoglycemic diagnostic categories

- After glucagon stim test: (see Fig 5-5)
  - Serum glucose at 30 minutes > 30 mg/dL?
    - Yes
      - Insulin > 2 IU/mL
      - BOHB < 2 mm
      - FFA < 2 mm
      - Dx: Hyperinsulinism
      - Consult Endocrinology to start Diazoxide 5 mg/kg/dose PO q 8 hours
      - IV Dextrose discontinued?
        - Yes
          - If on regular feeds and stable BG, continue medical therapy
        - No
          - If unable to wean IV Dextrose: Dx: Persistent Hypoglycemia
          - Consult Endocrinology prior to progressing to next level of care (Octreotide, Surgery)
    - No
      - Insulin < 2 IU/mL
      - BOHB > 2 mm
      - FFA > 2 mm
      - Abnormal GH/cortisol
        - Yes
          - Dx: Panhypopituitarism
        - No
          - Genetic evaluation:
            - Acylcarnitine analysis
            - Lactate
            - Triglycerides
            - Uric Acid
            - Plasma Amino acids
            - Urine organic acids

In neonates suspected of having a congenital hypoglycemia disorder a treatment goal of BG >70 mg/dL is recommended. (strong recommendation, low quality evidence)

For high-risk neonates without a suspected congenital hypoglycemia disorder, a goal of >60 mg/dL is still suggested (i.e. SGA, IDM). (weak recommendation, very low quality)

Consultation with a specialist should be considered before planning discharge from the nursery for neonates with known genetic or other persistent forms of hypoglycemia. In these cases “safety” fasting test may be recommended to ensure that BG can be maintained above 70 mg/dL if a feeding is missed (minimum 6 - 8 hours). (GRADE 2D, expert consensus opinion)

**Suggested Laboratory Evaluation for Persistent Hypoglycemia**

Check blood sugar every 3 hours

When blood sugar < 60 mg/dL, check every 1 hour *

When blood sugar < 50 mg/dL, draw critical blood samples before treating hypoglycemia

- Plasma glucose level
- Plasma insulin level
- Free fatty acids
- Plasma cortisol and growth hormone
- Serum beta-hydroxybutyrate

After drawing critical blood samples, treat with glucagon IM (see Fig 5-5 for dosing) and recheck serum glucose at 30 minutes and cortisol and growth hormone at 60 minutes. Start IV dextrose as appropriate to maintain blood sugar above 60 mg/dl. If patient is unstable while hypoglycemic, bolus with 2 mL/kg of D_{10W}.

Other laboratory studies that may be necessary in identifying specific disorders include:

- C-peptide
- Acylcarnitine profile
- Plasma amino acids
- Pyruvic acid **
- Serum ammonia and lactate
- Urine organic acids and ketones

*Run glucose levels in the lab STAT rather than by POC alone.

**Immediately after blood is drawn, add exactly 1 mL of whole blood to a chilled pyruvate collection tube (available from send out section of lab). Mix well and place on ice. Deliver to lab ASAP.

**Suggested Reading**

**Approach to Disorders of Sexual Development**


**Hypothyroxinemia of Prematurity**


**Steroid Therapy for Adrenal Insufficiency**


**Transitional Neonatal Hypoglycemia**


**Persistent Hyperglycemia**

Section 6: Genetics

Editors: Mohan Pammi and Ganga Gokulakrishnan

6.1 Inborn Errors of Metabolism .......................78
Rebecca J. Burke
William J. Craigen
Ganga Gokulakrishnan

6.2 Genetic Testing ........................................85
Seema Lalani
Mohan Pammi
6.1 Inborn Errors of Metabolism

Introduction

Genetic biochemical abnormalities in newborns comprise a large group of individually rare disorders with a number of stereotypic presentations. More than 300 distinct metabolic disorders are recognized and novel entities continue to be described.

Metabolic disorders may be undetected (overlooked) or misdiagnosed because of their rarity and non-specific symptomatology. In acute disease, inborn errors of metabolism (IEM) are frequently not considered until more common conditions, such as sepsis, are excluded. Since newborns have a limited set of responses to severe overwhelming illness—with such non-specific findings as lethargy, poor feeding, and vomiting—clinical assessment is difficult. In general, the clinical context needs to influence the decision to carry out a metabolic evaluation and the breadth of the investigation. For example, a sepsis workup of a clinically ill newborn should lead to consideration, not the exclusion, of a metabolic evaluation. The high-risk patient is a full-term infant with no risk factors for sepsis who develops lethargy and poor feeding. In addition, diagnostic testing of blood and urine is informative only if collected at the proper time relative to the acute presentation. Novel biochemical technologies—such as tandem mass spectrometry—enhance the ability to arrive at specific diagnoses.

Thus, a need remains for a high clinical suspicion in the appropriate diagnosis and treatment of metabolic disorders. While it is important to inquire whether others in the family have been similarly affected, since most of these conditions exhibit autosomal recessive inheritance, frequently the family history does not reveal prior affected individuals.

Increasingly, syndromic diseases are recognized as being caused by IEM (e.g., Smith–Lemli–Opitz syndrome, due to a defect in cholesterol biosynthesis; Zellweger syndrome, due to defects in peroxisomal biogenesis; and neuronal migration abnormalities and related cerebral malformations caused by a variety of disorders of energy metabolism).

Screening for metabolic disease does not require a long list of tests; simply assessing the acid/base balance, ammonia and lactate levels, and a urinalysis can provide enough information in the acute setting to direct further testing. Infants diagnosed with IEM should receive Developmental referral and ECI (Early Childhood Intervention) referral.

Categories of IEM

In the overall assessment of a clinical scenario, two general categories of IEM can be considered:

- disorders that involve only one physiologic system; e.g., isolated hemolytic anemia due to disorders of glycolysis, and
- more generalized defects in a metabolic pathway common to more than one organ system or secondarily affecting more than one organ system. For example, hyperammonemia reflects a liver-specific abnormality of ureagenesis but secondarily affects central nervous system function. This second category can be further divided into three distinct clinical scenarios:

  » Disorders that affect the synthesis or breakdown of complex molecules (e.g., the lysosomal storage disorders) - this group of disorders tends to have a progressive, somewhat fixed course independent of dietary intake or intercurrent events such as infection. While this class of disorders can present in the newborn period (e.g., fetal hydrops secondary to lysosomal storage disorder or fulminant hepatitis associated with alpha-1-antitrypsin deficiency), diagnoses typically are made later in infancy or childhood. This group of disorders will not be discussed in detail.

» Systemic disorders that lead to acute intoxication from accumulation of toxic compounds preceding the metabolic block - Early diagnosis and prompt treatment can significantly improve the clinical outcome. This category includes urea cycle defects, organic acidemias, and other amino acidopathies, such as maple syrup urine disease. Many of the conditions in this group of disorders exhibit clinical similarities, which may include a symptom-free interval that ranges from hours to weeks followed by clinical evidence of intoxication (e.g., encephalopathy, vomiting, seizures, or liver failure). This group of disorders also tends to have a recurrent pattern with the waxing and waning of the offending metabolites. Treatment of these disorders requires the reduction or elimination of the offending compounds either through hemodialysis, a special diet, cofactor supplementation, or provision of a diversionary metabolic pathway.

» Systemic disorders that result from a deficiency in energy production or utilization - Since the brain, heart, skeletal muscle, and liver depend heavily on energy metabolism, these organs tend to be the primary site of pathology. This category includes a broad array of metabolic pathways, such as the mitochondrial respiratory chain, glycogen synthesis or breakdown, gluconeogenesis defects, and fatty acid oxidation defects. Signs and symptoms in this group reflect the specific organ systems involved, such as hypoglycemia, elevated lactic acid, liver failure, myopathy, cardiac failure, failure to thrive, and sudden death, or some combination of features.

Clinical Presentation

Clinical presentations may depend in part on the underlying biochemical defect but also on environmental effects such as infections and choice of nutritional source (Fig 6–1). Suspect an IEM when a child has a well period followed by a precipitous or more insidious decline in neurologic status. Presentation may be acute with potential for stroke–like sequelae, or progressive where development changes from normal to slower progress and skill loss. Onset of disorder may precede birth followed by further neurological deterioration post-birth. IEM may be categorized by their most prominent neurological, behavioral or other clinical characteristics.

In the intoxication type of disorders, the typical pattern is one of an apparently healthy infant who becomes increasingly fussy and disinterested in feeding. This may be accompanied by vomiting, which can be so severe as to be mistaken for pyloric stenosis.
Most metabolic disorders will have encephalopathy as a component of the clinical picture. Encephalopathy typically is a consequence of hyperammonemia, but also may be due to cerebral toxicity of particular fatty acids, as seen in certain defects in fatty acid oxidation such as medium-chain acyl-CoA dehydrogenase deficiency (MCAD), organic acids such as glutaric aciduria, or an accumulation of unusual highly reactive compounds such as sulfites and sulfocysteine in sulfite oxidase deficiency. In addition, particular amino acids have direct toxic effects via distinct mechanisms, such as glycine, which is elevated in the CSF of patients with non-ketotic hyperglycinemia (NKHG: glycine encephalopathy), or branched chain amino acids, which are increased in maple syrup urine disease.

In contrast, the alert but hypotonic infant suggests a different set of disorders, both syndromic, such as Prader-Willi syndrome or spinal muscular atrophy, and metabolic, such as Pompe disease (glycogen-storage disease type II [GSD2]).

Hyperammonemia

Hyperammonemia must be considered in encephalopathic patients since no other biochemical abnormalities (with the exception of plasma amino acid analysis) reliably suggest the presence of hyperammonemia. Prompt recognition of hyperammonemia is imperative for a good outcome; the correlation is clear between length of time that a patient is hyperammonemic and degree of neurologic damage. Hyperammonemia may be:

- only biochemical abnormality, as in the urea cycle disorders, or
- part of a broader biochemical perturbation such as profound acidosis (as seen in various organic acidurias) or hypoglycemia (as seen in hyperinsulinism associated with over activity of the enzyme glutamate dehydrogenase as a result of gain of function mutation).

Hypoglycemia

Hypoglycemia can be a prominent feature in IEM and may be associated with encephalopathy, seizures or both. Abnormalities associated with hypoglycemia in neonates include:

- glycogen-storage disease (GSD), in particular GSD1A due to glucose-6-phosphatase deficiency,
- GSD1B caused by glucose-6-phosphate translocase deficiency, and
- GSD3 due to debrancher deficiency.

GSD1A and 1B patients typically have signs and symptoms in the neonatal period, while GSD3 tends to come to attention later in the first year. Abnormalities in blood chemistries that support the diagnosis of GSD1 include hyperlipidemia, uric acidemia, and lactic acidemia, while patients with GSD3 exhibit elevated ALT and AST, and elevated CPK in most patients. DNA testing can establish the diagnosis of GSD1A and preclude the need for liver biopsy.

Other IEM in which hypoglycemia is a prominent feature include:

- fatty acid oxidation disorders (especially MCAD),
- gluconeogenesis defects
- mitochondrial respiratory chain disorders

Disorders of Fatty Acid Oxidation

Although disorders of fatty acid oxidation may be associated with hypoglycemia and can be clinically apparent in the newborn period, e.g., MCAD, VLCAD, or CPT2, the typical patient is older. Such hypoglycemia is usually observed late in the course of the disease and hence is an ominous sign. About 20 different enzyme defects are associated with fatty acid metabolism and the clinical scenario varies considerably.

Some patients will have a myopathic presentation that may be associated with rhabdomyolysis and cardiomyopathy; others will have a hepatic phenotype with features of hepatitis, hypoglycemia, and hyperammonemia.

Screen for these disorders with a plasma acyl-carnitine profile, urine acyl-glycine analysis, and urine organic acid analysis, which identify accumulated intermediates of fatty acid oxidation. Treatment is directed at avoiding the mobilization of fats, treating any secondary carnitine deficiency, and
possibly bypassing any block in long-chain fatty acid oxidation (depending on the enzyme step involved) by providing medium-chain fats in the diet.

Although disorders with obvious systemic features usually significantly affect neurologic status, on rare occasions this is not the case. For example, an inborn error in glutathione synthesis (pyroglutamic aciduria) is associated with profound neonatal acidosis and hemolysis, yet neurologic problems typically are absent or mild.

An abnormal odor is apparent in various metabolic disorders, including sweaty feet in isovaleric acidemia or glutaric aciduria type 2, and an aroma of maple syrup in maple syrup urine disease (MSUD).

**Maternal-Fetal Interactions**

Some maternal-fetal interactions can affect either the mother or the infant or both. While the placenta often will detoxify the fetus in urea cycle disorders or organic acidurias, a number of disorders, such as those that affect energy production, have an in utero onset.

Likewise, an affected fetus can have a toxic effect on the mother. For example, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency has been unequivocally associated with the development of hemolysis elevated liver function and low platelets (HELLP) syndrome and fatty liver of pregnancy in some carrier (heterozygous) mothers, and several other disorders of fatty acid metabolism have been similarly linked to maternal disease.

Conversely, mothers who have poorly controlled phenylketonuria (PKU) are at high risk of delivering infants with microcephaly and congenital heart disease from in utero exposure to elevated circulating phenylalanine despite being genotypically unaffected.

Finally, the metabolic stress of childbirth can precipitate a metabolic crisis in a mother who has not been previously identified as affected (e.g., post-partum hyperammonemia and death have been reported in mothers who are heterozygous for X-linked ornithine transcarbamylase deficiency, whether or not the fetus is affected)

**Clinical Features**

**Fetal Hydrops**

Fetal hydrops can be a manifestation of a large number of IEM, in particular various lysosomal storage disorders. A list of genetic disorders that have been associated with hydrops is provided (Table 6–1).

**Neurologic Manifestations**

**Tone** - In a variety of metabolic disorders, tone frequently is abnormal; most commonly hypotonia is seen. In addition to encephalopathy, posturing or stereotyped movements, as seen in MSUD or hyperammonemia, may give the impression of peripheral hypertonia. Infants with MSUD in particular may exhibit opisthotonus. Dystonia may be an early finding in a subset of disorders, in particular glutaric aciduria type 1 (glutaryl-CoA dehydrogenase deficiency), with selective injury to the basal ganglia, and in disorders of neurotransmitter synthesis such as L-amino acid decarboxylase deficiency, where autonomic instability is quite prominent.

<table>
<thead>
<tr>
<th>Table 6–1. Metabolic disorders, chromosomal abnormalities, and syndromes associated with nonimmune fetal hydrops</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lysosomal Storage Disorders</strong></td>
</tr>
<tr>
<td>- sialidosis</td>
</tr>
<tr>
<td>- I-cell disease</td>
</tr>
<tr>
<td>- galactosialidosis disease</td>
</tr>
<tr>
<td>- infantile sialic acid/Salla disease</td>
</tr>
<tr>
<td>- Niemann-Pick disease types A and C</td>
</tr>
<tr>
<td>- Wolman disease/acid lipase deficiency</td>
</tr>
<tr>
<td>- Farber lipogranulomatosis/ceramidase deficiency</td>
</tr>
<tr>
<td>- GM1 gangliosidosis/beta galactosidase deficiency</td>
</tr>
<tr>
<td>- Gaucher disease/glucocerebrosidase deficiency</td>
</tr>
</tbody>
</table>

**Hematologic Disorders (associated with hemolysis)**

- alpha-thalassemia
- pyruvate kinase deficiency
- glucose-6-phosphate dehydrogenase deficiency
- glucose-phosphate isomerase deficiency

**Chromosome Abnormalities**

- Turner syndrome (45,X)
- trisomy 13
- trisomy 18
- trisomy 21
- triploidy
- other chromosomal rearrangements

**Other Genetic Disorders/Syndromes**

- Noonan syndrome
- McKusik-Kaufman syndrome
- Neu-Laxova syndrome
- Kippel-Trenaunay-Weber syndrome
- Diamond-Blackfan syndrome

**Disorders of fetal movement**

- arthrogryposis
- Pena-Shokeir sequence (fetal akinesia)

**Lethargy** - in the intoxication disorders, lethargy becomes more prominent and seizures may be apparent as the infant is increasingly obtunded.

**Tachypnea** - the development of tachypnea may reflect a central effect of hyperammonemia early in its course. Tachypnea may also be a response to progressive metabolic acidosis.

**Apnea** - In contrast, infants with NKHG often present with apnea as the initial clinical feature, only later developing seizures.

**Posturing** - Posturing associated with intoxication is perceived as seizure activity though, with rare exception, true convulsions are an inconsistent feature of IEM. Seizures dominate the clinical picture in pyridoxine-dependent and folinic-acid–responsive seizures. Also associated with seizures are sulfite oxidase deficiency, the related disorder molybdenum cofactor deficiency, and peroxisomal biogenesis...
disorders such as Zellweger syndrome. Likewise, the glucose transporter defect (GLUT 1) can be considered in infants with seizures, and a CSF glucose determination is diagnostic.

**Ophthalmological features/examination** - Cataracts may develop when metabolites are deposited or can be part of an energy disorder (e.g., Sengers syndrome; mitochondrial DNA depletion). Corneal clouding may occur in storage disorders.

**Disorders of energy production** - These disorders have a more variable neurologic picture.
- Often the infant has no well interval and typically is hypotonic.
- Hypertrophic cardiomyopathy is a frequent feature and dysmorphism and malformations, especially of the brain, can be attendant findings.
- While neurologic signs are prominent, coma rarely is a feature.
- Dystonia has been noted in a number of children with respiratory chain disorders, in particular complex I deficiency.
- Lactic acidemia with or without metabolic acidemia is a frequent, although not invariable, finding.

**Liver Disease**
Liver disease may be a prominent feature in a number of disorders. Hepatomegaly associated with hypoglycemia suggests GSD1 or GSD3, defects in gluconeogenesis, or fatty acid oxidation disorders. Evidence of liver failure (with jaundice, a coagulopathy, hepatocellular necrosis, hypoglycemia and ascites) suggests galactosemia, tyrosinemia type 1, respiratory chain disorders, disorders of glycoprotein glycosylation, or, in infants exposed to fructose-containing formula, hereditary fructose intolerance. Significant hepatic dysfunction and liver failure can also be observed in urea cycle disorders such as ornithine transcarbamylase (OTC) deficiency.

While deficiency of LCHAD, fatty acid transport, the carnitine palmitoyltransferases (CPTI/CPTII) and carnitine acylcarnitine translocase may lead to liver failure, most other disorders of fatty acid oxidation do not. Cholestatic jaundice without liver failure is a feature of the fatty acid oxidation disorders, disorders of bile acid metabolism and transport, Niemann-Pick type C, citrin deficiency (a partial urea cycle disorder), peroxisomal biogenesis disorders, and alph1-antitrypsin deficiency. Distinguishing liver failure as a manifestation of an IEM from non-genetic etiologies can be quite challenging. Biochemical tests for IEM can be very abnormal secondary to hepatic insufficiency. For example, elevated plasma tyrosine and methionine is a frequent finding in liver failure. Depletion of mtDNA (e.g., Alpers syndrome, DGUOK or MPV17 deficiency) often leads to infantile liver failure, as does other forms of mitochondrial disease such as MTU1 deficiency that do not exhibit depletion.

**Cardiac Disease**
Functional cardiac disease is one manifestation of energy disorders. Both dilated and hypertrophic cardiomyopathy can be seen, occasionally in the same patient over time. An echocardiographic finding of left ventricular non-compaction may accompany a respiratory chain disorder or may be associated with the X-linked disorder, Barth syndrome, in which skeletal myopathy, 3-methylglutaconic aciduria, and episodic neutropenia co-exist. Fatty acid oxidation disorders such as LCHAD, VLCAD, or CPT2 can often lead to infantile cardiomyopathy. While Pompe disease has infantile, adolescent, and adult variants, it typically is several weeks to months of life before the infantile form exhibits the full clinical picture of severe hypotonia, mild hepatomegaly (without hypoglycemia) and hypertrophic cardiomyopathy (with giant QRS complexes). Conduction abnormalities may accompany several disorders of fatty acid metabolism.

**Laboratory Evaluation**
In any infant with a suspected IEM, initial laboratory evaluation should include electrolytes, glucose, lactate, ammonia, blood pH, complete blood count, and urinalysis.

Screening tests that detect a large number of IEM can be distinguished from tests that address a single specific entity, the former being of more value in the initial evaluation. It is important to draw the labs when the infant is acutely ill in order to obtain the most accurate results possible. When evaluating a sick infant, certain features direct the testing.

**Blood ammonia level** - should be determined promptly in encephalopathic infants. Draw the sample from a free-flowing vein or artery, place it on ice, and immediately assay in the laboratory. Values less than 100 micromolar/L are of little significance in newborns and do not provide an explanation for the encephalopathy. However, ammonia values can change rapidly and repeated determinations may be indicated depending on the clinical circumstances. Ammonia levels also may be elevated in instances of severe hepatic disease due to other causes (e.g., neonatal herpes infection) or in vascular anomalies such as persistent ductus venosus.

**Plasma amino acid analysis** - This is an excellent screening test for a number of amino acidopathies and some organic acidurias. When ammonia is elevated, plasma glutamine and plasma alanine are often increased. Elevated alanine also is seen in the face of lactic acidosis, whether due to a genetic disorder or not (e.g., hypoxic injury). Glycine typically is increased in a disorder of glycine breakdown—NKHG, and certain organic acidurias such as propionic or methylmalonic acidemia (historically referred to as ketotic hyperglycinemias).

Urea cycle disorders often can be distinguished by plasma amino acid analysis. Elevated citrulline can be observed in 4 disorders:
- citrullinemia type 1 (argininosuccinate synthetase deficiency),
- citrullinemia type 2 (citrin deficiency),
- argininosuccinate lyase deficiency, and
- severe pyruvate carboxylase deficiency (a defect in gluconeogenesis).

In addition to modest elevation of citrulline, identifying argininosuccinic acid in plasma or urine is diagnostic for argininosuccinate lyase deficiency. Elevated arginine is a constant finding in untreated arginase deficiency, although these patients generally are not symptomatic in the newborn period and hence may be missed by newborn screening.
Several urea cycle disorders cannot be reliably distinguished by plasma amino acid analysis and require additional tests, including urine orotic acid. The branched-chain amino acids leucine, valine, and isoleucine are elevated in MSUD, with leucine values typically 10- to 20-fold elevated. The finding of alloisoleucine is diagnostic for MSUD. Defects in serine biosynthesis are reflected in low plasma and CSF serine levels. These infants have a neurologic presentation, as manifested by seizures and microcephaly, and may exhibit IUGR, cataracts, skin anomalies and contractures. CSF amino acid analysis is required to establish the diagnosis of NKHG but otherwise is of limited value. Combined increases in lactate and glycine may point to a group of disorders causing lipoic acid deficiency.

Determining the acid/base status of an infant and the presence or absence of an anion gap helps to distinguish organic acidurias and related disorders from urea cycle disorders, the latter typically not exhibiting metabolic acidemia. The level of lactic acid in blood is influenced by several factors, including adequacy of perfusion and whether a fasting or post-prandial sample was used. If the sample is drawn incorrectly, or is not assayed promptly, lactic acid levels often are spuriously elevated. Truly elevated (greater than 2 mM) venous lactic acid should prompt a search for an underlying cause; the higher the level, the greater the urgency. Moderate elevations in lactic acid may not be accompanied by changes in blood pH.

Elevated lactic acid can accompany a number of inherited conditions, including:
- a variety of organic acidurias,
- disorders of glycogen breakdown,
- pyruvate dehydrogenase deficiency,
- respiratory chain disorders,
- gluconeogenic defects, and
- vitamin cofactor transport or metabolism such as biotin or thiamine.

The finding of lactic acidemia should, at a minimum, prompt a complete metabolic evaluation. On occasion, severe lactic acidosis may resolve spontaneously later in infancy without explanation.

For certain organic acidurias such as propionic aciduria, glutaric aciduria type 2, or methylmalonic aciduria, hyperammonemia is a frequent, but not constant, finding. While lactic acid may increase modestly in organic acidurias, the often profound acidosis, and very prominent anion gap, is attributable to accumulation of the offending organic acid. Because of bone marrow suppression by the organic acid, severe leukopenia and thrombocytopenia may present, mimicking features of sepsis. Likewise, the finding of urine ketosis in a newborn should prompt a search for an IEM. With MSUD or defects in ketolysis (e.g., 3-ketothiolase deficiency or succinyl-CoA transferase deficiency), large amounts of ketones may be present in the urine and, conversely, defects in fatty acid oxidation typically demonstrate a hypoketotic state. Since carnitine is an important component of fatty acid metabolism, analyzing acylcarnitines in plasma (acylcarnitine profile) is a sensitive screen for many but not all of these disorders, and often is diagnostic for other organic acidurias.

This is a major component of newborn screening.

**Urine organic acid analysis** – This is an excellent screening test for a large number of IEM. Since some diagnostic compounds are short-lived and volatile, urine collected in the acute phase of the illness and processed immediately yields the best diagnostic sensitivity. Determining urine orotic acid can be quite helpful in distinguishing the different urea cycle disorders. More recently, it was recognized that disturbed mitochondrial function, as seen in respiratory chain disorders, also may lead to an elevation in orotic acid due to the role of mitochondria in pyrimidine metabolism.

**Urine-reducing substance** - detects galactosemia and related disorders. However, false-positive results occur following certain antibiotics, and elevated galactose can be seen in several other conditions in which the liver is not clearing galactose, including
- tyrosinemia type 1,
- citrin deficiency,
- Fanconi-Bickel syndrome (GLUT2 deficiency),
- disorders of bile acid metabolism, and
- vascular shunts such as persistent ductus venosus.

**Total plasma homocysteine** - can be helpful in distinguishing several IEM. Since most plasma homocysteine is bound to protein, routine amino acid analysis may not detect significant elevations in homocysteine. Homocysteine may be elevated both in acquired and inherited abnormalities of vitamin B12 metabolism, including maternal B12 deficiency. It may be an isolated finding or may be elevated in concert with methylmalonic acid. Hence, obtaining a B12 level in an infant with a suspected organic aciduria can be useful to sort out these possibilities before administering 1 mg of hydroxocobalamin IM. Disorders of B12 metabolism may require considerably more B12 to improve homocysteine levels.

Homocystinuria is a rare disorder that typically escapes detection in infancy, and therapy with pyridoxine can be curative. Since homocysteine is prothrombotic, it should be measured when investigating vascular events in infants and children. As newborn screening is expanded to include a large number of other conditions, homocystinuria should be routinely detected in newborns. The distinguishing feature between homocystinuria caused by deficiency of cystathionine beta synthase and homocystinemia associated with B12 metabolism is the presence of very elevated methionine in the former case. Low homocysteine values can be seen in patients with sulfite oxidase or molybdenum cofactor deficiency. Sulfonylcysteine is found in both conditions, while certain urine purines will be elevated in the latter condition.

**Muscle biopsy** - when the clinical picture and plasma lactate measurements suggest a mitochondrial or respiratory chain disorder, a muscle biopsy may be recommended in consultation with the Genetics team. The muscle biopsy is analyzed for histologic or histochemical evidence of mitochondrial disease and may lead to recommendations of more genetic tests for specific mitochondrial diseases. Respiratory chain complex studies are then usually carried out on skeletal muscle or skin fibroblasts. DNA sequencing or quantitation of mtDNA in affected tissues may be indicated.
Online Resources
Several websites, including www.genetests.org, provide information on specific disorders, tests currently available, and references to laboratories performing specific testing; online references such as The Metabolic and Molecular Basis of Inherited Disease and UptoDate are widely used in practice. Specialist Metabolic-Genetic consultation may helpfully guide investigation.

Treatment
Initial treatment of an infant with a suspected IEM depends in part on the initial laboratory evaluation, including electrolytes, glucose, lactate, ammonia, blood pH, complete blood count, and urinalysis. In general, plasma amino acid and urine organic acid analyses usually can be obtained within 24 hours, while an acylcarnitine profile may take 48 to 72 hours.

However, treatment can begin before the diagnosis of a specific disorder is established and should not be delayed while awaiting specialized laboratory results. Aggressive correction of acidosis with bicarbonate, infusion of glucose for hypoglycemia, and provision of vitamin cofactors all can be done while a specific diagnosis is pursued.

Cystic Fibrosis
A newborn screen for cystic fibrosis may be normal, return a result of an elevated immunoreactive trypsinogen (IRT), or a very elevated IRT. IRT is an exocrine pancreatic protein which is elevated in CF and other GI diseases. If a baby’s initial newborn screen at 24 to 48 hours of life has an elevated IRT, the newborn screen should be repeated at 1 to 2 weeks of age. If the repeat newborn screen is then negative, no further action is necessary.

However, if the IRT remains elevated, the State of Texas will automatically carry out a DNA analysis on the sample. This DNA analysis is a 40 + 2 panel and identifies approximately 96% of patients in Texas. The DNA analysis takes 2 days and may return no mutations, 1 mutation, or 2 mutations. If there are no mutations identified, no sweat testing is required but the patient should be carefully watched for the development of any respiratory symptoms. If there are 1 or 2 mutations identified, the patient should be referred for sweat testing. The baby must be a minimum weight of 2 kg, a minimum gestational age of 36 weeks, and a minimum chronological age of 2 weeks to qualify for a sweat test. If any newborn screen returns a result of a very elevated IRT, that baby’s screen is immediately referred by the State for DNA analysis. It is important to note that an elevated IRT may also be caused by the stress of critical illness. In addition, a baby may have a false negative result as well if s/he has received multiple blood transfusions.

Infants with positive sweat tests and 2 mutations require a Pulmonary Medicine consultation. Patients with clinical indications of CF (e.g., meconium ileus) should receive evaluation with sweat test irrespective of the newborn screen result and should also be evaluated by Pulmonary Medicine. Should further gene sequencing be necessary, a full genetic panel through BCM is able to sequence the majority of the >1500 possible mutations for the disease.

For further information, please contact Pam Tuley, CF center coordinator at 832-822-1348, Patuley@texaschildren’s.org

Galactosemia
Infants with classical galactosemia frequently develop signs and symptoms of galactose toxicity before the results of newborn screening are available, requiring that pediatricians remain vigilant when persistent jaundice, coagulopathy, cataracts, or sepsis—particularly caused by E. coli is found.

Treatment is supportive in addition to substitution of the offending galactose-containing formula with a soy formula. Despite good dietary compliance two thirds of children with classic galactosemia exhibit neurologic sequelae including developmental delay, dysarthria, tremor and, rarely, ataxia.

GSD1
GSD1 can be managed acutely by glucose infusion and bicarbonate. Unlike cases of hyperinsulinism, the glucose requirements should not be greater than those of fasting infants. A nighttime milk drip using a soy based formula and addition of polycose to daytime feeds usually prevents hypoglycemia. Older children can be treated with cornstarch (1.5 to 2 gm/kg per dose, 4 to 6 times per day) to maintain blood glucose.

In older children, treatment of hyperuricemia is needed, and in patients with GSD1B, chronic neutropenia requires treatment with G-CSF.

MSUD
MSUD, a defect in the branched chain ketoacid dehydrogenase leading to elevated leucine, valine and isoleucine, can be a diagnostic challenge in that most metabolic parameters are not very disturbed and, given the prominent neurologic features, other etiologies (such as herpes encephalitis, intracerebral hemorrhage, or epilepsy) are first sought. Modest acidosis and, when present, mild hyperammonemia are the rule, however, urine ketones are typically notably increased. Brain edema, especially of the cerebellum and brain stem, frequently is observed. Because of this, excessive fluid resuscitation can be catastrophic in older children.

Provision of non-protein calories and insulin can help improve the metabolic abnormalities, and providing a branched-chain amino-acid–free formula allows protein synthesis to proceed, reducing the levels of the toxic branched-chain amino acids.

Careful monitoring of amino acid levels in the plasma is required since valine and isoleucine supplementation usually is needed to reduce leucine levels.

Depending on the clinical severity, dietary management with a branched chain amino acid free formula or hemodialysis can be used to rapidly reduce leucine levels.

Organic Aciduria
A newborn who is hyperammonemic and severely acidotic can be assumed to have an organic aciduria. In this setting, intravenous administration of L-carnitine (100 to 300 mg/kg per day divided t.i.d.) can relieve secondary carnitine deficiency and help to remove the offending organic acid. In addition to bicarbonate, providing calories in the form of glucose and insulin can reverse the catabolic state that contributes to metabolic perturbations. Administration of the vitamins thiamine (100 mg), biotin (10 mg), and hydroxycobalamin (1 mg) will address vitamin- responsive...
forms of organic acidurias. Frequently the hyperammonemia will respond to these therapies promptly, avoiding the need to dialyze the infant. Carbaglu (carglumic acid) can improve the hyperammonemia associated with organic acidurias.

**PKU**

Infants with PKU or milder hyperphenylalaninemia have no acute metabolic decompensation and treatment should be initiated by 2 to 3 weeks of life. Treatment involves a low-phenylalanine diet (in infancy, a phenylalanine-free formula supplemented with regular formula to provide the prescribed amount of phenylalanine) for life with frequent monitoring of plasma phenylalanine levels. With good dietary compliance, developmental outcomes are very good.

**Urea Cycle Disorders**

An infant with a urea cycle disorder, if identified early in the course, may not have secondary metabolic consequences, such as respiratory acidosis, found in those infants diagnosed later. The acid/base status tends to respond much more readily to bicarbonate than in the organic acidurias, and hydration and glucose alone improves the biochemical parameters. Infants with ornithine transcarbamylase deficiency frequently present with respiratory symptoms and hypotonia shortly after birth.

Severe hyperammonemia typically requires hemodialysis; other treatment options using medications to provide alternative pathways for excess nitrogen excretion (phenylacetate and benzoate; Ammonul) are available.

Surgical placement of dialysis catheters of appropriate size is essential for effective dialysis. While dialysis is being orchestrated, a priming infusion of sodium phenylacetate, and sodium benzoate (250 mg/kg of each) along with 200 to 600 mg/kg of arginine in 25 to 35 mL/kg of 10% dextrose can be administered over 90 minutes. The same doses then are given over 24 hours.

While the availability of Ammonul is typically limited to tertiary care hospitals, arginine is widely available. The dose of arginine depends on which urea cycle disorder is suspected but until a diagnosis is established 600 mg/kg is recommended. The arginine replenishes intermediate molecules of the urea cycle and replaces the arginine normally generated by the urea cycle for protein synthesis to reverse protein catabolism. Administration of arginine alone is effectively curative in argininosuccinate lyase deficiency. While it would not be indicated for Arginase deficiency, this condition is generally not symptomatic in neonates.

Again, glucose and insulin infusion can help treat urea cycle disorders and, for the most common urea cycle disorder (X-linked ornithine transcarbamylase deficiency), oral citrulline (200 mg/kg per day) can help reduce ammonia levels. Administration of any of these medications should be done in consultation with the Genetics Service.

**Newborn Screening**

Currently the state of Texas requires that all newborns be screened twice. The first screen is obtained between 24 and 48 hours of age and the second between the first and second week of life. Using highly sensitive, high throughput technology (tandem mass spectrometry), enhanced newborn screening detects a large number of additional IEM (e.g., many of the disorders of fatty acid oxidation, organic acidurias, and amino acidopathies), often before the onset of symptoms. Expanded newborn screening in Texas includes 31 core disorders (including hearing screen and critical congenital heart disease [CCHD] screen) and 24 secondary disorders (Table 6–2). Ideally, the first test should follow a protein-containing meal to detect elevated phenylalanine. Accurate quantitation depends on the blood spot filter paper being adequately saturated. Testing is performed by the Texas Department of Health, which, for the detection of galactosemia, currently measure only GALT (galactose-1- phosphate uridyl transferase) activity directly. This fails to detect those infants with elevated galactose from other causes.

Expanded testing is also available commercially in Texas. Information regarding additional metabolic screening is available upon request from the Genetics Service.

### Table 6–2. Newborn Screening Program in Texas

<table>
<thead>
<tr>
<th>Disorder Group</th>
<th>Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amino acid disorders</strong></td>
<td>Argininosuccinic Acidemia (ASA)</td>
</tr>
<tr>
<td><strong>Fatty acid oxidation disorders</strong></td>
<td>Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)</td>
</tr>
<tr>
<td><strong>Organic acid disorders</strong></td>
<td>3-Methylcrotonyl-CoA Carboxylase Deficiency (3MCC)</td>
</tr>
<tr>
<td><strong>Other disorders</strong></td>
<td>Cystic Fibrosis (CF)</td>
</tr>
</tbody>
</table>
6.2 Genetic Testing

**Karyotype or Chromosome Analysis** - The karyotype is a method by which the number and appearance of chromosomes in the cell are analyzed microscopically. Chromosome analysis has much lower resolution for detecting genomic deletions or duplications and has largely been replaced by chromosomal microarray analysis (CMA) in the evaluation of children with multiple congenital anomalies and unexplained intellectual disability. However, chromosome analysis remains the first-line genetic test in the evaluation of certain conditions such as balanced translocations, triploidy, mosaicism, and some sex chromosomal abnormalities including Turner syndrome. Karyotype is also recommended for all patients with Down syndrome to determine if the patient has trisomy 21 or a translocation, as the detection of a translocation may affect recurrence risks for the parents. Karyotype study is also recommended for evaluation of other common aneuploidies such as trisomy 18 and 13. Chromosome analysis may take 2-3 weeks to result.

**FISH (Fluorescent In Situ Hybridization)** - FISH is a method in which a fluorescent DNA probe is hybridized to chromosomes to test whether a specific portion of the chromosome is present or absent. Thus, FISH is used to detect specific duplications or deletions. With the advent of CMA, FISH is less commonly used to test for deletion or duplication syndromes (e.g., del 22q11.2). However, in a situation where a CMA cannot be obtained, FISH for a specific deletion syndrome may be helpful if a patient’s presentation is highly suspicious for a particular syndrome. One advantage of FISH is that test results may be obtained in 48-72 hours if the test is ordered STAT and the sample is received during working hours on the same day as collection. Thus, FISH has become useful for obtaining preliminary results regarding trisomies, particularly trisomy 18 and 13. In addition, STAT FISH for the presence of the X chromosome and SRY may be recommended in the setting of a suspected disorder of sex development.

**Chromosomal Microarray Analysis (CMA)**

CMA, using microarray-based comparative genomic hybridization (array CGH), is available through the BCM Cytogenetics Laboratory and other commercial laboratories. With a single test, CMA can detect genomic disorders that were previously identified using chromosome analysis or FISH. CMA includes probes for all the known microdeletion/duplication syndromes (more than 65 conditions), pericentromeric regions, and subtelomeric regions. Additionally, CMA includes probes that cover many single genes, and thus can detect exon-specific deletions or duplications within these genes. Typically, when considering array CGH, the “CMA-comprehensive” version is recommended. The advantage of the CMA-comprehensive is that SNP (single nucleotide polymorphism) data are included in the analysis along with the oligonucleotides, and thus areas of AOH (absence of heterozygosity) and uniparental isodisomy may be identified. CMA provides a major advance to assist the clinician in the identification of patients in which a genetic cause of disability is strongly suspected. CMA is limited to detection of gain or loss of genomic material. It will not detect balanced translocations, inversions, small balanced insertions, trinucleotide repeat disorders, or point mutations that may be responsible for the clinical phenotype. Furthermore, CMA may detect copy number variants of unknown significance, and counseling regarding the significance of such findings may require parental testing for the variant in question to determine if the variant is inherited from a parent or de novo in origin in the child. Lastly, the CMA tests that incorporate SNP data will identify consanguinity.

**Single Gene Testing**

Single gene testing (e.g., sequencing to identify base substitutions or small insertions or deletions) with or without deletion/duplication analysis (e.g., to detect large deletions or duplications) is the genetic testing method of choice when the differential diagnosis has been narrowed to a single disorder that is associated with one or a small group of genes. For example, if biochemical genetics testing is consistent with a diagnosis of ornithine transcarbamylase (OTC) deficiency, sequencing and deletion/duplication of the OTC gene is the test of choice. If spinal muscular atrophy is strongly suspected in an infant with hypotonia, then single gene testing for this diagnosis should be requested.

**Gene Testing Panels** - Gene sequencing panels are useful when testing (typically sequencing) for a specific group of genes is desired. Gene testing panels are typically offered for specific diagnoses (e.g. Noonan syndrome panel) or for specific phenotypes (e.g. hypoglycemia panel). Panels can help the clinician interrogate all the known genetic causes of a particular condition simultaneously, and the advancements in DNA sequencing technology (Next Generation Sequencing; NGS) allow for large panels of relevant genes to be developed for use in a timely and cost-effective manner.

**WES (Whole Exome Sequencing)** - Unlike single gene testing, whole exome sequencing evaluates the coding sequences of thousands of genes simultaneously. The “exome” refers to all of the protein coding regions of all genes (approximately 20,000) and requires a “capture” step to isolate the DNA regions encoding exons. As a result of the wide coverage of the genome, sequence changes in genes that are unrelated to the phenotype in question may be identified. For example, mutations in genes associated with adult-onset disorders such as breast cancer genes may be identified in neonates with this test (referred to as “Incidental Findings” and reported as “actionable results”, currently constituting ~60 genes). Thus, whole exome sequencing is a complex test and requires consent prior to ordering the test. Families should get pre-test counseling and be aware of all possible test results (carrier status, paternity identification, etc) in order to select the information that they would like to receive in the report. Whole exome sequencing is typically performed in patients in whom a specific diagnosis is not obvious even though their phenotype is suspicious for a genetic etiology, for conditions in which a specific genetic test or panel is not available, or for conditions in which the list of associated genes is quite large. In addition, this test may be ordered in patients who are critically ill as the CMA + WES may be the most comprehensive genetic testing available and, in many cases, may provide the best prospects for diagnosis. To facilitate a result in a critically ill patient, WES should be ordered as a “Critical Trio Whole Exome Sequencing” which has a 2-3 week turnaround time. In such cases, it is important to remember that even if a genetic diagnosis will not alter
management of the patient it may be useful for families in
determining recurrence risk and in planning future
pregnancies. Currently, the Critical Trio WES provides a
specific diagnosis in up to 50% of infants. WES has limitation
in that it does not detect trinucleotide repeat disorders such as
congenital myotonic dystrophy. At present, WES is not
regularly utilized for assessment of copy number changes in
the genome. High resolution CMA is recommended to
increase the chance of finding a deletion not detected by DNA
sequencing.

**Suggested Reading**

**Inborn Errors of Metabolism**

   Metabolic and Molecular Basis of Inherited Disease*,

2. Thorburn DR, Sugiana C, Salemi R, Kirby DM,
   Worgan L, Ohtake A, Ryan MT. Biochemical and
   molecular diagnosis of mitochondrial respiratory chain
disorders. *Biochim Biophys Acta* 2004;1659(2-3): 121–
   128.

3. Wolraich ML, Drotar DD, Dworkin PH Perrin EC, eds.
   Developmental- Behavioral Pediatrics Evidence and
   Practice. *Metabolic Disorders Summary* ML

**Genetic Testing**

The most updated and most commonly recommended CMA is
the CMA comprehensive (CMA HR+SNP) v 10.1.
[https://www.bcm.edu/research/medical-genetics-labs/test_detail.cfm?testcode=8665](https://www.bcm.edu/research/medical-genetics-labs/test_detail.cfm?testcode=8665) for more details.
Section 7: Hematology
Editors: Caraciolo Femandes and Joseph Garcia-Prats

7.1 Approach to the Bleeding Neonate ............... 88
  Mufeed Ashraf
  Charles Roitsch

7.2 Platelet Disorders ..................................... 89
  Mufeed Ashraf
  Charles Roitsch

7.3 Transfusion of Blood Products ..................... 90
  Athis Arunachalam
  Gregory Valentine

7.4 Pathophysiology and Differential Diagnosis of Jaundice .............. 92
  Ann Gerges
  Bridget Cross

7.5 Management of Neonatal Jaundice ............... 94
  Bridget Cross
  Alice Obuobi

7.6 Polycythemia ......................................... 97
  Joseph Garcia-Prats
  Jamie J. McKissick

7.7 Neonatal Thrombosis ................................. 99
  Athis Arunachalam
  Emily Rodman
7.1 Approach to the Bleeding Neonate

Bleeding problems are commonly encountered in the neonatal intensive care unit. Thrombocytopenia is probably the most common problem, but coagulation abnormalities also are observed, and the two often coexist. Although most bleeding problems in the NICU reflect acquired disorders, inherited conditions occasionally present in the neonatal period. Initiation of therapy for clinically significant bleeding may confound the interpretation of diagnostic studies and delay a definitive diagnosis. Thus, appropriate initial investigation and management of these conditions is crucial.

Neonatal Hemostatic System

Normal hemostasis is a highly complex process that depends on a series of interactions that occur between platelets, endothelial cells, and hemostatic proteins. Historically, the normal platelet count for newborns has been assumed to be similar to adults (150,000 to 450,000/µL). However, healthy preterm and term newborns can have counts significantly outside these ranges: 104,000 to 750,000/µL, representing the 5th and 95th percentiles, respectively. The normal platelet count increases in postnatal life in a sinusoidal fashion with two peaks, at 2-3 weeks and 6-7 weeks. At birth, concentrations of many of the hemostatic proteins are low, as they are solely synthesized by the fetus and do not cross the placenta. Vitamin K dependent factors (II, VII, IX, X) are initially decreased due to decreased concentrations of antithrombin, protein C, and protein S. Despite the functional immaturity and apparent counterbalances, healthy term and preterm infants rarely display overt bleeding. The hemostatic system matures rapidly during the early weeks and months of life, and the concentrations of most hemostatic proteins reach near-normal adult values by 6 months of age.

Abnormal Bleeding

The diagnostic approach to the bleeding neonate should take into account the infant’s history and clinical condition. On the basis of this information, a presumptive diagnosis may be entertained and preliminary investigations and treatment planned (Table 7–1). In the case of bleeding in the early newborn period, important considerations may include:

- maternal history
- details of the labor and delivery
- examination of the placenta
- infant’s physical examination
- vitamin K administration
- need for resuscitation

The clinical condition of the infant provides valuable clues to likely diagnoses, as healthy infants are more likely to have immune-mediated or genetic causes of bleeding, while infants with systemic illness are more likely to have bleeding caused by infection, asphyxia, necrotizing enterocolitis, or disseminated intravascular coagulation (DIC). The infant should be examined to determine the bleeding sites, the extent and type of bleeding, and the presence of skin or mucosal lesions, jaundice, hepatosplenomegaly, or dysmorphic features. Initial laboratory studies should include:

- complete blood count (CBC)
- prothrombin time (PT)
- activated partial thromboplastin time (aPTT)

For infants at risk for DIC, fibrinogen concentration and fibrin split products (d-dimer) should be performed. Infants who appear ill should be evaluated and treated for sepsis.

Inherited Coagulation Disorders

Hemophilia is the most common inherited bleeding disorder to present in the newborn period. Hemophilia A (factor VIII deficiency) presents more frequently than hemophilia B (factor IX deficiency) and both exclusively affect males due to the X-linked recessive inheritance pattern. Bleeding most commonly manifests from iatrogenic causes (prolonged oozing from venipuncture site, circumcision, etc.), but can also present as isolated intracranial or extracranial hemorrhage (e.g. cephalohematoma or subgaleal hemorrhage). Isolated prolongation of aPTT will be present followed by the confirmation of serum factor levels. Interestingly, it is difficult to diagnose mild hemophilia B in the neonatal period due to previously mentioned relative reduction in factor IX level after birth. If hemophilia is suspected, acute management consists of the following:

- avoidance of invasive monitoring procedures

| Table 7–1. Differential diagnosis of bleeding in the neonate |
|-----------------|-----|-----|-----------------|
| Clinical Evaluation | Platelet Count | PT | PTT | Likely Diagnosis |
| ‘Well’ | N | N | N | Bleeding due to local factors (trauma, anatomic abnormalities), qualitative platelet abnormalities, factor XIII deficiency |
| | N | N | ↑ | Hereditary clotting factor deficiencies |
| | N | ↑ | ↑ | Hemorrhagic disease of the newborn (vitamin K deficiency) |
| | ↓ | N | N | Immune thrombocytopenia, occult infection, thrombosis, bone marrow infiltration/ hypoplasia |
| ‘Sick’ | N | N | N | Compromised vascular integrity (associated with hypoxia, prematurity, acidosis, hyperosmolality) |
| | N | ↑ | ↑ | Liver disease |
| | ↓ | N | N | Platelet consumption (infection, NEC, renal vein thrombosis) |
| | ↓ | ↑ | ↑ | DIC |

‘Well’ implies the bleeding problem is an isolated issue. ‘Sick’ implies that the bleeding problem is not an isolated issue, but part of another/systemic disorder.

N, ↑, and ↓ represent normal, increased, and decreased respectively.

Adapted with permission from Lippincott Williams & Wilkins, Inc. from Gooin AM, Neufeld E. Bleeding. In: Cloherty JP, Eichenwald EC, Stark AR (eds). Manual of Neonatal Care, 2004; permission conveyed through Copyright Clearance Center, Inc.
The causes of neonatal thrombocytopenia primarily fall into two broad categories: decreased production and increased destruction, although occasionally both may co-exist. Immune-mediated thrombocytopenia is commonly seen in the early newborn period, especially in otherwise healthy newborns. The most common of these is neonatal alloimmune thrombocytopenia. Thrombocytopenia developing or

### Table 7-2. Causes of neonatal thrombocytopenia

<table>
<thead>
<tr>
<th>Increased destruction or consumption of platelets</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Immune thrombocytopenia</td>
</tr>
<tr>
<td>• Autoimmune</td>
</tr>
<tr>
<td>• Alloimmune</td>
</tr>
<tr>
<td>• Drug-induced</td>
</tr>
<tr>
<td>• Peripheral consumption</td>
</tr>
<tr>
<td>• Hypersplenism</td>
</tr>
<tr>
<td>• Kasabach-Merritt syndrome</td>
</tr>
<tr>
<td>• Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>• Thrombosis</td>
</tr>
<tr>
<td>• Type 2B von Willebrand disease</td>
</tr>
<tr>
<td><strong>Decreased production of platelets</strong></td>
</tr>
<tr>
<td>• Congenital thrombocytopenias</td>
</tr>
<tr>
<td>• Infiltrative bone marrow disorders</td>
</tr>
<tr>
<td>• Infection-associated marrow suppression: bacterial, viral, or fungal</td>
</tr>
<tr>
<td>• Preeclampsia</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
</tr>
<tr>
<td>• Infection</td>
</tr>
<tr>
<td>• Asphyxia</td>
</tr>
<tr>
<td>• Dilution</td>
</tr>
</tbody>
</table>

Laboratory diagnosis of DIC is usually based on a typical pattern of reduced platelets, prolonged coagulation variables (PT, aPTT with or without thrombin clotting time), reduced fibrinogen, and increased d-dimers or other markers of fibrin or fibrinogen degradation. As DIC is a secondary process, it is important that the underlying cause is promptly recognized and treated. Management of DIC is essentially supportive with the use of fresh frozen plasma, cryoprecipitate, and platelets to try to maintain adequate hemostasis. Fresh frozen plasma (10 to 15 ml/kg) is used to replace multiple hemostatic proteins, and cryoprecipitate (5 to 10 ml/kg) is preferred to treat hypofibrinogenemia.

Neonatal Alloimmune Thrombocytopenia (NAIT)
NAIT is a unique etiology for neonatal thrombocytopenia that can have life threatening hemorrhagic consequences. It occurs in approximately 1 in 2000 live births. It is important to quickly recognize the neonate in whom NAIT is a diagnostic consideration. Prompt initiation of the appropriate treatment is crucial in these infants as well as the appropriate serologic testing and follow up.

**Background** – NAIT occurs when fetal platelets express antigens (human platelet antigens, HPA) against which there are circulating maternal antibodies. The HPA-1 (formerly known as PlA1) is responsible for NAIT in approximately 75 to 90 percent of cases in Caucasians; in Asians, HPA-4 (Yuk/Pen) is the most frequent cause of NAIT.

NAIT may be distinguished clinically from other etiologies of neonatal thrombocytopenia by the more frequent occurrence of severe thrombocytopenia (usually < 50,000/µL) and bleeding manifestations regardless of platelet counts. Intracranial hemorrhage has been reported to occur in up to 20% of patients with NAIT, making this the most common cause of intracranial hemorrhage in term neonates.
Diagnostic evaluation and treatment for NAIT are distinct from other etiologies of neonatal thrombocytopenia, and require prompt collaboration among the treating clinician, pediatric hematologist, and blood bank physician. Delay of management could cause a detrimental outcome for the neonate. Thrombocytopenia may resolve in the first 2 to 3 weeks of life.

**Definitions—NAIT** should be considered in the differential diagnosis of a neonate (term or preterm) who is < 7 days old and has severe thrombocytopenia (usually <50,000/µL) for which there is no clear explanation. The other CBC parameters are usually normal. These infants are clinically well appearing, and may have family history of transient neonatal thrombocytopenia.

**I. Clinical management of neonates with suspected NAIT**

A. Consider consultation with a pediatric hematologist and a blood bank physician. For some infants, this may necessitate transfer to a tertiary-care facility.

B. If NAIT is suspected and a criterion listed below is met, promptly initiate treatment with platelet transfusions. Do NOT wait for definitive test results. Platelet products of choice are washed, irradiated maternal platelets or antigen negative platelets; however, if not immediately available, random donor platelets should be given instead. Repeat transfusion of random donor platelets as needed until maternal washed platelets or antigen negative platelets are available. (Discretion is advised when using random donor platelets in a female Rh-negative infant as this would sensitize the infant to the Rh antigen.)

Platelet transfusion criteria in NAIT:

1. Platelet count is less than 30,000/µL in an uncomplicated, term infant

2. Platelet count is less than 50,000/µL in an uncomplicated, preterm infant (i.e. less than 37 weeks gestation)

**Note:** Consider transfusion at a higher platelet count (e.g. less than 100,000/µL) in very low birth weight infants (less than 1500 grams), who are at high risk for intraventricular hemorrhage (IVH) and other co-morbid conditions.

C. Check platelet counts 10 minutes to 1 hour after transfusion. Since the recovery and half-life of random donor platelets, presumably antigen positive, are not optimal, carefully monitor the platelet count. Maternal platelets generally result in higher and longer-lasting platelet counts.

D. Administer IVIG (1 gram/kg). This may be repeated if no increase in platelet counts occurs following the initial dose.

E. To administer maternal platelets, consult with the Blood Bank physician to initiate procedure for maternal platelet collection for transfusion to the infant. Maternal platelets are transfused to the infant as soon as possible. The blood bank will initiate and conduct testing to identify the platelet antibody. Once the platelet antibody is identified, the blood bank will try to obtain the corresponding antigen negative platelet units.

**Note:** Steroids are not indicated for the treatment of NAIT.

**II. Clinical follow up for the infant**

A. During acute inpatient course:

1. Follow (at a minimum) daily platelet count to assess response to therapy.

2. Obtain radiologic evaluation on all thrombocytopenic infants (head ultrasound vs. CT) even if the infant is asymptomatic.

3. Perform definitive laboratory testing for NAIT.

B. After discharge from the hospital:

1. Follow-up with a hematologist should be planned for all infants with NAIT. Even if the neonate does not have severe thrombocytopenia, work-up for the parents may be needed prior to subsequent pregnancies.

2. Family testing results and counseling about future pregnancies must be discussed and carefully documented.

---

**7.3 Transfusion of Blood Products**

**Transfusion of Packed Red Blood Cells (PRBC):**

Before initial transfusion, written informed consent must be obtained using the Disclosure Panel information outlined by Texas law. After discussion with the attending physician, a note that outlines indications for transfusion should be placed in the patient’s chart.
General indications for blood transfusions in neonates are:

- **Acute, hypovolemic shock** - The goal of therapy is prompt correction of the estimated blood volume deficit with improvement of accompanying circulatory derangements. Whole blood is preferred, but rarely available acutely. Volume expansion may be initiated with normal saline followed by packed RBCs as soon as available.

- **Acute cardiopulmonary disease** - Transfusion may be indicated if hematocrit is less than 40% in association with symptoms or if circulatory insufficiency occurs in the presence of a calculated acute deficit of greater than 10%. Symptoms include hypotension, oliguria, lactic acidosis, or impairment of pulmonary perfusion.

- **Diseases associated with low PaO\textsubscript{2} or circulatory insufficiency** - Transfusion may be indicated to improve central oxygen content even if hematocrit is in normal range.

- **Chronic anemia (e.g., prematurity)** - Transfusion is indicated only if specific symptoms related to anemia occur, such as persistent tachycardia, poor weight gain, or apnea without other discernible cause.

- **Blood group incompatibilities** - Simple transfusion may be indicated if anemia produces specific symptoms or evidence of impaired tissue oxygenation.

- **Chronic cardiopulmonary disease** - Transfusion may be indicated if signs such as persistent resting tachycardia suggest high cardiac output state specifically related to anemia.

Decision to transfuse should be based on the symptoms related to anemia and laboratory parameters (Hct/Hb, reticulocyte count). There are no universally accepted guidelines. See Table 7-3 for suggested thresholds.

<table>
<thead>
<tr>
<th>Table 7-3. Guidelines for PRBC transfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Status</strong></td>
</tr>
<tr>
<td>Severe cardiopulmonary disease (mechanical ventilation requiring high FiO\textsubscript{2}, high mean airway pressure, hypotension)</td>
</tr>
<tr>
<td>Anemia with unexplained tachycardia, frequent apnea, poor weight gain with adequate nutrition, or unexplained lethargy.</td>
</tr>
<tr>
<td>Stable anemia independent of signs</td>
</tr>
</tbody>
</table>

**Erythropoietin**

Premature infants have low plasma erythropoietin levels. They typically respond to administration of recombinant human erythropoietin (rh EPO) with an increased reticulocyte count within 96 hours and an increased hematocrit in approximately 5 to 7 days. However, EPO administration has little impact on exposure to transfusions in these patients, even when given within the first 4 days after birth. Additionally, use of EPO in preterm infants has been associated with an increased incidence of hemangiomas. We do not recommend routine use of EPO and consider its use only in special circumstances (strong recommendation, moderate quality evidence).

**Monitoring for Anemia**

Laboratory testing (a hemoglobin/hematocrit with a reticulocyte count, if indicated) to investigate the degree of physiologic anemia of infancy/prematurity should be considered as needed based on an infant’s clinical status, need for positive pressure/oxygen support, size, recent phlebotomies, and most recent hematocrit. Frequency of such testing may vary from every 1 to 2 weeks in the sick, tiny premature infant on positive pressure support to once a month or less in a healthy, normally growing premature infant. Efforts should be made to cluster such routine sampling with other laboratory tests.

**Transfusion of Fresh Frozen Plasma (FFP)**

FFP is a plasma product made from whole blood and contains all of the coagulation factors and other proteins that were initially in the original unit of blood.

FFP is primarily indicated to replace acquired coagulation factor deficiencies in the following conditions:

- DIC,
- Liver failure
- Vitamin K deficiency- (Factors II, VII, IX, and X)

However, FFP is not a concentrate of any specific factor, and it should not be used as primary therapy to treat specific coagulation factor deficits such as with hemophilia A, hemophilia B, Factor VII deficiency or Factor XIII deficiency (strong recommendation, moderate quality evidence). Instead, for these situations, specific coagulation factor concentrates exist and should be used instead.

The decision to use FFP is made when a patient’s coagulation studies are found to be abnormal (such as in DIC), specifically when PT, PTT, or INR are elevated. FFP should be given in 10-15 mL/kg boluses to replace the hemostatic proteins (10%-30% of most factors) that have likely been consumed in DIC.
such toxicity is avoided by the binding of bilirubin to albumin and is potentially neurotoxic. However, the end-tidal carbon monoxide concentration (ET-COc) is an equimolar amount of bilirubin and carbon monoxide (CO). Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble. Degradation of heme produces bilirubin that is fat soluble.

Postnatally, bilirubin is formed from breakdown of heme by the reticuloendothelial system, producing unconjugated bilirubin. The end-tidal carbon monoxide concentration (ET-COc) is an index of total bilirubin production. Unconjugated bilirubin can cross cell membranes and is potentially neurotoxic. However, such toxicity is avoided by the binding of bilirubin to albumin during transport. Under normal circumstances only a small amount of bilirubin is found in the unbound state. The functional bilirubin binding capacity of albumin is the major determinant of risk of toxicity when the serum bilirubin level is elevated. Albumin binding capacity is reduced by acidosis, immaturity, and the presence of competitive substances such as salicylates, sulfonamides, and free fatty acids. Free fatty acids are particularly important competitors for bilirubin binding sites in preterm infants. The presence of such competitive substances increases the proportion of free bilirubin present and, thus, increases the risk of kernicterus.

The liver converts bilirubin to a water-soluble, non-toxic conjugated form. Transport proteins then facilitate passage across the cell membrane into the biliary tree for passage into the intestine with bile flow. Bilirubin ultimately is passed in stool in a variety of forms. A small proportion of conjugated bilirubin is deconjugated in the gut and reabsorbed into the circulation (enterohepatic circulation). Conjugation and intracellular transport both may be impaired in preterm infants.

In a fetus, bilirubin metabolism is more complex. Bilirubin is presented to the placenta for excretion in the fat-soluble (unconjugated) form. To facilitate this, the enterohepatic circulation of bilirubin is quite active. The brush border of the intestines contains enzymes, such as beta-glucuronidase, that deconjugate the water-soluble conjugated bilirubin that is excreted into the lumen of the gut. Then unconjugated bilirubin is reabsorbed into the fetal serum to be recycled to the placenta for ultimate excretion. An understanding of the differing nature of antenatal and postnatal metabolism of bilirubin helps to clarify the effects of superimposed disease processes.

Animal studies using tracer-labeled bilirubin have demonstrated 3 factors contributing to excess bilirubin levels in the newborn period:

- **Shortened RBC survival time (about 90 days compared to 120 days for adults)** Normally this is insignificant but it becomes the major contributor to net bilirubin load in hemolytic disorders.

- **Reduced intrahepatic conjugation of bilirubin** - This usually is related to immaturity of enzyme systems. Although rarely of importance in term infants, it may become a significant factor in a preterm or critically ill infant.

- **Enterohepatic recirculation of bilirubin** - Because this process continues at the accelerated intrauterine rate for several days after birth, it is the most important component of non-pathologic jaundice (physiologic or breast-milk jaundice). It may become a significant factor in any disease process that delays bowel function and stool passage.

### Risk Factors for Severe Hyperbilirubinemia

#### Differential Diagnosis of Jaundice

Increased serum bilirubin results from increased production, increased enterohepatic circulation, or decreased elimination.

**Risk of hyperbilirubinemia is related to total serum bilirubin level, postnatal age, gestational age, and impact of co-existing illnesses.**
More than half of healthy term infants and most preterm infants develop hyperbilirubinemia, and the incidence is highest in breastfed infants. Many will have visible jaundice but a visual estimate of the bilirubin level may be inaccurate, especially in darkly pigmented infants. In about 8% of infants, the bilirubin level exceeds the 95th percentile for postnatal age during the first week of life. Peak bilirubin levels in term or late preterm infants usually occur on day 3 to 5 of age. It is convenient to think of causes of jaundice in relation to timing of occurrence. A common problem involves hospital admission of healthy term infants at 4 to 7 days of age with total serum bilirubin (TSB) levels of 20 mg/dL or higher. Infant’s with severe hyperbilirubinemia (TSB) levels ≥25 mg/dL are potentially at risk for bilirubin-induced encephalopathy, kernicterus, and long term neurological sequelae.

**Jaundice Appearing on Day 1 of Life**

Presumed to be pathologic. Assume hemolytic process and seek specific etiology.

Primary causes include:

- Isoimmune hemolysis due to Rh, ABO, or minor blood group abnormalities. Coombs test usually is positive, and specific transplacentally acquired antibody can be identified in the serum of the infant. Anemia may be severe or absent depending on degree of sensitization. In general, isoimmune hemolytic disorders carry the greatest risk of kernicterus because intermediary products of heme breakdown compete with bilirubin for albumin binding sites and promote higher levels of free bilirubin than most other forms of hyperbilirubinemia. There is little relationship between bilirubin levels and severity of anemia or between cord bilirubin level and ultimate peak level.
- Intrinsic RBC defects (i.e. hereditary spheroctosis, elliptocytosis, G-6-PD deficiency, etc.)
- Hemoglobinopathies rarely cause significant jaundice but may exacerbate other problems.

**Jaundice Appearing Later in the First Week**

- Breastfeeding failure jaundice due to ineffective or insufficient breastfeeding
- Non-pathologic jaundice - In most cases, these are healthy term or late preterm infants who have so-called physiologic or breastmilk–related jaundice in which the enterohepatic circulation of bilirubin persists or is exaggerated. Studies using ET-COc measurements suggest increased bilirubin production also is a contributing factor. Highest incidence occurs in breastfed infants and bilirubin levels may peak somewhat later (day 5 or 6) and levels above 10 mg/dL may persist somewhat longer. The upper safe level of bilirubin in these patients is unknown. Although risk of kernicterus is quite low, reported cases have increased in recent years. Specific intervention depends upon total serum bilirubin level and postnatal age.
- Occasionally jaundice secondary to sepsis, metabolic disorders, hypothyroidism, polycythemia, cephalohematoma or excessive bruising may manifest during this time period.

**Table 7–4. Risk factors for severe hyperbilirubinemia**

<table>
<thead>
<tr>
<th>Major risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Predischarge TSB or TcB level in the high-risk zone (Fig 7–2)</td>
</tr>
<tr>
<td>- Jaundice observed in the first 24 hours</td>
</tr>
<tr>
<td>- Blood group incompatibility with positive direct antiglobulin test, other known hemolytic disease (e.g.G6PD deficiency, elevated ETCOc)</td>
</tr>
<tr>
<td>- Gestational age 35–36 weeks</td>
</tr>
<tr>
<td>- Previous sibling received phototherapy</td>
</tr>
<tr>
<td>- Cephalohematoma or significant bruising</td>
</tr>
<tr>
<td>- Exclusive breastfeeding, particularly if nursing is not going well and weight loss is excessive</td>
</tr>
<tr>
<td>- East Asian race</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minor risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Gestational age 37–38 weeks</td>
</tr>
<tr>
<td>- Jaundice observed before discharge</td>
</tr>
<tr>
<td>- Previous sibling with jaundice</td>
</tr>
<tr>
<td>- Macrosomic infant of a diabetic mother</td>
</tr>
<tr>
<td>- Maternal age 25 years or younger</td>
</tr>
<tr>
<td>- Male gender</td>
</tr>
</tbody>
</table>

Decreased risk factors (in order of decreasing importance)

- TSB or TcB level in the low-risk zone (Fig 7–2)
- Gestational age 41 weeks or greater
- Exclusive bottle feeding
- Black race

Race as defined by mother's description.

**Jaundice Persisting or Appearing Past the First Week**

- Sepsis, either bacterial or viral
- Cystic fibrosis or malformations or functional abnormalities of the GI tract leading to delayed passage of meconium and prolonged enterohepatic recirculation of bilirubin
- Inborn errors of bilirubin metabolism (Crigler-Najjar or Gilbert syndromes)
- Persistent breast milk jaundice

**Cholestatic Jaundice**

In these cases, the conjugated and unconjugated bilirubin fractions are elevated and the condition usually is more chronic. **(Ch 11.3- Cholestasis Gastroenterology)**

Causes include:

- TPN cholestasis
- neonatal hepatitis
- chronic, nonspecific cholestasis vs. biliary atresia

**Evaluation**

Maternal prenatal testing should include ABO and Rh typing. If the mother is blood type O, Rh-negative, antibody screen positive or had no prenatal blood group testing, then a direct Coombs test, blood type, and Rh (D) type are recommended on the infant or cord blood. In infants noted to be jaundiced in the first 24 hours of life, total and direct serum bilirubin level should be obtained. Bilirubin levels cannot be adequately assessed by evaluation of skin color. Further workup is warranted if the bilirubin level is elevated or the direct Coombs is positive.
A basic workup for pathologic causes of jaundice might include serum total and direct bilirubin level, hemoglobin and hematocrit, reticulocyte count, direct Coombs test, and determination of maternal and infant blood type. These studies usually will establish a diagnosis of hemolytic disease, if present, and antibody screening of infant serum will detect the specific offending antibody. If the cause of hyperbilirubinemia is not due to isoimmune hemolysis, evaluation and/or testing for other causes should be performed and subspecialty consultation considered. The possibility of G-6-PD deficiency as a contributor to neonatal jaundice must be considered since 11-13% of African-Americans are deficient and the diagnosis could be missed. A peripheral blood smear may be useful as well.

### 7.5 Management of Neonatal Jaundice

#### Follow-up of Healthy Term and Late-term Infants at Risk for Hyperbilirubinemia

In an attempt to address the increasing number of reports of kernicterus in healthy infants 35 or more weeks’ gestation, the American Academy of Pediatrics (AAP) published recommendations for risk reduction strategies in July 2004. All infants 35 weeks’ or greater gestation who are discharged from the hospital before or at 72 hours of life should have a total serum bilirubin (TSB) measured on capillary blood before discharge (at the time of the metabolic screen), and the resultant bilirubin value should be plotted on the hour-specific nomogram predicting sub-sequent risk of severe hyperbilirubinemia (Fig 7-2). Additionally, all infants should have a follow-up evaluation at 3 to 5 days of age, when the bilirubin level usually is highest. Timing of this evaluation is determined by the length of nursery stay and the presence or absence of risk factors for hyperbilirubinemia. (Table 7-5)

#### Management

General measures of management include early feeding to establish good caloric intake. The AAP discourages interruption of breastfeeding in healthy term newborns. In these infants, supplementing nursing with water or dextrose water does not lower bilirubin levels. A main goal of feeding is the stimulation of bowel motility and increased stooling to decrease enterohepatic circulation of bilirubin; however, other options, beyond simple observation, are recognized, including supplementing breastfeeding with formula or breast milk obtained by pump or temporary interruption of breastfeeding with formula substitution, any of which can be accompanied by phototherapy.

#### Table 7-5. Hyperbilirubinemia: age at discharge and follow-up

<table>
<thead>
<tr>
<th>Age at Discharge (hours)</th>
<th>Follow-up Assessment (age in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;24</td>
<td>By 72</td>
</tr>
<tr>
<td>24-47.9</td>
<td>By 96</td>
</tr>
<tr>
<td>48-72</td>
<td>By 120</td>
</tr>
</tbody>
</table>

#### Phototherapy

Efficacy of phototherapy is determined by:
- light source (blue-green spectrum is best),
- irradiance or energy output in the blue spectrum, and
- surface area exposed.

Light in the 450-nanometer (blue-green) range converts unconjugated bilirubin to soluble, nontoxic photoisomers. It also stimulates bile flow and excretion of bilirubin in bile, as well as enhancing gut motility. Degradation of bilirubin increases with increasing blue light irradiance.

#### Standard phototherapy

Use for infants who meet the AAP guidelines for phototherapy but with TSB not at or near exchange transfusion levels. (strong recommendation, moderate quality evidence) Use a high-intensity phototherapy device per institution availability placed at a distance of 12 inches (30.5 cm) from the patient. This will deliver an irradiance of > 12 microWatts/cm²/nm. Checking the light intensity before each use is recommended where feasible to confirm correct positioning and irradiance of the light over the infant.

#### Intensive phototherapy

Use for infants with TSB levels at or near exchange transfusion levels. Intensive phototherapy combines an over-head high-intensity phototherapy device with a fiber-optic phototherapy pad placed beneath the infant. The overhead device should be positioned to deliver an irradiance dose of at least 30 microWatts/cm²/nm as measured with a radiometer. The fiber optic pad should be covered only with a disposable cover furnished by the manufacturer. This technique both increases delivered irradiance and recruits additional surface area for light exposure.

In healthy term infants, discontinue phototherapy when TSB levels fall below 13 to 14 mg/dL. In infants without hemolytic disease, average bilirubin rebound is less than 1 mg/dL. In most cases, no further bilirubin measurements are necessary.
Intravenous Immune Globulin

Administration of intravenous immune globulin (IVIG) to infants with isoimmune hemolytic disease has been shown to decrease the need for exchange transfusion. (strong recommendation, moderate quality evidence) An infant with isoimmune hemolytic disease whose TSB level rises despite intensive phototherapy or is within 2 to 3 mg/dL of the exchange transfusion level should be given intravenous immune globulin (0.5 to 1 g/kg over 2 hours). This dose can be repeated if needed in 12 hours.

**Indications for Exchange Transfusion**

The classic indication for exchange transfusion in Rh erythroblastosis is a serum bilirubin level of 20 mg/dL. This disease carries a greater risk of kernicterus than other forms of hemolytic or non-hemolytic jaundice because of the brisk hemolysis, which produces high levels of intermediary products of heme breakdown that compete for albumin binding sites. Exchange transfusion also has been used to manage other types of isoimmune blood group incompatibilities (such as ABO and minor group incompatibility), using the same threshold bilirubin level of 20 mg/dL.

Risk of kernicterus in healthy term newborns with non-hemolytic jaundice is low and the role of exchange transfusion remains uncertain. The AAP has reviewed these issues in a published practice guideline. Management recommendations are summarized in Fig 7–4.

In addition to the TSB level, the ratio of bilirubin to albumin (B/A) can be used as an additional factor to determine the need for exchange transfusion. Using the 3 risk categories in Fig 7–4, the B/A ratios at which should be considered are 8.0, 7.2, and 6.8 TSB mg/dL to albumin g/dL for infants at low, medium, and higher risk.

**Exchange Transfusion**

Exchange transfusion is used primarily to manage infants with isoimmune hemolytic disease with hyperbilirubinemia. Occasionally, it is used to treat extremely high bilirubin levels of other pathologic origin.

**Planning**

Place the infant in an environment that provides:

- Total bilirubin. Do not subtract direct reacting or conjugated bilirubin.
- Risk factors = isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3.0 g/dL (if measured).
- For well infants 35-37/7 wk can adjust TSB levels for intervention around the medium risk line. It is an option to intervene at lower TSB levels for infants closer to 35 wks and at higher TSB levels for those closer to 37/7 wk.
- If the total serum bilirubin does not decrease or continues to rise in an infant with risk factors, it is an option to provide conventional phototherapy in hospital or at home at TSB levels 2–3 mg/dL (35–50 mmol/L) below those shown but home phototherapy should not be used in any infant with risk factors.

Note: These guidelines are based on limited evidence and the levels shown are approximations. The guidelines refer to the use of intensive phototherapy which should be used when the TSB exceeds the line indicated for each category. Infants are designated as “higher risk” because of the potential negative effects of the condition listed on albumin binding of bilirubin, and the blood-brain barrier, and the susceptibility of the brain cells to damage by bilirubin.

“Intensive phototherapy” implies irradiance in the blue-green spectrum (wavelengths of approximately 430–490 nm) of at least 30 μW/cm² per nm (measured at the infant’s skin directly below the center of the phototherapy unit) and delivered to as much of the infant’s surface area as possible. Note that irradiance measured below the center of the light source is much greater than that measured at the periphery. Measurements should be made with a radiometer specified by the manufacturer of the phototherapy system.

**Table 7-6. Guidelines for Management of Hyperbilirubinemia in Low Birth weight Infants**

<table>
<thead>
<tr>
<th>Total Serum Bilirubin levels (mg/dL) to initiate therapy</th>
<th>Phototherapy</th>
<th>Exchange Transfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 750 grams</td>
<td>≥ 5</td>
<td>&gt; 13</td>
</tr>
<tr>
<td>750-999 grams</td>
<td>≥ 5</td>
<td>≥ 7</td>
</tr>
<tr>
<td>1000-1499 grams</td>
<td>7 – 9 *</td>
<td>10 – 12</td>
</tr>
<tr>
<td>1500-1999 grams</td>
<td>10 – 12 *</td>
<td>13 – 15</td>
</tr>
<tr>
<td>2000-2500 grams</td>
<td>13 - 15 *</td>
<td>14 – 15</td>
</tr>
</tbody>
</table>

* For infants ≥ 1000 grams, in the first 96 hours, consider using the higher risk line in Figures 7-3 & 7-4 (graph for treatment of jaundice in infants 35 weeks or greater), if line has a lower threshold than the numbers in Table 7-6 above.

Lower concentrations should be used for infants who are sick (presence of acidosis, sepsis, hemolytic disease, hypoaalbuminemia, etc).

For SGA and LGA infants, consider using the “50th percentile weight for GA” to decide TSB level for treatment.

In VLBW infants, TSB measured per guidelines in “Care for the VLBW infants” at 24 hours and daily for the first few days.

**Sections:**

- Section of Neonatology, Department of Pediatrics, Baylor College of Medicine
- Section 7—Hematology

**Table 7-6**

Guidelines for Management of Hyperbilirubinemia in Low Birth weight infants

**Figure 7–3. Guidelines for phototherapy in hospitalized infants of 35 or more weeks’ gestation.**

- Place the infant in an environment that provides:
- Total Serum Bilirubin levels (mg/dL) to initiate therapy
- Phototherapy
- Exchange Transfusion

 reproduced with permission from Pediatrics, Vol 114(1), pages:297–316. Copyright © 2004 by the AAP.
Preparation

- Have immediately available: oxygen, suction, and emergency equipment for resuscitation.
- Obtain a sterile, disposable exchange transfusion set to provide all equipment needed for the procedure.
- Order blood as the equivalent of whole blood.

- Ask the blood bank to mix packed RBCs and plasma to a resulting hematocrit of 40%. Optimal efficiency occurs with a double-volume exchange. Thus, the amount of blood required is 2 times the blood volume (90 mL/kg × body weight × 2) plus an additional 30 to 50 mL to prime the tubing system before the procedure.

Equipment

- Perform the exchange using the #8 French catheter supplied in the exchange set.
- Fill the catheter with heparinized saline and pass it into the umbilical vein.
- Optimally, position for catheter tip is the level of the right diaphragm. If the position cannot be achieved, advance catheter only far enough to obtain free flow of blood when gentle suction is applied. Confirm catheter position with a radiograph.
- Secure the catheter at the umbilicus during the procedure.
- Routine priming with albumin before exchange transfusion is not currently indicated.

Instructions to assemble the tubing system are in the exchange set and should be followed to the letter. The result will be a completely closed system that allows each step of the procedure to be performed by simply turning the main stopcock one stage clockwise.

Occasionally, circumstances arise that prevent the use of standard exchange transfusion methodology. These usually are technical, and the attending physician decides what form of alternative methodology is most appropriate for the circumstances.

Before the Exchange

Completely prime the system with donor blood and exhaust all air before beginning the exchange.

Important Points to Remember

- Turn the stopcock clockwise only.
- Exchange increments of 5 to 20 mL of blood, depending on patient size and condition.
- On the form provided in the exchange set, document the amount of blood in and out for each pass.
- Take and record vital signs every 15 to 30 minutes.
- Routine infusion of calcium salts during an exchange is not recommended.

Exchange Procedure

Most double-volume exchanges should be completed in 1 to 1.5 hours.

- Using the master stopcock, initially remove 5 to 20 mL of blood from the infant for any required studies.
- Turn the stopcock clockwise one step to the waste bag port, and flush.
- Turn the stopcock clockwise one step to the donor blood port, and draw replacement donor blood.
- Turn the stopcock clockwise one step.
- Infuse the donor blood into the patient.
- After a short dwell time, draw 5 to 20 mL of blood from the catheter.
• Turn the stopcock clockwise one step to the waste bag port, and flush.
• Turn the stopcock clockwise one step, and draw a similar amount of blood from the donor bag.
• Turn the stopcock clockwise one step.
• Infuse the donor blood into the infant.
• Repeat this procedure as necessary to complete a double volume of exchange.

After the Exchange
• Closely monitor vital signs for 2 hours after the procedure.
• Send a blood sample for CBC, TSB, calcium, electrolytes.

Send a new blood sample for typing to be available if another exchange is required.

Delayed Cord Clamping
Placental transfusion by delayed cord clamping or milking of the cord in preterm infants has been associated with improved neonatal outcomes including increased hematocrit, decreased need for transfusion, hemodynamic stability requiring decreased use of vasopressors and decrease in intraventricular hemorrhage. No major differences in neonatal benefits have been observed when delayed cord clamping is compared to milking of the cord. The use of delayed cord clamping in preterm infants < 28 weeks and high risk pregnancies is still being studied.

In healthy term infants, growing evidence suggests that delayed cord clamping increases early hemoglobin concentrations and iron stores in infants, and likely to be beneficial as long as access to treatment for jaundice requiring phototherapy is available.

7.6 Polycythemia
Neonatal polycythemia is defined as a venous hematocrit or hemoglobin concentration that is greater than two standard deviations above the normal value for gestational and postnatal age. This condition affects approximately 1 to 5 percent of newborns. Most affected infants are asymptomatic. Clinical features may include cyanosis, tachypnea, tachycardia, vomiting, poor feeding, hypoglycemia, and hyperbilirubinemia and are thought to result from hyperviscosity and/or the metabolic effects of an increased red blood cell mass.

Diagnosis - A term infant is considered to be polycythemic if the hematocrit from a peripheral venous sample is greater than 65%. The diagnosis is based upon peripheral venous samples because of the variability in measurements obtained from capillary samples (heel sticks).

Hematocrits of blood from venous samples (venous sample or from UVC) are usually 5%-15% lower than those obtained from capillary samples.

Management
• There is no consensus in the management of infants with polycythemia due to lack of evidence behind various treatment strategies. The following guidelines are offered in an effort to minimize variation in our practice.
• Management of asymptomatic infants is usually guided by the hematocrit with emphasis on ensuring adequate hydration, glucose intake and monitoring for neurologic and cardiovascular symptoms and common complications, such as hypoglycemia and hyperbilirubinemia (Fig 7-5) (strong recommendation, moderate quality evidence).
• Optimal management of symptomatic infants has not been determined. Some practitioners may choose to lower the hematocrit by use of a partial volume exchange transfusion (PET). While PET may improve cerebral blood flow and hemodynamic parameters, it has not been shown to alter long-term outcomes, and in one study has shown to be associated with an increased risk of adverse GI symptoms and NEC. See Fig 7-5 for recommended management strategies (strong recommendation, moderate quality evidence).
• If a partial exchange transfusion is done for polycythemia, replace the removed blood with an equal volume of normal saline.
• If a decision is made to perform PET, it should be done as soon as possible as the neonatal hematocrit and blood viscosity peaks between two and four hours after birth.
• Calculate the exchange volume using the formula below.

\[
\text{Vol (replaced)} = \frac{(Hct_{\text{initial}} - Hct_{\text{desired}}) \times \text{Weight (kg)} \times 80 \text{ mL/kg}}{Hct_{\text{initial}}}
\]

<table>
<thead>
<tr>
<th>Table 7-7. Causes of neonatal polycythemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythrocyte transfusion (passive)</td>
</tr>
<tr>
<td>• Delayed clamping of the umbilical cord (e.g. &gt;2 minutes after birth)</td>
</tr>
<tr>
<td>• Uncontrolled or precipitous delivery</td>
</tr>
<tr>
<td>• Intrapartum hypoxia</td>
</tr>
<tr>
<td>• Twin-to-twin transfusion (10 to 15 percent of monochorionic twins)</td>
</tr>
<tr>
<td>• Maternal-fetal transfusion (rare)</td>
</tr>
<tr>
<td>Increased intrarterine erythropoiesis (active)</td>
</tr>
<tr>
<td>Placental insufficiency</td>
</tr>
<tr>
<td>• Preeclampsia</td>
</tr>
<tr>
<td>• Other hypertensive disorders</td>
</tr>
<tr>
<td>• Other vascular disorders</td>
</tr>
<tr>
<td>Maternal hypoxemia due to cardiac or pulmonary disorders</td>
</tr>
<tr>
<td>• Cardiac or pulmonary disorders</td>
</tr>
<tr>
<td>• Drugs (e.g. propranolol)</td>
</tr>
<tr>
<td>• Smoking</td>
</tr>
<tr>
<td>• High altitude</td>
</tr>
<tr>
<td>• Post term delivery</td>
</tr>
<tr>
<td>Infant risk factors</td>
</tr>
<tr>
<td>• Large for gestational age</td>
</tr>
<tr>
<td>• Maternal diabetes mellitus</td>
</tr>
<tr>
<td>• Beckwith-Wiedemann syndrome</td>
</tr>
<tr>
<td>• Endocrine abnormalities (congenital adrenal hyperplasia, hypothyroidism, hyperthyroidism)</td>
</tr>
<tr>
<td>• Chromosomal anomalies (trisomy 21, 18, and 13)</td>
</tr>
</tbody>
</table>
There are limited data on the efficacy and safety of PET in neonates. IV: intravenous; CBC: complete blood count; BP: blood pressure; BUN: blood urea nitrogen; PET: partial exchange transfusion.

* For a complete list of causes, See Table 7-7 Causes of neonatal polycythemia.

Asymptomatic infants are included in this algorithm to provide guidance for situations when polycythemia is an incidental finding on laboratory testing performed for other reasons (e.g. sepsis evaluation). We do not routinely measure the hematocrit to screen for polycythemia in term infants who appear well.

Δ Observation includes ongoing assessment of symptoms; monitoring intake, urine output, and daily weight; serial blood glucose and bilirubin testing (frequency depends on initial results); and repeat hematocrit every 12 to 24 hours until polycythemia has resolved.

◊ The main rationale for administering IV hydration is to prevent hypoglycemia. Hypoglycemia is a common complication of polycythemia, particularly if the hematocrit is >70%. Dextrose-containing IV fluids are provided for the first 24 to 48 hours of age at a rate of at least 100 mL/kg per day (glucose infusion rate of 6 to 8 mg/kg per min), while the infant is closely monitored.

Algorithm reproduced with permission from: Garcia-Prats JA. Neonatal polycythemia. In: UpToDate. Post TW (Ed), UpToDate, Waltham, MA. (Accessed on June 20, 2018) Copyright © 2018 UpToDate, Inc. For more information visit www.uptodate.com.
7.7 Neonatal Thrombosis

Introduction
Neonates are at the greatest risk for development of thrombosis. Although several prothrombotic disorders are implicated in neonatal thrombosis, their specific role in this pathology is not well established. More than 80% of thromboembolic events are related to the use of central venous and or arterial catheters (CVAC). Neonatal thrombosis is rapidly increasing; recent reports cite ~6.8 per 1000 NICU admissions when compared to 2.4 per 1000 NICU admissions in 1995.

Risk factors
Prenatal risk factors include maternal infections, preeclampsia, diabetes, PROM, placental diseases, emergency cesarean delivery, inherited thrombophilia. Neonatal risk factors include sepsis, IUGR, asphyxia, hypotension, polycythemia (HCT>65%), cardiac disease, major surgery, CVAC, mechanical ventilation.

Catheter related thrombosis (CRT)
Presence of central venous catheter (CVC) is one of the most important risk factor for thrombosis. In a recent meta-analysis, the incidence of CRT was 9.2% (1.1%-66.7%). UVC’s are typically associated with asymptomatic transient thrombosis. A fibrin layer has shown to form within 2 days of inserting a catheter setting the stage for thrombus development. CRT can present with catheter dysfunction, limb swelling distal to insertion site, recurrent CLABSI’s (especially with same organism). Spontaneous regression of neonatal thrombi can occur. Also, CRT can increase in size causing complications.

Clinical presentation
In many instances, identification of thrombus is an incidental finding. A thrombus identified in the first few days of life has a high chance of being associated with inherited thrombophilia, especially in the presence of positive family history. Clinical features are highly variable and depend on the site and size of thrombus.

Venous Thrombosis

Extremities: swelling, pain, cyanosis, hyperemia.

Portal vein - Portal vein thrombosis (PVT) is usually asymptomatic and spontaneous regression can occur especially in cases with partial thrombi (>70%). It is specifically related to intrahepatic placement of UVC placement. PVT can uncommonly lead to the development of portal hypertension (splenomegaly, GI bleeding, gastroesophageal varices, and abdominal pain) and liver atrophy.

Renal Vein - Renal vein thrombosis (RVT) typically presents in male infants and has a left side presentation in majority cases. Classic clinical triad of RVT: hematuria, proteinuria and abdominalmass. Hypertension can be a late finding.

Vena Cava - swelling of face and head with superior vena cava syndrome, unexplained pleural effusion or ascites as a result of inferior vena cava syndrome, both kidneys palpable, hematuria, lower leg edema.

Cerebral sinus venous - Cerebral sinus venous thrombosis (CSVT) may present in the first week of life, often with seizures, lethargy, apnea, irritability, and poor feeding.

Arterial thrombosis - Typically preceded by the use of catheters.

Extremities - pain, discoloration (pallor, mottling, or purple to black), swelling, prolonged capillary refill time, loss of pulses, decreased temperature

Renal Artery - Hypertension, which, in severe cases, leads to renal failure.

Investigations

Imaging
Imaging studies should document the presence and extent of thrombus. Doppler US is the initial imaging study of choice for thrombus in the upper venous system, lower limbs, superior vena cava (SVC), inferior vena cava (IVC) and aorta. ECHO is useful for thrombus located in the SVC. Alternate imaging modalities that could be used, depending on the site of thrombus, are MRA, MRV and CTA.

Baseline coagulation studies
CBC, PT, PTT, antithrombin, fibrinogen, D-dimer as needed, and platelet count.

Additional lab studies
It is highly recommended to consult with the Hematology Service prior to performing advanced thrombosis workup. Routine testing for genetic thrombophilia in neonates with thrombosis is controversial. In most cases, the results of thrombophilia testing will not influence immediate management of the patient (exceptions include rare severe deficiencies such as, protein C, protein S, antithrombin, which should be considered in cases of large thrombus burden and/or purpura fulminans). If advanced evaluation is considered, the studies are ordered as a DVT panel (Table 7-8). Step 1 tests are the most helpful in this age group and should be obtained first. Steps 2 and 3 may be obtained in any order based on clinical discretion.

Table 7-8. Three step DVT panel

<table>
<thead>
<tr>
<th>Step 1</th>
<th>Step 2</th>
<th>Step 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein C, Protein S, Antithrombin, Factor 8, Lupus</td>
<td>Anticardiolipin antibody, Anti-β2-GP1, Lipoprotein (a)</td>
<td>FV Leiden, Prothrombin gene mutation</td>
</tr>
<tr>
<td>1 blue top, 2.7 mL</td>
<td>1 red top, 3.0 mL</td>
<td>1 purple top, 1.0 mL</td>
</tr>
</tbody>
</table>

Management
The principles of management of neonatal thrombosis are largely based on case series, cohort studies and expert opinion. The treatment options include a) observation, b) anticoagulant or thrombolytic therapy c) surgery. A risk stratified treatment recommendation (Table 7-9) and clinical algorithms (Figure 7.6) are suggested below (weak recommendations, low quality evidence).
**Figure 7.6. Clinical Algorithm for Neonatal Thrombosis**

- **Thrombus**
  - **Low Risk**
    - "wait and watch" (until resolution):
      - Re-image in 3-7 days then alter frequency based on findings (1-4 weeks)
  - **Moderate Risk**
    - Consult Hematology
      - If CRT: consider line removal based on IV need and clinical status
      - Therapy and follow up plan guided by Hematology service
      - Baseline Coagulation Studies
      - Anticoagulation therapy to be started with guidance from the Hematology service
      - Thrombus to be followed closely with imaging.
  - **High Risk**
    - Consult Hematology STAT
      - Order ‘Baseline Coagulation Studies’ STAT
      - Order ‘Anticoagulation Therapy’ STAT after discussing with Hematology service.
      - Management driven by multidisciplinary team
  - **Post Cardiac Cath**
    - Assess pulse, cap refill, limb temp and perfusion: q15 min x 4 then, q30 min x 2 then, qhour x 4 then, q4h x 24 hours
    - STAT Call to I.C team or Cardiology fellow (Voalte33347), if after hours. Escalate to Cath attending if no response.
      - Order bedside Doppler USG (test may be unreliable, if pressure dressing present)
      - Cardiology team will guide further tests and therapy (Lovenox or Heparin or tPA if needed).
      - If limb/life threatening ischemia, STAT call to Hematology, Transfusion and Plastic surgery oncall team by the ‘NEO-Cardiology’ team.
  - **Thrombus resolved**
    - Maximum of 3 months LMWH/UFH
  - **Thrombus propagating Signs/ Symptoms noted**
    - Stop LMWH /UFH

**Anticoagulation Therapy:**
- **LMWH:** Preferred if: no increased bleeding risk, no planned invasive procedure(s) within 24-48h
- **UFH:** Preferred if:
  - Significant renal impairment and invasive procedure(s) within 24-48 h, increased

**Baseline Coagulation studies prior to starting anticoagulation:**
- CBC, PT, PTT, fibrinogen, anti-thrombin (AT) and D-dimer
- HUS (if infant at risk for IVH)

**I.C:** Interventional Cardiology team
Treatment (Tables 7-10, 11, 12)

Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are the agents of choice for the management of neonatal thrombosis. LMWH has several advantages over UFH: less frequent laboratory monitoring, subcutaneous administration (and therefore no need for an intravenous line), and ability to discharge on home therapy. Patients with renal dysfunction should not be managed with enoxaparin (LMWH) as it is renally eliminated. Patients with renal dysfunction and acute thrombosis can be managed with UFH.

In general, venous thrombi are typically treated with either UFH or LMWH for 6 weeks to 3 months of total therapy. Repeat ultrasound should be obtained to assess the resolution of the thrombus prior to discontinuation of anticoagulation. If the thrombus was associated with a central line, prophylactic anticoagulation may be considered until the line is removed, but clinical judgement should prevail. Obtain heparin level and PT 4 hours after loading dose and 4 hours after every infusion rate change. Once stable, heparin level and PT should be checked every 12 hours, and platelet counts every 3 days.

Key points in treatment:
• In ‘High Risk’ cases, especially in life/limb threatening scenarios, anticoagulation therapy should be started ASAP by the attending neonatologist with guidance of the hematology service.
• Total duration of treatment for venous thromboembolism is between 6 weeks to 3 months.
• For acute femoral artery thrombosis, at least 5-7 days of therapeutic anticoagulation should be completed.
• Heparin should be stopped 2-4 hours prior to surgery/invasive procedure. Lovenox should be stopped at least 24 hours prior to surgery/invasive procedure.
• Removal of CVAC catheters should be considered in CRT, depending on continued need for venous access and the patient’s clinical status. The Chest guidelines recommend 3-5days of anticoagulant therapy prior to line removal, but clinical judgement should prevail.
• Atrial/Ventricular thrombi and cerebral sinus venous thrombi (CSVT) have high risk for complications. Cardiology service for Atrial/Ventricular thrombi and Neurology service for CSVT should be consulted immediately.

Table 7-9. Risk stratification*

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Risk</td>
<td>Non-occlusive and asymptomatic venous thrombus (CRT, PVT, unilateral RVT), chronic organized venous thrombus.</td>
</tr>
<tr>
<td>Moderate Risk</td>
<td>Any symptomatic or acute occlusive venous thrombus without ischemia or organ failure (CRT,RVT,PVT), Bilateral RVT, propagating venous thrombus on serial imaging, thrombus extending into central vein (SVC, IVC).</td>
</tr>
<tr>
<td>High Risk</td>
<td>Any arterial thrombus, Any thrombus causing limb ischemia or organ injury (renal impairment, cardiac failure), occlusive central artery or vein (Aorta, SVC, IVC), symptomatic pulmonary embolism.</td>
</tr>
</tbody>
</table>

* Cerebral sinus venous thrombosis and thrombosis related to congenital heart disease are excluded.

Table 7-10. Heparin for Line Patency

To prevent clot formation in central lines, heparin 1 unit/mL containing fluids should be continuously administered using the following rates:

<table>
<thead>
<tr>
<th>Weight</th>
<th>UAC</th>
<th>UVC</th>
<th>PICC</th>
<th>PAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1250 grams</td>
<td>0.3 mL/hr</td>
<td>0.3 mL/hr</td>
<td>0.5 mL/hr</td>
<td>0.5 mL/hr</td>
</tr>
<tr>
<td>&gt; 1250 grams</td>
<td>0.5 mL/hr</td>
<td>0.5 mL/hr</td>
<td>0.5 mL/hr</td>
<td>0.5 mL/hr</td>
</tr>
</tbody>
</table>

Table 7-11. Enoxaparin Dosage and Titration

**Enoxaparin**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Goal level = 0.5-1</th>
<th>Prophylaxis</th>
<th>Goal level = 0.2-0.4</th>
<th>Dose Titration</th>
<th>Time to Repeat Lovenox® Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial dose</td>
<td>&lt; 2 months age</td>
<td>0.35-0.49</td>
<td>0.15-0.19</td>
<td>Increase dose by 25%</td>
<td>4 h after next dose</td>
</tr>
<tr>
<td>Rounding</td>
<td>&gt; 2 months age</td>
<td>0.05-1</td>
<td>0.2-0.4</td>
<td>Increase dose by 10%</td>
<td>4 h after next dose</td>
</tr>
<tr>
<td></td>
<td>Weight &lt; 2.5 kg</td>
<td>1.6-2</td>
<td>0.41-1</td>
<td>Keep same dosage</td>
<td>Check level weekly (4 h after dose)</td>
</tr>
<tr>
<td></td>
<td>Weight &gt; 2.5 kg</td>
<td>&gt;2</td>
<td>&gt;2</td>
<td>Decrease dose by 20%</td>
<td>4 h after next dose</td>
</tr>
</tbody>
</table>

Anti-Xa levels (a.k.a. Lovenox Level) should be obtained 4 hours after administration of enoxaparin to accurately assess laboratory value. A minimum of 2 doses of enoxaparin should be administered prior to obtaining the first anti-Xa level to allow for a steady state concentration.

**Lovenox® Level (units/mL)**

<table>
<thead>
<tr>
<th>Treatment Goal level = 0.5-1</th>
<th>Prophylaxis Goal level = 0.2-0.4</th>
<th>Dose Titration</th>
<th>Time to Repeat Lovenox® Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.35</td>
<td>0.15-0.19</td>
<td>Increase dose by 25%</td>
<td>4 h after next dose</td>
</tr>
<tr>
<td>0.35-0.49</td>
<td>0.2-0.4</td>
<td>Increase dose by 10%</td>
<td>4 h after next dose</td>
</tr>
<tr>
<td>0.5-1</td>
<td>1.6-2</td>
<td>Keep same dosage</td>
<td>Check level weekly (4 h after dose)</td>
</tr>
<tr>
<td>1.1-1.5</td>
<td>0.41-1</td>
<td>Decrease dose by 20%</td>
<td>4 h after next dose</td>
</tr>
<tr>
<td>1.6-2</td>
<td>&gt;2</td>
<td>Decrease dose by 30% and hold dose for 3 hours from next due time</td>
<td>4 h after next dose</td>
</tr>
</tbody>
</table>

Repeat Lovenox® level; hold all doses until Lovenox® level is 0.5 units/mL, then decrease dose by 40%

Check level every 12 h until Lovenox® level <0.5 units/mL

Guidelines for Acute Care of the Neonate, Edition 26, 2018–19 101
Table 7-12. Heparin Dosage & Titration

<table>
<thead>
<tr>
<th>Heparin Level</th>
<th>Goal level = 0.3-0.7 units/mL</th>
<th>Goal level = 70-101 (seconds)</th>
<th>Dosage Adjustment</th>
<th>Time to Repeat Heparin level &amp; PTT</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.2</td>
<td>&lt;60</td>
<td></td>
<td>Give 50 units/kg bolus and increase infusion rate by 10%</td>
<td>4 h after rate change</td>
</tr>
<tr>
<td>0.2-0.29</td>
<td>60-69</td>
<td></td>
<td>Increase infusion rate by 10%</td>
<td>4 h after rate change</td>
</tr>
<tr>
<td>0.3-0.7</td>
<td>70-101</td>
<td>Keep the same</td>
<td>Every 12 h</td>
<td></td>
</tr>
<tr>
<td>0.71-0.8</td>
<td>102-112</td>
<td>Decrease infusion rate by 10%</td>
<td>4 h after rate change</td>
<td></td>
</tr>
<tr>
<td>0.81-0.99</td>
<td>113-130</td>
<td>Hold infusion for 30 minutes and decrease infusion rate by 10%</td>
<td>4 h after rate change</td>
<td></td>
</tr>
<tr>
<td>≥1</td>
<td>&gt;130</td>
<td>Repeat heparin level; hold infusion for 60 minutes and decrease infusion rate by 15%</td>
<td>4 h after rate change</td>
<td></td>
</tr>
</tbody>
</table>

Suggested Reading


2. Fernandes CJ. Neonatal Thrombocytopenia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2017.


9. Neonatal Thrombosis: TCH Evidence Based Outcomes Center 2009

Section 8: Infectious Diseases
Editors: Mohan Pammi and Michael Speer

8.1 Bacterial Sepsis ........................................104
  Tiffany L. Molina
  Maria Kristine Reyes

8.2 Group B Streptococcus ...............................105
  Colleen Brand

8.3 Cytomegalovirus .....................................107
  Alana Thomas
  Gregory Valentine

8.4 Fungal Infection .....................................107
  Mohan Pammi

8.5 Gonococcal Disease .................................110
  Colleen Brand

8.6 Hepatitis B ...........................................110
  Alana Thomas
  Gregory Valentine

8.7 Hepatitis C ...........................................111
  Alana Thomas
  Gregory Valentine

8.8 Herpes Simplex .....................................112
  Alana Thomas
  Gregory Valentine

8.9 Human Immunodeficiency Virus ..................113
  Ann Gerges

8.10 Respiratory Syncytial Virus ......................114
  Ann Gerges

8.11 Rotavirus ...........................................115
  Michael Speer

8.12 Syphilis, Congenital ...............................115
  Michael Speer

8.13 Tuberculosis .......................................116
  Mona Khattab

8.14 Varicella Zoster (VZV) .............................117
  Mona Khattab

8.15 Zika Virus ..........................................118
  Mohan Pammi
  Gregory Valentine
8.1 Bacterial Sepsis

General Points
If bacterial sepsis is suspected, cultures should be obtained and antibiotic therapy initiated promptly. In neonates with bacterial meningitis, blood cultures can be sterile in as many as 15% to 50% of cases.

If an infant is ELBW (less than 1000 grams), has renal dysfunction, or is to be treated for more than 72 hours with gentamicin, serum levels should be monitored. [Sec 17-Medications]

“Outbreaks” in any NICU may dictate temporary changes in the empirical drug regimens suggested below.

A serum ammonia level should be drawn if lethargy, hypotonia, or both are present in term infants more than 72 hours of age with suspected sepsis.

Blood Cultures
Current semi-automated, computer assisted blood culture systems identify bacterial pathogens rapidly, within 24–36 hours. Candida species also will grow in this system, but occasionally can take longer.

Age 0 to 72 Hours (Early-Onset, Maternally Acquired Sepsis)

Indications for Evaluation

Term Infants (infants greater than 37 weeks’ gestation)

- Infant exhibits signs suggesting sepsis: cultures and antibiotics are indicated.
- Born to a mother who has fever (greater than 100.4°F, 38°C) before delivery or within 24 hours afterwards: review the maternal history and obtain information from the obstetrician. If the obstetrician considers maternal chorioamnionitis, endometritis or other systemic bacterial infection to be present in the mother, an evaluation (cultures) is done and empirical antibiotics are given to the infant.
- Delivered after prolonged rupture of membranes (greater than 18 hours), but has no signs suggesting infection, and mother had no fever or other signs suggesting infection: observe in hospital for 48 hours. If the infant’s clinical condition changes to suggest the presence of infection, obtain cultures and initiate antibiotics.

Preterm Infants (infants less than 37 weeks’ gestation)

- Prolonged rupture of membranes (greater than 18 hours), maternal fever (greater than 100.4°F) before or within 24 hours after delivery, chorioamnionitis, maternal antibiotic therapy for a suspected bacterial infection or signs of sepsis in the infant: obtain cultures and initiate antibiotics.
- If none of these risk factors is present and the infant is delivered by cesarean section without labor or ruptured membranes, evaluation is not necessary unless sepsis is suspected clinically

Evaluation

Term Infants

- Infants with signs of sepsis (e.g., respiratory distress, hypotension, lethargy, apnea, temperature instability, seizures, tachycardia, vomiting, diarrhea, abdominal distention, poor feeding, jaundice etc.) Evaluate with a CBC, obtain cultures of blood and CSF, and initiate antibiotics. If a blood culture grows a pathogen, a repeat culture of blood should be obtained 24-48 hours after initiation of appropriate therapy and until sterility is documented. If CSF culture grows a pathogen, repeat a CSF culture 24-48 hours after appropriate therapy to document sterility. In patients with skin lesions with purulent drainage, pustules or vesicles either related to a surgical incision site or not, clinicians should strongly consider sending the fluid from the skin lesion for culture.

- Healthy-appearing term infants. Evaluate with a blood culture and initiate non-meningeal doses of ampicillin in combination with gentamicin. These infants should receive close follow-up by their pediatricians after discharge. These infants should receive an appointment to either a clinic or their primary care provider 2-5 days after discharge. If the infant develops signs of sepsis after the initiation of antibiotics, reevaluate the infant with a CBC, a lumbar puncture (LP), and obtain another blood culture. Antibiotics should be increased to meningeal levels.

Preterm Infants

- Signs of sepsis. Obtain a CBC, and cultures of blood and CSF, and initiate antibiotics. If the blood culture grows a pathogen, a repeat culture of the blood should be obtained 24-48 hours after initiation of appropriate therapy and until sterility is documented. If CSF culture grows a pathogen, a repeat a CSF culture 24-48 hours after appropriate therapy is recommended to document sterility.

- Healthy-appearing infants at risk for early-onset sepsis. Evaluate by obtaining a CBC and blood culture (a LP is at the discretion of the Neonatology attending) and initiate meningeal doses ampicillin in combination with gentamicin. If the infant develops signs of sepsis [see above], or has a positive blood culture, perform another CBC, a LP, and a repeat blood culture.

- Very low birth weight infants who have a clinical course and an evaluation that make sepsis extremely unlikely may not require a lumbar puncture. If the infant’s clinical course is not compatible with infection and the blood culture is negative, performing a LP is at the discretion of the Neonatology attending physician.

Initial Empirical Therapy

For doses, refer to Sec 17-Medications.

If CSF is abnormal or cannot be obtained when a lumbar puncture is performed or if gram-negative organisms are suspected, give cefotaxime or ceftazidime at meningal doses

If CSF is normal, administer ampicillin at non-meningeal doses in combination with gentamicin.
Duration of Therapy

**Infants with signs of sepsis** - Ten days of therapy is given if sepsis is proven or strongly suspected; 14 to 21 minimum days depending upon etiologic agent and clinical course, is given if meningitis is proven or strongly suspected. If cultures are negative and the clinical course is not felt to be compatible with sepsis, discontinue antibiotics no longer than 48 hours after therapy initiated. Treatment of culture negative sepsis for more than 48 hr is discouraged because recent evidence suggests that with correctly performed blood cultures of 1ml volume, sensitivity of detecting bacteremia is close to 100%.

**Healthy-appearing infants or those whose course does not suggest sepsis** - Therapy in term infants can be discontinued when the blood culture is documented to be sterile after 24 to 48 hours of incubation.

Late-Onset Infection

Age older than 3 days and continuous Level 1-4 care. Consider maternal and hospital-associated sources for infection. *(See Figure 8–1)*

Indications for Evaluation

Signs of sepsis or focal infections such as pneumonia, urinary tract infection, soft tissue infection, bone or joint infection, NEC, or meningitis is present.

Evaluation

Obtain a CBC and cultures of blood, CSF, and urine (preferably by bladder tap). In certain circumstances, consider pleural fluid, abscess material, bone, joint or peritoneal fluid cultures when infection is localized to those sites. A tracheal aspirate culture that grows a pathogen, including CONS, may not define pneumonia and can reflect colonization of the endotracheal tube. In infants less than 1500 grams, there can be difficulty in obtaining an uncontaminated urine specimen by catheterization. However, urine culture, preferably by bladder tap, in this birth weight group, is always indicated for infants who are being evaluated for:

- suspected fungal infection,
- known renal anomalies, or
- more than one episode of gram-negative bacteremia without a source identified.

In other VLBW infants, the likelihood of a primary UTI is between 7% and 10%; omitting a urine culture is at the discretion of the attending physician.

Ancillary inflammatory assays may assist ruling out infection and in minimizing unnecessary antibiotic exposure. CRP has been the best studied and in evaluation of late onset sepsis, a CRP at 18-22 hours after initiation of work-up may be helpful in diagnosing or ruling out infection. A CRP value ≤1 mg/dL is unlikely to be present in bacterial infection, Routine measurements of CRP in well appearing infants are not otherwise recommended to screen for infection.

Procalcitonin is another inflammatory marker that has been used in the evaluation of sepsis. It is not recommended for routine use in the general assessment of an infant with features of late onset sepsis. It may be considered in special circumstances at the discretion of the attending neonatologist.

The cut off threshold of >0.5 g/mL suggests bacterial infection.

Initial Empirical Therapy

For doses refer to Sec 17-Medications

**Sepsis without a focus** - Administer vancomycin and gentamicin. All BCM-affiliated NICUs have had endemic methicillin-resistant S. aureus strains since 1988, and most coagulase negative staphylococcal isolates (approximately 85%) are methicillin resistant.

**Suspected disseminated staphylococcal infection**

Administer both vancomycin and nafcillin with gentamicin until culture results and antibiotic susceptibilities are known. Nafcillin is more effective than Vancomycin in the treatment of MSSA.

**NEC (pneumatosis or presumed perforation)** - Assuming that CSF is normal, treat initially with ampicillin and gentamicin. If there is concern regarding peritonitis or perforation add clindamycin for anaerobic coverage. If ileus due to sepsis is suspected, vancomycin may be used in substitution for ampicillin. However, if cultures are negative at 48 hours, vancomycin must be discontinued. Continued empirical therapy for 7 to 10 days if treating for NEC even if blood cultures are negative.

**Meningitis** - If suspected or proven, an Infectious Disease consultation and at least 24-hour observation in the Level III/IV NICU are recommended to assist with management. The infant should be empirically treated with ampicillin, gentamicin and, if gram-negative organisms are suspected, cefotaxime or cefazidime at meningeal doses.

**Infection of bone, joint, or both** - Administer vancomycin, nafcillin and gentamicin; an Infectious Diseases consultation early in the course is advised to determine whether surgical intervention is needed.

**Intravascular catheter-related infection (Central Line Associated Blood Stream Infection [CLABSI]).** Administer vancomycin and gentamicin. If caused by yeast, enterococcus, or gram-negative rods, S. aureus or multiple organisms, the catheter should be removed to eliminate the potential source of infection and prevent further dissemination. In patients who remain “septic” despite antibiotics or in whom secondary foci of infection appear on therapy, the catheter must be removed immediately.

### 8.2 Group B Streptococcus (GBS)

GBS caused approximately 7600 cases of sepsis and approximately 210 deaths per year in the U.S. before 1996. GBS is found in the maternal gastrointestinal and genitourinary tracts (15–35%) and infection results from vertical transmission during labor or delivery. Antibiotic therapy during pregnancy or intrapartum does not eradicate GBS from these sites. Since introduction of routine maternal GBS culture screening and intrapartum antibiotic prophylaxis (IAP), the incidence of early-onset (0-6 days) GBS infection is 0.24 per 1000 live births or 1-2 per 100 colonized women. The risk is increased in preterm infants, rupture of membranes longer than 18 hours, maternal fever >100.4°F, GBS UTI
Figure 8-1. Late-onset sepsis in newborn center patients, Level 2 and 3

1. Call to evaluate > 72-h-old infant with possible sepsis
   - Yes: GI symptoms and pt at risk for NEC –
     - No: High index of suspicion for sepsis #
     - Yes: Follow NEC algorithm, which should include workup for sepsis
   - No: OFF algorithm

2. CBC w/diff, blood culture x 2 (central and peripheral, ≥ 1 ml/bottle preferred but at least 0.5 ml/bottle, LP)
   - For infants > 1 kg and those susceptible to GU infection, check cath urine culture **; for infants < 1 kg consider suprapubic tap
   - Start antibiotics (usually Vanc/Gent unless indicated otherwise by history)
   - Obtain CRP 18–22 hrs after initial antibiotic order

3. After 24-hr evaluate:
   - 1. CRP
   - 2. Culture
   - 3. Pt status

4. Pt clinically ill OR cultures (+)
   - No: CRP ≥ 1 mg/dL ^
     - Yes: Continue antibiotics another 24 hr
     - No: Discontinue gent, continue vanc another 24 hr

5. Discontinue vanc and gent
   - Monitor cultures
   - Closely monitor clinical status, VS
   - Consider repeat CRP at ~48 hrs
   - If blood culture positive provide appropriate abx coverage
   - Check gent peak and trough with 3rd dose
   - If one of two blood cultures positive (+) for CONS, clinical picture inconsistent with infection, and CRP < 1; (+) culture may be contaminated. Consider DC abx. A repeat CRP < 1 may provide additional reassurance
   - Document decision/reason in chart

KEY
- ~: bilious emesis, abdominal distention, absent/hypoactive bowel sounds, abdominal discoloration, bloody stools
- #: high index of suspicion for sepsis (clinical correlation needed): central line, poor nutritional status, < 32 wks PMA, conditions w/ host immune defenses (disruption of skin integrity, autoimmune disease, HIV), lethargy, ↑ O₂ or vent support, significant worsening of central apnea, signs of localized infection, abnormal glucose homeostasis, hypotension
- *: vague s/i include: temp instability, feeding intolerance, milk ↑ in apnea/bradycardia episodes but consistent with prematurity
- **: GU risk factors: suspected fungal infection, known renal anomalies, history of > 1 episode of Gram (-) bacteremia w/o an identified source
- ^: CRP may be false (-) in case of leukopenia
during the current pregnancy or a previous infant with GBS infection. Signs of early onset disease occur within the first 24–48 hours of life in more than 95% of babies. It is usually characterized by septicemia (80-85%), pneumonia (5-10%), or meningitis (5–10%). Recurrence of GBS in appropriately treated infants is 1-3%. Gram stains typically show GPC in pairs or short chains. Growth in culture is diagnostic.

Recommendations in the 2015 edition of the AAP Red Book are maternal GBS culture-based and include: Maternal Prophylaxis based on culture screening at 35-37 weeks gestation. Penicillin, ampicillin, or cefazolin, if initiated 4 hours prior to delivery is considered to be adequate prophylaxis. Cefazolin is recommended if there is a maternal history of penicillin allergy. Clindamycin can be used only if the GBS isolate is known to be sensitive (GBS is resistant in about 30%). Vancomycin can also be used in mothers who are allergic to penicillin. The efficacy of clindamycin or vancomycin in preventing early-onset GBS is not established. In GBS-colonized women undergoing planned cesarean deliveries, routine intrapartum antibiotic prophylaxis is not indicated if labor has not begun or membranes have not ruptured.

Newborns with signs of sepsis should receive a full diagnostic work-up and treatment. In 2010, the American Academy of Pediatrics (AAP) and American College of Obstetricians and Gynecologists endorsed revised CDC guidelines which are outlined in the following algorithms (Fig 8–3 to Fig 8–7). The algorithms cover most circumstances and are useful in determining unit selection, recommended observation and treatment recommendations.

Infants who receive the limited evaluation are triaged to a Level 1 Newborn Nursery and are not candidates for short stay.

8.4 Fungal Infection (Candida)

General Points
The most common fungal infections are those due to Candida species and are usually caused by Candida albicans and Candida parapsilosis. However, in some NICUs the incidence of fungemia and disseminated disease due to other Candida species, such as C. tropicalis, C. lusitani, C. krusei, and C. glabrata, also occur. Disseminated candidiasis typically occurs in very low birth weight newborns (especially those less than 1000 grams or less than 27 weeks’ gestational age) and can involve almost any organ or anatomic site. Candidemia can occur with or without organ dissemination in patients with indwelling central lines. Systemic corticosteroid use as well as prolonged broad-spectrum antibiotics (especially third generation cephalosporins and meropenem) increases the risk of invasive candidiasis. Other reported risk factors include total parenteral nutrition, intralipids, abdominal surgery, and H2 blockers.

Evaluation
A presumptive diagnosis of disseminated infection can be made by isolation of Candida from blood, CSF, infected tissue, or urine obtained by suprapubic aspiration or catheterization (104 CFU/mL or greater). Invasive fungal dermatitis, which can be caused by Candida species or other fungi (e.g., Aspergillosis), is a diagnosis made by clinical suspicion and confirmed by histopathology of a skin biopsy.
Figure 8–3. Indications and nonindications for intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcus

**Intrapartum antibiotic prophylaxis (IAP) indicated**
- Previous infant with invasive GBS disease
- GBS bacteruria during any trimester of the current pregnancy *
- Positive GBS vaginal-rectal screening culture in late gestation † during current pregnancy *
- Unknown GBS status at the onset of labor (culture not done, incomplete, or results unknown) and any of the following:
  - Delivery at < 37 weeks' gestation †
  - Amniotic membrane rupture ≥ 18 hours
  - Intrapartum temperature ≥ 100.4°F (≥ 38.0°C) ‡
  - Intrapartum NAAT** positive for GBS

**Intrapartum GBS prophylaxis not indicated**
- Colonization with GBS during a previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)
- GBS bacteruria during previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)
- Negative vaginal and rectal GBS screening culture during in late gestation † during the current pregnancy, regardless of intrapartum risk factors
- Cesarean delivery performed before onset of labor on a woman with intact amniotic membranes, regardless of GBS colonization status or gestational age

Abbreviation: NAAT = Nucleic acid amplification tests
* Intrapartum antibiotic prophylaxis is not indicated in this circumstance if a cesarean delivery is performed before onset of labor on a woman with intact amniotic membranes
† Optimal timing for prenatal GBS screening is at 35–37 weeks' gestation
‡ Recommendations for the use of intrapartum antibiotics for prevention of early-onset GBS disease in the setting of threatened preterm delivery are presented in Figures 8–5 and 8–6
§ If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis
**NAAT testing for GBS is optional and might not be available in all settings. If intrapartum NAAT is negative for GBS but any other intrapartum risk factor (delivery at < 37 weeks' gestation, amniotic membrane rupture at ≥ 18 hours, or temperature ≥ 100.4°F (≥ 38.0°C) is present, then intrapartum antibiotic prophylaxis is indicated.

---

Figure 8–4. Algorithm for secondary prevention of early-onset group B streptococcal (GBS) disease among newborns

<table>
<thead>
<tr>
<th>Signs of neonatal sepsis?</th>
<th>yes</th>
<th>no</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal chorioamnionitis? §</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>GBS prophylaxis indicated for mother? **</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Mother received intravenous penicillin, ampicillin, or cefazolin for ≥ 4 hours before delivery?</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>≥ 37 weeks and duration of membrane rupture &lt; 18 hours?</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Either &lt; 37 weeks or duration of membrane rupture ≥ 18 hours?</td>
<td>yes</td>
<td>no</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Full diagnostic evaluation * Antibiotic therapy †</th>
<th>Limited evaluation ‡ Antibiotic therapy †</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation for ≥ 48 hours §§</td>
<td>Observation for ≥ 48 hours §§</td>
</tr>
</tbody>
</table>

* Full diagnostic evaluation includes a blood culture, a complete blood count (CBC) including white blood cell differential and platelet counts, chest radiograph (if respiratory abnormalities are present), and lumbar puncture (if patient is stable enough to tolerate procedure and sepsis is suspected)
† Antibiotic therapy should be directed toward the most common causes of neonatal sepsis including intravenous ampicillin for GBS and coverage for other organisms (including Escherichia coli and other gram-negative pathogens) and should take into account local antibiotic resistance patterns
§ Consultation with obstetric providers is important to determine the level of clinical suspicion for chorioamnionitis. Chorioamnionitis is diagnosed clinically and some of the signs are non-specific.
‡ Limited evaluation includes blood culture (at birth), and CBC with differential and platelets (at birth and/or at 6–12 hours of life)
** See table 8–3 for indications for intrapartum GBS prophylaxis
†† If signs of sepsis develop, a full diagnostic evaluation should be conducted and antibiotic therapy initiated
 §§ If ≥ 37 weeks' gestation, observation may occur at home after 24 hours if other discharge criteria have been met, access to medical care is readily available, and a person who is able to comply fully with instructions for home observation will be present. If any of these conditions is not met, the infant should be observed in the hospital for at least 48 hours and until discharge criteria are achieved.
††† Some experts recommend a CBC with differential and platelets at age 6–12 hours.
Ophthalmologic examination, lumbar puncture, in addition to abdominal ultrasonography and echocardiogram are indicated (in most cases) in suspected disseminated candidiasis (i.e., all VLBW infants with candidemia). MRI of the brain with contrast is appropriate for evaluation of Candida infection in the CNS. These diagnostic imaging studies should be performed in the late 2nd or third week of therapy since initial evaluation can be misleading early in the course of therapy.

**Chemoprophylaxis**

Several studies, including 3 multicenter randomized studies, have compared the effect of prophylactic intravenous fluconazole versus placebo for six weeks in very low or extremely low birth weight infants. Both colonization with Candida spp. and invasive candidiasis have been significantly reduced with prophylaxis. The prophylaxis regimen is safe and in NICUs using this approach for 6 and 10 years, respectively, no resistant Candida sp. have emerged. The 2015 Red Book recommends routine fluconazole prophylaxis for infants weighting less than 1000 g at birth in NICU’s where the incidence in the NICU is moderate (~5-10%) or high (>10%). This recommendation is based on moderate quality of evidence.

**Treatment**

Systemic candidiasis requires treatment with amphotericin B deoxycholate (1.0 mg/kg per day over 2 hours). Renal indices (serum BUN and creatinine) as well as serum potassium levels initially must be deter- mined frequently. Flucytosine (150 mg/kg per day orally in 4 divided doses) can be considered in combination with amphotericin B if CNS infection by C. albicans is present. Length of therapy will vary with site(s) of infection and with clinical response. Disseminated fungal disease due to unusual fungi and yeast (Aspergillus, Curvularia, Fusarium, Trichosporon, and rare species of Candida) has
been reported in very low birth weight infants and require specific antifungal therapy. Indwelling vascular catheters must be removed as soon as feasible. Consultation with the Infectious Disease Service is suggested for any patient with systemic candidiasis or other invasive fungal infection.

### 8.5 Gonococcal Disease

Gonococcal infection is the second most common STI in the US. Infections in the newborn usually involve the eyes. Other sites of infection include septicemia, arthritis, meningitis, or scalp abscess. Transmission is through contact with exudate and secretions from infected mucosal surfaces with an incubation period of 2 to 7 days.

#### Managing Asymptomatic Infants

All infants should receive routine eye prophylaxis immediately after birth (may be delayed up to 1 hour to promote mother-infant bonding). If the mother has untreated gonorrhea at the time of delivery, the infant should receive a single dose of ceftriaxone. (See the AAP Redbook or the Hospital formulary for current dosing recommendations.)

#### Managing Symptomatic Infants

In cases of symptomatic neonatal disease, cultures of blood, cerebrospinal fluid, eye discharge, or other sites of infection (e.g., synovial fluid) should be obtained to delineate the extent of infection and determine the antibiotic susceptibility of the organism. Testing for other STIs is recommended.

A single dose of ceftriaxone is appropriate for infants with gonococcal ophthalmia. These infants should be hospitalized and evaluated for disseminated infection, including arthritis or septicemia. For disseminated gonococcal disease, parenteral ceftriaxone or cefotaxime (if hyperbilirubinemia is present) is administered for 7 days and in documented meningitis for 10 to 14 days. (See the AAP Redbook or the Hospital formulary for current dosing recommendations.)

Both the mother and her sexual partner(s) should be evaluated and treated appropriately. All cases of gonorrhea must be reported to local public health officials.

### 8.6 Hepatitis B

#### Vaccine Use in Neonates

Hepatitis B virus (HBV) may be transmitted vertically from mothers with acute hepatitis during pregnancy or with the hepatitis B surface antigen (HBsAg) carrier state. The risk of an infant with perinatal exposure is 70% to 90%.

- All mothers will have an HBsAg determination performed before or at the time of delivery.
- All outborn newborn admissions should have maternal blood sent to the laboratory for HBsAg testing if results of hepatitis screening are not otherwise available.
- The results of the maternal HbsAg test should be ascertained before the infant is discharged.

#### Maternal Screen Status Positive

- Give Hepatitis B Immune Globulin (HBIG) 0.5 mL IM and Hepatitis B vaccine (10 mcg/mL) 5 mcg IM as a one-time order. Give concurrently with separate syringes at separate sites according to current dosage guidelines.
- Give to term or preterm infants within 12 hours of birth.
- For preterm infants who weigh less than 2 kg at birth, do not count the initial dose of vaccine in the required 3-dose schedule, and give the subsequent 3 doses in accordance with the schedule.
- Thus, a total of 4 doses are recommended in this circumstance.
Schedule follow-up with the primary care provider at 1 (preferable) to 2 months chronological age (regardless of BW or GA) and at 6 months of age to receive doses 2 and 3 of the vaccine. Emphasize to the parents the importance of the follow-up.

With appropriate immunoprophylaxis, including HBIG, breastfeeding of babies born to HBsAg-positive mothers poses no additional risk of HBV transmission.

Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of at least 3 doses of a licensed Hepatitis B vaccine series at age 9 to 18 months.

Unknown
If the report of the maternal screen is not available within 12 hours of age, all infants should receive hepatitis B vaccine (10 mcg/mL) 5 mcg. If the mother is determined to be positive, infants with a birth weight greater than 2 kg should receive HBIG (0.5 mL) as soon as possible, but within 7 days of birth. Preterm infants who weigh less than 2 kg at birth should be given HBIG (0.5 mL) as well as vaccine within 12 hours of birth because of the poor immunogenicity of the vaccine in these patients. This initial vaccine dose should not be counted in the required 3 doses to complete the immunization series.

If mother is HBsAg-negative, the infant should complete the vaccination schedule recommended below for routine immunization of term and preterm infants, respectively.

Routine Vaccination

Term infants’ vaccination schedule:
Dose 1: Birth (before discharge).
Dose 2: 1 through 2 months after initial dose.
Dose 3: 6 through 18 months of age.

Premature infants’ birthweight (< 2000 grams) vaccination schedule:
Dose 1: These infants should receive the first dose of hepatitis B single antigen vaccine starting at 1 month of chronological age or at hospital discharge if before 1 month of chronologic age.

If single antigen vaccines are used:
Dose 2: 1 to 2 months after initial dose. Dose 3: 6 through 18 months of age.

If combination vaccines are used:
Dose 2: 2 months chronologic age
Dose 3: 4 months chronologic age
Dose 4: 6 mo (Pediarix) or 12 through 15 mo (Comvax)

In general, the various brands of age-appropriate hepatitis B vaccines are interchangeable within an immunization series. The immune response using 1 or 2 doses of a vaccine produced by one manufacturer followed by 1 or more subsequent doses from a different manufacturer is comparable to a full course of immunization with a single product. However, one should attempt to use the same product throughout the series, if possible.

Serologic testing is not necessary after routine vaccination.

Recommended Doses of Hepatitis B Virus Vaccines

Infants whose mothers’ status is HBsAg positive, in addition to 0.5 mL HBIG IM

- Recombivax HB vaccine, pediatric formulation, 5 mcg (0.5 mL) IM
- Energix-B, 10 mcg (0.5 mL) IM

Infants whose mothers’ status is HBsAg negative

- Recombivax HB vaccine, pediatric formulation, 5 mcg (0.5 mL) IM
- Energix-B, 10 mcg (0.5 mL) IM

Follow-up

The attending physician is responsible for follow-up and to order additional doses of vaccine. If the patient remains hospitalized, the NNP-NNC or physician will order hepatitis B vaccine doses 2 and 3 according to the schedule appropriate for that patient. At BTGH, signed consent must be obtained before administering any vaccine.

8.7 Hepatitis C Virus Infection

Hepatitis C virus is transmitted by perinatal exposure of blood from infected mothers. Serologic testing is recommended for anti-HCV in infants born to women previously identified to be HCV infected because about 5% of those infants will acquire the infection. Maternal coinfection with HIV increases transmission.

The duration of passive maternal antibody in infants is about 18 months. Therefore, testing for anti-HCV should not be performed until after 18 months of age.

Testing for HCV RNA by NAAT can determine HCV viremia at an early age. The test is not recommended for use in the first month of life. If HCV RNA testing at 1 to 2 months of age determines that an infant is HCV infected, the Infectious Disease Service should be consulted for further follow-up and recommendations. Transmission by breastfeeding has not been documented; consideration should be given to stopping breastfeeding for a period of time if the nipples are cracked or bleeding.
8.8 Herpes Simplex Virus (HSV)
Newborns of Mothers with Suspected HSV

Neonatal herpes simplex virus (HSV) infection is uncommon, but it may be devastating. The incidence has been estimated at 1/3,000 to 1/20,000 live births. Most infected neonates (70%) are born to women with neither a history of genital herpes nor active lesions. With primary infections at the time of delivery, there is a 25% to 60% risk of disease transmission; with recurrent infection, the risk decreases to < 2%. Exposure of the newborn typically occurs during delivery through the birth canal (intrapartum transmission). Documented in utero and post-partum transmission is rare. Of those infants who become infected, more than 75% are born to mothers without a history or clinical finding of herpes infection during pregnancy.

Neonatal HSV can present as:

- disseminated, systemic infection involving the liver and lung predominantly, but also other organs including the central nervous system (CNS),
- localized CNS disease, or
- localized infection involving the skin, eyes, or mouth.

Disseminated HSV has a mean age of onset of 7 days, but can occur at any time between birth and 4 weeks of age. In the 2nd or 3rd week of life, infections most often involve the skin, eye, or mouth or any combination of those sites or the CNS (localized). Symptoms may arise as late as 6 weeks of age, but this is uncommon. Early signs of HSV frequently are non-specific and subtle. The possibility of HSV should be considered in any neonate with vesicular lesions or with unexplained illness (including respiratory distress, seizures, or symptoms of sepsis). Mortality and morbidity are high with disseminated or CNS disease, even with treatment. Virtually all HSV infections in neonates are symptomatic. Infection may be caused by either HSV type 1 or type 2. Other viruses (e.g., enterovirus [enterovirus, echovirus and coxsackie A & B virus], adenovirus) also may cause systemic disease that mimics overwhelming bacterial sepsis. Whenever systemic viral infection is suspected, appropriate viral cultures (i.e., skin lesions [e.g., vesicles], rectal, oropharynx, nasopharyngeal, urine, conjunctiva, CSF) should be obtained. CSF should be sent for cell count, glucose and protein, as well as culture. A CBC with differential and platelet count, along with electrolytes and liver and renal function tests should be performed. Polymerase chain reaction (PCR) studies on an aliquot of CSF for HSV DNA are particularly useful in evaluating HSV encephalitis. A whole blood sample for HSV PCR can be helpful in diagnosing HSV viremia or disseminated disease. PCR for enterovirus RNA in CSF can be performed to help distinguish between the 2 etiologies. Serological tests generally are not helpful.

A Careful History
A careful exploration of both the paternal and maternal history is critical in determining the risk of HSV infection in the neonate. If the mother or father has a history of HSV infection, a detailed history should be obtained to determine:

- when and how the diagnosis was made,
- the time of the last symptoms, and

any treatment (if any) given to the mother.

A negative maternal history does not exclude the possibility of infection in a neonate with symptoms suggestive of HSV infection because many women with primary or recurrent HSV infection are asymptomatic.

At-Risk Infants
Consider infants at-risk that are born by any delivery method to a mother with either HSV genital lesions at delivery or during the post-partum hospitalization, or a positive maternal HSV culture at delivery, regardless of the nature of the maternal infection status (e.g., primary or secondary [i.e., recurrent]).

Factors in the mother or the newborn that might increase disease transmission in infants found to be at risk include:

**Maternal**
- primary genital infection
- cervical or vaginal rather than vulvar lesions
- status (primary or recurrent) is unknown
- rupture of membranes more than 4 hours

**Neonatal**
- prematurity (37 or fewer weeks’ gestation)
- fetal scalp monitor
- skin trauma or laceration at delivery

Management of At-Risk Infants
Consultation with the Infectious Disease Service may be considered for all at-risk infants to ensure that HSV cultures and PCR are properly collected and transported to the Virology Laboratory at Texas Children’s Hospital, if necessary, and to determine the need for antiviral treatment.

The infant may be observed in an open crib in continuous rooming in or in contact isolation. Contact precautions should be observed by anyone who handles the infant. (At BTGH, these babies are placed in an incubator with contact isolation in ICN if the mother is unable to room-in.) The mother should be instructed that before touching her infant she should carefully wash her hands and wear a clean hospital gown. Infants with HSV infection should be placed in an isolation room (when available) with contact isolation.

- Breastfeeding is permitted unless breast or hand HSV lesions are present. The mother or family member with oral lesions should not kiss or nuzzle the infant; they should wear a surgical mask until lesions have crusted and dried. Mothers with oral or breast lesions should be instructed in proper hygiene and have no infant contact with the lesions until they are healed.

- When an asymptomatic infant is ~24 hours of age, cultures for isolating HSV should be obtained from swabs of the nasopharynx, conjunctivae, mouth, rectum, and scalp electrode site, if present. All sites are sampled and duplicate swabs are placed into viral transport media, agitated, and discarded. Positive cultures taken before this time may reflect contamination rather than viral replication. In mothers with active genital herpes that...
represents a primary infection or the status is unknown, a neonatal blood HSV DNA PCR and ALT also should be obtained. Further, CSF cell count, chemistries, and HSV PCR should be gotten in these infants and acyclovir started. In mothers with known recurrent genital herpes a HSV blood PCR should also be obtained in addition to the cultures, but acyclovir should not be started.

- If HSV cultures and PCR are negative at 72 hours, then the infant is a candidate for home follow-up if all the events below can be arranged:
  1. Parent education about early symptoms and signs of HSV infection in the infant (skin lesions, poor feeding, fever, lethargy, etc.).
  2. Visiting nurse follow-up at home at 10 to 14 days of life. (BTGH)

Do not promise families discharge unless both events have been arranged. If the events above cannot be accomplished, the infants must be observed in the hospital until the cultures are finalized as being negative or negative for 96 hours after being set up for cell culture, whichever is shorter.

If HSV cultures or blood PCR are positive, or if the infant develops symptoms consistent with HSV disease, CSF cell count, chemistries, and HSV PCR as well as a serum ALT and CBC diff and platelet count should be obtained and treatment started. Also, consultation with the Infectious Diseases and Ophthalmology Services may be considered to assist in the evaluation and management.

**Treatment**

- In most asymptomatic patients born of mothers with recurrent herpes, no treatment is necessary. However, in certain situations, an infant’s risk of infection is so great that empiric parenteral antiviral therapy may be warranted even before the onset of overt disease. This includes all infants whose mothers have active lesions at birth and the infection is primary or the maternal status is unknown. If the mother is found to have recurrent infection and the HSV PCR and cultures are negative, acyclovir can be stopped. Treat these and culture-positive or symptomatic infants as follows:

  - Acyclovir 60 mg/kg per day in 3 divided doses for 14 days given intravenously if the disease is limited to the skin, eyes, or mouth; 21 days if disseminated, blood HSV DNA positive indicating viremia, or involved the CNS. The dose should be decreased in patients with impaired renal function. A repeat CSF HSV PCR near the end of a 21-day course of treatment is recommended. If the PCR is still positive, continue intravenous acyclovir for 7 more days and repeat the CSF PCR at the end of that time.

  - In infants born to mothers with primary HSV infection, but CSF indices are not indicative of infection, blood and CSF PCR are negative and the serum ALT is normal, treat with intravenous acyclovir for 10 days.

  - If ocular involvement, 1% trifluridine, 0.1% iododeoxyuridine, or 0.15% ganciclovir as well as systemic therapy.

- The use of oral acyclovir suppressive therapy for 6 months following treatment of acute neonatal HSV disease has been shown to improve neurodevelopmental outcomes in infants with HSV CNS disease and to prevent skin recurrences in infants with any disease. The dose is 300 mg/m2/dose, administered 3 times daily.

- Monitoring of absolute neutrophil counts should be performed at 2 and 4 weeks after initiating suppressive therapy and then monthly thereafter during the treatment period. Disseminated enteroviral infection currently has no treatment, although high dose IVIG has been used, especially if myocarditis is present (ID consult required).

---

### 8.9 Human Immunodeficiency Virus (HIV)

Perinatal transmission of HIV accounted for more than 90% of pediatric HIV infections in the U.S. in prior decades; at present, it is virtually the only route of acquisition. Zidovudine therapy of selected HIV-infected pregnant women and their newborn infants reduced the risk of perinatal transmission by about two thirds. Present antiretroviral therapy for the pregnant mother with HIV infection is similar to that for non-pregnant adults (www.aidsinfo.nih.gov). The long-term effects of these drugs on a fetus is unknown and long-term follow-up of an infant is recommended. Delivery by elective cesarean section before rupture of the fetal membranes and onset of labor decreases transmission to <2% when a mother receives antiretroviral therapy.

**Treatment of Newborn Infants**

Breastfeeding should be avoided since HIV can be transmitted via breastmilk. Worldwide, an estimated one third to one half of cases of mother-to-child transmission of HIV occur as a result of breastfeeding. Infants should be bathed and cleansed of maternal secretions (particularly bloody secretions) as soon as possible after birth.

Consultation with the Retrovirology or the Allergy & Immunology Service to assist with the diagnostic evaluation and management is recommended.

- Zidovudine (AZT) should be given as soon as possible after birth to a newborn infant who is born of a mother with HIV infection whether or not she received treatment. A newborn infant whose mother’s HIV infection status is unknown should have rapid HIV antibody testing performed on the mother or the infant and the test results should be reported immediately to the physician to allow effective prophylaxis to be administered to the infant ideally within 12 hours.

- Continue treatment for the first 6 weeks of life.

**Dosage**

- **ZDV ≥ 35 weeks gestation:** 4 mg per kg body weight per dose given orally twice daily, started as soon after birth as possible and preferably within 6-12 hours of delivery or, if unable to tolerate oral agents, 3 mg per kg body weight per dose intravenously, beginning within 6-12 hours of delivery, then every 12 hours through 6 weeks of age.

---
Infants with hemodynamically significant congenital heart disease. Palivizumab does not prevent infection from RSV.

Management of RSV Infection
Patients with suspected or proven RSV (or other respiratory viral) infection are not admitted to the Newborn Center.

Indications for Use of Palivizumab
When palivizumab prophylaxis is given, it should be started within 2-3 days prior to NICU discharge or promptly after discharge. Palivizumab is continued throughout the season with injections given monthly. It does not interfere with the response to other vaccines. The maximum number of doses for a season is 5. Fewer doses could be administered to infants discharged during RSV season.—Palivizumab prophylaxis should be considered for infants:

- born <29 weeks 0 days gestation and ≤12 months at start of RSV season
- born <32 weeks, 0 days gestation with chronic lung disease (defined as needing ≥21% oxygen for first 28 days of life)

- Should receive palivizumab in 1st year of life
- Should receive palivizumab in 2nd year of life if receiving continued medical support in the form of chronic corticosteroid therapy, diuretic therapy, supplemental oxygen (bronchodilator use alone is not an indication)

- with hemodynamically significant congenital heart disease at ≤12 months of age
- in the immediate post-operative period after cardiac bypass, ECMO during RSV season and ≤24 months if would otherwise qualify due to primary diagnosis (due to mean decrease of serum palivizumab concentration of 58%)
- who are profoundly immunocompromised (e.g., s/p solid organ/hematopoietic stem cell transplantation) or s/p cardiac transplantation during RSV season and ≤24 months
- with neuromuscular disease, or a congenital airway anomaly which interferes with ability to clear airway secretions

- with cystic fibrosis with evidence of chronic lung disease/nutritional compromise and ≤12 months of age

Palivizumab prophylaxis should be discontinued (for the current RSV season) in any patient who experiences a breakthrough RSV hospitalization. This is recommended since the chance of a second hospitalization during the same season is remote (<0.5%).

Palivizumab is not recommended to prevent nosocomial RSV infection.

**Dosage**
Administer 15 mg/kg IM according to package instructions.
8.11 Rotavirus

Rotavirus infection is highly contagious and is transmitted by the fecal-oral route. In Houston, it occurs only in late winter and spring. It causes diarrhea, emesis, fever and may rarely cause abdominal distention in premature neonates, as well as NEC. Thus, in an infant with the above clinical findings, it is recommended that a stool sample be sent for examination for viral particles by electron microscopy. Other diagnostic tools include EIAs, which have high sensitivity and specificity, electrophoresis and silver staining, reverse transcriptase-polymerase chain reaction (RT-PCR) assay for detection of viral genomic RNA, and culture.

There are currently 2 licensed live attenuated vaccines: RotaTeq, RV5 and Rotarix, RV1. Rotateq is given as a 3-dose regimen; Rotarix as a 2-dose regimen; both are oral vaccines. Rotavirus immunization is recommended for all infants at the time of discharge from the hospital if they meet age criteria. The first dose should be administered between 6 weeks of age and 14 weeks 6 days. Subsequent doses are administered at intervals of 4 weeks with the maximum age for the last dose being 8 months 0 days. Latex rubber is contained in the applicator of RV1; therefore, that vaccine should not be given to any infant with risk of latex allergy (e.g., neural tube defect).

8.12 Syphilis, Congenital Evaluation

Evaluation and therapy of any infant thought to have congenital syphilis is primarily based on maternal history. By law all mothers are serologically screened for syphilis during the 3rd trimester with either a RPR or a treponemal antibody test (Syphilis IgG). If the RPR is positive, a TP-PA is done. If the mother’s 3rd trimester syphilis status is unknown when she presents for delivery, a treponemal antibody test is done upon admission to L&D. If the treponemal antibody test is positive, then an RPR is performed. If the RPR is positive, a confirmatory syphilis test is done with either a TP-PA or FTA-ABS. No infant should be discharged before the maternal serologic status is known. If the maternal RPR is positive, her documented treatment history (including diagnosis, date(s) of treatment, drug, drug dosage, and follow-up serologies) and clinical status must be determined to decide what evaluation or therapy her infant requires.

The HIV-STD Surveillance Section of the City of Houston Health Department keeps records of RPR-positive patients. This office may provide useful information on maternal therapy and prior serologies. To retrieve data, they require mother’s name(s), maternal name, alias, and date of birth. Maternal history of treatment should be confirmed, through City Health or the medical facility rendering treatment, and documented in the chart. The HIV-STD Surveillance Section, City of Houston Health Department, can be reached at 832-393-5080 or fax 832-393-5230 or 5232, from 8am to 5pm, Monday through Friday.

Next, determine if the mother’s therapy was documented and adequate to prevent congenital infection.

Adequate maternal treatment being:
- Treatment with 2.4 million units once with benzathine penicillin for primary, secondary, or early latent syphilis.
- Treatment with 2.4 million units of benzathine penicillin weekly for 3 consecutive weeks for late latent syphilis.
- During pregnancy, penicillin is the only appropriate drug. (See CDC STD guidelines for adequate non-penicillin treatment before pregnancy.)
- Treatment completed least 4 weeks before delivery.
- RPR monitored during pregnancy.
- Documented, expected serologic response (sustained fourfold or greater drop in titer; e.g., an RPR decrease from 1:16 to 1:4).

History that does not meet the preceding criteria is considered inadequate treatment and is evaluated and treated as outlined below.

Assessment

Symptomatic Infants or Infants Born to Symptomatic Mothers

Full evaluation including CBC with diff/platelets, CSF cell count, protein concentration, and CSF VDRL, x-ray of long bones; 10 to 14 days of penicillin therapy; report the case. Follow-up should be by private pediatrician or by arrangement with ID service.

Asymptomatic Infants
- Mother adequately treated more than 4 weeks prior to delivery: Infant requires RPR and TP-PA. If RPR is the same or < fourfold of the maternal titer at delivery, give a single dose, IM benzathine PCN 50,000 units/kg/dose as a single dose if mother treated during pregnancy, or if mother was treated before pregnancy and infant follow-up is uncertain. If the RPR is > fourfold of the maternal titer, consider giving 10 days of intravenous therapy. No treatment needed for infants if mother was adequately treated before pregnancy, maternal titers are low and stable, and infant follow-up is certain. Follow-up should be by private pediatrician or by arrangement with ID service.
- Mothers who were never treated, were inadequately treated, whose treatment was undocumented, were treated less than 4 weeks before delivery, were treated during pregnancy with a non-penicillin regimen, have no documentation of declining RPRs after therapy, or no documentation of RPRs, or have maternal evidence or reinfection or relapse: The infant should have a full evaluation and receive either 10 days of therapy or a single dose of IM benzathine PCN 50,000 units/kg/dose as a single dose (most experts recommend IV therapy). If any part of the evaluation is abnormal, not done, and uninterpretable or if follow-up is uncertain, the 10-day course is required. Follow-up by private pediatrician or by arrangement with ID service.
- If evaluation is abnormal, treat the baby with 10 days of IV penicillin. Follow-up by a private pediatrician or arrangement with ID service.
Biologic False-positive RPR
This diagnosis is unusual and requires documented, serial, antenatal, repeatedly low-titer RPR with a nonreactive TP-PA. If antenatal documentation is not available, the baby should be evaluated and receive at least a single dose of benzathine penicillin (since in early primary syphilis the, RPR may convert to positive before the TP-PA).

If a biologic false-positive is confirmed, the infant should have a baseline RPR and TP-PA (RPR should be low or nonreactive, TP-PA should be nonreactive) and follow-up by a private pediatrician or by arrangement with ID service.

Since IgG is transferred across the placenta, at birth the TP-PA of the baby is not diagnostic of congenital syphilis and usually reflects only the mother’s status.

Evaluation for At-Risk Infants
- Careful physical examination
- CBC with differential/platelets
- Baseline RPR and baseline TP-PA (infant sample not cord blood)
- LP for CSF VDRL, cell count, and protein
- X-rays of long bones
- Other clinically indicated tests, (e.g., ABER, CXR, CBC, UA, LFTs)

Therapy
Administer either aqueous penicillin G or procaine penicillin G as detailed below. Ampicillin is not an appropriate therapy because CSF levels cannot be sustained with ampicillin. Infants with HIV-positive status will require at least 21 days of therapy.

Dosing
Aqueous penicillin G potassium 100,000 to 150,000 units/kg per day, IV, given as 50,000 units/kg per dose for 10 days. Every 12 hours if < 7 days of life; every 8 hours if older than 1 week. Some would treat neurosyphilis with 14 days of penicillin.

Procaine penicillin G 50,000 units/kg per day, IM, as a single daily dose for 10 days.

If 24 or more hours of therapy is missed, the entire course must be restarted.

ID Consultation
Neurosyphilis or severe symptomatic syphilis warrants an ID consult. Mothers who are HIV positive or have AIDS may have variable response to syphilis therapy; therefore, their infants may be at higher risk for syphilis. ID consultation regarding therapy may be indicated.

Follow-up
Follow-up should occur at 2, 4, 6, and 12 months of age. At 2, 4, 6 and 12 months of age; repeat serum RPR testing should be done at 3, 6, and 12 months of age. Titers should have decreased by 3 months of age and become non-reactive by 6 months of age. Infants with increasing titers should be re-evaluated.

8.13 Tuberculosis
Newborns of PPD-Positive Mothers
These guidelines pertain only to term, healthy newborns. They are nursed in the Level 1 setting.

- Mothers who have been screened (by history, prenatal records, and CXR) by the OB service and deemed non-infectious are allowed contact with their infants.
- The AAP recommends continued direct breastfeeding except if mother has pulmonary TB and is contagious, untreated or treated (< 3 weeks), has multidrug resistant
tuberculosis or non-adherent to treatment. In these cases infant is isolated and mother is encouraged to provide expressed breast milk as an alternative. Breastfed infants do not require pyridoxine supplementation unless they are receiving isoniazid.

- Mothers with documentation of adequate management for TB disease or infection (prenatal records or TB Control records) and found to be noninfectious are not separated from their infants.
- All household contacts and family members who visit the nursery should be screened adequately (history of cough, night sweats, or weight loss) for historical evidence of past or present tuberculosis. Those visitors who are found to be symptomatic (possibly contagious) wear isolation attire.
- Household contacts and family members with symptoms suggestive of TB infection or disease should be referred to TB Control for placement of PPDs, chest x-ray, chemoprophylaxis, follow-up, etc.
- When the mother is found to be non-infectious and the newborn is ready for discharge, discharge is not delayed pending screening of household contacts and family members.

While congenital tuberculosis is rare, in utero infection can occur via the maternal blood stream or by aspiration/swallowing of infected amniotic fluid. In a baby with suspected infection the following should be performed: a tuberculin skin test (TST), chest radiograph, lumbar puncture, and appropriate cultures of blood, urine and CSF. Immunologic based testing that measure ex vivo interferon-gamma production from T-lymphocytes in response to stimulation is not recommended to replace the TST even though most TSTs in newborns are negative. The placenta should always be examined and cultured.

Treatment and follow-up of the infant should be guided by the infectious disease consultant.

### 8.14 Varicella-Zoster Virus (VZV) Exposure in Newborns

Approximately 90% to 95% of women of childbearing age have antibody to varicella-zoster virus (VZV). Thus, infection during pregnancy is rare, occurring in only 0.7 of 1,000 pregnancies. The incubation period (exposure to onset of rash) usually is 14 to 16 days (range 10 to 21). Most neonatal transmission of VZV is vertical; however, intrauterine infection may occur albeit rarely.

**Clinical Syndromes Varicella Embryopathy**

Varicella embryopathy occurs during the 1st or early 2nd trimester. Clinical signs include cutaneous scarring of the trunk (100%), limb hypoplasia, encephalitis with cortical atrophy (60%), low birth weight (60%), and rudimentary digits, chorioretinitis or optic atrophy, cataracts or microphthalmia, and clubfoot (30% to 40%). The risk of defects in a woman having a first trimester VZV infection is approximately 2.3%. Infants who are prenatally exposed to VZV, even if asymptomatic, may have measurable varicella-specific IgM antibody during the newborn period, have persistent varicella-specific IgG immunity after 1 year of age without a history of postnatal varicella, or demonstrate positive lymphocyte transformation in response to VZV antigen.

**Note:** Infants with intrauterine infection do not require varicella-zoster immune globulin (VariZIG).

### Perinatal Exposure

Classically, a mother’s exposure to varicella occurs in the last 2 to 3 weeks of pregnancy. Neonatal disease generally occurs during the first 10 days of life. Timing is critical.

- Maternal disease onset 6 days or more before delivery with neonatal clinical infection in the first 4 days of life. This infection is mild due to passage of maternal antibodies.
- Maternal disease onset within 5 days or less before delivery or within 48 hours of delivery allows insufficient time for the development of maternal IgG and passive transfer of antibody protection to the fetus, and is associated with neonatal clinical infection between 5 and 10 days of age. This infection can be fulminant with mortality rates of 5% to 30%. In these neonates, VZV infection may be characterized by severe pneumonia, hepatitis, or meningoencephalitis.

**Varicella-Zoster Immune Globulin (VariZIG) and Intravenous Immune Globulin (IVIG)**

Varicella-Zoster Immune Globulin (VariZIG) is a purified human immune globulin preparation made from plasma containing high levels of anti-varicella antibodies. VariZIG does not prevent varicella, though it might help to modify the clinical disease. If VariZIG is not available, IVIG may be used.

**Indications for VariZIG**

- Newborn infant of a mother who had onset of chickenpox within 5 days or less before delivery or within 48 hours after delivery.
- Exposed premature infants (28 or more weeks’ gestation) whose mother has no history of chickenpox or do not have signs of immunity.
- Exposed premature infants (less than 28 weeks’ gestation or 1000 grams or less) regardless of maternal history

Vaccination should be delayed until 5 months after VariZIG administration. Varicella vaccine is not indicated if the patient develops clinical varicella after the administration of the IVIG for post exposure prophylaxis.

VariZIG is not indicated for normal, term infants exposed to varicella including those whose mothers develop varicella more than 2 days postnatally.

Exposure is defined as contact in the same 2-to 4-bed room, adjacent in a ward, or face-to-face contact with an infectious staff member or patient with varicella.

**Dosing**

To be most effective, VariZIG should be administered within 96 hours of exposure, ideally within 48 hours. CDC recommends administration of VariZIG as soon as possible.
after exposure to varicella-zoster virus and within 10 days. The dose for term or preterm newborns is 125 units/10 kg body weight, up to a maximum of 625 units IM. Do not give VarizIG intravenously. VarizIG is lyophilized and must be reconstituted for intramuscular administration.

**Indications for IVIG**

However, if VarizIG is not available within 96 hours of exposure, intravenous immune globulin (IVIG) can be used. The recommended dose for post exposure prophylaxis is 400 mg/kg administered once. This is a consensus recommendation; no clinical data exist demonstrating effectiveness of IVIG for post exposure prophylaxis of varicella. The indications for IVIG are the same as those for VarizIG. Any patient receiving IVIG should subsequently receive varicella vaccine, provided that the vaccine is not contra-indicated. Vaccination should be delayed until 5 months after IVIG administration. Varicella vaccine is not indicated if the patient develops clinical varicella after the administration of the IVIG for post exposure prophylaxis. Any patient who receives passive immunoprophylaxis should be observed closely for signs or symptoms of varicella for 28 days after exposure because IVIG might prolong the incubation period by one or more weeks. Antiviral therapy (intravenous or oral acyclovir, oral valacyclovir, oral famciclovir) should be instituted immediately if signs or symptoms of varicella disease occur in this high-risk population. The route and duration of antiviral therapy should be determined by specific host factors, extent of infections and initial response to therapy. An Infectious Disease Service consult is recommended.

**Isolation**

Airborne and contact isolation are recommended for infants born to mothers with varicella and if still hospitalized, until 21 days of age or 28 days of age if they receive VarizIG.

**Discharge**

Infants who receive VarizIG may go home with their mothers and should be followed closely. Document a working home telephone number and involve Social Services as needed.

Infants who have not received VarizIG should be discharged home after maternal lesions have crusted over. If varicella infection is present in the household, the newborn should remain hospitalized until these lesions in household contacts are crusted over. Again, close follow-up and parental education before discharge are imperative.

**Note:** No surface cultures are necessary. No eye ointment is necessary.

---

**Routine Immunization of Hospitalized Infants**

For current recommended immunization schedules and current updates see [http://www.cdc.gov/vaccines/schedules](http://www.cdc.gov/vaccines/schedules).

---

**8.15 Zika Virus (ZIKV)**

**Background**

Zika virus (ZIKV) is a single-stranded RNA arbovirus in the *Flaviviridae* family primarily transmitted via the bite of an infected mosquito of the *Aedes* genus. Initially from Africa, it has since spread throughout Asia, Oceania, and now is in South and Central America with endemic cases being reported in the Texas-Mexico border. Most commonly, the infection is asymptomatic. However, older children and humans can have flu-like symptoms and even Guillain-Barre Syndrome associated with ZIKV infection. If a pregnant woman is infected, Congenital Zika Syndrome can occur.

**Congenital Zika Syndrome (CZS)**

Pregnant women infected with ZIKV during pregnancy can have normal fetuses. However, in some infected women, several key findings have been found to occur in their fetuses which are collectively called CZS. A neonate need not have all the symptoms to be considered CZS. The symptoms of CZS are the following:

- Microcephaly (FOC < 3rd percentile)
- Intracranial calcifications
- Ophthalmic anomalies
- Brain anomalies

The diagnosis of CZS microcephaly is made when the FOC is disproportionately small when compared to the length and weight of the neonate and not explained by other etiologies. Neonates with CZS may develop microcephaly during the first year of life. Ophthalmic anomalies include macular atrophy, hyperopia, chorioretinitis, pigment mottling of the macula, lack of foveal reflex, colobomas, and optic nerve hypoplasia.

**Evaluation**

If a neonate is born to a mother with laboratory evidence of ZIKV infection OR a neonate has clinical findings suggestive of CZS (see above) with a maternal link suggestive of possible transmission, then that neonate should undergo ZIKV screening which should include the following:

- Comprehensive physical examination
- Head ultrasound
- Standard hearing assessment (ABR)
- Laboratory testing within 2 days of birth (cord blood not recommended)
  - Zika RT-PCR of infant serum and urine
  - Infant blood for Zika virus IgM ELISA
- Consider RT-PCR and IgM testing of the CSF

A lumbar puncture is not recommended for the sole purpose of evaluating for ZIKV infection. If a lumbar puncture is obtained for other reasons, then the CSF should be sent for PCR and IgM testing for ZIKV. If the infant has negative testing of the blood and urine, then CSF testing should strongly be considered to investigate for ZIKV infection. There are documented cases of infants who have only had CSF return positive for ZIKV when blood and urine were both negative. Depending upon the results of these tests, the neonate should receive further evaluations and follow up per the Zika screening guidelines.

- Consider storing the placenta, which may be required for potential histopathological evaluation for ZIKV pending infant's testing
Breastfeeding Recommendations
Of note, although ZIKV has been detected in breast milk, there have been no reported cases describing transmission of ZIKV through breastfeeding. Therefore, the CDC currently continues to recommend that women who have been diagnosed with ZIKV infection can still breastfeed their infants as the benefits outweigh the risks.

Treatment
Although many different therapies are under investigation, there are currently no FDA recommended therapies for the treatment of CZS in affected neonates.

Isolation
Routine universal precautions should be followed for patients with confirmed or suspected CZS. It is not necessary at this time to use contact precautions if the only concern is for CZS.

Discharge and Follow-Up
Referral to the Infectious Diseases Zika Clinic at Texas Children’s Hospital is recommended. This specialty clinic will help facilitate multidisciplinary follow up and coordination of subspecialty follow up care.

*Maternal link includes the following:
• travel to an area that is known to have endemic ZIKV cases, or
• sexual activity with an individual who has traveled to an area known to have endemic ZIKV cases

Suggested Readings/References
Bacterial Sepsis

Group B Streptococcal References

Cytomegalovirus References

Fungal Infection References

Gonococcal Disease References

Hepatitis B References

Herpes Simplex References

HIV References


Syphilis References

TB References

Varicella Zoster Virus References

Zika References

Section 9: Neurology
Editors: Christopher J. Rhee and Mufeed Ashraf

9.1 Encephalopathy ...........................................122
    Ashley Lucke
    Christopher J. Rhee

9.2 Seizures ................................................... 124
    Simon Yousef Kayyal
    Emily Rodman

9.3 Cerebral Hemorrhage and Infarction ........ 126
    Leah I. Elizondo
    Christopher J. Rhee

9.4 Neural Tube Defects ....................................128
    Ashley Lucke
    Christopher J. Rhee

9.5 Drug-Exposed Infants ................................. 129
    Mayra Freeman-Ladd
    Lisa Owens
    Jennifer Placencia

9.6 Pain Assessment and Management .............. 132
    Jennifer Placencia
    Emily Rodman

9.7 Vein of Galen ........................................... 134
    Ashley Lucke
    Christopher J. Rhee
9.1 Encephalopathy

A diagnosis of neonatal encephalopathy may be considered when an infant has both a change in mental status and an abnormal neurological examination. Alterations in mental status include hyperalertness, drowsiness, stupor, or even coma. Common neurological findings include abnormal tone (increased or decreased), seizures, non-habituating primitive reflexes, tremors, apnea, weak suck, and sometimes a bulging fontanel. The modified Sarnat classification (Table 9–1) is the tool most frequently used to describe the severity of encephalopathy and is most appropriate for infants with hypoxic-ischemic encephalopathy (HIE).

Neonatal encephalopathy may be seen in infants with:
- Metabolic abnormalities (hypocalcemia, hypoglycemia)
- Toxins (hyperammonemia, kernicterus)
- Inborn errors of metabolism
- Intracranial hemorrhage
- Cerebral infarction
- CNS developmental anomalies (holoprosencephaly)
- Infections (sepsis, meningitis, CNS TORCH infection)
- HIE

The cause of the encephalopathy is not always immediately known, and automatically ascribing it to HIE is not appropriate. However, certain peripartum scenarios (placental abruption, severe fetomaternal hemorrhage, maternal hypotension/shock, prolonged labor, multiple births, chorioamnionitis, placental insufficiency, IUGR) may place a newborn at increased risk for hypoxia-ischemia. Infants with hypoxic-ischemic injury severe enough to cause neurologic sequelae usually are severely depressed at birth (Apgar score ≤3 at 5 minutes of life), exhibit a significant acidosis (pH <7 in cord arterial blood), and have evidence of injury to other organs (pulmonary, renal, hepatic, cardiac, bowel, bone marrow) along with the encephalopathy. Up to 10% of infants with HIE may not exhibit obvious multi-organ injury, even though encephalopathy may be severe.

Evaluation

Evaluation of an infant presenting with encephalopathy includes an in-depth history and a complete neurologic examination. Sequential neurologic examinations should be performed to assess what often is an evolving encephalopathic picture. The maximum Sarnat stage reached by an infant can provide prognostic information. In addition, the worst Sarnat staging of a properly conducted exam will be used to inform the need to initiate therapeutic hypothermia. The initial neurologic evaluation also includes initiation of continuous video EEG at admission (continues through rewarming) and MRI with spectroscopy at 5–6 days of life.

A head ultrasound (HUS) with resistive indices (in EPIC, type “include resistive indices” in order comments) should also be performed to rule out severe intracranial hemorrhage and should be performed 8–12 hours after initiation of cooling.

Additional evaluation upon admission includes CBC with differential and platelets, lumbar puncture, blood culture, blood glucose, calcium, magnesium, and electrolytes.

<table>
<thead>
<tr>
<th>Category</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of Consciousness</td>
<td>Irritable or hyperalert</td>
<td>Lethargic</td>
<td>Stupor or coma</td>
</tr>
<tr>
<td>Spontaneous Activity</td>
<td>Increased movements, jittery</td>
<td>Decreased activity</td>
<td>No activity</td>
</tr>
<tr>
<td>Posture</td>
<td>Mild distal flexion</td>
<td>Strong distal flexion</td>
<td>Decerebrate/extension</td>
</tr>
<tr>
<td>Tone</td>
<td>Normal/ Slightly Increased</td>
<td>Hypotonia</td>
<td>Flaccid</td>
</tr>
<tr>
<td>Primitive Reflexes:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suck</td>
<td>Uncoordinated /Biting</td>
<td>Weak/ Unsustained</td>
<td>Absent</td>
</tr>
<tr>
<td>Moro</td>
<td>Exaggerated</td>
<td>Incomplete</td>
<td>Absent</td>
</tr>
<tr>
<td>Autonomic System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pupils</td>
<td>Dilated</td>
<td>Constricted</td>
<td>Deviated, Non-reactive to light</td>
</tr>
<tr>
<td>Heart Rate</td>
<td>Tachycardia</td>
<td>Bradycardia</td>
<td>Varies widely*</td>
</tr>
</tbody>
</table>

*Heart rate shows wide variations between <100 and >120

Only newborns with moderate-to-severe encephalopathy should receive therapeutic hypothermia.


Depending upon the history and presentation, additional indicated studies may include blood ammonia level, serum and CSF lactate levels, serum and CSF amino acids, urine organic acids, and troponin I level.

An evaluation of the placenta should be requested from pathology as it may indicate infectious or clotting issues which may be involved in the etiology of the encephalopathy.

If a hypoxic-ischemic etiology is strongly suspected, baseline hepatic and renal assessment, as well as an echocardiogram can be useful.

If the infant’s primary problems are hypotonia, respiratory depression, or both, spinal cord injury and neuromuscular diseases need to be considered.

Intervention/Therapies

Usual care for neonatal HIE is supportive intensive care which includes correcting metabolic and electrolyte disturbances, stabilizing pulmonary and hemodynamic instability, treating seizures, and monitoring other organ systems for dysfunction. Eleven international multicenter randomized clinical trials including 1,505 infants investigated the safety and efficacy of therapeutic hypothermia as a therapy for HIE in newborns ≥35 weeks’ gestation. Per the Cochrane review, therapeutic hypothermia if begun within 6 hours of birth, resulted in reduction in the mortality and/or major neurodevelopmental disability. The first trial, the CoolCap Study, which employed selected head cooling and used amplitude-integrated EEG (aEEG) abnormalities as entrance criteria, showed improved survival without severe disability (once newborns with severe
aEEG abnormalities were excluded). The NICHD trial, using whole body hypothermia, also found improved survival without severe disability in treated infants at 18 months of age. Importantly, benefits observed at 18–22 months of age persist to early school age, as shown in the CoolCap and NICHD follow-up trials. An expert panel convened by the NICHD concluded that therapeutic hypothermia, if offered, needs to be performed using a rigorous set of criteria and a published protocol.

Therapeutic hypothermia is available in the TCH NICU. Infants must meet biochemical and physical exam criteria to receive therapeutic hypothermia (strong recommendation, high quality evidence).

**Treatment Criteria for Whole Body Cooling**

1. \( \geq 35 \) weeks’ gestation,

   AND

2. Biochemical evidence of a hypoxic-ischemic event:
   a) \( \text{pH} \leq 7.00 \) or base deficit \( \geq 16 \text{ mmol/L} \) on cord gas or within first hour of life (in any blood sample),

   OR

   b) if no blood gas, or \( \text{pH} \geq 7.01–7.15 \), or base deficit between 10 and 15.9 \( \text{mmol/L} \); presence of an acute perinatal event (e.g. late or variable decelerations, cord prolapse, cord rupture, uterine rupture, maternal trauma, hemorrhage, or cardiorespiratory arrest) and an Apgar score \( \leq 5 \) at 10 minutes of age or assisted ventilation at birth and continued for \( \geq 10 \) minutes,

   AND

3. Evidence of moderate-to-severe encephalopathy: seizures or the presence of 1 or more signs in at least 3 of the following 6 Sarnat categories for moderate or severe encephalopathy (level of consciousness, spontaneous activity, posture, tone, primitive reflexes [suck or Moro], and autonomic nervous system [pupils, heart rate, or respiration]). Mark “severe” encephalopathy if seizures are present or if there are more signs and symptoms in the severe than the moderate column. If the signs and symptoms are equally distributed between severe and moderate columns, the severity is based on the level of consciousness (Table 9-1).

Cooling should be initiated within 6 hours of birth (including passive cooling). Passive cooling should be initiated at the referral hospital after the infant has been determined to be a candidate for therapeutic hypothermia, by having all heat sources removed from the infant. It is critical to tell the referring care providers to monitor temperature every 15 minutes, and if the temperature goes \( <33.5^\circ \text{C} \), to turn on the radiant warmer until the transport team arrives to prevent overcooling. Active servo-controlled therapeutic hypothermia (with continuous rectal temperature) will be used during transport from the referral hospital to the TCH NICU unless infants are transferred from hospitals within the Texas Medical Center (since infants from nearby hospitals may be better served by getting to TCH as soon as possible to receive the definitive therapy instead of taking the time to initiate active cooling). For inborn infants (born at the Pavilion for Women), if the determination is made that a newborn is a candidate for therapeutic hypothermia, then passive cooling should be initiated, and the infant transported to the TCH Level 4 NICU.

In the TCH NICU cooling and rewarming is done according to specific protocols (refer to nursing bedside manual for complete details of process). Infants are cooled to 33.5°C (33–34°C) esophageal core body temperature for 72 hours using a servo-controlled cooling blanket system. The incubator or radiant warmer heat source is turned off throughout the procedure. Pediatric Neurology Service should be contacted for initiation of continuous bedside EEG. It is desirable to have arterial and central venous access during cooling, if possible. Low-dose morphine should be used to prevent agitation or shivering that occurs during therapeutic hypothermia.

During rewarming esophageal and skin temperature is monitored continuously. Rewarming is done slowly with 0.5°C increases in servo “set temp” every hour until set point reaches 36.5°C for 1 hour. Then the radiant warmer is turned on with servo set point 0.4°C above the infant’s skin temperature. When the skin temperature reaches 36.5–37°C, the infant is returned to standard NICU temperature control care. Infants receiving whole body cooling will receive a Pediatric Neurology consult. Follow-up post-hospitalization will include a Neurology clinic visit and referral to the TCH Meyer Developmental Center clinic.

**TCH Total Body Cooling Protocol**

Please refer to bedside manual for complete details of cooling process.

- Have cooling blanket ready on the radiant warmer
- Core body temperature measured by esophageal temperature probe with placement confirmed by CXR to be located at 2/3 the distance of the esophagus
- Use order set: IP NEO THERAPEUTIC HYPOTHERMIA ADMISSION (EPIC)
- Therapeutic hypothermia for 72 hours
- All external heat sources turned off
- Desired patient temperature is set at 33.5°C with goal temperature 33–34°C
- Vital signs and urine output recorded every hour
- Total fluid goal (including medications and flushes) on day 1 of 40–45 ml/kg/day (do not give fluid boluses simply for low urine output). For day 2–3 fluid guidelines, see Nutrition chapter.
- NPO during cooling and rewarming
- Use the HIE Admission H&P note template “NEO IP NEO H&P (EPIC) and record initial and daily Sarnat stage (dot phrase: “Sarnat”) in the History and Physical and daily progress notes
- Neurologic assessment every hour until goal patient temperature achieved, then every 4 hours
• Continuous video EEG initiated immediately on admission
• Morphine drip (load with 0.1 mg/kg and then begin at 0.01 mg/kg/hour and adjust dose to limit shivering (maximum dose 0.03 mg/kg/hour) for the entire 72 hours of cooling
• Cranial ultrasound (with resistive index) at 8–12 hours after initiation of cooling
• Reposition infant every 2 hours while cooled to prevent skin breakdown
• Recommended labs to be drawn during cooling (or more often as needed):
  » Glucose: on admission, then every hour x 6 hours, then every 12 hours x 2, then daily x 4 days
  » CBC with differential and PLT: on admission, then daily x 3 days
  » Strongly consider infection as a cause of encephalopathy and obtain a blood culture on admission (if not collected at the referral hospital) and begin antibiotics
  » PT, PTT, fibrinogen: on admission, then daily x 3 days
  » Chem10, ionized calcium: on admission, then daily x 3 days
  » Arterial blood gases: on admission, then every 6 hours x 4, then every 12 hours x 2, and then daily x 3 days (or more frequently as needed)
  » LFTs: on admission and then daily for 3 days
  » Rewarming begins after 72 hours to increase temperature 0.5°C every hour until goal temperature of 36.5°C
  » Schedule neonatal brain MRI (including spectroscopy) for day 5–6 (NO CONTRAST)

Outcomes
The outcome of neonatal encephalopathy depends upon the etiology. In infants with encephalopathy due to a metabolic disorder, outcome will be related to the specific disorder. Similarly, outcome of encephalopathy related to an infectious etiology will depend upon the specific infection. If encephalopathy is due to hypoxic-ischemic injury, outcome is good if the infant has an EEG and a neurologic exam that are normal by 7 days of age. Outcomes also can be related to maximum Sarnat stage reached which is an indication of the severity of the neonatal encephalopathy. Long-term developmental and neurologic follow-up is indicated in all cases of neonatal encephalopathy. Outcome studies from the major cooling trials have indicated that whole body hypothermia is safe, is associated with improved survival and reduced severe neurodevelopmental disability at 18 months, and the benefits noted at 18 months persist to early school age. Infants receiving whole body cooling should be referred to the TCH Desmond Developmental Center for long-term follow up and to the Pediatric Neurology Clinic. If admitted to the Woodlands campus, developmental and neurologic follow-up should occur in the Woodlands.

9.2 Seizures
Overview and Pathogenesis
A seizure results from an abnormal, synchronous discharge of a population of neurons. This discharge is the result of a failure of neuronal ATP-dependent sodium-potassium pumps leading to cell depolarization. Since energy is required to power the pump, a deficiency in cerebral energy substrates (glucose and oxygen) can lead to seizure activity. Increased availability of glutamate (an excitatory neurotransmitter) with hypoxemia, ischemia, and/or hypoglycemia can also lead to seizures. Deficit of inhibitory neurotransmitters (e.g., pyridoxine dependency) is another cause of neonatal seizures. Finally, membrane alterations leading to increased sodium permeability (e.g., hypocalcemia and hypomagnesemia) can lead to neonatal seizures.

Neonates are especially prone to seizures because the mechanisms that lead to the inhibition of seizure activity are not yet fully developed. Neonatal seizures appear clinically different than seizures in children and adults due to this immaturity. Further, seizures do not progress as they do in older individuals because dendritic/axonal branching and synaptic connections are not fully developed. Since myelination is also not yet complete in cortical efferent systems, seizures may occur without motor manifestations. These types of seizures are often referred to as subclinical seizures (or electrographic seizures); seizures that appear on an EEG without overt clinical manifestations.

The short-term result of a prolonged seizure, due to decreased ATP, release of excitatory amino acids, and cardiopulmonary compromise is neuronal death. Further, recurrent neonatal seizures can render the brain more susceptible to the development of epilepsy later in life. The long-term effects of recurrent seizures are altered neurodevelopment. Thus, prompt identification and immediate treatment of seizures is important.

Diagnosis
The diagnosis of neonatal seizures depends on the ability to accurately recognize them. The most common etiologies of neonatal seizures are listed in Table 9-2. Seizures can be categorized as: subtle, clonic, tonic, and myoclonic. Subtle seizures are simply motor or autonomic changes that are not better described as clonic, tonic, or myoclonic seizures. Examples of subtle seizures include sustained opening of the eyes with fixation, chewing, pedaling motions, and apnea. An EEG is helpful in determining if episodes concerning for seizures are epileptic or non-epileptic. Clonic seizures can be focal or multifocal and involve rhythmic jerks, usually 1–3 jerks per second, with the rate declining with progression of the seizure. Tonic seizures can be focal, multifocal, or generalized, and involve sustained posturing of a limb or tonic extension of extremities. Myoclonic seizures are best described as sudden jerks of muscle groups and can be focal, multifocal, or generalized. Myoclonic seizures can be distinguished from clonic seizures because of the faster speed of the myoclonic jerk and predilection for flexor muscle groups.

Neonatal seizures should be distinguished from jitteriness which is non-epileptic activity. Jitteriness can appear as tremor-like movements and can be secondary to anoxic brain
Injury, drug withdrawal, or electrolyte abnormalities. Unlike neonatal seizures, jitteriness usually does not involve an abnormality of gaze or eye movement, and the movements in jitteriness are usually exquisitely stimulus-sensitive and can be stopped with passive flexion.

**Work-up**

The work-up and management of neonatal seizures begins with the H&P. Information provided in the H&P should help in narrowing down the differential diagnosis, and thus dictate the proper work-up. It is imperative that the work-up include evaluation of easily treatable (and reversible) conditions, such as hypoglycemia, electrolyte disturbances, and infectious meningitis/encephalitis. Thus, a typical work-up for neonatal seizures includes:

- Serum glucose, sodium, potassium, calcium, phosphorous, and magnesium
- CSF with cell count and differential, gram stain, culture, protein, and glucose

An EEG will be useful in determining whether “abnormal movements” are associated with electrographic seizures. Importantly, treatment of suspected epileptic activity should not be delayed until an EEG is performed. An EEG will also be useful in identifying subclinical seizures in those receiving neuromuscular blockade. Finally, an EEG is useful in defining the interictal background features which are of value in estimating prognosis.

An MRI of the brain should also be obtained to assess for epileptogenic lesions (areas of anoxic brain injury, cortical malformations, disorders of neuronal migration, etc.). If there is concern for anoxic brain injury, spectroscopy should also be performed. Also, a cranial ultrasound can detect major intracranial hemorrhages and structural abnormalities, but may not detect superficial cortical hemorrhage, such as subarachnoid bleeding.

If the above work-up fails to identify the etiology of neonatal seizures, then specific serum, urine, and CSF tests should be performed (e.g., serum amino acids and urine organic acids) to rule out inborn errors of metabolism or genetic conditions.

**Treatment**

**Initial Treatment**

Securing the airway and providing adequate oxygenation and ventilation, as well as cardiovascular and metabolic support, are crucial in the management of an infant with seizures. Appropriate antibiotic therapy should be initiated if infection is suspected, and metabolic derangements corrected, if present:

- **Hypoglycemia** – (Ch 5.4 Hypoglycemia)
- **Hypocalcemia** – (Ch Sec 13.4 Hypocalcemia)

Recurrent seizures that are not immediately due to correctable causes warrant the prompt use of an anti-epileptic drug (AED). The optimal AED for neonatal seizures is unknown. Published studies comparing phenobarbital to phenytoin as initial therapy did not show any difference in efficacy. However, because phenytoin has a very narrow therapeutic range (levels need to be measured frequently) as well as the concerns for cardiotoxicity with Fosphenytoin, it is recommended to use phenobarbital as the initial drug of choice. If treatment with phenobarbital does not eradicate seizures, an additional drug may be considered. If the infant is clinically stable and the seizures are brief and/or infrequent, the addition of another drug may carry higher risks than the seizures per se.

The suggested order of drug therapy for the acute management of neonatal seizures is listed below:

- **First-line: Phenobarbital** (strong recommendation, very low quality evidence): 20 mg/kg given intravenously at a rate of 1–2 mg/kg/min. Two additional 10 mg/kg doses (total phenobarbital dose of 40 mg/kg) can be given, if needed. Obtain a level 2 hours after the loading dose. The desired phenobarbital level is 20–40 mcg/mL. Be aware of respiratory depression associated with administration of phenobarbital that may warrant intubation.

- **Second-line: Lorazepam** (weak recommendation, very low quality evidence): given as an initial intravenous bolus of 0.1 mg/kg. An additional intravenous bolus dose of 0.1–0.15 mg/kg can be given 15–30 minutes later, while awaiting other AEDs. Respiratory depression necessitating intubation may occur.
Second-line: Fosphenytoin (weak recommendation, very low quality evidence): 20 mg/kg given intravenously at a rate of 0.5–1 mg/kg/min. Obtain a level 2 hours after the loading dose. The desired total phenytoin level is 15–20 mcg/mL (must adjust for albumin level). Hypotension and cardiac arrhythmias have occurred with Fosphenytoin administration.

First or Second-line: Levetiracetam (strong recommendation, very low quality evidence): 20–40 mg/kg given intravenously at a rate of 2–5 mcg/kg/minute. Levetiracetam can be considered as a first-line agent for patient who is not in status epilepticus (i.e. do not have clustering of seizures or have seizures lasting > 5 minutes). For patients in status epilepticus, phenobarbital should be used as the first-line abortive agent. It should be noted that there are no randomized clinical trials evaluating the efficacy or safety of Levetiracetam (Keppra®). However, Keppra® has a well-tolerated safety profile that includes low protein binding and no drug-to-drug interactions. Case series have suggested the safety of levetiracetam in neonates and animal models as it does not cause neuronal apoptosis in the immature brain. Efficacy data has also been encouraging. Maintenance dosing with levetiracetam can be used at 20–60 mg/kg/day divided three times daily.

Pyridoxine (strong recommendation, very low quality of evidence): Pyridoxine-dependent epilepsy is an inborn error of metabolism that is characterized by recurrent seizures in the neonatal period that do not respond to conventional AEDs but respond to pyridoxine (Vitamin B6). If pyridoxine-dependent epilepsy remains in the differential in an acutely seizing infant, it is reasonable to provide IV doses of pyridoxine (1–5 doses of 100 mg (there is a risk for respiratory failure) followed by maintenance dosing of oral pyridoxine at 15–30 mg/kg/day or up to 200 mg/day in neonates. Treatment with oral pyridoxine should be continued until negative biochemical or genetic testing excludes pyridoxine-dependent epilepsy. It is important to discontinue pyridoxine when no longer needed given that the side effect of long-term use is peripheral neuropathy.

Outcome and Duration of Treatment
Because etiology may be the most important factor that determines neurodevelopmental outcome, it is not clear if treating the actual neonatal seizure decreases the risk for poor outcome. Two Cochrane reviews raised doubts about the benefits of treating each seizure. The first review in 2001, updated in 2004, concluded that, “at present there is little evidence from randomized controlled trials to support the use of any of the anticonvulsants currently used in the neonatal period.” The second review in 2007 concluded that, “at the present time, AEDs given to term infants in the immediate period following perinatal asphyxia cannot be recommended for routine clinical practice, other than in the treatment of prolonged or frequent clinical seizures.” In addition, there is a growing body of data from animal models of seizures that certain AEDs used to treat neonatal seizures may produce widespread neuronal apoptosis. Given the lack of sufficient evidence for improved neurodevelopmental outcome and the potential for additional brain injury with anticonvulsant therapy, care should be exercised in selecting which infants warrant treatment.

Although duration of therapy depends on the underlying illness and the physical examination, it is recommended that ongoing treatment be limited to 1 agent, if possible, and be administered for the shortest possible time period.

9.3 Cerebral Hemorrhage and Infarction
Periventricular, Intraventricular Hemorrhage (PIVH)
Periventricular, intraventricular hemorrhage (PIVH) is 1 of 2 major neuropathologies of prematurity and is a major cause of death in premature infants. The overall frequency of PIVH has remained constant over the past 10 years and is reported to affect approximately 28% of all VLBW infants. Because no epidemiological data are available, the true incidence in the US is unknown. The severity of PIVH is inversely proportional to gestational age and birth weight, occurring in 40% of infants with birth weight 500–750 g compared to 20% of infants 1001–1250 g. Approximately 50% of PIVH occurs within the first postnatal day, and virtually all occurs within 1 week of birth. Because the majority of babies who incur PIVH are asymptomatic, screening with HUS is routinely practiced.

The pathogenesis of PIVH is poorly understood, but is thought to encompass intravascular, vascular and extravascular factors. Intravascular factors include fluctuating systemic blood pressure, an increase or decrease in cerebral blood flow, an increase in cerebral venous pressure and platelet and coagulation disturbance. Vascular factors include the tenuous integrity of the germinal vascular bed and its vulnerability to hypoxic-ischemic injury. Extravascular factors include the excessive fibrinolytic activity that is present in the germinal matrix.

The site of the majority of PIVH is the subependymal germinal matrix, a primitive vascular network that is most prominent between 28 and 34 weeks gestation and which involutes by term gestation.

PIVH is classically graded as I to IV:
- **Grade I** – hemorrhage contained within the germinal matrix.
- **Grade II** – IVH with no ventricular dilatation/distension.
- **Grade III** – IVH with ventricular dilatation/distension.
- **Grade IV** – parenchymal hemorrhage. This lesion is rarely bilateral and often is referred to as a periventricular hemorrhagic infarction (PHI).

The risk of PIVH in term infants is low (<1% of live births) and the hemorrhage usually originates from either the choroid plexus or the germinal matrix overlying the roof of the fourth ventricle.

Notable sequelae of PIVH are post-hemorrhagic hydrocephalus (PHH) and porencephaly. PHH occurs in approximately 25% of infants with PIVH, while porencephaly is noted in 5–10%, all of whom incurred a grade IV PIVH.
It is recommended that all premature infants \(<30\) weeks’ gestation undergo a screening HUS at \(7–10\) days of age (strong recommendation, moderate quality evidence). If ventricular dilatation is noted, serial HUSs at weekly intervals are warranted to ascertain if ventricular dilatation is static or progressive. If ventricular dilatation is not noted on the initial scan and there are no extenuating reasons to do a repeat HUS sooner, a follow up HUS at \(36–40\) weeks postmenstrual age is recommended. A brain MRI to delineate the presence and extent of periventricular leukomalacia (PVL) is preferable to the HUS, if it can be obtained without having to heavily sedate the infant.

The management of PHH is aimed at maintaining low intracranial pressure and normal perfusion of the brain, as well as decreasing axonal stretch during early development. Repeated lumbar or ventricular punctures have not been shown to arrest the development of symptomatic hydrocephalus. Because elevated protein levels and high red blood cell counts in the ventricular fluid, as well as small infant size, are associated with an increased risk of shunt obstruction, several temporizing measures have been employed, including the placement of continuous external ventricular drainage, implantation of a ventricular access device to allow intermittent safe ventricular drainage (reservoir), or creation of a temporizing shunt construct draining fluid into the subgaleal space. Ventricular access devices and ventriculo-subgaleal shunts have unique advantages and disadvantages but are superior to continuous external drainage because of the high rate of ventriculitis associated with the latter. The decision regarding the need for a shunt usually is delayed until the protein content in the ventricular fluid has decreased and an infant weighs approximately \(1500\) g.

Mortality in infants with severe PIVH (grade III–IV) is about \(20\%\). In infants with grade IV PIVH, \(>50\%\) of survivors develop PHH. Long-term outcome depends both on the severity of the IVH and associated white matter lesions.

**Periventricular Leukomalacia (PVL)**

PVL is the most common neuropathology of prematurity. Unlike Grade IV PIVH, a lesion that is unilateral, PVL is symmetrical. The spectrum of PVL ranges from large cystic lesions located at the external angles of the lateral ventricles to microscopic areas of focal necrosis scattered throughout the deep cortical white matter.

The overall frequency of PVL is unknown, because the vast majority of the lesions cannot be detected with commonly used cranial imaging techniques. Studies using sophisticated MRI techniques suggest that \(70\%\) of premature infants have some degree of PVL with \(20\%\) having moderate to severe lesions. The pathogenesis of PVL is poorly understood but is thought to involve multiple interacting pathways operating to injure the immature white matter. Risk factors for PVL include twin gestation, nosocomial infection, PIVH, PDA, and NEC. In addition, late preterm infants who undergo cardiac surgery and those with congenital diaphragmatic hernias are at increased risk. The optimal time to screen for PVL is at \(36–40\) weeks’ postmenstrual age. As stated above, a brain MRI to delineate the presence and extent of PVL is preferable to the HUS if it can be obtained without having to heavily sedate the infant. The hallmark of PVL is spastic diplegia; however, long-term outcome depends on the extent of PVL and any associated lesions.

**Perinatal and Neonatal Stroke (term and near-term infant)**

The term “perinatal stroke” describes localized or multifocal infarction/ necrosis within an area of cerebral vascular distribution that may occur between \(20\) weeks’ gestation and \(28\) days after birth. Approximately \(80\%\) of these are ischemic in origin, with the remainder due to cerebral venous thrombosis or hemorrhage. Causes include vascular malformations, coagulopathies, prothrombotic disorders, trauma, infections and embolic phenomenon. The broader category of “intracranial hemorrhage” shares many of the same etiologies. Perinatal stroke mostly occurs in term or near term infants and the definition excludes the spectrum of SEH-IVH in preterm infants. The lesions are prone to cavitation within the brain and are a common cause of cerebral palsy in term and near term infants.

Estimated incidence of perinatal stroke is \(1\) in \(2,300–5,000\) births. The infarction may be either arterio-ischemic or veno-occlusive in nature. Arterial infarctions are typically unilateral and appear as wedged-shaped lesions in the distribution of the anterior, middle and/or posterior cerebral artery with approximately \(60\%\) occurring in the area of the left middle cerebral artery. Venous infarctions usually are located in deep cortical grey matter, specifically the thalamus. Infants commonly present with seizures, apnea or poor feeding in the early neonatal period but may be asymptomatic. Perinatal and birth history is often unremarkable. Prompt diagnostic workup is important because antithrombotic therapy may be appropriate in selected circumstances.

MRI is the imaging modality of choice but CT may be more accessible in the acute setting. Detailed family history and pathologic examination of placenta and umbilical cord is recommended. Additional work up depends upon clinical circumstances but usually includes EEG and Neurology Service consultation. Evaluation for infection may be indicated. No consensus exists regarding routine evaluation for coagulopathies and prothrombotic disorders. Cost/benefit ratio of such testing has not been established. In neonates with stroke, consideration should be given to Hematology Service consultation to help determine appropriate patients for selective studies or intervention.

A clinical guideline for diagnosis and management of ischemic stroke in children has been developed by the TCH Evidence-Based Outcomes Center and is available on the physician web site. Though informative, this guideline excludes patients \(<1\) month of age.

Published outcome studies suggest that approximately half of affected infants will have a major disability. The most common abnormality is hemiplegia and/or motor asymmetry. Approximately a third of the infants have a deficit in vision, usually a field cut, and about \(15\%\) will develop seizures. The outcome for an infant depends on the type, extent and location of the lesion.

**Traumatic Birth Injuries (Nervous System)**

Trauma to the head, nerves, and spinal cord can be divided into extracranial hemorrhage (cephalohematoma and subgaleal), intracranial hemorrhage (subarachnoid, epidural, subdural, cerebral and cerebellar), nerve injury (facial,
cervical nerve roots including brachial plexus palsy, phrenic nerve injury, Horner syndrome and recurrent laryngeal injury), and spinal cord injury. Potential causes include a rigid birth canal, a large baby relative to the size of the birth canal, abnormal fetal presentation (breech, face, brow, and transverse lie) and instrumented deliveries. Caesarean delivery does not eliminate the risk of trauma, especially if vaginal delivery with forceps and/or vacuum extraction was attempted before delivery.

**Head Trauma**

Cephalohematoma (Ch 10.5-Extracranial Swelling)

Skull Fractures (Ch 10.8-Neuromusculoskeletal)

Subgaleal Hemorrhage (Ch 10.5-Extracranial Swelling.)

Intracranial Hemorrhages

Intracranial hemorrhage is rare but can be seen with vacuum extraction or forceps assisted delivery. The incidence ranges from 1 in 600–1000 live births. The types of hemorrhage include epidural, subdural, subarachnoid, and to a lesser extent intraventricular and/or intraparenchymal.

The clinical presentation is variable and depends on the type, location, and extent of the hemorrhage. For infants with signs of increased intracranial pressure (full fontanel, hypertension, bradycardia, and irregular breathing) close observation for signs of herniation is warranted, and a neurosurgical consult obtained if decompression is needed.

Brachial Palsies and Phrenic Nerve Injury (Ch 10.8 Neuromusculoskeletal.)

**Spinal Cord Injury**

Spinal cord injury can be caused by excessive traction or torsion during delivery. Infants with spinal cord injury usually are delivered by breech extraction or require mid-forceps application. Rarely, spinal cord injury can result from vascular occlusion of the spinal cord after umbilical catheterization or from venous air embolism.

Clinical presentation includes respiratory failure, weakness, and hypotonia. Neurologic signs may include:

- paralysis with areflexia in the lower extremities and variable involvement of the upper extremities depending on the level of injury,
- diaphragmatic breathing,
- presence of a sensory level,
- distended bladder,
- patulous anus, and
- Horner syndrome

Later findings include the development of spasticity and hyperreflexia. Formal imaging should include spinal MRI, though ultrasound and spine radiographs can be used to rule out surgical lesions such as hematomas or dysraphisms.

Treatment is primarily supportive and includes mechanical ventilation, maintenance of body temperature, bowel and bladder care, prevention of infection, and appropriate physical therapy.

At the time of initial presentation, stabilization of head and neck while consulting a neurosurgeon and neuroradiologist is mandatory to avoid worsening of the injury.

**Outcome**

Outcome is related to the persistence of neurologic signs during the first few postnatal days. Infants exhibiting some spontaneous respiratory effort by 24 hours have a good chance of having independent daytime breathing and good motor function.

### 9.4 Neural Tube Defects

Neural tube defects (NTD) are among the most common birth defects, ranking second after congenital heart disease. The etiology of NTDs is unknown and most cases are isolated. NTDs can occur as part of syndromes either in association with chromosomal abnormalities or because of environmental factors. The incidence of NTDs is reduced by folic acid supplementation before and during pregnancy. NTDs encompass a spectrum of malformations that include anencephaly, encephalocele, meningomyelecele, and spina bifida occulta, the latter being the most common and least severe of NTDs. Anencephaly is characterized by the absence of the cranial vault, as well as part or most of the cerebral hemispheres. An encephalocele is a hernia of part of the brain and the meninges through a skull defect, usually in the occipital area. Spina bifida is a defect in the vertebral column through which the spinal cord and the meninges might herniate creating a meningomyelecele.

**Meningomyelecele**

The incidence of meningomyelecele in the US is 0.2–0.4/1000 live births. The Eastern and Southern regions have higher incidences than the West and females are more affected than males. The recurrence risk is 1.5–3% with 1 affected sibling and 5.7–12% with 2 affected siblings. Associated anomalies include hydrocephalus, Chiari II malformation, hydrosyringomyelia, or spinal arachnoid cyst.

Nerve damage can continue postnataally, if the lesion is not managed appropriately.

**Prenatal Surgery**

A multicenter, randomized controlled trial of prenatal vs. postnatal repair of myelomeningocele demonstrated that prenatal surgery reduced the need for shunting, improved motor outcomes and neurocognitive function at 30 months when surgery was performed <26 weeks' gestation. The greatest benefit was seen in neonates with ventricle size <10mm at the time of fetal repair. The trial was stopped for efficacy of prenatal surgery. However, the prenatal surgery was associated with maternal risks (placental abruption, spontaneous rupture of membranes and uterine dehiscence) and fetal risks (preterm delivery, RDS and apnea). This surgery is currently available in the TCH Fetal Center (strong recommendation, high quality evidence).
Immediate Management

- Avoid latex gloves at all times.
- Place the infant in the prone position immediately after delivery to avoid traumatic injury to the defect and spinal cord.
- Cover the lesion with non-adhesive gauze wet with sterile Ringer’s Lactate or saline and plastic wrap to create a barrier from the environment and decrease fluid loss.
- Notify the neurosurgical service.
- Amoxicillin is recommended (10 mg/kg/day) for UTI prophylaxis.
- Infants who require resuscitation at delivery and need to be supine should be placed on a doughnut shaped cushion to support the defect.

Evaluation

The infant should be examined thoroughly with emphasis on the neurologic examination (spontaneous movement, muscle strength, sensory level, deep tendon reflexes, and anocutaneous reflex). Imaging studies are needed to ascertain the level of the defect and any associated anomalies (hydrocephalus, Chiari malformation, tethered cord). Fronto-occipital circumference needs to be measured daily and serial HUSs are recommended to monitor the progression of hydrocephalus, especially since most infants will require a shunt device. Once the infant can be placed supine, a urological evaluation, including a renal ultrasound and VCUG, need to be done. Based on the clinical course and physical examination further diagnostic tests may be needed. The evaluation of infants who underwent fetal surgery to close a NTD is the same.

Discharge planning

Infants with NTDs require the services of many specialists and disciplines. All infants should be referred to the Spina Bifida Clinic at TCH, a multidisciplinary clinic staffed by neurosurgeons, urologists, orthopedists and PM&R physicians. Services available at the clinic include social services, nutrition, OT and PT. A physician from the clinic should be contacted before discharge to meet with the family.

The role of a clinician treating such patients is not limited to the traditional medical treatment, but also includes preparing the parents to adapting to their children’s disabilities.

Outcomes

Occipital encephalocele – mortality is 40–50%, and only about 15% of survivors will have a normal outcome.

Postnatal Meningomyelocele Repair – mortality is 15-30%; 30% IQ <80; 50% will not be able to live independently

Fetal Meningomyelocele Repair – coordination and gait deficits still present but at significantly lower rate than postnatally repaired; 30% still need maximal assistance with life tasks; no improvement in bowel/bladder incontinence have been shown compared to postnatal repair.

9.5 Drug-exposed Infants

Background

Exposure of infants in utero to both prescription and illicit drugs has risen over the past 10 years. This rise corresponds with the Institute of Medicine recommendation to treat pain as a public health priority. This shift in the focus on pain management has led to more liberal use of prescribed opiates in pregnant women for complaints such as back pain. There has also been an increase in illicit use of opioids (both oxycodone and heroin) and opioid substitution programs (e.g., methadone and buprenorphine maintenance clinics). Opioid abuse has also shifted from a primarily inner city or low socioeconomic population to include all demographic and socioeconomic groups. Infants born to mothers with a history of chronic opioid use during pregnancy are at risk for withdrawal after birth. 55–94% of infants exposed in utero to opiates will have withdrawal symptoms. In addition, other substances including antidepressants and anxiolytics may produce withdrawal symptoms.

Pathophysiology

Opiate drugs are low molecular weight, polar, and water soluble. They easily cross the placenta and the blood-brain barrier of the fetus. Opiates also have a prolonged half-life in the fetus as compared to adults or older children. When the infant is separated from the placenta during the birth process, the discontinuation of the opioid results in the Neonatal Abstinence Syndrome (NAS).

Presentation

NAS produces a constellation of symptoms primarily involving the neurologic and gastrointestinal systems. Neurologic symptoms include tremors, irritability, and excessive crying. Excoriation of extensor surfaces or nasal tip results from excessive movement creating friction against bedding. Seizures can occur but are rare. The cry is high-pitched, shrill, and persists for excessive lengths of time. These infants have decreased sleep cycles. GI symptoms include excessive sucking behaviors, voluminous eating, and diarrhea. The large feeding volumes can exacerbate the loose stools and lead to excoriation in the diaper and perianal area. The pain of skin breakdown can worsen the crying episodes. Vomiting and excessive stools may inhibit growth. Other symptoms include sneezing, nasal stuffiness, fever, sweating and tachycardia.

Maternal Drug and Alcohol History

A thorough history of maternal drug and alcohol use during pregnancy is essential to management of the drug-exposed newborn. If a history is not available (i.e., previously obtained by clinic or obstetrician), interview the mother to obtain the following information:

- Specific drugs or types of drugs:
  - Illicit: heroin, PCP, cocaine, etc.
  - Prescription drugs: tranquilizers, opioids (pentazocine, hydromorphone, methadone), diet pills, etc.
  - Over-the-counter: dextromethorphan, bromides, etc.

- Pattern of use (amount, frequency, duration of drug use, with detailed history especially during last trimester of pregnancy).

- Treatment (involvement in drug treatment or voluntary detoxification during pregnancy).
Nursery Admission
Infants with intrauterine exposure to drugs (identified by maternal history or positive urine drug screen) other than marijuana or cocaine should be admitted to Level 2 NICU. Infants with intrauterine exposure only to marijuana or cocaine are admitted to the Level 1 nursery but should be treated the same as all other drug-exposed babies. Common indications for toxicology testing in the neonate include no or limited maternal prenatal care, placental abruption, preterm delivery, intrauterine growth restriction, and cardiovascular accident of mother or child. First-line workup for suspicion of drug-exposed infants should begin with a meconium drug screen with the first stool. Meconium will reflect drug use after 20 weeks, is more sensitive than urine, and results will return in a few days. The most reliable results require collection of meconium free of urine.

Urine screen (15–20 mL) can also be done; however, it only reflects exposure in the previous 48 hours. Umbilical cord segment testing is also commercially available.

Observation of drug-exposed infants for the presence of withdrawal is essential. A scoring system such as the modified Finnegan can be used to document signs and symptoms, lending consistency to the parameters being evaluated and scored providing a tool to guide management decisions. Consider asking Obstetricians to test for Hepatitis C if maternal IV drug exposure.

All infants should be scored every 3 hours immediately after a feeding with the modified Finnegan Scoring System.

At-risk asymptomatic infants need to be observed for 5 days. However, a select group of patients may be discharged after 48–72 hours of observation if the following criteria are met:

- No maternal drug use during last trimester, or a history of cocaine or marijuana use only.
- Infant urine screen is negative, or it is positive only for cocaine or marijuana.
- Maternal HIV, hepatitis B, and RPR status known; appropriate evaluation and treatment completed.
- Infant is AGA or LGA and ≥37 weeks’ gestation.
- No dysmorphic features.

Neonatal Abstinence Syndrome

Treatment Protocol
The use of weaning protocols decreases the duration of pharmacological treatment, decreases length in hospital stay, and decreases the use of adjunctive drug therapy.

Non-Pharmacologic Treatment
Non-pharmacological interventions should be used before pharmacological interventions are initiated. Non-pharmacological interventions include: swaddling or containment, decreased sensory and environmental stimulation (clustering care), and exposure to minimal light and noise. Frequent feedings with higher calories are also very helpful. Encourage breastfeeding if it is not contradicted per guidelines. Rocker-beds have not shown to be beneficial and are therefore not recommended. Only vertical rocking (and not horizontal) should be used. When scores increase despite non-pharmacological interventions, pharmacological intervention should be initiated with either morphine or phenobarbital depending on the drug of abuse.

Pharmacologic Treatment: Morphine (strong recommendation, high quality evidence)
Treatment should be initiated if an infant has 3 consecutive scores >8 OR average of 8 or higher of 3 scores OR 1 score >12 (after verifying there was no confounding reason for the 1 elevated score). Scores <8 indicate that symptoms are controlled.

Initiation Phase: Morphine 0.05 mg/kg/dose q 3 hours PO

Escalation Phase: May increase morphine by 0.03 mg/kg/dose q 3 hours PO until symptoms are controlled, as demonstrated by average scores decreasing to <8 in 24 hours

Stabilization Phase: Maintain the same dose for at least 48 hours, with scores <8 before weaning.

Weaning Phase: Wean the dose by 10% of the original dose every 24 hours. Use 10% as the weaning factor for the rest of the treatment. Do not weight adjust the medication. Do not adjust or change the frequency of the medication. Keep frequency every 3 hours due to the short half-life of morphine. Morphine can be discontinued when the dose is <0.02 mg/kg/dose. If an infant has been very difficult to wean, or if has been on morphine for a prolonged period, in rare circumstances, interval can be weaned before discontinuation.

Backsliding: If infant has 2 consecutive NAS scores >8 during the weaning process, assure that non-pharmacological measures are optimized before going back to the previous dose at which the patient was stable. If the infant’s scores remain elevated (even after physical exam to ensure nothing else is wrong/bothering the infant), either weight adjust medication and/or continue to increase dose in a stepwise fashion until patient’s scores are ≤8. Once stabilized on a new dose for minimum of 48 hours, resume 10% wean but consider weaning at less frequent intervals, e.g., q 48 hours instead q 24 hours.

Adjunctive Treatment
Phenobarbital is used as an adjunctive agent when the morphine dose has reached >0.3 mg/kg/dose and scores are still >8; OR unable to wean morphine for >3 consecutive days OR/AND if polysubstance abuse is suspected or confirmed. Phenobarbital is also used as the drug of choice for NON Opiate NAS. Phenobarbital will not improve gastrointestinal symptoms associated with NAS.

Table 9-3. Onset, duration, and frequency of NAS caused by various substances

<table>
<thead>
<tr>
<th>Drug</th>
<th>Onset, hours</th>
<th>Duration, days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heroin</td>
<td>24-48</td>
<td>8-10</td>
</tr>
<tr>
<td>Methadone</td>
<td>48-72</td>
<td>up to 30 or more</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>36-60</td>
<td>up to 28 or more</td>
</tr>
<tr>
<td>Prescription opioids</td>
<td>36-72</td>
<td>10-30</td>
</tr>
<tr>
<td>SSRI</td>
<td>24-48</td>
<td>2-6</td>
</tr>
<tr>
<td>TCA’s</td>
<td>24-48</td>
<td>2-6</td>
</tr>
<tr>
<td>Methamphetamines</td>
<td>24</td>
<td>7-10</td>
</tr>
</tbody>
</table>

Adapted with permission from Pediatrics, Vol 134(2), pages e547. Copyright ©2014 by the AAP.
Table 9-4. Suggested management of procedural pain in neonates at Baylor College of Medicine affiliated hospital NICU's

<table>
<thead>
<tr>
<th>System</th>
<th>Signs and Symptoms</th>
<th>Score</th>
<th>am</th>
<th>pm</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Excessive high-pitched (or other) cry</td>
<td>2</td>
<td>7</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>(cry face)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Continuous high-pitched (or other) cry</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(cry face)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sleeps less than 1 hour after feeding</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sleeps less than 2 hours after feeding</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sleeps less than 3 hours after feeding</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperactive moro reflex</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Markedly hyperactive moro reflex</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild tremors disturbed</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate-severe tremors disturbed</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild tremors undisturbed</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate-severe tremors undisturbed</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased muscle tone</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Excoriation (specific area)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myoclonic jerks</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Generalized convulsion</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sweating</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fever less than 101 (99–100.8°F / 37.2–38.2°C)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fever greater than 101 (38.4°C and higher)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frequent yawning (greater than 3–4 times / interval)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mottling</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal stuffiness</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sneezing (greater than 3–4 times / interval)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal flaring</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respiratory rate greater than 60 / min</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respiratory rate greater than 60 / min with retractions</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Excessive sucking</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poor feeding</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regurgitation</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Projectile vomiting</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Loose stools</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Watery stools</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total score every 2 to 4 hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signature of scorer(s)

Use of Neonatal Abstinence Scoring Sheet

Neonatal abstinence score sheet. Check sign or symptom observed at various time intervals and add scores for total at each evaluation. (Modified from Finnegan LP, Katenbach K: The assessment and management of neonatal abstinence syndrome. In Hoekelman RA, Nelson N, editors: Primary pediatric care, ed 3, St Louis, 1992, Mosby.)

Staff will begin tool at the most appropriate time and to choose the best scoring intervals, if necessary.

Baseline scores should be taken prior to weaning or a minimum of 2 hours after admission or both.

Scoring interval is every 4 hours.

Scoring for infants demonstrating scores 8 or higher automatically becomes ever 2

Pharmacologic intervention is needed when the total abstinence score is 8 or higher for 3 consecutive scorings or when the average of 3 scores is 8 or higher.

Immediate action is needed for scores of 12 or higher.

All observations are scored within the scoring interval and not at one particular time. (Water stools seen 2 hours earlier would be scored at the next scoring interval.)

Reflexes should be elicited only when infant is awake.

Count respirations for a full minute.

Prolonged crying is scored whether or not it is high-pitched.

NAS monitoring can be stopped 48 hours after opioid has been discontinued if NAS scores continue to be between 0 and 7.
There are many different recommendations for the dosing and weaning of phenobarbital. Phenobarbital levels of 20–30 mcg/mL have been proven to be effective in the treatment of NAS. Other medications (e.g., clonidine) can be used as well for adjunctive treatment of NAS.

**Initiation Phase:** Loading dose: 20 mg/kg/dose PO

**Escalation Phase:** May increase phenobarbital by 5 mg/kg/dose every 8 to 12 hours to a maximum dose of 40 mg/kg

**Maintenance Phase:** 1–4 mg/kg/dose q 12 hours (Most references recommend 2.5 mg/kg/dose q 12 hours). The maintenance dose should begin 12 to 24 hours after the loading dose.

**Weaning Phase:** The current dose should be maintained until scores are <8 for 3 days. Wean by 10% every 24 hours or 20% every 48 hours until the medication is discontinued entirely.

**Feeding Guidelines:**

**General:**
- Breastfeeding is encouraged when appropriate.
- Caloric needs may be as high as 150–250 cal/kg/day
- Frequent small volumes of hypercaloric (22–24 cal/oz) feeding or breastmilk every 3 hours may help minimize hunger and improve growth.
- Soy or "specialized formula" (Similac Sensitive) may improve feeding tolerance.
- Breastfeeding is encouraged in the following situations:
  - Stable methadone maintenance or buprenorphine regardless of dose
  - Substance abuse treatment provider endorses the Mother
  - Plan to continue substance abuse treatment during the postpartum period
  - Negative maternal urine toxicology testing at delivery, except for prescribed medications
  - Consistent prenatal care
  - Breastfeeding is contraindicated in the following:
    - No prenatal care or limited prenatal care
    - Medical contraindication to breastfeeding (such as HIV or lesion on the breast)
    - Relapsed into illicit/licit substance abuse 30 days prior to delivery
    - Inability to engage in substance abuse treatment or in treatment but not willing to consent for counselor contact
    - Positive maternal urine toxicology testing for illicit substances at delivery
    - No confirmed plans for postpartum substance abuse treatment
    - No confirmed plans for pediatric care
    - Demonstration of behavioral qualities or other indicators of active substance use
    - Maternal use of cocaine, diazepam, lithium, and possibly phenothiazines

**Discharge**

Patients must be monitored and observed for ≥48 hours off medications before discharge. An appointment with the primary physician must be secured before discharge to ensure proper follow-up. If a baby’s drug screen is positive, the case should be referred to Harris County Children’s Protective Services (CPS). If the case has been referred to CPS, notify CPS before allowing the baby to leave the hospital.

### 9.6 Pain Assessment and Management

**Assessment**

Pain assessment is essential for optimal pain management. Pain should be assessed on admission and at regularly defined intervals throughout an infant’s hospitalization. Developmental maturity, behavioral state, previous pain experiences and environmental factors all may contribute to an inconsistent, less robust pattern of pain responses among neonates and even in the same infant over time and situations. Therefore, what is painful to an adult or child should be presumed painful to an infant even in the absence of behavioral or physiologic signs. This general rule, along with the use of a valid and reliable instrument, should be used to assess pain.

Pain can be most effectively assessed using a multidimensional instrument that incorporates both physiologic and behavioral parameters. Multidimensional instruments with evidence of validity, reliability, and clinical utility include:
- PIPP, Premature Infant Pain Profile,
- CRIES, Crying, Requires increased oxygen administration, Increased vital signs, Expression, Sleeplessness, and
- NIPS, Neonatal Infant Pain Scale.

Physiologic measures should be used to assess pain in infants who are paralyzed for mechanical ventilation or who are severely neurologically impaired. Because the use of paralytic agents masks the behavioral signs of pain, analgesics should be considered.

**Non-pharmacologic Pain Management**

Non-pharmacologic approaches may be used for minor to moderately stressful procedures to help minimize pain and stress while maximizing an infant’s ability to cope with and recover from the painful procedure. All aspects of care-giving should be evaluated for medical necessity to reduce the total number of painful procedures to which an infant is exposed. Behavioral measures that may be employed to manage minor pain experienced by the infant include:
- Hand-swaddling technique known as facilitated tucking (holding the infant’s extremities flexed and contained close to the trunk).
Pacifiers for nonnutritive sucking (NNS). NNS is thought to modulate the transmission or processing of nociception through mediation by the endogenous non-opioid system.

Sucrose is used to relieve neonatal pain associated with minor procedures such as heel stick, venipuncture, intravenous catheter insertion, eye exam, immunization, simple wound care, percutaneous arterial puncture, lumbar puncture and urinary catheter insertion. Studies demonstrate that a dose of 24% sucrose given orally about 2 minutes before a painful stimulus is associated with statistically and clinically significant reductions in pain responses. This interval coincides with endogenous opioid release triggered by the sweet taste of sucrose. Pain relief is greater in infants who receive both NNS and sucrose. The following dosing schedule is recommended:

- **Infants <35 weeks corrected age:** 0.2 mL/dose every 2 minutes up to 3 doses; maximum dose for 1 procedure = 0.6 mL.**
- **Infants ≥35 weeks or more corrected age:** 1 mL/dose every 2 minutes up to 3 doses, maximum dose for 1 procedure = 3 mL.**
- Kangaroo care (skin-to-skin contact) has been found to be beneficial for pain associated with heel sticks in preterm infants ≥32 weeks’ postmenstrual age.

** Per pain protocol only 3 series of doses may be given in one 24-hour period. Additional doses will require an additional physician’s order.

### Pharmacologic Pain Management

Pharmacologic approaches to pain management should be used when moderate, severe or prolonged pain is assessed or anticipated. Pharmacologic approaches in the NICU primarily consist of systemic analgesic therapy (opioid and non-opioid). Sedatives, including benzodiazepines and barbiturates, do not provide pain relief and should only be used when pain has been ruled out.

Opioids remain the most common class of analgesics administered in the NICU, particularly morphine sulfate and fentanyl citrate. The following dosages are based on acute pain management; neonates with chronic pain, or during end-of-life. Longer dosing intervals often are required in neonates <1 month of age due to longer elimination half-lives and delayed clearance of opioids as compared with adults or children >1 year of age. Efficacy of opioid therapy should be assessed using an appropriate neonatal pain instrument. Prolonged opioid administration may result in the development of tolerance and dependence. Tolerance to opioids usually is managed by increasing the opioid dose. Neonates who require opioid therapy for an extended period of time should be weaned slowly. Refer to Weaning Opioid Guidelines in this chapter.

---

**Table 9-5. Suggested management of procedural pain in neonates at Baylor College of Medicine affiliated hospital NICU’s**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Pacifier</th>
<th>Sucrose</th>
<th>Sedation/Conduction of Facilitated Tucking</th>
<th>Local Anesthetic</th>
<th>Opioids</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heel lance, venipuncture</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>Consider venipuncture in full-term and older preterm infants; skin-to-skin contact with mother.</td>
</tr>
<tr>
<td>Percutaneous inserted venous catheter</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percutaneous arterial puncture/catheter</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral arterial or venous cutdown</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical control line</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Umbilical arterial or venous catheter</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumbar puncture</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subcutaneous or intramuscular injection</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>Give drugs intravenously whenever possible. Consider acetaminophen prophylactically for immunizations.</td>
</tr>
<tr>
<td>ET intubation (nonemergent)</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ET suction</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasogastric- orogastric tube</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Gentle technique and appropriate lubrication.</td>
</tr>
<tr>
<td>Chest tube</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>Consider thoracocentesis before chest tube insertion. Anticipate need for intubation and ventilation.</td>
</tr>
<tr>
<td>Circumcision</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Dorsal penile nerve block, subcutaneous ring block, or caudal block usingplain or buffered lidocaine. Consider acetaminophen for postoperative pain.</td>
</tr>
<tr>
<td>Ongoing analgesia for routine NICU care and procedures</td>
<td>✓  +/-</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>Avoid long-term sedation. Avoid midazolam. Minimize stress from environmental sound and light levels in the NICU.</td>
</tr>
</tbody>
</table>

Morphine Sulfate
- **Intermittent IV dose** – 0.05–0.1 mg/kg over 5 to 10 minutes every 4–6 hours
- **Intermittent PO dose**
  - **Neonates**: 0.08–0.1 mg/kg every 4–6 hours
  - **Infants <6 months**: 0.08–0.1 mg/kg q3–4 hours
  - **Infants >6 months**: 0.2–0.5 mg/kg every 3–4 hours
- **Continuous IV infusion dose** – loading dose is 0.05–0.1 mg/kg over 5 minutes followed by a continuous infusion of 0.01–0.02 mg/kg/hour as a starting dose. The infusion should be titrated by no more than 0.02 mg/kg/hour every 30 minutes. If up-titration is necessary, a bolus is likely needed.

**Fentanyl Citrate**
- **Intermittent IV dose** – 1–2 mcg/kg/dose over 5 minutes every 2–4 hours
- **Continuous IV infusion dose** – 0.5–1.0 mcg/kg/hour as a starting dose. Drip can be titrated by no more than 1 mcg/kg/hour every 30 minutes.

While opioid-induced cardiorespiratory side effects are uncommon, neonates should be monitored closely during opioid therapy to prevent adverse effects.

Acetaminophen
Acetaminophen is a non-steroidal anti-inflammatory drug commonly used short-term for mild to moderate pain in neonates. Intermittent dose and interval is based on the age and weight of the patient. Refer to hospital formulary for dosing.

If the oral route is unavailable, the rectal route is an alternative option for infants. Intravenous acetaminophen is also an option for pain relief in a patient who is NPO. Rectal administration has a longer duration of action than the intravenous route.

Procedural Pain Management
Newborn infants, particularly those born preterm, are routinely subjected to an average of 61 invasive procedures from admission to discharge, with some of the youngest or sickest infants experiencing >450 painful procedures during their hospital stay. These frequent, invasive, and noxious procedures occur randomly in the NICU and many times are not routinely managed with either pharmacologic or non-pharmacologic interventions. The International Evidence-Based Group for Neonatal Pain provides guidelines for preventing and treating neonatal procedural pain. Suggested strategies for the management of diagnostic, therapeutic and surgical procedures commonly performed in the Baylor-affiliated hospital NICUs are summarized in Table 9–5.

Weaning Opioid Guidelines
Opioid tolerance and dependence may occur in neonates with *in utero* exposure. More frequently in our unit, it occurs in neonates who receive analgesic therapy postnatally. Most of the time, patients receive opioids for a duration that necessitates weaning before discontinuation. This can be accomplished by weaning from the original therapy or converting the patient to oral therapy (especially if patient no longer requires a central line for any other therapy). Weaning generally occurs over a similar duration to the patient’s exposure to opioids.

Opioid Weaning Options
If risk factors for pain remain and/or an infant has elevated pain scores or exhibits physical and/or behavioral signs of pain, opioid weaning will be deferred and pain will be managed.

There are 3 opioid weaning options (based on duration of opioid therapy and/or dosage during therapy):
- **Short-term opioid therapy** (<3 days for fentanyl and <5 days for morphine):
  - Therapy can be discontinued without weaning.
- **Intermediate** opioid therapy (3–5 days to 2 weeks)
  - Must wean before discontinuing. How much to wean and how quickly depends on duration, dose, and patient clinical factors (e.g., pulmonary hypertension. Stop NAS monitoring 48 hours after opioid has been discontinued if NAS scores remain ≤7.
- **Long-term** opioid therapy (>2 weeks and/or maximum fentanyl >10 mcg/kg/hour or morphine >0.1 mg/kg/hour)
  - Wean opioid as described under intermediate weaning option,
  - OR
  - Convert patient to oral morphine if patient can tolerate oral therapy, continuous infusion dose is low enough for conversion, and central line can be removed. Be cautious when converting fentanyl to morphine in young infants; the conversion factors are different than those for older patients. Conversion to methadone should only be considered in patients who are not dependent upon their opioid for sedation and who require long-term weaning. The long half-life of methadone does not make it ideal for use in patients who can be weaned quickly.

The pharmacist should determine the weaning factor (calculated by taking the percentage that is going to be weaned and multiplying it by the original dose) which will be the amount that the dose will be decreased. This weaning factor will not change throughout the weaning process even as the doses overall become smaller. The weaning factor should be a straight mg dose (not mg/kg because the weight changes during the treatment). Use the modified Finnegan scoring system to monitor withdrawal in the patient.

**CAUTION:** this scoring system is only validated for newborns so it must be interpreted cautiously when used for older babies. Review what signs/symptoms the patient is being scored for and determine if that is appropriate behavior for that age. An alternative withdrawal scoring scale may be necessary for patients >28 days of life.

### 9.7 Vein of Galen Malformation (VGAM)
Vein of Galen malformation is caused by a failure of the fetal Vein of Markowski to involute at 11–12 weeks’ gestational age. Persistence leads to abnormal venous connections and dilation beyond 11-12 weeks’ gestation, leading to dilation of
the Vein of Markowski which consequently drains into the Vein of Galen. Blood quickly flows from the arterial vessels directly to low resistance venous systems without a capillary bed in between causing rapid circulation, high venous blood volumes, and venous pressure. Cardiac output is shunted toward the VGAM (as much as 80%) leading to poor systemic perfusion and blood supply. To compensate for the VGAM steal phenomenon, heart rate and total blood volume increase. Over time, this leads to high output cardiac failure.

**Signs and Symptoms of VGAM**
- High output cardiac failure
- Compromised coronary artery perfusion
- Pulmonary blood flow and venous return
- Pulmonary vascular resistance
- R to L shunt across the ductus arteriosus (if patent)
- Prerenal injury
- Hepatic insufficiency
- Venous return/CVP
- Intracranial pressure

**Evaluation of VGAM**
Evaluation of an infant presenting with VGAM includes imaging of the VGAM itself as well as assessment of end organ injury secondary to decreased systemic perfusion.

- If at TCH Woodlands, transfer infant to the TCH main campus West Tower level 4 NICU
- An echocardiogram should be ordered STAT to evaluate cardiac function
- A head ultrasound should be ordered STAT even if brain MRI or CT scan has been done to provide a baseline for future serial HUS comparisons
- An MRI of the brain without contrast should be ordered to evaluate the size of the VGAM (when the infant is stable and after initial evaluation and treatment)
- Obtain a full liver and coagulation panel to evaluate for hepatic insufficiency and synthetic function
  - Obtain serum BUN and creatinine due to risk of pre-renal injury secondary to decreased systemic perfusion
  - A STAT EEG must be ordered as many neonates with VGAM have subclinical seizures which is an important prognostic indicator
  - Daily FOCs should be ordered to monitor for hydrocephalus
  - Consults: Cardiology, Neurology, Neurosurgery, Interventional Neuroradiology (STAT, do not wait until morning)
  - The Bicêtre Score) must be calculated to determine if the patient is a candidate for palliative care only (<8), emergent embolization (8–12), or medical management with delayed embolization (>12). *(Table 9-6)*
    - If Bicêtre Score is between 8–12, emergently call Neurosurgery and Interventional Radiology for evaluation of an emergent embolization (Do not wait until morning)
    - If Bicêtre Score is <8, call Palliative Care Service, and discuss with colleagues if treatment is indicated

**Medical Management**

For patients with a Bicêtre Score >12 medical management consists of the following:
- Cardiac preload reduction strategies such as diuretics and fluid restriction
- Inotropic support to increase contractility and cardiac output
- Regular monitoring of liver function and coagulation studies with transfusion of blood products as needed
- Regular monitoring of renal function and urine output
- Daily FOC measurements and neurologic examinations

---

**Table 9-6. Bicêtre neonatal evaluation score**

<table>
<thead>
<tr>
<th>Points</th>
<th>Cardiac function</th>
<th>Cerebral function</th>
<th>Respiratory function</th>
<th>Hepatic function</th>
<th>Renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>Overload, no</td>
<td>Subclinical,</td>
<td>Tachypnea, finishes</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>medical treatment</td>
<td>isolated EEG</td>
<td>bottle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>medical treatment</td>
<td>abnormalities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Failure; stable</td>
<td>Non-convulsive</td>
<td>Tachypnea, does not</td>
<td>No hepatomegaly,</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>with medical</td>
<td>intermittent</td>
<td>finish bottle</td>
<td>normal hepatic function</td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment</td>
<td>neurologic signs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Failure, not</td>
<td>Isolated convulsion</td>
<td>Assisted ventilation,</td>
<td>Hepatomegaly, normal</td>
<td>Transient anuria</td>
</tr>
<tr>
<td></td>
<td>stable with</td>
<td></td>
<td>normal saturation FIO</td>
<td>hepatic function</td>
<td></td>
</tr>
<tr>
<td></td>
<td>medical treatment</td>
<td></td>
<td>&lt;25%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Ventilation</td>
<td>Seizures</td>
<td>Assisted ventilation,</td>
<td>Moderate of transient</td>
<td>Unstable diuresis with treatment</td>
</tr>
<tr>
<td></td>
<td>necessary</td>
<td></td>
<td>normal saturation FIO</td>
<td>hepatic insufficiency</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;25%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Resistant to</td>
<td>Permanent</td>
<td>Assisted ventilation,</td>
<td>Abnormal coagulation,</td>
<td>Anuria</td>
</tr>
<tr>
<td></td>
<td>medical therapy</td>
<td>neurological signs</td>
<td>desaturation</td>
<td>elevated enzymes</td>
<td></td>
</tr>
</tbody>
</table>

*EEG, electroencephalogram; FIO², fractional inspired oxygen. Maximal score = 5(cardiac) + 5 (cerebral) + 5 (respiratory) + 3 (hepatic) +3 (renal) = 21.

Reprinted with permission of Oxford University Press from Neurosurgery by Congress of Neurological Surgeons in The management of vein of galen aneurysmal malformations. Lasjaunias, Pierre. Vol 59, No.5. Copyright ©2006; permission conveyed through Copyright Clearance Center, Inc.
Endovascular Embolization

Endovascular embolization has become the standard of care treatment for VGAM and has led to improved neurologic outcomes. The goal is not to completely occlude the entire VGAM, but a large enough component to restore satisfactory circulatory physiology and minimize vascular steal of systemic organs and neighboring areas of developing brain. Selection and timing of embolization is challenging and the current best scoring system is the Bicêtre Score. A recent meta-analysis of endovascular embolization (treatment timing according to Bicêtre score) showed improved neurologic outcome in >60% of neonates treated (strong recommendation, high quality evidence).

Suggested Reading

Hypoxic-ischemic Encephalopathy

Seizures

Cerebral Hemorrhage and Infarction

Neural Tube Defects

Drug-Exposed Infants

Pain Assessment and Management

Vein of Galen Malformation
Section 10: Newborn Care
Editors: Tiffany McKee-Garrett and Catherine Gannon

10.1 Routine Care ...........................................138
   Tiffany McKee-Garrett

10.2 Cardiac Murmurs ....................................140
   Catherine Gannon

10.3 Dental ..................................................140
   Tiffany McKee-Garrett

10.4 Dermatology ..........................................141
   Sangeetha Athis Rajh
   Tiffany McKee-Garrett

10.5 Extracranial Swelling ..............................142
   Charles Roitsch

10.6 Feeding..................................................143
   Stephanie Blair Deal

10.7 Hospital Discharge .................................146
   Cecilia Torres Day
   Sangeetha Athis Rajh

10.8 Neuromusculoskeletal .......................147
   Jenelle Little
   Tiffany McKee-Garrett

10.9 Newborn Screening ..............................150
   Charleta Guillory

10.10 Urology .............................................151
    Sangeetha Athis Rajh
    Charles Roitsch
10.1 Routine Care

Introduction
Clinical issues in normal newborns provide challenges different from those that occur in the intensive care nursery, yet they are just as important. The physician should begin with a firm understanding of the transitional period and then progress to understanding normal findings and common abnormalities.

Transitional Period
Infants undergo a complex sequence of physiologic changes as they make the transition from intrauterine to extrauterine life. This transition is successful in almost all infants, although some may have cardiopulmonary abnormalities that require intervention.

Every effort should be made to facilitate 24-hour rooming-in of baby with mother. Observation of the healthy infant during the transitional period may occur in the mother’s room with intermittent assessment by nursing personnel.

Bathing
A newborn’s first bath is usually given during the first day of life when stability through the transitional period has been demonstrated, including normal blood glucose values for babies at risk for hypoglycemia. Before the umbilical cord falls off, a newborn should have sponge baths only. Thereafter, infants can be placed directly into warm water (warm to touch on the inside of one’s wrist or elbow). In general, the first bath should be as brief as possible, in a warm room, and using mild, non-perfumed soaps.

Cord Care
Keeping the umbilical cord clean and dry is as effective and safe as using antiseptics and shortens the time to cord separation. Evidence does not support the use of frequent alcohol applications for routine cord care.

To reduce maternal concerns about cord care, health care providers should explain the normal process of cord separation, including appearance and possible odor. The parents should be instructed to keep the umbilical cord open to the air for natural drying and to use only water at the base of the cord to remove any discharge that may develop. The umbilical cord usually separates from the abdomen 6 to 14 days after birth.

Eye Care
As part of the initial newborn exam, the eyes are examined for reaction to the light, pupil size, general alignment and appearance of the conjunctiva and cornea. If mucopurulent material is produced from the lacrimal puncta when the lacrimal sac is pressed against the bones of the nose and medial orbital wall, there might be an obstruction of the nasolacrimal system. Repeated massage of the lacrimal sac at the medial canthal area serves to flush out the stagnant tears and decrease the risk of infection. A congenital dacryocystocele can manifest as a firm, medium-sized, bluish mass adjacent to the medial canthus. This distended lacrimal sac is filled with mucoid material and can become secondarily infected. Conservative management with topical or systemic antibiotics and massage is often successful, and referral to ophthalmology is recommended. The bulbar and palpebral conjunctivae are normally moist and pinkish. Redness or exudate is abnormal and often indicates infection.

Eye Prophylaxis and Vitamin K Administration
The incidence of gonococcal disease is approximately 0.3 cases per 1000 live births. Gonococcal conjunctivitis was the leading cause of infant blindness before the introduction of ocular prophylaxis by Credé in 1881, and it remains an important neonatal disease in developing countries. Ocular prophylaxis to prevent ophthalmia neonatorum is mandated in all 50 states. Texas Health and Safety Code, §81.091, requires a physician, nurse, midwife or other person in attendance at childbirth to provide ocular prophylaxis to prevent ophthalmia neonatorum. Appropriate prophylaxis includes the application of a 1 to 2 cm ribbon of 0.5% erythromycin to the eyes within 2 hours of birth. The erythromycin should not be flushed from the eye. After 1 minute, excess ointment can be wiped off.

All newborns are given vitamin K1 (phytonadione) as an IM dose of 0.5 to 1.0 mg within the first 6 hours of life. Vitamin K is essential for the formation of clotting factors II, VII, IX, and X. Fetal vitamin K is derived from the mother; however, placental transfer of the vitamin is poor. A newborn obtains vitamin K from the diet and putrefactive bacteria in the gut. Therefore, production of the vitamin is dependent upon the initiation of feeding. Vitamin K levels in breastmilk are also low, even in mothers who are taking supplements. In a recent study, the average vitamin K1 intake of a breastfed infant corresponded to 7-13% of the recommended dietary intake of 10 mcg/day.

The risk of Vitamin K deficient bleeding (VKDB) is enhanced by the following clinical situations, further emphasizing the importance of prophylaxis at birth:

• breast-fed infants where lactation takes several days to become established
• infants who may not be enterally fed for several days
• infants with intestinal malabsorption defects
• infants of mothers who are on anticonvulsant medications, specifically phenytoin.

VKDB is classified according to when it presents:

• Early VKDB: occurs within 24 hours of birth. Seen almost exclusively in newborns whose mothers took vitamin K inhibiting drugs during pregnancy.
• Classic VKDB: 24 hours to 7 days of age.
• Late VKDB: 2-24 weeks of age.

VKDB in the newborn can manifest as bleeding from various sites such as, needle puncture sites, the circumcision site, the umbilical stump, the GI tract, and the brain. 30-60% of babies with late onset VKDB will have intracranial bleeding which can result in long term neurological sequelae and possibly death.

Without prophylaxis, the incidence of early and classical VKDB ranges from 0.25 – 1.7%. The incidence of late VKDB is estimated at 4.4-7.2 per 100,000 infants. Either oral or parenteral administration of vitamin K has been shown to prevent early-onset VKDB. However, parenteral administration of vitamin K is best for the prevention of late-
onset VKDB. Additionally, an oral form of Vitamin K for the prevention of VKDB has not been approved for use in the United States. Administration of neonatal vitamin K is not required by law in the state of Texas. However, if a parent refuses Vitamin K administration, a discussion should ensue with the provider about the role of IM vitamin K for the prevention of VKDB, and the potential devastating consequences of vitamin K refusal. Despite counseling, if a parent refuses vitamin K prophylaxis, the practitioner must provide detailed documentation in the permanent medical record. Additionally, if available at the institution, a refusal of medical treatment form should be signed by the parent and placed in the medical record.

### Nails

Newborn fingernails are small and grow quickly. They should be trimmed as needed using an emery board or nail clippers made specifically for babies. Fingernails should be kept short and smooth to prevent scratching.

### Non-Sterile Deliveries

When a non-sterile delivery occurs, always question whether the infant was placed at risk for infection. Each case must be considered individually. However, if the umbilical cord was not cut with sterile scissors or a sterile scalpel, prevention of neonatal tetanus may be a consideration, although the risk is quite low. Most mothers who have been immunized for tetanus have adequate levels of tetanus antibodies to protect their infants. When the mother’s immunization status is unknown, or inadequate, and the umbilical cord was not cut in a sterile fashion, tetanus immune globulin, 250 IU, IM -- regardless of the age or weight should be given as soon as possible. If tetanus immune globulin is unavailable, IVIG is recommended.

### Security

Before a newborn leaves Labor & Delivery, the parent(s) and the infant receive matching identification bracelets bearing mother’s name and other identifying data. Hospital staff should always check these bracelets when an infant is taken from or returned to the mother’s room. Only the parents and authorized hospital personnel, clearly identified by ID badges, should transport infants in the hospital. It is also standard of care to place an electronic monitor on the baby as an additional security measure. These monitors will cause an alarm to sound in the event the monitor (i.e., infant) approaches an exit.

### Skin

A newborn’s skin may be sensitive to chemicals in new clothing or detergent residues. All washable items should be laundered with mild detergents and double-rinsed before use. In general, newborn skin does not need any lotions, creams, oils, or powders. If skin is excessively dry or cracked, apply only skin care products made for infants.

### Sleep Position

The AAP recommends that healthy infants be placed in a supine position for sleep. A supine position confers the lowest risk for sudden infant death syndrome (SIDS). The side position is not recommended. Soft surfaces, such as pillows, soft mattresses or sheepskin should not be placed under infants. The use of pacifiers at naptime and bedtime throughout the first year of life has been associated with a reduced risk of SIDS. Rarely will conditions such as gastroesophageal reflux and upper airway anomalies preclude the recommended supine position. Nighttime sleeping in car seats or baby swings is not recommended.

### Social Issues

A Social Work consultation in the newborn nursery is recommended for the following situations:

- Maternal age 16 years or younger, or mother is multiparous and less than 18 years of age
- Maternal history of drug abuse
- Maternal history of mental illness
- Suspected abuse of the mother (either mental or physical) by a family member or significant other.
- Significant maternal postpartum complications necessitating discharge of baby without the mother.

### Urination and Bowel Movements

Twenty-five percent (25%) of males and 7% of females will void at delivery, and 98% of all infants will urinate within the first 30 hours of life. Newborns may void as frequently as every 1 to 3 hours or as infrequently as 4 to 6 times a day, First voids occurring on the warmer at delivery need to be clearly documented in the baby’s medical record. Any infant with suspicion of failure to void within the first 30 hours of life requires a thorough examination, with focus on palpable, enlarged kidneys or a distended bladder, as well as a careful neurologic examination of the lower extremities. It is important to also ensure that the baby is receiving adequate intake (Ch 10.6-Feeding). Diagnostic investigation with ultrasound, and urology consultation if abnormal exam findings are present, should be considered.

Meconium usually is passed within the first 48 hours of life. Any infant who does not pass stool in the first 48 hours of life requires further evaluation. Over several days, the stool transitions to a yellow-green color and looser consistency. Bowel movement frequency varies. Many infants will stool after each feeding (gastrocolic reflex), others only once every several days. In general, formula-fed infants have at least one bowel movement a day; breast-fed infants usually have more. Change diapers as frequently as an infant wets or soots. Clean the area with mild soap and water. Keeping the area as clean and dry as possible prevents most irritations and diaper rash.

If redness occurs, change the diapers more frequently, expose the area to air to promote healing, and consider applying a protective barrier of ointment. Excoration of the diaper area is common in the early newborn period and should be treated with simple barrier preparations such as zinc oxide (Desitin™, A&D Ointment™) or petroleum jelly (Vaseline™), in lieu of expensive preparations such as Aquaphor™ or those that contain cholestyramine.

If a red, raised, pinpoint rash develops, irritation persists, or the creases are involved, a secondary Candida infection may be present and should be treated with topical nystatin or antifungal azole.
Vaccines
As recommended by the AAP and the Advisory Committee on Immunization Practices of the CDC, all babies with a birth weight greater than or equal to 2 kg should receive the first Hepatitis B vaccine (HBV) by 24 hours of age. Infants with a birth weight < 2 kg should receive the first (HBV) at one month of age, or at hospital discharge, whichever occurs first. (Ch 8.6-Hepatitis B).

10.2 Cardiac Murmurs
One of the most common abnormalities noted in the physical exam of an otherwise asymptomatic neonate is a murmur. Appropriate management requires knowledge of the transitional circulation (Sec 3-Cardiac Care).

Normally, upon delivery and initiation of spontaneous respiration, pulmonary vascular resistance drops rapidly with increased pulmonary blood flow and a transient reversal of blood flow at the level of the atria and ductus arteriosus. Based on these changes, murmurs in the first 24-48 hours of life often reflect flow through the ductus arteriosus or turbulent flow in the branches of the pulmonary arteries.

While much of the focus of the cardiac examination is on the presence or absence of a murmur, auscultatory findings must be assessed in the context of the rest of the cardiac exam including:

- assessment of general well-being by inspection,
- respiratory rate and work of breathing,
- peripheral perfusion,
- absence or presence of central cyanosis,
- upper and lower extremity pulses, and
- Inspection and palpation of the precordium.

Assessment
Murmurs are common in the neonatal period. The majority of these murmurs are physiologic and can be separated into several main types.

Ductus arteriosus murmur represents left-to-right blood flow through the ductus as the pulmonary vascular resistance falls and before the ductus closes. Often it is heard in the first day of life. The murmur can be continuous but most often is mid-systolic and crescendo. It is best heard at the cardiac base and over the left scapula. It often disappears by the second day of life as the ductus closes functionally. When a murmur consistent with a ductus arteriosus is heard, serial exams are indicated. If the murmur persists or the infant becomes symptomatic, consider a more complete workup.

Pulmonary branch stenosis murmur results from turbulent blood flow in the pulmonary artery branches secondary to:

- rapidly falling pulmonary vascular resistance
- difference in the diameters between the main pulmonary branch and the left and right pulmonary branches
- acute angle of the branches

The murmur of pulmonary branch stenosis is benign and is heard best over the cardiac base and lung fields with radiation to the axillae and back.

Pathological murmurs heard on the first day generally are related to obstructed ventricular outflow. They are heard best at the left or right upper sternal border and typically are grade 2 or 3 and systolic. Murmurs that are consistent with increased blood flow over normal semilunar valves, such as those occurring with atrial septal defects, are rarely heard in the first week of life. Murmurs consistent with a ventricular septal defect often are not heard on initial exam and usually are first heard late on the first day or into the second or third day of life. Initially the murmur may be assessed as being unremarkable, resembling a benign flow murmur but, as the pulmonary vascular resistance drops, the murmur becomes more evident. The murmur of a ventricular septal defect is heard best over the mid to lower-left sternal border. The murmur is harsh and high-pitched and often obliterates the first heart sound.

Workup
Once a murmur is detected, the extent of the workup is based on several factors. In an asymptomatic infant with a heart murmur, the likelihood that the murmur indicates congenital heart disease has been reported to be less than 10%.

Asymptomatic murmurs that do not require a workup usually are grade 1 or 2, do not radiate significantly, and are not heard over the ventricular outflow tracks.

Consider a workup for murmurs that are greater than or equal to grade 2 to 3 with extensive radiation, and any murmur heard best over the ventricular outflow tracks. The cardiac work-up consists of a chest X-ray to evaluate heart size, an ECG, four extremity blood pressures, and pre and post-ductal pulse oximetry readings in room air. An echocardiogram and consultation with a Cardiologist may be necessary; this should be discussed with the Newborn Attending or the Senior Resident.

10.3 Dental
Natal teeth are present at birth and neonatal teeth erupt from birth to 30 days after birth. The incidence of natal or neonatal teeth is 1:2000 live births, 15% have a family history of natal or neonatal teeth, and natal teeth are more common than neonatal teeth (4:1). In 95% of cases, both types of teeth correspond to normal primary dentition, while 5% are supernumerary. The teeth are more prevalent on the mandible than the maxilla (10:1). Although usually an isolated finding, natal teeth may be associated with some syndromes such as Ellis-van Creveld syndrome, Sotos syndrome, pachyonychia congenita, and Hallerman-Streiff syndrome. Treatment of natal teeth can include observation only, smoothing of the incisal edge to prevent discomfort during breastfeeding, or extraction.

The decision to keep or extract a natal or neonatal tooth should be evaluated on a case-by-case basis.

Factors to consider include:

- implantation and degree of mobility
- interference with breastfeeding
- risk of aspiration (especially in someone with specific inability to protect the airway)
- normal dentition vs. supernumerary - supernumerary teeth are typically extracted
Some evidence demonstrates the importance of keeping a tooth that is part of the normal dentition since premature loss of a primary tooth may cause a loss of space and collapse of the developing mandibular arch with consequent malocclusion in permanent dentition. Consider consultation with a pediatric dentist or the Oral and Maxillofacial surgery service if extraction is desired or the management approach is unclear.

10.4 Dermatology

Birthmarks

The majority of birthmarks noted in the newborn period are not of medical significance and warrant only close observation.

Common benign birthmarks include:

- **Salmon patches** (a.k.a. macular stain, nevus simplex, “stork bite”, “angel’s kiss”) - are the most common vascular malformations, are of capillary origin, and almost always fade without need for intervention.

- **Mongolian spots** - are the most common form of cutaneous hyperpigmentation seen in neonates and are caused by dermal melanocytosis. They are present in 96% of African-American babies and 46% of Hispanic babies. They are less common in Caucasian babies. Mongolian spots are benign and typically fade by adulthood.

- **Infantile hemangiomas** - are the most common benign tumors of infancy, consist of proliferation of vascular endothelium, are not typically present at birth, and are characterized by phases of rapid proliferation followed by involution in greater than 80% of patients. Very few require active therapy (see following section).

Occasionally, certain skin findings may require further investigation and/or Dermatology consult. These include:

- **Café au lait spots** - may be a first sign of neurofibromatosis. These are often seen in healthy children, but six or more spots greater than 0.5 cm in diameter warrant further investigation or consult.

- **Nevus-Flammeus (Port-Wine Stain)** - typically a darker red and larger than the salmon patch, and it may be indistinguishable from early infantile hemangiomas. These do not fade and can be associated with Sturge-Weber syndrome, particularly if large and located in the distribution of the first two branches of the trigeminal nerve, or in the setting of macrocephaly or seizures.

- **Nevi, melanocytic** - benign proliferations of cutaneous melanocytes, present either at birth or within the first few weeks of life. The incidence of congenital melanocytic nevi (CMN) is approximately 1%. Newborns with large CMN (>9cm on the head or >6cm on the body) should be referred to dermatology for close follow-up due to the risk of malignant transformation associated with large lesions.

- **Infantile Hemangiomas** - further investigation is necessary and treatment may be needed if the lesion is in a concerning location such as periorbital, the beard area, the midline back, more than 10 are present or if they are large, ulcerated or painful.

- **Depigmented lesions** - Multiple hypo pigmented (ash-leaf) macules should raise concern of tuberous sclerosis, particularly in the setting of seizures and/or heart murmur.

- **Nevi, sebaceous** - occur in 0.3% of newborns. Typically located on the scalp or face, these lesions are isolated smooth plaques that are hairless, round or linear, slightly raised, and range from pink to yellow, orange, or tan. Large lesions require investigation, particularly in the setting of abnormal neurological findings and/or seizures, and may become a cosmetic concern during adolescence secondary to the onset of verrucous hyperplasia. A variety of benign and malignant tumors may arise from within sebaceous nevi but this is uncommon.

**Dimples**

Skin dimples - may be either simple depressions in the skin of no clinical significance or actual sinus tracts connecting to deeper structures. Dimples are often seen over bony prominences such as the knee joint. If found over long bones, consider the diagnosis of congenital hypophosphatasia or other bony disorders. Skin dimples located over the sacrum or lower back are often normal. Occasionally these dimples can reflect occult spinal dysraphism (OSD).

In general, a sacral or lower back dimple is benign if all of the following are noted:

- Solitary lesion
- Located within the gluteal cleft
- Located less than 2.5 cm above the anus
- Completely covered by skin

Certain findings associated with sacral or lower back dimples warrant further evaluation. These findings include:

- Location more than 2.5 cm above the anus
- Multiple dimples
- Diameter greater than 5 mm
- Presence of cutaneous markers such as:
  - Duplicated gluteal cleft
  - Dermal sinuses (if discharge is present, immediate referral to neurosurgery is warranted due to risk of bacterial meningitis or intraspinal abscess.)
  - Mass or lipoma
  - Hypertrichosis
  - Vascular lesions (i.e., hemangioma or telangiectasia)
  - Dyschromic lesions
  - Aplasia cutis congenita
  - Polypoid lesions (i.e., skin tags or tail-like appendages)

MRI is more reliable than ultrasound for the diagnosis of OSDs. However, because ossification of the vertebral arches does not occur before 3 months of age, ultrasound is a useful, non-invasive tool for evaluating sacral dimples in the newborn nursery. If the ultrasound is abnormal, an MRI of the spine should be performed.

**Ear Tags and Pits**

The incidence of pre-auricular skin tags and/or ear pits (PSEP) is estimated to be 0.3-5%. Often PSEPs are familial, they are
twice more common in females than in males, and more common in blacks than whites. Infants with ear anomalies (as well as those with facial, head, or neck anomalies) have a higher risk for hearing impairment. Inclusion in the Universal Newborn Hearing Screening Program should detect hearing loss and OAE has been shown to be sufficient screening for infants with PSEPs. Babies with isolated PSEPs are not at increased risk for renal anomalies, however, isolated preauricular pits or tags accompanied by one or more of the following warrants a renal ultrasound:

- other malformations or dysmorphic features
- family history of deafness,
- maternal history of gestational diabetes.

In the absence of these findings, renal ultrasonography is not indicated.

**Forceps Marks**

Forceps marks may occur where instruments were applied and may be associated with nerve, soft tissue, or bony injury. Periorbital bruising may indicate an eye injury. Consult an ophthalmologist to evaluate for the presence of hyphema or vitreous hemorrhages. Ear injury may be associated with inner ear hemorrhage and fracture of the temporal bone requiring an ENT evaluation.

**Lacerations**

Lacerations may occur during cesarean sections and commonly affect the scalp, buttocks, and thighs. Superficial wounds can be treated with wound closure adhesive strips. Deeper wounds, especially if bleeding, should be sutured by Surgery. Consider a Plastic Surgery consult if the laceration is located on the face. Keep the affected areas clean to minimize risk of infection.

**Nipples, Extra**

Incidence of supernumerary nipples is 2 to 3 per 1000 live births. They are more common in darkly pigmented racial groups and occur along the milk line. The breast tissue may present as another fully developed nipple or as an oval, pigmented spot that is smaller than half the size of the normal nipple. There is no association with other anomalies.

**Rashes, Benign**

**Erythema Toxicum (urticaria neonatorum)** is the most common rash in term infants (40% to 50% of newborns) and is self-limiting and benign. It is not seen in premature infants and is rarely seen in postmature infants. It usually appears in the second or third day of life although it can be present at birth (18% to 20% of infants). It is seldom seen after 14 days of age. The etiology is unknown. Biopsy or a stain of the material in the lesions reveals eosinophils.

**Pustular melanosis** is a skin eruption consisting of vesicopustules and pigmented macules and has a reported incidence of 0.5% to 2% of newborn infants. The lesions usually are present at birth and are not associated with systemic symptoms or evidence of discomfort. The pigmented macules (freckles) persist for weeks to several months. It is a self-limiting, benign condition that requires no therapy and is more common in darkly pigmented infants.

---

**Scalp Electrode Marks**

Electrode marks result from direct monitoring of the fetal heart rate during labor. Applying an electrode to a fetal scalp or other presenting part may lead to lacerations, hematomas, and superficial abrasions. Usually only local treatment is required. If an abscess develops, evaluate for possible sepsis.

**Subcutaneous Fat Necrosis**

Subcutaneous fat necrosis is characterized by necrosis and crystallization of subcutaneous fat with an inflammatory and foreign-body–like giant cell reaction, which most often is found in the subcutaneous fat adjacent to a bony structure. This usually occurs during the first week of life and is described as a well-defined red or purple induration of variable size appearing on the skin. The nodules are not tender or warm. Most frequently it is seen in large-for-gestational-age infants, especially those born via vaginal or traumatic delivery, and those with birth asphyxia. There is risk of hypercalcemia when extensive subcutaneous fat necrosis is present. Lesions usually self-resolve within 1-2 months but may persist longer if calcified.

---

**10.5 Extracranial Swelling**

**Caput Succedaneum**

Caput succedaneum is a vaguely demarcated area of edema and bruising of the presenting portion of the scalp during a vertex delivery. The soft tissue swelling extends across suture lines and may be associated with petechiae, purpura, and ecchymoses. Usually no specific treatment is indicated and resolution occurs within several days.

**Cephalohematoma**

A cephalohematoma is a subperiosteal collection of blood usually affecting the parietal bones. The bleeding generally occurs during labor or delivery and is caused by the rupture of diploic blood vessels. The incidence is 0.4% to 2.5% of live births.

**Clinical Manifestations**

A cephalohematoma is sharply demarcated by periosteal attachments to the surface of one cranial bone and will not extend across suture lines. Cephalohematomas are characterized by the absence of overlying discoloration and potentially delayed appearance due to slow subperiosteal bleeding. Generally, cephalohematomas are benign; however, some may be associated with complications such as skull fractures (rare), hyperbilirubinemia, hyperkalemia, infection, and anemia.

**Management**

Cephalohematomas typically require no intervention and spontaneously resorb by 2 weeks to 3 months of age. Calcification may occur when the hematoma does not resolve spontaneously. Calcium deposits can cause a bony swelling that may persist for several months, less often years, and rarely even into adulthood. Incision or aspiration of the cephalohematoma is contraindicated.
Subgaleal Hemorrhage

Subgaleal hemorrhage (SGH) is a form of extracranial bleeding that occurs just under the scalp and may become massive and life-threatening. The occurrence of SGH is highest with vacuum extraction deliveries, but can also occur with spontaneous vaginal delivery. The incidence of SGH is estimated to be 59/10,000 for vacuum extraction deliveries and 4/10,000 for spontaneous vaginal deliveries. The risk of SGH increases with failed vacuum extraction, “rocking” motion of the vacuum cap on the newborn skull, and multiple pulls with the vacuum. The source of the bleeding is thought to be from rupture of emissary veins causing blood accumulation between the galea aponeurosis of the scalp and the periosteum.

Clinical Manifestations

Subgaleal hemorrhage may present with rapidly progressing, diffuse cranial swelling, ill-defined borders, and firm, pitting, or fluctuant consistency possibly with fluid waves. SGH often displaces the ears anteriorly and causes periorbital swelling and ecchymosis. The anatomic limits of SGH include the fronto orbital margins, posterior nuchal ridge and lateral temporal fascia. Extracranial symptoms include signs of hypovolemia (pallor, tachycardia, shock) and CNS injury (lethargy, hypotonia, seizures). The potential for massive blood loss into this space (up to the entire neonatal blood volume) contributes to the high mortality rate of 25% associated with this lesion. (Table 10–1.)

Table 10–1. Features of extracranial swelling

<table>
<thead>
<tr>
<th>Feature</th>
<th>Cephalohematoma</th>
<th>Subgaleal hemorrhage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>crosses sutures</td>
<td>crosses sutures</td>
</tr>
<tr>
<td>Findings</td>
<td>firm edema</td>
<td>diffuse, shifts</td>
</tr>
<tr>
<td></td>
<td>vaguely</td>
<td>dependently, fluid-like</td>
</tr>
<tr>
<td>Timing</td>
<td>noted at birth</td>
<td>at birth or hours later</td>
</tr>
<tr>
<td>Blood Volume</td>
<td>None to very little</td>
<td>10-40 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;50-40 mL</td>
</tr>
</tbody>
</table>

Evaluation and Management

Treatment of SGH begins with early recognition and is an important key to intact survival. When subgaleal hemorrhage is suspected, the infant must be closely monitored in the NICU, with frequent vital signs, serial head circumference measurements, serial hematocrits, and close observation for signs of hypovolemia. The infant’s head circumference will increase 1 cm with each 40 mL of blood deposited in the subgaleal space. Treatment includes volume resuscitation initially with normal saline, followed by packed red cells and fresh frozen plasma when available to promptly restore blood volume. If SGH is suspected (and the infant is stable) a head CT will be helpful in distinguishing SGH from other forms of extracranial swelling. A neurosurgical consultation should be obtained for infants who continue to worsen despite aggressive volume resuscitation.

10.6 Feeding
Breastfeeding

Breastfeeding has long been recognized as the superior form of nutrition during the first year of life. The American Academy of Pediatrics (AAP) recommends exclusive breastfeeding for the first 6 months of life and encourages practitioners to “promote, protect, and support” the practice of breastfeeding. Formula fed infants have significantly more respiratory, middle ear, and gastrointestinal infections than breast -fed infants. Additionally, formula -fed babies are more likely to develop allergic and autoimmune infections and have a higher incidence of Sudden Infant Death Syndrome (SIDS). Physicians should encourage all mothers to breastfeed and must be able to assist new mothers with common breastfeeding issues.

Lactation Consultations

All BCM-affiliated hospitals have Lactation Consultants who can provide information about breastfeeding to parents and hospital staff. These consultants function to aid breastfeeding mothers, and are competent in the evaluation of the mother-baby breastfeeding dyad. All breastfeeding mothers should be offered a lactation consult during the postpartum/newborn hospital stay.

Contact Information for Lactation consultants:

• Texas Children’s Hospital – 832-824-6120
• Ben Taub Hospital, Breastfeeding Clinic - 713-873-3350

Methods and Practices

A newborn should be put skin to skin with mother as soon after delivery as possible and allowed unlimited access to the breast. The AAP recommends the initiation of breastfeeding within the first hour after birth. If the mother is unable to breastfeed immediately after delivery, donor breast milk may be available in some hospitals for baby’s first feedings. Breastfeeding should occur with baby hunger cues, usually at a frequency of 8-12 times a day, and lasting until the infant is satisfied, which is usually for a duration of 10 to 15 minutes on each breast. Breastfeeding is a supply-and-demand phenomenon; frequent and effective emptying of the breast promotes a more plentiful milk supply. Frequent breastfeeding is necessary for a good milk supply to be established. Water supplements should not be given to newborns. Introduction of a pacifier before breast feeding is well established (~ first 4 weeks of life) should be discouraged as it may decrease breastfeeding success.

Assessment of Breastfeeding

Infant signs of effective breast feeding include:

• Maintains deep latch on to breast.
• Long jaw movements observed
• Some swallowing heard/observed
• Minimal to no maternal discomfort

Assess all breast-fed newborns for adequate hydration status within a few days after delivery, especially if mother is nursing for the first time.
The following are guidelines for breastfeeding and output during the first few days:

- **Birth-24 hours:**
  - Frequent Skin to Skin (STS)
  - At least 8 breastfeeding attempts (volume will be ~2-7 ml/meal)
  - 1 urine/1 or more stool

- **24-48 hours:**
  - Frequent STS
  - ≥8 breastfeeding (volume will be ~5-15 ml/meal)
  - 2 urine/2 or more stools

- **48-72 hours:**
  - ≥8-12 breastfeeding (volume will be ~10-20 ml/meal)
  - 3 urine/3 or more stools.

Most babies have at least 1 wet diaper for each day of life up to day 6, at which time expect about 6 wet diapers per day. The breastfed newborn usually has 1 stool with each feeding, however, stooling patterns are variable and should not be exclusively used as an indicator of effective breast feeding. The stools of breastfed babies are typically yellow, seedy and have a loose consistency, while formula stools are more formed and occur less frequently. Mothers who are nursing for the first time may need additional reassurance that these stools are normal. Loose bright green stools in a breastfed infant may be an indication that the mother has an oversupply of milk and the infant is getting too much foremilk compared to hindmilk. In these situations, the mother may need lactation assistance in achieving a more appropriate balance of foremilk and hindmilk for the infant.

**Ankyloglossia**

Ankyloglossia, commonly known as tongue-tie, is a congenital oral anomaly characterized by an abnormally short or tight lingual frenulum which restricts the mobility of the tongue. Ankyloglossia in the newborn has a reported incidence as high as 4.8%, is more common in males and often runs in families.

Per the AAP Section on Breastfeeding, “Tongue-tie is a significant clinical entity which, when symptomatic, should be treated as early as possible.” Several published studies have shown frenulotomy to be an effective means to resolve breastfeeding difficulties associated with ankyloglossia. In infants with suspected ankyloglossia, collaboration between the baby’s nurse, the lactation team, and the pediatrician should occur to help identify candidates for frenulotomy. Lactation consultants in some of our institutions utilize an objective tool when assessing babies with feeding difficulties and suspected ankyloglossia. (Table 10–2)

**Supplementation: Healthy Term Newborns**

A mother who plans to breastfeed should be encouraged to feed her baby on demand and avoid any formula supplementation. If medically indicated, babies can be supplemented with expressed breast milk (EBM), pasteurized donor human milk or, if these are not available standard infant formulas can be used. When supplementation is medically necessary, the volume given to the infant should be appropriate for his/her age in order to prevent overfeeding that can interfere with breastfeeding (see “Supplementation Guidelines” below).

**Indications for Supplementation: Infant Issues**

- Asymptomatic hypoglycemia unresponsive to appropriate and frequent breastfeeding
- Significant dehydration (10% weight loss or greater with insufficient urine output, hypernatremia, lethargy, poor feeding) not improved with lactation support and intervention.
- Weight loss of greater than 7% associated with delayed lactogenesis II (DOL 5 or later).
- Continued meconium stools on DOL 5
- Poor milk transfer despite an adequate milk supply

### Table 10-2. Tongue range of motion

<table>
<thead>
<tr>
<th>Circle “Yes”, “No” or “Unable to Assess” for each assessment item and record totals below</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LOOK</strong></td>
</tr>
<tr>
<td><strong>Rounded tongue tip?</strong></td>
</tr>
<tr>
<td>Stimulate tongue movement by running finger pad along lower and upper gum ridge and/or brushing lips in downward motion</td>
</tr>
<tr>
<td><em>Observe tongue tip as rounded without evidence of cleft, notch, tension or distortion with movement</em></td>
</tr>
<tr>
<td><strong>Motion of tongue wave-like?</strong></td>
</tr>
<tr>
<td>Insert pinky finger pad-side up to junction of hard and soft palate; feel the tongue movement on finger during suck bursts</td>
</tr>
<tr>
<td><em>Complete, rhythmic peristalsis with each suck; begins with tip elevation to mid-blade to posterior tongue; NO AREA FLAT</em></td>
</tr>
</tbody>
</table>

Two or more “NO” items may indicate a restrictive range of motion and potential feeding difficulties **TOTAL FOR EACH ITEM**
Indications for Supplementation: Maternal Issues

- Sheehan syndrome (Postpartum hemorrhage followed by absence of lactogenesis)
- Primary glandular insufficiency
- Breast pathology/surgery resulting in poor milk production.

Supplementation Guidelines

**Type:** Colostrum/EBM and/or DBM (donor breast milk) is first choice, then formula.

**Method:** tube feeding at breast (such as Medela® Supplemental Nursing System (SNS) or Lact Aid Nursing Trainer) is first choice where available, then syringe, spoon, cup, or bottle. Method should be determined in consultation with mother.

**Amount per feed:**
- Birth-24 hours: 2-5 mls
- 24-48 hours: 5-15 mls
- 48-72 hours: 15-30 mls

**Supplementation, Vitamins and Iron**

The AAP recommends exclusive breastfeeding for 6 months. Exclusive breastfeeding for more than 6 months has been associated with increased risk of iron deficiency anemia at 9 months of age. It is recommended that starting at 4 months of age, exclusively breastfed term infants receive an iron supplementation of 1 mg/kg/day and continue supplementation until appropriate iron-containing complimentary foods have been introduced. The AAP also recommends a daily intake of vitamin D of 400 IU/day for all infants. Breastfeeding infants can achieve this with an over the counter infant vitamin D supplement (i.e., 1 ml/day of D-Vi-Sol®) beginning in the first few days of life. Breastfed term infants who are < 2500 g birthweight need a daily iron supplement in addition to vitamin D. (Sec 12-Nutrition) For a lactating mother on a normal diet, the need for vitamin supplementation is not well documented. Some vegetarian diets (especially vegan diets) are deficient in B12, and B12 deficiency has been documented in breastfed infants of some vegetarian mothers. Thus, continued intake of prenatal vitamins may be helpful for lactating vegetarian women.

**Weight Loss**

Infant weight loss during the first several days after birth is physiologic. The AAP recommends prompt evaluation of newborns with > 7% weight loss with a careful feeding history, physical exam, and breast feeding assessment (see Assessment of Breastfeeding above). Historically, weight loss of up to 10% has been considered within normal limits. Babies delivered by C-section tend to lose more weight than babies delivered vaginally. A recent study of exclusively breast fed infants demonstrated 50%tile for weight loss to be 7% for vaginally delivered infants, and 9% for infants delivered by C-section.

Infants should stop losing weight by DOL 5 and typically regain their birthweight by 10-14 days of age. Once feeding is established, newborns are expected to gain 20-30 gm/day. If intake seems sufficient and weight loss persists, consider evaluation for failure to thrive.

**Working Mothers**

Ideally, nursing mothers should continue to provide their infants with human milk after returning to work. An efficient, double electric breast pump can facilitate this (hand powered or battery powered pumps are less effective in maintaining a milk supply). Federal law (Section 7 of the Fair Labor Standards Act) requires an employer to provide both reasonable break time and a place, other than a bathroom, that is shielded from view and free from intrusion for an employee to express breast milk for her nursing child for one year after the child’s birth. If neither nursing nor expressing milk at work is desired by the mother, she should be encouraged to continue nursing whenever with her infant and to supplement feedings with an iron-containing formula while separated from her infant. If good breastfeeding has been established, the mother’s body usually will adjust to the new schedule.

**Contraindications to Breastfeeding**

(See also Sec. 12-Nutrition)

Very few contraindications to breastfeeding exist. These include:

- Infants with classic galactosemia
- Mothers who are positive for human T-cell lymphotropic virus type I or II
- Mothers with untreated brucellosis
- Maternal active, untreated tuberculosis (TB)(breastfeeding is allowed after a minimum of 2 weeks of treatment and documentation that the mother is no longer infectious)
- Active herpes simplex lesions on the breast
- HIV-positive mother (in the U.S.)
- Maternal illicit drug use

**Maternal Medications**

Most medications are thought to be compatible with breastfeeding, although few have actually been well studied. Additionally, breastfeeding is generally not recommended for mothers receiving medication from the following classes of drugs: amphetamines, chemotherapy agents, ergotamines, and statins. If mothers desire to breastfeed while taking a medication with some potential risk to the infant, it may be beneficial to consult with a pharmacist in order to determine the optimal timing of medication administration in relation to breastfeeding to decrease the transmission of the medication into breastmilk.

Useful resources for determining the safety of maternal medications while breastfeeding include:

- LactMed: an internet source with comprehensive information regarding the safety of maternal medications and breastfeeding. This website can be accessed at http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm
- “Medications in Mothers” by Dr. Thomas Hale.
- Additional information on this topic can be accessed via Dr. Hale’s website at http://www.infantrisk.com

**Formula and Expressed Breast Milk**

Breast feeding is the ideal and most physiologic method of infant feeding, but there are circumstances in which an infant may need to be bottle fed either with expressed breast milk (EBM) or formula.
Many of the immune benefits of breastfeeding will be delivered by bottle-feeding with EBM, depending upon how the EBM is collected, the storage temperature and the length of time it is stored. Therefore, expressed breast milk feeding is preferable to formula feeding. Risks exist with both expressed breast milk and formula feeding. These include contamination/infection risks, improper mixing of formula and breast milk and formula feeding. Knowledge of proper storage and preparation are essential to mitigating these risks.

Expressed Breastmilk Storage
EBM may be safely stored at different temperatures for a variety of time frames (Table 10-3). To thaw frozen EBM, place the frozen EBM in a refrigerator overnight or in a bowl of warm water. Never microwave breastmilk to warm it. After thawed, it must be used within 24 hours. Milk left in the feeding container after a feeding can be contaminated with oral flora and should not be reused.

Table 10-3. Expressed breastmilk storage

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room temperature (up to 77°F or 25°C)</td>
<td>6 to 8 hours</td>
</tr>
<tr>
<td>Insulated cooler bag with ice packs</td>
<td>24 hours</td>
</tr>
<tr>
<td>Refrigerator (39º F or 4º C)</td>
<td>5 days</td>
</tr>
<tr>
<td>Freezer compartment within a refrigerator (5ºF or -15ºC)</td>
<td>2 weeks</td>
</tr>
<tr>
<td>Freezer compartment of refrigerator/freezer with separate door (0ºF or -18ºC)</td>
<td>3-6 months</td>
</tr>
<tr>
<td>Deep freezer (-4ºF or -20ºC)</td>
<td>6-12 months</td>
</tr>
</tbody>
</table>

Formula Preparations
In the newborn nursery, an iron-fortified, 19-20-calorie-per-ounce bovine milk-based formula is suitable for most term babies. 19 cal/oz formula is not recommended for use in babies less than 37 0/7 weeks gestation. Several types of formula are available:

- **Ready-to-Food** - No preparation is required and if unopened, can be left at room temperature until expired. This is the most convenient and sterile preparation, but also the most expensive.

- **Concentrate** - Mix equal parts of formula concentrate and water. Use prepared formula within 2 hours of preparation if left at room temperature. Formula concentrate can be stored in a refrigerator for up to 48 hours if covered.

- **Powder** - Thoroughly mix 1 level scoop with 2 ounces of sterile water. Powder formula is lightweight and the least expensive. Unmixed powder may be stored in a bottle for several days without spoiling. Bacterial contamination of powdered formulas has been reported. However, in general, the use of powder infant formulas is safe for healthy full-term infants, although caution should be used, especially in the first month to ensure clean technique in preparing the formula.

Bottle Feeding During the First Weeks
Bottle fed term newborns will often eat more than breastfeed infants, especially in the first few days. They usually start by feeding approximately 0.5 ounce (15 ml) per feed and increase gradually. Infants usually will take 2 to 3 ounces every 3 to 4 hours during the first few weeks. By the end of the first month, they typically will take 4 ounces every 4 hours. Feeding on demand usually is best. Supplemental iron and vitamins are generally not needed for term infants receiving iron-fortified formula, unless the infant is SGA. (Ch 12.3-Enteral Nutrition)

10.7 Hospital Discharge
The AAP Committee on the Fetus and Newborn recommends that the hospital stay of the mother and her infant be long enough to identify early problems and to ensure adequate maternal recovery and readiness for discharge. An assessment of maternal and family preparedness and competency to provide newborn care at home is a condition for discharge. Every effort should be made to keep mothers and infants together in support of a simultaneous hospital discharge.

Minimum Criteria for Discharge

- Normal physical examination and uncomplicated perinatal course that has not identified any abnormalities requiring continued hospitalization.
- Stable vital signs for 12 hours before discharge, including thermal stability in open crib.
- Infant has completed 2 successful, consecutive feedings and has urinated adequately and passed stool spontaneously at least once. Successful latch, swallow, and satiety of the breast fed infant should be documented in the medical record by a caregiver knowledgeable in breastfeeding. The ability to coordinate sucking, swallowing and breathing should be documented for bottle fed infants.
- Infant has been adequately monitored for sepsis based on maternal risk factors and in accordance with current guidelines for management of neonates with suspected or proven early-onset sepsis.
- Maternal laboratory data has been obtained and reviewed as normal or negative.
- Infant laboratory data has been obtained and interpreted.
- Newborn metabolic, hearing, and CCHD screening has been performed.
- Clinical risk for subsequent hyperbilirubinemia has been assessed. Follow-up plans have been instituted as recommended in the AAP’s clinical practice guidelines for the management of hyperbilirubinemia.
- No evidence of excessive bleeding from circumcision site for at least 2 hours.
- Appropriate education to mother has been provided regarding normal feeding and voiding patterns, general infant care and jaundice recognition.
- If not previously vaccinated, the infant’s mother should receive the Tdap vaccine immediately after the infant is born. Other adult family members or caretakers who anticipate close contact with the infant should be encouraged to receive the Tdap vaccine.
- Family, environmental, and social risk factors (domestic violence, history of child abuse/neglect, homelessness, teen mother, history of substance abuse) have been assessed and addressed.
• Family members, or other support persons, familiar with newborn care are available to the mother and infant after discharge.

• A car safety seat that meets Federal Motor Vehicle Safety Standard 213 has been obtained and is available before hospital discharge.

Early Discharge
Infants discharged early, as defined by a postpartum length of stay less than 48 hours, must be at least 37 0/7 weeks old, have a normal physical examination, uncomplicated perinatal course and have outpatient follow-up within 48 hours of discharge; If this cannot be ensured, discharge should be deferred until a mechanism for follow-up is identified. A permanent medical home for the infant should also be identified prior to discharge. When considering an infant for early discharge, it is important to perform a careful, thorough evaluation to identify problems that could present after discharge. Potentially serious neonatal problems that may not present before 48 hours of life include:

• hyperbilirubinemia (Ch 7.5-Management of Neonatal Jaundice),
• gastrointestinal obstruction
• ductus-dependent congenital heart defects
• bacterial and viral sepsis including HSV
• inborn errors of metabolism.

It is imperative to instruct mothers about early recognition of danger signs (lethargy, poor feeding, respiratory distress, temperature instability, and seizures). A follow-up appointment should be scheduled and its importance emphasized to the infant’s primary caregiver before the newborn is discharged early.

Infants of group B streptococcus-positive mothers are not eligible for early discharge with one exception. Newborns ≥ 37 weeks gestation, whose mothers received adequate intrapartum GBS prophylaxis, may be eligible for early discharge if continued close observation at home can be assured and early follow-up (within 24 hours) with the pediatrician has been arranged.

The timing of discharge should be the decision of the physicians caring for the mother and the newborn based on these guidelines. For infants born at Ben Taub, the Texas Health Steps Newborn Follow-Up Clinic is recommended for all infants discharged early.

10.8 Neuromusculoskeletal Consequences of Labor and Delivery
Since many clinical findings (e.g., prolonged labor, macrosomia, dystocia, and cephalopelvic disproportion) are related to the malposition of an infant, such consequences of labor and delivery may be unavoidable despite superb obstetrical care.

Fractures
Clavicle - The clavicle is the most frequently fractured bone in newborns (0.2% to 16% of vaginal deliveries). Most often, the fracture is unilateral and greenstick type but may be displaced. Frequently, they are asymptomatic. Discoloration, swelling, localized crepitus, and absent ipsilateral Moro reflex may be observed. Non displaced fractures may have minimal or no findings on the first day exam. If pain is associated with the fracture, it can be splinted by pinning the infant’s sleeve to the chest with the elbow flexed at 90 degrees for comfort. Pain usually subsides by 7 to 10 days when a callus forms at which time immobilization may be discontinued. The great majority of clavicular fractures will present with minimal or no findings in the first few days of life. An x-ray can be obtained to document the fracture was present at birth.

Humerus - The humerus is the second most common bone fractured. The fractures usually are in the diaphysis. Occasionally the fracture is complete with overriding of the fragments. A greenstick fracture may be overlooked until a callus is present. A complete fracture frequently presents with immobility of the affected arm and an absent ipsilateral Moro reflex. Treatment is immobilization in adduction for 2 to 4 weeks maintaining the arm in a hand-on-hip position with a triangular splint or Velpeau bandage. Healing is associated with callus formation and union of fragments occurring by 3 weeks. Obtain Orthopedics consult.

Femur - Femoral fractures are relatively uncommon. They occur in the middle third of the shaft and are transverse. Frequently there is an obvious deformity or swelling of the thigh associated with pain and immobility of the affected leg. Traction-suspension may be necessary for shaft fractures. The legs may be immobilized in a Spica cast or a simple splint for up to 3 to 4 weeks until adequate callus has formed and new bone growth started. Obtain Orthopedics consult.

Skull - Skull fractures are uncommon because at birth the skull bones are less mineralized and more compressible than other bones. Open sutures also allow alterations in the head’s contour, easing passage through the birth canal. Skull fractures can be linear or depressed, and are easily diagnosed with plain radiographs of the skull. Linear fractures usually heal within several months and rarely will a leptomeningeval cyst develop. Depressed skull fractures with a visible indentation on the skull and are often associated with a forceps assisted delivery; in these instances, further imaging (CT scan) is recommended to assess for associated intracranial lesions. Neurosurgical consultation is necessary for depressed skull fractures greater than one centimeter in depth and/ or associated intracranial lesions, as these usually require surgical intervention.

Neurological
Brachial Plexus Palsies
The incidence of birth-related brachial plexus injury varies from 0.3 to 2 per 1000 live births. Brachial plexus injury is manifested by a transient or permanent paralysis involving the muscles of the upper extremity after trauma to the spinal roots of C-5 through T-1 during birth. Depending on the site of injury, the forms of brachial plexus palsy commonly seen are Erb palsy, Klumpke palsy, and facial nerve palsy.

Erb palsy - is the most common injury and presents with the affected upper extremity being limp, the shoulder adducted and internally rotated, the elbow extended, the forearm pronated, and wrist and fingers flexed (waiter’s tip position) resulting from injury of C-5 and C-6 roots.

Klumpke palsy - is less common and presents with lower arm paralysis involving the intrinsic muscles of the hand and the long flexors of the wrist and fingers resulting from injury of C-8 and T-1 roots. Dependent edema, cyanosis, and atrophy of
Developmental Dysplasia of the Hips
Examination to identify developmental dysplasia of the hips (DDH) is the most common musculoskeletal evaluation in the neonatal period. DDH is an evolving process and is not always detectable at birth. Hip dysplasia may occur in utero, during perinatal period, or infancy and childhood. All newborns should be examined for hip dislocation, and this examination should be part of all routine health evaluations up to 2 years of age, when a mature gait is established. The etiology of DDH is unknown, but appears to involve physiologic factors (i.e., ligamentous laxity) and mechanical factors (i.e., intrauterine positioning).

Most infants with a birth-related brachial plexus injury (90% to 95%) require only physical therapy. The primary goal of treatment is prevention of contractures while awaiting recovery of the brachial plexus. Partial immobilization and appropriate positioning are helpful in the first 2 weeks because of painful traumatic neuritis. Referral to OT/PT while the baby is hospitalized is encouraged. Outpatient follow-up of babies with brachial plexus injuries who are born at Ben Taub can be done at Shriner’s Hospital. A referral form will need to be completed before the appointment. Babies born at TCH will require outpatient referral to a pediatric orthopedist who specializes in this type of injury.

Facial nerve palsy - results from compression of the peripheral portion of the nerve by forceps or by prolonged pressure on the nerve by the maternal sacral promontory, a fetal tumor, or an abnormal fetal position. Central nerve paralysis from contralateral CNS injury involves the lower half or two-thirds of the face. Peripheral paralysis is unilateral; the forehead is smooth on the affected side and the eye is persistently open. With both forms of paralysis, the mouth is drawn to the normal side when crying and the nasolabial fold is obliterated on the affected side. Differential diagnoses include Möbius syndrome and absence of the depressor anguli muscle of the mouth (aka asymmetric crying facies). Radiologic and electro diagnostic studies may be indicated. Most facial palsies secondary to compression of the nerve resolve spontaneously within several days and most require no specific therapy except for the application of artificial tears to the eye when necessary to prevent corneal injury.

Phrenic Nerve Injury
Isolated phrenic nerve injury is rare. Diaphragmatic paralysis often is observed with the ipsilateral brachial nerve injury. Chest radiograph shows elevation of the diaphragm on the affected side. Fluoroscopy reveals elevation of the affected side and descent of the normal side on inspiration. Mediastinal shift to the normal side is noted on inspiration. Electrical stimulation of the phrenic nerve may be helpful in cases in which the palsy is secondary to surgery. The infant may present with signs of respiratory distress and may require mechanical ventilation. Most infants recover spontaneously.

Risk Factors for DDH include:
• Firstborns: due to the confines of the primigravid uterus.
• Breech positioning at > 34 WGA: DDH is associated in as many as 23% of breech presentations, even after external cephalic version (ECV). The left hip is involved more often than the right.
• Female gender (more than 6 times higher than males).
• Positive family history
• Diminished intrauterine space: i.e., LGA, multiple gestation, fibroids.

Additionally, careful hip examination should be performed for babies with musculoskeletal anomalies related to tight intrauterine “packaging”, such as congenital torticollis and metatarsus adductus.

Assessment and Management
Diagnostic clues to DDH include:
• asymmetrical number/placement of thigh skin folds
• lack of spontaneous movement in lower extremities
• uneven knee levels (Galeazzi sign)
• discrepancy in leg length
• limitation of hip abduction (generally not present in infants < 3 months of age)
• positive Klisic test (the line between the greater trochanter and the anterior superior iliac spine passes below the umbilicus instead of a normal trajectory through the umbilicus)
• positive Barlow test (a “clunking” sensation when the femur – at a 90-degree angle to the examining surface – is dislocated posteriorly when light, downward pressure, is applied to the knee).
• most important: positive Ortolani test (a “clunking” sensation when the physician abducts the thigh to the table from the midline while lifting up on the greater trochanter with the finger).

If the newborn has a positive Ortolani test, or limited or asymmetric abduction, obtain a Pediatric Orthopedic consultation. Repeated hip exams should be limited for babies with suspected DDH.

For infants with a positive Barlow maneuver, serial exams by the PCP or Orthopedic Surgery should be performed to ensure hip stability. In the Ben Taub nurseries, Orthopedic Surgery should be consulted for babies with a positive Ortolani or Barlow test, and outpatient follow-up at Shriner’s Hospital or Texas Children’s Hospital should be arranged. At TCH, the Orthopedic Surgery service should be consulted for babies with suspected DDH, with outpatient follow-up arranged per the consulting physician.
Infants with risk factors (male or female breech > 34 WGA, family history of DDH, or history of clinically unstable hip) who have a normal exam during the newborn hospitalization should be referred for outpatient hip ultrasound at 6 weeks of age.

Jitteriness
Jitteriness in the newborn is a frequent finding and often is confused with neonatal seizures. Many potential etiologies exist, including metabolic disturbances, hypoxic-ischemic encephalopathy, drug withdrawal, hypoglycemia and hypocalcemia. A distinguishing feature is that jitteriness tends to be stimulus-sensitive, becoming most prominent after startle, and its activity can cease by holding the baby’s arm, neither of which is true for seizures. These movements are not accompanied by EEG changes and require no specific treatment. Jitteriness from drug withdrawal often presents with tremors, whereas clonic activity is most prominent in seizures. Reversing transient metabolic disturbances can reduce the jitteriness.

Positional Deformities
Postural, or positional, deformities include asymmetries of the head, face, chest, and extremities. They are often associated with conditions related to intrauterine crowding such as, primigravid uterus, multiple gestation, LGA infants, etc. Most correct spontaneously. The most common positional deformities involve the feet.

Positional Deformations of the Lower Extremities
Metatarsus adductus is the most common congenital foot deformity in which the forefoot is adducted while the hind foot remains in neutral position. It is due to intrauterine positioning and a small percentage of these infants have congenital hip dysplasia, thus warranting a careful examination of the hips. Treatment is usually conservative as 90% + will resolve without intervention.

Calcaneovalgus feet is a common newborn positional deformity in which the hind foot is in extreme dorsiflexion while the forefoot is abducted. Treatment is usually conservative and the condition typically resolves in the first 6 months of life.

Talipes Equinovarus (Clubfoot) is a complex condition that involves both the foot and lower extremity. It is characterized by the foot being excessively plantar flexed, with the forefoot swung medially and the sole facing inward. Club feet can be can be classified as follows:

- Congenital clubfoot is the most common type. It is usually an isolated anomaly without a well-delineated etiology. Current management is based upon manipulation that includes casting and bracing (referred to as the Ponseti method).
- Syndromic clubfoot is associated with intrinsic etiologies of club feet including connective tissue, genetic or neuromuscular disorders, or syndromes, i.e. spina bifida, myotonic dystrophy, trisomy 18, etc.

- Positional clubfoot is due to intrauterine crowding or breech position. It is not a true club foot. It is a normal foot that has been held in a deformed position in utero. The positional clubfoot easily corrects to a normal position with manipulation. It usually self-resolved by 4-12 months of age.

Polydactyly
Polydactyly is the most common hand anomaly noted in the newborn period; reported incidence is 1:300 live births for blacks and 1:3000 for whites. The inheritance pattern may be autosomal recessive or autosomal dominant. It can be an isolated malformation or part of a syndrome.

The most commonly seen defect in the nursery is postaxial (ulnar) polydactyly. Often, the extra digit is pedunculated and without bone. Ligation by tying off the extra digit with suture carries the risk of infection and undesirable cosmetic outcome. Thus, consultation with Pediatric Surgery is recommended for removal. If bone is present in the extra digit, outpatient follow-up with pediatric surgery, plastic surgery or orthopedics should be arranged when the baby is older, as the procedure is more complicated when bone is involved.

Syndactyly
Syndactyly (isolated syndactyly) is reported in 1:3000 live births and may be either a sporadic finding or an autosomal dominant trait. Syndactyly of the second and third toe is the most commonly reported location of the anomaly (noted to affect more males than females). The second most frequent type is isolated syndactyly of the middle and ring fingers. When present in the hand, surgery usually is performed to improve function. If noted on the feet, surgery is indicated if the toes are angular.

Newborn Falls
Newborn falls in the hospital are uncommon and typically occur in the setting of co-sleeping, or when a breast feeding baby slips out of the arms of a sleepy mother. Newborn drops are also reported in the literature, occurring when a weak or sleepy caregiver attempts to stand-up while holding the newborn. Upon admission, many of our Baylor-affiliated nurseries provide education regarding the risks of newborn falls and require the mother to sign an agreement that she will not co-sleep with her baby, and that she will call for assistance when she feels too tired to care for her newborn independently. Guidelines for management of a newborn who has fallen or been dropped are as follows:

- Immediate examination by a physician or advance practice provider.
- Assess the mechanism of injury (i.e. height of fall, type of surface on which baby landed).
- If there is concern for head injury, the preferred diagnostic test is head CT w/o contrast (not skull films), because intracranial hemorrhage may be present in the absence of skull fracture.
- Consider extended monitoring in the NICU.
10.9 Newborn Screening

**State Newborn Screening, Dried Blood Spot Screening**

Texas Department of State Health Services (DSHS) requires newborn blood spot screening for multiple genetic disorders and congenital conditions for which early intervention is expected to decrease morbidity and mortality of Texas newborns. Texas currently screens for 53 various disorders, 29 of which are core conditions, and 24 of which are secondary conditions. Secondary conditions are discovered during the testing for core conditions. These conditions are considered to be clinically significant and may lack a clear natural history or medical therapy. The disorders screened in Texas include: cystic fibrosis, congenital hypothyroidism, galactosemia, hemoglobinopathies, congenital adrenal hyperplasia, biotinidase deficiency, severe combined immune deficiency (SCID), and inborn errors of metabolism (amino acid disorders, organic acid disorders, and disorders of fatty acid oxidation). Regardless of feeding status or prematurity, specimens are collected on all newborns at 24 to 48 hours of age. A second newborn screen is repeated at one to two weeks of age. Blood transfusions can cause invalid results, therefore, the first screen should be collected prior to the first intervention, including babies on ECMO or babies requiring emergency blood transfusions. Transfused newborns must be retested six to eight weeks following transfusion. (Ch 6.2-Genetic Testing)

**Abnormal blood spot screens**

**Ben Taub General Hospital (BTGH)**

Abnormal newborn screen results are received through the Newborn Screening Program Office of Carolyn Fairchild. For infants still on the inpatient service, the primary medical team is notified. For discharged patients, primary follow-up is coordinated through DSHS with assistance through Carolyn Fairchild’s office when needed.

**Texas Children’s Hospital (TCH)**

Abnormal results of infants admitted to BCM Neonatology Attendings are routed to the Newborn and Infant Screening Service (NB ISS) (832-824-1093).

**Hearing Screening**

The prevalence of newborn hearing loss is approximately 1 to 2 per 1000 live births, with an incidence of 1-3 per 1000 in the normal newborn nursery population and 20 to 40 per 1000 in the NICU population. Only 50% of newborns with significant congenital hearing loss can be detected by high-risk factors. Newborn hearing screening using a physiologic assessment tool is required by law for all babies born in Texas. The rate of failed newborn hearing screens should be less than 5%. High risk infants, including those admitted to the NICU for more than 5 days, should be screened with auditory brainstem response (ABR) instead of an otoacoustic emissions (OAE). A urine or saliva CMV PCR or culture should be obtained on all newborns who fail the ABR (unilaterally or bilaterally). Hearing screening will occur prior to discharge, once screening criteria are met:

- ≥34 weeks
- in open crib

For newborns with a prolonged hospitalization, the goal is to screen by one month of age, if the above criteria have been met. Diagnosis of hearing loss should occur before 3 months of age, with intervention by 6 months of age. Infants readmitted to the hospital within the first month of life should be re-screened when there are conditions associated with potential hearing loss such as:

- Hyperbilirubinemia requiring exchange transfusion.
- Culture + sepsis/meningitis

**Critical Congenital Heart Disease (CCHD) Screening**

Congenital heart defects are the most common birth defect, with an incidence of 9/1000 births in the United States. Some of these defects are critical, requiring early intervention and management to save the life of the baby. In fact, Critical Congenital Heart Disease (CCHD) is the leading cause of death in infants less than 1 year of age. In the United States, 4800 infants (2/1000 live births) are born annually with CCHD. Early diagnosis and timely intervention of CCHD can significantly reduce morbidity and mortality and lead to better outcomes. Newborn screening with pulse oximetry has been shown to be useful for the detection of seven primary targets of CCHD. These seven defects represent 17–31% of all congenital heart defects.
These defects are:

- Hypoplastic Left Heart Syndrome
- Pulmonary Atresia (with intact atrial septum)
- Tetralogy of Fallot
- Total Anomalous Pulmonary Venous Return
- Transposition of the Great Arteries
- Tricuspid Atresia
- Truncus arteriosus

Texas law requires all newborns to be screened for CCHD. Screening should occur after 24 hours of age, but before hospital discharge. Screening is done by obtaining and comparing pre and post ductal oxygen saturations via pulse oximetry (Fig 10–1). Other heart defects are as severe as the main screening CCHD targets. Unfortunately, post oximetry screening does not detect these as consistently as the above seven CCHD disorders. Infants with a positive screen (fail) require prompt attention for further evaluation. Texas state law also requires reporting of all infants with confirmed CCHD.

**Risk Based Screening: Glucose Screening**

Babies at risk for hypoglycemia include those who are LGA, SGA, preterm (GA < 37 weeks), and infants of diabetic mothers (IDM). Babies who are in one or more of these categories should have an initial glucose screen at 30 mins to 2 hours of life, and at regular intervals during the first 12 to 24 hours of life to ensure euglycemia. 40% oral glucose gel is available in some Baylor-affiliated newborn nurseries for the initial treatment of hypoglycemia. Glucose gel is administered in conjunction with oral feeds (breast, EBM/DBM, formula). Refer to Sec 5- Endocrinology Chapters 5.4-6 for management of babies with persistent hypoglycemia despite administration of oral glucose gel and oral feeds.

10.10 Urology

**Single Umbilical Artery**

This anomaly occurs in 0.7% to 1% of singletons and in 3% to 7% of multiple births. The incidence is low in black infants and higher in neonates with aneuploidy or other congenital malformations. Among infants with a single umbilical artery (SUA), the prevalence of cardiac and renal anomalies is significantly higher than the general population (7% and 5% respectively). These infants are also 2 times more likely to have intratrauerine growth restriction. The finding of other associated anomalies is not specific for any one organ system. Further investigation of an infant with SUA is recommended only when another major anomaly is suspected. Infants with an isolated SUA generally have a good prognosis with similar outcomes to unaffected infants.

**Urinary Tract Dilation (UTD)**

**Introduction**

Advances in ultrasonography make possible an earlier and more accurate prenatal diagnosis of urinary tract abnormalities. Prenatal diagnosis of fetal urinary tract dilation (also termed antenatal hydronephrosis) occurs in 1-2% of all pregnancies.

UTD can be caused by a variety of conditions, such as (in order of prevalence):

- Transient dilation of the collecting system
- Ureteropelvic Junction obstruction (UPJ)
- Vesicoureteral reflux
- Ureterovesicular Junction obstruction (UVJ)
- Multicystic dysplastic kidney disease
- Posterior urethral valves
- Other anatomic abnormalities i.e. ureterocele, duplication, cysts etc.

Often, the cause of UTD cannot be diagnosed prior to birth, thus postnatal imaging is necessary to determine the etiology of UTD and guide further management.

**Risk factors for Postnatal Uropathy:**

UTD associated with the following ultrasonographic findings confers an increased risk of urinary tract pathology:

- Abnormal anterior-posterior renal pelvis diameter (APRPD) measurement. Knowledge of this measurement is necessary to direct the postnatal work-up of fetal UTD. (Table 10–5)
- Calyceal dilation
- Abnormal parenchymal thickness
- Abnormal parenchymal appearance
- Ureteral dilation
- Abnormal bladder appearance
- Unexplained oligohydranmios.

### Table 10-5. Normal APRPD Values

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt; 28 weeks</th>
<th>&gt;28 weeks</th>
<th>Postnatal</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRPD</td>
<td>&lt; 4 mm</td>
<td>&lt; 7 mm</td>
<td>&lt; 10 mm</td>
</tr>
</tbody>
</table>

must have postnatal evaluation of the urinary tract specifically, infants with antenatal hydronephrosis detected by third trimester ultrasound require postnatal evaluation. Postnatal evaluation is not needed for infants in whom antenatal hydronephrosis was seen on an earlier ultrasound, but has resolved by third trimester (or the most recent) prenatal ultrasound. Appropriate postnatal evaluation of UTD includes two ultrasound evaluations. Even if the first ultrasound is interpreted as normal, a second ultrasound needs to be obtained. Because the neonate has relatively low urine output in the first few days of life, there is a tendency to underestimate the severity of hydronephrosis when the postnatal ultrasound is done prior to 48 hours of age. Thus, it is recommended that the first ultrasound be done at >48 hours after birth, but before 2-4 weeks of age. The second ultrasound is performed at 1-6 months. Postnatal ultrasound prior to 48 hours of age is considered in the following scenarios:

- Antenatal ultrasound findings concerning for obstructive urinary tract pathology (i.e. fetal hydronephrosis or other findings suggestive of bladder outlet or urethral obstruction)
- If appropriate outpatient follow-up cannot be ensured. Consultation with pediatric urology may be helpful to guide outpatient follow-up.
Consultation with pediatric urology may be helpful to guide outpatient follow-up.

**Urinary Tract Prophylaxis**

The use of amoxicillin prophylaxis to prevent urinary tract infections is controversial. To date, there have been no prospective randomized trials to evaluate the efficacy of prophylactic antibiotics in children with UTD. Amoxicillin prophylaxis (10 mg/kg once daily) for babies with a history of UTD is approached on an individualized basis.

**Circumcision**

**Indications**

The AAP states that, although health benefits are not great enough to recommend routine circumcision for all male newborns, the evaluation of current evidence indicates that the health benefits of newborn male circumcision outweigh the risks.

Additionally, the procedure’s benefits justify access to this procedure for families who choose it. Specific benefits identified include prevention of urinary tract infections, penile cancer, and transmission of some sexually transmitted infections, including HIV. Male circumcision performed during the newborn period has considerably lower complication rates than when performed later in life.

The decision to circumcise an infant should be one of personal choice for parents. It is important that parents discuss the risks and benefits of circumcision with their physician before delivery. If a decision for circumcision is made, the AAP recommends that procedural analgesia (local anesthesia) be provided; BCM-affiliated providers prefer either the subcutaneous ring block technique or dorsal penile nerve block using 1% lidocaine without epinephrine. 24% sucrose solution is provided to the infant orally during the procedure (Ch 9.6—Pain Assessment and Management).

**Contraindications**

Circumcision is contraindicated for:

- medically unstable infants
- infants with genital anomalies (i.e. hypospadias)
- Infants with a family history of bleeding disorders, (i.e. Von Willebrand, hemophilia): these infants should have appropriate screening laboratory tests before the procedure.
- Parental refusal of Vitamin K (in some units, including TCH and Ben Taub)
- Consider delaying circumcision in boys with bilateral cryptorchidism.

For premature newborns, the recommendation is to delay circumcision until the baby is close to hospital discharge. Circumcision is not contraindicated in infants with a history of urinary tract dilation.

Referral to a Pediatric Surgeon or Pediatric Urologist should be considered when:

- an infant is 44 weeks or greater corrected gestational age, or
- an infant’s weight is more than 10 pounds, or
- a size 1.6 Gomco is required, or any combination of these circumstances exist.

**Post-Procedure Care**

Closely observe infants for excessive bleeding for at least 1 to 2 hours post-circumcision. Parents should examine the area every 8 hours for the first 24 hours post-circumcision. Liberally apply petroleum jelly for at least 3 to 5 days to circumcisions done with a Gomco or Mogen clamp. Circumcisions done with a Plastibel clamp require routine hygiene only. Parents should report any erythema, edema, or foul odor of the penis. A white-yellowish exudate may develop on the penis; this is normal and is not an indication of infection. Infants usually void urine within 8 hours after circumcision. Discharge home should not be delayed while awaiting urine output in the recently circumcised newborn.

**Uncircumcised Infants**

Parents should keep their baby’s penis clean with soap and water, as would be done for the rest of the diaper area. They should be counseled that the foreskin will adhere to the glans for several months to years and, therefore, should not be forcibly retracted. When the foreskin is easily retractable, it should be retracted during each bath so the glans can be cleaned. After cleaning, the foreskin should be reduced over the glans.

**Cryptorchidism (Undescended Testes)**

Undescended testes represent the most common genital anomaly in male infants. The incidence is 1:125 male infants but is much higher in premature infants and those with a positive family history. Cryptorchidism may be unilateral (75% to 90%) or bilateral (10% to 25%), with the right testis more commonly involved than the left.

Descent of the testes occurs during the last 3 months of gestation and is under hormonal control. A cryptorchid testis may be anywhere along the line of testicular descent, most commonly in the inguinal canal.

A cryptorchid testis may be confused with a retractile testis, an otherwise normal testis with an active cremasteric reflex that retracts the testis into the groin. This testis can be “milked” into the scrotum. Potential implications of cryptorchidism include malignancy, infertility, testicular torsion, and inguinal hernia.

**Treatment**

Initial management of cryptorchidism is to confirm the condition, which is best done with serial physical examinations. When cryptorchidism is bilateral, ultrasonography can be useful for locating testes in the abdomen and confirming the newborn is male. In many boys, the testis will descend in the first few months of life thus, management after discharge includes monthly follow-up. However, testicular descent is extremely unlikely after 6 months of age. Ideally, surgical correction should be carried out by 1 year of age.

**Hernias**

Inguinal hernias are common in neonates but rarely are present at birth. They are most common in males and premature infants, and they present a risk of testicular entrapment and strangulation.

Guidelines for Acute Care of the Neonate, Edition 26, 2018–19
Hydroceles

Hydroceles arise from an abnormal collection of fluid in the tunica vaginalis that has failed to invaginate after descent of the testis. They are clinically recognized as scrotal masses that trans illuminate. At birth, up to 15% to 20% of male infants may have some degree of hydrocele. Complete spontaneous resolution can be expected within a few weeks to months.

Hypospadias

Hypospadias is defined as the urethra opening onto the ventral surface of the penis (as opposed to the tip of the penis) and is reported to occur in 3 to 8 per 1000 live births. Hypospadias is the second most common genital abnormality in male newborns. It occurs less frequently in blacks (0.4%) than in whites (0.6%). Approximately 87% of cases are glanular or coronal hypospadias, 10% are penile, and 3% are scrotal or perineal. Other anomalies that may be seen with hypospadias include meatal stenosis, hydrocele, cryptorchidism (8% to 10% of cases), and inguinal hernia (8% of cases).

Assessment and Management

Mild hypospadias (glanular to penile) without associated genital abnormalities or dysmorphic features is usually an isolated anomaly and requires no further work-up. Conversely, severe hypospadias (scrotal to perineal), is more likely to be accompanied by an endocrinopathy, disorder of sexual differentiation (DSD), and/or chromosomal abnormality.

Evaluation and management should include:

- history of possible maternal progestin or estrogen exposure,
- family history of hypospadias, endocrine or intersex disorders,
- careful genital examination to assess for accompanying anomalies (urethral meatus, chordee, scrotal folds),
- ultrasound assessment for absence of gonads and/or presence of a uterus if a DSD is suspected, particularly when hypospadias is accompanied by cryptorchidism. (Sec 5-Endocrinology)
- evaluation for gross abnormalities of the kidneys (if the hypospadias is severe),
- measurement of stretched penile length.

Further diagnostic studies should be done depending on the risk for endocrine or intersex disorders, and appropriate consultative services should be involved (Urology, Endocrinology, etc.) Ideally, surgical repair of hypospadias is done late in the first year of life.

Testicular Torsion

Testicular torsion occurs most in newborns with cryptorchidism particularly in the neonatal period, infancy and, occasionally, in utero. It can present clinically as a scrotal mass with reddish to bluish discoloration of the scrotal skin. Usually, the patient is otherwise well. Torsion of the unpalpable cryptorchid testis is difficult to identify early because pain and irritability may be intermittent, and some neonates have an abdominal mass. Torsion can lead to irreversible damage of the testis within 6 hours of the occurrence. Testicular salvage is almost unheard of because the torsion often occurs prenatally during testicular descent.

Testicular torsion is considered a urologic emergency; call for a Urology consult as soon as the diagnosis is suspected.

Suggested Reading

Section 11: Gastroenterology
Editors: Amy Hair and Muralidhar Premkumar

11.1 Spontaneous Intestinal Perforation ..........156
  Viral Dave
  Tiffany Molina

11.2 Intestinal Failure and
  Intestinal Rehabilitation.......................157
  Nidia Espinosa
  Laura Gollins
  Amy Hair
  Adriana Massieu

11.3 Cholestasis .............................................158
  Athis Arunachalam
  Laura Gollins
  Agnes Mandy

11.4 Intravenous Lipid Emulsions.....................160
  Muralidhar Premkumar

11.5 Gastroesophageal Reflux .........................161
  Amy Hair
  Adriana Massieu
  Jennifer Placencia
11.1 Spontaneous Intestinal Perforation (SIP)

SIP is an abdominal emergency most commonly seen within the first 10 days of life of VLBW and ELBW preterm infants. It is characterized by an isolated perforation of the terminal ileum. Prevalence is 2-3% in VLBW and 5% in ELBW infants. Median gestational age of affected neonates is 25-27 weeks, with a male predominance. Mortality and neurodevelopmental morbidity is comparable to that of NEC, with estimations of death as high as 19-39%.

Risk Factors
Prematurity and early exposure (<8 days of age) to postnatal dexamethasone has been shown to increase the risk of SIP. The correlation between SIP and either postnatal hydrocortisone or indomethacin exposure is not clear. However, feeding regimens may affect the risk of SIP, as early enteral feeding has been shown to decrease the risk of SIP regardless of indomethacin exposure.

Infection with coagulase-negative Staphylococcus or Candida albicans have been described in SIP. Whether these infections occur before or after SIP is unknown.

Presentation
Acute onset abdominal distension with hypotension in the first week (range 0-15 days) of life should raise the concern for SIP. Unlike NEC, infants with SIP may have a black-bluish discoloration of the abdomen that can extend to the groin region.

Diagnosis
SIP should be strongly suspected based on clinical findings in an infant in the first 10 days of life. Definitive diagnosis is based on operative findings of an isolated perforation with otherwise normal bowel.

Abdominal radiograph in the supine and cross-table lateral/left lateral decubitus position should be obtained in evaluation of an infant with suspected SIP. Findings may include pneumoperitoneum or a gasless abdomen without evidence of pneumatosis intestinalis or portal venous gas. Ultrasound may show echogenic free fluid. Laboratory studies may indicate leukocytosis, anemia, thrombocytopenia and elevated serum bilirubin and alkaline phosphatase.

Treatment
Initial management of infants affected by SIP includes cessation of enteral feedings, nasogastric decompression, intravenous antibiotics, appropriate parenteral nutrition, stabilization with fluid resuscitation and use of inotropic medication.

IV antibiotics should be administered empirically with ampicillin or vancomycin, gentamicin, and clindamycin.

Pediatric surgery should be consulted immediately. Surgical options consist of:

- Placing a percutaneous peritoneal drain (PPD), or
- Performing an exploratory laparotomy with bowel resection

Current evidence supports surgical intervention with PPD as the initial treatment for SIP. PPD, a bedside procedure that avoids the risks of anesthesia and laparotomy in severely ill infants. The drain should be monitored closely and gradually backed out once drainage has ceased. Laparotomy should be reserved in cases of reaccumulation of free air in the abdomen, ongoing sepsis, fistula formation, or bowel obstruction.

After return of normal bowel function, enteral feedings may be reinitiated in a graduated manner. Contrast studies may be required if gastrointestinal tract patency is uncertain.

Long-term surgical complications of SIP are lower than that of NEC. However, infants affected by SIP have greater risks of ROP, IVH and white matter injury.

Necrotizing Enterocolitis (NEC)
NEC is the most common abdominal emergency in preterm infants. It occurs in 3% to 10% of VLBW infants and occasionally occurs in older preterm or full-term infants with predisposing conditions (Congenital heart disease, gastroschisis and severe IUGR). Mortality can be as high as 30% with a high rate of sequelae.

Prevention
There are no absolute methods for preventing NEC. In VLBW infants, use of an exclusive human milk diet and adherence to feeding protocols have reduced the overall incidence of NEC to <5% and NEC requiring surgery within 2 weeks of onset to about 1%. Whether these strategies may successfully be used in other high-risk groups, including babies with some forms of congenital heart disease or abdominal wall defects is unknown.

Early attention to clinical symptoms of feeding intolerance including abdominal distension, bloody stools, and emesis is essential. However, reliance on occult blood measurement is not effective in identifying developing NEC.

Presentation
Infants who have NEC can present with abdominal distension, feeding intolerance, emesis, bilious residuals, gross rectal bleeding, diarrhea, and/or abdominal wall discoloration with or without crepitus or induration of the abdominal skin. Systemic manifestations are similar to those that indicate sepsis. Symptoms may progress to frank apnea and bradycardia followed by cardiovascular collapse.

Diagnosis
The differential diagnosis includes ileus secondary to sepsis, isolated perforation, meconium peritonitis, Hirschsprung-associated enterocolitis, cow’s milk protein intolerance, and malrotation with volvulus and acute intestinal obstruction.

The clear presence of pneumatosis intestinalis is diagnostic in the presence of other clinical symptoms, especially bloody stools. Other laboratory data that support NEC include thrombocytopenia, neutropenia, disseminated intravascular coagulation (DIC), elevated lactate acid levels, and electrolyte abnormalities including hyperkalemia and hyponatremia.

Laboratory evaluation often includes:

- Cultures of blood, cerebrospinal fluid, and urine, (catheterized urine sample in infants > 1500 g, no bladder taps should be done)
- CBC, electrolytes, BUN, and creatinine
- Blood gas
- Lactic acid level
Serial AP abdominal films, with or without left lateral decubitus film, are performed approximately every 6 to 12 hours to monitor for pneumatosis intestinalis, portal venous gas, perforation, fixed dilated loops of bowel or worsening bowel gas pattern.

**Treatment**
For suspected or proven cases of NEC, enteral feeding is discontinued and total parenteral nutrition (TPN) is initiated. A Replge tube, with low intermittent suction, is placed in the stomach for decompression of GI tract. Usually suction is continued until clinical symptoms such as ileus and pneumatosis resolve.

Parenteral antibiotic therapy is begun empirically with either ampicillin or vancomycin, and gentamicin. Clindamycin is added if peritonitis, perforation or bowel necrosis is suspected.

Pediatric surgery should be consulted early in the disease course. Patients with suspected NEC who have resolution of radiographic findings and return of a normal clinical exam and bowel function within 48 to 72 hours may be candidates for early re-feeding at 5 days after the initial presentation. The most common indication for surgery is pneumoperitoneum. Other indications may include rapid clinical deterioration, development of intestinal mass or obstruction, or radiographic appearance of a fixed loop of bowel.

Surgical choices consist of:
- Performing an exploratory laparotomy with staged resection and enterostomy, or
- Placing a primary peritoneal drain (PPD).

Despite the potential interventions and optimal medical management, the mortality rate remains between 10% and 30%. Currently, although there is sufficient evidence to recommend the use of probiotics in neonates for the prevention of NEC, unavailability of safe regulated preparations is a barrier for clinical implementation.

Complications that can occur after NEC include malabsorption, intestinal stricture formation, intestinal failure, dependence upon long term parenteral nutrition, intestinal failure-associated liver disease, growth restriction, and long term neuromorbidity.

**11.2 Intestinal Failure and Intestinal Rehabilitation**
Intestinal failure (IF), previously described as short bowel syndrome, is a condition of malabsorption that results from small bowel resection, congenital anatomical defect, or functional dysmotility that requires prolonged parenteral nutrition (PN).

While no absolute number can be placed on the length of remaining bowel necessary for successful enteral nutrition, previous studies have shown that infants with less than 10% of their expected normal small bowel length for age have a nearly 80% chance of mortality. Currently, however, infants with very short remaining bowel segments are candidates for long-term intestinal rehabilitation. Normal bowel length for a term infant is approximately 200 to 250 cm and is generally half that length in premature infants born less than 30 weeks gestation.

**Importance**
The management of infants with IF is clinically challenging. Close monitoring is needed to ensure proper growth and nutrition as well as to recognize and treat associated complications. Although the survival of these patients has improved with the advent of PN, there is still significant morbidity associated with this form of nutrition including prolonged hospitalization, catheter-related sepsis, and intestinal failure-associated liver disease (IFALD). An important goal is to promote optimal intestinal adaptation as early as possible in order to transition patients to full enteral nutrition while maintaining adequate nutrition and growth velocity. A multidisciplinary approach with coordinated efforts from the neonatology, nutrition, GI, and surgical teams is key to successful intestinal rehabilitation.

**Goals**
The primary goal is to identify patients at high-risk for the development of IF and subsequent complications in order to formulate a multidisciplinary management plan early in the clinical course to maximize intestinal rehabilitation and provide liver protection from IFALD. These patients would include any neonate/infant who:

1. Has undergone small bowel resection of either more than 30% of the total small intestine or more than 50 cm of small intestine.
2. Has undergone a small bowel resection of any length and develops a conjugated hyperbilirubinemia ≥ 1.5 mg/dL.
3. Existing or anticipated parental nutrition dependence for 4 or more weeks regardless of the amount of bowel loss.
4. Has a history of abdominal wall defect, congenital intestinal atresia, malrotation with volvulus, spontaneous intestinal perforation, or necrotizing enterocolitis (Stage 2 or greater).

**Short-term Goals**
Short-term goals include early initiation of minimal enteral nutrition to begin the bowel adaptive process. Human milk, either mother’s own milk or donor milk, is the preferred choice for these feedings because of the immunoglobulins and trophic factors it contains. However, if malabsorption and feeding intolerance persist, an amino acid-based formula (Elecare, Alfamino or Neocate) may be necessary. Bottle or breast feedings, even in small volumes, should be considered if the infant is deemed ready to tolerate enteral feeds. This proactive approach to initiate oral feeding can potentially reduce oral aversion and aid in the rehabilitation process.

**Long-term Goals**
Intestinal growth and adaptation is a slow and progressive process, and advances in enteral nutrition need to be undertaken with this in mind. In severe cases of intestinal failure, the goal of full enteral nutrition might not be achieved during the course of hospitalization. Such infants will require home PN until that goal is achieved. Frequent re-evaluation of progress in enteral nutrition intake, and careful monitoring for IFALD must be undertaken. Discharge planning should be initiated well in advance of planned discharge if home PN is to be used. This includes cycling of PN and initiation of post-discharge training.
Bacterial Overgrowth
Bacterial overgrowth is a common complication of IF. Areas of dysmotility and bowel dilation offer an ideal environment for abnormal bacterial propagation. The adverse effects of bacterial overgrowth may include: abdominal pain, worsening intestinal motility, changes in stool frequency and/or consistency, mucosal ulceration with bleeding, deconjugation of bile acids, and the generation of toxic byproducts such as D-lactic acid. Bacterial overgrowth is thought to enhance bacterial translocation, which may lead to systemic complications. A strategy for either prophylaxis or treatment of bacterial overgrowth is the administration of enteral/oral Metronidazole (Flagyl) at 7.5 mg/kg/dose given twice daily for one week each month. In rare instances, the duration of prophylaxis may be extended. Bacterial overgrowth is thought to enhance intestinal motility, changes in stool frequency and/or consistency and bowel dilation offer an ideal environment for abnormal bacterial propagation. The adverse effects of bacterial overgrowth are more common in patients that are kept NPO. Initiation of bacterial overgrowth prophylaxis or treatment should be discussed with the NICU Intestinal Rehabilitation team.

Iron therapy
Infants with limited absorptive capacity may require intravenous iron. Since iron is not provided in PN, infants who have been on PN for more than six weeks are at increased risk for iron deficiency. If such an infant is on minimal feeds and is anticipated to require PN for an additional four weeks, serum ferritin levels should be obtained. Several newer formulations of parenteral iron have become available in recent years, including ferric carboxymaltose. This drug has an improved safety profile compared to other forms of IV iron, including iron dextran. The NICU Intestinal Rehabilitation team should be consulted to consider maintenance iron therapy in such infants.

Replacement Fluids for Losses - Combined Replogle and Ostomy Output
0.9% normal saline (NS) without any additives is the preferred replacement fluid for Replogle and other ostomy losses. 0.45% NS, or 0.9% NS with dextrose or electrolyte additives are not recommended except in special circumstances. If additional electrolyte supplementation is required, adjustments should be made to PN based on laboratory values. When the combined Replogle and ostomy output exceeds 20 mL/kg/day, the entire amount of output should be replaced. Based on the volume of output, the frequency and amount of replacement fluids for losses should be increased based on Table 11.1.

### Table 11-1. Replacement Fluids for Replogle and Ostomy Output

<table>
<thead>
<tr>
<th>Combined Output</th>
<th>Replacement Fluids</th>
<th>Timeframe for Re-assessment</th>
<th>Lab Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20 mL/kg/day</td>
<td>No replacement</td>
<td>Every 24 hours</td>
<td>Routine labs</td>
</tr>
<tr>
<td>20-30 mL/kg/day</td>
<td>0.5 mL NS for each 1 mL output over 12-24 hrs</td>
<td>Every 12-24 hours</td>
<td>Routine labs</td>
</tr>
<tr>
<td>30-40 mL/kg/day</td>
<td>0.5 mL NS for 1 mL output over 12 hrs</td>
<td>Daily electrolytes</td>
<td></td>
</tr>
<tr>
<td>&gt;40 mL/kg/day</td>
<td>0.5 mL NS for 1 mL output over 4 hours</td>
<td>Every 4 hours</td>
<td>Daily electrolytes</td>
</tr>
</tbody>
</table>

1 Replace the full volume of output at 0.5 mL NS to each 1 mL output.
2 If Sodium greater than 140 mmol/L, may consider the use of 0.45%NS. Close monitoring of clinical status including urine output, and laboratory evaluation of these patients should frequently be done, since very high volume outputs might warrant 1:1 replacement.

are higher because they also measure the “delta” bilirubin fraction. As a result, CB measurements are preferred for management decisions. Conjugated hyperbilirubinemia in a neonate is defined as a serum CB ≥1.0 mg/dL. If the total serum bilirubin (TSB) is <5.0 mg/dL or greater than 20 percent of the TSB if the TSB >5.0 mg/dL. In infants with IFALD usually a serum CB ≥2.0 mg/dL is used for defining cholestasis. However, therapeutic measures are instituted in infants with IFALD when CB reaches 1.5 mg/dL.

**Significance**
Unlike unconjugated bilirubin, conjugated bilirubin is not directly toxic to tissues, but can be a sign of significant, potentially fatal, underlying liver disease. It can be caused by diseases that need prompt surgical intervention, such as biliary atresia, or diseases that need immediate medical intervention, such as certain metabolic diseases. Hence, it is important to reach a diagnosis in a timely manner.

**Screening**
All infants admitted to either well-baby or special care nurseries who are less than 4 months of age should have a screening conjugated or direct bilirubin when feasible. In newborns, this should occur within 48 hours of age. For infants discharged prior to two weeks of life, if the initial level exceeds the laboratory’s normal range, the level should be rechecked at the 2 weeks well child check. If the level remains abnormal, the infant should be referred to the pediatric liver service. For infants that remain hospitalized, if the initial level exceeds the laboratory’s normal range, a repeat test should occur at one week of life. If the level remains abnormal, pediatric liver service should be consulted and a stepwise approach to diagnosis as suggested under “investigations” section should be performed.

**Etiology**
The common causes of conjugated hyperbilirubinemia include biliary atresia (BA), neonatal hepatitis, Alagille syndrome, choledochal cysts, sepsis, intestinal failure-associated liver disease (IFALD), and genetic or metabolic liver diseases (e.g., galactosemia, tyrosinemia, hypothyroidism, alpha-1 antitrypsin deficiency, and neonatal hemochromatosis).

IFALD is one of the most common etiologies of cholestasis encountered in the NICU population. This condition typically presents in infants who are on prolonged parenteral nutrition.
(2 weeks or more) with elevated CB. Major risk factors are prematurity, the absence of enteral feeds and sources of inflammation including, surgeries, infections, small intestinal bacterial overgrowth and illness such as SIP and NEC.

Assessment
A thorough history should be taken, including any complications that occurred during pregnancy such as infection. A family history and detailed history of prior pregnancies should also be obtained.

Clinical assessment should include a detailed examination for dysmorphic features, hepatosplenomegaly, bleeding, cardiac murmurs, and any signs and symptoms of sepsis. In addition, assess the color of the stools and urine (pale stools and dark urine suggest cholestasis).

Investigations and Consultations
A Liver Team consult should be requested when a diagnosis other than sepsis or IFALD is suspected. The Liver Team will help guide the evaluation, including determining whether a liver biopsy is indicated. In addition, the Liver Team will help coordinate potential surgical or medical therapies. Many of these therapies are most effective when started earlier. Early evaluation should include an abdominal Ultrasound (USG), CBC and blood culture. If USG is concerning for BA or other obstructive etiology, the Pediatric Liver Team should be consulted. If USG is normal, focused investigations could be ordered per Table 11-2 based on the clinical scenario and in consultation with the Pediatric Liver Team.

A Genetics consult should be considered if any of the following is present: a) family history of conjugated hyperbilirubinemia or liver disease, b) dysmorphic features, c) cardiac murmur.

### Table 11-2. Laboratory investigations

<table>
<thead>
<tr>
<th>Tests</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific cultures and or serologies</td>
<td>Viral Hepatitis</td>
</tr>
<tr>
<td><strong>Initial testing:</strong></td>
<td></td>
</tr>
<tr>
<td>plasma amino acids, urine organic acids, acylcarnitine profile, ammonia, lactate, pyruvate.</td>
<td>Metabolic disorders</td>
</tr>
<tr>
<td>Specific testing:</td>
<td></td>
</tr>
<tr>
<td>urine reducing substances, urine succinyl acetone, AAT concentration and phenotype deficiency.</td>
<td>Galactosemia, Tyrosenemia, AAT deficiency</td>
</tr>
<tr>
<td>Serum and urine bile acids</td>
<td>Bile acid synthesis disorders</td>
</tr>
<tr>
<td>Free T4 and TSH</td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Sweat chloride and mutation analysis</td>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Ferritin, transferrin saturation</td>
<td>Neonatal hemochromatosis</td>
</tr>
<tr>
<td>Peripheral smear for red cell morphology, blood typing (maternal and infant), and Coombs test</td>
<td>Mixed causes of unconjugated and conjugated hyperbilirubinemia</td>
</tr>
<tr>
<td>Hepatobiliary scintigraphy</td>
<td>Assess bile duct patency</td>
</tr>
<tr>
<td>Liver biopsy</td>
<td>Distinguishes biliary atresia from neonatal hepatitis</td>
</tr>
</tbody>
</table>

Treatment
The treatment of cholestasis should primarily be directed toward the underlying condition. Other supportive treatments include:

- **Feeding** - Treatment of IFALD includes the reestablishment of enteral nutrition as tolerated. Feeding human milk, premature infant formula, or both can be appropriate for VLBW infants with cholestasis. Premature infant formulas and amino acid based formulas contain relatively high amounts of medium-chain triglycerides. An amino acid-based formula or a protein hydrolysate formula is commonly used for these infants when human milk is not available or well tolerated.

- **Ursodiol** - (ursodeoxycholic acid [UDCA]). This bile acid of animal origin is a potent choleretic and is indicated in the management of cystic fibrosis, primary biliary cirrhosis, and dissolution of cholesterol gallstones. It is given orally and appears moderately safe. It is potentially beneficial for infants who have an intact ileocecal valve and are tolerating feeds ≥ 20-40 mL/kg/day. If the terminal ileum has been resected, UDCA will not be efficiently absorbed, and bile acid-induced diarrhea may occur. The dose ranges from 15 to 45 mg/kg per day divided into two or three doses. It should be considered in infants who are enterally fed and have significant evidence of cholestasis (conjugated bilirubin level ≥ 1.5 mg/dL). Therapy should continue as long as cholestasis is evident, either in laboratory tests (elevated serum indices in the liver panel), low fat-soluble vitamin levels, or elevated serum bile acid levels. If the patient is being evaluated for a bile acid synthesis defect, then UDCA treatment should be withheld until the evaluation has been completed.

- **Fat-soluble vitamins** – Parenteral nutrition (PN) should provide sufficient vitamins A, D, and E (largely irrespective of volume). If bleeding occurs, additional vitamin K can be given parenterally at a dose of 1 mg/day. Infants on enteral nutrition usually only require standard multivitamins, although the use of fat-soluble vitamins (in a water-soluble formulation) may be considered.

- **Trace Minerals** - Since trace minerals such as copper and manganese are excreted in the bile, in cholestasis they may accumulate in the liver and exacerbate hepatic dysfunction. Therefore, in the presence of cholestasis (conjugated bilirubin ≥ 1.5 mg/dL), it is recommended to reduce trace minerals in the PN. However, infants have a requirement for copper and will ultimately develop a copper deficiency in the absence of adequate copper provision. In the presence of cholestasis (conjugated bilirubin ≥ 1.5 mg/dL) without either jejunostomy or ileostomy, trace minerals should be provided 3 times per week (Monday, Wednesday and Friday) rather than daily. Parenteral zinc should be provided at maintenance levels daily. In infants where cholestasis is present with either jejunostomy or ileostomy, additional zinc may be provided to compensate for gastrointestinal losses. Copper, zinc, and selenium levels should be monitored every four weeks or as medically feasible in infants with cholestasis while on PN. Lab monitoring of trace mineral levels may indicate the need for further adjustments to supplementation.
Inclusion Criteria for compassionate use of Omegaven® described with the use of Omegaven® because of the risk of bleeding, though theoretical concerns have not been addressed. Essential fatty acid deficiency and increased risk of side effects. Conjugated bilirubin is usually noted to increase over the first week followed by a gradual decline resulting in complete resolution over a period of about 7 ± 2 weeks. The use of Omegaven® has so far proven to be safe with no known short-term side effects. Essential fatty acid deficiency and increased risk of bleeding, though theoretical concerns have not been described with the use of Omegaven®.

11.4 Intravenous Lipid Emulsions

**Intralipid® (Omega-6 Fatty Acids rich Lipid Emulsion)**

Intralipid® is a soybean oil based lipid emulsion rich in omega-6 fatty acids. It was approved for use in the US in 1972. There is a strong association between higher doses of Intralipid® and IFALD, which is thought to be due to the higher content of phytoestrogens, a skewed omega-6: omega-3 ratio, and lower content of antioxidants (vitamin E).

**Omegaven® (Omega-3 Fatty Acids rich Lipid Emulsion)**

Omegaven® (Fresenius Kabi, Germany) is an intravenous fish oil-based lipid emulsion rich in omega-3 fatty acids. Omegaven®, an intervention in the treatment of IFALD, has been shown to facilitate faster resolution of cholestasis, reduction in both the rate of liver transplants, and mortality in these patients. Omegaven® is currently not approved by the FDA for general use. However, it is approved by the FDA to be used ONLY on a compassionate basis under an Investigational New Drug (IND) protocol for the treatment of IFALD. The etiopathogenesis of IFALD is multifactorial. The presence of phytoestrogens and high omega-6 to omega-3 fatty acids in the conventional soy-based lipid emulsion (Intralipid®) is thought to be an important factor. The beneficial effects of Omegaven® have been attributed to several factors including the high content of omega-3 fatty acid (FA) and their anti-inflammatory effects, the absence of phytoestrogens, high content of vitamin E and decreased de novo lipogenesis. Following the initiation of Omegaven® the level of conjugated bilirubin is usually noted to increase over the first week followed by a gradual decline resulting in complete resolution over a period of about 7 ± 2 weeks. The use of Omegaven® has so far proven to be safe with no known short-term side effects. Essential fatty acid deficiency and increased risk of bleeding, though theoretical concerns have not been described with the use of Omegaven®.

**Exclusion Criteria**

- Evidence of viral hepatitis or primary liver disease as the primary etiology of their cholestasis
- Clinically severe bleeding not able to be managed with routine measures
- Congenital lethal conditions or other health conditions that suggest a high likelihood of death even if the infant’s cholestasis improves.

**Use of Omegaven®**

Once an infant meets eligibility for Omegaven®, the NICU Intestinal Rehabilitation team is to be consulted to confirm the eligibility and to obtain the informed consent of the parent or guardian of the infant. Intralipid® is then discontinued and Omegaven® is initiated at 1 g/kg/day by continuous infusion over 24 hours/day. Omegaven® may be given over 16-22 hours/day if PN is cycled in preparation for discharge. Providing more than 1 g/kg/day is not allowed by the FDA under this protocol. Omegaven® can be provided via a central or peripheral line. Since Omegaven® is provided at 1g/kg/d, the glucose infusion rate in the PN may need to be increased as tolerated to 14-17 mg dextrose/kg per minute to provide sufficient calories for growth.

**Duration of Treatment**

Patients are considered to have resolved cholestasis when the conjugated bilirubin is < 2 mg/dL, which typically requires 6-10 weeks of therapy. Omegaven® is continued until enteral nutrition is tolerated at ≥ 80 mL/kg/day, even if cholestasis resolves sooner. Under some circumstances, Omegaven® may be continued for conjugated hyperbilirubinemia even after full enteral nutrition is attained if the infant otherwise has an ongoing need for intravenous access. This should be discussed with the intestinal rehabilitation team.

If a patient who has received Omegaven® in the past needs to resume PN for any reason (e.g., post-operative course), the patient may be considered for further use of Omegaven®, even if the conjugated bilirubin is < 1 mg/dL. Cases should be individually discussed with the NICU Intestinal Rehabilitation team, as in some cases resumption of Intralipid® may be appropriate. In addition, patients who are readmitted to any unit at TCH after being on Omegaven® in the NICU may resume Omegaven®. This is done because the liver function tests may remain abnormal for several months despite normalization of conjugated bilirubin levels and the infant would likely benefit from the anti-inflammatory effects of omega-3 FA.

**Home Use of Omegaven®**

Home use of Omegaven® is available with follow up by the TCH Pediatric Intestinal Rehabilitation Clinic Team. If a patient is referred to TCH for Omegaven® but has not previously received it at another institution, the FDA requires the patient to be admitted for a 48-hour inpatient stay for the initiation of Omegaven®. Patients transferred to TCH for home use treatment who have received Omegaven® at another institution are not required to be admitted and can be seen in the clinic directly.

**Inclusion Criteria for compassionate use of Omegaven®**

- Greater than 14 days of age and less than 5 years of age
- Conjugated bilirubin >2 mg/dL
- Expected to require PN for at least an additional 28 days.
Monitoring
Conjugated bilirubin and serum triglycerides are measured just prior to the initiation of Omegaven®. Serum triglycerides should be measured again within 48 hours after initiation. Conjugated bilirubin and serum triglycerides are measured once a week thereafter until discontinuation of Omegaven®. Liver function tests (AST, ALT, and GGT) are also monitored every other week. PT, PTT, INR, fibrinogen and platelet count should be monitored prior to initiation of Omegaven® and every 4 weeks thereafter.

SMOFlipid® (Multi component lipid emulsion)
SMOFlipid® is the latest new generation intravenous lipid emulsion comprised of 30% soybean oil, 30% MCT (coconut oil), 25% Olive oil and 15% Fish oil. SMOFlipid® was approved by the FDA for use in adults in 2016. The current evidence suggests that the use of SMOFlipid® in infants is safe. However, its efficacy in either the prevention or treatment of IFALD in infants is not proven. In an effort to pursue evidence-based practice, we discourage off-label use of SMOFlipid® in our NICUs outside of IRB approved research protocols. Currently, the use of SMOFlipid® in infants in our NICU is strictly restricted to the following IRB approved research protocols.

1. Protocol H-34444 permits the off-label use of SMOFlipid® in those infants who have resolving IFALD (CB < 2 mg/dL) but have growth failure while on Omegaven® or on lipid limiting strategy. This protocol allows better growth by providing SMOFlipid® at 3g/kg/d while consolidating resolution of cholestasis.

2. Protocol H-37367 is a phase 3 RCT study comparing SMOFlipid® to Intralipid®. Under this protocol, infants at risk for either intestinal failure or prolonged PN are randomized to either Intralipid® or SMOFlipid® at regular doses up to 3 g/kg/d for at least 28 days. Outcomes include cholestasis, growth and essential fatty acid deficiency. If any of these infants develop cholestasis (CB ≥ 1.5 mg/dL) SMOFlipid® is discontinued and treatment with Omegaven® is initiated.

Currently, the lipid of choice in all our infants within our NICUs is still Intralipid. For those who develop IFALD, Omegaven® is the lipid of choice for the treatment of cholestasis.

The perceived need for SMOFlipid® should be discussed with member of the NICU Intestinal Rehabilitation Team.

Recognizing Underlying End-Stage Liver Disease
Premature infants with hepatomegaly, splenomegaly, elevated liver panel indices, or evidence of liver functional impairments may have an underlying liver disease and should be considered for Liver Team consultation. In neonates who are unable to advance enteral nutrition, IFALD warrants concern. Liver failure can develop as early as 4 months. Findings of worsening conjugated hyperbilirubinemia, elevated PT, glucose instability, worsening hepatosplenomegaly, caput medusa, ascites, and GI bleeding from portal hypertension suggest the development of an irreversible liver disease. In these infants, the Liver Team should be consulted as early as possible after failure to advance enteral nutrition is recognized. This consultation will help determine if the infant is a candidate for transplantation of the liver and/or intestine.

11.5 Gastroesophageal Reflux (GER)
Gastroesophageal reflux (GER) is defined as the passage of gastric contents into the esophagus. GER commonly occurs during infancy and does not require medical intervention. Not all spitting is due to reflux and the differential diagnosis can include gastrointestinal anatomic abnormalities, metabolic disorders, or renal dysfunction. Although preterm infants frequently have GER, in most cases there is no temporal relationship between GER and apnea of prematurity.

The clinical findings that indicate GER should be documented in the medical record before instituting medical management. In addition, attempt non-pharmacologic approaches, such as positioning and, if appropriate, changes to the duration and rate of the feeding. The use of prokinetic agents in healthy preterm infants is strongly discouraged. Adverse events have been associated with thickened feedings, therefore this intervention is not recommended in routine management of GER. The neonatology section of BCM recommends that no infant in any of our Level 2, 3 or 4 NICUs be provided any commercial thickening agent (Simply Thick and similar products) designed to be added to infant formula or human milk.

Consideration of the use of such agents should only be done in the context of an IRB-approved research protocol. The use of such commercial thickening agents is absolutely contraindicated in preterm infants, or former preterm infants, both during the hospitalization and after discharge due to the risk of NEC.

GER disease (GERD) is defined as symptoms or complications of GER. Certain infants may be at increased risk of GERD including those with congenital diaphragmatic hernia, esophageal atresia repairs (see GER treatment under Section on Surgery), abdominal wall defects, and intestinal failure. GERD can present with symptoms of anorexia, dysphagia, odynophagia (pain on swallowing), arching of the back during feeding, irritability, hematemesis, anemia, or failure to thrive. These infants often display true esophageal and GI dysmotility, leading to increased risk of esophagitis and gastritis. In this subset of infants, treatment with either H2 receptor antagonists or proton pump inhibitors (PPIs) produce relief of symptoms and promote esophageal healing, although PPIs have superior efficacy. Recent pharmacokinetic studies of at least one PPI have shown them to be well tolerated and provide dose related acid suppression in infants 1-24 months of age. Transpyloric feedings or fundoplication may need to be considered in the most severe cases to prevent long-term sequelae.

Note: Use of H2 receptor antagonists in the neonatal population is associated with increased risk for NEC and gram-negative bacteremia. Though this level of evidence is not available for the proton pump inhibitors (PPIs), the same degree of caution should be extended to the PPIs due to the same end use result of increased gastric pH.
Ranitidine (Zantac) - a H₂ receptor antagonist (oral and intravenous forms available). Compatible as an additive with parenteral nutrition.

Lansoprazole (Prevacid) - proton pump inhibitor (PPI) (available as oral suspension and tablet)

Pantoprazole (Protonix) - proton pump inhibitor (PPI) (available intravenously). Not compatible with parenteral nutrition.

Metoclopramide (Reglan) - a prokinetic agent that has been used, although data do not support efficacy in infants. The FDA has placed a Black Box warning on the chronic use of metoclopramide, as it has been linked to tardive dyskinesia even after the drug has been discontinued. The symptoms are rarely reversible and there is no known treatment. The use of this agent in our population is strongly discouraged under all circumstances.

Bethanechol (Urecholine) - a cholinergic agent that has been used, although data do not support efficacy in infants. Routine use of this agent in our population is discouraged. Its potential use should be discussed with the Intestinal Rehabilitation Team.

Erythromycin

Erythromycin has been used as a prokinetic agent to treat feeding intolerance and reflux in infants. There is insufficient evidence to recommend the use of Erythromycin to treat feeding intolerance in preterm infants as shown in a meta-analysis of 10 randomized controlled studies evaluating the efficacy of erythromycin in the prevention and treatment of feeding intolerance in preterm infants. The use of Erythromycin could be considered after 14 days of life in an infant with significant feeding intolerance due to moderate to severe GI dysmotility (see dosing below). Its potential use should be discussed with the Intestinal Rehabilitation Team.

Erythromycin Dosing for Infants - Erythromycin ethylsuccinate orally 5 to 10 mg/kg/dose every 6 hours; start at lower dose and assess for efficacy. Caution should be used with prolonged use due to the possibility of developing pyloric stenosis. Clinical judgment should be used with long-term use.

Suggested Reading

Section 12: Nutrition
Editors: Diane Anderson and Amy Hair

12.1 Initiation and Intravenous Fluids ................... 164
Laura Gollins
Muralidhar Premkumar

12.2 Parenteral Nutrition................................ ........ 165
Diane Anderson
Amy Carter
Agnes Mandy

12.3 Enteral Nutrition ................................ ............ 167
Amy Hair
Patrice Hochevar
Laura Lucas
Adriana Massieu

12.4 Nutrition Assessment..................................... 178
Diane Anderson
Elizabeth Bacon

12.5 Guidelines for Oral Feeding ...................... 179
Laura Caudill
Lisa Owens

12.6 Discharge Nutrition Preparation ................... 181
Nidia Espinosa
Elizabeth Sager
12.1 Initiation and Intravenous Fluids

In this chapter, high-risk neonates are defined as all term and preterm infants admitted to the NICU or Level 2 nurseries. Differentiation is made between high-risk, extremely or very low birth weight infants, and healthy preterm infants as needed.

Human milk is the preferred nutrition for infants. A healthy infant should be put to the breast within one hour of delivery. Support mothers who intend to breastfeed or provide milk for their infants. (Ch 12.3 Enteral Nutrition and Ch 12.5 Oral Feeding)

Initial Orders After Delivery

Initiate intravenous fluid (IVF) with 5% to 10% dextrose to provide an initial glucose infusion rate (GIR) of 4.5 to 6 mg glucose/kg per minute. Some ELBW infants may only tolerate 3.5-4.5 mg glucose/kg per minute in the first day of life.

- Infants ≤ 24 6/7 weeks GA, initiate 5% dextrose at 100 mL/kg/day
- Infants 25 0/7 -26 6/7 weeks GA, initiate 10% dextrose at 80 mL/kg/day
- Use 10% dextrose if birthweight (BW) ≥ 1000 grams

Initial PN: Neonatal Early & Starter Solutions

(See Tables 12-1, 2, 3, and 4)

Providing amino acids and lipids as soon as possible will reverse a negative nitrogen balance and improve glucose homeostasis. Early nutrition is especially effective in infants < 1500 grams. Infuse parenteral nutrition at an appropriate volume based on body weight and clinical condition. (Table 12-4 for recommended nutrient composition.)

Standard Starter Solution (Neonate/Infant)

Standard starter solution contains only glucose, amino acids, calcium, and water. No changes can be made to this solution. Parenteral nutrition should be ordered to include phosphorus within the first 24 hours of life. Vitamins and trace minerals are automatically added by the pharmacy. (Table 12–5b)

- Begin PN upon admission for infants < 1500 grams, for infants with major congenital heart disease (any requiring a prostaglandin infusion or pressor support), and for infants with congenital bowel abnormalities such as gastroschisis or omphalocele.
- Use standard starter solution when the pharmacy is unavailable for PN compounding (1 pm to 10 am). Starter solutions will provide 3% amino acids.
- Limit standard starter solutions to a maximum of 100 mL/kg/day. Provide any additional fluid required as a piggyback IVF.
  - Infants ≤ 24 6/7 weeks GA, initiate 5% dextrose containing starter solution at 100 ml/kg/day.
  - Infants 25 0/7 -26 6/7 weeks GA, initiate 10% dextrose containing starter solution at 80 ml/kg/day.

<table>
<thead>
<tr>
<th>Table 12–1. Parenteral nutrient goals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nutrient</strong></td>
</tr>
<tr>
<td>Energy kcal/kg</td>
</tr>
<tr>
<td>Protein g/kg</td>
</tr>
<tr>
<td>Fat g/kg</td>
</tr>
<tr>
<td>Glucose mg/kg minute</td>
</tr>
<tr>
<td>Calcium mmol/kg</td>
</tr>
<tr>
<td>Phosphorus mmol/kg</td>
</tr>
<tr>
<td>Potassium mEq/kg</td>
</tr>
<tr>
<td>Sodium mEq/kg</td>
</tr>
</tbody>
</table>

* Early fluid and nutrient needs and tolerance will vary by gestational age, birth weight and clinical condition.

a Infants with GI diseases, surgery, other protein-losing state, or long- term PN may require 4 g/kg per day of protein.
b 5 mL/kg of 20% IL = 1 g fat/kg
c Standard starter and peripheral PN provides 1.2 mmol/100mL calcium gluconate and central PN provides 1.75 mmol/100mL. There is 40 mg of elemental calcium per mmol of calcium gluconate.
d Provide standard calcium and phosphorus in a 1:1 molar ratio. Phosphorus should be added to PN within 24 hours of life.
e Peripheral PN provides 1.2 mmol/100mL potassium phosphate and central PN provides 1.75 mmol/100mL. There is 31 mg of phosphorus per mmol of potassium phosphate.
f Sodium or potassium will be provided as a salt with phosphorus.
g There is 1.4 mEq of potassium per mmol of potassium phosphate.
h There is 1.3 mEq of sodium per mmol of sodium phosphate.

<table>
<thead>
<tr>
<th>Table 12–2. PN calculations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GIR (mg/kg per min)</strong></td>
</tr>
<tr>
<td>Dextrose</td>
</tr>
<tr>
<td>Protein</td>
</tr>
<tr>
<td>Fat (IL 20%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 12–3. Conversion factors for minerals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Element</strong></td>
</tr>
<tr>
<td>Calcium</td>
</tr>
<tr>
<td>Phosphorus</td>
</tr>
<tr>
<td>Sodium</td>
</tr>
<tr>
<td>Potassium</td>
</tr>
<tr>
<td>Chloride</td>
</tr>
<tr>
<td>Magnesium</td>
</tr>
</tbody>
</table>

- Initiate calcium and phosphorus once PN can be written. In infants < 1000 g BW, limit calcium gluconate to 1.0 mmol/100 mL at 100 mL/kg/day or 1.0 – 1.2 mmol/kg/day in the first 72 hours of life as tolerated.
- Add phosphorus (either as potassium phosphate or sodium phosphate) in a 1:1 mmol ratio to calcium as early as can be provided.
Table 12-4. Early neonatal solutions (0 to 48 hours of age)

<table>
<thead>
<tr>
<th>Component</th>
<th>Standard Starter</th>
<th>Early PN</th>
<th>Amount/100 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose</td>
<td>5% or 10%</td>
<td>5-10%</td>
<td>5 to 10 g/100 mL</td>
</tr>
<tr>
<td>Amino acids</td>
<td>3%</td>
<td>3%</td>
<td>3 g/100 mL</td>
</tr>
<tr>
<td>NaCl</td>
<td>0</td>
<td>0</td>
<td>equivalent to 516 – 430 mg/100 mL</td>
</tr>
<tr>
<td>K2HPO4</td>
<td>0</td>
<td>1.0 mmol</td>
<td>0.5 mEq</td>
</tr>
<tr>
<td>MgSO4</td>
<td>1.2 mmol</td>
<td>1.0 mmol</td>
<td>0.5 mEq</td>
</tr>
<tr>
<td>KCl</td>
<td>0.5 mEq</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Heparin</td>
<td>1 unit/mL</td>
<td>1 unit/mL</td>
<td></td>
</tr>
</tbody>
</table>

1Standard Starter: When PN room is closed (1 pm to 10:00 am) contains no cysteine, phosphorous, trace minerals, or vitamins. No changes.

2Early PN should be ordered with GIR of 4.5-6 mg glucose/kg/min, amino acids at 2.4-3 g/kg, calcium and phosphorus at 1 mmol per 100 mL. Sodium or potassium will be added with the phosphorus addition. No additional sodium, potassium or chloride is generally indicated. Vitamins and trace minerals will be added by pharmacy. Nutrition modifications can be ordered as needed.

- Initiate intravenous lipids (IL) when PN is started. The inclusion of protein and fat with glucose aids with glucose control.
  - For infants ≤ 750 g BW, initiate lipids via infusion pump at 0.1 mL/hour over 12 hours due to the syringe size required to include adequate priming. Check a TG (triglyceride) level at approximately 4 and 12 hours after initiation of therapy. If TG level is > 250 mg/dL, stop the infusion and repeat TG level in 12 – 24 hours or sooner as clinically indicated. Advance as tolerated if TG is < 250 mg/dL. If a rate of 0.1 mL/hour is not tolerated after several attempts, please discuss with our clinical pharmacy specialists the use of special lower volume syringes that can be run at < 0.1 mL/hr.
  - For infants 751-1000 g, initiate IL at 5 mL/kg/day (1 g/kg/day) with TG monitoring before advancement.
  - For infants > 1000 g who are SGA or IUGR, have received postnatal steroids or have presumed sepsis, initiate IL at 5 mL/kg/day (1 g/kg/day) with TG monitoring before advancement.
  - For infants > 1000 g BW who are AGA and are not receiving postnatal steroids or believed to be septic, initiate IL at 10 mL/kg/day (2 g/kg/day). Monitoring of TG is generally not needed before advancement of IL in this group of infants.

- At 24 hours of age or whenever the first daytime ability to write PN (which can be within hours of birth), transition to standard parenteral nutrition. Sodium chloride and potassium chloride are generally not indicated.

- Magnesium should not be omitted from PN unless serum Mg level is > 3.9 mg/dL. Monitor serum Mg level and when < 3.0 mg/dL, resume Mg in PN.

<table>
<thead>
<tr>
<th>Component</th>
<th>per 100 mL</th>
<th>Comments</th>
<th>Intakes at 130 mL/kg per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>12.5%</td>
<td></td>
<td>16 g/kg per day</td>
</tr>
<tr>
<td>Amino acids</td>
<td>2.8%</td>
<td>TrophAmine</td>
<td>3.6 g/kg per day</td>
</tr>
<tr>
<td>NaCl</td>
<td>2.6 mEq</td>
<td>= 2.6 mmol Na</td>
<td>3.4 mEq/kg per day</td>
</tr>
<tr>
<td>K2HPO4 Calcium</td>
<td>1.75 mmol P</td>
<td>= 54 mg P</td>
<td>2.3 mmol/kg per day; 71 mg/kg per day</td>
</tr>
<tr>
<td>KCl</td>
<td>0.2 mEq</td>
<td>K from KCl</td>
<td>0.26 mEq/kg per day</td>
</tr>
<tr>
<td>Lipid</td>
<td>10%</td>
<td>1 to 3 g/kg per day</td>
<td>3 g/kg per day; 15 mL/kg per day</td>
</tr>
<tr>
<td>Cysteine</td>
<td>30 mg/g amino acids;</td>
<td>always add proportional to amino acids</td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>1 unit/mL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Uses  to calculate parenteral nutrient concentrations during fluid restriction. When providing greater than 130 mL/kg to meet fluid needs, adjust nutrients to meet goals and prevent toxicity.

12.2 Parenteral Nutrition (PN)

PN refers to intravenous nutrition (including glucose, amino acids, lipids, vitamins, and minerals) to provide a total nutrition source for an infant.

PN Goals (Tables 12–1, 12–5)

- Begin with the standard solution as specified in Table 12–5a and advance volume as tolerated to a maximum of 130 mL/kg per day, which will meet most nutrient requirements. In critically ill infants who require substantial volume infusion of medications or who need frequent adjustment of electrolytes, consider concentrating PN constituents into a smaller volume as medically feasible. When providing greater than 130 mL/kg to meet fluid needs, adjust nutrients to meet goals and prevent toxicity.

Carbohydrate

- Provides the main energy source for an infant.
- Limit dextrose to 12.5% when administered by peripheral line.
- Generally initiate at a glucose infusion rate (GIR) of 4.5 to 6 mg glucose/kg per minute. Some ELBW infants may only tolerate 3.5-4.5 mg glucose/kg per minute in the first day of life.
- Generally advance by 1-2 mg glucose/kg per minute if blood glucose <130-150 mg/dL.
- Advance glucose usually to a goal GIR of 11-12 mg glucose/kg per minute.
- If glucose persistently >280-300 mg/dL, reduce GIR to 3.5 mg glucose/kg per minute prior to initiating insulin.
Amino Acids

- All infant PN solutions routinely use the amino acid solution TrophAmine®, which promotes plasma amino acid concentrations similar to the breastfed infant. Premasol® may also be used.

- Current recommendations are 3.5 - 4 g protein/kg per day (preterm infants) and 1.5-3 g protein/kg per day (term infants). Infants with poor growth, gastrointestinal disease, surgery, or other protein-losing states require up to 4 g protein/kg per day.

- Provide a maximum of 3 grams of protein/kg/day for infants <24 6/7 GA for the first 3 days of life.

- The amino acid cysteine is always added at 30 mg/g amino acids, which improves Ca and P solubility.

Intravenous Lipid (IL)

IL provides essential fatty acids and is a calorie-dense energy source.

- 20% IL (50% linoleic acid), 2 kcal/mL.

- Linoleic acid, an essential fatty acid, must be provided at 3% or greater of total kilocalories to meet the essential fatty acid requirement. Intralipid® at 0.5 to 1 g (2.5 to 5 mL) per kilogram per day will provide minimum requirements.

- Use a continuous infusion at a constant rate. Initiate per protocol. (Ch 12.1 Initial PN: Neonatal Early and Starter Solutions)

- Generally advance lipid infusion rate by 1 g/kg/day. For infants ≤750 g BW advance by 0.5-1g/kg/day if TG is <250 mg/dL. Monitor after each advancement.

- Infants that are SGA, IUGR, on steroids, or those believed to be septic may require serum triglyceride (TG) monitoring before every advancement targeting values <250 mg/dL.

- Monitoring of TG is generally not needed with every advancement in infants not listed above.

- Advance as tolerated to a goal of 3 g/kg/day (15 mL/kg/day)

Some infants may potentially have TG values of 200-400 mg/dL. IL should be provided at 0.5 g/kg/day despite these values. If values are above 400 mg/dL, hold IL, recheck TG, and resume IL at 0.5 g/kg/d (2.5 mL/kg/day) when <400 mg/d

Lipid limiting strategy (LLS) for Parenteral Nutrition Associated Liver Disease. There is increasing evidence that limiting the Intralipid® infusion rates to 1 g/kg/day may benefit infants with Parenteral Nutrition Associated Liver Disease (PNALD) and a conjugated bilirubin ≥ 1.5 mg/dL. Some VLBW infants may require 2 g/kg/day of lipids for growth. Consultation with the nutrition service should be obtained. It is not necessary to decrease prophylactically the Intralipid® infusion rate in the absence of any evidence of cholestasis. When lipid limiting strategy is initiated, caregivers at TCH and other BCM affiliated nurseries should discuss the potential need of Omegaven® in the future with either Dr. Premkumar or Dr. Hair. (Ch 11.3-Cholestasis)

Table 12-5b ASPEN recommendations for vitamins

<table>
<thead>
<tr>
<th>Vitamins</th>
<th>Preterm (per kg)</th>
<th>Term (per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A (IU)¹</td>
<td>700-1500</td>
<td>2300</td>
</tr>
<tr>
<td>Vitamin D (IU)²</td>
<td>40-160</td>
<td>400</td>
</tr>
<tr>
<td>Vitamin E (IU)³</td>
<td>2.8-3.5</td>
<td>7</td>
</tr>
<tr>
<td>Vitamin K (mcg)</td>
<td>10</td>
<td>200</td>
</tr>
<tr>
<td>Vitamin C (mg)</td>
<td>15-25</td>
<td>80</td>
</tr>
<tr>
<td>Thiamin B₁ (mg)</td>
<td>0.2-0.35</td>
<td>1.2</td>
</tr>
<tr>
<td>Riboflavin B₂ (mg)</td>
<td>0.15 -0.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Pyridoxine B₆ (mcg)</td>
<td>150-200</td>
<td>1000</td>
</tr>
<tr>
<td>Niacin (mg)</td>
<td>4-6.8</td>
<td>17</td>
</tr>
<tr>
<td>Pantothenic acid (mg)</td>
<td>1-2</td>
<td>5</td>
</tr>
<tr>
<td>Biotin (mcg)</td>
<td>5-8</td>
<td>20</td>
</tr>
<tr>
<td>Folate (mcg)</td>
<td>56</td>
<td>140</td>
</tr>
<tr>
<td>Vitamin B₁₂ (mcg)</td>
<td>0.3</td>
<td>1</td>
</tr>
</tbody>
</table>

Conversions: 1 Vitamin A (3.33 IU=1 mcg), 2 Vitamin D (40 IU=1 mg), 3 Vitamin E(1 IU=1 mg)

Vitamins and Minerals

- M.V.I. Pediatric is provided as a standard dose based on weight. Recommended intakes are listed. (Table 12–5b)

- Limit peripheral calcium and phosphorous to 1.2 mmol/100 mL

- Since solubility of Ca and P is a concern, never reduce the amino acids to less than 2.4% without reducing the Ca and P. At 2.4% amino acids, up to 2 mmol of calcium gluconate and potassium phosphate may be provided per 100 mL. Usual additions of acetate (1 to 2 mEq/100 mL) should not affect solubility. Do not remove P from PN for more than 48 hours without also adjusting Ca and following serum ionized calcium.

- Sodium phosphate can replace potassium phosphate in the same molar concentrations when potassium intake needs to be limited or potassium phosphate is not available.

- Give standard calcium and phosphorous in most cases in a 1:1 mmol ratio. For infants < 1000 g BW, follow ionized calcium levels and serum phosphorous daily as the amount of calcium and phosphorus in PN is advanced in the first 3 days of life or until levels are stable. If ionized calcium is > 1.45 mmol/L, check serum phosphorous as infant may have a low phosphorus. (Ch 13-4 Hypocalcemia and Ch 13.5 Hypercalcemia)

Trace Elements

The pharmacy adds trace elements as a standard dose based on infant weight and product availability. Recommended intakes are listed. (Table 12–5c)

- In infants with significant secretory losses of Zn (e.g., those with gastrointestinal diseases or surgery), increase the Zn concentration by 400 mcg/kg per day for preterm infants and by 100 to 250 mcg/kg per day for term infants.
Alterations in trace element provision:

In Cholestasis - Since copper and manganese are excreted in the bile, in cholestasis, they may accumulate in the liver and cause worsening hepatic dysfunction. In the presence of cholestasis (conjugated bilirubin ≥1.5 mg/dL) it is recommended to reduce trace minerals in the PN. Growing infants, however, have a requirement for copper and will ultimately develop copper deficiency in the absence of adequate copper supplementation. Copper and zinc levels should be monitored every 4 weeks in infants with cholestasis while on PN. In the presence of cholestasis without either jejunostomy or ileostomy, trace minerals (including copper and manganese) should be provided 3 times per week (Monday, Wednesday and Friday), and parenteral zinc should be provided at maintenance levels daily. In the presence of cholestasis with either jejunostomy or ileostomy, apart from the above supplementation, extra zinc should be provided to compensate for gastrointestinal losses. Lab monitoring of copper and zinc levels may indicate the need for further adjustments to supplementation. In some circumstances such biochemical monitoring may not be feasible. In those instances, copper and zinc should be supplemented despite cholestasis, but levels should be checked when medically feasible.

In renal failure - Because of accumulation of selenium and chromium, reduce frequency of administration.

In infants with cholestasis or renal failure, continue zinc daily per guidelines (Table 12-5c).

Carnitine

Carnitine is a nitrogen-containing compound required for the transfer of fatty acids into the mitochondria. Human milk contains 3 to 5 mg/ dL of carnitine. Add L-carnitine (10 mg/kg per day) if the infant is expected to be on PN exclusively for longer than 14 days.

Volume Restricted PN (Severe Lung Disease or Total Body Cooling)

Infants with severe cardiopulmonary disease or those requiring total body cooling should be provided at least 2 g/kg/day of protein with an attempt to provide 2.5-3 g/kg/d as soon as feasible. Use of volume to provide protein is of greater importance in this setting than providing more than 1 g/kg/d of lipids or high concentrations of calcium and phosphorus. It is important to maintain both total blood phosphorous and magnesium within physiological ranges. Blood levels should be monitored daily during cooling with adjustment of PN based on blood levels. Recommended goal parenteral nutrition composition for ECMO given in Table 12-6a.

Recommended goal parenteral nutrition composition for cooling given in Table 12-6b.

Managing Slow Growth in PN-nourished Infants

- Treat abnormalities that are unrelated to nutrition that might affect growth, such as metabolic acidosis, hyponatremia, increased work of breathing, cold stress, anemia, use of steroids, and infection.
- Assure that intake is within recommended levels. Adjust PN as appropriate.
- Generally, the unbalanced addition of carbohydrate is not recommended to increase total calorie intake.

### Table 12-5c. ASPEN recommendations for trace elements

<table>
<thead>
<tr>
<th>Trace Elements (mcg/kg per day)</th>
<th>Preterm</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td>400¹</td>
<td>250²</td>
</tr>
<tr>
<td>Copper</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Iodine</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Manganese</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Selenium</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Chromium</td>
<td>0.0006</td>
<td>0.0006</td>
</tr>
</tbody>
</table>

Preterm infants require 400 mcg/kg per day of zinc. Provide supplementation as indicated. ²Term infants require 250 mcg/kg per day of zinc initially; when >3 months of age, 50 mcg/kg per day is recommended. Adjust TPN accordingly.

### Table 12-6a. Volume restricted goal PN for ECMO 70mL/kg + 15 mL/kg fat (3 grams/kg)¹

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Order/100mL</th>
<th>Amount/kg</th>
<th>Goal Intake/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose</td>
<td>22%</td>
<td>15.4 g</td>
<td>16 g (11-12 mg/kg/min)</td>
</tr>
<tr>
<td>Protein</td>
<td>5%</td>
<td>3.5 g</td>
<td>2-3 (term) 3.5-4 (preterm)</td>
</tr>
<tr>
<td>Calcium</td>
<td>1.75 mmol</td>
<td>1.2 mmol</td>
<td>1.5-2 mmol</td>
</tr>
<tr>
<td>Phosphorous</td>
<td>1.75 mmol</td>
<td>1.2 mmol</td>
<td>1.5-2 mmol</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.5 mEq</td>
<td>0.2 mEq</td>
<td>96 kcal (PN + IL) 90-110 kcals</td>
</tr>
</tbody>
</table>

¹Order electrolytes as needed. Order vitamins and trace minerals.

### Table 12-6b. Volume restricted PN for Total Body Cooling 40 mL/kg + 5 mL/kg fat (1 gram/kg)¹

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Order/100mL</th>
<th>Amount/kg</th>
<th>Goal Intake/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose</td>
<td>25%</td>
<td>10 g</td>
<td>16 g (11-12 mg/kg/min)</td>
</tr>
<tr>
<td>Protein</td>
<td>5%</td>
<td>2 g</td>
<td>2-3 (term) 3.5-4 (preterm)</td>
</tr>
<tr>
<td>Calcium</td>
<td>1.2 mmol</td>
<td>0.5 mmol</td>
<td>1.5-2 mmol</td>
</tr>
<tr>
<td>Phosphorous</td>
<td>1.2 mmol</td>
<td>0.5 mmol</td>
<td>1.5-2 mmol</td>
</tr>
<tr>
<td>Magnesium</td>
<td>1 mEq</td>
<td>0.4 mEq</td>
<td>52 kcal (PN + IL) 90-110 kcs</td>
</tr>
</tbody>
</table>

¹Order electrolytes as needed. Order vitamins and trace minerals.

Stop Parenteral Nutrition

- Stop IL when feeds are greater than or equal to 80 mL/kg per day.
- Stop PN when feeds are greater than or equal to 100 mL/kg per day except in infants with intestinal failure.

### 12.3 Enteral Nutrition

- Infants, especially VLBW/LBW infants, should start feeds as soon as possible (within 6 to 12 hours of birth) if medically stable (see below). For ELBW infants, consider starting feeds on the first day of life if medically feasible.
Section 12—Nutrition

Table 12-7a Suggested feeding schedules 1,2

<table>
<thead>
<tr>
<th>BW (g)</th>
<th>Initiation Rate</th>
<th>When to Advance</th>
<th>Advancement Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤750</td>
<td>15-20 mL/kg per day</td>
<td>Maintain for 3 - 5 days</td>
<td>10-20 mL/kg per day</td>
</tr>
<tr>
<td>751-1250</td>
<td>15-20 mL/kg per day</td>
<td>Maintain for 3 days</td>
<td>10-20 mL/kg per day</td>
</tr>
<tr>
<td>1251-1500</td>
<td>20 mL/kg/day</td>
<td>If feeds tolerated, may advance after 24-48 hours</td>
<td>20 mL/kg per day</td>
</tr>
<tr>
<td>1501-2000</td>
<td>20 mL/kg/day</td>
<td>If feeds tolerated, may advance after 24-48 hours</td>
<td>25-40 mL/kg per day</td>
</tr>
<tr>
<td>2001-2500</td>
<td>25-30 mL/kg/day</td>
<td>Advance daily</td>
<td>25-40 mL/kg per day</td>
</tr>
<tr>
<td>Stable &gt; 2500</td>
<td>50 mL/kg/day or ad-lib with minimum. Cardiac babies: 20 mL/kg per day</td>
<td></td>
<td>25-40 mL/kg per day</td>
</tr>
</tbody>
</table>

1 Individual initiation and advancement rates based on patient’s weight, age and clinical status.
2 Feedings for infants < 1500 grams are usually best given on a pump for 30-60 minutes.

- Infants < 1250 g should start on trophic feeds at 15-20 mL/kg/day. Trophic feeds should generally not count towards the total fluid volume.
- Verbal assent should be obtained and documented in the electronic medical record at admission for feeding donor human milk (DHM) whenever it is used. Initial orders for feedings in these infants should specify that DHM is the secondary feeding choice after maternal expressed breast milk (EBM). Formula should not be listed as a backup feeding for infants < 1500 grams. The use of donor milk may be considered for all infants but infant formula is also an appropriate backup for infants > 1500 g birthweight.
- Initiation of enteral feedings and advancement rates should be individualized based on a patient’s weight, age, and medical stability. Low dose pressors, including dopamine (usually 5 mcg/kg/min or less) are compatible with initial trophic feeds. Umbilical catheters do not preclude trophic feeding. Trophic feeds are typically continued for 3 days for infants 751-1250 g and may continue for 5 days for infants ≤ 750 grams birthweight. Trophic feedings may be prolonged if the infant requires high dose pressor support. Trophic feedings can be provided during indomethacin or ibuprofen therapy. Twenty four hours after the last dose of medication, feedings can be advanced.
- Feedings should be given as bolus feedings every 3 hours. Consider bolus feeds every 3 hours given on a pump over 30 minutes in presence of feeding intolerance. Due to fat loss in tubing, it is preferred not to give continuous feeds unless severe feeding intolerance. (Tables 12–7a, 7b, 7c, 7d and 7e)

---

Section of Neonatology, Department of Pediatrics, Baylor College of Medicine

Figure 12-1. Feeding tolerance algorithm

Check gastric residual volume (GRV) every 3 hours for infants receiving > 40 mL/kg of feedings or infant appears ill. There is no strong evidence for the evaluation of residuals in most VLBW infants. Evaluate infant if residuals exceed 50% of the feeding volume or the infant has other symptoms of feeding intolerance.

Further Evaluation
- Abdominal distension or discoloration or tenderness
- Increased apnea or respiratory changes
- Lethargy or temperature instability

PE Normal / Minimal Clinical Symptoms
- Evaluate overall status, including possibility of sepsis as indicated
- Hold current feeding
- Proceed with abdominal X ray in most cases unless has rapid clinical improvement

Abdominal X Ray

Persistent Large GRV
- Consider feeds on pump over 30 minutes to 2 hours
- Re-evaluate serially
- Consider decrease in feed volume for 24-48 hrs

Normal
- Re-evaluate hourly
- Restart feedings with next feed if symptoms improve
- If clinical symptoms persist or X ray equivocal, may need IV fluids and additional X rays

Abnormal
- Medical or surgical management of process identified (NEC, sepsis, obstruction)

Providing Oral Care with Mother’s Own Colostrum/Breast Milk

Purpose
Colostrum is rich in cytokines, growth factors and immune cells that provide bacteriostatic, bacteriocidal, antiviral, anti-inflammatory and immunomodulatory protection against infection. Closer in composition to amniotic fluid than mature breast milk, colostrum is the optimal transition for the infant’s immature gastrointestinal tract. Studies have found that providing oral care with expressed colostrum or breast milk is safe and may impart protection from these factors in an infant that may not be ready to feed.
Procedure
NICU staff, but preferably parents, should initiate oral care using colostrum or expressed breast milk within 4 hours of birth or as soon as milk is available. Infants should receive oral care regardless of gestation, weight, NPO status, or medical stability at care times only, in accordance with unit policy. Contraindications to oral care with colostrum align with medical contraindications to breastfeeding, such as maternal HIV or TB infection.

**Feeding and Nutrition Goals**
Human milk is recommended for infants (see exceptions in Human Milk section of this chapter). Unless feeding intolerance necessitates a slower pace, follow the schedules in Tables 12–7a, 7b, 7c, 7d, 7e and Figure 12–1. Volumes are approximate. Nutrient components of human milk & fortified human milk are listed in Table 12-10a. When infant formula is used, it should be selected based on the infant’s gestation, birth weight and/or medical condition (Tables 12-8, 12–9 and 12-10b).

The volume of full feedings that enables a good growth rate (15-20 g/kg per day if less than 2000 grams, and 20 to 30 grams per day if greater than or equal to 2000 grams) usually is:
- Infants less than 34 weeks’ postmenstrual age (PMA),
- 160 mL/kg fortified human milk (24-26 kcal/oz).
- 150 mL/kg per day of high protein preterm formula (24 kcal/oz).
- 160-170 mL/kg per day premature transitional formula (22 kcal/oz).
- Infants of PMA 34 weeks or greater,
  - 180 to 200 mL/kg per day of unfortified human milk or term formula (20 kcal/oz).
  - Cue-based feeding with a minimum of 150 mL/kg per day may be used.
- **Energy intakes** of 100 to 130 kcal/kg per day will meet the needs for term and premature infants.
- **Protein intakes** of 3.5 to 4.5 g/kg per day will meet the needs for premature infants. Protein intakes of 1.5 g/kg per day will meet the needs of healthy term infants. Illness or surgery increases protein needs to 2-3 g/kg per day for the term infant.

**Human Milk**
Human milk is the first choice for feeding, and the nutrient content of human milk is the basis for infant nutrition guidelines. Thus, the caloric distribution and nutrient content of infant formulas are based on that of human milk. Known

---

### Table 12-7b. BW ≤ 750 g feeding guidelines

<table>
<thead>
<tr>
<th>Day of Life</th>
<th>Kcal/oz EBM or Donor EBM</th>
<th>Feeding Volume (mL/kg/day)</th>
<th>TPN (mL/kg/day)</th>
<th>Lipids (mL/kg/day)</th>
<th>Total Fluid (mL/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20</td>
<td>15-20³</td>
<td>100⁴</td>
<td>2.5⁵</td>
<td>130</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>15-20³</td>
<td>100</td>
<td>2.5-5</td>
<td>140</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>15-20³</td>
<td>100</td>
<td>5-10</td>
<td>140</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>15-20³</td>
<td>100</td>
<td>10-15</td>
<td>140</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
<td>15-20³</td>
<td>110</td>
<td>15</td>
<td>150</td>
</tr>
<tr>
<td>6</td>
<td>20</td>
<td>40</td>
<td>95</td>
<td>15</td>
<td>150</td>
</tr>
<tr>
<td>7</td>
<td>20-26 (add Prolact + 6)⁶</td>
<td>60</td>
<td>75</td>
<td>15</td>
<td>150</td>
</tr>
<tr>
<td>8</td>
<td>20-26 (Prolact + 6)</td>
<td>80</td>
<td>55-70</td>
<td>15 Off Lipids</td>
<td>150</td>
</tr>
<tr>
<td>9</td>
<td>20-26 (Prolact + 6)</td>
<td>100</td>
<td>50</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>10</td>
<td>20-26 (Prolact + 6)</td>
<td>100</td>
<td>50</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>11</td>
<td>24 (Similac HMF)²</td>
<td>120</td>
<td>Off TPN</td>
<td>0</td>
<td>120</td>
</tr>
<tr>
<td>12</td>
<td>24 (Similac HMF)</td>
<td>140</td>
<td>0</td>
<td>0</td>
<td>140</td>
</tr>
<tr>
<td>13</td>
<td>24 (Similac HMF) or 26 (Prolact + 6)⁸</td>
<td>150-160</td>
<td>0</td>
<td>0</td>
<td>150-160</td>
</tr>
</tbody>
</table>

1. EBM = expressed breast milk
2. Anticipated total fluids include TPN, lipids, TKO’s, medications and flushes. Volume available for TPN may differ depending on volume of meds, flushes, etc.
3. Recommend begin enteral feeds within the first day of life if medically stable (i.e. not intubated or requiring pressors except low dose dopamine). Trophic feeds generally do not count towards total fluid. See Table 13-2 in Ch 13.1 Fluid and Electrolyte Therapy
4. Standard starter used when TPN room closed (1PM – 10AM).
5. For infants ≤750 gram birth weight, initiate lipids at 2.5 ml/kg/day. See IL initiation protocol.
6. Add Prolact +6 to EBM at 60 mL/kg.
7. If Prolacta is unavailable use Similac HMF Hydrolyzed Protein Concentrated Liquid. After 1 day of 100 mL/kg of enteral feeds, fortify EBM with 4 packets of Similac HMF Hydrolyzed Protein Concentrated Liquid to reach 24 kcal/oz.
8. Add poly-vi-sol and fer-in-sol after parenteral nutrition is discontinued for infants consuming EBM + Prolacta and fer-in-sol after parenteral nutrition is discontinued for infants consuming EBM + Similac HMF. The infant should be at least 14 days of age for iron supplementation.
9. Provide iron supplementation at 2-3 mg/kg for infants ≤1500 g birthweight.
### Table 12-7c. BW 751-1250g feeding guidelines

<table>
<thead>
<tr>
<th>Day of Life</th>
<th>Kcal/oz EBM&lt;sup&gt;1&lt;/sup&gt; or Donor EBM</th>
<th>Feeding Volume (mL/kg/day)</th>
<th>TPN (mL/kg/day)</th>
<th>Lipids (mL/kg/day)</th>
<th>Total Fluid&lt;sup&gt;2&lt;/sup&gt; (mL/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20</td>
<td>15-20&lt;sup&gt;3&lt;/sup&gt;</td>
<td>80&lt;sup&gt;4&lt;/sup&gt;</td>
<td>5-10&lt;sup&gt;5&lt;/sup&gt;</td>
<td>80-110</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>15-20&lt;sup&gt;3&lt;/sup&gt;</td>
<td>80-100</td>
<td>5-10</td>
<td>120-130</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>15-20&lt;sup&gt;3&lt;/sup&gt;</td>
<td>80-100</td>
<td>10-15</td>
<td>120-130</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>40</td>
<td>80</td>
<td>15</td>
<td>120-135</td>
</tr>
<tr>
<td>5</td>
<td>20-26 (add Prolact + 6)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>60</td>
<td>70</td>
<td>15</td>
<td>150</td>
</tr>
<tr>
<td>6</td>
<td>20-26 (Prolact + 6)</td>
<td>80</td>
<td>50-70</td>
<td>15 or Off Lipids</td>
<td>150</td>
</tr>
<tr>
<td>7</td>
<td>20-26 (Prolact + 6)</td>
<td>100</td>
<td>50</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>8</td>
<td>24 (add Similac HMF)&lt;sup&gt;7&lt;/sup&gt;</td>
<td>100</td>
<td>50</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>or 26 (Prolact + 6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>24 (Similac HMF)</td>
<td>120</td>
<td>Off TPN</td>
<td>0</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>26 (Prolact + 6)</td>
<td>140</td>
<td>0</td>
<td>0</td>
<td>140</td>
</tr>
<tr>
<td>10</td>
<td>24 (Similac HMF)</td>
<td>140</td>
<td>0</td>
<td>0</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>26 (Prolact + 6)</td>
<td>150-160</td>
<td>0</td>
<td>0</td>
<td>150-160</td>
</tr>
<tr>
<td>11</td>
<td>24 (Similac HMF) or 26 (Prolact + 6)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>150-160</td>
<td>0</td>
<td>0</td>
<td>150-160</td>
</tr>
</tbody>
</table>

<sup>1</sup> EBM = expressed breast milk  
<sup>2</sup> Anticipated total fluids include TPN, lipids, TKO’s, medications and flushes. Volume available for TPN may differ depending on volume of meds, flushes, etc.  
<sup>3</sup> Recommend begin enteral feeds within 6-12 hours after birth if medically stable for VLBW/LBW infants. For ELBW infants, initiate on the first day if medically stable (i.e. not intubated or requiring pressors except low dose dopamine). Trophic feeds generally do not count towards total fluid.  
<sup>4</sup> Standard starter used when TPN room closed (1PM – 10AM).  
<sup>5</sup> For infants 751-1000 grams birth weight, initiate lipids at 5mL/kg/day. See IL initiation protocol.  
<sup>6</sup>Add Prolact +6 to EBM at 60 mL/kg.  
<sup>7</sup>If Prolacta is unavailable use Similac HMF Hydrolyzed Protein Concentrated Liquid. After 1 day of 100 mL/kg of enteral feeds, fortify EBM with 4 packets of Similac HMF Hydrolyzed Protein Concentrated Liquid to reach 24 kcal/oz  
<sup>8</sup>Add poly-vi-sol and fer-in-sol after parenteral nutrition is discontinued for infants consuming EBM + Prolacta and fer-in-sol after parenteral nutrition is discontinued for infants consuming EBM + Similac HMF. The infant should be at least 14 days of age for iron supplementation.  
<sup>9</sup> Provide iron supplementation at 2-3 mg/kg for infants < 1500 g birth weight

### Table 12-7d. BW 1251-1500 g feeding guidelines

<table>
<thead>
<tr>
<th>Day of Life</th>
<th>Kcal/oz EBM&lt;sup&gt;1&lt;/sup&gt; or Donor EBM</th>
<th>Feeding Volume (mL/kg/day)</th>
<th>TPN (mL/kg/day)</th>
<th>Lipids (mL/kg/day)</th>
<th>Total Fluid&lt;sup&gt;2&lt;/sup&gt; (mL/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1&lt;sup&gt;3&lt;/sup&gt;</td>
<td>20</td>
<td>20</td>
<td>70&lt;sup&gt;4&lt;/sup&gt;</td>
<td>10</td>
<td>80</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>40</td>
<td>60</td>
<td>15</td>
<td>100-120</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>60</td>
<td>40</td>
<td>15</td>
<td>100-120</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>80</td>
<td>40</td>
<td>Off Lipids</td>
<td>100-120</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
<td>100</td>
<td>50</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>6</td>
<td>24 (add Similac HMF)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>100</td>
<td>50</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>7</td>
<td>24 (Similac HMF)</td>
<td>120</td>
<td>Off TPN</td>
<td>0</td>
<td>120</td>
</tr>
<tr>
<td>8</td>
<td>24 (Similac HMF)</td>
<td>140</td>
<td>0</td>
<td>0</td>
<td>140</td>
</tr>
<tr>
<td>9</td>
<td>24 (Similac HMF) or 26 (Prolact + 6)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>150-160</td>
<td>0</td>
<td>0</td>
<td>150-160</td>
</tr>
</tbody>
</table>

<sup>1</sup> EBM = expressed breast milk  
<sup>2</sup> Anticipated total fluids include TPN, lipids, TKO’s, medications and flushes. Volume available for TPN may differ depending on volume of meds, flushes, etc.  
<sup>3</sup> Recommend begin enteral feeds within 6-12 hours after birth if medically stable (i.e. not intubated or requiring pressors except low dose dopamine). Trophic feeds generally do not count towards total fluid.  
<sup>4</sup> Standard starter used when TPN room closed (1PM – 10AM).  
<sup>5</sup> After 1 day of 100 mL/kg of enteral feeds, fortify EBM with 4 packets of Similac HMF Hydrolyzed Protein Concentrated Liquid to reach 24 kcal/oz.  
<sup>6</sup> Provide iron supplementation at 2-3 mg/kg for infants < 1500 g birthweight.
contraindications to use of human milk are galactosemia, maternal HIV-positive status, current maternal substance abuse, maternal chemotherapy, and miliary TB. Most medications are compatible with breastfeeding. Contact the Texas Children’s Hospital Lactation Program with any questions regarding specific medications.

TCH Donor Human Milk Protocol
Maternal assent must be obtained and documented in the electronic medical record prior to giving any donor human milk product. All very low birth weight infants (<1500 g) are eligible for donor HM.

Other potential indications for donor HM (infants >1500 g):
• History of NEC - Recommend using for all with Stage 2 or above.
• Major congenital heart disease.
• Significant feeding intolerance especially in infants with abdominal wall defects.
• Family request. It is important to respect the family’s choices and in every case where a mother requests “no formula” this should be honored unless there is a special medical indication to use an infant formula

Prolacta® (Donor Human Milk Fortifier) Indications:
• BW ≤ 1250 grams.
• Intolerance to bovine milk-based HMF
• Other possible uses (individualized decision, discuss with nutrition team).

Prolacta® Cream (Donor Human Milk Cream Supplement):
• Premature infants receiving a diet of mother’s milk or donor human milk fortified with Prolacta® at full feeds are eligible for Prolacta® Cream if weight gain is suboptimal for 3-5 days.

### Table 12-6. BW 1501-2000 g feeding guidelines

<table>
<thead>
<tr>
<th>Day of Life</th>
<th>Kcal/oz EBM/Donor EBM® or premature formula</th>
<th>Feeding Volume (mL/kg/day)</th>
<th>IVF (mL/kg/day)</th>
<th>Total Fluids (mL/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20-24</td>
<td>20</td>
<td>60</td>
<td>80</td>
</tr>
<tr>
<td>2</td>
<td>20-24</td>
<td>50</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>3</td>
<td>20-24</td>
<td>80</td>
<td>20</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>20-24</td>
<td>110</td>
<td>Off IVF</td>
<td>110</td>
</tr>
<tr>
<td>5</td>
<td>24</td>
<td>110</td>
<td>0</td>
<td>110</td>
</tr>
<tr>
<td>6</td>
<td>20-24</td>
<td>130</td>
<td>0</td>
<td>130</td>
</tr>
<tr>
<td>7</td>
<td>20-24</td>
<td>150</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>8</td>
<td>20-24</td>
<td>150</td>
<td>0</td>
<td>150</td>
</tr>
</tbody>
</table>

1. EBM = expressed breast milk
2. Individualize initiation and advancement rates and total fluids based on patient’s weight, age and clinical status.
3. Initiate feedings with EBM/donor EBM 20 kcal/oz or Similac Special Care 24 kcal/oz High Protein or Enfamil Premature 24 kcal/oz High Protein.
4. After 1 day of ≥100 mL/kg of enteral feeds, EBM feeds are fortified with 4 packets of Similac HMF Hydrolyzed Protein Concentrated Liquid to reach 24 kcal/oz for infants birth weight <2000 g or < 34 weeks PMA. The infant should be at least 14 days of age for iron supplementation.
5. Provide iron supplementation at 2 mg/kg for infants 1500 to 2500 g birthweight.

### Table 12-7. Milk selection

<table>
<thead>
<tr>
<th>Milk</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human milk</td>
<td>Milk initiation for all infants and single milk source for infants &gt; 2000 g or &gt; 34 weeks PMA</td>
</tr>
<tr>
<td>Human milk + Prolacta3,4,5</td>
<td>Birth weight ≤ 1250 g</td>
</tr>
<tr>
<td>Human milk + bovine milk-based fortifier4,5,6</td>
<td>Birth weight 1251 - 2000 g and &lt; 34 weeks PMA</td>
</tr>
<tr>
<td>Premature infant formula with iron7</td>
<td>Birth weight &lt; 2000 g or &lt; 34 weeks PMA</td>
</tr>
<tr>
<td>Term formula with iron7</td>
<td>Birth weight &gt; 2000 g or &gt; 34 wks PMA and able to consume at least 180 mL/kg/day</td>
</tr>
<tr>
<td>Premature transitional formula</td>
<td>Premature infants post discharge with birth weight &lt;1800 g</td>
</tr>
</tbody>
</table>

PMA = post-menstrual age
1. Consider donor human milk supplementation of mother’s milk for infants <1500 g.
2. See Table 12-9 for special use formulas.
3. Add Prolact +6 at 60 mL/kg EBM.
4. To avoid nutrient overload, fortified human milk or premature infant formula should not be fed ad lib.
5. To avoid nutrient overload, fortified human milk or premature infant formula should not be fed ad lib.
6. For infants ≤1250 BW, if Prolacta fortifier is not available, infants should receive mother’s own milk or donor milk fortified with Similac HMF Hydrolyzed Protein Concentrated Liquid.
7. The neonatology section recommends use of term 20 kcal/oz formula for premature infants when term formula is indicated.
8. May be provided as initial feedings for healthy infant whose birth weight is 1800 to 2200 g. Data regarding nutrient needs for this weight group are limited.

### Table 12-8. Suggested Prolacta® concentrations when using Prolacta® cream according to feeding volume.

<table>
<thead>
<tr>
<th>Total EN volume (mL/kg/day)</th>
<th>Prolacta® Fortifier</th>
<th>Protein (g/kg/day)</th>
<th>Prolacta® Cream</th>
</tr>
</thead>
<tbody>
<tr>
<td>160</td>
<td>Prolact +6</td>
<td>3.8</td>
<td>2 kcal/oz</td>
</tr>
<tr>
<td>150</td>
<td>Prolact +6</td>
<td>3.6</td>
<td>2 kcal/oz</td>
</tr>
<tr>
<td>140</td>
<td>Prolact +8</td>
<td>4.1</td>
<td>2 kcal/oz</td>
</tr>
<tr>
<td>130</td>
<td>Prolact +8</td>
<td>3.8</td>
<td>2 kcal/oz</td>
</tr>
</tbody>
</table>

In general, it is our practice to transition off donor human milk, donor human milk fortifier and donor milk cream at 34 weeks PMA as the peak incidence of NEC occurs at 31-33 weeks PMA in premature infants.

Transitioning babies from donor HM to formula (assuming no mother’s milk available) may be done as follows (assuming formula is tolerated):
• Day 1, add 1 formula feeding
• Day 2, add 2 formula feedings
• Day 3, add 4 formula feedings
• Day 4, all formula feedings
### Table 12-9 Indications for human milk and infant formula usage in high-risk neonates

<table>
<thead>
<tr>
<th>Milk/Formula</th>
<th>Indication for Use</th>
<th>Carbohydrate</th>
<th>Protein</th>
<th>Nutrient Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Low Birth Weight Infants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor human milk fortifier (pasteurized)</td>
<td>supplement to breast milk for infants &lt; 1250 g birthweight fortified with minerals and electrolytes</td>
<td>lactose, galacto-oligosaccharides</td>
<td>concentrated human milk protein</td>
<td>human</td>
</tr>
<tr>
<td>Donor human milk cream fortifier (pasteurized)</td>
<td>caloric fortifier</td>
<td>none</td>
<td>none</td>
<td>human milk cream</td>
</tr>
<tr>
<td>Human milk fortifier bovine milk-base</td>
<td>supplement to breast milk for premature infants</td>
<td>maltodextrin, modified corn starch</td>
<td>casein hydrolysate</td>
<td>MCT oil, soy oil, coconut oil, DHA, ARA</td>
</tr>
<tr>
<td>Premature formulas 20, 24 (high and regular protein) or 30 kcal/oz with iron</td>
<td>premature infants</td>
<td>corn syrup solids or maltodextrin, and lactose</td>
<td>nonfat milk, whey protein concentrate</td>
<td>40–50% MCT oil, soy, high oleic sunflower, and/or coconut oils, DHA, ARA</td>
</tr>
<tr>
<td>Premature transitional formulas 22 kcal/oz with iron</td>
<td>discharge formula for infants with birth weight &lt;1800 g, on limited volume intake or history of osteopenia or poor growth</td>
<td>Maltodextrin or corn syrup solids and lactose</td>
<td>nonfat milk and whey protein concentrate</td>
<td>20–25% MCT oil, soy oil, coconut oil, and/or high oleic sunflower or safflower oil, DHA, ARA</td>
</tr>
<tr>
<td><strong>Special Use</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alfamino®</td>
<td>cow’s milk protein allergy, multiple food allergies, eosinophilic GI disorders, malabsorptive conditions, short bowel syndrome</td>
<td>corn syrup solids, potato starch</td>
<td>100% synthetic amino acids</td>
<td>43% MCT oil, soy bean, high oleic sunflower, and high 2-palmitic vegetable oils, DHA, ARA</td>
</tr>
<tr>
<td>Alimentum®</td>
<td>sensitivity to intact protein (cow’s milk), protein malabsorption, severe food allergies, or fat malabsorption</td>
<td>sucrose, modified tapioca starch or corn maltodextrin</td>
<td>casein hydrolysate with added amino acids</td>
<td>33% MCT oil, high-oleic safflower, soy oils, DHA, ARA</td>
</tr>
<tr>
<td>Elecare®</td>
<td>intolerance to intact protein (cow’s milk) or hydrolyzed protein, protein malabsorption, malabsorption, severe food allergies, short bowel syndrome, eosinophilic GI disorders, or GI tract-impairment</td>
<td>corn syrup solids</td>
<td>100% synthetic amino acids</td>
<td>33% MCT oil, high oleic safflower, soy oils, DHA, ARA</td>
</tr>
<tr>
<td>Enfaport®</td>
<td>chylothorax, LCHAD deficiency, available as 30 kcal/oz, can be prepared at 20 kcal/oz for infants</td>
<td>corn syrup solids</td>
<td>nonfat milk, whey protein concentrate</td>
<td>83% MCT oil, soy oil, DHA, ARA</td>
</tr>
<tr>
<td>Gerber Extensive HA®</td>
<td>cow’s milk protein allergy</td>
<td>corn maltodextrin, potato starch</td>
<td>enzymatically hydrolyzed whey protein isolate</td>
<td>49% MCT oil, soy, high oleic sunflower, high 2-palmitic vegetable oils, DHA, ARA</td>
</tr>
<tr>
<td>Neocate Infant DHA/ARA®</td>
<td>cow milk allergy, multiple food allergies</td>
<td>corn syrup solids</td>
<td>100% synthetic amino acids</td>
<td>33% MCT oil, high-oleic sunflower, sunflower, canola oils, DHA, ARA</td>
</tr>
<tr>
<td>Nutramigen® (Liquids)</td>
<td>intact protein allergy (cow and soy milks)</td>
<td>corn syrup solids, modified corn starch</td>
<td>casein hydrolysate with added amino acids</td>
<td>palm olein, soy, coconut, high, oleic sunflower oil, DHA, ARA</td>
</tr>
<tr>
<td>Puramino®</td>
<td>severe cow’s milk protein allergy (not effectively managed by an extensively hydrolyzed formula), multiple food protein allergies, protein malabsorption, malabsorption, short bowel syndrome, and eosinophilic esophagitis</td>
<td>corn syrup solids, modified tapioca starch</td>
<td>100% free amino acids</td>
<td>33% MCT oil, high-oleic sunflower, soy oils, DHA, ARA</td>
</tr>
<tr>
<td>Pregestimil®</td>
<td>fat malabsorption, sensitivity to intact proteins</td>
<td>corn syrup solids, modified corn starch</td>
<td>casein hydrolysate with added amino acids</td>
<td>55% MCT oil, soy, high-oleic sunflower and/or safflower oils and/or corn oil, DHA, ARA</td>
</tr>
<tr>
<td>Similac® PM 60/40, low iron</td>
<td>low mineral formula for infants with hypocalcemia or hypercalcemia due to hyperparathyroidism or renal disease</td>
<td>lactose</td>
<td>whey protein concentrate, sodium caseinate</td>
<td>high-oleic safflower, soy, coconut oils</td>
</tr>
<tr>
<td>Gerber® Good Start® Gentle</td>
<td>normal nutrition for term infants, low mineral formula for infants with hypocalcemia or renal disease</td>
<td>corn maltodextrin, lactose, galacto-oligosaccharides</td>
<td>whey protein concentrate (from cow’s milk, enzymatically hydrolyzed, reduced in minerals)</td>
<td>palm olein, soy, coconut, high oleic safflower or sunflower oils, DHA, ARA</td>
</tr>
<tr>
<td><strong>Standard Term Formula/Milk</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human milk, 20 kcal/oz</td>
<td>recommended for all infants; fortification needed for premature infants</td>
<td>lactose</td>
<td>whey, casein</td>
<td>human milk fat</td>
</tr>
<tr>
<td>Term formulas with iron, 19/20 kcal/oz</td>
<td>normal nutrition for term infants</td>
<td>Lactose and/or corn maltodextrin, galacto-oligosaccharides, and/or polydextrose</td>
<td>nonfat milk, whey protein concentrate or whey protein concentrate (from cow’s milk, enzymatically hydrolyzed, reduced in minerals)</td>
<td>vegetable oil (palm olein and/or coconut, soy, high oleic sunflower and/or high oleic safflower oils), DHA, ARA</td>
</tr>
<tr>
<td>Soy formulas with iron, 19/20 kcal/oz**</td>
<td>galactosemia, hereditary lactase deficiency (rare), vegetarian diet, not indicated for use in preterm infants</td>
<td>corn syrup solids or corn maltodextrin and/or cornstarch, sucrose</td>
<td>soy protein isolate or enzymatically hydrolyzed soy protein isolate</td>
<td>vegetable oil (soy, coconut and/or palm olein oil, high oleic safflower and/or high oleic sunflower oils), DHA, ARA</td>
</tr>
</tbody>
</table>

*Premature infants receiving milk or formulas not designed for premature infants may be at risk for osteopenia. Serum calcium, phosphorus and alkaline phosphatase activity should be monitored, and calcium, phosphorus and vitamin D supplementation may be indicated.

**Soy formulas are not recommended for premature infants due to the development of osteopenia and poor growth. Osteopenia is due to the lower formula mineral content and the presence of soy phytates that bind phosphorus and make it unavailable for absorption.
In order to facilitate back-transfer of VLBW infants closer to home, once all elements of transfer are in place, certain low risk VLBW infants may be eligible to be transitioned off donor human milk fortifier (Prolacta®) after review with the TCH Neonatal Nutrition Team. Infants receiving donor HM or donor human milk fortifier should transition to formula at least one week prior to discharge.

**Infants Less Than 34 Weeks’ Gestation or Less Than 2000 Grams Birth Weight**

Initiation of enteral feedings and advancement rates should be individualized based on a patient’s weight, age, and clinical status. Infants < 1250 grams should start on trophic feedings as soon as possible. Ill infants may be considered for trophic feeding as soon as clinically stable. Test feedings with water feedings is discouraged. Trophic feedings are to enhance GI maturation not primarily to provide energy or nutrients. If tolerated and clinical condition permits, advance by 10-20 mL/kg per day to full enteral feedings. Consider bolus feedings every 3 hours given on a pump over 30 minutes in presence of feeding intolerance. Trophic feedings can enhance feeding advancement, increase gastrin and other enteric hormone levels, and facilitate a maturing intestinal motor pattern.

- Infants who cannot feed orally require oro(naso)gastric feedings.
- Coordination of oral feeding often is developed by 32 to 34 weeks gestation.
- For initiation and advancement rates, Tables 12-7a, 7b, 7c, 7d, and 7e.
- Add Prolact+6 (26 kcal/oz) (liquid donor human milk-based fortifier) when infant is at 60 mL/kg per day unfortified human milk.
- Add Similac® HMF Hydrolyzed Protein Concentrated Liquid fortifier when an infant has tolerated at least 100 mL/kg per day unfortified human milk or if unfortified human milk has been used at greater than 50 mL/kg per day for 5 to 7 days. Add 4 packets of fortifier per 100 mL.

### Table 12-10a. Nutritional components of human milk and fortified human milk

<table>
<thead>
<tr>
<th></th>
<th>Energy (kcal/oz)</th>
<th>Protein (g/dL)</th>
<th>Fat (g/dL)</th>
<th>Carbohydrate (g/dL)</th>
<th>Calcium (mg/dL)</th>
<th>Phosphorus (mg/dL)</th>
<th>Potassium (mg/dL)</th>
<th>Chloride (mEq/dL)</th>
<th>Sodium (mEq/dL)</th>
<th>Zinc (mg/dL)</th>
<th>Vitamin A (IU/dL)</th>
<th>Vitamin D (IU/dL)</th>
<th>Chloride (mEq/dL)</th>
<th>Total Solute Load (mOsm/Kg/H2O)</th>
<th>Overall osmolarity (mOsm/Kg/H2O)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human milk</td>
<td>20</td>
<td>68</td>
<td>0.9</td>
<td>5</td>
<td>3.5</td>
<td>46</td>
<td>8</td>
<td>47</td>
<td>23</td>
<td>13</td>
<td>0.8</td>
<td>1.2</td>
<td>1.2</td>
<td>0.2</td>
<td>160</td>
</tr>
<tr>
<td>EBM + Prolact+4 = 24³</td>
<td>24</td>
<td>82</td>
<td>1.9</td>
<td>9</td>
<td>4.6</td>
<td>50</td>
<td>8.2</td>
<td>40</td>
<td>121</td>
<td>64</td>
<td>2.2</td>
<td>2.3</td>
<td>1.8</td>
<td>0.9</td>
<td>189</td>
</tr>
<tr>
<td>EBM + Prolact+6 = 26³</td>
<td>26</td>
<td>90</td>
<td>2.4</td>
<td>11</td>
<td>5.2</td>
<td>52</td>
<td>8.4</td>
<td>38</td>
<td>122</td>
<td>64</td>
<td>2.3</td>
<td>2.2</td>
<td>1.8</td>
<td>0.9</td>
<td>204</td>
</tr>
<tr>
<td>EBM + Prolact+8 = 28³</td>
<td>28</td>
<td>97</td>
<td>2.9</td>
<td>12</td>
<td>5.7</td>
<td>53</td>
<td>8.4</td>
<td>35</td>
<td>122</td>
<td>64</td>
<td>2.3</td>
<td>2.3</td>
<td>2</td>
<td>0.9</td>
<td>218</td>
</tr>
<tr>
<td>EBM + Prolact+10 = 30³</td>
<td>30</td>
<td>105</td>
<td>3.5</td>
<td>13</td>
<td>6.3</td>
<td>54</td>
<td>8.6</td>
<td>33</td>
<td>123</td>
<td>64</td>
<td>2.4</td>
<td>2.3</td>
<td>1.9</td>
<td>0.9</td>
<td>233</td>
</tr>
<tr>
<td>EBM + Prolact+8 (1:1 ratio) = 30³</td>
<td>30</td>
<td>104</td>
<td>3.5</td>
<td>13</td>
<td>6.3</td>
<td>54</td>
<td>8.5</td>
<td>33</td>
<td>147</td>
<td>76</td>
<td>2.6</td>
<td>2.6</td>
<td>2.2</td>
<td>1.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Liquid Similac FEBM 22²</td>
<td>22</td>
<td>75</td>
<td>1.7</td>
<td>9</td>
<td>3.6</td>
<td>43</td>
<td>8.6</td>
<td>46</td>
<td>76</td>
<td>43</td>
<td>1.1</td>
<td>2.0</td>
<td>1.8</td>
<td>0.7</td>
<td>0.3</td>
</tr>
<tr>
<td>Liquid Similac FEBM 24²</td>
<td>24</td>
<td>80</td>
<td>2.4</td>
<td>12</td>
<td>3.6</td>
<td>41</td>
<td>9.2</td>
<td>46</td>
<td>119</td>
<td>68</td>
<td>1.4</td>
<td>2.7</td>
<td>2.3</td>
<td>1.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Liquid Similac FEBM 26²</td>
<td>26</td>
<td>86</td>
<td>3.2</td>
<td>15</td>
<td>3.7</td>
<td>38</td>
<td>9.8</td>
<td>45</td>
<td>167</td>
<td>95</td>
<td>1.6</td>
<td>3.4</td>
<td>2.9</td>
<td>1.7</td>
<td>0.6</td>
</tr>
<tr>
<td>Similac FEBM² + NeoSure = 27</td>
<td>27</td>
<td>91</td>
<td>2.7</td>
<td>12</td>
<td>4.2</td>
<td>42</td>
<td>10.2</td>
<td>45</td>
<td>129</td>
<td>73</td>
<td>1.5</td>
<td>3</td>
<td>2.5</td>
<td>1.3</td>
<td>0.6</td>
</tr>
<tr>
<td>Similac FEBM² + EnfaCare = 27</td>
<td>27</td>
<td>90</td>
<td>2.7</td>
<td>12</td>
<td>4.2</td>
<td>41</td>
<td>10.2</td>
<td>45</td>
<td>131</td>
<td>74</td>
<td>1.5</td>
<td>2.9</td>
<td>2.6</td>
<td>1.3</td>
<td>0.6</td>
</tr>
<tr>
<td>Similac FEBM² + NeoSure = 30</td>
<td>30</td>
<td>99</td>
<td>2.9</td>
<td>12</td>
<td>4.7</td>
<td>43</td>
<td>11.1</td>
<td>45</td>
<td>138</td>
<td>78</td>
<td>1.6</td>
<td>3.4</td>
<td>2.8</td>
<td>1.4</td>
<td>0.8</td>
</tr>
<tr>
<td>Similac FEBM² + EnfaCare = 30</td>
<td>30</td>
<td>98</td>
<td>2.9</td>
<td>12</td>
<td>4.6</td>
<td>42</td>
<td>11.1</td>
<td>45</td>
<td>140</td>
<td>79</td>
<td>1.6</td>
<td>3.2</td>
<td>2.8</td>
<td>1.4</td>
<td>0.8</td>
</tr>
</tbody>
</table>

1 Adapted from Pediatric Clinics of North America, Vol 48; Picciano, MF. Appendix. Representative Values for Constituents of Human Milk. 263-264, Copyright 2001, with permission from Elsevier.
2 Adapted from Jensen RG, ed. Handbook of Milk Composition. Copyright 1995 with permission from Elsevier.
3 Values obtained from mature human milk (AAP) and Prolacta.com
4 NA = not available
5 FEBM = expressed breast milk with Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid

Guidelines for Acute Care of the Neonate, Edition 26, 2018–19
Section 12—Nutrition

Section of Neonatology, Department of Pediatrics, Baylor College of Medicine

of milk (24 kcal/oz). One packet of bovine-based fortifier
equals 7.5 kcal per packet and is 5 mL.
•

For infants < 1250 g BW, if Prolact+® fortifier is not
available, infants should receive mother’s own milk or
donor human milk fortified with Similac® HMF
Hydrolyzed Protein Concentrated Liquid.

•

Generally, milk volume and concentration are not
increased at the same time when using bovine fortifier.
Advance the volume of fortified human milk until weight
gain is satisfactory.

•

Satisfactory weight gain is 15-20 g/kg per day when < 2
kg.

Table 12-10b. Nutritional components of commercial formulas

%kcals

g/dL

% kcals

g/dL

% kcals

Calcium
mg/dL

Phosphorus
mg/dL

Sodium
mEq/dL

Potassium
mEq/dL

Chloride
mEq/dL

Zinc
mg/dL

Iron
mg/dL

Vitamin A
IU/dL

Vitamin D
IU/dL

Potential Renal
Solute Load
mOsm/ dL

Osmolality
mOsm/Kg/ H2O

Carbohydrate

g/dL

Fat

kcal/dL

Protein

kcal/oz

Energy

Enfamil Premium Infant 20

20

68

1.4

8

3.6

48

7.6

44

53

29

0.8

1.9

1.2

0.7

1.2

203

41

12.5

300

Good Start Gentle 20

20

68

1.5

9

3.5

46

7.8

46

45

26

0.8

1.9

1.3

0.5

1.0

203

51

13.3

250

Similac Advance 20

20

68

1.4

8

3.7

49

7.6

43

53

28

0.7

1.8

1.2

0.5

1.2

203

51

12.7

310

Similac Pro-Advance 19

19

64

1.3

8

3.5

49

7.1

43

53

28

0.7

1.8

1.2

0.5

1.2

192

48

12.3

310

Enfamil 24RTF

24

81

1.7

8.5

4.3

48

9.1

43.4

63

35

0.9

2.2

1.5

0.8

1.5

242

60

15.4

370

Similac Advance 24

24

81

1.7

8

4.4

49

9.1

45

63

34

0.8

2.2

1.5

0.6

1.5

243

61

15.2

NA3

Enfamil Premature 20

20

68

2.2

13

3.4

44

7.3

43

111

61

2.1

1.7

2

1.0

1.2

912

203

20.0

260

Similac Special Care 20

20

68

2.0

12

3.7

47

7.0

41

122

68

1.3

2.2

1.6

1.0

1.2

845

101

18.8

235

24

81

2.9

14

4.0

44

8.5

42

133

73

2.5

2.0

2.4

1.2

1.5

1089

242

26.0

300

24

81

2.7

13

4.0

44

8.7

43

133

73

2.5

2.0

2.4

1.2

1.5

1089

242

25.0

320

24

81

2.7

13

4.4

47

8.1

40

146

81

1.5

2.7

1.9

1.2

1.5

1014

122

24.0

280

24

81

2.4

12

4.4

47

8.4

41

146

81

1.5

2.7

1.9

1.2

1.5

1014

122

22.6

280

27

90

3.1

14

4.6

45

9.7

43

150

82

2.8

2.3

2.8

1.4

1.6

1231

271

28.4

NA3

Similac Special Care27 HP4

27

91

2.9

13

5.5

55

8

35

164

91

1.8

3

2.1

1.4

1.6

1141

137

26.0

305

Enfamil Premature30

30

100

3.3

13

5.1

44

10.8

43

167

91

3.1

2.5

3.1

1.5

1.8

1370

300

30.0

320

Similac Special Care 30

30

101

3.0

12

6.7

57

7.8

31

183

101

1.9

3.4

2.3

1.5

1.8

1268

152

28.2

325

Enfamil EnfaCare 22

22

75

2.1

11

3.9

47

7.8

42

90

50

1.2

2.0

1.7

0.8

1.4

338

56

18.4

230

Similac NeoSure 22

22

74

2.1

11

4.1

50

7.5

40

78

46

1

2.7

1.6

0.9

1.3

260

52

18.7

250

Enfamil EnfaCare 24

24

80

2.2

11

4.2

47

8.4

42

97

53

1.3

2.1

1.8

0.8

1.4

354

60

19.7

NA3

Similac NeoSure 24

24

80

2.2

11

4.4

50

8.1

40

84

50

1.1

2.9

1.7

1.0

1.4

280

56

20.2

NA3

Enfamil EnfaCare 27

27

89

2.5

11

4.6

47

9.3

42

107

59

1.4

2.4

2

0.9

1.6

392

66

21.8

NA3

Similac NeoSure 27

27

90

2.5

11

5.0

50

9.1

40

95

56

1.3

3.2

1.9

1.1

1.6

316

63

22.7

NA3

Enfamil EnfaCare 30

30

100

2.8

11

5.2

47

10.4

42

120

66

1.6

2.7

2.2

1.0

1.8

440

74

24.5

NA3

Similac NeoSure 30

30

101

2.8

11

5.6

50

10.2

40

106

63

1.4

3.6

2.1

1.2

1.8

354

71

25.5

NA3

Nutramigen 20 (Liquids)

20

68

1.9

11

3.6

48

7.0

41

64

35

1.4

1.9

1.7

0.7

1.2

203

34

16.9

320

Pregestimil 20

20

68

1.9

11

3.8

49

6.9

40

64

35

1.4

1.9

1.7

0.7

1.2

236

34

16.9

290

Pregestimil 24

24

81

2.3

11

4.5

49

8.2

40

76

42

1.6

2.3

2.0

0.8

1.5

282

40

20.0

340

Similac Alimentum 20

20

68

1.9

11

3.7

48

6.9

41

71

51

1.3

2.0

1.6

0.5

1.2

203

30

17.1

370

Elecare 20

20

68

2.1

15

3.3

43

7.3

42

79

57

1.4

2.7

1.2

0.8

1.2

186

41

18.7

350

Neocate 20

20

68

1.9

11

3.5

46

7.3

43

79

56

1.2

1.9

1.5

0.8

1.0

190

50

16.8

340

PurAmino 20

20

68

1.9

11

3.5

47

7.2

42

64

35

1.4

1.9

1.7

0.7

1.2

202

34

16.9

350

Alfamino 20

20

68

1.9

11

3.4

45

7.4

44

80

53

1.1

1.8

1.6

1.1

1.2

214

38

16.9

330

Similac PM 60/40 20

20

68

1.5

9

3.8

50

6.9

41

38

19

0.7

1.4

1.2

0.5

0.5

204

41

12.4

280

Enfaport 20

20

67

2.4

14

3.7

46

6.8

40

64

35

0.9

2.0

1.7

0.7

1.2

240

34

19.4

170

2

Enfamil Premature24 HP

4

Enfamil Premature24
Similac Special Care24 HP

4

Similac Special Care 24
Enfamil Premature 27 HP

1

4

All formulas are with iron Ready-to-Feed NA = not available HP = High Protein

174

2

3

4

Guidelines for Acute Care of the Neonate, Edition 26, 2018–19


Vitamin and Mineral Supplementation

• Consider stopping fortification of human milk or premature formula at about 34 weeks PMA in preparation for discharge, if growth and bone indices are appropriate and if patient is not being fluid restricted.

• Healthy premature infants who are consuming all feeds by mouth can receive unfortified human milk.

Infants 34 or More Weeks’ Gestation or 2000 Grams or Greater Birth Weight

• Breastfeeding or expressed breast milk (EBM) is encouraged. If infant is not breastfeeding, use term or premature transitional infant formula with iron. (Table 12–8)

• Milk volumes in the first 4 days of life are generally low in full term infants. Most infants will not need more than 30–40 mL/kg/day total daily volume in the first 48 hours of age or more than 50 mL/kg/day in the third and fourth days of life. Feeding orders should reflect this.

• For initiation and advancement rates, (Tables 12–7a, and 7e).

• Infants who are unable to feed orally require oro(naso)gastric feedings.

• Generally, infants 34 or more weeks’ gestation or 2000 grams or more birth weight receiving full oral feedings at an adequate volume do not need fortification of human milk, premature formula, or premature transitional formula.

Vitamin and Mineral Supplementation

• Full-term, breast-fed infants should receive a vitamin D supplement of 400 IU per day (use D-Vi-Sol®, 1 mL per day).

Supplemental iron and vitamins are not needed for term infants receiving iron-fortified formula. (The AAP recommends using only iron-fortified formulas.)

• Healthy term, breast-fed infants do not need iron supplementation until 4 months of age, at which time they should be initiated at 1 mg/kg/day. Early iron supplementation should be considered for infants who have had significant blood loss in the neonatal period or thereafter. Earlier iron supplementation is required for infants < 2500 grams birthweight at 2 mg/kg per day.

When to Use Human Milk Enriched with Formula or Concentrated Formula

Generally, infants born at 34 weeks’ gestation or at 2000 grams or greater will progress easily to full oral feeding on the diets discussed above. Additional nutrition support is indicated for those infants who:

• Have slow growth (less than 20 grams per day for infants greater than or equal to 2 kg or less than 15 grams/kg per day for infants less than 2 kg),

• Manifest abnormal biochemical indices (low serum phosphorus, high alkaline phosphatase activity, or low BUN),

Need a restricted milk volume (less than 150 mL/kg per day), or have diagnoses such as BPD or CHD that require nutrient dense milk or formula.

For infants fed human milk, consider breastfeeding plus a few teachings of formula. Formula powder may be added to expressed human milk to equal 24, 27, or 30 kcal/oz milk.

Recognize potential risk of powdered formula use if this is chosen.

For term infants fed formula, use term liquid concentrate formula when available and prepare to desired caloric density greater than 20 kcal/oz.

For preterm infants fed formula, use ready-to-feed preterm 30 kcal/oz formula and mix with high protein preterm 24 kcal/oz formula to achieve greater than 24 kcal/oz formula. Continue these diets until abnormalities resolve or fluid restriction is liberalized.

Statement about use of powdered formulas – Powdered infant formulas are not commercially sterile and Cronobacter spp contamination has been reported with its use. When infant formula is fed to immuno-compromised infants, including preterm infants, ready-to-feed formulas or liquid formula concentrate mixed with sterile water are preferred. Powdered formula is indicated when there is no available alternative that meets the infant’s nutrient needs.

Tube-feeding Method

A variety of methods are available for tube feeding, and the approach used should be individualized for each patient:

• Intermittent bolus feeding mimics the feed-fast pattern and may be associated with less feeding intolerance. This can be done as a true bolus or as a feeding given over 30 minutes to 1 hour by pump.

• Continuous infusion is beneficial for infants with intestinal failure or gastrointestinal dysmotility. It may also be tried for infants < 1000 g birthweight who do not tolerate feeds, although it is best to try to resume feeds over 30 minutes to 1 hour as soon as possible in these cases.

Transpyloric continuous infusion may be needed in infants with severe gastroesophageal reflux, marked delays in gastric emptying, or both.
Other Considerations

Low lactose products and soy-based infant formulas should generally be avoided in this population. There are no data to support a benefit to their use as optimal nutrition in any group of infants. Infants with evidence of severe reflux or colic type symptoms should be evaluated by our nutrition team before switching formulas. We do not recommend the use of products such as simethicone drops.

Statement about the use of commercial thickening agents

The Neonatology Section of BCM recommends that no infant be provided any commercial thickening agent designed to be added to infant formula or human milk in any of our Level 2, 3 or 4 NICUs. Consideration of the use of such agents should only be done in the context of an IRB-approved research protocol.

Infants with Chylothorax

For infants with chylothorax, a diet low in long chain fatty acids (LCFAs) minimizes the accumulation of chylous effusions in the pleural cavity. A diet regimen in which the fat source is primarily medium chain triglycerides (MCTs) with a minimal amount of LCFAs to prevent essential fatty acid deficiency (EFAD) is recommended. As human milk is high in LCFAs, it is recommended that infants receiving maternal human milk have the milk skimmed to produce lower fat milk.

Since skimmed human milk is lower in calories, essential fatty acids, and fat-soluble vitamins, it requires fortification of these nutrients. It is recommended that skimmed human milk be fortified with Enfaport® to equal 20 calories per ounce. Enfaport® can also be used if fortification above 20 calories per ounce is needed (i.e., for fluid restriction). Multi-vitamin and iron supplementation is also recommended to meet vitamin and iron needs. Education on preparation of skimmed human milk mixed with formula will need to be provided to parents prior to discharge.

If an infant is discharged home on a diet regimen with skimmed human milk, it is necessary for the caregiver(s) to bring the maternal expressed breast milk (EBM) to the Milk Bank once to twice a week (depending on the supply of EBM) to have the milk skimmed for home use. This must be coordinated prior to discharge. Contact the nutrition team with any questions.

Table 12–12. Enteral Vitamin and Mineral Supplementation

<table>
<thead>
<tr>
<th>Premature infants receiving:</th>
<th>Adjusted by Weight or Condition</th>
<th>Vitamin/Iron Supplementation per day (suggested)</th>
<th>Iron Goals (mg/kg per day)*</th>
<th>Vitamin D Goals (IU/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortified breast milk (Prolacta)</td>
<td>&lt; 2.5kg</td>
<td>2-3 mg/kg Fe 1 mL MV&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2-4</td>
<td>400</td>
</tr>
<tr>
<td>Fortified breast milk (Prolacta)</td>
<td>If osteopenia or elevated alkaline phosphatase activity &gt; 800</td>
<td>2-3 mg/kg Fe 1 mL MV&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2-4</td>
<td>800</td>
</tr>
<tr>
<td>Fortified breast milk (Similac HMF Hydrolyzed Protein Concentrated Liquid)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>If osteopenia or elevated alkaline phosphatase activity &gt; 800</td>
<td>2-3 mg/kg Fe 1 mL D-Visol (400 IU)</td>
<td>2-4</td>
<td>200-400</td>
</tr>
<tr>
<td>Preterm formula</td>
<td>None</td>
<td>2-4</td>
<td>200-400</td>
<td></td>
</tr>
<tr>
<td>Fortified breast milk (Similac HMF Hydrolyzed Protein Concentrated Liquid)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>If osteopenia or elevated alkaline phosphatase activity &gt; 800</td>
<td>2-3 mg/kg Fe 1 mL D-Visol</td>
<td>2-4</td>
<td>800</td>
</tr>
<tr>
<td>Preterm formula</td>
<td>If osteopenia or elevated alkaline phosphatase activity &gt; 800</td>
<td>1 mL D-Visol</td>
<td>2-4</td>
<td>800</td>
</tr>
<tr>
<td>Non-fortified human milk</td>
<td>&lt; 2.5kg&lt;sup&gt;3&lt;/sup&gt;</td>
<td>2 mg/kg Fe 1 mL MV&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2-4</td>
<td>400</td>
</tr>
<tr>
<td>Non-fortified human milk</td>
<td>&gt; 2.5kg</td>
<td>1 mL MV with Fe&lt;sup&gt;4&lt;/sup&gt;</td>
<td>2-4</td>
<td>400</td>
</tr>
<tr>
<td>Transitional formula</td>
<td>&lt; 5 kg</td>
<td>0.5 mL MV with or without Fe&lt;sup&gt;5&lt;/sup&gt;</td>
<td>2-4</td>
<td>400</td>
</tr>
<tr>
<td>Transitional formula</td>
<td>&gt; 5 kg or &gt; 6 months</td>
<td>None</td>
<td>2</td>
<td>400</td>
</tr>
<tr>
<td>Term formula</td>
<td>&lt; 3 kg</td>
<td>0.5 mL MV with Fe&lt;sup&gt;4&lt;/sup&gt;</td>
<td>2-4</td>
<td>400</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Term infants receiving:</th>
<th>Adjusted by Weight or Condition</th>
<th>Vitamin/Iron Supplementation per day</th>
<th>Iron Goals (mg/kg/day)*</th>
<th>Vitamin D Goals (IU/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human milk</td>
<td>LOS &lt; 1 week, &gt; 2.5 kg</td>
<td>1 mL D-Visol</td>
<td>(at 4 months)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>400</td>
</tr>
<tr>
<td>Human milk</td>
<td>LOS &gt; 1 week, SGA &lt; 2.5 kg, or multiple blood draws</td>
<td>1 mL MV with Fe&lt;sup&gt;4&lt;/sup&gt;</td>
<td>2</td>
<td>400</td>
</tr>
<tr>
<td>Term formula</td>
<td>&gt; 2.5kg</td>
<td>None</td>
<td>1</td>
<td>400&lt;sup&gt;7&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

1 MV = Poly-Vi-Sol
2 Fortified breast milk (Similac HMF Hydrolyzed Protein Concentrated Liquid)
3 At discharge and 2 kg or greater can be discharged with 1 MV with Fe as infant will grow into iron intake
4 Tri-Vi-Sol with iron or Poly-Vi-Sol with iron
5 Infant will receive 2 mg of iron/kg at 150 mL/kg of transitional formula. Goal is 2 to 4 mg iron/kg.
6 Or iron containing complementary foods at 6 months
7 May take several weeks to achieve
8 Initiate iron supplementation when full feeds are tolerated and infant is at least 14 days of life
9 Provide iron supplementation at 2-3 mg/kg for infants < 1500 g birthweight and at 2 mg/kg for infants 1500 to 2500 g birthweight
Infants with Intestinal Failure and Rehabilitation

General guidelines for feeding infants with intestinal failure and rehabilitation are located in Ch 11.2 Intestinal Failure and Intestinal Rehabilitation.

Infants with Probiotic Indications

Infants with severe diarrhea or post NEC, may benefit from probiotics supplementation. Consult with nutrition team before introducing probiotics to a NICU infant. A formula containing probiotics or Gerber® Soothe Colic Drops Probiotic Supplement may be used. Pasteurized and frozen human milk fed infants may in some cases also benefit from probiotics. In general, we do not routinely add probiotics to the diet of all infants, but these can be considered in the presence of symptoms including feeding intolerance.

Infants with Transfusion and Risk of Necrotizing Enterocolitis

Evidence relating to the risk of NEC associated with transfusion (TANEC) is limited, primarily retrospective, and conflicting. The evidence is based on infants who received non-human milk containing enteral nutrition.

There are few data to base a definitive approach in our nurseries. The results of a meta-analysis suggests the existence of TANEC especially in premature infants fed diets using infant formula. Given available literature, we suggest the following to enhance consistency in practice amongst our group:

- Infants born at < 32 weeks PMA who receive a transfusion when < 36 weeks PMA should have one feed held. Infant would remain NPO for approximately 6 hours, 3 hours before and 3 hours after transfusion. Infants receiving human milk may have trophic feeds continued or feeds decreased to trophic feeds during this time period. Infants should have a glucose-containing IV infusion provided when NPO (or trophic feeds), but not necessarily during the infusion if only one IV access site is available for the transfusion itself.

- After completion of the transfusion, infants who are receiving human milk should resume full feeds after the single held feed with close observation of clinical status. Those receiving infant formula should have feeds resumed more slowly with resumption of full volume feeds within 12-24 hours based on close clinical observation.

- Older infants do not need feedings held except for infants with a history of NEC, intestinal failure or cardiac disease in whom consideration should be given for holding feeds as per the protocol above.

Managing Slow Growth in Enterally-Fed Infants

Intervention may be considered for weekly weight gain of less than 15 grams per/kg per day in infants less than 2000 grams or of less than 20 grams per day in infants greater than or equal to 2000 grams. Progress with the following steps sequentially. Allow 3 to 4 days between changes to the nutrition plan to allot sufficient time to evaluate the effects of any nutritional change(s). (Ch 12.4 Nutrition Assessment)

Managing Slow Growth in Human-milk-fed Premature Infants

Consider the following sequentially as listed:

- Evaluate for evidence of feeding intolerance such as abnormal stools, persistent gastric residuals, or excessive reflux (emesis).

- Treat clinical conditions unrelated to nutrition that might affect growth such as acidosis, hyponatremia, increased work of breathing, cold stress, anemia, use of steroids, and infections including UTI.

- Ensure human milk fortifier has been added to human milk as Prolact+6® or as bovine milk-based fortifier 4 packets per 100 mL.

- Provide bolus tube feeding when tolerated because continuous infusions increase loss of fat.

- Advance the volume as medically feasible. Increase volume of fortified expressed breast milk (FEBM) to 150 mL/kg per day then advance stepwise as tolerated to about 160 mL/kg per day.

- If at goal feeding volume when using Prolacta®, ensure protein intake is meeting estimated needs then add Prolacta® Cream at 2 kcal/oz.

- After initiating Prolacta® Cream, request nutrient analysis by milk bank of mother’s own milk to determine fat and protein content. If results show milk is lower in caloric density, may increase to Prolacta Cream 4 kcal/oz.

- Advance to Prolact+8® (28 kcal/oz) or Prolact +10® (30 kcal/ oz) if needed. Use Prolact +8® (prepared at a 1:1 ratio to equal +10 (30 kcal/oz.) when Prolact +10 is not available.

- Consider the use of hind milk if the milk bank confirms sufficient milk supply. (Speak with a lactation consultant.)

- Consult with nutrition team to consider advancing bovine-milk based fortifier to 26 kcal/oz.

- Provide 1-4 feedings of 30 kcal/oz premature formula alternated between fortified expressed breast milk (FEBM)

- Consider adding premature transitional formula powder to the FEBM to increase the nutrient density to greater than 24 kcal/oz. Recognize potential risk of powdered formula use if this is chosen.

Managing Slow Growth in Formula-fed Premature Infants

- Evaluate for evidence of feeding intolerance such as abnormal stools, persistent gastric residuals, or excessive reflux (emesis).

- Ensure that correct formula (iron-fortified premature formula 24 kcal/oz) is given.

- Advance volume to 150 mL/kg per day.

- When fluid volumes are restricted, use ready-to-feed preterm 30 kcal/oz formula. Preterm 30 kcal/oz formula may be mixed with preterm 24 kcal/oz formula to achieve a caloric density greater than 24 kcal/oz.

- If poor growth persists and all other methods are exhausted, then consider using single modulars. Discuss with the registered dietitian for your team.
12.4 Nutrition Assessment

Growth
Monitor growth (weight, length, and head circumference) as a sign of adequate nutrient intake. The goal of nutrition support in high-risk neonates is to mimic the intrauterine growth rate. Body weight, weekly length, and weekly head circumference are plotted electronically on the appropriate growth charts. Compute weight gain rates over the previous week. An electronic app is available for the Fenton growth charts at http://www.ucalgary.ca/fenton. In this electronic app, tools are available to calculate percentiles and z-scores to compare neonatal growth. (Table 12–13, Fig 12–5a, Fig 12–5b.)

Biochemical Monitoring
- Serum albumin is not useful in routine screening of nutritional status and it should not be ordered except in extraordinary situations. Its half-life approximates 21 days. Albumin levels may be affected by infection, liver disease, shifts in body fluid status, rapid growth, and prematurity.
- Serum prealbumin has a shorter half-life of 2 to 3 days. Levels followed over time might rarely be helpful to assess nutritional status. Prealbumin also may be affected by liver disease, infection, rapid growth, and prematurity. It may occasionally be helpful in our older infants with complex disorders affecting growth. Discuss with nutrition team before ordering.
- Serum alkaline phosphatase is an indicator of bone mineralization problems, rapid bone growth, and biliary dysfunction. To determine the cause of the elevated serum alkaline phosphatase, it is helpful to measure serum P, Ca, and conjugated bilirubin. Low serum alkaline phosphatase is a marker of zinc deficiency but is not sensitive. Serum Zn is needed if this is being considered.

Parenteral Nutrition
Blood glucose concentration should be monitored in all infants receiving intravenous glucose infusions. For most infants, daily monitoring is recommended until blood glucose concentration is stable. For ELBW, stressed or septic infants (or those receiving insulin infusion) more frequent monitoring is necessary usually every 6 to 12 hours.

See intravenous lipid section in this chapter for monitoring guidelines. An ionized calcium and phosphorus should be measured at 24 hours of age and daily during the first 3 days of age until levels have normalized. See sections on hypocalcemia, hypercalcemia and hyperphosphatemia in the metabolic chapter.

Labs to monitor as clinically indicated after 14 days of parenteral nutrition: BUN, Ca, P, alkaline phosphatase activity, electrolytes, glucose, direct bilirubin (conjugated), and ALT. All infants should have an initial conjugated bilirubin measurement made in the first 48 hours of life. (Sec 11-Gastroenterology and Table 12-14)

Suggested labs for infants ≤ 24 6/7 weeks (1st week of life):
- BG in delivery room, then check every hour, times 2 until stable. If glucose bolus is given, check BG 30 minutes after bolus.

Suggested labs for infants 25-26 6/7 weeks (1st week of life):
- BG in delivery room, then 1 hr. after fluids started.
- BG/lytes and bili panel at 12 hrs.
- Monitor Na and BG every 12 hrs. for first 48 hrs.
- Obtain Chem 10 and ionized calcium daily for 1st 3 days.
- Obtain TG with every advancement

Suggested labs for infants 27-28 6/7 weeks (2nd week of life):
- BG should be measured at 24 hours of age and daily during the first 3 days of age until levels have normalized.
- Monitor electrolytes and blood glucose every 6 hrs for first 48 hrs.

Suggested labs for infants ≥ 28 6/7 weeks (3rd week of life):
- Obtain Chem 10 and ionized calcium daily for 1st 3 days.
- Obtain TG with every advancement

Enteral Nutrition
- Infants with birth weight less than 1500 g. Monitor serum phosphorus and alkaline phosphatase activity around day of age 35. Monitor weekly until alkaline phosphates is < 600 IU/L and serum phosphorus is > 4.5 mg/dL. Once alkaline phosphatase activity has declined to < 600 IU/L and serum phosphorus is stable at > 4.5 mg/dL there is no further need for monitoring. Hemoglobin should be monitored as clinically indicated and before discharge. Consider measurement of a serum ferritin before discharge in infants with a hemoglobin < 10 g/dL.
- Infants > 1500 g birthweight. There is no indication for any routine nutritional lab monitoring except for a hemoglobin before discharge. Infants who are fluid restricted or have a prolonged course to full feeds should have phosphorous, alkaline phosphatase activity and hemoglobin monitored as clinically needed.
- Infants receiving Prolacta® should have serum phosphorus monitored 3 to 5 days after TPN is discontinued. Consider checking additionally 1 week later if initial value is > 8 mg/dL. Serum phosphorus >10 mg/dL may require holding Prolacta® from every other feed or all feeds for 1-2 days. Obtain an ionized calcium and creatinine when serum phosphorus >10 mg/dL. Oral calcium supplementation is generally not recommended in this setting. Discuss with nutrition team if Prolacta® is removed for more than 48 hours.

<table>
<thead>
<tr>
<th>Table 12–13. Growth rate guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Newborn Infants (Premature and Term)</td>
</tr>
<tr>
<td>&lt; 2 kg</td>
</tr>
<tr>
<td>≥ 2 kg</td>
</tr>
<tr>
<td>Older Infants (&gt; 4 months corrected gestational age)</td>
</tr>
<tr>
<td>4 to 8 months</td>
</tr>
<tr>
<td>9 to 12 months</td>
</tr>
</tbody>
</table>

- Monitor electrolytes and BG every 6 hrs for first 48 hrs.
- BG/lytes and bili panel at 12 hrs.
- Obtain Chem 10 and ionized calcium daily for 1st 3 days
- Obtain TG with every advancement

Guidelines for Acute Care of the Neonate, Edition 26, 2018–19
Table 12-14. Suggested Lab Table

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjugated bilirubin</td>
<td>All infants screened during the first 48 hours of life.</td>
</tr>
<tr>
<td>Ionized Calcium Glucose</td>
<td>Obtain at 24 hours of age for at risk infants admitted to the NICU including infant of diabetic mother, SGA, IUGR, and premature infants.</td>
</tr>
<tr>
<td>TPN Glucose</td>
<td>Blood glucose concentrations should be monitored in all infants receiving glucose infusions until stable.</td>
</tr>
<tr>
<td>Ionized Calcium, Phosphorus</td>
<td>Obtain ionized calcium at 24 hrs of age, then daily for first 3 days of life, as Ca and phos are advanced or until levels are stable.</td>
</tr>
<tr>
<td>BUN, Ca, Phos, Alk Phos, Conjugated Bilirubin, Glucose, Electrolytes, ALT</td>
<td>Monitor after 14 days on TPN as clinically indicated.</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>BW ≤ 750. Obtain TG at 4 &amp; 12 hours after initiation of IL. Stop IL if TG is &gt;250mg/dL. Advance as tolerated if TG is &lt;250mg/dL.</td>
</tr>
<tr>
<td></td>
<td>BW 751-1000g. Monitor TG with every advancement.</td>
</tr>
<tr>
<td></td>
<td>BW ≥ 1000g, SGA, IUGR, received postnatal steroids, or believed to be septic. Monitor TG with every advancement.</td>
</tr>
<tr>
<td></td>
<td>Monitoring TG is generally not needed with every advancement in infants not listed above.</td>
</tr>
<tr>
<td>Zinc, Copper</td>
<td>Every 4 weeks while on TPN with cholestasis as medically feasible.</td>
</tr>
<tr>
<td>Ferritin</td>
<td>Infants on TPN support for &gt;6 weeks, expected to require TPN for an additional 4 weeks.</td>
</tr>
<tr>
<td>Enteral Alkaline Phosphatase, Phosphorus</td>
<td>BW &lt;1500g. (Monitor on 35 days of age)</td>
</tr>
<tr>
<td></td>
<td>Monitor weekly until Alk phos &lt;600 and phos &gt;4.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>No need to monitor once Alk phos is &lt;600 units/L and phos is &gt;4.5 mg/dL.</td>
</tr>
<tr>
<td></td>
<td>BW ≥1500g. No need for routine nutritional monitoring. Monitor as clinically indicated.</td>
</tr>
<tr>
<td>Hgb</td>
<td>BW &lt;1500g. As needed &amp; prior to discharge</td>
</tr>
<tr>
<td></td>
<td>BW &gt;1500g. Monitor as clinically indicated.</td>
</tr>
<tr>
<td>Prolacta Phosphorus</td>
<td>Obtain 3-5 days after TPN discontinued, &amp; consider checking again 1 week later if phos &gt;8mg/dL.</td>
</tr>
<tr>
<td></td>
<td>Serum phosphorus &gt;10mg/dL may require holding Prolacta from all feeds for 1-2 days or providing with every other feed.</td>
</tr>
<tr>
<td></td>
<td>Obtain Ionized calcium and creatinine when phosphorus is &gt;10mg/dL.</td>
</tr>
</tbody>
</table>

1. See suggested labs for infants ≤27 weeks GA at birth.
2. Infants with persistent TG values of 200-400 mg/dL should receive IL at 0.5 g/kg/day.
3. Infants with TG values >400 mg/dL should resume IL at 0.5 g/kg/day when TG is <400mg/dL.

12.5 Guidelines for Oral Feeding
The majority of hospitalized neonates will have difficulty feeding orally by breast or bottle. This may be due to any of the following conditions:

- Inadequate oral feeding skills resulting from inadequate sucking and/or swallowing and/or coordination with respiration
- Clinical instability
- Congenital anomalies
- Neurological issues
- Prematurity
- Poor endurance and/or unstable state of alertness
- Inappropriate feeding approach
- Fig 12-3 Risk approach for assessing oral feedings.

Figure 12-2. Flow diagram to guide radiographic evaluation for severe osteopenia / rickets.

Figure 12-3. Risk approach for assessing oral feedings.

Table 12-3. Risk approach for assessing oral feedings

<table>
<thead>
<tr>
<th>Ask</th>
<th>Observe Determine</th>
<th>Assess</th>
<th>Classify</th>
<th>Treat-Manage</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMA</td>
<td>vital signs</td>
<td>&lt;32 wks GA</td>
<td>High risk</td>
<td>NPO</td>
</tr>
<tr>
<td>Medical/surgical problems</td>
<td>clinical stability feeding readiness feeding intolerance</td>
<td>≤35 wks GA</td>
<td>Low risk</td>
<td>PO/tube feeding</td>
</tr>
</tbody>
</table>

- NPO
- OG/NG
- GT
- Tube feeding
- Nonnutritive sucking
- Cue based feeding
- Consider feeding specialist consult
- PO/tube feeding
- Breastfeeding
- Ad libitum
Preparing for Oral Feeding (Breast or Bottle)
- Encourage breastfeeding first whenever possible.
- Assure parental involvement and appropriate education regarding developmental progression of oral feeding skills. Safe oral feeding and infant’s limited skills should be emphasized.
- Prepare infants for breastfeeding; initiate and encourage frequent skin-to-skin holding if infant is clinically stable.
- Request lactation support consults to initiate breastfeeding as early as possible. (Ch 12.5 Guidelines for Oral Feeding -Breastfeeding Low Birth Weight Infants)
- Initiate nonnutritive oral-motor stimulation (pacifier) during tube feedings as early as possible (e.g., stable, intubated).

Promoting a Positive Oral Feeding Experience
- Facilitate appropriate feeding skills (e.g., coordination of suck-swallow-breathe).
- Prevent oral feeding problems (e.g., oxygen desaturation, apnea, bradycardia, aspiration) to achieve safe feeding.
- Prevent oral feeding aversion.

To meet these goals:
- Offer a pacifier for nonnutritive sucking practice as early as possible (e.g., when intubated, during tube feeding).
- Provide appropriate feeding approach, i.e., allow infants to feed at their own pace. It is inappropriate to rush them to finish a feeding. Some infants need more time to develop appropriate sucking patterns, to coordinate suck-swallow-breathe, for catch-up breathing, and/or rest more frequently.
- Feed orally (PO) only as tolerated to minimize oral feeding aversion.
  » Do not force infants to finish a bottle feeding; if necessary, gavage remainder by NG tube.
  » It is more important to develop good feeding skills than to complete a feeding.
  » Encourage nursing staff to give detailed feedback on infant’s oral feeding performance.
  » Monitor feeding performance closely and document consistently.
  » Consider advancing the number of oral feedings per day if infant shows good feeding skills with no oral aversion and demonstrates adequate endurance, even if feedings are partially completed.

Starting Oral Feeding
- At 32 to 34 weeks postmenstrual age (PMA), if clinically stable
  » May provide during nasal CPAP if medically stable.
- Starting oral feedings at 30 weeks PMA may not result in earlier attainment of full oral feedings or discharge, but is safe for infants who are not severely tachypneic or receiving positive pressure.
- When feeding readiness cues are present (e.g., sucking on pacifier, waking or fussing near feeding times, maintaining a drowsy-to quiet alert/active state)

Oral Feeding Difficulties
- Clinical signs: oxygen desaturation, apnea, bradycardia, coughing, choking, poor skin color (e.g., mottling, dusky, blue), aspiration, increased work of breathing, distress signs (e.g., panic look, pulling away, fingers splay, arching), poor tone.
- Risk factors for overt and silent aspiration: long-term intubation, severe hypotonia, neurological issues (e.g., craniofacial paralysis, tracheotomy, ventilation-dependency).
- Lactation consultants are available for initiation and progression of breastfeeding.
- At TCH, occupational therapist consultations are in the admission order sets. Occupational therapists will provide non-nutritive oral stimulation, bottle feeding assessments, bedside swallow assessments, transition to spoon feeding, and co-consult with speech pathologist for craniofacial disorders.
- Speech pathologists will evaluate for clinical signs of dysphagia or swallowing issues (e.g., aspiration), swallow function study, and co-consult with occupational therapists for craniofacial disorders with suckling as tolerated.
- The use of swallow function studies to evaluate feeding disorders should be carefully considered by the medical team due to the radiation exposure of this test and limited evidence of clinical correlation of findings.

Breastfeeding Low Birth Weight Infants
It is critical for the medical team to support a mother’s decision to provide breast milk and breastfeed her premature infant. Lactation support professionals are available to assist mothers with milk expression and breastfeeding. Activities promoting breastfeeding include:
- Early skin-to-skin contact between infant and mother augmented with suckling as tolerated.
- Encouraging frequent breast stimulation (every 3 hours or 7 to 8 times per day) in the first few weeks after birth to promote an adequate milk supply.
- Introducing the breast before the bottle.
- Educating mothers on appropriate diet and potential effects of her medication(s).
- Provide initial and ongoing lactation consultant support as needed.
• A visual map is provided to mothers to show the various stages of providing their breast milk to their infant during the NICU hospitalization. (Fig. 12-4)

Initiation and Progression
• Consultation with the mother prior to oral feeding initiation to determine her feeding goals (i.e., exclusive breastfeeding, breast and bottle) will allow for an integrated plan.
• Once an infant shows signs of interest in latching on and is clinically stable, initiate nutritive breastfeeding:
  » Consider lactation consultation for initial breast feeding to determine efficacy and to assess infant’s feeding ability.
• If indicated, measure milk intake during early breastfeeding by test weighing procedures.
  » Test weighing measures are performed by weighing the clothed infant under exactly the same conditions before and after breastfeeding on an electronic scale.
  » Pre- and post-weights (1 gram of weight change = 1 mL of milk intake) provide an objective measure of milk transfer. This will be indicative of the infant’s feeding ability and need for supplemental milk feedings provided by gavage or bottle feeds after breastfeeding attempts. It is usually best to limit this evaluation to once or twice a day, but it can be particularly helpful in the initial phases of transitioning a preterm infant towards breastfeeding.
  » Consider delaying initiation of bottle feedings until the infant achieves two successful breastfeeds a day for mothers who wish to achieve exclusive breastfeeding.

12.6 Discharge Nutrition Preparation
• Change diet to the home regimen at least 3 to 4 days before discharge to allow ample time for evaluation of intake, tolerance, and growth.
• Instruct parents on milk supplementation, formula preparation, and vitamin/mineral supplementation as indicated.

Breastfeeding Success at Home
• Breastfeeding progression prior to discharge will depend upon the mother’s availability and her infant’s feeding ability.
• Pre-discharge education and planning is key to breastfeeding success.
• Consultation with the lactation consultant will provide individualized feeding strategies to assist in progression of breastfeeds.

**Figure 12-4. My feeding care map**

My Feeding Care Map

Pumping  Colostrum Feeding  Kangaroo Care  First Tastes of Milk  Practice Feeding By Mouth  Feeding Without Feeding Tube

Birth  31 Weeks  33 Weeks  35 Weeks +

I plan to feed at the breast:
☐ Yes ☐ No

*(Carmichael-Swanner, Hurst, Hair, July 2016)*
Factors to consider for an individualized discharge nutrition plan include:

- Infant’s nutrient and growth needs
- Infant’s oral feeding ability
- Need for test-weighing procedures at home (uncommonly needed)
- Need to continue breast pumping to protect milk supply.

Consideration of the above factors will ensure an optimal nutrition plan to meet the infant’s needs, while supporting mother’s breastfeeding plan.

**Infants on Fortified Breast Milk**

- Discontinue bovine milk based fortifier (HMF) for infants greater than 2000 grams and greater than 34 weeks’ gestation and use unfortified human milk (breastfeeding or expressed breast milk) ad lib.
- HMF is not recommended after discharge.
- Infants who are less than 1500 grams at birth:
  - If infant is to be discharged on plain human milk, suggest up to 3 feedings per day with a premature transitional formula and the remainder as breastfeeding. Premature transitional formula (22 kcal/oz) is available as a liquid ready-to-feed.
  - If infant is receiving mother’s expressed breast milk and not breastfeeding, can consider adding premature transitional formula powder (Enfamil® EnfaCare® or Similac® NeoSure®) to expressed breast milk to make 24 to 30 kcal/oz milk. This regimen is less favored due to the risk of powdered infant formulas. Suggest delaying introduction of powder formula until infant is ~48 weeks PMA.
  - In special cases (such as intolerance to cow’s milk protein or refusal to use any infant formula), a former very low birth weight (VLBW) infant, being at risk for nutritional insufficiency including both growth-failure and metabolic bone disease, may benefit from direct dosing with minerals including calcium and phosphorus. Discuss with nutrition team. In addition to providing multivitamins and iron, it is recommended that infants be evaluated 2 to 4 weeks after discharge. This evaluation should include weight, length, fronto-occipital circumference (FOC), serum phosphorus, and alkaline phosphatase activity.

**Infants on Premature or Premature Transitional Formula**

Transition to premature transitional formula (Enfamil® EnfaCare® 22 kcal/oz or Similac® NeoSure® 22 kcal/oz) for infants of birth weight less than 1800 grams or infants with a poor growth history, fluid restriction, or abnormal laboratory indices.

Encourage parents to use ready-to-feed only (until ~48 weeks PMA).

Premature infants may receive transitional formula up to 6 to 9 months corrected age. Infants may demonstrate catch-up growth quickly after discharge and can be changed to a standard term formula at 48-52 weeks post-menstrual age if weight and length (for corrected gestational age), and weight-for-length are all at least at the 25% percentile for age.

Continuously monitor nutritional status including intakes, growth, and biochemical indices as indicated.

**On WIC prescription:** Order Ready-to-Feed ONLY for 3 months. OK to give powder after 3 months. Check 6 months for requested length of issuance of formula.

**Vitamins and Iron**

Table 12–11.

**Introduction of Solid Food to Older Premature Infant**

In the NICU, the purpose of introducing solid foods is to meet the patients’ developmental milestones, not nutritional needs which are met through milk or formula intake.

Parents should be involved in this important milestone in their infant’s life. Please make every attempt to have a parent present for the baby’s first solid food feeding.

Consider an Occupational Therapy consult to assess developmental appropriateness and to assist with solid food introduction along with caregivers and parents.

The AAP recommends that solid foods be introduced at 6 months of age.

For the premature population, this is 6 months corrected gestational age.

**Signs of Readiness for Solid Foods**

- Medically stable and does not have an endotracheal tube,
- Functional swallow and not at risk for aspiration,
- Able to sit with support; 60 to 90 degrees, and
- Good head and neck control or can achieve good positioning.

**Solid Food Guidelines**

- Introduce single-ingredient baby foods one at a time and continue 3 to 5 days before introducing an additional new food.
- Iron-and zinc-fortified infant cereals and meats are excellent first foods.
- For infants with history of intestinal failure consider non-starchy vegetable (i.e. green beans) as a first food.
Suggested Reading


Figure 12-5a. Fenton growth chart—girls
Figure 12-5b. Fenton growth chart-boys

Curves equal the WHO Growth Standard at 50 weeks.

Sources: Intrauterine section - Germany (Weighat 2016). United States (Olsen 2010), Australia (Roberts 1996), Canada (Kremer 2007), Scotland (Bonelli 2008), and Italy (Berlino 2010). Post term section - the World Health Organization Growth Standard, 2006.

www.ucalgary.ca/fenton
Section 13: Fluid and Electrolyte Management
Editors: Ganga Gokulakrishnan and Muralidhar Premkumar

13.1 Fluid and Electrolyte Therapy .......................188
   Ganga Gokulakrishnan
   Laura Gollins

13.2 Glucose Monitoring ................................ .......188
   Ganga Gokulakrishnan
   Muralidhar Premkumar

13.3 Hyperkalemia and Hypokalemia ....................189
   Melissa M. Carbajal
   Muralidhar Premkumar

13.4 Hypocalcemia and Hypocalcemic Seizures...190
   Amy Hair
   Jennifer Placencia

13.5 Hypercalcemia and Hyperphosphatemia ......192
   Amy Hair
   Jennifer Placencia

13.6 Metabolic Acidosis and the Use of Sodium
   Bicarbonate...................................................192
   Ganga Gokulakrishnan
   Muralidhar Premkumar
13.1 Fluid and Electrolyte Therapy
Water Balances
The chief routes of water loss in infants are evaporation (through the skin and from the lungs) and urinary losses. About 65% of evaporative (insensible) water loss occurs via the skin and is related to surface area, skin maturity, humidity, and air temperature. About 33% of evaporative loss occurs via the lungs and is related to respiratory rate and environmental humidity. Decreasing humidity increases evaporative water loss. A wide range of insensible water loss exists in infants due to wide variations in size and conditions of the environment.

Table 13-1. Fluid (H2O) loss (mL/kg/day) in standard incubators

<table>
<thead>
<tr>
<th>Weight (g)</th>
<th>Evaporative</th>
<th>Urine</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1000</td>
<td>65 (100)</td>
<td>45</td>
<td>110</td>
</tr>
<tr>
<td>1001-1250</td>
<td>55 (80)</td>
<td>45</td>
<td>100</td>
</tr>
<tr>
<td>1251-1500</td>
<td>38 (60)</td>
<td>45</td>
<td>83</td>
</tr>
<tr>
<td>&gt;1500</td>
<td>17 (25)</td>
<td>45</td>
<td>62</td>
</tr>
</tbody>
</table>

1 Increases due to radiant warmer, phototherapy or extreme prematurity

A radiant warmer or phototherapy increases evaporative losses 50-190%. A humidified environment can greatly reduce insensible losses and allow for better fluid/electrolyte management. Infants < 32 weeks’ gestation and/or < than 1250 grams birth weight should be placed into humidified incubators, if available. Normal urine water loss is around 45 mL/kg/day. This volume allows for excretion of the usual solute load and maintenance of adequately dilute urine.

Daily maintenance fluids are given to replace evaporative and urine water losses as well as any unusual loss that might be present.

Neonatal replacement fluid requirements vary widely depending upon environmental conditions, body weight, and gestation. Table 13-2 shows suggested total fluid requirements (mL/kg/day) by birth weight based on anticipated fluid needs to replace losses. The anticipated fluid needs include parenteral nutrition volume, TKOs (keep open fluids) for catheters such as UAC, UVC, or central line, medications, and flushes. If fluid losses are increased due to loss from high urine output, orogastric tube, Replogle tube, or chest tubes, infants will require more total fluids. Monitoring of serum sodium is recommended to help guide total fluid adjustment for infants <1000 g birth weight.

Electrolyte Balance
Electrolyte composition of fluid evaporated from skin and lungs, as well as that lost as urine, normally is hypotonic (20-40 mEq of Na and K per liter). Usual maintenance electrolyte recommendations after first 24-48 hours of life are: Sodium (2-4 mEq/kg/day) and Potassium (2-3mEq/kg/day) Fluid losses from gastric or small bowel drainage should be replaced with normal saline as outlined in GI chapter.

Short-term Intravascular Fluid Therapy (Day 1-3)
Goals of therapy include:

- Prevent hypoglycemia.
- Provide protein-sparing carbohydrate calories at basal metabolism rate (30-35 kcal/kg per day).
- Provide protein-sparing amino acids in appropriate VLBW infants (Sec 12-Nutrition)
- Limit negative fluid balance to 1-2% of birth weight per day.

Fluid Composition
Calculate water need independently of electrolyte needs; then combine the two to determine IV fluid composition.

Example: Maintenance fluids for 3-day-old, 2-kg infant

(a) Water needs = 100 mL/kg/day × 2 kg = 200 mL per day
(b) Na, K needs = 4 mEq/kg/day × 2 kg = 8 mEq per day
(c) IV fluids = 200 mL per day × 24 hours
(a) Fluid prescription = D$_2$W + 2 mEq NaCl + 2 mEq KCl/100 mL to run at 8.3 mL/hour

13.2 Glucose Monitoring
Plasma glucose concentration should be monitored in all infants receiving intravenous (IV) glucose infusions. For most infants, daily monitoring is recommended until plasma glucose concentration is stable. For known high risk patients (or those receiving insulin infusions) more frequent monitoring is necessary.

At birth, the umbilical cord glucose is less than that in the mother (up to 1/3 lower level). Postnatal plasma glucose levels diminish and reach a nadir by 1-2 hours of age with mean values in the range of 50-60 mg/dL. Values may fall as low as 30 mg/dL in some asymptomatic infants. Healthy term or near term neonates should exhibit mean plasma glucose values > 60 mg/dL after 48 hours of life.

In certain high risk infants, the postnatal blood glucose may not rise appropriately or may fall to subnormal levels resulting in hypoglycemia.

Infant at high risk for hypoglycemia include:

- Prematurity
- IUGR
- IDM
- LGA
- Sepsis
- Disorders producing hyperinsulinism

Table 13-2. Suggested total fluid requirements (mL/kg/day)*

<table>
<thead>
<tr>
<th>Birth Weight (g)</th>
<th>Day 0-1</th>
<th>Day 2</th>
<th>&gt;Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;750</td>
<td>130</td>
<td>140</td>
<td>150</td>
</tr>
<tr>
<td>751-1000</td>
<td>110</td>
<td>130</td>
<td>150</td>
</tr>
<tr>
<td>1001-1250</td>
<td>80-110</td>
<td>120</td>
<td>150</td>
</tr>
<tr>
<td>1251-1500</td>
<td>80</td>
<td>100-120</td>
<td>150</td>
</tr>
<tr>
<td>1501-2000</td>
<td>65-80</td>
<td>100</td>
<td>150</td>
</tr>
<tr>
<td>&gt;2000</td>
<td>65-80</td>
<td>100</td>
<td>150</td>
</tr>
</tbody>
</table>

*Neonatal replacement fluid requirements vary widely depending upon environmental conditions, body weight and gestation.

*Most healthy term infants will not require a feeding volume greater than 30-40 ml/kg/day on DOL 1-2 and about 50 ml/kg/day by DOL 3-4.
Hyperkalemia and Hypokalemia

Hyperkalemia is a medical emergency that requires close observation of the patient, continuous cardiac monitoring, and measurement of serial potassium levels.

Normal serum potassium levels in neonates range between 4 and 6.5 mEq/L.

Levels above this range warrant investigation, though some may be a result of hemolysis or sampling artifacts. The etiology for hyperkalemia in neonates includes:

- decreased removal of potassium (acute renal failure, positive potassium balance in the premature infant during the first days of life, adrenal failure as in congenital adrenal hyperplasia, and medications such as Captopril)
- increased load of potassium (hemolysis, IVH, hematoma, excess potassium administration)
- redistribution of potassium from cells (common with metabolic acidosis, also seen with sepsis, necrotizing enterocolitis, and medications such as digoxin)
- factitious causes (hemolyzed blood such as in heel-stick specimen, thrombocytosis).

Evaluation and Treatment

Specific laboratory studies helpful in determining the etiology and management of hyperkalemia include electrolytes, BUN, creatinine, platelet count, blood gas, serum ionized calcium, total calcium and magnesium levels. An infant should be assessed for cardiac changes associated with progressive increases in serum potassium levels (i.e., peaked T waves, prolonged PR interval, loss of P wave, widening QRS, sine wave QRST, first-degree AV block, ventricular dysrhythmia, and, finally, asystole).

Suspected Hyperkalemia

Immediately change to an IV solution without potassium. If the infant is on gentamicin, hold doses pending evaluation of renal status and gentamicin trough levels. Keep in mind that the effects of hyperkalemia can be worsened by hypocalcemia and hypomagnesemia.

Hyperkalemia with Cardiac Changes

Acutely perform the following interventions.

- With continuous cardiac monitoring, give 100 mg/kg per dose (1 mL/kg per dose) IV of 10% calcium gluconate or 20 mg/kg per dose (0.2 mL/kg per dose) of 10% calcium chloride rapidly over 1 minute. This will decrease myocardial excitability and, therefore, prevent cardiac arrhythmia. May repeat calcium dose in 10 minutes if abnormal cardiac changes persist. Administration of calcium does not lower serum potassium levels.
- Give sodium bicarbonate 1 to 2 mEq/kg IV bolus over 5-10 minutes; 1 mEq/kg of sodium bicarbonate will lower potassium by 1 mEq by driving potassium ions into the cells. If the infant has respiratory acidosis, correct this first, before administering sodium bicarbonate.
- To enhance transfer of potassium ions into the intracellular compartment, give 4 mL/kg D10W (400 mg/kg) followed by 0.1 unit/kg regular insulin (glucose alone is ineffective). The desired ratio is 1 unit of insulin for every 4 grams of glucose. However, some critically ill infants may have concurrent hyperglycemia and may require reduction in glucose dose to 2 mL/kg D10W (200 mg/kg). The bolus dose may be repeated if necessary or a continuous insulin infusion started at 0.05 unit/kg/hr in conjunction with an increase in GIR.

Hypokalemia

Renal K+ wasting is most commonly caused by the administration of diuretics, particularly loop and thiazide diuretics. Loop diuretics inhibit the coupled reabsorption of Na+/K+/Cl at the luminal border of the thick ascending loop (TAL). There is both flow dependent K+ secretion and enhanced K+ secretion caused by the resultant increase in aldosterone and diuretic induced alkalosis, further exacerbating the electrolyte abnormalities. Hypokalemia also may be associated with correction of acidosis or increased uptake of glucose by cells. Acute correction via bolus therapy of mild-moderate hypokalemia is not necessary. Correction of serum K of 2.5-3.4 mEq/dl can usually be achieved gradually by increasing IV or oral potassium supplements from the usual 2-3 mEq/kg/day to the range of 4-6 mEq/kg/day. Severe hypokalemia, with serum K+ less than 2.5 mEq/dl, is a risk factor for neurologic or cardiac decompensation and should be corrected using IV infusion guidelines outlined in the “Short Term Potassium Replacement” order set, followed by monitoring of serum K+ to ensure value > 2.5 mEq/dl after intervention. Diuretics should not be given until serum K+ has been corrected above 2.5 mEq/dl.

Chloride Supplements

Chronic diuretic therapy induces hypochloremic metabolic alkalosis with total body potassium depletion. Infants receiving chronic diuretics need chloride supplementation of 2 to 4 mEq/kg per day in addition to usual nutritional needs. This should be provided as potassium chloride with no sodium chloride provided unless serum sodium < 130 mEq/L or potassium is elevated for age. Serum chloride should be > 90 mg/dL and never maintained < 85 mg/dL. In general, total potassium and sodium chloride supplementation should not exceed 4-5.
Seizures

Clinical symptoms, including jitteriness and prolongation of the breaths, suggest hypocalcemia. If total Ca is used, usually a value less than 8 mg/dL indicates hypocalcemia. Although many infants may not be symptomatic until the serum chloride is above 85-90 mEq/dl.

13. 4 Hypocalcemia and Hypocalcemic Seizures

Hypocalcemia has two primary forms, usually referred to as early or late onset. Rarely, hypocalcemia is associated with other conditions in the newborn or with exchange transfusion.

Early Hypocalcemia

Early hypocalcemia usually is related to one of the following conditions:

- Prematurity - transient hypoparathyroidism or lack of responsiveness of the bone to parathyroid hormone.
- Infant of diabetic mother - decreased parathyroid hormone (PTH) or increased calcitonin.
- Post-asphyxia - release of tissue phosphorus.
- Severe intrapartum growth restriction—lack of calcium transfer across the placenta.

Diagnosis

Calcium (Ca) exists in both the ionized and non-ionized states. Only the ionized fraction maintains homeostasis and prevents symptoms associated with hypocalcemia. Therefore, it is preferred to evaluate ionized Ca directly. The relationship between total and ionized Ca is not linear—total serum Ca is not a reliable predictor of ionized Ca. There is a relatively greater ionized Ca for any total Ca when a patient is very premature (low total protein) or acidic. Therefore, the greatest risk for hypocalcemia is in large, alkalotic babies.

For very low birth weight infants, an ionized Ca of less than 0.8 mmol/L is considered evidence for hypocalcemia (normal range 0.9 to 1.45 mmol/L). For infants greater than 1500 grams birth weight, it is advisable to maintain a higher level of both ionized and total calcium. For these infants, an ionized Ca less than 1 mmol/L suggests hypocalcemia, although many infants may not be symptomatic at levels of 0.8 to 1 mmol/L. If total Ca is used, usually a value less than 8 mg/dL indicates hypocalcemia.

Clinical symptoms, including jitteriness and prolongation of the Q-T interval, are not reliable indicators of hypocalcemia.

Hypomagnesemia

The role of magnesium (Mg) in hypocalcemia is poorly defined. Mg deficiency inhibits PTH function and, therefore, it may not be possible to adequately treat hypocalcemia if there is concurrent hypomagnesemia. However, adequate definitions of hypomagnesemia or optimal therapy do not exist. In general, a serum Mg less than or equal to 1.5 mg/dL suggests hypomagnesemia and the need for intravenous Mg therapy (normal range 1.6 to 2.6 mg/dL). Rapid IV pushes of Mg are not indicated. For maintenance therapy, administer Mg sulfate 25 to 50 mg/kg per dose (0.2 to 0.4 mEq/kg per dose) over at least 2 hours twice daily until the serum Mg normalizes (greater than 1.5 mg/dL).

Evaluation

Monitor the ionized Ca of infants who are at risk for hypocalcemia. An ionized Ca should be measured at 24 hours of age and every 12 hours until the infant is receiving Ca either from TPN or from a milk source and has a stable normal ionized Ca value. This usually occurs by 48 to 72 hours of age.

Therapy

Very low birth weight infants - Start treatment when the ionized Ca is less than 0.8 mmol/L in infants whose birth weight is 1500 grams or less. If the infant is asymptomatic, consider beginning TPN as the calcium source as soon as possible. If TPN cannot be started, add Ca gluconate at 500 mg/kg per day via continuous IV infusion. In general, Ca should not be given intravenously for more than 48 hours without providing phosphorus (P) because of the risk of hypercalcemia. When removing the potassium phosphate from TPN due to concerns about hyperkalemia, it is important to remove the calcium as well if the phosphorus is to stay out of the TPN for longer than 48 hours.

Larger infants (greater than 1500 grams) - Treatment may be needed for ionized Ca less than 1 mmol/L in larger infants. This is because of the possibility of seizures or other symptoms that have been reported at levels up to 1 mmol/L in full-term infants. Infants who are alkalotic are at high risk for hypocalcemia. If the infant is on oral feeds, intravenous Ca may not be needed but serum Ca and P should be monitored regularly. For infants requiring intravenous therapy, begin therapy with IV Ca gluconate at 500 mg/kg per day given via continuous infusion.

Symptomatic infants of any size - For symptomatic infants (e.g., seizures) of any size, 100 mg/kg of Ca gluconate or 20 mg/kg of Ca chloride may be given over 10 to 20 minutes with concurrent cardiorespiratory monitoring. Administration of IV calcium gluconate should always be followed by administration of maintenance Ca gluconate to the IV solution (500 mg/kg per day).

Late Hypocalcemia

Late hypocalcemia is a frequent entity associated with low serum calcium and high serum phosphorus. It was classically associated with the introduction of whole cow’s milk to the diet in the first days of life. Now it is seen in some infants who are fed routine commercial formula. It may present with seizures or be identified on routine testing in asymptomatic infants. Peak age of appearance is 5 to 14 days of life. Although the etiology is not always clear, generally it is believed to be related to transient hypoparathyroidism leading to hypocalcemia and hyperphosphatemia in the presence of a high (relative to human milk) phosphorus intake. An unusual cause is DiGeorge syndrome, which consists of thymic hypoplasia, hypocalcemia, cardiac (usually aortic arch) anomalies and abnormal facies. Any infant presenting with seizures at the end of the first week of life or in the second week of life should be evaluated.
Assessment and Management of Seizures Due to Hypocalcemia in Infants 3 to 10 Days of Age Born at Greater Than 34 Weeks’ Gestation

Initial Assessment
After a complete history and physical examination, total calcium, ionized calcium, serum phosphorus, serum magnesium, intact parathyroid hormone, FISH for chromosome 22q deletion and chest radiograph for thymic shadow are recommended. The chest radiograph, parathyroid hormone and FISH can wait until the baby is stable. If sepsis/meningitis is suspected, appropriate evaluation should be done and treatment started with antibiotics and acyclovir, but this may not always be necessary if seizures are likely due to hypocalcemia and the infant is otherwise well. EEG and CT scans can also wait until the calcium therapy has been given and are not needed when the diagnosis is evident based on laboratory values. Anticonvulsant therapy and neurology consultation are not usually indicated. Endocrine consult is optional in the presence of a typical history and if a thymus is seen on CXR.

Intravenous Medication Therapy
After initial laboratory evaluation is performed, give a bolus infusion of calcium gluconate 100 mg/kg IV over 30 minutes. This will provide the patient with approximately 10 mg/kg of elemental calcium since calcium gluconate is approximately 10% elemental calcium.

- If a central line is in place, begin calcium gluconate infusion at 1000 mg/kg/day (~100 mg/kg/day of elemental calcium). If central line is not available, calcium gluconate infusion must be limited to 600 mg/kg/day (~60 mg/kg/day of elemental calcium) regardless of iCa value given the increased risk of extravasation and soft tissue injury. If clinical response is inadequate, then the risks and benefits of obtaining central access to provide higher amounts of calcium should be considered. Ionized calcium should be drawn one hour after the first bolus, then every 4 hours initially. The frequency of sampling can be reduced to every 6-8 hours when iCa is > 1.0 and seizures have stopped.

- If the ionized calcium is less than 1.0 mmol/L after the initial bolus infusion, give an additional bolus infusion of calcium gluconate 100 mg/kg IV over 30 minutes (~10 mg/kg of elemental calcium) and continue calcium gluconate infusion at current rate.

- Correct hypomagnesemia if serum magnesium is less than 1.6 mg/dl with magnesium sulfate 25 mg/kg IV given over 1 hour. Check serum magnesium after completing the infusion and repeat the same dose every 12 hours until the magnesium level is more than or equal to 1.6 mg/dl. Rarely are more than 2 doses needed.

The calcium infusion should be managed using the following algorithm:

If ionized calcium is 1.00 - 1.20 mmol/L: maintain infusion rate, no need for additional bolus infusions. If no further seizures occur, can start feedings (see below) and start oral supplementation. It is common for seizures to persist until the iCa is greater than 1.00 for 1-2 hours. (Refer to Oral Therapy section below.)

When ionized calcium is 1.21-1.30 mmol/L: decrease calcium gluconate infusion to 250 mg/kg/day (~25 mg/kg/day of elemental calcium). If not already started, start feeds and begin oral supplementation. If iCa is 1.21 or greater on two measurements and feeds with oral calcium supplement have been started and tolerated, can stop IV calcium infusion. Refer to Oral Therapy section below for dosing instructions.

When ionized calcium is 1.31 or greater and feeds and oral calcium supplements have been started and tolerated, can discontinue intravenous calcium gluconate infusion if it has not already been stopped. At this point, patient should be on feeds and oral calcium supplementation (usually providing ~50 mg/kg/day of elemental calcium).

Once intravenous calcium infusion has been discontinued, calcium and phosphorus measurements can be reduced to every 8-12 hours.

Oral Therapy
Initiate feeds with Similac® PM 60/40, Good Start® or breast milk (all of these are acceptable feedings) when ionized calcium is more than or equal to 1.0 mmol/L and no clinical seizures have occurred within the past 2 hours. Good Start® has the lowest phosphorus content of routine infant formulas and is therefore a readily obtained alternative. If family wishes to switch back to another formula, this can usually be done 1-2 weeks after hospital discharge.

Oral calcium supplementation should be started with calcium gluconate (Neo-Calglucon®). Start with calcium gluconate at 720 mg/kg/day Divided four times daily which will provide approximately 50 mg/kg/day of elemental calcium. Each milliliter of Neo-Calglucon® provides 360 mg of calcium gluconate which equates to 23 mg of elemental calcium. Try not to exceed oral calcium gluconate doses of 1200 mg/kg/day (approximately 75 mg/kg/day of elemental calcium) as this product is hyperosmolar and can cause diarrhea. If Neo-Calglucon® is on backorder, oral calcium gluconate should be considered after discussion with clinical pharmacy and nutrition team. The use of calcium carbonate in neonates is strongly discouraged due to the relatively high gastric pH in infants limiting absorption of calcium carbonate.

- Pt. may be discharged on Similac® PM 60/40 or Good Start® with oral calcium supplementation (providing 25-50 mg/kg/day of elemental calcium), with follow-up by endocrine service or the primary pediatrician 24-48 hours after discharge. Can usually discharge after 24 hours of iCa > 1.3 on oral therapy if reliable follow-up is assured. May be able to stop the oral calcium supplement, monitor for 24 hours and discharge without the need for oral calcium at home.

- If calcitriol is continued at discharge, the patient must have Endocrine Service follow-up. It should be rare that calcitriol is continued after discharge.

» The use of calcitriol is at the discretion of the Endocrine Service if they are involved in the patient’s care. If begun IV, switch to oral dosing as soon as feeds are started.
13.5 Hypercalcemia or Hyperphosphatemia

The ionized calcium (iCa) should usually be between 0.8 and 1.45 mmol/L in VLBW infants, and between 1.0 and 1.4 mmol/L in larger infants. The maximum iCa usually is 1.40 to 1.45 mmol/L. Hypercalcemia above this level in the neonatal period is usually associated with TPN use, especially in VLBW infants.

Mild hypercalcemia (1.45 to 1.65 mmol/L) or mild hyperphosphatemia (> 9mg/dL) is common and does not warrant specific therapy. If it persists, a small change in the calcium-to-phosphorous (Ca/Phos) ratio (no more than a 20% change in the mmol/mmol ratio) usually will correct this within 48 hours. Under no circumstances should calcium be removed from the TPN for an iCa lower than 1.8 mmol/L.

Infants with moderate hypercalcemia (≥ 1.6 mmol/L) should have their Ca/Phos ratio decreased to about 0.5:1 to 0.8:1. Do not remove all the calcium unless the iCa is greater than 1.8 mmol/L. Hypercalcemia provides no known therapeutic benefit in any condition, especially with levels above 1.6 mmol/L, which may be associated with severe calcium deposition in various tissues, including the brain. Avoid withdrawing calcium or phosphorus or markedly changing their ratio for longer than 24 hours. If calcium is completely removed from the TPN, phosphorous intake generally should be decreased by 50% or deleted, depending on serum phosphorous levels. This should rarely be done for longer than 24 hours, and iCa must be measured every 12 hours if either calcium or phosphorus is reduced by 50% in the TPN.

When the iCa is below 1.45 mmol/L, resume IV calcium at levels similar to usual ratios.

During the first days of life, initiating intravenous calcium therapy in the absence of TPN, or giving supplemental calcium in addition to that provided in TPN, usually is not necessary in non-high-risk groups. There is no evidence that higher levels of calcium are beneficial, and they could pose a substantial risk of inadvertent tissue calcification.

13.6 Metabolic Acidosis and the Use of Sodium Bicarbonate

Treatment of acidosis in neonates using sodium bicarbonate has been common for many years. However, evidence that correction of acidosis with sodium bicarbonate improves outcome of cardiopulmonary dysfunction remains lacking. Several lines of evidence suggest a much more limited role for this agent.

1. Acidosis associated with respiratory distress in neonates is mainly respiratory (due to hypercarbia), or mixed. Infusion of bicarbonate in the face of impaired ventilation induces production of additional CO₂ that cannot be removed. This CO₂ diffuses into the intracellular space and worsens intracellular acidosis.

2. No human studies have demonstrated a beneficial effect of bicarbonate on survival or outcome following CPR.

The NRP no longer recommends use of buffers during neonatal resuscitation.

3. Effect of bicarbonate infusion on blood pH, if any, is transient.

4. No studies have demonstrated increased survival or reduced morbidity in neonates with respiratory distress receiving sodium bicarbonate.

5. If a true metabolic acidosis is present, it is a result of renal or GI tract loss of base, hydrogen ion load in excess of renal excretory function, edema or generation of organic acid such as lactate. None of these underlying disorders is corrected by sodium bicarbonate. The underlying mechanism itself should be the target of therapeutic intervention.

6. Increasing evidence suggests potential adverse effects of sodium bicarbonate administration. Several retrospective studies have reported a strong association between rapid infusions of bicarbonate and IVH in premature infants. Human and animal studies demonstrate impaired myocardial and circulatory function, increase cerebral blood volume, worsening intracellular acidosis and diminished tissue oxygen delivery in association with bicarbonate administration.

Based upon current evidence, we do not recommend use of sodium bicarbonate in neonates with acute cardiopulmonary disease and a base deficit except in exceptional circumstances. Acute circumstances in which infusion of sodium bicarbonate may be appropriate include management of certain cardiology patients, symptomatic hyperkalemia, babies with severe lactic acidosis associated with circulatory insufficiency (while attempting to stabilize circulatory function) or initial management of a severe organic acidemia.

Metabolic Acidosis

Metabolic acidosis is a frequently encountered problem in the NICU. It is important to determine the anion gap, as it will allow differentiating the etiologies into two categories, gap and non-gap acidosis. Anion gap is calculated as [Na⁺]+[(Cl⁻)] + [HCO₃⁻)]. Generally, a gap greater than 15 mEq/L is defined as an increased anion gap. Though there are numerous etiologies for metabolic acidosis, the common causes encountered are: 1) lactic acidosis (with increased anion gap) secondary to critical illness, hypoxia, shock, sepsis and 2) metabolic acidosis seen in VLBW infants as a result of inadequate bicarbonate absorption in their immature kidneys (with normal anion gap). Other examples include renal failure, GI losses from an ileostomy or chronic TPN use in VLBW babies. These infants have persistent normal anion gap metabolic acidosis without marked elevation in lactate levels.

Many preterm infants, especially those < 1500g, benefit from addition of acetate to their TPN or, uncommonly, base supplementation (such as Bicitra) in their oral diet. Typically, 1-2 mEq/100 ml of sodium or potassium acetate are added each day to TPN. Need for a higher concentration is rare but, if necessary, care providers should take note of the added cation in determining total sodium and potassium needs. Under no circumstances should sodium bicarbonate be added to TPN that includes calcium as sodium bicarbonate in the presence of calcium increases the risk for precipitation.
Section 14: Surgery
Editors: Jonathan Davies and Timothy Lee

14.1 Perioperative Management .......................194
  Jonathan Davies
  Timothy Lee

14.2 Peripheral and Central Venous Access ......195
  Jonathan Davies
  Lindsay Whittington

14.3 Specific Surgical Conditions ....................196
  Ashley Bruns
  Milenka Cuevas Guaman
  Pablo Lohmann
  Bernadette White
14.1 Perioperative Management

In emergent cases, initial evaluation is focused on doing a concise history and physical examination concurrent with resuscitation of the infant and preparation for surgical intervention.

Fluid, Electrolytes and Nutrition:

Most neonates with an emergent surgical condition will lose fluids by:

- evaporation from exposed bowel
- by “third spacing” of fluid in obstructed bowel
- by direct loss through emesis

Therefore, fluid restriction following diagnosis is not indicated in these babies. They should be given maintenance fluids with electrolytes as well as replacement fluids. Appropriate intravenous access is necessary to achieve adequate fluid resuscitation. A general rule of thumb is that for every hour with an open abdomen, there is approximately 15 to 20 ml/kg of insensible losses.

If shock is present in a neonate with a surgical problem, it is likely due to hypovolemia unless proven otherwise.

Deficits secondary to intravascular volume depletion can, and should, be corrected prior to surgery with proper fluid resuscitation, including blood products.

In neonates with intestinal obstruction, a large size gastric sump tube should be placed, preferably a Replogle tube, connected to intermittent or low constant suction after hand-aspiration of the stomach. Occluding the gastric decompression tube with a syringe should be avoided because it prevents decompression of the stomach and intestines.

Infants undergoing elective surgery may be given:

- formula up to 6 hours before surgery
- breast milk up to 4 hours before surgery
- clear liquids containing glucose up to 2 hours prior to elective surgery

No infant should remain without fluid intake for longer than 6 hours. If surgery is delayed, IV fluids should be started.

Pre-Operative Evaluation

Initial laboratory evaluation includes blood for type and cross-match, CBC, and platelet count. In patients with significant fluid losses, serum electrolyte measurements are necessary in order to determine empirical fluid and electrolyte replacement. Baseline and follow-up blood gases are indicated in the evaluation of a severely compromised neonate.

Polycythemia (HCT greater than 60) may be seen in neonates with gastroschisis and if a patient is symptomatic, a partial exchange transfusion may be warranted.

In the pre-operative phase, for major abdominal or thoracic procedures, there should be a type and cross for 20 cc/kg of PRBCs. Other blood products should be obtained based on the pre-operative lab parameters or due to underlying medical conditions.

Blood Products

The Texas Children’s Hospital Blood Bank uses leukocyte-depleted and irradiated blood for neonatal transfusion. Once a unit of blood has been ordered, the blood bank will hold that unit for up to a week for further patient-specific transfusion. Blood and blood products are usable if stored in properly chilled coolers at the bedside for up to 4 hours. Platelets should remain at room temperature. For procedures in the NICU, requested blood and blood products should be at the bedside before the procedure starts.

Complications

Anesthesia

Complications are uncommon but can be related to:

- allergies, side effects and toxicities to the anesthetic and the sedative agents
- administration of fluids and the blood products, and
- respiratory/airway

Surgery

Early post-operative complications (< 14 day) are:

- bleeding
- wound infection or dehiscence
- anastomotic leak for a bowel anastomosis (most commonly occurs around post-operative day#4)
- abdominal compartment syndrome

Late post-operative complications (> 14 days) are:

- Intestinal adhesion leading to bowel obstruction
- Intestinal fistula formation
- Incisional hernia
- Ostomy complications

Post-Operative Management

Stomas, Intestinal

The long-term success of a stoma depends on the type of stoma created, the location selected for placement, careful attention to surgical technique, and the prevention and treatment of common complications. Morbidity from stoma formation remains a significant problem.

Decompressive ostomies are used primarily in emergent situations of imminent bowel rupture or to protect a distal anastomosis.

The most common decompressive ostomies in pediatric surgery are:

- diverting colostomies (including divided sigmoid loop colostomies) for infants with imperforate anus
- leveling colostomies, for children with Hirschsprung disease.

When the bowel is completely divided, as in the case of a bowel resection, the distal end can be over sown and left in the peritoneal cavity or brought out as a mucous fistula. The mucous fistula is decompressive if there is a known or potential distal obstruction, such as an imperforate anus, or stricture from necrotizing enterocolitis (NEC). In babies with proximal jejunostomies with or without short-gut syndrome,
the mucous fistula also can be used to refeed the effluent from the proximal stoma. Diverting stomas in the small bowel differ from colostomies in that the liquid consistency and high volume of stool can be very corrosive to surrounding skin. Furthermore, small intestinal stomas can lead to fluid loss and electrolyte derangements.

To prevent skin breakdown, the stoma must be constructed so that it is not flush the skin. This technique allows for a more secure placement of the ostomy bag and prevents skin breakdown. In a tiny premature infant with NEC, the formal maturation of a stoma often is difficult. In these cases, limited fixation of the exteriorized bowel to the skin may be sufficient. Ischemia of these fragile stomas is very frequent in the immediate postoperative period. As long as the mucosa at the level of the fascia is viable, these stomas usually will heal and function well.

Attention to skin care is essential. The site should be kept clean and dry at all times. The ostomy bag may be left in place for 1 to 3 days, but should be changed any time there is leakage and should be emptied when 1/3 full. When changing the bag, all old adhesive must be removed and the site cleaned with soap and water avoiding excessive scrubbing.

If dermatitis develops, local wound care can be thought of as analogous to that of diaper rash. The area should be carefully and completely washed and dried. A protective ointment or cream (such as one that contains zinc oxide or petroleum), mechanical skin barriers, or both, should be applied around the stoma before the ostomy bag is placed. Irritation from the corrosive enteric content can also be improved with Stomahesive™ powder, which helps absorb fluid.

Cellulitis should be treated with antibiotics (usually a first generation cephalosporin) and monilial infections with mycostatin powder or ointment. Allergic dermatitis is unusual, but will respond to topical steroid cream therapy.

Other complications of stomas include:

- peristomal hernias
- prolapse
- retraction
- stricture formation

These occur often in newborns requiring stoma creation for treatment of NEC. Dilatation may be successful in treating some strictures, but revision of the ostomy often is required.

### 14.2 Peripheral and Central Venous Access

#### Peripheral

Because of the shorter catheter length, peripheral venous access is superior to central venous access for rapid volume infusion.

Sites for peripheral venous access include the veins in:

- hand
- forearm
- lower leg or foot
- scalp

Surgical cutdown or percutaneous central access is indicated after percutaneous attempts at cannulation have failed.

Sites for cutdown or percutaneous central line placement include:

- the saphenous and femoral veins in the lower extremities
- the external jugular
- the internal jugular
- facial veins in the neck

Subclavian veins may be accessed percutaneously, inferior to the clavicle. Vascular cutdown carries a significantly higher risk of infection compared with percutaneous cannulation.

#### Midline

A midline catheter is inserted peripherally and threaded to an area of greater blood flow in the proximal portion of the extremity. Mid-clavicular tip placement should be avoided as this location is associated with an increased risk of thrombus formation.

Midlines are an attractive option for vascular access in select infants due to longer life-span and fewer PIV restarts. A midline may be considered in patients who need relatively short term (5-7 days), but stable peripheral access (e.g. patient undergoing tracheostomy and will need drips maintained for several days until airway is stable). Also consider when there is poor access and a central line is contraindicated (e.g. septicemia). A PICC that could not be successfully threaded to central location during insertion may also be secured in place as a midline and safely used.

Safety of infusion of fluids through a midline catheter is similar to those that can safely be administered through a PIV.

When compared with central catheters, midlines have higher rates of phlebitis, occlusion, and leaking. Currently, no data exist to support a limit to the dwell time of a properly functioning midline catheter.

#### Central

Central venous access is indicated when there is need for prolonged access for medications, need for hyperosmolar medications/ fluids, TPN, when there is inability to attain peripheral access, and, rarely, for hemodynamic monitoring and access for drawing blood.

Peripherally inserted central catheters (PICCs) have decreased the need for surgically placed central lines. These catheters are placed via a peripheral vein in upper or lower extremity and threaded to a central position. A PICC may last for several weeks or months and often is placed by neonatal advanced practice nurses.

Non-tunneled (CVC/PERC) catheters can be placed percutaneously into the internal jugular, subclavian, and femoral veins. These are not meant for long term access, but most commonly placed in emergent situations when no other access has been successful. It is recommended to leave in for no longer than 5-7 days given higher risk of complications, especially infection.
Complications of placing central lines include:

- malposition
- pneumothorax
- perforation of a vein or artery with resulting hemothorax and/or cardiac tamponade, pneumopericardium, infection, and arrhythmias

Placing the catheters under fluoroscopic guidance, obtaining radiographs immediately after placement, or both, will minimize these complications.

Late complications of central lines include:

- breaking or cracking of the line or its constituents
- central line associated bloodstream infection (CLABSI)
- tunnel or insertion site infections
- occlusion
- catheter migration
- phlebitis
- bacteremia from accessing the line
- venous thrombosis

Line thrombosis may be treated by instilling 1.0 mL of tissue plasminogen activator (TPA; 5000 international units per 1 mL vial). If aspiration of the clot is not possible in 1 hour, repeat the instillation and attempt aspiration again in 2 hours. If the line is occluded, a volume of 0.1 mL of 0.1 N HCl may be used after consultation with a surgeon. HCl is most useful when occlusion is thought to be secondary to precipitation of total parenteral nutrition.

Tunneled central lines require local and sometimes general anesthesia for removal. The Dacron cuff must be dissected away from the subcutaneous tissue.

Central Line Tip Position
The catheter tip should be placed in the SVC or thoracic IVC. Outside a vena cava, the catheter tip is subjected to smaller diameter vessels, vein curvature, and venous valves that increase the risk of the catheter contacting and damaging the vessel wall. Appropriate SVC placement is described as the T3–T5 level but this depends on infant anatomy and radiographic technique. Appropriate IVC tip placement is not well defined, but we recommend a tip location between the right atrium and the diaphragm, described as T8–T10 based on current evidence.

Placement in the right atrium is not recommended due to risk of arrhythmia and perforation potentially leading to tamponade. Brachiocephalic and subclavian veins have decreased diameter and lack laminar blood flow, and are not considered central.

Additional Information on Peripheral and Central Venous Access
Additional information on peripheral, midline and central lines can be found in the National Association of Neonatal Nurses (NANN) Peripherally Inserted Central Catheters practice guidelines (http://www.nann.org/)

### 14.3 Specific Surgical Conditions

#### Bronchopulmonary Sequestration (BPS)

BPSs are segments of nonfunctioning lung with no connection to the tracheobronchial tree and an anomalous systemic arterial blood supply. Most are unilateral and most often are located in or adjacent to the left lower lobe. Fetal ultrasound often demonstrates a blood supply arising from a systemic artery, usually the aorta. It may be difficult to distinguish BPS from CCAM.

A significant arteriovenous shunt can occur through the sequestration and result in:

- high output cardiac failure
- hydrops
- pulmonary hemorrhage

Extralobar sequestration rarely requires resection unless a symptomatic shunt exists. Intralobar sequestrations are electively resected because of the risk of infection.

#### Chylothorax

Chylothorax, the most common cause of pleural effusion in the newborn, is most often either idiopathic or caused by injury to the thoracic duct.

**It also can be caused by:**

- congenital malformation of the thoracic duct
- congenital fistulae
- pulmonary lymphangiectasia
- venous obstruction
- obstruction of the lymphatic channels

In general, conservative antenatal management is recommended since many resolve spontaneously. Postnatally, chylothorax usually presents as respiratory distress with diminished breath sounds and pleural effusion on chest radiograph. Pleural tap demonstrates lymphocytosis and elevated triglycerides. Recurrent symptomatic pleural effusions may be treated with thoracentesis. If repeated taps are necessary, a chest tube should be considered. Because
chylous fluid is produced at an increased rate when the child is being fed enterally, it is important for the infant to be challenged with enteral feedings before removing a chest tube. Long-chain fatty acids increase chyle flow and worsen the chylothorax. A diet with medium-chain fatty acids as the main source of fat will reduce chyle production. Total parenteral nutrition often is successful in decreasing chyle production and may be preferable in the initial management of chylothorax. Somatostatin is reported to help in decreasing the duration of chylothorax. Patients should be given 2 to 4 weeks of nonoperative therapy before surgical therapy is considered. Resolution of chylothorax is reported in up to 80% of cases treated with MCT, TPN, and chest tube drainage.

**Congenital Cystic Adenomatoid Malformation (CCAM)**

CCAMs are rare lesions that are almost always unilateral and usually only affect a single lobe. On prenatal ultrasonography they appear as an echolucent cystic mass. Mediastinal shift, polyhydramnios, and hydrops may occur. Doppler studies demonstrate the absence of a systemic vascular supply. There may or may not be associated anomalies. Ultra-fast magnetic resonance imaging (MRI) of the fetus can be useful, especially for differentiating CCAM from other diagnoses such as sequestration. Lesions are most often classified as either macrocystic or microcystic, based on ultrasonographic and pathologic findings. The less common microcystic lesions are generally solid echogenic masses with multiple small cysts and are associated with a worse prognosis.

Fetal CCAMs should be followed with serial ultrasonography. Many will decrease in size or appear to completely resolve before birth; others may increase in size and cause hydrops. The natural history of CCAMs is that they will usually enlarge up to 28 weeks gestation where they will then plateau in their growth curve and often begin to involute. The presence of hydrops is a grave prognostic sign with only isolated cases of survival reported. If the CCAM does not resolve or regress, the severity of presentation relates to the volume of the mass and to the associated findings. Infants with severe pulmonary hypoplasia may have associated pulmonary hypertension. Even if the mass regressed before birth, postnatal CT scans should be performed.

Poor outcomes of infants with hydrops before 32 weeks make the fetus a candidate for prenatal intervention. One prenatal predictor for fetal intervention is the congenital cystic adenomatoid malformation volume ratio (CVR), which is calculated by dividing the CCAM volume by the head circumference. A CVR greater than 2.0 has the highest sensitivity and specificity for predicting development of hydrops and heart failure and the need for fetal intervention. The fetus with a large CCAM, with or without hydrops, ideally should be delivered at a facility with the capacity for prenatal counseling, including:

- fetal surgery options
- high-frequency ventilation
- ECLS
- emergent pediatric surgical intervention

Once stabilized, early resection of the mass is indicated in all infants with clinical symptoms. Even for children without symptoms, postnatal resection of all CCAMs is recommended because of the possibility of later development of rhabdomyosarcoma arising from within the lesion.

**Congenital Diaphragmatic Hernia (CDH)**

The incidence of CDH is approximately 1 in 4000 live births. Associated anomalies are common, occurring in about 50% of patients.

**Anomalies include:**

- congenital heart disease
- neural tube defects
- skeletal anomalies
- intestinal atresias
- renal anomalies
- pulmonary sequestrations

Prenatal sonogram can detect the presence of CDH as early as 12 weeks’ gestation. Delivery should occur in a center with neonatal and surgical teams experienced in the care of these infants. Most infants have onset of respiratory distress in the delivery room.

**Physical examination may also reveal:**

- a scaphoid abdomen
- absence of breath sounds on the ipsilateral side
- displacement of heart sounds to the contralateral side

For further details in management refer to Ch 2.8 – Congenital Diaphragmatic Hernia.

**Long-term sequelae include:**

- chronic lung disease
- reactive airway disease
- pulmonary hypertension
- cor pulmonale
- gastroesophageal reflux
- hearing loss
- developmental delay
- motor deficits

Some inherited disorders (e.g., Pallister-killian Syndrome [tetrasomy 12p mosaicism], trisomy 18, Fryns syndrome) have CDH as part of their presentation. Therefore, consultation with the Genetics Service should be considered.

**Congenital Lobar Emphysema (CLE)**

CLE, like CCAMs, almost always occur within a single pulmonary lobe, most often the left upper lobe.

**Identified causes of CLE include:**

- intrinsic bronchial abnormalities
- mucus plugs
- extrinsic compression

However, in at least 50% of reported cases, no apparent obstruction can be found. Congenital cardiac or vascular abnormalities are found in approximately 15% of infants with CLE.

Diagnosis is usually made in the postnatal period when an infant has worsening respiratory difficulties. Chest radiograph usually shows an overdistended, emphysematous lobe in one lung.
Preoperative management depends on the severity of symptoms. A relatively asymptomatic infant may be maintained with oxygen. Progressive pulmonary insufficiency from compression of adjacent normal lung requires resection of the involved lung. Treatment of the asymptomatic, hyperlucent lobe is controversial. There is no evidence that leaving it impairs development of the remaining lung, but infectious complications often occur and lead many to resect even the clinically asymptomatic CLE.

**Esophageal Atresia and Tracheal Fistula**

The incidence of esophageal atresia (EA) is 1 in 3000 to 5000 live births. The most common type is EA with a tracheal fistula (TF) to the distal esophageal pouch (86%); others include pure esophageal atresia without a fistula (7%), a fistula without atresia (4%), and, more rarely, fistulas to the proximal or to both the proximal and distal pouches. An infant with EA often presents with excessive secretions, noisy breathing and episodes of choking and cyanosis, which worsen if the child is fed. Diagnosis is confirmed by inability to pass an orogastric tube. There may be abdominal distention secondary to air-trapping within the gastrointestinal tract in cases with a distal fistula (7%). The presence of other anomalies should be ascertained by careful examination of the patient (e.g., VACTERL).

Preoperative management requires passage of a suction tube (Replogle) into the proximal esophageal pouch. The infant’s head should be elevated 30 degrees to minimize risk of aspiration of oral secretions and reflux of gastric secretions via the TF. Total parenteral nutrition should be initiated. It is advisable to avoid heavy sedation and muscle relaxants because spontaneous respiratory effort generates tidal volume with negative rather than positive ventilation decreasing the risk of gastric over distention. Positive pressure ventilation should be avoided, if possible.

If intubation is necessary and there is a distal TF, emergent gastrostomy and fistula ligation also may be necessary. Infants should be assessed for associated anomalies. Most immediately necessary is echocardiography to identify the location of the aortic arch and cardiac anomalies, which affect intraoperative management.

A primary repair usually can be accomplished at birth, even in very small infants. Postoperative management should include continuing broad spectrum antibiotics during the perioperative period and decompressing the stomach via continuous drainage of the nasogastric or gastrostomy tube. The nasogastric tube should be left in place until a dye study documents the integrity of the surgical repair (generally obtained at 5 to 7 days postoperatively). If the nasogastric tube becomes dislodged, it should be left out. Suctioning of the oral cavity should be done with a marked suction catheter that will not reach to the anastomotic site. Intubation should be continued until the risk of extubation failure is low.

Tracheomalacia is frequent and often responsive to prone positioning, but sometimes requiring reintubation, and very occasionally requiring aortopexy or reconstruction.

**Other common complications include:**
- anastomotic leak
- gastroesophageal reflux (in approximately 40% of patients)
- anastomotic stricture
- aspiration

**GER Treatment in EA**

All infants with a history of repaired EA have a significant predisposition for reflux due to an abnormal GE junction related to their primary repair. Studies have reported incidence to be up to 50% in EA patients, with 47% requiring medical management and 33% progressing to fundoplication on long-term follow up. Prolonged acid exposure to the anastomosis can result in stricture formation. This can lead to gastric metaplasia which is noted frequently in EA patients. Limited studies suggest that medical treatment may decrease GI and/or respiratory symptoms in a subset of EA patients, but the benefit to decreasing complications such as anastomotic site stricture have not been proven. However, due to the high prevalence of GER and potential for complications, the ESPGHAN-NASPGHAN recommends that GER be treated with acid suppression using PPIs as first-line therapy in all EA patients in the neonatal period up to the first year of life or longer depending on the persistence of GER (strong recommendation, low quality evidence).

**Extracorporeal Life Support (ECLS)**

ECLS is an important modality for infants and children with cardiorespiratory failure due to reversible causes. Formerly referred to as extracorporeal membrane oxygenation (ECMO), ECLS not only provides for delivery of O\(_2\), but also eliminates CO\(_2\), and supports myocardial failure.

**ECLS Circuit**

The circuit basically functions as a pump to add O\(_2\), eliminate CO\(_2\), and warm blood before returning it to the patient. The circuit is comprised of several components.

**Cannulae**

**Venoarterial (most common)** - venous inserted through right internal jugular vein with tip of cannula situated within the right atrium, arterial cannula into right common carotid artery with tip residing in aortic arch.

**Venovenous** - single, dual-lumen catheter inserted through right internal jugular vein with the tip of the catheter in right atrium

**Physiology of ECLS**

**Venoarterial**

O\(_2\) delivery is dependent on extracorporeal flow, native cardiac output, O\(_2\) uptake by extracorporeal membrane, and O\(_2\) uptake by native lungs. If the native lungs are not exchanging gas, as occurs in early stages of ECLS, the oxygen-rich blood from ECLS circuit mixes with blood ejected from the left ventricle to determine the patients PaO\(_2\). Increasing PaO\(_2\) may result from increasing extracorporeal flow (decreasing the blood flow through the native lung or the shunt fraction), a reduced
cardiac output (also decreases the shunt), and improved native lung function. Reduced cardiac output may be associated with pericardial effusion causing tamponade, hemotorax or pneumothorax, or cardiac failure. Reduced PaO\textsubscript{2} results from increased native cardiac output or decreased extracorporeal flow. CO\textsubscript{2} elimination is dependent upon membrane surface area, sweep gas flow and CO\textsubscript{2} content. Slow flow through the membrane will effectively eliminate all CO\textsubscript{2}. The perfusion in neonates on venoarterial ECLS is nonpulsatile; therefore, increased extracorporeal flow will lower systolic blood pressure but maintain the mean arterial blood pressure.

**Venovenous**

O\textsubscript{2} delivery is dependent on native cardiac output, O\textsubscript{2} uptake by the extracorporeal membrane, and O\textsubscript{2} uptake by native lungs. The degree of recirculation (determined by extracorporeal flow) at the atrial level determines PaO\textsubscript{2} in the right atrium which traverses the lungs to the left heart. Delivery of this oxygenated blood is determined by native cardiac output. During venovenous ECLS the O\textsubscript{2} saturation is seldom greater than 95%. In contrast to venoarterial ECLS, PaO\textsubscript{2} levels in the 40 to 50 range are to be expected during venovenous ECLS. Increased PaO\textsubscript{2} results from improved native lung function and less atrial recirculation. Decreasing PaO\textsubscript{2} is generally from increased atrial recirculation. This can be improved by gentle manipulation of the cannula to direct returning blood through the tricuspid valve. Cannula repositioning can be guided by transthoracic ECHO to optimize the flow dynamics within the right atrium (i.e., prevent recirculation). The CO\textsubscript{2} elimination is the same as venoarterial ECLS. Increasing extracorporeal flow rates on venovenous ECLS also may increase recirculation at the atrial level thus reducing O\textsubscript{2} delivery. Hemodynamically, blood flow is pulsatile, and extracorporeal flow has no effect on the arterial waveform.

**Abdominal Cavity**

**Duodenal Atresia**

Duodenal atresia occurs in approximately 1 in 5,000 to 10,000 live births and occurs when the duodenum does not recanalize after the seventh week of gestation.

**Prenatal diagnosis of duodenal atresia can be made on:**

- prenatal ultrasonography in the setting of polyhydramnios
- a dilated stomach and duodenal bulb (i.e., double bubble sign)
- scant meconium in the distal bowel

Neonates present with bilious vomiting (the obstruction is distal to the ampulla of Vater in 85% of cases) and/or feeding difficulties. Physical examination may show a distended abdomen. The classic “double bubble” may be seen on abdominal radiograph. Air in the distal bowel suggests a partial atresia or web. The differential diagnosis of bilious emesis includes: malrotation with volvulus, distal atresias, and Hirschsprung disease. If there is any question, malrotation and volvulus can be ruled out with an upper GI study.

Initial management should involve nasogastric or orogastric decompression, fluid resuscitation and evaluation for associated anomalies. Significant cardiac defects are present in 20% of infants with duodenal atresia, and almost 30% of infants with duodenal atresia have trisomy 21.

Duodenoduodenostomy is the preferred treatment, although duodenojejunostomy may be performed instead based on size of the baby and size of the defect.

Survival rates are about 90% with good long-term prognosis. Morbidity and mortality are related to associated anomalies and resulting short gut complications. There’s a higher risk of mortality if BW <2kg.

**Gastrochisis and Omphalocele**

**Gastrochisis**

Gastrochisis is a congenital defect of the abdominal wall leading to herniation of abdominal contents. The defect is usually to the right of the umbilical cord. Malrotation is always present and 10% to 15% have associated intestinal obstructions. Other associated anomalies are rare. Gastrochisis is associated with increased maternal serum alpha-fetoprotein and can be diagnosed on prenatal ultrasound. Upon delivery, the bowel should be placed in a bowel bag, or covered with damp Kerlix® gauze and sterile occlusive dressing. A Replogle nasogastric tube should be placed and put to continuous suction. The infant should be positioned (usually on the side) to prevent kinking of the mesentery and bowel ischemia. Using towels to support the bowel can also be helpful. Systemic intravenous antibiotics (usually ampicillin and gentamicin) are given to protect the contaminated amnion and viscera. IV access should be obtained, preferably in upper extremity, leaving a site for a PICC line to be placed.

Unlike normal neonates, infants with gastrochisis may require up to 200 to 300 mL/kg in the first 24 hours of life because of third-space losses and evaporation. Fluid administration should be guided by tissue perfusion and urine output. Early intubation should be performed to avoid intestinal distention following prolonged bag-mask ventilation.

**The options for surgical treatment include:**

- reduction of the bowel and primary closure of the skin and fascia
- placement of a silo constructed in the operating room and sewn to the fascia
- placement of a Silastic® spring-loaded silo in the NICU

**Which treatment is chosen depends on many factors including:**

- the size and position of the bowel
- size of the abdomen
- required peak ventilator pressures with reduction
- condition of the baby

No randomized trial has been performed to determine the optimal choice. If a silo is placed, it is gradually decreased in size until the bowel contents are reduced into the abdomen and a delayed primary repair can be performed. A tight abdominal closure can result in respiratory compromise, decrease in venous return, and abdominal compartment syndrome. The infant must be closely monitored after closure. Bowel function may not return for days to weeks following repair and long term TPN is necessary.
Omphalocele
Omphalocele is a persistent opening in the midline abdominal wall that results from incomplete fusion of the cephalic, lateral, and caudal tissue folds, leaving an open umbilical ring and visceral that are covered by a thin sac of amnion and peritoneum. Many omphalocles are diagnosed on prenatal ultrasound. Maternal alpha-fetoprotein may or may not be elevated.

A Replogle nasogastric tube should be placed and put to continuous suction. An intact sac should be covered with a moist dressing or intestinal bag. Ruptured sacs are treated like gastroschisis defects. More than half of infants with omphalocele have associated anomalies and preoperative assessment should be undertaken.

Surgical treatment depends on the size of the infant’s abdomen, the size of the defect, and associated anomalies. The goal of surgical treatment is to close the abdomen without creating abdominal compartment syndrome. Closing fascial defects less than 4 cm usually is easy. Close hemodynamic monitoring for 24 to 48 hours after primary closure is essential, but infants usually can be advanced to full feeds within several days.

If the defect is too large for closure, or if there are severe associated abnormalities, omphalocles may be allowed to epithelialize with the application of topical agents (e.g., silver sulfadiazine). Epithelialization occurs over several weeks or months and leaves a hernia defect that needs to be repaired at a later date.

Late complications may include:
- gastroesophageal reflux
- volvulus (all infants with omphalocele have non-rotation)
- ventral and inguinal hernias

Outcome depends upon associated congenital anomalies with cardiac anomalies playing the largest determinant of survival.

Hirschsprung Disease (HD)
HD (congenital aganglionic megacolon) is the most common cause of intestinal obstruction in newborns, and is more common in boys. HD is familial in 4% to 8% of patients.

Most newborns with HD present with abdominal distension, emesis and failure to pass meconium by 24 hours of age. Physical examination usually shows a distended, soft abdomen. Rectal examination leading to an explosive stool is very suggestive. Abdominal radiographs usually show distended loops of bowel. Contrast enema can show a transition zone, where the rectum has a smaller diameter than the sigmoid colon. However, contrast enema may be inaccurate in up to 20% of newborns. Failure to completely evacuate contrast on a 24-hour follow-up abdominal radiograph also suggests HD. Definitive diagnosis is made by finding aganglionosis and hypertrophied nerve trunks on a suction rectal biopsy.

Initial management should involve nasogastric or orogastric decompression and fluid management. The initial goal of therapy is decompression by either rectal irrigations or colostomy. If a primary pull-through is planned in the immediate postnatal period, irrigations may be performed for a few days or weeks. If the baby has other medical problems, a leveling colostomy is performed by doing serial frozen section biopsies to identify the transition between normal and aganglionic bowel. The definitive pull-through is delayed for 2 to 3 months or until the child reaches 5 to 10 kg.

Hirschsprung-associated enterocolitis (HAEC) can rapidly lead to sepsis and even death. HAEC is characterized by:
- abdominal distention
- constipation
- diarrhea
- explosive, watery, foul-smelling stool on rectal examination.

Enterocolitis can occur either before or after definitive treatment. Parents should be well-educated in its presentation and the need for rapid medical treatment. Repeated episodes warrant investigation to rule out a retained aganglionic segment.

Imperforate Anus (IA)
Diagnosis of IA is almost always made at the time of the first newborn physical examination. The lack of an anal opening usually is fairly obvious, but a midline raphe ribbon of meconium or a vestibular fistula may not become apparent for several hours. The diagnosis of high IA versus low IA may be clarified by performing a delayed (24 to 36 hour) abdominal radiograph in the prone position with a marker on the anal dimple.

IA may comprise part of the VACTERL association. Due to this association, the pre-operative work-up for these patients include a cardiac ECHO, chest and abdominal radiograph, renal ultrasound, and spinal ultrasound (tethered cord).

Initial management should involve nasogastric or orogastric decompression and fluid resuscitation. Perineal fistulas may be dilated or repaired by perineal anoplasty. When possible, primary repair is via primary posterior sagittal anorectoplasty. Intermediate and high imperforate anomalies (distance over 1 cm) require initial colostomy and delayed posterior sagittal anorectoplasty. Recovery after posterior sagittal anorectoplasty is usually rapid. Male patients may require a Foley catheter for 3 to 7 days depending on the complexity of the repair. Anal dilatations with Hegar dilators are begun 2 weeks after surgery. The parents are subsequently required to continue with serially larger dilators until the appropriate size is achieved. Once the desired size is reached, the dilatations are tapered. When this has been completed, a colostomy, if present, can be closed.

Sequelea of anorectal malformations can include:
- constipation
- fecal incontinence
- rarely, urinary incontinence

Long-term, well-coordinated bowel management programs are essential to achieve optimal bowel function.
Inguinal Hernia
The processus vaginalis is a peritoneal diverticulum that extends through the internal inguinal ring. As the testicle descends during the final trimester from its intra-abdominal position into the scrotum, a portion of the processus surrounding the testes becomes the tunica vaginalis. If the portion of the processus vaginalis in the canal persists, this creates the potential for a hernia. Fluid may be trapped in the portion of the processus surrounding the testis in the scrotum, creating a hydrocele. Almost all pediatric inguinal hernias are indirect (through the inguinal canal). While most infant hydroceles resolve spontaneously within 12 to 18 months, a hernia never spontaneously resolves and requires surgery to prevent incarceration and strangulation of intra-abdominal structures and irreversible damage to the testes. The incidence of inguinal hernia is low in term infants, but increases to 16% to 25% in infants of less than 28 weeks’ gestational age. The younger the infant, the higher the risk that the hernia will become incarcerated. Thirty-one percent of incarcerated hernias occur in infants less than 2 months of age.

Risk factors for increased incidence of hernia in infants include:
- chronic respiratory disease
- increased intra-abdominal pressure (ascites, repair of omphalocele or gastroschisis, ventriculoperitoneal shunts, and peritoneal dialysis)
- exstrophy of the bladder
- connective tissue disorders

Hernias often present as a smooth, firm mass lateral to the pubic tubercle in the inguinal canal. The mass may extend into the scrotum and will enlarge with increased intra-abdominal pressure (crying or straining).

Symptoms suggesting an incarcerated hernia include:
- pain
- emesis
- irritability

The mass usually is well defined and does not reduce spontaneously or with attempts at manual reduction. Incarcerated hernias in children can rapidly evolve into strangulation and gangrene of hernia contents. Surgical consultation should be obtained immediately.

Intestinal Atresia
Small bowel atresia is a congenital occlusion of the intestinal lumen secondary to an intrauterine mesenteric vascular occlusion that causes a complete obstruction. Children with jejunoileal atresia typically have no other associated anomalies. The most common associated conditions are cystic fibrosis, malrotation, gastroschisis, along with low birth weight and multiparity. Intestinal atresia has also been associated with maternal smoking and cocaine use.

Hereditary multiple intestinal atresia (HMIA) is a rare autosomal recessive disorder of multiple intestinal atresias, commonly seen in French Canadians and can be associated with combined immune deficiency.

Diagnosis of intestinal atresia usually is made soon after birth, within the first 1-2 days. Key features are abdominal distension and bilious vomiting, with the majority failing to pass meconium by 48 hours. Prenatal history may include polyhydramnios with dilated, echogenic bowel on prenatal ultrasound. Abdominal radiographs typically show dilated air-filled loops of proximal bowel with no air in the rectum. “Triple-bubble” sign refers to air in the dilated stomach, duodenum and proximal jejunum. Contrast enema may be required to rule out other diagnoses such as meconium plug, meconium ileus, and Hirschsprung disease.

Preoperative preparation includes:
- nasogastric or orogastric decompression
- fluid resuscitation
- broad-spectrum antibiotics

The bowel distal to the atresia is resected and an end-to-end anastomosis is performed. A nasogastric tube is used to decompress the stomach until bowel function returns. Post-op complications include anastomotic leak, stenosis at the site of anastomosis, and short gut syndrome. Mortality is about 10% (90% survival) with prematurity, associated anomalies, infection and short gut syndrome as major contributors to mortality.

Malrotation and Midgut Volvulus
Midgut volvulus is one of the most serious emergencies during the newborn period since a delay in diagnosis and subsequent gangrene of the midgut is almost uniformly fatal. Ninety-five percent of infants with volvulus have bilious vomiting.

Abdominal radiographs may show:
- a normal bowel gas pattern
- a gasless abdomen
- dilated intestine suggesting small bowel obstruction
- duodenal obstruction with a double bubble

Surgical consultation should be immediately obtained when the diagnosis is suspected. Unless immediate surgery is required for signs of peritonitis or deterioration of the child with an acute abdomen, the diagnosis should be rapidly confirmed with an upper GI study. A few hours may be the difference between a totally reversible condition and death (loss of the entire midgut). A nasogastric tube must be placed, IV resuscitation must be started, and the infant must be immediately transported to either the radiology suite or the operating room.

Recurrent volvulus can occur in up to 8% of cases.

Surgical repair via Ladd procedure consists of anticlockwise derotation of volvulus, removal of Ladd’s bands, broadening mesenteric root, and placing small bowel on the right and large bowel on the left.
Meconium Ileus (MI)
MI accounts for almost 1/3 of all obstructions in the small intestine in newborns, and occurs in about 15% of infants with cystic fibrosis. Over 90% of patients with MI have cystic fibrosis. A family history of cystic fibrosis is common.

Infants with MI usually present with abdominal distention, bilious vomiting, and failure to pass meconium in the first 24 to 48 hours. “Doughy,” dilated loops of distended bowel may be palpated on abdominal examination. Radiographs of the abdomen show bowel loops of variable sizes with a soap-bubble appearance of the bowel contents. Contrast enema typically demonstrates a microcolon with inspissated plugs of meconium in the lumen.

Initial treatment begins with a Gastrografin® enema. Under fluoroscopic control, Gastrografin® and water is infused into the rectum and colon. This usually results in a rapid passage of semiliquid meconium that continues for the next 24 to 48 hours. Follow-up radiographs should be obtained. Multiple Gastrografin enemas are often required.

Operative intervention is indicated for MI if:
• the Gastrografin® enema fails to relieve the obstruction
• abdominal calcifications suggest meconium peritonitis
• the diagnosis is not clear
• the infant appears too ill for non-operative treatment

Miscellaneous
Cloacal Malformations and Cloacal Exstrophy
The incidence of cloacal anomalies is 1 in 20,000 live births. They occur exclusively in females and are the most complex of anorectal malformations.

A persistent cloaca (Latin for “sewer”) is the confluence of the rectum, vagina, and urethra into one common channel. A persistent cloaca can be diagnosed on physical examination that shows a single perineal orifice. An abdominal mass, representing a distended vagina (hydrocolpos), may be present.

The goals of early management are to:
• detect associated anomalies
• achieve satisfactory diversion of the gastrointestinal tract
• manage a distended vagina
• divert the urinary tract when indicated

A colostomy with mucous fistula should be performed since total diversion of the fecal stream is necessary to prevent urosepsis.

Diagnosing a persistent cloaca correctly is vital because 50% of infants have hydrocolpos and 90% of babies have associated urological problems. Infants should be evaluated with abdominal and pelvic ultrasonography. Both pediatric surgery and urology services should be consulted. If an obstructive uropathy is missed, it may lead to urosepsis and renal failure.

Spinal ultrasonography should be performed during the first 3 months of life since 40% of infants may also have a tethered cord, which may result in urinary and bowel dysfunction and disturbances of motor and sensory function of the lower extremities.

Definitive repair of a persistent cloaca is a serious technical challenge and should be performed in specialized centers by pediatric surgeons and urologists.

The goals of surgical treatment are to achieve:
• bowel control
• urinary control
• normal sexual and reproductive function

Significant urologic and anorectal issues may involve:
• sex assignment
• surgical treatment
• long-term follow-up

Cloacal exstrophy - the most severe cloacal anomaly, involves an anterior abdominal wall defect in which 2 hemibladders are visible, separated by a midline intestinal plate, an omphalocele, and an imperforate anus.

Initial surgical treatment during the newborn period involves:
• closing the omphalocele
• repairing the bladder
• creating a vesicostomy
• performing a colostomy for fecal diversion

Sacrococcygeal Teratomas
Sacrococcygeal teratomas (SCT) represent the most common neonatal tumor with an incidence of 1 in every 35,000-40,000 live births. There is an unexplained female predisposition with a 3:1 female to male ratio. In the era of increased use of routine prenatal imaging, most SCTs are diagnosed in utero with ultrasound. Fetal MRI serves as an adjunct imaging modality because it is able to differentiate SCT from other sacral pathologies such as myelomeningoceles.

Sacrococcygeal teratomas are most commonly classified using the Altman classification:
• Type 1 – is predominantly external
• Type 2 – is external with an intrapelvic component
• Type 3 – is primarily intrapelvic and intraabdominal with a small external component
• Type 4 – is presacral with no external component

Although neonates with SCT usually have good prognosis, fetuses with SCT are at high risk for complications in utero and perinatally, usually due to the size and vascularity of the lesion. Poor outcomes of prenatally diagnosed SCTs have been associated with factors such as increased vascularity, presence of a solid tumor and a tumor volume to fetal weight ratio (TFR) greater than 1.2. Large, highly vascular SCTs are associated with high mortality and morbidity usually due to polyhydramnios causing premature labor and birth and high-output cardiac failure leading to placentomegaly or hydrops. Repeated ultrasound assessment of prenatally diagnosed SCT is therefore important to evaluate any increase in the size of the tumor.
Factors such as fetal hydrops and premature labor may necessitate fetal intervention including open fetal excision/debulking and intrauterine endoscopic laser ablation. In the immediate neonatal period, neonates with SCTS may require management in the intensive care unit if they have complications such as prematurity, high-output cardiac failure, disseminated intravascular coagulation and rupture or bleeding for the tumor. An uncommon but highly lethal scenario is bleeding from a large SCT tumor. In this situation, placement of a temporary tourniquet around the base of the tumor may be a lifesaving intervention that allows the child to make it to the operating room.

SCTs are otherwise managed postnatally with surgical resection, once the infant is stable. The prognosis is dependent on presence of malignancy and the ability to completely resect the tumor. Most SCT recurrences occur within 3 years of resection therefore all patients should be monitored with physical examination and lab studies including AFP and CA 125 every three months for at least 3 years.

**Suggested Reading List**

**Peripheral and Central Venous Access**


**Specific Surgical Conditions**


Section 15: End-of-Life Care

Editors: Karen E. Johnson and Frank Placencia

15.1 Introduction .................................................206
    Alana Thomas

15.2 Assessment of Pain and Discomfort ........... 207
    Karen E. Johnson
    Frank Placencia
    Jennifer Placencia

15.3 Understanding and Communicating at the End-of-Life ........................................209
    Karen E. Johnson
    Frank Placencia

15.4 Determination of Limitation or Redirection of Life Sustaining Treatment...............210
    Karen E. Johnson
    Frank Placencia

15.5 Transition to Comfort Care ......................... 213
    Karen E. Johnson
    Jennifer Placencia
    Alana Thomas

15.6 Death of the Infant ......................................214
    Karen E. Johnson
    Frank Placencia
    Alana Thomas

15.7 The Grief Process ................................. 216
    Karen E. Johnson
    Frank Placencia

15.8 Circumstances Unique to BTGH ................ 217
    Cathy Gannon
    Karen E. Johnson
15.1 Introduction

Palliative care is specialized care focused on improving the quality of life for patients and their families facing the problems associated with chronic, life-threatening or terminal illness, through the prevention and relief of suffering. Growing evidence suggests that families of children with life-threatening and chronic conditions benefit from palliative care and that earlier discussions and initiation can improve symptom management and quality of life.

In 2000, the American Academy of Pediatrics (AAP) first described the principles of palliative care for children and called for a palliative care model using an integrated interdisciplinary approach. This statement was reaffirmed in 2007, with a policy statement in 2013 enhancing these concepts.

The palliative care model is founded on the following principles:

1. Respect for the dignity of patients and families
2. Access to competent and compassionate palliative care
3. Support for caregivers
4. Improved professional and social support for families in need of palliative care
5. Continued improvement of pediatric palliative care through research and education

Palliative care includes pain/symptom control and management, focusing on enhancing quality of life, emphasizing the assessment and treatment of the body, mind, and spirit to prevent suffering for children and families living with life-threatening or terminal conditions. AAP supports an integrated model of palliative care that begins when illness is diagnosed, continues through the disease trajectory and often co-exists with conventional treatments, and continues through and after death (Fig 15-1).

Qualifying Patients

Patients who should receive palliative care include:

1. Newborns at the threshold of viability (<24 weeks or <500 grams)
2. Newborns with complex or multiple congenital anomalies
3. Newborns not responding to Neonatal Intensive Care interventions (either slow deterioration or an acute life threatening event) or those deemed to have a terminal or irreversible condition
4. Newborns with a severe complex chronic illness which may become life-threatening

Domains of Palliative Care

The National Consensus Project (NCP) published clinical practice guidelines for quality palliative care by outlining 8 domains of care.

The domains of care include:

1. Structure and Processes of Care
2. Physical Aspects of Care
3. Psychological and Psychiatric Aspects of Care
4. Social Aspects of Care
5. Spiritual, Religious and Existential Aspects of Care
6. Cultural Aspects of Care
7. Care of the Imminently Dying Patient
8. Ethical and Legal Aspects of Care

Further information may be found at www.nationalconsensusproject.org

Palliative Care in the Hospital Setting

Palliative care provided in the tertiary hospital setting is best coordinated through the use of an interdisciplinary palliative care team which includes a physician, nurse and/or nurse practitioner, social worker, spiritual advisor and a child life therapist, and may include a family advocate, clinical pharmacist, dietician, bioethicist, and psychiatrist or psychologist. Because palliative care patients receive interventions from such diverse disciplines, it is important that the primary care physician/team coordinate these efforts.

Palliative Care Consultations

Perinatal Pediatric Advanced Care Team (PPACT) consultations are available at TCH for Fetal Center and Newborn Center referrals. To obtain a consultation, please call the main Neonatology Service number, 832-826-1380. (Fig 15-2)

For postnatal palliative care consultation at TCH, please call the Pediatric Advance Care Team (PACT) at 832-822-7228 Monday through Friday or for urgent questions or concerns, call 281-763-4622, available 24 hours a day, 7 days a week. Perinatal Palliative Care Consultations are also available at Ben Taub General Hospital through an interdisciplinary team. Most are done while an expectant mother is admitted and are part of her prenatal consult, which is obtained by calling 713-873-9210. Outpatient consultations are encouraged and can be arranged with advance notice through an EPIC referral, which goes to the neonatologist, social worker, and child life specialist on our team. (Ch 15.8 Circumstances Unique to BTGH)
15.2 Assessment of Pain and Discomfort

Pain is one of the most common symptoms experienced by infants with serious or life-threatening conditions. Unfortunately, much of pediatric pain is undertreated. It is important to be able to recognize and treat all types of pain, including acute pain, chronic pain, recurring pain, procedural pain, and end-of-life pain. Physiologic indicators such as vital sign changes, or behavioral indicators such as facial grimacing, may not be as reliable or may be absent in a chronically or critically ill infant. In order to treat pain effectively, it must first be accurately assessed. Multiple validated neonatal pain assessment tools are available. At Texas Children’s Hospital the CRIES and PIPP instruments are used.

CRIES Scale
The CRIES scale is used for infants > than or = 38 weeks of gestation. Characteristics of crying, oxygen requirement, changes in vital signs, facial expression, and sleep state are scored. A maximal score of 10 is possible. If the CRIES score is > 4, further pain assessment should be undertaken, and analgesic administration is indicated for a score of 6 or higher. (Table 15-1)

PIPP Scale
The PIPP scale is used for infants < or = 37 weeks of gestation. To use the PIPP scale, the behavioral state is scored by observing the infant for 15 seconds immediately before and after a painful event, and before and after pain medication is given (30 minutes after intravenous and 1 hour after oral medication). The baseline heart rate, oxygen saturation, and facial expression are assessed. Any changes from baseline should be noted for 30 seconds.

The total pain score is then calculated:
- 6 or less = Minimal to no pain
- 7-12 = Mild pain
- >12 = Moderate to severe pain
- N-PASS is the pain scale used in the BTGH NICU for all patients. (Table 15-3)

Table 15-1. CRIES Scale

<table>
<thead>
<tr>
<th>Date/Time</th>
<th>Crying</th>
<th>Grimacing and non-cry vocalization</th>
<th>Expression</th>
<th>Sleepless</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics of cry are high pitched</td>
<td>No cry or cry that is not high-pitched</td>
<td>Characteristic cry of pain is high pitched</td>
<td>Grimace and non-cry vocalization present</td>
<td>Quiet sleep</td>
</tr>
<tr>
<td>0 –</td>
<td>0 –</td>
<td>0 –</td>
<td>0 –</td>
<td></td>
</tr>
<tr>
<td>1 –</td>
<td>1 –</td>
<td>1 –</td>
<td>1 –</td>
<td></td>
</tr>
<tr>
<td>2 –</td>
<td>2 –</td>
<td>2 –</td>
<td>2 –</td>
<td></td>
</tr>
<tr>
<td>Moderate to severe pain</td>
<td>Moderate to severe pain</td>
<td>Moderate to severe pain</td>
<td>Moderate to severe pain</td>
<td></td>
</tr>
<tr>
<td>Total Score</td>
<td>Total Score</td>
<td>Total Score</td>
<td>Total Score</td>
<td></td>
</tr>
</tbody>
</table>

Table 15-2. PIPP Scale

<table>
<thead>
<tr>
<th>Gestational age</th>
<th>Behavioral state</th>
<th>Maximum heart rate</th>
<th>Maximum oxygenation saturation</th>
<th>Brow bulge</th>
<th>Eye squeeze</th>
<th>Nasolabial furrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 36 weeks</td>
<td>Active awake</td>
<td>0-4 BPM increase</td>
<td>0-2.4% decrease</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>≥ 32-35 weeks</td>
<td>Eyes open</td>
<td>5-14 BPM increase</td>
<td>2.5-4.9% decrease</td>
<td>0% or 9% of time</td>
<td>0% or 9% of time</td>
<td>0% or 9% of time</td>
</tr>
<tr>
<td>2-23 weeks</td>
<td>No facial movements</td>
<td>15-24 BPM increase</td>
<td>5.0-7.4% decrease</td>
<td>Minimum 10-39% of time</td>
<td>Minimum 10-39% of time</td>
<td>Minimum 10-39% of time</td>
</tr>
<tr>
<td>&lt;28 weeks</td>
<td>Active sleep</td>
<td>≥ 25 BPM increase</td>
<td>≥ 7.5% decrease</td>
<td>Moderate 40-69% of time</td>
<td>Moderate 40-69% of time</td>
<td>Moderate 40-69% of time</td>
</tr>
</tbody>
</table>

Table 15-3. N-PASS Scale

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Minimal to no pain</th>
<th>Moderate to severe pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score</td>
<td>0-9</td>
<td>10-19</td>
</tr>
</tbody>
</table>

Neonatal Abstinence Syndrome (NAS) scoring should never be used for pain assessment.
The synthetic opioids and therefore, should not have to be titrated up as quickly as inducing than the synthetic opioids, given its longer half-life resulting respiratory distress. Morphine may be less tolerance

Narcotic Analgesics

Pharmacologic Management
Once identified, it is important to alleviate pain in acute, chronic or life-threatening illness. To achieve adequate analgesia/sedation, medications optimally should be scheduled or given by continuous infusion with intermittent bolus doses as needed in order to avoid fluctuations in blood levels and breakthrough pain or discomfort. In addition, infants should always receive a bolus dose of narcotic or sedative prior to starting or increasing the infusion rate.

The intravenous route is the preferred delivery route. Intranasal administration is an alternative option for patients who do not have intravenous access. In general, IM or SC injections should only be used as a last resort to avoid additional discomfort in the patient. Oral medications may be used if patient has no IV access, but will not provide as rapid relief as IV medications. Please also refer to Table 15-4 for further dosing information. **Because of the unique nature of the palliative care setting, medication dosing may differ from the usual recommendations for neonatal analgesia or conscious sedation.

Narcotic Analgesics

Morphine has several advantages over other narcotics. It provides pain relief, elicits a sense of euphoria and promotes histamine release, which results in vasodilatory properties. These properties may decrease venous return, thereby decreasing cardiogenic pulmonary vascular congestion and resultant respiratory distress. Morphine may be less tolerance inducing than the synthetic opioids, given its longer half-life and therefore, should not have to be titrated up as quickly as the synthetic opioids. (Table 15-4)

- In general, narcotic dosing should be titrated to effect. There is no set maximum dose. If a patient is habituated on an opioid infusion, the hourly dose of the infusion can be used for bolus dosing.

Pharmacologic Management

Habituated Patients
If adequate sedation is difficult to achieve in a narcotic or benzodiazepine resistant patient, consultation with the Clinical Pharmacy Specialist or Anesthesia/Pain Management Service should be considered.

Alternative Route Medications
In the patient who does not have intravenous access, a combination of oral morphine and chloral hydrate may be used. Intranasal medications may also be given

- Intranasal administration of fentanyl and midazolam has been found to be effective in pediatric palliative care.
- Chloral hydrate may be given as a 50 mg/kg dose PO/PR (usual range 25–75 mg/kg per dose). Repeat doses should be used with caution due to accumulation of drug and metabolites.

Adjunct Medications

- Acetaminophen 10mg/kg to 15 mg/kg PO, PR may be given every 4 to 6 hours for mild discomfort. See TCH Formulary for specific weight and age based dosing.
- Sucrose 24% 1 mL to 2 mL PO every 6 hours for term babies and 0.1 mL to 0.4 mL PO every 6 hours for preterm babies may be given while if providing nutritive or non-nutritive support.

Please see pharmacological management at End-of-life for details specific to therapy focusing on that time period of palliative care.
15.3 Understanding and Communicating at the End-of-Life

Introduction

Death in a tertiary care center neonatal intensive care unit is, unfortunately, a common occurrence. More children die in the perinatal and neonatal period than at any other time in childhood. Extremely premature infants and those with congenital anomalies serve to dramatically increase the mortality rate in the NICU setting. It is therefore vital that the intensive care physician is well-versed in the grief process, and able to address end-of-life care issues with the family in a receptive and culturally sensitive manner.

Definitions

- **Grief** - intense sorrow or deep mental anguish; arising from the loss of someone or something loved, usually through death.
- **Mourning** - a cultural complex of behaviors in which the bereaved participate, or are expected to participate.
- **Bereavement** - the period of time during which grief is experienced and mourning occurs.
- **Hospice** - provides support and care for patients and their families in the final phase of a terminal disease so that they can live as fully and comfortably as possible.

Attachment in Pregnancy

Attachment to the baby begins before birth. The mother usually bonds closely with her baby while pregnant. Thus, the death of a fetus or infant means the loss of both the baby and the parents’ hopes and dreams for their baby and leaves them with an overwhelming sense of failure.

Professional and Societal Perceptions of Death and Grieving

Expectant parents have faith in modern medicine and are not likely to think that their child may die, especially after the first trimester of pregnancy. Further, in our culture, there is significant social pressure to believe in miracles and use as much technology as possible to save lives. Parents may feel obligated to choose to continue extensive and invasive medical interventions because these are seen by society as “heroic” and “courageous” choices. Parents who choose other options often feel judged, isolated and unsupported by their families, friends, and by society in general.

Health professionals frequently are uncomfortable with the thought of death or grieving. Historically, professional support for grieving families and caregivers has been lacking. Grief education is not routinely included in medical training. In addition, parents sometimes perceive healthcare provider behaviors to be thoughtless and insensitive. Health professionals realize the importance of honest communication and empathy with parents around the time of death, as well as the need for continued support of the grieving family after the death has occurred.

---

### Table 15-4. Pharmacologic management for neonatal end-of-life care

<table>
<thead>
<tr>
<th>Class</th>
<th>Route</th>
<th>Dosing</th>
<th>Frequency</th>
<th>Important Features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Narcotics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>IV, IM, SC</td>
<td>0.1 mg/kg/dose</td>
<td>Q2-4 hours</td>
<td>• There is no set maximum dose. Meds should be titrated to effect</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>0.03 mg/kg/hr</td>
<td>continuous</td>
<td>• Pain relief, euphoria and vasodilatory effects</td>
</tr>
<tr>
<td></td>
<td>PO</td>
<td>double IV dose</td>
<td></td>
<td>• Decreases air hunger</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Less tolerance inducing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Longer half-life</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>IV</td>
<td>1-2 mcg/kg/dose 1-2 mcg/kg/hr</td>
<td>Q2-4 hours</td>
<td>• May not provide adequate pain control due to short half life</td>
</tr>
<tr>
<td></td>
<td>Intransal</td>
<td>1-2 mcg/kg/dose</td>
<td>Q10 minutes</td>
<td>• Infants receiving a fentanyl infusion should also receive a morphine bolus immediately prior to discontinuation of support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• May give up to 3 doses in 30 minutes for labored breathing, concern for pain/discomfort (specifically for intransal fentanyl in NBs with comfort care plan)</td>
</tr>
<tr>
<td><strong>Benzodiazepines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>IV</td>
<td>0.1-0.2 mg/kg/dose</td>
<td>Q2-4 hours</td>
<td>• May be used in conjunction with narcotics to achieve moderate sedation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Anxiolytic and sedative properties but no pain control</td>
</tr>
<tr>
<td>Midazolam</td>
<td>IV</td>
<td>0.1-0.2 mg/kg/dose 0.06 mg/kg/hr</td>
<td>Q1-2 hours</td>
<td>• Shorter duration of action than lorazepam</td>
</tr>
<tr>
<td></td>
<td>Intransal</td>
<td>0.2-0.3 mg/kg/dose Give half of dose in each nare</td>
<td>continuous</td>
<td></td>
</tr>
<tr>
<td><strong>Habituated patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>IV</td>
<td>1-3 mg/kg/hr</td>
<td>continuous</td>
<td>• May be helpful in patients who are narcotic or benzodiazepine resistant</td>
</tr>
<tr>
<td>Propofol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexmetatomidine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patients with no IV access</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloral hydrate</td>
<td>PO or PR for chloral hydrate</td>
<td>25-50 mg/kg/dose</td>
<td>Q2-4 hours</td>
<td>• May be required in rare cases as an anesthetic agent; an anesthesia/pain service consult should be obtained.</td>
</tr>
<tr>
<td>Alternating with morphine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adjunct medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>PO, PR, PO</td>
<td>10-15 mg/kg 1-2 mL 0.1-0.4 mL (for preemies)</td>
<td>Q4-6 hours</td>
<td>• May be used in conjunction with narcotics to achieve moderate sedation</td>
</tr>
<tr>
<td>24% sucrrose</td>
<td></td>
<td></td>
<td>Q6 hours</td>
<td></td>
</tr>
</tbody>
</table>

* Due to the unique nature of the palliative care setting, medication dosing may differ from the usual recommendations for analgesia or conscious sedation in neonates.
15.4 Determination of Limitation or Redirection of Life Sustaining Treatment

Forgoing (which includes non-initiation or withdrawal) of life sustaining treatment for newborns must consider several key areas:

1. Decisions about forgoing life sustaining treatment should be made by the health care team in collaboration with the parents, who must be well-informed about the condition and prognosis of their infant.

2. Parents should be involved in the decision-making process to the extent that they choose.

3. Compassionate comfort care should be provided to all infants, including those for whom intensive care is not provided.

4. It is appropriate to provide intensive care when it is thought to be of benefit to the infant, and not when it is thought to be harmful, of no benefit, or futile. Deference should be given to the parents’ perception of what is beneficial.

The goal for the primary team, and subspecialty consulting services in partnering with the parents, is to design a course of action that is in the baby’s best interest. Goals of care should be mutually agreed upon by all involved. In 2017, the AAP updated its policy on forgoing life-sustaining treatment.

The Texas Advance Directives Act and its Application to Minors

If an infant is to be transitioned from curative to comfort care and this entails forgoing of life-sustaining treatment, it is important to determine if s/he is a qualified patient under the Texas Advanced Directives Act (TADA). The TADA, also known as the Texas Futile Care Law (1999), states that a qualified patient is one with either an irreversible or a terminal condition. A patient must have only one of the two conditions to qualify for TADA.

An irreversible condition is one that may be treated but is never eliminated, leaves a person unable to care for or make decisions for him- or herself, and is fatal without life-sustaining treatment provided in accordance with the prevailing standard of medical care.

A terminal condition is an incurable condition caused by injury, disease or illness that according to reasonable medical judgment will produce death within six months, even with available life-sustaining treatment provided in accordance with the prevailing standard of medical care.

The baby’s mother, legal father, or legal guardian may sign or verbally agree to an advanced directive or make treatment decisions for the affected infant. The TADA also empowers the attending physician to invoke an institutional review process if parents persist in demanding interventions that the attending physician believes to be inappropriate.

The 1984 “Baby Doe” amendment to the Child Abuse Prevention and Treatment Act (CAPTA) directs Child Protective Services to investigate cases to prevent the withholding of medically indicated treatment from disabled infants with life threatening conditions. The amendment defines treatment as NOT medically indicated if the infant is irreversibly comatose, if it would merely prolong dying, not be effective in ameliorating or correcting all of the life-threatening conditions, if it would be futile in terms of survival, or if it would be virtually futile in terms of survival and be inhumane. Definitions for “life threatening,” “prolong dying” and “virtually futile” are in an appendix to 42 U.S.C. § 5106, do not have the force of law, and have never been enforced in Texas or any other state.

Special Circumstances Surrounding Delivery Room Resuscitation

No federal law or Texas state law mandates delivery room resuscitation in all circumstances. According to the Neonatal Resuscitation Program (NRP), it is ethically and legally acceptable to withhold or withdraw resuscitative efforts if the parents and health professionals agree that further medical intervention would be burdensome, merely prolong dying, or would not offer sufficient benefit that would improve the baby’s outcome.

Parents and health care providers must have accurate and current information regarding potential infant survival and outcomes. Joint decision making by both the parents and the physician should be the standard. Given the uncertainties of gestational age assessment and fetal weight determination, it will usually be necessary to examine the baby at birth before making firm statements to parents and others regarding providing or withholding resuscitation.

In specific cases when parents request that all appropriate resuscitative measures be performed in the face of a high or uncertain morbidity and/or mortality risk, it may be appropriate to offer the infant a trial of therapy that may be discontinued later. Alternatively, some parents may not want full resuscitation of their child; the appropriate response in these cases will depend upon the circumstances. Ethical and legal scholars agree that there is no distinction between withholding and withdrawing life-sustaining treatments.

Developing Consensus between the Medical Team and the Family

All members of the medical team should meet prior to meeting with the family to reach an agreement regarding recommendations for redirection of care. One spokesperson (usually the attending physician of record) should be established to maintain continuity of communication.

Disagreement between the Medical Team and the Family

The infant’s parents serve as legal and moral fiduciaries for their child, and the relationship of parents to children is a responsibility, not a right. Because infants are incapable of making decisions for themselves, their parents become their surrogate decision makers. The physician serves as a fiduciary who acts in the best interest of the patient using the most current evidence-based medical information. In this role as an advocate for their patients, physicians oversee parental decisions. Thus, the patient’s best interest standard overrides the doctrine of informed consent and right to refusal of care.
Even in the best of circumstances people of good conscience may disagree. If individual caregivers’ ethical standards conflict with those of the parents or the primary team, the caregiver is free to remove herself or himself from the care of the patient in accordance with hospital and unit policies. In circumstances of disagreement between the family and medical team, other professionals (e.g., social worker, family relations team, chaplaincy, palliative care and/or clinical ethics) may be of help in further discussions. In both instances, the director of nursing and the medical director should be notified.

The AAP and other organizations support addressing these considerations with the utmost regard for families’ viewpoints, continuing a process of respectful and honest information sharing as the patient’s condition and the family’s understanding evolve over time. Differences between family caregivers or between the care team and family decision-makers can be approached by using basic principles of negotiation and conflict resolution.

It is often helpful to discuss ethical cases with colleagues with particular ethics expertise, or with a larger group. The following members are members of the Texas Children’s Hospital Clinical Ethics Committee:

- Yunus Ahmadi, M.D.
- Emily Christiansen, R.N.
- Frank Placencia, M.D.
- Gauthum Suresh, M.D.
- Alana Thomas, M.D.

To request that a case be reviewed in Neonatal Ethics Rounds, please contact Drs. Frank Placencia, or Alana Thomas.

**Clinical Ethics Committee Consultation**

Before requesting an Ethics Consultation, consider requesting that the case be reviewed in Neonatal Ethics Rounds. Doing so may avoid the need for consultation, or may potentially expedite it. If further agreement with the family cannot be reached, a clinical ethics consult may be obtained by contacting the chairpersons (below) through the page operator:

At Texas Children’s Hospital:
James A. Thomas, MD
Chief of Clinical Ethics/Co-Chair Clinical Ethics Committee
Office: 832-826-6230/832-826-6223
TCH Pager: 97534
jathomas@bcm.edu

Laurel Hyle, JD, MPH
Chief of Clinical Ethics/Co-Chair Clinical Ethics Committee
Office: 832-826-4660
Laurel.Hyle@bcm.edu

At Ben Taub General Hospital:
Joey Fisher, M.D., M.P.H.
Please page for an ethics consult through the Ben Taub page operator 713-873-2010.

If the parents request full resuscitative measures in direct opposition to the opinion of the medical team and the infant is responsive to those measures, the infant should continue to be supported while the ethics committee’s deliberations are ongoing.

**Patients in Child Protective Services Custody**

Policy of the Texas Department of Family and Protective Services is that any decision to withdraw or redirect care of a qualified patient in the custody of CPS must have the concurrence of an ethics committee with knowledge of the patient’s case, and must also be approved by a court.

**Imparting Difficult Information**

Building a therapeutic relationship and establishing good communication between the medical team and the family is paramount. When talking with the family, the following phrases and ideas can be used as a “communication toolbox,” and the most important aspects of the conversation are highlighted in bold.

- **Meet in a quiet, private place**
- **Introduce yourself**
- **Refer to the baby by name**
- **Ask what the parents know about their baby’s condition**
- **Ask permission to give more information about the baby**
- **Give a warning shot** - for example, tell the family that the news you have to give them is not good, or not what you wanted it to be
- **Pause** - give the family a moment to prepare themselves to hear what you have to say
- **State the bad news clearly and speak directly** - Keep the message concise and use lay language. Expect to repeat the message several times as the shock of the information you are conveying may interfere with the family member hearing what you have to say. Do not use euphemisms for disease or death. Say “he is dying or is dead” rather than “he passed away.”
- **Be honest**
- **Review the goals** - Tell the family about two goals of medicine. The first is to add time to life. The second is to add quality to life. If medical interventions do neither, it is no longer appropriate to continue those interventions.
- **Offer choices, if possible** - Inform the parents that there is nothing curative to offer their child. State that the current therapy can continue as it is, but that the outcome will not change. Alternatively, all artificial life support can be discontinued, comfort care provided, and the parents can give their dying infant the love of a mother and father.
- **Give a recommendation** - in cases where there is a choice to make regarding further treatment or redirection of care. A unified approach and clear recommendation from the healthcare team is appropriate and may relieve parents of the some of the burden of decision making in the end-of-life context. The words “withdrawal of treatment”, “withdrawal of care”, or “there is nothing else we can do” should be avoided. Explain that the infant will continue to be cared for, the family will be supported, and that any symptoms of discomfort will be aggressively managed.
• **Wait quietly** - Periods of silence allow the family to process information more effectively. It also conveys that you are there to support them. Wait for receptive body language from the family before proceeding. The family will not hear the next piece of information until they are ready.

• **Convey empathy** - Parents recognize and appreciate sincerity, compassion, tenderness and emotional availability from the physician and team members conveying bad news. Statements such as “I wish (the test, the surgery, the diagnosis) was different” convey sincerity and help to forge a closer connection with the family.

• **Focus on compassion** - The fundamental question is how best to love this patient. A parent’s decision to withdraw life support is an extraordinary act of love and courage. Speaking in terms of loving the baby also focuses the conversation on parenting and gives the family permission to focus on end-of-life issues without feeling as if they are abandoning their role as the patient’s mother or father.

• **Ask if the parents have questions** - Ask especially about a family’s hopes and fears. Affirming parental concerns and asking about seemingly forbidden topics can help to alleviate fear and anxiety. Use open statements. For example, “Many parents feel as though they are causing their child’s death by stopping the ventilator. Are you worried about this?” Guide parents through the process—Families need to be prepared for the dying process. Knowledge about what can be expected, including color changes and reflexive gasping, decreases parental anxiety. Emphasize that support for the baby and the family will always be provided. The unpredictability of the time to death from the time of withdrawal of support should also be addressed.

• **Let the family know that they will not be abandoned** - For example, a conversation might include the statement: “We will continue to provide the best medical care for your infant that will include frequent assessments by trained staff. We will be adjusting medications so that your infant is comfortable.” Expect to have multiple conversations with the family.

• **Tell them exactly when you plan to meet with them again** - parents who experience a normal grief reaction will not hear all of what you have to say immediately after receiving distressing news.

• **Ask parents what their thoughts are and how they are coping with the information presented** - Asking parents these questions allows the practitioner to view the baby’s death from the parents’ perspective and to better meet the parents’ needs.

### Documentation

The attending physician of record should document in the chart the reasons why the patient qualifies for redirection of care, as well as the discussion of these qualifying factors with the surrogate decision maker (see who may execute a directive on behalf of a patient under the age of 18 below; however, in the NICU the surrogate decision maker will almost always be the parents). If the patient is actively dying, there is no need for this documentation to be witnessed. However, if the patient is being electively transitioned to comfort care or withdrawal/limitation of support and adequate time exists, a Directive to Physicians should be utilized. The Directive to Physicians may be verbal or written. If verbal, the conversation between the physician and the surrogate decision maker should be observed by two witnesses unrelated to the family and patient and who have no role in the patient’s medical care (see witness requirements below; these witnesses may be other medical personnel in the NICU who are not directly caring for the infant). The note should document that the surrogate decision maker agrees with the modification of the plan of care and should include the names of the witnesses. A Directive to Physicians may also be signed by the surrogate decision maker and two unrelated witnesses.

After the care team discusses the terminal and/or irreversible diagnosis and care plan with the family, a “Do Not Attempt Resuscitation” (DNAR) should be entered in the patient’s chart. The attending physician should honor the family’s wishes as previously documented when completing this form. If there is any uncertainty as to whether a specific intervention should be withheld, that decision should be discussed further with the family. In the case of the active withdrawal of life sustaining therapy, a DNAR form is not necessary.

Sec. 166.035. **EXECUTION OF DIRECTIVE ON BEHALF OF PATIENT YOUNGER THAN 18 YEARS OF AGE.** The following persons may execute a directive on behalf of a qualified patient who is younger than 18 years of age:

1. patient’s spouse, if the spouse is an adult;
2. patient’s parents, or
3. patient’s legal guardian.


Sec. 166.003. **WITNESSES.** In any circumstance in which this chapter requires the execution of an advance directive or the issuance of a non- written advance directive to be witnessed:

1. each witness must be a competent adult; and
2. at least one of the witnesses must be a person who is not:
   • a person designated by the declarant to make a treatment decision,
   • a person related to the declarant by blood or marriage,
   • a person entitled to any part of the declarant’s estate after the declarant’s death under a will or codicil executed by the declarant or by operation of law,
   • the attending physician,
   • an employee of the attending physician,
   • an employee of a health care facility in which the declarant is a patient if the employee is providing direct patient care to the declarant or is an officer, director, partner, or business office employee of the health care facility or of any parent organization of the health care facility,
   • a person entitled to any part of the declarant’s estate after the declarant’s death under a will or codicil executed by the declarant or by operation of law,
• a person who, at the time the written advance directive is executed or, if the directive is a non-written directive issued under this chapter, at the time the non-written directive is issued, has a claim against any part of the declarant’s estate after the declarant’s death.

Added by Acts 1999, 76th Leg., ch. 450, Sec. 1.02, eff. Sept. 1, 1999.

15.5 Transition to Comfort Care
Supporting the Family
The time around the death of a child is of profound importance. Most parents are in a deep state of shock at the time the baby dies, and immediately afterward. Medical caregivers are to guide parents and family members through the process of making memories, however brief, of their child. Parents being present and able to participate in the care of their dying infant, at the level with which they are comfortable, is extremely important in the experience of anticipatory mourning, fosters a sense of control, and facilitates preparation for the event of death.

1. The sequence of events should be described to parents in advance, and they may express preferences about the process. The parents should be educated about what to expect during the dying process and that not every newborn dies immediately after the ventilator is removed.

2. For NICU 3-4 patients in WT, please check with the charge nurse to see if the baby can be moved to the “Butterfly room” or a private room, if the family desires and if available at the Pavilion for Women-the mother’s door will be marked with the Newborn Center bereavement heart logo as a signal to all hospital staff to respect the family’s space with their dead or dying infant.

3. Visiting restrictions should be relaxed, and the parents should be provided with an environment that is quiet, private and will accommodate everyone that the family wishes to include. Child life specialists may help counsel siblings prior to the death of the infant. The hospital chaplain can assist with spiritual needs.

4. Low lighting is preferable.

5. One nurse and one physician should be available to the family at all times, and if possible the patient’s primary nurse and physician should be present at the time of the death.

6. Alarms and pagers of those in attendance should be silenced or turned off.

7. If no family is available, a Texas Children’s Hospital staff member should hold the baby as he or she dies.

8. A memory box should be created and given to the family based on their wishes before leaving the hospital, which may include:
   • Hair locks
   • Hand, foot, ear, lip and buttock prints, if desired
   • Hand and foot molds

9. The family should be encouraged to hold, bathe, dress and diaper their infant. There is no time limit for these activities. Parents or other family members may want to hold the baby after the body has been chilled in the morgue. The body may be gently re-warmed prior to their arrival under an open warmer or isothermal.

10. The family should be accompanied to their car by a member of the Texas Children’s Hospital staff. The assigned or on-call social worker should be contacted for parking validation.

11. The Perinatal Bereavement Committee provides parents with a bereavement support packet and canvas bag containing resource materials, funeral information, their child’s memory box, and a teddy bear.

12. The infant’s bed space should not be cleaned until the parents have left the unit.

13. The physician of record should notify the obstetrician, pediatrician, and any referring physicians of the infant’s death.

14. The death summary should designate who the follow up doctor will be to contact the family one month after the death and following autopsy completion.

Care of the Dying Infant
Care should focus on keeping the infant comfortable. The baby should be swaddled in warm blankets while being held, or kept warm by open warmer or isothermal. All painful interventions including blood draws should be discontinued. Intramuscular vitamin K administration or erythromycin eye prophylaxis may not be necessary. Breast, bottle, or naso- or orogastric feedings and pacifier use may provide comfort. However, feeding may cause pulmonary edema, aspiration pneumonia, worsen cardiac failure, or cause abdominal distention. All unnecessary intravenous catheters and equipment should be removed and wound sites covered with sterile gauze. Blow-by oxygen and gentle suctioning should be used as indicated.

It is important to differentiate symptoms of respiratory distress including increased work of breathing, grunting, and nasal flaring from agonal reflexive respirations that occur sporadically with long periods of accompanying apnea. Respiratory distress indicates that the patient is experiencing air hunger that should be immediately treated. Agonal respirations usually occur when the patient is unconscious and should not be a source of discomfort.
Pharmacologic Management at the End of Life

Although end-of-life care does not immediately dictate the need for medication, the majority of neonatal patients die from a painful ailment. It is important to alleviate pain at the end-of-life by achieving moderate to deep sedation in the affected patient, but respiratory depression is also a known side effect of many narcotics and sedatives. However, evidence from retrospective reviews and the neonatology literature suggests that the use of narcotics and sedatives does not shorten time to death. Moreover, the Doctrine of Double Effect states that “a harmful effect of treatment, even resulting in death, is permissible if it is not intended and occurs as a side effect of a beneficial action.” Thus, the main goal of medication use at the end-of-life is to keep the infant comfortable despite any known side effects.

Medical management should include both sedation with benzodiazepines and pain relief with narcotics. Narcotics alone may be insufficient in the management of air hunger and respiratory distress at the end-of-life. Habituated patients or those who are difficult to sedate are candidates for evaluation by Anesthesia/Pain Management specialists. Because of the unique nature of the palliative care environment, medication dosing frequently differs from usual recommendations for analgesia or conscious sedation in neonates. It is important to anticipate the acute symptoms expected when a patient is extubated. First doses of medication should be given prior to extubation, and an adequate level of sedation should be achieved to avoid patient air hunger. Responding to air hunger after extubation is frequently inadequate.

All medications other than those needed to promote comfort should be discontinued, unless otherwise requested by the family. Exceptions may include anti-epileptics, which offer seizure control and provide some level of sedation but should not be considered the primary sedative. There is no role for paralytics in end-of-life care as they prevent the medical team from adequately assessing the patient’s level of sedation or pain. If the infant was receiving neuromuscular blockade prior to the transition to comfort care, special attention should be paid to assure patient comfort under any residual paralytic effect.

Of note, morphine has several advantages over other narcotics in end-of-life care, and is especially effective at decreasing shortness of breath and air hunger. Fentanyl bolus dosing may not provide adequate pain control for a dying infant secondary to its short half-life. Infants receiving a fentanyl infusion should also receive a bolus morphine dose immediately prior to discontinuation of support, or in the event of observed distress.

15.6 Death of the Infant

Brain Death

There are no accepted guidelines to declaring brain death in neonates less than 37 weeks gestational age. Therefore, it is uncommon to declare brain death in the NICU. The process for declaring brain death is detailed in Texas Children’s Hospital’s “Determination of Brain Death” Procedure #1951. Per the policy, at least two different services must perform the brain death exam. Along with Neurology, it is advisable to consult with a member of Critical Care Medicine due to their expertise in assessing brain death.

Transitioning to Conventional Ventilation, Decreasing Ventilatory Support, and Removal of Endotracheal Tube

If the infant has been maintained on high frequency oscillatory ventilation, they should be transitioned to conventional ventilation to facilitate parental holding and bonding prior to extubation. The ventilator settings may be gradually decreased over a short period of time to assure that pain management and sedation is adequate; if the infant appears uncomfortable the titration of medications should be increased prior to the removal of the endotracheal tube. There is no need to monitor blood gases or chest imaging while weaning the ventilator prior to extubation. The process of weaning the ventilator will also increase hypoxemia and hypercarbia, which may contribute to the level of sedation.

Pronouncing the Death

The physician of record or fellow acting under the physician of record should always document the time of death in the chart. Declaring the patient’s time of death should not interfere with parental bonding.

The Option of No Escalation of Care

Parents faced with the prospect of their infant’s death may not be able to join in the decision to discontinue life support altogether. The family should again be informed that despite all available interventions, the known outcome for their infant remains unchanged. The option of continuing current support to give the parents time for memory-making with their baby may be offered as a bridge to the transition to comfort care.

Organ Donation

LifeGift Organ Donation Center should be notified within one hour of the patient meeting an imminent death trigger or at cardiac time of death. Imminent death triggers at Texas Children’s Hospital are as follows: prior to first brain death testing, changing the status of a ventilated patient to DNR, or after a transition of care meeting in the NICU. The phone call should be documented on the Inquiry for Organ/Tissue Donation and Consent for Postmortem Procedures aka “pink sheet” including phone caller’s name, time of the call to LifeGift, the LifeGift coordinator’s name, referral number and the response. If the patient is a potential organ donor, LifeGift will “follow” the patient and will consult regularly with the medical team. All cardiac times of death should be called into LifeGift on any patient 19 weeks of gestation or older, and should be documented on the “pink sheet.”

The LifeGift Liaisons are:

Texas Children’s Hospital:
Elise Passey, M.A. Ed.
713-906-2377 (mobile)
713-328-0662 (office)
epassy@lifegift.org

Ben Taub General Hospital:
Larry Leblanc
504-941-0050 (mobile)
lleblanc@lifegift.org
Medical Examiner
The medical examiner should be notified by the physician of record or the fellow acting under the physician of record after an infant death has occurred. The medical examiner is available 24 hours a day, 7 days a week including all holidays. In the State of Texas, notification of the medical examiner is required for all dead children under 6 years of age. The medical examiner’s office will determine if the body may be released to Texas Children’s Hospital or Ben Taub General Hospital. If the body is not released, the medical examiner will perform a mandatory autopsy. No parental permission is required.

Autopsy
If the body is released by the medical examiner, parental consent for an autopsy should be discussed shortly after death. Written or witnessed telephone consent is acceptable. Parents are often receptive to knowing that an autopsy will help them to clarify many aspects of their child’s disease process, in addition to providing insight as to why their child died. Studies have consistently shown that in approximately 30 to 50% of cases, the diagnosis of the infant was changed or new information was found at autopsy. Although autopsies may only be helpful in informing the family predicting recurrence risk in future pregnancies and future diagnostic testing of siblings in 6-10% of cases, the information may still be helpful.

It is also important to discuss that autopsy is not disfiguring. Although restrictions may be placed on the extent of the examination, an unrestricted, complete examination will provide the most comprehensive information and will have no impact on an open casket viewing. The procedure is completed within 3 to 4 hours, and the body is available to the funeral home on the same day. Limited autopsies regarding a tissue or organ of interest are also possible. In these cases, the pathology department does request that the chest of the infant is included in the evaluation if the parents agree. Genetic testing on blood or tissue may also be obtained without performing a complete autopsy. Imaging autopsy is also available for the perinatal population at TCH.

Autopsies are performed on weekdays between 9 am and 2 pm, and on Saturday between 8 am and 12 pm. However, a pathologist is on-call 24 hours a day 7 days a week, and an autopsy may be performed at any time if clinically indicated. Physicians and medical professionals caring for the patient are encouraged to attend the autopsy and discuss specific questions to be addressed with the pathologist. A verbal report is usually available in 72 hours and preliminary results within 7-10 days. The final autopsy report is complete in 6 to 8 weeks. The Texas Children’s Hospital pathology department performs autopsies for inpatients at no charge. Autopsies can be done on patients discharged home from TCH in hospice care. Consent may be obtained prior to, or at the time of death. The “follow-up” physician is responsible for contacting the family and initiating a post-autopsy consultation. Parents should be provided with a copy of the autopsy report at the time of the meeting.

When requesting an autopsy, a copy should be sent to Denita Wallace, as well as the follow-up physician.

If there are additional questions regarding an autopsy at TCH, contact:
Debra L. Kearney, M.D.
Associate Professor of Pathology
832-824-2250
832-824-1876
kearney@bcm.edu

Post Death Follow-Up
The death of an infant is a traumatic experience for any parent. As part of the healing process, it is common for parents to have questions about their infant’s hospital stay. Or they may want the opportunity to visit with hospital staff who cared for their child. As physicians it is our obligation to aid parents in the grieving process to the extent they desire. At Texas Children’s Hospital, in order to facilitate providing this aid, the following should occur:

On the Death Summary and the autopsy form, the “follow-up” attending should be identified. This attending is also responsible for signing the Death Certificate. The follow-up attending should be the regular daytime attending assigned to the infant, and not necessarily the attending on-call. This is consistent with the TX Department of State Health Services, Handbook on Death Registration. In the event that it is unclear who should be designated as the follow-up attending, consider the following in order:

1: The daytime attending on-service assigned to the infant
2: A previous daytime attending if the infant died soon after the attendings switched rotations (especially if the decision to forgo life-sustaining therapy (LST) was made by the previous attending).
3: The attending who led the discussion in which it was agreed to forgo further LST
4: The on-call attending when the infant died
5: The admitting attending
6: The L&D attending if the infant died in L&D.
7: Whomever signed the death summary but failed to identify one of the above.

In the event that a follow-up attending is not identified, Denita Wallace and Frank Placencia will use their discretion in identifying the follow-up attending.

The social workers routinely contact all families of deceased infants 1 month after death. At that contact, they will ask the family if they wish to be contacted by the follow-up physician. That information will be forwarded to the follow-up attending who will call interested families and offer to meet with them. It is advisable to have the social worker present during the phone call and meeting to address issues beyond the scope of our training. This meeting is in addition to the autopsy review meeting, which usually happens closer to 2-3 months after death. These meetings can be combined if that is the parents’ wish. After the phone call and/or meetings, a note should be entered into the chart for documentation purposes.

Though this process is specific to Texas Children’s Hospital, we encourage colleagues at our sister institutions to develop similar approaches to helping parents through the grieving process.
Hospice

Hospice care refers to a package of palliative care services (including durable medical equipment, diagnostic and therapeutic interventions), generally provided at a limited per diem rate by an interdisciplinary group of physicians, nurses, and other personnel, such as chaplains, health aides, volunteers and bereavement counselors. Hospice care provides a sup-port system for families with children discharged from the hospital with an irreversible or terminal condition. There are no time limits for referral to hospice care, and this care may be provided in a facility or at home. The assigned social worker can help with placement, and should be contacted for all referrals. Although it is not a prerequisite for hospice enrollment, an outpatient DNAR form should be completed prior to discharge if the family agrees. All prescription medications should also be filled prior to discharge. The family should be instructed to call the hospice rather than emergency personnel in the event of a home death.

Perinatal Hospice

Some parents confronted with a lethal fetal diagnosis may decide to continue their pregnancy to its natural conclusion. These families are best served through an interdisciplinary team (MD/RN/SW/CCLS) palliative care team, and PPACT is often consulted in these circumstances. The goals of perinatal hospice include shared decision-making with the family regarding pregnancy management, after-birth care, and preparation for the loss that is consistent with the family’s wishes and values. The mother should be encouraged to make a birth plan for her baby’s care after delivery. A hospice packet is available for parents in the TCH Newborn Center. Consideration of hospice care is appropriate if the baby does not expire soon after birth.

Funeral Homes

The family will be assisted with obtaining a funeral home for their deceased child by the appointed social worker or nursing staff. Funeral information is also provided in the bereavement support packet. In addition, Texas Children’s Hospital volunteer services department has a fund to assist families in financial need with $300 towards a funeral or cremation costs. Disbursement is coordinated by the appointed social worker.

Nursing Bereavement Support Checklist

The nursing staff is guided by a checklist which enables them to deliver care at the time of death in a uniform fashion to each family, including bereavement support materials, a sympathy card, and information on funeral homes in English or Spanish. In compliance with nursing guide- lines, the physician of record should notify the obstetrician, pediatrician, and any referring physicians of the infant’s death.

15.7 The Grief Process
Timing and Stages of Grief

There is no particular way that anyone “should” grieve. Elisabeth-Kubler Ross proposed five stages of grief as a pattern of phases that affected people experience, not always in sequence, when faced with their own or a loved one’s death. These stages are denial, anger, bargaining, depression and acceptance and are not always experienced in a linear fashion. Glen Davidson’s phases of bereavement suggest that shock and numbness are most intense in the first 2 weeks, followed by searching and yearning from the second week to 4 months, then disorientation from 5 to 9 months, and finally reorganization/resolution at 18 to 24 months. However, bereavement is unique to each individual. Up to one quarter of bereaved parents may display severe symptoms years after the death of their baby. Bereavement has been described as “relearning the world.” Parents’ ability to maintain a continued bond with their deceased child and integrate memories into a new reality is considered central to parental bereavement and adjustment.

Special Circumstances Relating to Fetal or Infant Death

Coping with the baby’s death is especially difficult because the length of time spent with the child is brief and few memories have been created. Parents may also feel responsible and guilty that their child has died. Support systems for bereaved parents may be weak, and community insensitivity is not uncommon. Bereaved parents often face caring for other children while mourning one or more who died, especially in cases of multiple births with one or more losses. Parents anticipating the death of their child may feel conflicting emotions of relief intermixed with sadness at the time of death. In addition, parents may grieve in different ways, and may not be available to each other as sources of support while experiencing their individual sorrow. Unresolved or delayed grief may result in a complicated grief reaction, and additional stressors including mental illness, low socioeconomic background, or a history of substance abuse can prolong and negatively impact the resolution of grief and integration of the loss. Psychiatric referral should be made for parents or family members experiencing atypical grief patterns. The Woman’s Place at the PFW offers psychiatric care to mothers followed in the Fetal Center.

Religious, Cultural, and Socioeconomic Differences Surrounding Death and Grieving

Religion and spirituality can be a source of comfort in the midst of loss. Customs and rituals of the individual family should be honored. Asking open-ended questions such as “What are your beliefs and how can we meet your spiritual needs?” is more effective than “Do you want your baby to be baptized?” or “Do you need a chaplain?” Religious references, even though well-intentioned, may cause offense. Families should be reassured that spiritual crises and questions such as “why me?” or “what did I do wrong?” are part of normal grief reactions.

The nursing staff is responsible for contacting the chaplain at the beginning of the dying process, regardless of the family’s faith tradition. When the infant is actively dying, contact the chaplain immediately. The chaplain is trained to make an assessment and provide the family with appropriate spiritual care and religious resources. At the family’s request, contact the chaplain to help arrange a special service in the hospital’s chapel or to officiate the funeral.

For some families, eye contact and touch may be expected; for others it may not be appropriate in their culture. When an infant is born with malformations, the mother may be blamed by other family members and education of the family may be
necessary. Many cultures express discomfort with death. Some cultures forbid autopsy, some parents may not wish to hold their dying or dead infant.

In families of lower socioeconomic status, they may view the cessation of intervention as a cost-cutting measure aimed at them. It will be necessary to explain to parents that their ability to pay is not the factor that determines goals of care for their child. These type issues exemplify the importance of providing culturally competent care in this setting. Telling parents that many caretakers might prefer palliative care for their own infants in the same situation may allow parents to see that their infant is not a subject of discrimination.

Language barriers may also be present. A hospital-employed medical interpreter should always be used for conversations regarding end-of-life care.

**Self-Care**

Working with the bereaved makes us aware of our own experienced and feared losses. If we have not appropriately mourned and re-located our own grief, it will be re-experienced in our interactions with families and predispose us to burn-out and compassion fatigue. Thus, it is important to consider our own feelings, coping styles, and behavior while communicating with parents at the end of their infant’s life.

To help support NICU staff, the Newborn Center hosts several Remember and Reflect events throughout the year.

---

15.8 Circumstances Unique to BTGH

Ben Taub Women’s and Infant’s Services has an active interdisciplinary palliative care team. Most of our services are provided to inpatients, but outpatient consultation is available for birth plan discussions with families whose fetus has been given a life limiting diagnosis and expects to deliver at BTGH.

In cases where comfort care is planned from delivery, the mother’s OB is the physician of record for baby when born alive until assumption of care by our faculty neonatologist/fellow is requested. NICU staff are always available to support and to answer questions from TCN, OB, or family members; and/or for orders for palliative medications, transfer of infant to MBU with mother after her recovery, or to the NICU when mother chooses not to have her baby rooming-in with her.

All babies with comfort care plans admitted to MBU have the NICU physicians as their care team until attending to attending sign-out can occur with the faculty neonatal hospitalist covering MBU during the daytime on weekdays. The NICU also provides nursing support to the TCNs and MBU nursing staff as needed but is not directly responsible for patient care.

A Perinatal/ Neonatal Nursing End-of-Life-Care Checklist is available in EPIC and a bereavement cart of supplies on our unit for our nursing staff to use for providing care at the time of death in a uniform fashion. This includes: notification of key members of the palliative care team – chaplain, social, work, and child life – as well as Life Gift and Now I Lay Me Down To Sleep; memory making; best practices for providing a supportive environment for family to grieve; and the appropriate paperwork required after each death.

If parents consent to an autopsy, the attending neonatologist must write “Requesting autopsy to determine cause of death” in a progress note or attestation of the death note in addition to autopsy consent being filled out appropriately. Imaging only autopsies are not available at BT, but limited autopsies are permitted though full autopsies preferred. For deaths outside L & D, the physician of record should notify the obstetrician and any consulting physicians of the baby’s death, and is responsible for contacting the family to offer to meet with them to discuss autopsy findings.

Each family is provided with bereavement support materials, a sympathy card, and information on the grieving process and support services outside the hospital in English or Spanish prior to discharge. All families that provide contact information with our team receive follow up phone calls and sympathy cards at key points in their grieving process.

**Suggested Reading**


10. Institute of Medicine 2014. Dying in America: Improving quality and honoring individual preferences near the end-of-life.

Section 16: Overview of Nursery Routines
Editors: Lakshmi Katakam and Mohan Pammi

16.1 Daily Routines ............................................220
    Senait Adebo
    Bheru Gandhi
    Lisa Owens

16.2 Ben Taub General Hospital .........................221
    Catherine Gannon

16.3 Texas Children’s Hospital ...........................223
    Rita Shah

16.4 TCH-The Woodlands Hospital ....................224
    Lisa Owens
16.1 Daily Routines

Charting
Charting at TCH and Ben Taub is now done electronically using the Electronic Medical Record (EMR). This software contains templates for most neonatal physician charting including H&P, progress notes, procedure notes and discharge summaries.

Lab Flow Sheets
The EMR contains a variety of selectable flow sheets for vital signs and laboratory values.

Problem Lists
Problem lists can be extremely helpful, especially with complex patients. In the EMR these can be entered in the form of appropriate diagnostic codes and should be kept current on all patients in all units. The problem list auto-populates in the daily note to ensure our severity of illness is accurately reflected. Updating problem list is essential when care transferred between teams. For resolved problems, be sure to check the resolved box so that only active problems remain.

Interim Summaries
This is a running summary of the patient’s hospital course and will become part of the discharge or transfer summary. There is an updated template that aims to keep the summaries succinct with relevant information necessary for transfer of care. These are to be regularly updated.

Procedure Notes
A note that includes clinical indications, appropriate procedural descriptions, parental consent, and outcome should accompany all procedures, including transfusions. A template is available in the EMR for this purpose but additional information can be added.

Weight Charts and Weekly Patient FOCs and Lengths
Daily weights should be ordered as well as weekly FOC and lengths (usually measured using length boards). These are recorded in the EMR and are plotted on growth charts. This information is extremely helpful in assessing the nutritional status and progress of our patients. The most current information should be available for rounds with our nutrition team.

Communicating with Parents
Physicians and nurse practitioners are expected to:

• Speak to the mother/father on admission of the infant to any nursery,

• Try to speak to the mother daily while she is in the hospital,

• Document in the chart the content of conversations (or the failed attempts if no phone or other response), and

• Write in the Progress Notes the regularity of parent visits when known.

Consultations
All requests for consultations should first be cleared through the Neonatology Faculty or Fellow.

Child Life
Child Life services is a field devoted to the psychosocial needs of hospitalized children and their families. In the nurseries, Child Life focuses on developmental needs of newborns, parent support, parent education, and sibling support and preparation. Specifically, Child Life can provide developmental support for infants identified to be at high risk for developmental delays and can offer hospitalized infants a variety of sensory and motor experiences that may facilitate development. Since infants view Child Life Specialists as safe, they can provide infants with noninvasive tactile stimulation and cuddling.

Child Life offers play and development classes for the parents of healthy infants to promote parental involvement and strong parent-infant bonding.

Individual support and education can be offered to parents who may have a difficult time attaching to their infant or who seem very scared and uncomfortable about touching and holding their infant. A photo book has been compiled to show to parents before they visit the NICU and to prepare them for what they will encounter. Child Life also can work with siblings who might be concerned about the baby who remains hospitalized. When a death occurs, either stillborn or neonatal, Child Life offers support and resources to the parents and family.

Occupational and Physical Therapy
Situations in which an OT-PT consult may be helpful include neurologic and musculoskeletal abnormalities, peripheral nerve injuries, chromosomal and non-chromosomal syndromes, feeding, and long-term respiratory problems.

Definitions
• **Premature** - less than 37 completed weeks’ (259 days) gestation at birth

• **Low Birth Weight (LBW)** - less than 2500 grams birth weight (7% of total births in the U.S.)

• **Very Low Birth Weight (VLBW)** - less than 1500 grams birth weight (3% of total births in the U.S.)

• **Extremely Low Birth Weight (ELBW)** - less than 1000 grams birth weight (1% of total births in the U.S.)

• **Small for Gestational Age (SGA)** - less than 10th percentile by weight, or 2 standard deviations below the mean by weight for gestational age

• **Intrauterine Growth Restriction (IUGR)** - deviations from the growth pattern established by fetal measurements on second trimester ultrasound

Discharge or Transfer Documentation
Discharge planning begins upon admission. Insuring or establishment of a medical home for our patients should begin with a query to the family for who will be the follow-up physician. If the family does not have one then every effort should be made to find a medical home for this patient long before discharge.

At discharge or transfer to room-in on the floor,
Record
• date of birth, gestational age, and birth weight,
• discharge or transfer weight,
• recent FOC,
• latest hematocrit, reticulocyte count (if relevant), newborn screen results and dates, and
• any other pertinent labs.

Note
• the arrangements for normal newborn care, clinic and/or consultants for follow-up, and dates of the appointments,
• discharge diet, and
• all medications (including iron and vitamins).

Order
• discharge medications (1- to 2-month supply) with transfer orders for floor.

At Ben Taub
For discharges that require Consultative Clinic follow-up, the discharge summary must be sent by fax to the follow-up physician(s). The discharge summary should include a problem list, relevant clinical information, list of medications, as well as condition and the plan of care at the time of discharge.

Infection Control
Hand Hygiene
All personnel who handle newborn infants in the unit should perform an initial scrub from fingertips to elbows using soap and water. Alternatively, alcohol-based hand cleansers may be used. Jewelry (except wedding bands) and watches should be removed before hand washing and should remain off until contact with the newborn is finished. Sleeves of clothing should remain above the elbows during hand hygiene and while caring for patients (including sleeves of white coats).

After the initial washing and before and after handling patients or their equipment, hands should be washed for 15 seconds with soap and water, or a golf ball-sized spray of alcohol-based foam, or an appropriate amount of alcohol-based gel. If hands are visibly soiled, they should be washed with soap and water. Hand hygiene should be performed before entering and after exiting patient rooms.

Gloves
Use of gloves is determined by individual hospital infection control policies. Hand hygiene should be performed before gloving and after glove removal.

Gowns
Cloth gowns are not required when entering the nursery. However, gowns are to be worn by anyone who will be holding an infant against their clothing or by anyone who requests a gown while in the nursery.

Liquid impermeable gowns should be worn when entering an isolation area only. These gowns are not to be worn outside of the isolation areas.

Masks, head covers, beard bags, and sterile gowns should be worn when placing umbilical catheters and percutaneous lines.

Individuals assisting with the procedure, or who must remain in the room, should also wear masks and head covers.

Stethoscopes
Each patient should have a dedicated stethoscope. Stethoscopes should be cleaned with alcohol before and after each patient use.

Isolation Area
In the isolation area, infection controls are to be strictly enforced. Hand hygiene is mandatory on leaving these areas even if there has been no patient contact. Cover gowns must be worn over scrub suits and removed when leaving this area.

Charts
Consider patient charts “dirty.” Hands must be washed after handling a chart and before handling a patient.

Nutrition Support after Discharge
(Ch 12.6-Discharge Nutrition Preparation.)

Parent Support Groups
A parent support group meets regularly at Texas Children’s Hospital and meetings of parents can be arranged at Ben Taub. Parents should be encouraged to take advantage of these services, especially if the infant has chronic problems.

ROP Screening
(Ch 1.1 General Care (Babies < 1500 grams) and Sec 1–Care of Very Low Birth Weight Babies)

Neurodevelopment Screening
A neurodevelopmental consult is required for all infants less than 1000 g birth weight and all infants treated with extracorporeal membrane oxygenation (ECMO). Requests for consults on infants who do not meet these criteria, but are considered high risk for neurodevelopmental problems by the attending physician, are done on an ad hoc basis. The request for consultation should be initiated at least two weeks prior to discharge, if feasible.

16.2 General Guidelines–Ben Taub General Hospital

Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS)
TeamSTEPPS is our patient safety and team work framework at Ben Taub Women’s Services (3rd floor). This includes multidisciplinary team huddles every morning and evening.

“I need clarification” is our STOP the LINE safety phrase for BT Women’s services. If you hear this phrase please notify your next in line supervisor right away to join the discussion.

Triage of Admissions
Newborn Nursery Transition Area
The normal newborn transition is with mother in L & D. More complex infants are transitioned in the Level 2 nursery or NICU. (Table 16–1)
Table 16-1. Triaging Babies for Transitioning at Ben Taub General Hospital

<table>
<thead>
<tr>
<th></th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestation Age by Mother’s Dates</td>
<td>≥ 36 weeks</td>
<td>32-35 weeks</td>
<td>&lt; 32 weeks</td>
</tr>
<tr>
<td>Weight</td>
<td>≥ 2250 grams</td>
<td>1801-2249 grams</td>
<td>≤ 1800 grams</td>
</tr>
<tr>
<td>5-minute Apgar</td>
<td>≥ 7</td>
<td>4-6</td>
<td>0-3</td>
</tr>
<tr>
<td>Meconium</td>
<td>Asymptomatic baby with or without meconium below the cords</td>
<td>Pedi Evaluation</td>
<td>Symptomatic with meconium below the cords</td>
</tr>
<tr>
<td>Respiratory distress</td>
<td>Maternal fever or PROM &gt; 24 hours without chorioamnionitis and asymptomatic baby</td>
<td>Maternal fever ≥ 101 and chorioamnionitis Or Pedi Evaluation – Baby with mild symptoms</td>
<td>Pedi Evaluation – Baby with significant symptoms</td>
</tr>
<tr>
<td>Sepsis risk factors</td>
<td>Maternal fever ≥ 101 and chorioamnionitis Or Pedi Evaluation – Baby with mild symptoms</td>
<td>Maternal fever ≥ 101 and chorioamnionitis Or Pedi Evaluation – Baby with mild symptoms</td>
<td>Pedi Evaluation – Baby with significant symptoms</td>
</tr>
<tr>
<td>Diabetic mother</td>
<td>All classifications</td>
<td>Symptomatic</td>
<td>High GIR need requiring central access</td>
</tr>
<tr>
<td>Congenital anomalies</td>
<td>Minor that are non-life threatening, e.g. club foot, renal pyelectasis, DDH, ear tags</td>
<td>Minor that are non-life threatening, e.g. club foot, renal pyelectasis, DDH, ear tags</td>
<td>Major anomalies</td>
</tr>
<tr>
<td>In-utero exposure</td>
<td>Marijuana or cocaine</td>
<td>Illicit drugs except marijuana or cocaine</td>
<td>Active maternal HSV lesions at delivery, maternal active TB, maternal varicella</td>
</tr>
<tr>
<td></td>
<td>HIV positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HSV without active lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PPD positive without active TB</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Blair-Deal, Gannon, Garcia-Prats March 2016)

Daily Activities

Rounds
Rounds are made daily during morning hours. In NICU we wear blue gloves in addition to hand hygiene for all patient contact.

Neo Rapid Response Team
(Neonatology Fellow, Upper level resident, Neo Charge Nurse, Neo Respiratory Therapist, Pedi intern) Labor and delivery has 12 LDRP’s (labor, delivery, recover, and post-partum) for low risk patients and 2 operative suites for caesarian sections and the delivery of high risk patients (Rooms 14 and 15). The need for our Neo RRT to attend a delivery is activated through designated pagers provided by the hospital. The pager will display the room number that the mother is delivering. This pager will also serve as a notice to respond to a code situation in other areas of the 3rd floor such as 3A (311 *1), 3B (311 *2), 3C (311 *3), Level 2 (311 *4) and 5555 for the first floor Emergency Room. In room stabilization is our practice with criteria in place for dealing with low risk and high-risk delivery situations (This will be included as part of your unit orientation). A five-person limit has been agreed upon for attendance in LDRPs.

Since there has been a great emphasis on reduction of wound infections on OB patients, all physicians are required to use BTGH laundered scrubs. Ensure you have access to the scrub Pyxis located in L & D on your first day of the rotation.

When entering the room, identify yourself and the team to the family and the delivering physician/midwife. After the delivery, please take the time to speak to the parents and the delivering physician/midwife regarding the status of their baby and the disposition of their baby after stabilization (e.g., “your infant is fine and should be able to transition with you” or “your baby will need antibiotics for a few days since you have an infection.”)

Scheduled Lectures
Neonatology lectures at Ben Taub are scheduled on a variety of topics Monday through Thursday at 8:30 am in the Neo Library for the NICU team and Monday – Friday at 12 noon in the 3rd-floor conference room which all residents and students on the nursery rotation should plan to attend. If needed, rounds will be interrupted to assure participation by residents.

Pediatric Grand Rounds each Friday from 8:30 to 9:30 am at Texas Children’s Hospital can be seen by videoconference in the 3-D classroom at Ben Taub.

Ordering Routine Studies
Routine Scheduled Labs, X rays, etc. Schedule lab work, X rays, ultrasound exams, etc. for routine times unless a true emergency exists. Nurses draw the labs in each unit at 5 am for routine morning labs. I Stat (POC) is available for blood gas analysis, glucose, and a basic metabolic panel in both level 3 and level 2 nurseries.

Ordering TPN and Other Fluids
At Ben Taub, TPN must be reordered daily. The order must be placed by 1 pm to be processed by the pharmacy to be started at 9 pm. If the fluids must be changed urgently due to metabolic instability when appropriate, simple IV fluids should be ordered. Please remember, there is no such order as a STAT TPN. All TPN orders are routine. Batch TPN in a D,W formulation is available in the Pyxis in the NICU.

Consultations
Cardiology
Currently, TCH pediatric cardiology provides limited services (ECG, Holter Scans, and cardiac echo) to our patients here at BTGH. Cardiac echo’s are available on a weekday 9 am – 4 pm by faxing an echo request form to the TCH echo lab and calling to confirm receipt of fax. Assistance in arranging an “urgent ECHO” or questions about follow-up can be discussed with the Outreach Cardiologist via the TCH page operator as soon as the appropriate paper work is completed.
See Pediatric Resident Reference Binder for necessary forms and complete process.

ECG’s are performed on the nursery service and sent digitally to the TCH electrophysiology lab. Turn-around time for the reports which are faxed to us is usually 24 hours. Holter scans are also done here and will be scheduled through our ECG lab here at BTGH. These scans are also sent to TCH electrophysiology with turn-around time of 48-72 hours.

Ophthalmology
For ROP screening guidelines, refer to Ch 1.1 General Care (Babies <1500 grams)

Notify Pediatric Ophthalmology upon the patient’s initial admission to the NICU by ordering the consult in EPIC. A book is kept once referral faxed with date of anticipated first exam, which are generally performed on Tuesdays.

Other Consultations
Other Consultations are called through TCH page operator.

Neurodevelopmental
Neurodevelopmental Follow up is available when needed for Harris Health patients at Pasadena Clinic twice a month or through the Meyers Center when referred by their PCP. We do not directly refer into the Desmond Neonatal High-Risk follow Up Clinic at TCH.

Transfer and Off-Service Notes
Every infant must have an off-service note or transfer note completed by the house officer at the appropriate times. When transferring a baby to TCH, please be sure to write the transfer note on a discharge note template in EPIC so it is recognized by my Health Information Management.

Discharge Planning
Texas Health Steps (THS) Newborn Follow up Clinic-Ben Taub
Criteria for patients referred to THS for early follow up
- All normal newborn (Level 1) infants should be encouraged to have their first early follow up appointment with Texas Health Steps (THS) clinic unless parents are unable to travel to Ben Taub. Ben Taub is now baby friendly and all mothers could really benefit from a post discharge lactation follow up at the breastfeeding clinic.

- Note that most other clinics do not have lactation consultants.

- Parking is free and validated for them.

- Mom will receive breastfeeding help with the lactation consultants.

- It is extremely difficult for the Newborn follow-up clinic to schedule an outpatient ECHO or referral, as it can take up to 1 hour of our nurses’ time, which makes managing patient load very difficult. So please do not send patients to clinic with a written plan of “ECHO (or other service or referrals) to be scheduled by THS for outpatient follow up.”

- If infant needs referral to another service for follow up after discharge, the referral and appointment must be made prior to discharge.

16.3 General Guidelines—TCH, WT and PFW NICUs
Triage of Admissions
The normal newborn transition is with mother in the Mother-Baby Unit (MBU). More complex infants are transitioned in the NICU. (Table 16–2).

Daily Routine
NICU rounds are made during morning hours. Residents who want to perform procedures or attend deliveries under the supervision of a member of the Neonatology Section are encouraged to do so during the afternoon and evening hours.
Schedule lab work, X rays, ultrasound exams, etc. for routinely scheduled times, unless a true emergency exists.

All procedures, including transfusions, should be accompanied by a note that includes indications and outcome.

At the time of discharge, all patients should have a final note that includes weight, FOC, hematocrit, newborn screen result, physician follow-up, discharge diet, and medications. Pertinent follow-up appointments also should be listed.

**Transfers from NICU to MBU**

For anticipated transfers to MBU, the resident is responsible for completing the following tasks (even if transfer is expected to occur after 5pm):

- Mother is an inpatient in the MBU or L&D and her discharge is not planned for the day of infant’s transfer.
- Identify the accepting MBU pediatrician
  - Options: Baylor newborn hospitalist, Kelsey-Seybold, or Private pediatrician
  - If unknown, ask the parents about follow-up pediatrician.
- Contact the accepting pediatrician to provide hand-off
  - Baylor: During daytime hours, use Voalte (“Pedi 1” or “Pedi 2”). After 4:30pm, page via SPOK (“PFW-Mother/Baby Units (NEO) on-call”)
  - Kelsey-Seybold: page the hospitalist 713-558-7645
  - Private pediatrician: contact their office
- Follow up any pending results (laboratory, radiology) and order AM labs if necessary.
- Complete Transfer note and include name of accepting physician
- Enter transfer orders in EPIC

**Transfer and Off-Service Notes**

Every infant must have an off-service note or transfer note completed by the house officer at the appropriate times.

**Texas Children’s Night Call Activities**

Night time patient care is provided by:
- Neonatology faculty and fellow
- Residents
- NNPs
- Transport Team

Night call activities involve transport and stabilization of new admissions, delivery room calls, ongoing management of patients, and response to patient emergencies in the nurseries. Preferentially, routine care, elective care, and patient transfers are done during daytime hours.

**Neurodevelopmental Follow-up**

High-Risk Developmental Follow-up Clinic

This multidisciplinary clinic provides longitudinal neurodevelopmental assessment of infants who weigh less than 1000 g at birth and all infants treated with extra-corporeal membrane oxygenation (ECMO). Clinic staff includes social work, PT/OT, neuropsychology, and neonatology. The timing of a clinic appointment is determined by the Developmental Care team and is based on risk factors for poor neurodevelopmental outcome.

**Table 16-2. Admission Criteria for Pavilion for Women MBU and NICU**

<table>
<thead>
<tr>
<th></th>
<th>MBU</th>
<th>NICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestation Age by Mother’s Dates</td>
<td>≥ 35 weeks</td>
<td>&lt; 35 weeks</td>
</tr>
<tr>
<td>Weight</td>
<td>≥ 2000 grams</td>
<td>&lt; 2000 grams</td>
</tr>
<tr>
<td>5-minute Apgar</td>
<td>≥ 7</td>
<td>&lt; 7</td>
</tr>
</tbody>
</table>

**Respiratory distress**

First 6 hours: suspected delayed transitioning without oxygen requirement, significant distress, hypoglycemia, or sepsis risk factors

Failed transition, significant distress, and/or oxygen requirement

**Suspected Sepsis**

Chorioamnionitis and asymptomatic infant requiring empiric antibiotics (amp and gent)

Symptomatic infant

**Neonatal Withdrawal Syndrome**

Comfort care patients

Neonatal abstinence scoring

**Congenital anomalies**

Minor anomalies that are non-life threatening (e.g. club foot, renal pyelectasis, DDH, ear tags)

Major anomalies
• In place of daily teaching bedside rounds, multidisciplinary rounds on all babies occur on Mondays and Thursdays at 11 am in the NICU conference room. All services are represented and each patient’s plan of care is reviewed.

• All Medical Center campus neonatology conferences and meetings are broadcast either by video or phone. Pediatric Grand rounds from 8.30 to 9.30 am is also broadcast on Friday.

• The Neonatologist and NNP are members of the house-wide code team and respond to all emergencies in the facility.

• TCH Woodlands has access to most subspecialists on campus. They can be reached via Spok. Unavailable is cardiac surgery, ECMO and neurosurgery.

• ROP screening exams are performed on Monday by the Ophthalmology team and the list is maintained and tracked in a process similar to TCH Main campus.

• There is a multispecialty developmental clinic on the outpatient campus. Disciplines participating in the clinic are nutrition, PO, OT, pulmonary and developmental pediatrics. A consult should be ordered prior to discharge to facilitate an initial developmental exam and introduction to the clinic. Follow up appointment to the clinic will be made at the time of discharge.
Section 17: Medications

Editors: Caraciolo Femandes and Mohan Pammi

17.1 Medication Dosing ..................................... 228
   Jennifer Placencia
   Emily Rodman

17.2 Managing Intravenous Infiltrations .......... 228
   Jennifer Placencia
   Emily Rodman

17.3 Common Antibiotics................................. 229
   Jennifer Placencia
   Emily Rodman
17.1 Medication Dosing
Usual dosing ranges of medications for newborns are detailed in Tables 17–1, 17-2, 17-3.

17.2 Managing Intravenous Infiltrations
(See Extravasation Guidelines – Texas Children’s Hospital Formulary)

Infiltration of intravenous (IV) fluids and medications can be associated with damage to the skin and underlying tissue. Hypertonic solutions, dopamine and calcium solutions, and blood may be especially caustic.

- Regular, close observation of the site by the staff helps identify this problem before it becomes serious.
- Secure peripheral IV lines with transparent tape or transparent polyurethane dressing so the insertion site is readily visible.
- Monitor peripheral IV site for any of the following: redness, blanching, edema, capillary refill greater than 3 seconds at the site, or difficulty irrigating the IV.
- Keep IV in place if aspiration is necessary or an antidote is required, else discontinue IV promptly
- Nurse to notify the physician after discontinuation of the peripheral IV if the site remains edematous, red, blanched, or dark in color.
- Elevate the involved extremity. If the site is on the scalp, elevate the head of the bed.
- If indicated in extravasation guidelines under the individual agent that has infiltrated, apply dry, cold or warm compresses. Do not apply heat, especially moist heat, to any IV fluid extravasation.
- Continued close assessment with frequent vital signs may be important.
- Plastic Surgery consultation may be indicated.

Hyaluronidase
Hyaluronidase is used to treat IV infiltration resulting from hypertonic solutions. It should not be used to treat extravasations secondary to dopamine, dobutamine, epinephrine or norepinephrine. Dilute 0.1 mL of hyaluronidase (200 units/mL) in 0.9 mL of normal saline for final concentration of 20 units/ml or order 5 single dose syringes from the pharmacy (20 units/mL). After skin preparation with providone-iodine and allowing the skin to dry for 1 minute, inject 0.2 mL (20 units/mL), subcutaneously or intradermally, into the leading edge of 5 separate extravasation sites with a 5- or 27-gauge needle. Needle should be changed after each 0.2 mL injection if injecting from a single syringe. Best results can be obtained if used within 1 hour of extravasation injury.

17.3 Common Antibiotics
Renal clearance in newborns is closely related to gestational age. Thus, elimination of antibiotics that are cleared by the kidney, as indicated by trough serum levels, is also related to postmenstrual age (PMA = gestational plus postnatal age). The recommendations in Table 17–1 provide general guidelines for selection of initial antibiotic doses and intervals based upon categories of postmenstrual age and body weight. Initial selected dose is designed to achieve serum levels effective against the spectrum of anticipated organisms. Interval of administration is intended to minimize risk of drug accumulation with possible toxicity. Antibiotic doses should be adjusted for weight gain on a weekly basis.

Serum Antibiotic Levels
Measurement of serum levels is necessary when treatment is anticipated for longer than 48 hours or if renal dysfunction is present. Peak and trough levels should be drawn before and after the third dose and a minimum of once weekly during therapy. Peak levels are obtained 30 minutes after the IV infusion is complete; a trough level is drawn immediately before the next dose. Both levels are necessary to determine safety and efficacy. Because aminoglycosides have potential for renal toxicity, measurement of BUN and creatinine and a urinalysis is recommended. For complicated or severe infections, a Pediatric Infectious Disease consultation is recommended.

There is a correlation between vancomycin serum trough levels and efficacy. Trough levels should be maintained between 10 and 20 depending on organism, MIC, source of infection, and other patient factors. For pediatric patients, vancomycin at an appropriate dose is not nephrotoxic when used alone. Vancomycin serum levels should be performed if one of the following criteria is met:

- Known or suspected renal dysfunction
- Patients in whom treatment is unsuccessful
- At the request of the Infectious Disease, Renal Service, or Clinical Pharmacy Specialist
### Table 17-1. Guidelines for initial antimicrobial doses and intervals

<table>
<thead>
<tr>
<th>Amoxicillin:</th>
<th>Nafcillin:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacteremia, Group B streptococcus (presumed or proven)/Early onset sepsis:</strong> IM, IV:</td>
<td><strong>Body weight 1-2 kg:</strong></td>
</tr>
<tr>
<td><strong>Note:</strong> Treatment of bacteremia without a defined focus should be for at least 10 days</td>
<td><strong>PNA ≤7 days:</strong> 25 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>Body weight ≤2 kg:</td>
<td><strong>PNA 8-28 days:</strong> 25 mg/kg every 8 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 100 mg/kg every 12 hrs</td>
<td><strong>Body weight &gt;2 kg:</strong></td>
</tr>
<tr>
<td>PNA 8-28 days: 50 mg/kg every 12 hrs</td>
<td><strong>PNA ≤7 days:</strong> 25 mg/kg every 8 hrs</td>
</tr>
<tr>
<td>Body weight &gt;2 kg:</td>
<td><strong>PNA 8-28 days:</strong> 25 mg/kg every 6 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 100 mg/kg every 12 hrs</td>
<td><strong>PNA &gt;28 days mild/mod:</strong> 100-150 mg/kg/DAY divided every 6 hrs</td>
</tr>
<tr>
<td>PNA 8-28 days: 50 mg/kg every 6 hrs</td>
<td><strong>PNA &gt;28 days severe:</strong> 150-200 mg/kg/DAY divided every 4-6 hrs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Meningitis, Group B streptococcal:</strong> IV:</th>
<th><strong>Meningitis:</strong> IV:</th>
</tr>
</thead>
<tbody>
<tr>
<td>PNA ≤7 days: 100 mg/kg every 8 hrs for 14 days</td>
<td><strong>PNA 0-7 days:</strong> 75 mg/kg/DAY divided every 8-12 hrs for 14-21 days</td>
</tr>
<tr>
<td>PNA &gt;7 days: 75 mg/kg every 6 hrs for 14 days</td>
<td><strong>PNA 8-28 days:</strong> 100-150 mg/kg/DAY divided every 6-8 hrs for 14-21 days</td>
</tr>
<tr>
<td>PNA &gt;28 days: 75 mg/kg every 6 hrs for 14 days</td>
<td><strong>PNA &gt;28 days:</strong> 200 mg/kg/DAY divided every 6 hrs for 14-21 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>General dosing, susceptible non-GBS infection:</strong> IM, IV:</th>
<th><strong>Penicillin GK:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight &lt;1 kg:</td>
<td><strong>General dosing, susceptible infection (non-CNS):</strong> IM, IV:</td>
</tr>
<tr>
<td>PNA ≤14 days: 50 mg/kg every 12 hrs</td>
<td><strong>Body weight &lt;1 kg:</strong></td>
</tr>
<tr>
<td>PNA 15-28 days: 50 mg/kg every 8 hrs</td>
<td><strong>PNA ≤14 days:</strong> 25,000-50,000 units/kg every 12 hrs</td>
</tr>
<tr>
<td>Body weight 1-2 kg:</td>
<td><strong>PNA 15-28 days:</strong> 25,000-50,000 units/kg every 8 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 50 mg/kg every 12 hrs</td>
<td><strong>PNA &gt;1 kg:</strong></td>
</tr>
<tr>
<td>PNA 8-28 days: 50 mg/kg every 8 hrs</td>
<td><strong>PNA ≤7 days:</strong> 25,000-50,000 units/kg every 12 hrs</td>
</tr>
<tr>
<td>Body weight &gt;2 kg:</td>
<td><strong>PNA 8-28 days:</strong> 25,000-50,000 units/kg every 8 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 50 mg/kg every 8 hrs</td>
<td><strong>PNA &gt;28 days mild/mod:</strong> 100,000-150,000 units/kg/DAY divided every 6 hrs</td>
</tr>
<tr>
<td>PNA 8-28 days: 50 mg/kg every 8 hrs</td>
<td><strong>PNA &gt;28 days severe:</strong> 200,000-300,000 units/kg/DAY divided every 4 hrs</td>
</tr>
<tr>
<td>PNA &gt;28 days mild/mod: 50-100 mg/kg/DAY divided every 6 hrs</td>
<td><strong>Meningitis, Group B streptococcal:</strong> IV:</td>
</tr>
<tr>
<td>PNA &gt;28 days severe: 100-150 mg/kg/DAY divided every 6 hrs</td>
<td><strong>PNA 0-7 days:</strong> 250,000-450,000 units/kg/DAY divided every 8 hrs</td>
</tr>
<tr>
<td><strong>Amoxicillin:</strong></td>
<td><strong>PNA 8-28 days:</strong> 450,000-500,000 units/kg/DAY divided every 6 hrs</td>
</tr>
<tr>
<td><strong>UTI prophylaxis (hydronephrosis, vesicoureteral reflux):</strong> IV: 25 mg/kg once daily</td>
<td><strong>PNA &gt;28 days:</strong> 450,000-500,000 units/kg/DAY divided every 6 hrs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ampicillin:</strong></th>
<th><strong>Vancomycin:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UTI prophylaxis (hydronephrosis, vesicoureteral reflux):</strong> PO: 10 to 15 mg/kg once daily</td>
<td><strong>Weight-based dosing:</strong> IV:</td>
</tr>
<tr>
<td><strong>Ceftazidime:</strong></td>
<td><strong>PNA ≤7 days:</strong></td>
</tr>
<tr>
<td><strong>General dosing, susceptible infection (non-CNS):</strong> IM, IV:</td>
<td>&lt;1,200 g: 15 mg/kg every 24 hrs</td>
</tr>
<tr>
<td>Body weight &lt;1 kg:</td>
<td>1,200 to 2,000 g: 10-15 mg/kg every 12-18 hrs</td>
</tr>
<tr>
<td>PNA ≤14 days: 50 mg/kg every 12 hrs</td>
<td>≥2,000 g: 10-15 mg/kg every 8-12 hrs</td>
</tr>
<tr>
<td>PNA 15-28 days: 50 mg/kg every 8-12 hrs</td>
<td><strong>PNA ≤7 days:</strong></td>
</tr>
<tr>
<td>Body weight 1-2 kg:</td>
<td>&lt;1,200 g: 15 mg/kg every 24 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 50 mg/kg every 12 hrs</td>
<td>1,200 to 2,000 g: 10-15 mg/kg every 8-12 hrs</td>
</tr>
<tr>
<td>PNA 8-28 days: 50 mg/kg every 8-12 hrs</td>
<td>&gt;2,000 g: 10-15 mg/kg every 6-8 hrs</td>
</tr>
<tr>
<td>Body weight &gt;2 kg:</td>
<td><strong>PNA &gt;28 days mild/mod:</strong> 40-45 mg/kg/DAY divided every 6-8 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 50 mg/kg every 12 hrs</td>
<td><strong>PNA &gt;28 days severe:</strong> 45-60 mg/kg/DAY divided every 6-8 hrs</td>
</tr>
<tr>
<td>PNA 8-28 days: 50 mg/kg every 12 hrs</td>
<td><strong>Meningitis:</strong> IV:</td>
</tr>
<tr>
<td>PNA &gt;28 days mild/mod: 90-150 mg/kg/DAY divided every 8 hrs</td>
<td><strong>PNA ≤7 days:</strong></td>
</tr>
<tr>
<td>PNA &gt;28 days severe: 200-300 mg/kg/DAY divided every 8 hrs</td>
<td><strong>&lt;9 kg:</strong> 12 mg/kg every 12 hrs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cildamycin:</strong></th>
<th><strong>HIV infection, treatment:</strong> Use in combination with other antiretroviral agents; standard neonatal doses may be excessive in premature infants; PO, IV:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General dosing, susceptible infection:</strong> IM, IV, PO:</td>
<td><strong>GA &lt;30 wks:</strong> 2 mg/kg increase to 9 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>Body weight &lt;1 kg:</td>
<td>at 4 wks of age increase to 3 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>PNA ≤14 days: 5 mg/kg every 12 hrs</td>
<td>at ≥8-10 wks of age increase to 12 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>PNA 15-28 days: 5 mg/kg every 8 hrs</td>
<td><strong>GA ≥30 &amp; &lt;35 wks:</strong> 2 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>Body weight 1-2 kg:</td>
<td>at PNA 15 days increase to 3 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 5 mg/kg every 12 hrs</td>
<td>at ≥6-8 wks of age increase to 12 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>PNA 8-28 days: 5 mg/kg every 8 hrs</td>
<td><strong>GA ≥35 wks:</strong> 4 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>Body weight &gt;2 kg:</td>
<td>at ≥4 wks of age increase to 12 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>PNA ≤7 days: 5 mg/kg every 8 hrs</td>
<td><strong>Weight-directed dosing:</strong> PO:</td>
</tr>
<tr>
<td>PNA 8-28 days: 5 mg/kg every 6 hrs</td>
<td>4-&lt;9 kg: 12 mg/kg every 12 hrs</td>
</tr>
<tr>
<td>PNA &gt;28 days mild/mod: 20 mg/kg/DAY divided every 8 hrs</td>
<td><strong>IV:</strong> Use IV route only until oral therapy can be administered</td>
</tr>
<tr>
<td>PNA &gt;28 days severe: 40 mg/kg/DAY divided every 8-12 hrs</td>
<td><strong>GA &lt;30 wks:</strong> 1.5 mg/kg at 4 wks of age increase to 2.3 mg/kg every 12 hrs</td>
</tr>
</tbody>
</table>

<p>| <strong>Gentamicin:</strong> | <strong>GA ≥30 &amp; &lt;35 wks:</strong> 1.5 mg/kg at ≥8-10 wks of age increase to 9 mg/kg every 12 hrs |
| Postmenstrual Age Based Dosing IM, IV: | <strong>GA ≥30 &amp; &lt;35 wks:</strong> 1.5 mg/kg at PNA 15 days increase to 2.3 mg/kg every 12 hrs |
| &lt;30 weeks: | at ≥6-8 wks of age increase to 9 mg/kg every 12 hrs |
| PNA ≤14 days: 5 mg/kg every 48 hrs | <strong>GA ≥30 wks:</strong> 3 mg/kg at ≥4 wks of age increase to 9 mg/kg every 12 hrs |
| PNA &gt;14 days: 5 mg/kg every 36 hrs | <strong>30-34 weeks:</strong> 5 mg/kg every 24 hrs |
| PNA ≤14 days: 5 mg/kg every 48 hrs | <strong>35-43 weeks:</strong> 4 mg/kg every 24 hrs |
| PNA &gt;14 days: 5 mg/kg every 36 hrs | <strong>≥ 44 weeks:</strong> 2.5 mg/kg every 8 hrs |</p>
<table>
<thead>
<tr>
<th>Emergency Medications</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adenosine (3 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>Initial:</strong> 0.1 mg/kg If not effective within 2 minutes, give 0.2 mg/kg</td>
<td><strong>Rapid IV push over 1-2 seconds; flush with saline before and after</strong></td>
<td><strong>Administer in a central catheter or at a peripheral IV site as proximal to trunk as possible (i.e. not in lower arm, hand, lower leg, or foot).</strong></td>
</tr>
<tr>
<td><strong>Albumin 5%</strong></td>
<td><strong>IV:</strong></td>
<td><strong>10-20 mL/kg per dose</strong></td>
<td><strong>Over 2-4 hours</strong></td>
<td><strong>For volume repletion only. For albumin replacement, use albumin 25%</strong></td>
</tr>
<tr>
<td><strong>Calcium chloride 10% (100 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>20 mg/kg per dose</strong></td>
<td><strong>Give as IV push over 3-5 minutes</strong></td>
<td><strong>Hyperkalemia, cardiac arrest with hypocalcemia. Do not give in line with phosphate-containing fluids.</strong></td>
</tr>
<tr>
<td><strong>Calcium gluconate (100 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>100 mg/kg per dose</strong></td>
<td><strong>Give as slow IV push over 5-10 minutes</strong></td>
<td><strong>Do not give through line with phosphate-containing fluids.</strong></td>
</tr>
<tr>
<td><strong>Cardioversion (synchronized)</strong></td>
<td><strong>0.5 to 1 J/kg initially; If not effective, increase to 2 J/kg.</strong></td>
<td><strong>Sedate if possible, but do not delay cardioversion.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dextrose 10%</strong></td>
<td><strong>IV:</strong></td>
<td><strong>10 mL/kg per dose</strong></td>
<td><strong>Hyperkalemia 4 mL/kg with 0.1 units/kg regular insulin</strong></td>
<td><strong>For hypoglycemia and hyperkalemia.</strong></td>
</tr>
<tr>
<td><strong>Epinephrine (0.1 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>0.01-0.03 mg/kg (0.1-0.3 mL/kg) per dose</strong></td>
<td><strong>IV push Follow with 5 manual breaths for ET admin</strong></td>
<td><strong>Maximum 0.1 mg (1 mL). Repeat every 3-5 minutes for pulseless arrest, PEA, asystole, bradycardia.</strong></td>
</tr>
<tr>
<td><strong>Fentanyl (5 mcg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>1 mcg/kg per dose</strong></td>
<td><strong>Rapid IV push over 1 minute Follow with 5 manual breaths for ET admin</strong></td>
<td><strong>Consider for pulseless VT/VF. Not for SVT.</strong></td>
</tr>
<tr>
<td><strong>Lidocaine (10 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>1 mg/kg per dose</strong></td>
<td><strong>Rapid IV push over 1 minute Follow with 5 manual breaths for ET admin</strong></td>
<td><strong>Consider for pulseless VT/VF. Not for SVT.</strong></td>
</tr>
<tr>
<td><strong>Naloxone (0.4 mg/mL)</strong></td>
<td><strong>IV, IM:</strong></td>
<td><strong>0.1 mg/kg per dose; repeat every 2-3 minutes if needed</strong></td>
<td><strong>IV push over 30 seconds Follow with 5 manual breaths for ET admin</strong></td>
<td><strong>All pain relief will also be reversed. May precipitate withdrawal.</strong></td>
</tr>
<tr>
<td><strong>Sodium bicarbonate 4.2% (0.5 mEq/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>2 mEq/kg per dose</strong></td>
<td><strong>IV push over 2 minutes</strong></td>
<td><strong>Use in code situations is discouraged. May lead to IVH and worsen intracellular acidosis.</strong></td>
</tr>
<tr>
<td><strong>Intubation Medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Atropine (0.1 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>0.02 mg/kg per dose</strong></td>
<td><strong>Rapid IV push</strong></td>
<td><strong>No minimum dose.</strong></td>
</tr>
<tr>
<td><strong>Fentanyl (5 mcg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>1-2 mcg/kg per dose</strong></td>
<td><strong>Administer over 5 minutes if no paralytic is used</strong></td>
<td><strong>Analgesia should be used prior to intubation. To make fentanyl 5 mcg/mL concentration: Draw 1 mL fentanyl 50 mcg/mL and dilute with 9 mL NS. For intranasal: NO atomizer is used, give half of total dose in each nostril. Use 50 mcg/mL concentration.</strong></td>
</tr>
<tr>
<td><strong>Vecuronium (1 mg/mL)</strong></td>
<td><strong>IV:</strong></td>
<td><strong>0.08-0.1 mg/kg per dose</strong></td>
<td><strong>Rapid IV push</strong></td>
<td><strong>Preparation: 10 mL saline added to 10 mg vial to make 1 mg/mL</strong></td>
</tr>
<tr>
<td><strong>Continuous Infusions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alprostadil (5 mcg/mL)</strong></td>
<td><strong>IV continuous infusion:</strong></td>
<td><strong>0.0125-0.1 mcg/kg/min</strong></td>
<td><strong>Titrate to effect</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Dopamine (1.6 mg/mL)</strong></td>
<td><strong>IV continuous infusion:</strong></td>
<td><strong>2.5-20 mcg/kg/min</strong></td>
<td><strong>Preparation: Dilute to 5 mL of 3.2 mg/mL concentration dopamine in 5 mL of D5W</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Epinephrine (0.05 mg/mL)</strong></td>
<td><strong>IV continuous infusion:</strong></td>
<td><strong>0.01-1 mcg/kg/min</strong></td>
<td><strong>Preparation: Dilute 0.5 mL of 1 mg/mL epinephrine in 10 mL of D5W</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Phenylephrine (0.1 mg/mL)</strong></td>
<td><strong>IV continuous infusion:</strong></td>
<td><strong>0.1-0.5 mcg/kg/min</strong></td>
<td><strong>Preparation: Dilute 0.1 mL of 10 mg/mL phenylephrine in 9.9 mL NS</strong></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Dose</td>
<td>Infusion Time</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Sedation/Pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fentanyl</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>1-2 mcg/kg per dose</td>
<td>Run bolus on pump over 5 minutes</td>
<td>Tolerance may occur within 3-5 days. More sedative properties than morphine. Preferred opioid in patients with renal dysfunction.</td>
<td></td>
</tr>
<tr>
<td>IV continuous infusion: Initial IV bolus: 1-2 mcg/kg, then start at 0.5-1 mcg/kg per hour; titrate by 1 mcg/kg/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lorazepam</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV, anxiety and sedation: 0.05 mg/kg per dose (range 0.02-0.1 mg/kg) every 4-8 hrs</td>
<td></td>
<td></td>
<td>Injection contains 2% benzyl alcohol, polyethylene glycol, and propylene glycol, which may be toxic to newborns in high doses. Avoid benzodiazepine use in patients &lt; 44 weeks PMA due to neurodegenerative properties.</td>
<td></td>
</tr>
<tr>
<td>IV, status epilepticus: 0.1 mg/kg per dose; may repeat in 10-15 min.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Midazolam</strong></td>
<td></td>
<td>Run bolus on pump over 5 minutes</td>
<td>Avoid benzodiazepine use in patients &lt; 44 weeks PMA due to neurodegenerative properties.</td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>0.05-0.15 mg/kg per dose every 2-4 hours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV continuous infusion:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 32 weeks PMA: 0.03 mg/kg/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 32 weeks PMA: 0.06 mg/kg/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titrate by 0.01 mg/kg/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Morphine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV/IM/SQ:</td>
<td>0.05-0.1 mg/kg per dose every 4-8 hours</td>
<td></td>
<td>Tolerance may occur within 5-7 days. Avoid in patients with renal dysfunction.</td>
<td></td>
</tr>
<tr>
<td>IV continuous infusion: Initial IV bolus: 0.05-0.1 mg/kg, then start 0.01 mg/kg/hr, titrate by 0.01 mg/kg/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cosyntropin Low Dose Stim Test</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>1 mcg once</td>
<td>IV push</td>
<td>Check cortisol levels before the dose and at 30 minutes and 60 minutes after the dose.</td>
<td></td>
</tr>
<tr>
<td><strong>Ibuprofen lysine</strong></td>
<td></td>
<td>Infuse on pump over 15 minutes</td>
<td>For treatment of PDA. Preferred over indomethacin due to lower incidence of nephrotoxicity.</td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>10 mg/kg once, then 5 mg/kg q 24 for 2 doses (Base doses on birth weight)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Indomethacin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>0.1 mg/kg every 24 hours for 3 doses (Base doses on birth weight).</td>
<td>Infuse on pump over 15 minutes</td>
<td>For IVH prophylaxis in neonates ≤ 26 6/7 weeks gestation or &lt;800 grams birth weight. Start within 12 hours of birth.</td>
<td></td>
</tr>
<tr>
<td><strong>Levetiracetam</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>20-40 mcg/kg given intravenously at a rate of 2-5 mcg/kg/minute</td>
<td>See neurology chapter for more details on levetiracetam use in status epilepticus.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV, PO, maintenance dose: 10 mg/kg/DAY divided three times daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Milrinone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>0.375-0.75 mcg/kg per min as a continuous infusion; titrate dose to effect.</td>
<td></td>
<td>Loading doses may cause significant hypotension. Avoid in severe obstructive aortic or pulmonic valvular disease.</td>
<td></td>
</tr>
<tr>
<td><strong>Phenobarbital</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV, loading dose:</td>
<td>20 mg/kg loading dose, then 10 mg/kg per dose at 20-minute intervals until the seizure is controlled or a total dose of 40 mg/kg is reached.</td>
<td>Assess serum concentrations. Goal maintenance level 20-40 mcg/mL.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV, PO, maintenance dose: 3-4 mg/kg/DAY once daily; increase to 5 mg/kg/DAY if needed (usually by second week of therapy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ursodiol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO:</td>
<td>30-45 mg/kg per day given in 2-3 divided doses</td>
<td></td>
<td>For use in cholestasis. Suspension is compounded. Please allow time for outpatient prescription planning before discharge.</td>
<td></td>
</tr>
<tr>
<td><strong>Vecuronium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV:</td>
<td>0.1 mg/kg per dose every 1-2 hours as needed; maintenance: 0.03-0.15 mg/kg per dose</td>
<td>Half-life prolonged in hepatic disease. Caution should be used as duration of effect may be prolonged in these patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV, continuous infusion: 0.06-0.09 mg/kg per hour</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1-1. Admission labs, 3

Table 1-2. Labs during early hospitalization, days 1 to 3, 3

Table 2-1a. Calculation of effective FiO2, Step 1, 16

Table 2-1b. Calculation of effective FiO2, Step 2, 16

Table 2-2. Ventilator manipulations to effect changes in PaO2 and PaCO2, 20

Table 2-3. Assessing Readiness for extubation, 20

Table 2-4. Useful respiratory equations, 22

Table 2-5. Definition of BPD, 24

Table 2-6. Comparison of ventilator strategies and goals during progression of early disease to established BPD, 27

Table 3-1. Considerations for improving oxygen transport balance, 41

Table 3-2. Interpretations of oxygen extraction ratio (OER), 41

Table 3-3. Interventions to alter SVR and PVR, 42

Table 3-4. Blood pressure thresholds (3rd percentile) according to post conceptual age in preterm infants, 44

Table 3-5. Blood pressure thresholds according to postnatal age in healthy term neonates, 44

Table 3-6. Common factors contributing to systolic hypotension, 44

Table 3-7. Common factors contributing to diastolic hypotension, 44

Table 3-8. Differential diagnosis of cardiac lesions based on symptoms, 51

Table 4-1. Sources of heat loss in infants, 63

Table 4-2. Neutral thermal environmental temperatures: Suggested starting incubator air temperatures for clinical approximation of a neutral thermal environment, 65

Table 5-1. Metabolic disorders, chromosomal abnormalities, and syndromes associated with nonimmune fetal hydrops, 80

Table 6-1. Newborn Screening Program in Texas, 84

Table 6-2. Differential diagnosis of bleeding in the neonate, 88

Table 7-1. Causes of neonatal thrombocytopenia, 89

Table 7-2. Guidelines for PRBC transfusion, 91

Table 7-3. Risk factors for severe hyperbilirubinemia, 93

Table 7-4. Hyperbilirubinemia: Age at discharge and follow-up, 94

Table 7-5. Guidelines for management of hyperbilirubinemia in low birth weight infants, 95

Table 7-6. Causes of neonatal polycythemia, 97

Table 7-7. Three step DVT panel, 99

Table 7-8. Risk stratification, 101

Table 7-9. Heparin for line patency, 101

Table 7-10. Enoxaparin dosage and titration, 101

Table 7-11. Heparin dosage and titration, 102

Table 8-1. Treponema and non-treponema serologic tests in infant and mother, 116

Table 8-2. Modified Sarnat criteria for defining encephalopathy, 122

Table 8-3. Most common etiologies of neonatal seizures, 125

Table 8-4. Onset, duration and frequency of NAS caused by various substances, 130

Table 8-5. Neonatal abstinence scoring system, 131

Table 8-6. Suggested management of procedural pain in neonates at BCM affiliated hospital NICUs, 133

Table 9-1. Suggested management of procedural pain in infant and mother, 116

Table 9-2. Most common etiologies of neonatal seizures, 125

Table 9-3. Onset, duration and frequency of NAS caused by various substances, 130

Table 9-4. Neonatal abstinence scoring system, 131

Table 9-5. Suggested management of procedural pain in neonates at BCM affiliated hospital NICUs, 133

Table 9-6. Bicetre neonatal evaluation score, 135

Table 10-1. Features of extracranial swelling, 143

Table 10-2. Tongue range of motion, 144

Table 10-3. Expressed breastmilk storage, 146

Table 10-4. Risk for developmental dysplasia of the hip, 148

Table 10-5. Normal APRPD values, 151

Table 11-1. Replacement fluids for replogle and ostomy output, 158

Table 11-2. Laboratory investigations, 159

Table 11-3. Parenteral nutrient goals, 164

Table 12-1. PN calculations, 164

Table 12-2. PIPP scale, 170

Table 12-3. Conversion factors for minerals, 164

Table 12-4. Early neonatal solutions (0 to 48 hours of age), 165

Table 12-5a. Components of standard central parenteral nutrition (PN) for premature infants, 165

Table 12-5b-5c. ASPEN recommendations for vitamins, 166

Table 12-6a-6b. Volume restricted TPN for ECMO – 70 mL/kg + 15mL fat (3 grams)/kg, 167

Table 12-7a. Suggested feeding schedules, 168

Table 12-7b. BW ≤ 750 grams feeding guidelines, 169

Table 12-7c. BW 751-1250 grams feeding guidelines, 170

Table 12-7d. BW 1251-1500 grams feeding guidelines, 170

Table 12-7e. BW 1501-2000 grams feeding guidelines, 171

Table 12-8. Milk selection, 171

Table 12-9. Indications for human milk and infant formula usage in high-risk neonates, 172

Table 12-10a. Nutritional components of human milk and fortified human milk, 173

Table 12-10b-10c. Nutritional components of commercial formula, 174

Table 12-11. Suggested Prolacta concentration when using Prolacta cream according to feeding volume, 171

Table 12-12. Enteral Vitamin and mineral supplementation, 176

Table 12-13. Growth rate guidelines, 178

Table 12-14. Suggested lab table, 179

Table 13-1. Fluid (H2O) loss (mL/kg per day) in standard incubators, 188

Table 13-2. Suggested total fluid requirements (mL/kg per day), 188

Table 14-1. Central line radiographic landmarks, 196

Table 15-1. Cries scale, 207

Table 15-2. PIPP scale, 207

Table 15-3. N-PASS: Neonatal pain, agitation and sedation scale, 208

Table 15-4. Pharmacologic management for neonatal end of life care, 209

Table 16-1. Triaging babies for transitioning, 222

Table 16-2. Admission criteria for Pavilion for Women MBU & NICU, 224

Table 17-1. Guidelines for initial antimicrobial doses and intervals, 229

Table 17-2. Medication administration chart, 230

Table 17-3. Medication administration chart, continued, 231
Figures

Figure 1-1. Double-lumen system, 5
Figure 1-2. Suggested catheter tip placement; anatomy of the great arteries and veins, 6
Figure 2-1. The ventilation correction steps, 10
Figure 2-2. Algorithm for weaning CPAP, HFNC and LFNC, 18
Figure 3-1. Distribution of blood flow as percentage of combined fetal cardiac output, 40
Figure 3-2. Relationship between oxygen delivery and consumption, 41
Figure 3-3. Relationship of CO and EDV, 42
Figure 3-4. Relationship of LV Pressure and ESV, 42
Figure 3-5. Algorithm for assessment and treatment of hypotension according to systolic, diastolic, and combined systolic and diastolic categories, 46
Figure 4-1. Effects of environmental temperature on oxygen consumption and body temperature, 64
Figure 5-1. Management of infant with suspected DSD, 68
Figure 5-2. Pathways of adrenal hormone synthesis, 69
Figure 5-3. Diagnostic approach to atypical genitalia, 70
Figure 5-4. Screening for and management of postnatal glucose homeostasis, 73
Figure 5-5. Persistent hypoglycemia evaluation flow diagram, 75
Figure 5-6. Persistent hypoglycemic diagnostic categories, 75
Figure 6-1. Presentations of metabolic disorders, 79
Figure 7-1. Guidelines for platelet transfusion in the newborn, 90
Figure 7-2. Nomogram for designation of risk based on the hour-specific serum bilirubin values, 94
Figure 7-3. Guidelines for phototherapy in hospitalized infants of 35 or more weeks’ gestation, 95
Figure 7-4. Guidelines for exchange transfusion in infants 35 or more weeks’ gestation, 96
Figure 7-5. Algorithm for management of neonatal polycythemia, 98
Figure 7-6. Clinical algorithm for neonatal thrombus, 100
Figure 8-1. Late-onset Sepsis in Newborn Center Patients, Level 2 and 3, 106
Figure 8-2. Incidence of early- and late-onset group B streptococcus, 107
Figure 8-3. Indications and no indications for intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcus, 108
Figure 8-4. Algorithm for secondary prevention of early-onset group B streptococcal (GBS) disease among newborns, 108
Figure 8-5. Algorithm for screening for group B streptococcal (GBS) colonization and use of intrapartum prophylaxis for women with preterm labor (PTL), 109
Figure 8-6. Algorithm for screening for group B streptococcal (GBS) colonization and use of intrapartum prophylaxis for women with preterm premature rupture of membrane (pPROM), 109
Figure 8-7. Recommended regimens for intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal (GBS) disease premature rupture of membrane (pPROM), 110
Figure 8-8. Time course of acute hepatitis B at term and chronic neonatal infection, 111
Figure 8-9. Algorithm for evaluation of positive maternal RPR, 116
Figure 10-1. Newborn screening algorithm for critical congenital heart disease, 150
Figure 12-1. Feeding tolerance algorithm, 168
Figure 12-2. Flow diagram to guide radiographic evaluation for rickets, 179
Figure 12-3. Risk approach for assessing oral feedings, 179
Figure 12-4. My feeding care map, 181
Figure 12-5a. Fenton preterm growth chart - girls, 184
Figure 12-5b. Fenton preterm growth chart - boys, 185
Figure 15-1. Complimentary and concurrent components to care, 206
Figure 15-2. Algorithm for PPACT consult, 207
Anomalies, 19, 34-35, 37, 53-54, 57, 107

Anhydrosis, 56-57, 107

Antibiotics, 2, 45, 82-83, 122, 124-125, 159, 164-166, 169, 172, 188

Anemia, 3, 27, 48, 50, 78, 91, 118, 122, 125, 159, 164-166, 169, 172, 188

Anorectal malformation, 151

Anosmia, 69

Anomalies, 19, 34-35, 37, 53-54, 70, 81-82, 85, 97, 105, 118, 122, 125, 128-129, 139, 142, 148, 151-153, 179, 190, 197-202, 206, 209, 222, 224

Ankylosis, 144

Antibiotics, 2, 45, 82, 104-105, 107, 124, 138, 156, 191, 195, 198-199, 201, 222, 224, 227-228

Anticonvulsants, 89, 126, 136

Ascites, 81, 98-99, 161, 201-202

Asphyxia, 45, 47-48, 55, 64, 88-89, 95-97, 99, 126, 142, 190

Atresia, 42, 43, 51, 93, 102, 150-151, 157-159, 161, 197-199, 201

Atropine, 13, 18, 229-230

Autopsy, 213-215, 217

β-blockers, 50, 56-57, 107

Bacterial infection, 104-105

Bathing, 40, 60, 63, 138

Ben Taub General Hospital, 150, 158, 206, 211, 215-214, 221-222

Benign neonatal hematosiderosis, 150

Benign neonatal hematomas, 150

Bilateral hydrocephalus, 150

Biliary atresia, 42, 43, 51, 93, 102, 150-151, 157-159, 161, 197-199, 201


Breast milk (see human milk), Drug-exposed infants, 132

Low birth weight infants, 171-172, 180

Bronchopulmonary Dysplasia (BPD), 3-4, 10, 16-17, 24, 27-28, 30, 32

Bronchopulmonary Sequestration (BPS), 44, 196

Caffeine, 2, 10-111, 13, 30, 31

Caffeine citrate, 2, 4, 13

Calcaneal valgus, 149

Calcium, 26, 28, 52, 96-97, 122, 124-125, 142, 164-167, 178-179, 182, 189-192, 228-230

Candidiasis, 107, 109-110, 119

Cannulae, 15, 198

Captopril, 50-52, 189

Caput succedaneum, 143

Cardiac disease, 42, 43, 50, 53-54, 81, 97, 99, 177

Cardiogenic shock, 44, 47

Cardioversion, 57, 230

Carnitine, 74, 79, 80-84, 167

Catheters, 4-6, 34, 53, 84, 99, 101, 110, 168, 188, 195-196, 203, 213, 221

Umbilical venous (see UVC),

Cataracts, 81

Care, routine, 31, 60, 138, 224

Central respiratory drive, 11-12

Central venous access, 34, 54, 73, 123, 195, 203

Cephalohematoma, 88, 93, 127, 142-143

Cerebral hemorrhage and infarction, 126, 136

Child Protective Services, 210-211

Chloride, 28, 69, 159, 164-165, 173-174 189-190, 230

Chlorothiazide, 28

Cholestasis, 93, 158-161, 166-167, 179

Chromosomal abnormalities, 80, 85, 89, 128

Chromosomal Microarray (CMA), 70, 85-86

Chronic Lung Disease (see BPD)

Chylothorax, 56, 172, 176, 196-197


Fetal, 40

Transitional, 40, 140

Circumcision, 88, 138, 146, 152

Citrulline, 81, 84

Clavicle, 19, 147, 195-196

Clinical ethics committee, 211, 214

Cloacal exstrophy, 202

Club feet (Talipes Equinovarus), 149

Coagulation disorders, 88-89

Comfort care, 140, 209-214, 216-217, 214, 216, 224

Congenital Cystic Adenomatoid Malformation (CCAM), 196-197

Congenital Diaphragmatic Hernia (CDH), 4, 7, 14, 19, 21-23, 33-37, 45, 197

Congenital heart disease (CHD), 5, 17, 24, 29, 40, 42-44, 49-50, 57-58, 80, 84, 101, 122-123, 128, 146, 150-151, 164, 171, 175, 197

Congenital Lobar Emphysema (CLE), 197-198

Congenital malformations, 151

Congestion, 4, 23, 40, 47, 52, 208

Consultations, 139, 143, 159, 180, 206, 220, 222-223

Lactation, 143

Social work, 139

Palliative care, 206
<table>
<thead>
<tr>
<th>Index</th>
<th>Section of Neonatology, Department of Pediatrics, Baylor College of Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E</strong></td>
<td>Ductal-dependent lesions, 53, 55</td>
</tr>
<tr>
<td></td>
<td>Echocardiogram, 34, 45, 55-56,</td>
</tr>
<tr>
<td></td>
<td>109, 122, 135, 140, ECMA, 3-5,</td>
</tr>
<tr>
<td></td>
<td>14, 22, 33-27, 45, 47, 49, 61, 92, 100-102, 114, 150, 167, 198, 221,</td>
</tr>
<tr>
<td></td>
<td>224-225 Electrolyte therapy, 169-170, 172, 188</td>
</tr>
<tr>
<td></td>
<td>Erythema toxicum, 142</td>
</tr>
<tr>
<td></td>
<td>Esophageal atresia, 161, 198</td>
</tr>
<tr>
<td></td>
<td>Eye prophyaxis, 2, 110, 138, 213</td>
</tr>
<tr>
<td></td>
<td>Erythropoietin, 91</td>
</tr>
<tr>
<td></td>
<td>Exchange transfusion, 4-5, 48,</td>
</tr>
<tr>
<td></td>
<td>91, 94-98, 150, 190, 194</td>
</tr>
<tr>
<td></td>
<td>Extracorporeal Life Support (ECLS), 198-199</td>
</tr>
<tr>
<td></td>
<td>Extracranial swelling, 142-143</td>
</tr>
<tr>
<td><strong>F</strong></td>
<td>Facial nerve palsy, 147-148</td>
</tr>
<tr>
<td></td>
<td>Fat necrosis, 142</td>
</tr>
<tr>
<td></td>
<td>Fat-soluble vitamins, 159, 176</td>
</tr>
<tr>
<td></td>
<td>Fatty acid, 64, 71-72, 74, 76, 78-82, 84, 92, 149-150, 160-161, 166-167,</td>
</tr>
<tr>
<td></td>
<td>176, 197 Fatty acid oxidation, 74, 78-82, 84, 150</td>
</tr>
<tr>
<td></td>
<td>Feeding formula, Bottle feeding, 93, 145-146, 180-181</td>
</tr>
<tr>
<td></td>
<td>Oral feeding, 54, 62, 66, 73, 157, 173, 175, 179, 180-183 Tube feeding,</td>
</tr>
<tr>
<td></td>
<td>145, 175, 177, 179-180</td>
</tr>
<tr>
<td></td>
<td>Femur, 147-148, 196</td>
</tr>
<tr>
<td></td>
<td>Fentanyl, 18, 36 133-134, 208-209, 214, 227, 230, 231</td>
</tr>
<tr>
<td><strong>G</strong></td>
<td>Fetal circulation, 40</td>
</tr>
<tr>
<td></td>
<td>Fetal hydrops, 78, 80, 203, 231</td>
</tr>
<tr>
<td></td>
<td>Fluid therapy, 188</td>
</tr>
<tr>
<td></td>
<td>Follow-up clinic, 2, 147, 223-224</td>
</tr>
<tr>
<td></td>
<td>Fractures, 142, 147</td>
</tr>
<tr>
<td></td>
<td>Funeral homes, 216</td>
</tr>
<tr>
<td></td>
<td>Fungal infection (Candida), 105, 109-110, 113, 119, 123, 139, 156</td>
</tr>
<tr>
<td></td>
<td>Furosemide, 28, 50-52, 190</td>
</tr>
<tr>
<td><strong>H</strong></td>
<td>Head trauma, 128</td>
</tr>
<tr>
<td></td>
<td>Hearing screening, 2-3, 27, 31, 84, 142, 150</td>
</tr>
<tr>
<td></td>
<td>Hemodialysis, 78, 83, 84</td>
</tr>
<tr>
<td></td>
<td>Hemorrhage, 23, 44, 48, 71, 74, 83, 88-90, 92, 97, 122, 125-127, 136,</td>
</tr>
<tr>
<td></td>
<td>142, 196</td>
</tr>
<tr>
<td></td>
<td>Hepatitis, 2, 35, 78-79, 93, 110-111, 117, 119, 128, 130, 140, 143, 158-</td>
</tr>
<tr>
<td></td>
<td>160, Hepatitis B, 110-111, 119, 130, 140, 234</td>
</tr>
<tr>
<td></td>
<td>Hepatitis C, 111, 130</td>
</tr>
<tr>
<td></td>
<td>atric, 33, 127, 161, 197</td>
</tr>
<tr>
<td></td>
<td>Inguinal, 200</td>
</tr>
<tr>
<td></td>
<td>Herpes Simplex Virus (HSV), 112-113, 147, 222</td>
</tr>
<tr>
<td></td>
<td>High-frequency Oscillatory Ventilation (HFOV), 19, 22-23, 34-35</td>
</tr>
<tr>
<td></td>
<td>Hirschsprung Disease (HD), 194, 199-201</td>
</tr>
<tr>
<td></td>
<td>Home ventilation, 31-32</td>
</tr>
<tr>
<td></td>
<td>Hormonal tests, 70</td>
</tr>
<tr>
<td></td>
<td>Hospice, 209, 215</td>
</tr>
<tr>
<td></td>
<td>Hospital discharge, 2-3, 95, 111, 140, 146-147, 150-151, 152, 191,</td>
</tr>
<tr>
<td></td>
<td>223</td>
</tr>
<tr>
<td></td>
<td>Human Immunodeficiency Virus (HIV), 2, 111, 113, 115-116, 119, 130, 132,</td>
</tr>
<tr>
<td></td>
<td>145, 151-152, 168-169, 170, 172, 229 TCH donor human milk protocol, 171</td>
</tr>
<tr>
<td></td>
<td>Human Milk, 26, 30, 54, 73, 144-145, 153, 156-157, 159, 161, 164-169,</td>
</tr>
<tr>
<td></td>
<td>170, 172, 229</td>
</tr>
<tr>
<td></td>
<td>Hylauronidase, 228</td>
</tr>
<tr>
<td></td>
<td>Hydroceles, 153, 201</td>
</tr>
<tr>
<td></td>
<td>Hydrocortisone, 29, 34, 48, 69, 72, 156</td>
</tr>
<tr>
<td></td>
<td>Hydronephrosis, 151, 153, 229</td>
</tr>
<tr>
<td></td>
<td>Hydrops, 78, 80, 196-197, 202-203, 233</td>
</tr>
<tr>
<td></td>
<td>Hyperammonemia, 78-80, 82-84, 122</td>
</tr>
<tr>
<td></td>
<td>Hyperbilirubinemia, 69, 71-92-95, 97, 101, 110, 142, 146-147, 150, 157-</td>
</tr>
<tr>
<td></td>
<td>161, 223</td>
</tr>
<tr>
<td></td>
<td>Hypercalcemia, 102, 142, 152, 166, 169, 172, 178, 190-192</td>
</tr>
</tbody>
</table>
Hyperglycemia, 48-49, 76, 189, 191
Hyperkalemia, 50, 56-57, 68, 71, 142, 156, 189-190, 192, 230
Hyperphosphatemia, 172, 178, 190, 192
Hypertrophic, 141
Hypopharynx, 12
Hypovolemic shock, 48, 91
Hypoxic respiratory failure, 14, 30, 35, 45, 49
Hypoxic-ischemic encephalopathy, 44, 122-126, 135-136, 148-149
Ibuprofen, 55-56, 168, 227, 230-231
Immunizations (see vaccines)
Imperforate anus, 194, 200, 202
Inborn errors, 73-74, 78, 86, 93, 122, 125, 147, 149-150
Incubators, 13, 56, 62-66, 73, 150, 188, 233
Indomethacin, 2, 4, 48, 55-56, 89, 156, 168, 231
Infant of Diabetic Mother (IDM), 73, 76, 150-151, 179, 188, 190
Inhaled medications, 28
Inhaled Nitric Oxide (iNO), 33, 45, 49
Intensive phototherapy, 94-96
Intestinal atresia, 197, 199, 201, 157
Intestinal failure and rehabilitation, 157, 158, 161, 167, 169, 174-175, 177, 181-182
Intravenous immune globulin, 95, 117
Intravenous Lipid (IL), 160, 161, 164-165, 166, 178
Jaundice, 81, 83, 88, 91-95, 97, 104, 107, 146-147, 158
Jitteriness, 73, 124-125, 149, 190
Karyotype, 68-69, 85
Ketogenesis, 74
Klumpke palsy, 147
Lactase, 138, 143-144, 171, 177, 180-181, 223
Lactic acid, 41, 43, 47, 78-79, 81-82, 156, 158, 192
Lansoprazole (Prevacid), 162, 195, 12
Larynx, 12
Lidocaine, 152, 230, 164, 167-172, 190, 233
Liver Disease, 81, 88, 157-162, 166, 178
Macrosomia, 147
Malformations, congenital, 151
Malrotation, 156-157, 199, 201
Manganese, 159, 167
Mechanical ventilation, 14-15, 18-32, 35, 37, 45, 47, 49, 55, 91, 99, 148
Meconium ileus (MI), 83, 201-202
Meconium, 11, 13-14, 17-18, 22-23, 35, 130, 139, 144, 156, 199-202, 222
Medical examiner, 215
Medication orders, 2
Inhaled medications, 28
Intravenous therapy, 115, 190
Meningitis, 3, 104-105, 107, 110, 119, 122, 125, 141, 150, 191, 228-229
Meningomyelocele (see neural tube defect), 128-129
Metabolic disorders, 50, 78-80, 86, 89, 93, 124, 159, 161, 189-190, 233-234
Metatarsus adductus, 148, 149
Methadone, 129, 132, 134
Metoclopramide (Reglan), 162
Human milk, 26, 54, 73, 144-145, 156-157, 159, 161, 164, 167-172, 190, 233
Midazolam, 37, 44, 208-209, 231
Midgut volvulus, 201
Milrinone, 34, 45, 47, 49, 56, 227
Minerals, 26, 159, 164-167, 172, 182, 201, 233
Mongolian spots, 141
MSUD, 80, 82-84
Murmurs, 43, 51, 140, 159
Muscle biopsy, 82
Nails, 139
Narcotics, 53, 208-209, 214
Nasal cannula, 15-18
Nasal CPAP, 4, 14-15, 31, 34, 180
Naloxone, 18, 230
Necrotizing Enterocolitis (NEC), 5-6, 21, 44, 54-55, 72, 88-89, 91, 97, 105, 127, 156-157, 159, 161, 168, 171, 177, 194-195
Neonatal Alloimmune Thrombocytopenia (NAIT), 89-90, 92
Neonatal hemostatic system, 88
Neural Tube Defects (NTD), 128-129, 136
Nevi, 141
Melanocytic, 141
Sebaceous, 141
Nevus-Flame (Port-Wine Stain), 141
Newborn screening, 50, 81-84, 137, 150-151, 153, 233-234
NICU environment, 16-17, 30, 59-63, 213, 216, 231
Nipples, 111, 142
Nitric oxide, 33, 46, 49
Non-sterile delivery, 139
Nutrition assessment, 163, 178-179
Nutrition support, 175, 178, 221
Post discharge, 181, 221
O
Occult spinal dysraphism (see neural tube defect)
Occupational therapy, 61, 180, 182, 220
Omega-fatty acids, 160
Omphalocele, 5, 51, 164, 199-203
Opioid withdrawal, 129-134, 208, 229, 231
Oral feeding, 3, 54, 62, 66, 73, 157, 173, 175, 179-183, 234
Organ donation, 214
Organic aciduria, 79-84
Osteopenia, 176, 179
Palivizumab (see RSV), 2, 30, 114, 120
Palliative care, 135, 206, 208-209, 211, 214, 216-217
Pantoprazole (Protonix), 162
Parents, 2, 17, 25, 40, 42, 44-45, 47, 51-56, 66, 127, 231
Penicillin, 107, 115, 116, 119, 229
Perioperative management, 194-195
Peripheral venous access, 21-22, 53-54, 97, 100, 160, 193, 195-196, 203
Periventricular Intraventricular Hemorrhage (PVIH), 126-127
Periventricular Leukomalacia (PVL), 3, 127
Persistent Pulmonary, Hypertension of the Newborn (PPHN), 14, 22-24, 32, 35, 40, 44-45, 47, 49
Phototherapy, 93-97, 188, 223, 234
Physical examination, 43, 50, 69, 74, 88, 116, 118, 126, 129, 146-147, 152, 191, 194, 197, 199-200, 202
Physical therapy, 61, 128, 146, 148, 220
Polyomyelitis, 72, 87, 91, 93, 97-99, 194, 233
Polydactyly, 149
Port-Wine Stain (Nevus-Flammeus), 141
Positional deformities, 61, 149
Tube, 19
Sleep, 60-62, 66
Postdischarge nutrition, 114, 146, 179, 181-182
Prostaglandin E, 40
Preauricular pits, 142
Pressure Support Ventilation (PSV), 20-21
Prevacid (Lansoprazole), 162
Protonix (Pantoprazole), 162
Pulmonary disease, 40, 50, 73, 167
Pulmonary hypertension, 13, 17, 24, 26, 27, 29, 30, 32, 34, 37, 40, 42-43, 45, 47, 49, 51, 57, 134, 197
Pulse oximetry, 11-12, 16-18, 23, 30, 40, 52, 53, 140, 151
Pustular melanosis, 142
Radiant warmers, 2, 4 13, 64-66, 96 123, 188
Rashes, 142
Reglan (Metoclopramide), 162
Respiratory care, 3, 7, 10-18
Respiratory distress, 2-3, 5, 10, 13-15, 17-18, 24, 43, 45, 47, 52, 71-72, 76, 89, 104, 112, 147-148, 192, 214, 222, 224
Respiratory pump, 11-12
Respiratory Syncytial Virus (RSV), 30, 114, 120
Resuscitation, 3-5, 10-11, 16, 37, 53, 64, 66, 83, 88, 96, 129, 143, 156, 192, 194, 199, 200-201, 210, 212
ROP screening, 2-3, 16, 30, 63, 156, 221, 223-225
Rotavirus, 114-115
Screens, 2, 150
Developmental, 3, 27, 221, 223-225, 227
Hearing, 2-3, 27, 31, 84, 142, 150, 221
Newborn, 3, 68, 71, 83-84, 142, 150, 221, 224
Seizures, 41, 54, 72, 78-82, 104, 112, 121-129, 135-136, 141, 143, 147, 187, 190-191, 233
Bacterial, 12, 104, 112, 119
Serum antibiotic level, 228
SIDS, 13, 61, 139, 143
Skin, 2, 23, 53, 63-66, 82, 88, 93, 95, 104, 107, 112-113, 117, 129, 133, 139, 141-144, 148, 153, 156, 180, 188, 195, 199, 228
Dimples, 141
Lesions, 104, 112-113
Shock, 41, 43, 44, 47, 48, 50, 53, 54, 68, 71, 91, 122, 192, 194, 211, 213, 216
Cardiogenic, 44, 47
Hypovolemic, 48, 91
Septic, 41, 44, 47
Short Bowel Syndrome (SBS) (see Intestinal Failure and Rehabilitation)
Skull, 128, 142, 149
Sleep position, 139
Social workers, 62, 68, 206, 211, 213, 215-216
Sodium bicarbonate, 84, 189, 192, 230
Solid food, 182
Sound, 60, 62-63
Specialized care, 3, 206
Spinal cord injury, 122, 128
Stabilization, 3, 5, 10, 54, 64, 128, 130, 156, 222, 224
Standard phototherapy, 94
Staphylococcal infection, 105
Startler solution, 164-166
Stomas, 194-195
Streptococcus, 105, 147, 234
Stroke, 42, 57, 78, 102, 125, 127
Subgaleal Hemorrhage (SGH), 88, 128, 143
Surfactant, 2-4, 10, 13-14, 19, 21, 23-25, 30-31, 34-35, 45, 47
Surgical conditions, 196, 203
Syndactyly, 149
Syphilis, 115-116, 120
T
Tachycardia, 44, 47, 49, 54, 56-57, 62, 66, 91, 97, 104, 122, 129, 143
Atrioventricular reentrant, 56
Atrioventricular nodal reentrant, 57
Supraventricular, 44, 47, 56-57
Tachypnea, 13, 20, 43, 52, 54, 57, 62, 66, 80, 97, 135
Talipes Equinovarus (Clubfoot), 149, 220, 224
Teeth, 140
Testicular torsion, 152-153
Texas Advance Directives Act, 210
Texas Children’s Hospital, 112, 119, 143, 148, 150, 171, 194, 207, 211, 213-216, 219, 221-228, 224, 226
Abnormal newborn screen, 150
General guidelines, 223
Lactation consultants, 143
Security, 139
Thermal regulation, 63-66
Thiazides, 28
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis, 4-6, 87-89, 99-102, 125, 127, 196</td>
</tr>
<tr>
<td>Thrombocytopenias, 49, 82, 88-90, 92, 102, 154, 233</td>
</tr>
<tr>
<td>Tongue-tie, 144</td>
</tr>
<tr>
<td>Total Parenteral Nutrition (TPN), (see Parenteral nutrition)</td>
</tr>
<tr>
<td>Trace elements, 166-167, 233</td>
</tr>
<tr>
<td>Trachea, 12, 19, 166</td>
</tr>
<tr>
<td>Tracheobronchomalacia, 25, 30</td>
</tr>
<tr>
<td>Tracheostomy, 10, 31-32, 195</td>
</tr>
<tr>
<td>Traumatic birth injuries, 127</td>
</tr>
<tr>
<td>Tuberculosis, 103, 116-117, 120, 145</td>
</tr>
<tr>
<td>U</td>
</tr>
<tr>
<td>Umbilical artery, 2, 4, 53, 55, 151</td>
</tr>
<tr>
<td>Umbilical cord, 40, 48, 97, 127, 130, 138-139, 188, 199</td>
</tr>
<tr>
<td>Umbilical Venous Catheter (UVC), 2-6, 34, 37, 99, 101, 188</td>
</tr>
<tr>
<td>Urea cycle disorder, 81, 84</td>
</tr>
<tr>
<td>Urology, 139, 151-152, 153, 202</td>
</tr>
<tr>
<td>Ursodiol, 159, 231</td>
</tr>
<tr>
<td>V</td>
</tr>
<tr>
<td>Vaccines, 111, 114, 115, 118, 140</td>
</tr>
<tr>
<td>Varicella-Zoster Virus (VZV), 117-118, 120</td>
</tr>
<tr>
<td>Varicella-Zoster Immune Globulin (VariZIG), 117-118, 120</td>
</tr>
<tr>
<td>Vascular malformations, 127, 141</td>
</tr>
<tr>
<td>Ventilation, 3-4, 9-11, 13-41, 45, 47, 49, 54-55, 61, 91, 99, 123,</td>
</tr>
<tr>
<td>125, 128, 132, 135, 148, 180, 192, 197-199, 208, 214, 217, 232</td>
</tr>
<tr>
<td>High-frequency Oscillatory Ventilation (HFOV), 14, 16-19, 21-23,</td>
</tr>
<tr>
<td>33-35, 214</td>
</tr>
<tr>
<td>Home ventilation, 31-32</td>
</tr>
<tr>
<td>Mechanical, 14-15, 18-32</td>
</tr>
<tr>
<td>35, 37, 45, 47, 49, 55, 91, 99, 148, Synchronized Intermittent</td>
</tr>
<tr>
<td>Mandatory Ventilation (SIMV), 2, 4, 19, 20-21, 32</td>
</tr>
<tr>
<td>Vital signs, 2, 4, 42, 53, 60, 96-97, 123, 132, 143, 146, 179,</td>
</tr>
<tr>
<td>207-208, 220, 228</td>
</tr>
<tr>
<td>Vitamins, 83, 145-146, 159, 164-167, 175, 182, 221, 233</td>
</tr>
<tr>
<td>Vitamin A, 2, 30-31, 37, 166, 173, 174-175</td>
</tr>
<tr>
<td>Vitamin K, 2, 88-89, 91, 138-139, 152-153, 159, 166, 213</td>
</tr>
<tr>
<td>VLBW, 2-4, 15, 20-21, 24, 28, 48, 55, 66, 70, 95, 105, 109,</td>
</tr>
<tr>
<td>126, 156, 159-160, 166-168, 170, 173, 182, 188, 192, 220</td>
</tr>
<tr>
<td>Volume expansion, 3, 35-26, 47-48, 5191</td>
</tr>
<tr>
<td>Volume Guarantee (VG), 4, 19, 31, 37</td>
</tr>
<tr>
<td>Volvulus, 156-157, 199-201</td>
</tr>
<tr>
<td>W</td>
</tr>
<tr>
<td>Weaning, 4, 14, 17, 19-20, 22-23, 26-27, 36, 49-50, 65-66, 73-74,</td>
</tr>
<tr>
<td>130, 132-134, 214</td>
</tr>
<tr>
<td>Withdrawal of care, 211</td>
</tr>
<tr>
<td>X</td>
</tr>
<tr>
<td>Xanthines, 12-13</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Zantac (Ranitidine), 162</td>
</tr>
</tbody>
</table>